<SEC-DOCUMENT>0001213900-23-024710.txt : 20230330
<SEC-HEADER>0001213900-23-024710.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230330165459
ACCESSION NUMBER:		0001213900-23-024710
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34471
		FILM NUMBER:		23781449

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2022_chinapharma.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 20:27:52 UTC 2023 -->
<html xmlns:cphi="http://www.chinapharmaholdings.com/20221231" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap-sup="http://fasb.org/us-gaap-sup/2022q3" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>or</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> TRANSITION REPORT UNDER SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from _________ to
_____________</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-34471</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>China Pharma Holdings, Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>(Exact name of registrant as specified in
its charter)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; "> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center; font-size: 10pt">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>73-1564807</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(State or other jurisdiction of</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>incorporation or organization)</i></p></td> <td style="text-align: center; font-size: 10pt">&#160;</td> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(IRS Employer <br/>
Identification No.)</i></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1"><b>Second Floor, No. 17, Jinpan Road</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Haikou</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Hainan Province</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">China</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">570216</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address of Principal Executive Offices) (Zip
Code)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
the area code: <b>(011) <ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">86</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">898-6681-1730</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CPHI</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName">NYSE</ix:nonNumeric> American</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities registered pursuant
to Section 12(g) of the Act: <b>None.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such report(s)), and (2) has been subject to
such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span></td> <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If securities are registered
pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the
registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate market value
of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last
sold, or the average bid and ask price of such common equity, as of the last business day of the registrant&#8217;s most recently completed
second fiscal quarter: $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd">10,601,665</ix:nonFraction> as of June 30, 2022, based on the closing price of $2.15 of the Company&#8217;s common stock on such
date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of outstanding shares of the registrant&#8217;s common stock
on March 24, 2023, was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">8,458,094</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Documents Incorporated by
Reference: None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: justify"><td style="width: 100%">&#160;</td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 10-K ANNUAL REPORT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FISCAL YEAR ENDED DECEMBER 31, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 8%">&#160;</td>
    <td style="vertical-align: top; width: 84%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_001">PART I</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_002">Business</a></span></td>
    <td style="text-align: center; vertical-align: bottom">1</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_002i">Risk Factors</a></span></td>
    <td style="text-align: center; vertical-align: bottom">15</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: center; vertical-align: bottom">44</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></a></td>
    <td style="text-align: center; vertical-align: bottom">44</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="text-align: center; vertical-align: bottom">44</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="text-align: center; vertical-align: bottom">44</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#c_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">45</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="text-align: center; vertical-align: bottom">45</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="text-align: center; vertical-align: bottom">45</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="text-align: center; vertical-align: bottom">46</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures about Market Risk</span></a></td>
    <td style="text-align: center; vertical-align: bottom">53</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="text-align: center; vertical-align: bottom">53</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="text-align: center; vertical-align: bottom">53</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: center; vertical-align: bottom">53</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="text-align: center; vertical-align: bottom">54</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdiction that Prevent Inspections</span></a></td>
    <td style="vertical-align: bottom; text-align: center">54</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#c_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">55</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="text-align: center; vertical-align: bottom">55</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="text-align: center; vertical-align: bottom">58</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters</span></a></td>
    <td style="text-align: center; vertical-align: bottom">61</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="text-align: center; vertical-align: bottom">62</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="text-align: center; vertical-align: bottom">62</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#c_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">63</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#c_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="text-align: center; vertical-align: bottom">63</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top; text-align: justify"><a href="#c_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="text-align: center; vertical-align: bottom">64</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-align: justify"><a href="#c_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT INDEX</span></a></td>
    <td style="text-align: center; vertical-align: bottom">65</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top; text-align: justify"><a href="#c_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The statements contained in
this report with respect to our financial condition, results of operations and business that are not historical facts are &#8220;forward-looking
statements&#8221;. Forward-looking statements can be identified by the use of forward-looking terminology, such as &#8220;anticipate&#8221;,
&#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;intend&#8221;, &#8220;seek&#8221;, &#8220;estimate&#8221;, &#8220;project&#8221;,
&#8220;could&#8221;, &#8220;may&#8221; or the negative thereof or other variations thereon, or by discussions of strategy that involve
risks and uncertainties. Management wishes to caution the reader of the forward-looking statements that any such statements that are contained
in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other
factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors
affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report
including in &#8220;Risk Factors&#8221; in Item 1A and some of which are discussed in our other filings with the SEC. These forward-looking
statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results
may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements
that have been made regarding anticipated events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These risk factors should
be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may
issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons
acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors
not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&#8217; expectations
or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date
of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act
of 1934, as amended (the &#8220;Exchange Act&#8221;) expressly state that the safe harbor for forward-looking statements does not apply
to companies that issue penny stock. If we are ever considered to be an issuer of penny stock, the safe harbor for forward-looking statements
may not apply to us at certain times.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="c_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1.</b>&#160;<b>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are principally engaged
in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence
and high-mortality diseases and medical conditions prevalent in the People&#8217;s Republic of China (the &#8220;PRC&#8221;). All of our
operations are conducted in the PRC, where our manufacturing facilities are located. We manufacture pharmaceutical products in the form
of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of our pharmaceutical
products are sold on a prescription basis and all of them have been approved for at least one or more therapeutic indications by the National
Medical Products Administration (the &#8220;NMPA&#8221;, formerly China Food and Drug Administration, CFDA) based upon demonstrated safety
and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, we
manufactured 19 pharmaceutical products for a wide variety of diseases and medical indications, each of which may be classified into one
of three general categories:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Basic generic drugs, which are common drugs in the PRC for which there is a very large market demand;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">First-to-market generic drugs, which are generic western drugs that are new to the PRC marketplace; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Modern Traditional Chinese Medicines, which are generally comprised of non-synthetic, plant-based medicinal compounds that have been widely used in the PRC for thousands of years. We apply modern production techniques to produce pharmaceutical products in different formulations, such as tablets, capsules or powders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In selecting generic drugs
to develop and manufacture, we consider several factors, including the number of other manufacturers currently producing this particular
drug, the size of the market for that drug, the proposed or required method of distribution, the existing and expected pricing for that
particular drug in the marketplace, the costs of manufacturing that drug, and the costs of acquiring or developing the formula for that
drug. We believe that generic drugs we have always been selecting to manufacture have large addressable markets and higher profit margins
relative to other generic drugs manufactured and distributed in the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we manufactured
comprehensive healthcare products and protective products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently own and
operate two production facilities in Haikou, Hainan Province, PRC. One has a construction area of 663.94 square meters, the other
factory has two buildings with production area of 20,282.42 square meters and 6,593.20 square meters. We implement quality control
procedures in this facility in compliance with the PRC&#8217;s Good Manufacturing Practices, or GMP standards, and applicable NMPA
regulations to ensure consistent quality in our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NMPA promulgated <i>Good
Manufacturing Practices for Pharmaceutical Products</i> (2010 revised version) on February 12, 2011 (effective as of March 1, 2011) (the
&#8220;Year 2011 GMP Standards&#8221;). The Year 2011 GMP Standards outlines the basic principles and standards for the manufacturing
of pharmaceutical products and the management of quality controls in the pharmaceutical products manufacturing industry in the PRC. All
of our production lines: tablets, capsules, dry powder, liquid injectables, solid oral solution Cephalosporins (specifically designated),
are in full compliance with the Year 2011 GMP Standards. A newly revised Drug Administration Law (the &#8220;New Law&#8221;) came into
effect on December 1, 2019. The New Law cancelled the GMP certification but impose the pilot inspection mechanism in the event that if
any production line(s) does not satisfy any pilot inspection under the New Law, the production on such production line(s) could be suspended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We market and sell our products
through 16 sales offices covering all major cities and provinces in the PRC. To comply with applicable Chinese laws relating to sales
of prescription drugs to certain hospitals and clinics, we also use a distribution system comprised of over 1,000 independent provincial-level,
city-level, and county-level distributors. Our sales system has further developed and expanded with the expansion of Chinese healthcare
reform, and our 16 provincial offices deliver our products to basic health care institutions as well as tier two and tier three hospitals
through the above mentioned distributors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate organizational
chart is set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Industry Background and Market Opportunities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the relevant
data of the pharmaceutical manufacturing industry released by the National Bureau of Statistics of the People's Republic of China (&#8220;NBS&#8221;),
as of July 2022, the cumulative value of the operating revenue of the pharmaceutical manufacturing industry in China was RMB1,609 billion,&#160;down
1.8% from the same period last year; The accumulated value of profit was RMB247 billion, down 30.7% from the same period last year. In
the first half of 2022, due to the pressure of industry revenue affected by the COVID-19, thee costs was not reduced and the profit pressure
was greater.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While fully enjoying the benefit
of rigid demand, the development of the pharmaceutical industry is also under the pressure of medical insurance fee control. According
to the data of NBS, the proportion of China&#8217;s population over the age of 65 has reached 14.9% by the end of 2022. With the gradual
deepening of population aging, the demand continues to be strong, but the ensuing medical insurance pressure has also become the main
theme of industrial policy changes in recent years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On one hand, more and more
people use medical insurance funds; on the other hand, fewer and fewer people pay premiums. Under this circumstance, population aging
has become one of the main factors aggravating the imbalance of medical insurance fund. According to the latest <i>Statistical Bulletin
on the Development of National Medical Insurance in 2021 </i>issued by NBS, the number of people participating in national basic medical
insurance reached 1.36 billion in 2021, and the participation rate remained stable at more than 95%. According to the <i>national medical
security plan for the 14<sup>th</sup> five-year-plan</i> issued by the General Office of the State Council of China on September 29, 2021,
personal health expenditure only occupied 27.7% of the total health expenditure in 2020, and it is planned to remain to be at around 27%
by 2025. This means that the vast majority of medical and health expenditure is being borne by the government and society. Under the background
of medical insurance adjustment, domestic drug sales have also experienced great changes. The use of adjuvant drugs has gradually fallen
out of favor, giving up the share of medical insurance funds for specialized drugs and tumor drugs with more clinical efficacy. Under
such policies, pharmaceutical enterprises have to carry out innovation and transform. And the overall environment of deepening medical
reform has greatly reduced the profits of generic pharmaceutical enterprises in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China National Healthcare
Security Administration (&#8220;NHSA&#8221;) has gradually promoted volume-based procurement for the entire national market, therefore,
pharmaceutical manufacturers have greatly reduced the price in order to win the bid. Since the start of procurement piloting in 11 cities
in 2018, there have been eight rounds of practices, showing the following trend:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market scale gradually
expanded: from 11 pilot cities to 31 provincial regions in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number and category of
drugs involved increased: each batch expanded from about 30 in the early stage to about 60.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the
information of the State Medical Security Administration, the seventh batch of national centralized procurement involves 60 drugs,
and the average price of the selected drugs is expected to be reduced by 48%. According to the agreed purchase volume, it is
estimated that a cost of RMB 18.5 billion can be saved per year. This has significantly reduced the price of drugs, thus
significantly reducing the expenditure of the medical insurance fund. On February 21, 2023, the filling and reporting of drug
information related to the eighth batch of national drug centralized procurement was officially launched. According to the published
scope of drug filling, there are 41 varieties and 181 specifications of drugs entering this round.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have observed the
continuous improvement in medical demand and consumption level in recent years, and the value of high-quality medicine with innovation
and consumption attributes has become prominent. In addition, China&#8217;s State Council issued <i>Some Policies and Measures on Accelerating
The Characteristic Development of Traditional Chinese Medicine</i> in February 2021. This policy proposes to follow the development law
of traditional Chinese medicine (TCM);conscientiously sum up the experience and practice in preventing and treating of COVID-19 using
TCM; promote the complementary and coordinated development of TCM and Western medicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impact from the New Coronavirus Global Pandemic
(&#8220;COVID-19&#8221;)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continued to operate under
the strict control and quarantine policies due to COVID-19 in 2022. Many places, including Haikou, the city where our headquarter and
production facility is located, have experienced compulsory government quarantines and lock-down. In this environment, our ordinary production,
procurement, sales, and logistics activities were under heavy negative pressure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the epidemic has entered
the era of Omicron mutant, its infectivity has been greatly enhanced, but its pathogenicity has been significantly weakened. In addition,
vaccination has been popularized and prevention and control experience has been accumulated. Some countries around the world have significantly
loosed the epidemic prevention and control, and moved to a new stage of coexistence with the virus. Recently, China's epidemic prevention
and control guidance has also been continuously optimized, which includes the end of zero-case policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 14, 2022, Director
General of the World Health Organization (WHO) Tan Desai said that it was expected that the COVID-19 epidemic would no longer constitute
a global health emergency sometime in 2023. From December 25, 2022, the China's National Health Commission of China will no longer release
daily epidemic information. On December 26, 2022, the National Health Commission issued the Plan for "Class B disease and Class B
Control" of COVID-19 Infection (the &#8220;Plan&#8221;). The Plan clearly points out that the "COVID-19 infection" will
be adjusted from " Class B disease and Class A Control " to " Class B disease and Class B Control " from January 8,
2023, which is a major adjustment of China's COVID-19 epidemic prevention and control policy. At the same time, the Plan points out that
quarantine infectious disease management measures will no longer be taken for people and goods entering the country. This means that China's
prevention and control will focus on "protecting health and preventing severe diseases" to minimize the impact of the epidemic
on economic and social development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Consistency Evaluation for Generic Drugs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the disclosure
of the State Drug Administration of China in May 2022: China's modern pharmaceutical industry started relatively late, and drug production
is dominated by imitation. More than 95% of the chemical drugs approved for marketing are generic drugs, covering nearly 30 treatment
fields such as cardio-cerebrovascular system, respiratory system, anti-tumor, anti-infection, etc., which basically satisfy public drug
demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the requirements
of the relevant documents of the State Council of China, in the reform of the review and approval system of drugs and medical devices,
the state has listed the improvement of the quality of generic drugs as one of the important reform objectives. For the generic drugs
that have been approved for marketing, the consistency evaluation shall be carried out in stages and batches according to the principle
of consistency with the quality and efficacy of the original drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 17, 2019, the State
Council released the &#8220;<i>Pilot Program for the Centralized Procurement and Use of Drugs by the State Organization</i>&#8221; (&#8220;the
Program&#8221;). According to the Program, the trial drugs are selected from the generic drugs that have passed the consistency evaluation,
and the state organizes the centralized purchase of drugs to reduce the drug price and reduce the burden of drug expenses on patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our company has actively promoted
the Evaluation process of several important products in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The PRC&#8217;s medical insurance system</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">National Healthcare Security Administration
(&#8220;NHSA&#8221;) issued the Statistical Bulletin on the Development of National Medical Security in 2021 (the
&#8220;Bulletin&#8221;) on June 8, 2022. The Bulletin showed the total income of the national basic medical insurance (including
maternity insurance) fund was RMB2.87 trillion in 2021, which represented an increase of 15.6% over the previous year. According to
the Bulletin, 1.36 billion people had participated in the national basic medical insurance (hereinafter referred to as the basic
medical insurance) by the end of 2021, and the participation rate was stable at more than 95%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China's medical insurance system
reform has gone through a long process. At present, it has gradually realized a comprehensive and multi-level medical insurance
system. After 2018, the establishment of the NHSA opened the prelude to a new stage of reform, and the rules and procedures of the
adjustment of the medical insurance catalogue and the national medical insurance negotiation have been gradually improved. From the
beginning of the negotiation in 2017, five rounds of negotiation access have been completed by December 2022, and then once a year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Medical insurance is the largest medical
service purchaser in China. Entering the Medical Insurance Catalogue (the &#8220;MIC&#8221; or the &#8220;Catalogue&#8221;) will
greatly help speed up the large-scale sales of drugs. The list of the MIC drugs was born in the first edition of the list in 2000,
revised for the first time in 2004, adjusted for the second time in 2009, and then remained unchanged for 8 years, significantly
affecting the availability of drugs and the efficiency of fund use. The Ministry of Human Resources and Social Security issued the <i>Notice
on Publicly Soliciting Opinions and Suggestions on Establishing and Perfecting the Dynamic Adjustment Mechanism of the Drug Catalog
of Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance</i> in April 2017, which gradually established the
dynamic adjustment mechanism. Starting from 2020, it is planned to update the MIC every year. <span style="font-size: 10pt">The
average time interval between obtaining approval and completing the formalities for entering the medical insurance list through
negotiation was 6.5 years in 2017, while it was reduced to 1.3 years in 2021.The frequency of products entering the MIC has greatly
accelerated. In the face of increasing medical and health demand and increasing medical insurance pressure, how to efficiently use
medical insurance funds has become the focus of the adjustment of the Catalogue in recent years. The latest version of the MIC was
officially implemented on March 1, 2023. 111 new drugs were added to the Catalogue, and the average price of drugs newly admitted
through negotiation and bidding decreased by 60.1% compared to the average price of drugs before the entering of MIC. The total
number of drugs in the latest version of the Catalogue reached 2,967, including 1,586 western medicines and 1,381 traditional
Chinese patent medicines and simple preparations; There are still 892 kinds of traditional Chinese medicine without
adjustment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">National medical insurance negotiation: In 2015, China first proposed
the general idea of centralized and classified drug procurement, and the drug price negotiation was also started. The negotiation for
the pilot procurement led by the National Health and Family Planning Commission was launched at the end of the same year, which also provided
practical experience for the subsequent national health insurance negotiation. After the establishment of the NHSA in 2018, the NHSA will
formulate and implement the rules of the medical insurance catalog access negotiation. Up to now, five batches of national medical insurance
negotiations have been completed, and the sixth negotiation in 2022 was completed on January 2023. Compared with previous years, the number
of drugs participating in this medical insurance negotiation has increased significantly. According to the list previously released by
the NHSA, 343 drugs have passed the formal review this year, including 198 new varieties of drugs outside the Catalogue and 145 new varieties
of drugs in the Catalogue. In addition, there are many kinds of anti-cancer drugs, high-value rare disease drugs and other major disease
drugs participating in this year's negotiations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that under the
background of national medical insurance cost control, centralized procurement of drugs and medical insurance negotiation should be the
new norm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Centralized Procurement of
Drugs (CPD)&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since November 2018, China's
national centralized procurement with volume has basically maintained the pace of two batches a year, and eight batches have been carried
out. Six batches of chemical drugs have been completed, one batch of biological drugs (insulin) has been completed, and the batch of traditional
Chinese medicine is still in progress. With the continuous promotion of the reform of CPD, the price of medicine has been squeezed. The
average price of the first six batches of centralized purchase was reduced by 53%, and the cumulative decrease in drug costs was more
than RMB260 billion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, the policy of "Increasing the
Speed and Expanding the Coverage" will continue to be promoted in the field of centralized drug procurement: it is required to
strive for the number of drug varieties to reach "100+" in each province, and the number of generic names of drugs
purchased by the state and local governments in each province will reach "350+". Under the new requirements, both national
and local volume-based procurement are accelerating, and the seventh batch of national procurement has been successfully completed
and implemented. The average price of the seventh batch of CDP was reduced by 48%, which is expected to decrease drug cost by
RMB18.5 billion annually.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">We believe that the pursuit
of innovation is imperative for providing the basic medical solutions needed by the majority of patients. We are passionate about protecting
human health, and we always adhere to the highest standards of ethics and integrity to fulfill our firm commitment to our customers and
patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe we are well-positioned
in a comparatively steadily growing industry in one of the fastest-growing economies in the world. With China&#8217;s per capita GDP exceeding
US$12,000 in 2022, consumption structure upgrade, and the establishment of a high-quality health care system has become one of the most
important tasks. We currently manufacture a number of off-patent branded generic drugs. Our diverse portfolio of products and new product
pipelines include products for high-incidence and high-mortality conditions in the PRC, such as cardiovascular, central nervous system
(&#8220;CNS&#8221;), infectious, and digestive diseases. We launched several epidemic prevention products such as medical masks, surgical
masks, KN95 masks, and N95 masks, and wash-free sanitizers since the outbreak of COVID-19 at year end 2019. In addition, we continue to
explore comprehensive healthcare market after the launch of Noni enzymes in 2018. China has entered a post epidemic era with the end of
the dynamic zero-COVID policy since December 2022. we will actively explore various health solutions for long-COVID in this environment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">Consistency evaluation of
our current existing major products will be the focus of our strategy in the near future. The consistency evaluation of generic drugs
will improve Chinese generic drugs quality and eliminate unqualified enterprises, so that high-quality generic drug companies are expected
to benefit from it. Consistency evaluation, together with the centralized drug procurement, are optimizing the competitive landscape of
the Chinese pharmaceutical industry. We believe that the market space and growth potential for Chinese generic drugs are huge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">A series of medical reform
policies introduced in recent years has profound and far-reaching impact on pharmaceutical companies. Therefore, early considerations
of the transformation and upgrading, as well as product positioning become very important. Based on more than twenty-year experience in
R&amp;D, production and marketing experiences, and our market insights, we have decided to gradually adjust our strategy to produce generic
and innovative drugs with high value in pharma-economics, good clinical efficacy and market differentiation. These include drugs that
treat chronic diseases prevalent in China, such as geriatric diseases, cancers, and nutritional products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt"></p><div>

</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 38.5pt">In addition, as another direction
of strategic development, we will actively explore digital interactive healthcare solutions on the Internet. After the advent of the Internet
era, marketing is no longer a vertical down logical relationship, but a decentralized form of interconnection. We will proactively adjust
our business focus and allocate resources to meet market development preferences, provide a more convenient user experience, better standard
treatment plans, and bring higher patient satisfaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">Our objective is to leverage
our expertise in the PRC for the development, manufacture and commercialization of pharmaceutical products. We intend to achieve this
objective by:</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><i>Promoting Our Existing Brands to Increase
Our National Recognition</i>. We intend to support and grow the existing recognition and reputation of our brands and to maintain our
branded pricing strategy through continued sales and marketing efforts through our production lines. To achieve this goal, we plan to
promote the efficacy and safety profile of our established prescription pharmaceutical products to physicians at hospitals and clinics
in all provinces of PRC through the efforts of our sales force, independent distributors and educational physician conferences and seminars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Promoting the progress of consistency
evaluation of our current existing main products. </i>We intend to cope with the latest policies and the GPO requirements. We aim to make
efficient use of our existing human and material resources, and strive to create favorable conditions for product sales and international
development through gaining a favorable result in the consistency evaluation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Exploring on the consumption healthcare
market. </i>Consumption healthcare generally refers to products or services that have certain medical features and can bring health improvement
to consumers, but are mainly paid by individuals (less dependent on medical insurance) and have brand effect. We have observed that it
has become a high growth field in recent years. It is not limited by medical insurance, and has low penetration rate and high growth.
It covers the fields of consumption of traditional Chinese medicine, physical examination, health care, rehabilitation and so on. We will
continue to actively explore this niche market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Expanding Our Distribution Network
to Increase Market Penetration</i>. We intend to expand our reach beyond our current 16 offices in the PRC to drive additional growth
of our existing and future products. We currently contract with over 1,000 distributors in the PRC and plan to expand on these relationships
to target new markets. We will continue our conservative sales strategy of increased cooperation with customers with reliable accounts
receivable collection performance. In addition, we plan to continue to broaden our marketing efforts outside of major cities in the PRC
and to increase our market penetration in cities and rural areas where we already have a presence. Over the long term, we also intend
to expand our presence beyond the PRC to international markets by working with international pharmaceutical companies to cross-sell our
products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Explore CDMO services. </i>Since
the State Council of China issued <i>The Pilot Scheme of Drug Marketing License Holder System</i> in 2016, we have been actively exploring
the CDMO market, especially in the field of high-end manufacturing. We will focus on developing CDMO of pharmaceutical preparations required
in the whole life cycle from preclinical, clinical trials, scale-up manufacturing to drug marketing. Make full use of our more than two
decades of whole process experience in China&#8217;s pharmaceutical industry to engage in pharmaceutical formula research, development,
NMPA production application, industrialization and commercialization. We strive to achieve internal and external coordination and complement
each other&#8217;s resources and advantages.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Acquiring Complementary Products
Lines, Technologies, Distribution Networks and Companies</i>. We intend to selectively pursue strategic acquisition opportunities that
we believe will grow our customer base, expand our product lines and distribution network, enhance our manufacturing and technical expertise
or otherwise complement our business or further our strategic goals. Pursuing strategic acquisitions is a significant component of our
growth strategy. The Company has not identified any strategic acquisition opportunities as of the date of this report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have a product
portfolio of 22 products, including 19 pharmaceutical products that address a wide variety of diseases and medical indications, and the
remaining are comprehensive healthcare and protective products. All of our pharmaceutical products have demonstrated safety and efficacy
in clinical trials sufficient to obtain approval by the NMPA and are sold on a prescription basis. The following table summarizes the
approved indications for our marketed products and the year in which each of such products was first marketed to our customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 29%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 57%; padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Year of</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Commercial</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Product</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Indication</b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Launch</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases</b></span></td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">CerebroproteinHydroloysate Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Memory decline and attention deficit disorder caused by the sequela of craniocerebral trauma and cerebrovascular diseases.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1996</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Gastrodin Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain, including vertigo, neuralgia and headaches.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2005</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Propylgallate for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cerebral thrombosis, coronary heart disease and complications after surgery such as thrombus deep phlebitis.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2006</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Ozagrel Sodium for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Acute thrombotic cerebral infarction and dyskinesia associated with cerebral infarction</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2006</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Alginic Sodium Diester Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis, cerebral embolism and coronary heart disease) and high lipoprotein blood disease.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2006</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Bumetanide for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Various edema diseases (including those associated with heart failure, hepatic cirrhosis, nephropathy, and pulmonary edema), hypertension, acute renal failure, hyperkalemia, hypercalcemia and for the rescue from acute drug poisoning.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2007</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Candesartan</span></td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Hypertension</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2013</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 29%"><span style="font-size: 10pt"><b>Anti-infection and Respiratory Diseases</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 57%; padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 12%; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Roxithromycin Dispersible Tablets</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pharyngitis and tonsillitis caused by Streptococcus pyogenes; sinusitis, tympanitis, acute and chronic bronchitis caused by acute bacterial infection, Mycoplasma pneumonia and Chlamydia pneumoniae; urethritis and cervical infection caused by chlamydia trachomatis; skin soft tissue infection caused by sensitive bacteria.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1995</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Cefaclor Dispersible Tablets</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tympanitis, lower respiratory tract infection, urinary tract infections and skin/skin tissue infection.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2002</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Cefalexin Capsules</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Acute tonsillitis caused by sensitive fungi, airway infections, such as pharyngitis, otitis media, nasal sinusitis and bronchitis; pneumonia, respiratory tract infection, urinary tract infections and skin soft tissue infections.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2002</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 29%"><span style="font-size: 10pt">Andrographolide</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 57%"><span style="font-size: 10pt">Detoxification, antibacterial and anti-inflammatory. For sore throat caused by upper respiratory tract infection</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 12%"><span style="font-size: 10pt">2003</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Clarithromycin Granules and Capsules</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Nasopharynx infection, lower respiratory tract infection, skin tissue infection, acute tympanitis and mycoplasma pneumonia caused by clarithromycin susceptible organisms; urethritis and cervical infection caused by chlamydia trachomatis; and the treatment of legionella infection, mycobacterium avium complex (MAC) infection and helicobacter pylori infection.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2004</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 29%"><span style="font-size: 10pt">Naproxen Sodium and PseudophedrineHydrochlorida Sustained Release Tablet</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 57%"><span style="font-size: 10pt">Relieves cold, sinus and flu symptoms, blocked nose caused by anaphylaxis rhinitis, runny nose, fever, sore throat, symptoms of myalgia in the limbs and pain around the joints.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 12%"><span style="font-size: 10pt">2005</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 10 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Digestive Diseases</b></span></td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Hepatocyte Growth-promoting Factor for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Serious viral hepatitis symptoms caused by various viral hepatitis types (acute, subnormal temperature, chronic serious disease early or middle period of hepatitis).</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2005</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Tiopronin</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Acute and chronic Hepatitis B, and for the relief of drug-induced liver injury.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2009</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Compound Ammonium Glycyrrhetate S for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Liver dysfunction caused by acute and chronic hepatitis; supplemental treatment to toxic/trauma hepatitis, liver cancer; also for the indication of food/drug poisoning, and drug allergy.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2009</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Omeparzole</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Gastroesophageal reflux disease, and other conditions caused by excess acidic formulations in the stomach, including gastric ulcers, recurrent duodenal ulcers and Zollinger-Ellison Syndrome.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2009</span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 29%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 57%; padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 12%; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Others</b></span></td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Vitamin B6 for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Vitamin supplement.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2005</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Granisetron Hydrochloride Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2006</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Comprehensive Healthcare and Protective Products</b></span></td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Noni Enzyme</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">natural, healthy and nutritionrich<br/>
a natural, healthy and nutrition-rich food supplement</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2018</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Sanitizer</span></td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">75% alcohol wash-free sanitizer</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2020</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Masks</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">KN95 Particulate Respirator, Disposable Medical Mask, Particle Filtering Mask, N95 Medical Protective Mask</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2020 to 2023</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are our revenues
by product category in millions (USD) for the years ended December 31, 2022 and 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0; text-indent: 0">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Twelve Months Ended<br/> December 31,</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0; font-weight: bold; text-align: justify; text-indent: 0"></td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Net Change</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; padding-left: 0; font-weight: bold; text-align: justify; text-indent: 0">Product
    Category</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in&#160;millions)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in&#160;millions)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in&#160;millions)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% Change</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0; width: 64%; text-align: justify; text-indent: 0">CNS Cerebral &amp; Cardio Vascular</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 6%; text-align: right">1.70</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 6%; text-align: right">2.68</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: justify">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">-0.98</td><td style="width: 1%; font-weight: bold; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 6%; text-align: right">-37</td><td style="width: 1%; text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0; text-align: justify; padding-left: 0">Anti-Viral' Infection &amp; Respiratory</td><td>&#160;</td>
    <td style="text-align: justify">$</td><td style="text-align: right">4.94</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">$</td><td style="text-align: right">5.22</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-0.28</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-5</td><td style="text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0; text-align: justify; padding-left: 0">Digestive Diseases</td><td>&#160;</td>
    <td style="text-align: justify">$</td><td style="text-align: right">0.40</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">$</td><td style="text-align: right">0.37</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">11</td><td style="font-style: normal; font-weight: normal; text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0; text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.06</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.37</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-0.31</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-23</td><td style="padding-bottom: 1.5pt; text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0; text-align: justify; padding-left: 0">Total</td><td>&#160;</td>
    <td style="text-align: justify">$</td><td style="text-align: right">8.10</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">$</td><td style="text-align: right">9.64</td><td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">-1.54</td><td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">16</td><td style="font-style: normal; font-weight: normal; text-align: justify">%</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the nature of the pharmaceutical
industry, we continually strive to change our product portfolio to respond to changes in market demand. Based on a foundation established
by a number of our widely-recognized prescription products, such as Cefaclor and Roxithromycin, we have launched and will continue to
launch a variety of pharmaceuticals. The core criteria for our selection of potential pipeline products is strong market demand, proven
efficacy, and safety. In an effort to gain an advantage in the marketplace, we often seek to improve the production process of the new
generic products we elect to manufacture or to improve the quality of a proposed product to increase its efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also adjust the delivery
systems and marketing for each of our products based on the product&#8217;s target patient group. We believe that maintaining a variety
of delivery systems (e.g. tablets, capsules, injectables and dry powders) for certain of our products targeted at different groups enhances
our competitive position in the marketplace. As a result, our sales and marketing personnel work closely with management and our research
and development personnel to determine which of our products can successfully be marketed for more than one delivery system and which
generic drugs in the marketplace may be good candidates for us to manufacture and distribute using different delivery systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Product Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research &amp; development
and innovation represent the core competitive advantage for a company&#8217;s sustainable growth. For pharmaceutical companies, products
with proprietary intellectual property are not only strategic resources for comprehensive strength, but also important tools to engage
in social responsibility. We have been focusing on the research and development of both first generic drugs and innovative drugs. Additionally,
we also have actively worked to meet unfulfilled medical needs by sticking to a market-oriented approach and continuously improving the
effectiveness and ease of use of our drugs, which are supported by our well-designed system for intellectual property management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC State Council issued
&#8220;<i>Opinions on Carrying out Consistency Evaluation on Quality and Efficacy of Generic Drugs</i>&#8221; on March 5, 2016, requiring
all manufacturers of generic chemical pipeline products to carry out Consistency Evaluations before they may obtain final registration
approval. Drugs failing to meet these requirements may not be re-registered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, due to this newly
issued NMPA production approved standards and experimental requirements, as with all other Chinese generic pharmaceutical companies, almost
all of our pipeline products have undergone major adjustments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s recent
research and development work is mainly aimed at promoting the consistency evaluation of several major products already on the market,
as well as the continued exploration of comprehensive health product categories.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is to release
to the market a product for the treatment of dysmenorrhea, which Ms. Li, Chairman and CEO of the Company, is one of the inventors. In
addition, the Company has launched N95 Medical Protective masks in early 2023. Since China ended its zero-case policy and no longer requires
shutdown or quarantine in December 2022, the market demand for prevention materials, such as masks has surged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Distribution and Customers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe we have a well-established
sales network. As our current pharmaceutical product portfolio is comprised mainly of prescription drugs, our major sales targets are
hospitals. As of December 31, 2022, we have&#160;16 sales offices covering all major provinces of China, and over 1,000 sales representatives
who assist in managing the delivery of pharmaceutical products, and our promotion and service with hospitals, doctors and local drug distributors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the nature of our products
and current governmental regulations, all of our customers are located in the PRC. We have established long-standing relationships with
most of our key customers through our operating subsidiary, Hainan Helpson Medical &amp; Biotechnology Co., Ltd. (Helpson), which was
formed in 1993.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Production Facilities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We manufacture and package
our products at our manufacturing facility in the Haikou Free Trade Zone in Haikou, Hainan Province. Our old manufacturing facility, which
was built in 2002, is approximately 8,000 square meters (approximately 12.4 million square feet); and our new building, approximately
20,000 square meters (approximately 31 million square feet), was completed in 2013. We have production lines conforming with the 2011
version of GMP certificates for different forms of our products including: tablets, capsules, dry power, liquid injectables, solid oral
solution Cephalosporins (specifically designated); other than that, we also have production lines for health care products and various
types of masks that meet national standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our existing production
lines have met the GMP Standards which became effective as of March 1, 2011. On December 1, 2019, the newly revised Drug Administration
Law (the &#8220;New Law&#8221;) came into effect, which cancelled the GMP certification but impose the pilot inspection mechanism.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Raw Materials</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We require a supply of a wide
variety of raw materials to manufacture our products. We employ purchasing staff with extensive knowledge of our products who work with
our product development, and formulations and quality control personnel to source raw materials for our products. Currently, we rely on
numerous suppliers in the PRC and overseas to deliver our required raw materials and believe we have at least three principal suppliers
for each of our most critical raw materials. Historically, we have not had difficulty obtaining raw materials from suppliers. For the
year ended December 31, 2022, our purchases of raw material purchases from our three top suppliers accounted for 21.7%, 11.1%, and 8.9%,
respectively. For the year ended December 31, 2021 suppliers accounted for 24.8%, 12.7%, and 11.8%, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Competition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe we have established
a commercially competitive position in the highly-fragmented pharmaceutical industry in China through our core competitive advantages,
as described below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have a highly-efficient commercialization
process for new products, including significant experience with the NMPA registration process.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have over 20 years of product-development
experience during which time we have implemented processes to efficiently introduce and market new and existing products to the Chinese
market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have a market-oriented product portfolio
and product lines.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product focuses on developing
and manufacturing medicines that help large patient groups, such as the infectious disease and cardio vascular disease patient groups.
Our diversified GMP-certified manufacturing facility includes various production lines targeting a variety of delivery mechanisms, such
as tablets, capsules, cephalosprine tablets, cephalosprine capsules, liquid-injectables and dry powder injectables, which enables us to
effectively manufacture a broad range of new drugs; other than that, we also have production lines for health care products and various
types of masks that meet national standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have product diversification to target specific
sub-markets.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We attempt to differentiate
our products from those of our competitors by changing, and, in many cases, improving certain physical aspects of our products to market
under different market segments. For example, to make our Cefaclor product more patient friendly to children and patients with swallowing
problems, we added an enteric coating to make our tablets easier to swallow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have a national sales network and a highly-trained
marketing team.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our experienced sales team
has industry knowledge and know-how to synergistically combine our strong market insight with successful commercialization platforms.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have developed high-quality relationships
with leading hospital and clinic administrators and physicians.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While sales of our pharmaceutical
products to hospitals are made through our distributors, we believe we have established long-term cooperation relationships with leading
hospitals and healthcare clinics throughout China resulting from our long-term promotional efforts and periodic physician seminars, so
that to improve the perception of our products in the marketplace and help us identify and select high-volume drugs to develop into new
generic products relatively early in the process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding such favorable
positioning, we are subject to intense competition. There are both local and overseas pharmaceutical enterprises that are engaged in the
manufacture and sale of potential substitute or similar pharmaceutical products in the PRC. These competitors may have more capital, better
research and development resources, better manufacturing and marketing capability, and more experience than we do.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our profitability may be adversely affected if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">the number of our competitors increases;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competitors engage in increased price competition; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competitors develop new products or product substitutes having comparable medicinal applications or therapeutic effects that are more effective, less costly and/or have more perceived benefits than those produced by us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, imported products
and China&#8217;s admission as a member of the World Trade Organization (&#8220;WTO&#8221;) creates increased competition. The PRC became
a member of the WTO in December 2001. As a result, competition in the pharmaceutical industry in the PRC intensified generally in two
respects. First, with lower import tariffs, imported pharmaceutical products manufactured overseas may become increasingly competitive
in terms of pricing. Second, we believe that well-established foreign pharmaceutical manufacturers may set up production facilities in
the PRC and compete with domestic manufacturers directly. With the expected increased supply of competitively-priced pharmaceutical products
in the PRC, we may face increased competition from foreign pharmaceutical products, especially in terms of high-end pharmaceutical products,
including certain types of products manufactured by U.S. manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We regard our packaging
designs, trademarks, trade secrets, patent and similar intellectual property as parts of our core competence that are critical to
our success. We rely on patent, trademark and trade secret law, as well as confidentiality agreements with certain of our employees,
distributors and others to protect our intellectual property rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2008, we purchased
the patented medical formula and the manufacturing processes for a cerebral/cardio-vascular indication from a third party laboratory.
In connection with that acquisition, we obtained the title of the patent. This patent expires in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2012, we acquired another
patent related to a medical formula for the treatment of cerebral/cardio-vascular diseases. This patent expires in 2029.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, we acquired a utility
model patent and an invention patent application regarding the creation of an ophthalmic oxygen enriched atomization therapeutic apparatus
through Helpson, our wholly owned subsidiary, from Chengdu Bonier Medical Technology Development Co., Ltd. (&#8220;Bonier&#8221;). Based
on the technology transfer agreement, Helpson will receive the utility model patent right of the technical invention and the patent application
right of the invention, and Bonier will provide relevant technical services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, we
owned 18 registered trademarks, including marks for eight of the 19 pharmaceutical products we manufacture, including the tradenames Fukexing,
Beisha, Shiduotai, Xinuo, Pusenlitai, Pusenouke, Shuchang, Shenkaineng, XERONINE, and Aronino, as well as marks for our AFGF logo, our
HPS logo, our two HELPSON logos and four other logos. The registration numbers of the 18 registered trademarks are as follows: No.1500459,
No.1511770, No.1535416, No.1537828, No.1535420, No.1272792, No.1272760, No.1330294, No.1327731, No.1330295, No.3993785, No. 4074317, No.4074321,
No. 4315247, No. 32445705, No. 32437940, No. 34711564, and No. 34711561.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Environmental Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We comply with the Environmental
Protection Law of China as well as applicable local regulations. In addition to statutory and regulatory compliance, we actively ensure
the environmental sustainability of our operations. Penalties may be levied upon us if we fail to adhere to and maintain certain standards.
Such failure has not occurred in the past, and we do not anticipate that it will occur in the future, but no assurance can be given in
this regard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Regulations Relating to
Pharmaceutical Manufacture Industry</i>. The pharmaceutical manufacture industry in China is highly regulated. The primary regulatory
authority is the NMPA, including its provincial and local branches. As a developer and producer of medicinal products, we are subject
to regulation and oversight by the NMPA and its provincial and local branches. The Medicinal Product Administration Law of the People&#8217;s
Republic of China provides the basic legal framework for the administration of the production and sale of pharmaceuticals in China and
covers the manufacturing, distribution, packaging, pricing and advertising of pharmaceutical products. These regulations set forth detailed
rules with respect to the administration of pharmaceuticals in China. We are also subject to other</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PRC laws and regulations that are applicable to
business operators, manufacturers and distributors in general.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Registration and Approval
of Medicine</i>. Pursuant to the PRC Provisions for Drug Registration, a medicine must be registered and approved by the NMPA before it
can be manufactured and sold. The registration and approval process requires the manufacturer to submit to the NMPA a registration application
containing detailed information concerning the efficacy and quality of the medicine and the manufacturing process and the production facilities
the manufacturer expects to use. A series of policies on consistency evaluation and drug review process have been issued in recent years,
and potentially more reforms and adjustments are underway in order to promote the pharmaceutical industry in China in line with the international
standards. In this context, we believe that the uncertainties in the timetables for obtaining NMPA production approvals for products under
research are increasing. If a manufacturer chooses to manufacture a pre-clinical medicine, it is also required to conduct pre-clinical
trials, apply to the NMPA for permission to conduct clinical trials and go through the clinical trials. If a manufacturer chooses to manufacture
a post-clinical medicine, it only needs to go through the clinical trials. In both cases, a manufacturer needs to file clinical data with
the NMPA for approval to manufacture after clinical trials are completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>New Medicine</i>. If a
new medicine is approved by the NMPA, the NMPA will issue a new medicine certificate to the manufacturer and impose a monitoring period
from one to five years. During the monitoring period, the NMPA will monitor the safety of the new medicine, and will neither accept new
medicine certificate applications for an identical medicine by another pharmaceutical company, nor approve the production or import of
an identical medicine by other pharmaceutical companies. As a result of these regulations, the holder of a new medicine certificate has
the exclusive right to manufacture it during the monitoring period. We currently have the new medicine certificates for our Pusenouke,
Cefaclor dispersible tablets and Roxithromycin dispersible tablets and Bumetanide for injection products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>National Production Standard
and Provisional Standard</i>. In connection with the NMPA&#8217;s approval of a new medicine, the NMPA will normally direct the manufacturer
to produce the medicine according to a provisional national production standard, or a provisional standard. A provisional standard is
valid for two years, during which time the NMPA closely monitors the production process and quality consistency of the medicine to develop
a national final production standard for the medicine, or a final standard. Three months before the expiration of the two-year period,
the manufacturer is required to apply to the NMPA to convert the provisional standard to a final standard. Upon approval, the NMPA will
publish the final standard for production. The NMPA has no statutory timeline to complete its review and grant approval for the conversion.
In practice, the approval for conversion to a final standard is time-consuming and could take a number of years. However, during the NMPA&#8217;s
review period, the manufacturer may continue to produce the medicine according to the provisional standard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Transitional
Period</i>. Prior to the latter of (1) the expiration of a new medicine&#8217;s monitoring period or (2) the date when the NMPA
grants a final standard for a new medicine after the expiration of the provisional standard, the NMPA will not accept applications
for an identical medicine nor will it approve the production of an identical medicine by other pharmaceutical companies.
Accordingly, the manufacturer will continue to have an exclusive production right for the new medicine during this transitional
period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Continuing NMPA Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical manufacturers
in China are subject to continuing regulation by the NMPA. If the labeling or its manufacturing process of an approved medicine is significantly
modified, a new pre-market approval or pre-market approval supplement will be required by the NMPA. A pharmaceutical manufacturer is subject
to periodic inspection and safety monitoring by the NMPA to determine compliance with regulatory requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NMPA has a variety of
enforcement actions available to enforce its regulations and rules, including fines and injunctions, recall or seizure of products, imposition
of operating restrictions, partial suspension or complete shutdown of production and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pharmaceutical Product Manufacturing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Permits and Licenses for
Pharmaceutical Manufacturers.</i> A pharmaceutical manufacturer must obtain a pharmaceutical manufacturing permit from the NMPA&#8217;s
relevant provincial branch. This permit is valid for five years and is renewable for an additional five-year period upon its expiration.
Our current pharmaceutical manufacturing permit, issued by the NMPA, will expire on November 8, 2025. We are confident the permit could
be renewed before its expiration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Good Manufacturing Practice.</i>
A pharmaceutical manufacturer must meet the Good Manufacturing Practice standards, or GMP standards, for each of its production facilities
in China in respect of each form of pharmaceutical product it produces. GMP standards include staff qualifications, production premises
and facilities, equipment, raw materials, environmental hygiene, production management, quality control and customer complaint administration.
Prior to December 1, 2019, if a manufacturer meets the GMP standards, the NMPA will issue to the manufacturer a Good Manufacturing Practice
certificate, or a GMP certificate, with a five-year validity period. However, for a newly-established pharmaceutical manufacturer that
meets the GMP standards, the NMPA will issue a GMP certificate with only a one-year validity period. The Year 2011 GMP Standards became
effective on March 1, 2011, and pharmaceutical manufacturers (except for manufacturers of injectables, blood products or vaccines, which
had a three-year grace period) had a five-year grace period to upgrade existing facilities to comply with the revisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our existing
production lines have met the Year 2011 GMP Standards. On December 1, 2019, the newly revised Drug Administration Law (the
&#8220;New Law&#8221;) came into effect. One of the major amendments is the cancellation of GMP certification. The New Law
eliminated the requirement that drug administration authorities shall assess drug manufacture enterprises and drug trading
enterprises, and issue assessment certificates. Instead, it requires that drug manufacturing enterprises and drug trading
enterprises establish and improve the quality management systems of manufacture and trade of drugs, and ensure that the process of
manufacturing and trading of drugs always meets all legal requirements. This means a stricter form of supervision is implemented
comparing to the prior GMP certificates system<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12290; </span><span style="font-size: 10pt">Our
production lines are subject pilot inspection under the New Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that GMP inspection
only switches to another form, which includes flight inspection, drug production license inspection (for on-site management and quality
system), as well as product inspection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Product Liability and Consumers Protection</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Product liability claims may
arise if any of our pharmaceutical products have a harmful effect on a consumer, who may make a claim for damages or compensation as an
injured party. The General Principles of the Civil Law of the PRC, which became effective in January 1987, stated that manufacturers and
sellers of defective products causing property damage or injury shall incur civil liabilities for such damage or injuries. The Civil Code
of the PRC, which came into force on January 1, 2021, stipulates that if damage is caused to others due to defects in products, the infringed
can claim compensation from the manufacturer of the products or the seller of the products. If the defect is caused by the producer, the
seller shall have the right to recover compensation from the producer. If the product is defective due to the fault of the seller, the
producer shall have the right to recover from the seller after making compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Product Quality Law of
the PRC was enacted in 1993 and amended in 2000 to strengthen the quality control of products and protect consumers&#8217; rights and
interests. Under this law, manufacturers and distributors who produce or sell defective products may be subject to confiscation of earnings
from such sales, revocation of business licenses and imposition of fines, and in severe circumstances, may be subject to criminal liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law of the PRC on the
Protection of the Rights and Interests of Consumers was promulgated on October 31, 1993 and became effective on January 1, 1994 to protect
consumers when they purchase or use goods or services. All business operators must comply with this law when they manufacture or sell
goods and/or provide services to customers. In extreme situations, pharmaceutical product manufacturers and distributors may be subject
to criminal liability if their goods or services lead to the death or injuries of customers or other third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the regulations
relating to pharmaceutical industry in China, Helpson is subject to the regulations applicable to a foreign invested enterprise in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Foreign Currency Exchange.
</i>Pursuant to the Foreign Currency Administration Rules promulgated in 1996 and amended in 1997 and various regulations issued by the
State Administration of Foreign Exchange, or the SAFE, and other relevant PRC government authorities, Renminbi is freely convertible only
to the extent of current account items, such as trade-related receipts and payments, interests and dividends. Capital account items, such
as direct equity investments, loans and repatriation of investment, require the prior approval from the SAFE or its local counterpart
for conversion of Renminbi into a foreign currency, such as U.S. dollars, and remittance of the foreign currency outside the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payments for transactions
that take place within the PRC must be made in Renminbi. Unless otherwise approved, PRC companies other than foreign investment enterprises
(FIEs) must convert foreign currency payments they receive from abroad into Renminbi. On the other hand, FIEs may retain foreign currency
in accounts with designated foreign exchange banks, subject to a cap set by the SAFE or its local counterpart.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dividend Distribution.
</i>Under the PRC regulations governing dividend distributions by wholly foreign-owned enterprises and Sino-foreign equity joint ventures,
wholly foreign-owned enterprises and Sino-foreign equity joint ventures in the PRC may pay dividends only out of their accumulated profits,
if any, determined in accordance with PRC accounting standards and regulations. Additionally, these foreign-invested enterprises are required
to set aside certain amounts of their accumulated profits each year, if any, to fund certain reserve funds. These reserves are not distributable
as cash dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, we
had 244 employees, among which 234 employees were full-time employees and 10 employees were temporary employees. None of our employees
is represented by a labor union and, in general, we consider our relationship with our employees to be good.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by applicable
Chinese law, we have entered into employment contracts with substantially all of our officers, managers and employees. We are working
towards entering into employment contracts with those employees who do not currently have employment contracts with us. The PRC enacted
a new Labor Contract Law, which became effective on January 1, 2008. We have updated our employment contracts and employee handbook and
are in compliance with such law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_002i"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1A. RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Factor Summary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The following are some material risks, any
of which could have an adverse effect on our business financial condition, operating results, or prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Risks Related to our Business and our Industry</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If our products do not attain
market acceptance among the medical community, our operations and profitability would be adversely affected;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we fail to meet standards
pursuant to the newly revised Drug Administration Law, certain production lines will be suspended and our profitability would be adversely
affected;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may be subject from time
to time to product recalls initiated by us or by the NMPA. Product recalls could impose significant costs on us and adversely affect
our ability to generate revenue;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we fail to develop new products
with high profit margins and our high-profit-margin products are replaced by competitors&#8217; products, then our gross will be adversely
affected;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Most of our products are off-patent
branded generics that can be manufactured and sold by other pharmaceutical manufacturers in the PRC which may increase the competition
we face;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we are not able to maintain
and enhance our brand recognition to maintain our competitive advantage, our reputation, business and operating results may be harmed;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Reimbursement may not be available
for our products, which could diminish our sales;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">The growth and success of our
business depend on our ability to successfully market our principal products to hospitals and their selection for medicine purchases;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our future research and development
projects may not be successful;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We cooperate with research
institutions and universities in the PRC for the research and development of certain new products and any failure of such research institutions
to meet our timing and quality standards may pose impairment loss on our financial results and our failure to continue such collaborative
arrangement could adversely affect our ability to develop new pharmaceuticals and our overall business prospects;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to obtain
regulatory approval for any of the new products and failure to obtain these approvals could materially harm our business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">New product development in
the pharmaceutical industry is time-consuming and costly and has a low rate of successful commercialization;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to successfully
identify and acquire new products or businesses;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We rely on distributors for
all of our revenues and failure to maintain relationships or to otherwise expand our distribution network would materially and adversely
affect our business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We rely on a limited number
of distributors for the majority of sales of our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our operations may be affected
if we could not pass the Consistency Evaluation requirement issued by the State Council for any of our current existing products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We face risks related to health
pandemics that could impact our sales and operating results;</span></td>
</tr></table><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our operations may be affected
if we could not obtain raw materials from our current key suppliers on acceptable terms;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to effectively
manage our employees and distribution network, and our reputation, business, prospects and brand may be materially and adversely affected
by actions taken by our distributors and third party marketing firms;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We have limited insurance coverage
and may incur losses resulting from product liability claims, business interruptions or claims that could be covered by D&amp;O Insurance;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our future liquidity needs
are uncertain and we may need to raise additional funds in the future.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Risks Related to Doing Business in China</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Adverse changes in political
and economic policies of the PRC government could have a material and adverse effect on the overall economic growth of China, which could
reduce the demand for our services and materially and adversely affect our competitive position;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">The PRC legal system has inherent
uncertainties that could limit our legal protections available to us;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">You may experience difficulties
in bringing original actions in the PRC against our company or our management based on U.S. or other foreign laws;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Because we receive substantially
all of our revenue in Renminbi, which currently is not a freely convertible currency, we are subject to changes in the PRC&#8217;s political
and economic decisions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We cannot be certain that the Chinese regulatory authorities will not impose more stringent restrictions on the convertibility of the Renminbi, especially for foreign exchange transactions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We are subject to the environmental protection laws of the PRC that may be costly to comply with and may adversely affect our manufacturing operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Compliance with China&#8217;s new Data Security Law, Measures on Cybersecurity Review, Personal Information Protection Law (second draft for consultation), regulations and guidelines relating to the multi-level protection scheme and any other future laws and regulations may entail significant expenses and could materially affect our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We are not required to submit an application to CSRC pursuant to the
M&amp;A Rules, nor are we subject to the cybersecurity review. However, based on the recent promulgation of the Trial Measures, which
are set to be effective on March 31, 2023, we may be required to complete the filing requirements when we have re-financing or any additional
offerings in future;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Although the audit report included in this prospectus was issued by U.S. auditors who are currently inspected by the PCAOB, if it is later determined that the PCAOB is unable to inspect or investigate our auditor completely, investors would be deprived of the benefits of such inspection and our ordinary shares may be delisted or prohibited from trading;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Risks Related to our Common Stock</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may be held in default on our convertible note, which could trigger
penalties that worsen our financial condition and potentially disqualify us from listing on the stock exchange where we are currently
listed;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price for our common stock may be volatile;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we issue additional shares
of our capital stock, our stockholders will experience dilution in their respective percentage ownership in the company;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">A large portion of our common stock is controlled by a small number of stockholders and as a result, these stockholders are able to influence and ultimately control the outcome of stockholder votes on various matters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We are likely to remain subject to &#8220;penny stock&#8221; regulations and as a consequence there are additional sales practice requirements and additional warnings issued by the SEC;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">There is substantial doubt about our ability to continue as a going concern;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We do not anticipate paying cash dividends on our common stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Business and our
Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The commercial success of our products depends
upon the degree of their market acceptance among the medical community. If our products do not attain market acceptance among the medical
community, our operations and profitability would be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our products depends upon the degree of market acceptance they achieve within the medical community, particularly among physicians and
hospital administrators. Physicians may not prescribe or recommend our products to patients and procurement departments of hospitals may
not purchase our products if physicians or hospital pharmacists do not find our products attractive. The acceptance and use of our products
among the medical community will depend upon a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">perception of physicians, patients
and others in the medical community as to the safety and effectiveness of our products;</span></td>
</tr></table><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the prevalence and severity
of any side effects;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the pharmacological benefit
of our products relative to competing products and products under development;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the efficacy and potential advantages
of our products relative to competing products and products under development;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the relative convenience and
ease of administration of our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the methods by which our pharmaceutical
products may be delivered to patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the effectiveness of our education,
marketing and distribution efforts and those of our distributors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">publicity concerning our products
or competing products and treatments; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the price of our products and
competing products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to meet standards pursuant to
the newly revised Drug Administration Law, the production at certain of our production lines will be suspended and our operations and
profitability would be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our existing production
lines have met the GMP Standards which became effective as of March 1, 2011. On December 1, 2019 the newly revised Drug Administration
Law (the &#8220;New Law&#8221;) came into effect. One of the major amendments of the New Law is the cancellation of GMP certification.
The New Law eliminated the requirement that drug administration authorities shall assess drug manufacture enterprises and drug trading
enterprises, and issue assessment certificates. Instead, it requires that drug manufacturing enterprises and drug trading enterprises
establish and improve the quality management systems of manufacture and trade of drugs, and ensure that the process of manufacturing and
trading of drugs always meets all legal requirements. This means a stricter form of supervision is implemented comparing to the prior
GMP certificates system.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While all of our existing
product lines are in full compliance with the GMP standards issued in 2011, in the event we fail to continually meet the requirements
of the GMP and receive the deficiency feedback from any pilot inspection under the New Law, the production on such production line(s)
could be suspended and our operations and profitability could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject from time to time to product
recalls initiated by us or by the NMPA. Product recalls could impose significant costs on us and adversely affect our ability to generate
revenue.</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our business, we must comply
with a variety of product safety and product testing regulations. In particular, our products are subject to, among other statutes and
regulations, those issued by the NMPA. If the NMPA issues any notices to cease the production, sale and use of any of our products, we
must comply with such requirements. As a result, we may incur significant costs in complying with cessation requirements, and our financial
results could be materially and adversely affected. Furthermore, concerns about potential liability or potential future changes in product
safety regulations may lead us to voluntarily recall or otherwise discontinue selling selected products, which could materially and adversely
affect our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2013, NMPA issued
a nationwide notice (the &#8220;NMPA Notice&#8221;) for the cessation of the production, sale and use of Buflomedil effective immediately.
The NMPA Notice was a result of the reevaluation done by the NMPA based on the indications from the recent Chinese and international research
materials, which found that the risks of side effects to the nervous system and the cardiovascular system from Buflomedil have surpassed
its clinical treatment benefits. The NMPA Notice was applicable to all the manufacturers and distributors in China who are in the business
of the production and sale of Buflomedil related products. As a result, we no longer produce Buflomedil after 2013.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recalls may also harm our
reputation, increase our costs and reduce our net sales. Governments and regulatory agencies in the markets where we manufacture and sell
products may enact additional regulations relating to product safety and consumer protection in the future or take other actions that
may adversely impact our business. The NMPA has the authority to revoke drug approvals previously granted and remove previously approved
products from the market for various reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to develop new products with
profit margins and our high-profit-margin products are replaced by competitors&#8217; products, then our gross and net profits margins
will be adversely affected.</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had gross profit margins
of -4.7% for the year ended December 31, 2022, compared to gross profit margins of 3.6% for the year ended December 31, 2021. The pharmaceutical
market in the PRC remains very competitive, and there may be pressure to reduce sale prices of products without a corresponding decrease
in the cost of sold products. To the extent that we fail to develop new products with high profit margins and our high-profit-margin products
are replaced by our competitors&#8217; products, our gross profit margins and net profit margins will be adversely affected. In addition,
three of our products are included in the National Essential Drug List (the &#8220;EDL&#8221;), which are subject to strict governmental
price controls. Therefore, our gross profit margin and net profit margins could be adversely affected notwithstanding any increase in
our revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products face substantial competition.
Other companies may discover, develop, acquire or commercialize products earlier or more successfully than we do.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate in a highly competitive
environment. Our products compete with other products or treatments for diseases that treat similar medical conditions. Many of our products
may compete against products that have lower prices, superior performance, greater ease of administration or other advantages. We would
face enhanced competition if competitive products are added to the National Medical Insurance Program. Our inability to compete effectively
could reduce sales or margins, which could have a material adverse effect on our results of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our competitors are
actively engaging in research and development in areas in which we have products or in which we are developing new product or new indications
for existing products. In the future, we expect that our products will compete with new drugs currently in development, drugs approved
for other indications that may be approved for the same indications as those of our products and drugs approved for other indications
that are used off-label. If alternatives to our products are dispensed or prescribed to patients, the volume of our products sold may
decline or we may be required to lower the prices of our products to remain competitive, either of which could negatively impact our sales.
In addition, an increasing number of foreign pharmaceutical companies have introduced their pharmaceutical products into the Chinese market.
Competitive products introduced by these companies can also negatively impact our sales and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Large Chinese state-owned
and privately owned pharmaceutical companies and foreign-invested or foreign pharmaceutical companies may have greater clinical, research,
regulatory, manufacturing, marketing, financial and human resources than we do. In addition, some of our competitors may have technical
or competitive advantages over us with respect to the development of technologies and processes. These resources may make it difficult
for us to compete with them to successfully discover, develop and market new products and for our current products to compete with new
products or new product indications that these competitors may bring to market. There may also be significant consolidation in the pharmaceutical
industry among our competitors. Alliances may develop among competitors, and these alliances may rapidly acquire significant market share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, in order to gain
market share in China, competitors may significantly increase their advertising expenditures and promotional activities or even engage
in irrational or predatory pricing behavior. In addition, our competitors may engage in inappropriate competition or illegal acts, such
as bribery. Third parties may actively engage in activities designed to undermine our brand name and product quality or to influence customer
confidence in our products. Increased competition may result in price reductions, reduced margins and loss of market share, any of which
could materially adversely affect our profit margins. We may not be able to compete effectively against current and future competitors.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Most of our products are off-patent branded
generics that can be manufactured and sold by other pharmaceutical manufacturers in the PRC which may increase the competition we face
and reduce our business profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most of our products are off-patent
branded generic pharmaceuticals and are not protected by intellectual property rights. As a result, other pharmaceutical companies may
sell equivalent products at a lower cost, and this might result in a commensurate loss in sales of our branded generic products or require
us to lower our prices to compete. If other pharmaceutical companies sell pharmaceutical products that are similar to our unprotected
products, we may face additional competition and our business and profitability may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business depends in part on our well-known
Helpson brand name, and if we are not able to maintain and enhance our brand recognition to maintain our competitive advantage, our reputation,
business and operating results may be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that market awareness
of our Helpson brand has contributed significantly to the success of our business. We also believe that maintaining and enhancing the
Helpson brand is critical to maintaining our competitive advantage. Although our sales and marketing staff will continue to further promote
our brand to remain competitive, we may not be successful. If we are unable to further enhance our brand recognition and increase awareness
of our products, or if we are compelled to incur excessive marketing and promotion expenses in order to maintain our brand awareness,
our business and results of operations may be materially and adversely affected. Furthermore, our sales and results of operations could
be adversely affected if the Helpson brand or our reputation is impaired by recalls or negative publicity for one of our branded products,
or certain actions taken by our distributors, competitors, third-party marketing firms or relevant regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reimbursement may not be available for our
products, which could diminish our sales or affect our ability to sell our products profitably.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market acceptance and sales
of our products also depend on a large extent on the reimbursement policies of the PRC government. The Ministry of Labor and Social Security
of the PRC or provincial or local labor and social security authorities, together with other government authorities, review the inclusion
or removal of drugs from the national medical insurance catalog or provincial or local medical insurance catalogs for the National Medical
Insurance Program every other year, and catalogs under which a drug will be classified affect the amounts reimbursable to program participants
for their purchases of those medicines. These determinations are made based on a number of factors, including price and efficacy. Generally,
there are two catalogs, the National Insurance Catalogue (&#8220;NIC&#8221;) and the EDL on which a product can be included. The products
selected for the EDL generally are selected from the NIC. A consumer can be reimbursed for the full cost of a medicine on the EDL and
can be reimbursed from 80% to 90% of the cost of a medicine listed on the NIC. Our Cefalexin, Clarithromycin and Omeprazole products are
currently included in the EDL. If government authorities decide to remove these products from the medicine catalogs, such removal may
reduce the affordability of our products and change the public perception regarding our products, which, in turn, would adversely affect
the sales of these products and reduce our net revenue. Furthermore, if we are unable to obtain approval from the relevant government
authorities to include our new products in the national, provincial or local medicine catalogs, sales of our new products maybe materially
and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The growth and success of our business depend
on our ability to successfully market our principal products to hospitals and their selection in tender processes used by hospitals for
medicine purchases.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future growth and success
significantly depend on our ability to successfully market our principal products to hospitals as prescription medicines. Approximately
80% of the end-customers of our products are hospitals. Hospitals may make bulk purchases of a medicine included in the national and provincial
medicine catalogs only if that medicine is selected under a government-administered tender process. A hospital&#8217;s interest in a particular
medicine is evidenced by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the inclusion of this medicine
on the hospital&#8217;s formulary, which establishes the scope of medicines physicians at this hospital may prescribe to their patients,
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the willingness of physicians
at a hospital to prescribe this medicine to their patients.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe effective marketing
efforts are critical in ensuring that hospitals and physicians are interested in purchasing our products. If our marketing efforts are
not effective, hospital administrators may not want to include our products in their formularies or may remove them from their formularies,
or physicians may not be interested in prescribing our products to their patients. As a result, we may find it difficult to maintain the
existing level of sales of our products, and our revenues and profitability may decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future research and development projects
may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The successful development
of pharmaceutical products can be influenced by many factors. Products that appear to be promising in their early phases of research and
development may fail to be commercially viable for various reasons, such as failing to obtain the necessary regulatory approvals. Additionally,
the research and development process for new products for which we may obtain an approval certificate is long. The process of conducting
basic research and various stages of tests and trials of a new product before obtaining an approval certificate and commercializing the
product may require ten years or longer. A few of our product candidates are in the early stages of pre-clinical study and clinical trials
and we must conduct a significant number of additional clinical trials before we can seek the regulatory approvals necessary to begin
commercial production and sales of these products. We cannot guarantee that our future research and development projects will be successful
or completed within their anticipated time frames or budgets, or that we will receive the necessary approvals from the relevant authorities
for the production of these products, or that these newly-developed products will achieve commercial success.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may obtain
approval for a competitive product before our product we are developing is approved. If this occurs, we may be precluded from getting
approval until the competitor&#8217;s monitoring period expires and realize little to no benefit from our research and development investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if such products can
be successfully commercialized, they may not achieve the level of market acceptance that we expect. Additionally, the pharmaceutical industry
is characterized by rapid changes in technology, constant enhancements of industry know-how and the frequent emergence of new products.
Future technological improvements and continual product developments in the pharmaceutical market may render our existing products obsolete
or affect their viability and competitiveness. Therefore, our future success will largely depend on our development capability, including
our ability to improve our existing products, diversify our product range and develop new and competitively-priced products that meet
the requirements of the changing market. Should we fail to respond to these frequent technological advances by failing to improve our
existing products, develop new products in a timely manner, or have these products reach a desirable level of market acceptance, our business
and profitability will be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cooperate with research institutions
and universities in the PRC for the research and development of certain new products and any failure of such research institutions to
meet our timing and quality standards may pose impairment loss on our financial results and our failure to continue such collaborative
arrangement or enter into such new arrangements could adversely affect our ability to develop new pharmaceuticals and our overall business
prospects</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
collaborating with third parties for the research and development of new products. We have maintained long-term cooperative relationships
with a number of research institutions and universities in the PRC. These research institutions and universities used to collaborate with
us in a number of research projects and certain of our products with approval certificates were developed by such research institutions.
Any failure of such research institutions to meet the required quality standards and timetables set forth in their research agreements
with us, or our inability to enter into additional research agreements with these research institutions on terms acceptable to us in the
future, may have an adverse effect on our ability to develop new medicines and on our business prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Company may resume
the development of these formulas in the future if sufficient funding and other favorable conditions arise, we cannot guarantee that we
will be able to enter into agreements with new parties on terms acceptable to us. Our inability to enter into such agreements or our failure
to maintain such arrangements could limit the number of new products that we develop and ultimately decrease our sources of future revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to obtain regulatory
approval for any of the new products and failure to obtain these approvals could materially harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All new medicines must be
approved by the NMPA before they can be marketed and sold in the PRC. The NMPA requires successful completion of clinical trials and demonstrated
manufacturing capability before it grants approval. It often takes a number of years before a medicine can be ultimately approved by the
NMPA. In addition, the NMPA and other regulatory authorities may apply new standards for safety, manufacturing, packaging, and distribution
of future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Complying with such standards
may be time-consuming and expensive and could result in delays in obtaining NMPA approval for our future product candidates, or possibly
preclude us from obtaining NMPA approval altogether. For example, due to the enhanced criteria introduced during the implementation process
of the trial of one of our products in the dried powder injectable and granule production lines in our old plant, the clinical trials
lasted longer than originally expected. Furthermore, our future products may not be effective or may prove to have undesirable or unintended
side effects, toxicities or other characteristics that may preclude us from obtaining regulatory approval and prevent or limit their commercial
use. The NMPA and other regulatory authorities may not approve the products that we develop and even if we do obtain regulatory approvals,
such regulatory approvals may be subject to limitations on the indicated uses for which we may market a product, which may limit the size
of the market for such product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New product development in the pharmaceutical
industry is time-consuming and costly and has a low rate of successful commercialization</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends in part
on our ability to improve our existing products and to develop new products. The development process for pharmaceutical products is complex
and uncertain, as well as time-consuming and costly. Relatively few research and development programs can finally develop a commercial
product. A product candidate that appears promising in the early phases of development may fail to reach the market for a number of reasons,
such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the failure to demonstrate safety
and efficacy in preclinical and clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the failure to obtain approvals
for intended use from relevant regulatory bodies, such as the NMPA;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our inability to manufacture
and commercialize sufficient quantities of the product economically; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">proprietary rights, such as
patent rights, held by others to our product candidates and their refusal to sell or license such rights to us on reasonable terms, or
at all.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delays in any part of the
development process or our inability to obtain regulatory approval of our products could adversely affect our operating results by restricting
or delaying our introduction of new products. Even if we successfully commercialize new products, these products may compete with our
mature products and may result in a reduction in the sales volume of our mature product or vice versa. Failure to develop, obtain necessary
regulatory clearances or approvals for or successfully commercialize or market potential new products or technologies could have a material
adverse effect on our financial condition and results of operations.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to successfully identify
and acquire new products or businesses</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our own product
development efforts, our growth strategy also relies on our acquisitions of new product candidates, products or businesses from third
parties. Any future growth through acquisitions will be dependent upon the continued availability of suitable acquisition candidates at
favorable prices and favorable terms and conditions. Even if such opportunities present themselves, we may not be able to successfully
identify them. Moreover, other companies, many of which may have substantially greater financial, marketing and sales resources, are competing
with us for the right to acquire such product candidates, products or businesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on distributors for all of our revenues
and failure to maintain relationships with our distributors or to otherwise expand our distribution network would materially and adversely
affect our business</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We sell our products exclusively
to pharmaceutical distributors in the PRC and rely on distributors for all of our revenues. We have business relationships with over 1,000
distributors in the PRC. For the year ended December 31, 2022, no customer accounted for more than 10.0% of sales, and three customers
accounted for 52.9%, 11.4%, and 10.4% of accounts receivable. In line with industry practices in the PRC, we enter into written sales
agreements with our distributors. However, such sales agreements are not in substance equivalent to a typical distribution agreement in
the United States. Each sales agreement is more in the form of a sales order and specifies one or several purchases of one or more products
without any continuing obligation to purchase any additional amount of products. In the event certain distributors choose not to continue
their relationship with us after completing their existing sales agreements, they can do so without breaching any contract or agreement,
our financial results could be adversely affected if we cannot find the substantially similar distributors in time under such circumstances.
In addition, some of our distributors may sell products that compete with our products. We compete for desired distributors with other
pharmaceutical manufacturers, many of which may have higher visibility, greater name recognition, financial resources, and broader product
selection than we do. Consequently, maintaining relationships with existing distributors and replacing distributors may be difficult and
time-consuming. Any disruption of our distribution network, including our failure to renew our existing distribution agreements with our
desired distributors, could negatively affect our ability to effectively sell our products and would materially and adversely affect our
business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on a limited number of distributors
for the majority of sales of our products</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on a limited number
of distributors for most of our net revenue. Our top five distributors in aggregate accounted for 20% and 21% of our net revenues in 2022
and 2021, respectively. We expect that a relatively small number of distributors will continue to account for a major portion of our net
revenue in the near future. Our dependence on a few distributors may expose us to the risk of substantial losses if a single large distributor
stops purchasing our products, purchases lower quantities of our products or goes out of business and we cannot find substitute distributors
on equivalent terms. If any of our large distributors reduces the quantity of the products they purchase from us or stops purchasing from
us, our net revenue would be materially and adversely affected.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operations may be affected if we could
not pass the Consistency Evaluation requirement issued by the State Council for any of our current existing products.</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generic drugs refer to drugs
with the same active ingredient, dosage form, delivery channel and therapeutic effects compared to the original drugs. The &#8220;Consistency
Evaluation&#8221; requires currently marketed generic products to prove their consistency in term of quality and therapeutic effect, and
substitutability during clinical trials with original drug. The Consistency Evaluation could enhance the development of pharmaceutical
industry, ensure drug safety and effectiveness, promote the upgrading and restructuring the pharmaceutical industry, and improve international
competitiveness. Both <i>Relevant Matters Related to the Implementation of the Opinions of the General Office of the State Council on
the Consistent Evaluation of the Quality and Efficacy of Generic Drugs</i> (No. 106 of 2016) issued on May 26, 2016, and <i>Announcement
of the General Administration on the Consistency Evaluation of the Quality and Efficacy of Generic Drugs</i> (No. 100 of 2017) issued
on August 28, 2017 require that if a drug has more than 3 manufacturers passed the consistency evaluation, then the drug manufacturers
without consistency evaluation valid status will have no access to participate in the drug Centralized Procurement. NMPA issued an official
document on The Implementation of the Evaluation of the Quality and Efficacy of Chemical Injection Generics on May 14, 2020, requiring
consistent evaluation for generics of pharmaceutical injections that are already on the market. If we fail to complete the consistency
evaluations for our generic drugs per the government&#8217;s requirements, our business and operation will be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operations may be affected if we could
not obtain raw materials from our current key suppliers on acceptable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We need a supply of a wide variety of raw materials to manufacture
our products. Currently, we rely on numerous suppliers in the PRC and overseas to deliver our required raw materials. We have at least
three principal suppliers for each of our most critical raw materials. For the year ended December 31, 2022, three suppliers accounted
for 21.7%, 11.1%, and 8.9% of raw material purchases and for the year ended December 31, 2021, three suppliers accounted for 24.8%, 12.7%,
and 11.8% of raw material purchases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have not
had difficulty obtaining raw materials from suppliers. However, we cannot assure in the future we will not encounter any difficulty in
obtaining the supplies, nor can we predict the impact on our suppliers of the current economic environment and other developments in their
respective businesses, either. Insolvency, financial difficulties or other factors may result in our suppliers not being able to fulfill
the terms of their agreements with us. Furthermore, such factors may render suppliers unwilling to extend contracts that provide favorable
terms to us or may force them to seek to renegotiate existing contracts. Although we believe we have alternative sources of supply for
the raw materials used in our business, termination of our relationships with any of our key suppliers could have a material adverse effect
on our business, financial condition or results of operations in the unlikely event that we are unable to obtain adequate raw materials
from other sources in a timely manner or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to effectively manage
our employees and distribution network, and our reputation, business, prospects and brand may be materially and adversely affected by
actions taken by our distributors and third party marketing firms.</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited ability to
manage and control the activities of our independent distributors and third-party marketing firms that we contract to promote our products
and brand name, therefore, our reputation, business, prospects and brand may be materially and adversely affected by actions taken by
them. Our distributors and third-party marketing firms could take one or more of the following actions, any of which could have a material
adverse effect on our business, prospects and brand:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">sell our products outside their
designated territory, possibly in violation of the exclusive distribution rights of other distributors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">fail to adequately promote our
products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">promote competing products in
lieu of our products; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">violate the anti-corruption
laws of China, the United States or other countries.</span></td>
</tr></table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, although our
company policies prohibit our employees from making improper payments to hospitals or otherwise engaging in improper activities to influence
the procurement decisions of hospitals, we may not be able to effectively manage our employees, as the compensation of our sales and marketing
personnel is partially linked to their sales performance. As a result, we cannot assure you that our employees will not violate the anticorruption
laws of the PRC, the United States and other countries. Such violations could have a material adverse effect on our reputation, business,
prospects and brand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to adequately manage
our employees, distribution network or third-party marketing firms, or their non-compliance with employment, distribution or marketing
agreements could harm our corporate image among hospitals and end users of our products and disrupt our sales, resulting in a failure
to meet our sales goals. Furthermore, we could be liable for actions taken by our employees, distributors or third-party marketing firms,
including any violations of applicable law in connection with the marketing or sale of our products, including China&#8217;s anticorruption
laws and the Foreign Corrupt Practices Act of the United States, or the FCPA. In particular, if our employees, distributors or third-party
marketing firms make any payments that are forbidden under the FCPA, we could be subject to civil and criminal penalties imposed by the
U.S. government.</p><div>




</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, the PRC government
has increased its anti-corruption measures. In the pharmaceutical industry, corrupt practices include, among others, acceptance of rebates,
bribes or other illegal gains or benefits by hospitals and medical practitioners from pharmaceutical manufacturers and distributors in
connection with the prescription of certain pharmaceuticals. Our employees, affiliates, distributors or third-party marketing firms may
violate these laws or otherwise engage in illegal practices with respect to their sales or marking of our products or other activities
involving our products. If our employees, affiliates, distributors or third-party marketing firms violate these laws, we could be required
to pay damages or fines, which could materially and adversely affect our financial condition and results of operations. In addition, PRC
laws regarding the types of payments to promote or sell our products that are impermissible are not always clear. As a result, we, our
employees, affiliates, our distributors or third-party marketing firms could make certain payments in connection with the promotion or
sale of our products or other activities involving our products which at the time could be reasonably determined to be legal but are later
deemed impermissible by the PRC government. Furthermore, our brand and reputation, our sales activities or the price of our common stock
could be adversely affected if we become the target of any negative publicity as a result of actions taken by our employees, affiliates,
distributors or third-party marketing firms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited insurance coverage and may
incur losses resulting from product liability claims, business interruptions or claims that could be covered by D&amp;O Insurance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The nature of our business
exposes us to the risk of product liability claims that is inherent in the research and development, manufacturing and marketing of pharmaceutical
products. Using product candidates in clinical trials also exposes us to product liability claims. These risks are greater for our products
that receive regulatory approval for commercial sale. Even if a product is approved for commercial use by an appropriate governmental
agency, there can be no assurance that users will not claim effects other than those intended resulted from the use of our products. While
no material claim for personal injury resulting from allegedly defective products has been brought against us to date, a substantial claim
or a substantial number of claims, if successful, could have a material adverse impact on our business, financial condition and results
of operations. Such lawsuits may divert the attention of our management from our business strategies, may be costly to defend and may
negatively impact our reputation and our Helpson brand&#8217;s reputation, and may harm the sales of our other branded products. In addition,
product liability insurance for pharmaceutical products is not available in the PRC. In the event of allegations that any of our products
are harmful, we may experience reduced consumer demand for our products or our products may be recalled from the market. We may also be
forced to defend lawsuits and, if unsuccessful, to pay a substantial amount in damages, legal fees, and other related expenses. In addition,
business interruption insurance available in the PRC offers limited coverage compared to that offered in many other countries. We do not
have any business interruption insurance. Any business disruption or natural disaster could result in substantial costs and diversion
of resources. Lastly, we currently do not have directors and officers insurance. In the event we or any of our directors or officers are
sued under any proceedings or actions that could be covered by a standard D&amp;O insurance, we may incur substantial costs and expenses
to defend such case.</p><div>




</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future liquidity needs are uncertain
and we may need to raise additional funds in the future.</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current operating
plans, we expect our existing resources to be sufficient to fund our existing operations for at least 12 months. However, we may need
to raise additional funds to expand our operations. In addition, we may need to raise additional funds if our expenditures exceed our
current expectations. This could occur for a number of reasons, including:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we decide to devote significant
amount of financial resources to the development of products that we believe to have significant commercialization potential;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we decide to acquire or license
rights to additional product candidates or new technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">some of our product candidates
fail in clinical trials or pre-clinical studies or prove not to be as commercially promising as we expected, and we are forced to develop
or acquire additional product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Some of our product candidates
require more extensive clinical or pre-clinical testing or clinical trials for these product candidates take longer to complete than
we currently expect; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we decide or are required to
conduct more high-throughput screening than expected against current or additional disease targets to develop additional product candidates.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify">Our</td><td style="text-align: justify">ability to raise additional funds in the future is subject
to a variety of uncertainties, including:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our future financial condition,
results of operations and cash flows;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">general market conditions for
capital-raising activities by pharmaceutical companies; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">economic, political and other
conditions in China and elsewhere.</span></td>
</tr></table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
our revenues will be sufficient to meet our operational needs and capital requirements. If we need to obtain external financing, we cannot
assure you that financing will be available in amounts or on terms acceptable to us, if at all. Our future liquidity needs and other business
reasons could require us to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity or equity-linked
securities could result in additional dilution to our stockholders. The incurrence of additional indebtedness would result in increased
debt service obligations and could result in operating and financing covenants that would restrict our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The failure to manage growth effectively
could have an adverse effect on our business, financial condition and results of our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rapid market growth of
our pharmaceutical products may pose more requirements or more costs on the employment management for managerial, operational, financial
and other purposes. As of December 31, 2022, we had 244 employees. To keep rapidly increasing trend of the Chinese pharmaceutical industry,
it will impose significant responsibilities upon the members of management to identify, recruit, maintain, integrate and motivate new
and old employees In addition, we may need to increase the salary, or the equity incentive plan for the employees to keep them in the
Company. Aside from the increased difficulties and increased costs in the management of human resources, we may also encounter working
capital issues, as we need increased liquidity to finance the purchases of raw materials and supplies, drug formulas for new products,
investment in research and development, acquisition of new businesses and technologies. Our failure to manage any of the above business
administration may lead to operational and financial inefficiencies that will have a negative effect on our profitability.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon key employees and consultants
in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability
to develop and market our products.</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent upon
the principal members of our management team, especially Ms. Zhilin Li, our Chairman, President and Chief Executive Officer. We cannot
not guarantee that Ms. Li will stay in the Company in the long run, and the loss of Ms. Li&#8217;s services would adversely affect our
ability to develop and market our products. We also depend in part on the continued services of our key scientific personnel and our ability
to identify, hire and retain additional personnel, including marketing and sales staff. We face intense competition for qualified personnel,
and the existence of noncompetition agreements between prospective employees and their former employers may prevent us from hiring those
individuals or subject us to suit from their former employers. While we attempt to provide competitive compensation packages to attract
and retain key personnel, many of our competitors are likely to have greater resources and more experience than we have, making it difficult
for us to compete successfully for key personnel.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our employees and
consultants were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors,
or at universities or other research institutions. Although there is currently no claim against us, we may be subject to claims that these
employees or consultants have, inadvertently or otherwise, used or disclosed trade secrets or other proprietary information of their former
employers. It may be necessary to for us to litigate and defend against these claims. Even if we successfully defend against these claims,
litigation could result in substantial costs and be a distraction to our management. If we fail to defend such claims, in addition to
paying monetary damages, we may lose valuable intellectual property rights or personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Power shortages, natural disasters, terrorist
acts or other calamities could disrupt our production and have a material adverse effect on our business, financial position and results
of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our products are produced
at our manufacturing facility in Hainan, China. A significant disruption at that facility, even on a short-term basis, could impair our
ability to timely produce and ship products, which could have a material adverse effect on our business, financial position and results
of operations. Our manufacturing operations are vulnerable to interruption and damage from natural and other types of disasters, including
earthquake, fire, floods, environmental accidents, power loss, communications failures and similar events. If any disaster were to occur,
our ability to operate our business at our facilities would be seriously impaired. For example, a once-in-forty-year 16 grade super typhoon
Rammasun hit Haikou on July 18, 2014, which caused us approximately $2.3 million (RMB14.2 million) in losses. Part of a warehouse was
flooded, some damage was caused to our new facility, and the water and electricity supply was suspended for several days, causing a brief
halt to our production activities and a delay in our obtaining GMP certification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we do not maintain
any insurance other than property insurance for some of our buildings, vehicles and equipment. Accordingly, unexpected business interruptions
resulting from disasters could disrupt our operations and thereby result in substantial costs and diversion of resources. Our production
process requires a continuous supply of electricity. We have encountered power shortages historically due to restricted power supply to
industrial users during summers when the usage of electricity is high and supply is limited or as a result of damage to the electricity
supply network. Because the duration of those power shortages was brief, they had no material impact on our operations. Longer interruptions
of electricity supply could result in lengthy production shutdowns, increased costs associated with restarting production and the loss
of production in progress. Any major suspension or termination of electricity or other unexpected business interruptions could have a
material adverse impact on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot guarantee the protection of our
intellectual property rights, and if infringement or counterfeiting of our intellectual property rights occurs, then our reputation and
business may be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To protect the brand names
of our products, we have registered and applied for registration of certain of our trademarks in the PRC. Currently eight of the 19 pharmaceutical
products we manufacture are marketed under a brand registered as a trademark in China. We also purchased a pharmaceutical compound from
a third party that we are seeking to develop into a further product. To date, we have not experienced any infringements of our trademarks
for sales of pharmaceutical products or our exclusive patent license, and we are not aware of any infringement of our intellectual property
rights. However, there is no guarantee that there will not be any infringements of our brand name or other registered trademarks or counterfeiting
of our products in the future. There is no guarantee that there will not be any third-party infringement of our patents. Should any such
infringement or counterfeiting occur, our reputation and business may be adversely affected. We may also incur significant expenses and
substantial amounts of time and effort to protect our intellectual property rights in the future. Such diversion of our resources may
adversely affect our existing business and future expansion plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Litigation may be necessary
in the future to enforce our intellectual property rights or to determine the validity and scope of the intellectual property rights of
others. However, because the validity, enforceability and scope of protection of intellectual property rights in the PRC are uncertain
and still evolving, we may not be successful in prosecuting these cases. In addition, any litigation or proceeding or other efforts to
protect our intellectual property rights could result in substantial costs and diversion of our resources and could seriously harm our
business and operating results. Furthermore, the degree of future protection of our proprietary rights is uncertain and may not adequately
protect our rights or permit us to gain or keep our competitive advantage. If we are unable to protect our trade names, trade secrets
and other propriety information from infringement, our business, financial condition and results of operations may be materially and adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Doing Business in China</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adverse changes in political and economic
policies of the PRC government could have a material and adverse effect on the overall economic growth of China, which could reduce the
demand for our services and materially and adversely affect our competitive position.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conduct substantially all
of our business and have historically derived all of our revenues in China. Accordingly, our business, financial condition, results of
operations and prospects are affected significantly by economic, political and legal developments in China. The Chinese economy differs
from the economies of most developed countries in many respects, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the degree of government involvement;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the level of development;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the growth rate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the control of foreign exchange;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">access to financing; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the allocation of resources.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Chinese economy
has experienced significant growth in the past 30 years, growth has been uneven, both geographically and among various sectors of the
economy. The Chinese economy has also experienced certain adverse effects due to the recent global financial crisis. The Chinese government
has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures benefit the
overall Chinese economy, but may also have a negative effect on us. For example, our operating results and financial condition may be
adversely affected by government control over capital investments or changes in tax regulations that are applicable to us, and by government
policies or guidance aimed at curtailing the perceived over-capacity of certain industry sectors, such as pharmaceutical companies. The
Chinese government has implemented certain measures, including interest rate increases, to control the pace of economic growth. These
measures may cause decreased economic activity in China, which could in turn reduce the demand for our products and materially and adversely
affect our operating results and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China&#8217;s economy has
been transitioning from a planned economy to a more market-oriented economy. Although in recent years the Chinese government has implemented
measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets and the
establishment of sound corporate governance in business enterprises, a substantial portion of the productive assets in China is still
owned by the Chinese government. The continued control of these assets and other aspects of the national economy by the Chinese government
could materially and adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Chinese government also
exercises significant control over China&#8217;s economic growth through the allocation of resources, controlling payment of foreign currency-denominated
obligations, setting monetary policy and providing preferential treatment to particular industries or companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any adverse change in the
economic conditions or government policies in China could have a material and adverse effect on overall economic growth and the level
of investments in health industries in China, which in turn could lead to a reduction in demand for our products and consequently have
a material and adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The PRC legal system has inherent uncertainties
that could limit the legal protections available to us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC legal system is a
civil law system based on written statutes. Unlike common law systems, it is a system in which decided legal cases have little precedential
value. In the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing commercial matters.
The overall effect of legislation enacted over the past 20 years has significantly enhanced the protections afforded to foreign-invested
enterprises in China. However, these laws, regulations and legal requirements are relatively recent and are evolving rapidly, and their
interpretation and enforcement involve uncertainties. These uncertainties could limit the legal protections available to foreign investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The practical effect of the
PRC legal system on our business operations in China can be viewed as two separate but intertwined considerations. First, as a matter
of substantive law, the Foreign Invested Enterprise laws provide significant protection from government interference. In addition, these
laws guarantee the full benefit of corporate articles and contracts to foreign invested enterprise participants. These laws, however,
do impose standards concerning corporate formation and governance that are not qualitatively different from the corporation laws found
in the United States. Similarly, PRC accounting laws mandate accounting practices that may not be consistent with the U.S. generally accepted
accounting principles. PRC accounting laws require that an annual &#8220;statutory audit&#8221; be performed in accordance with PRC accounting
standards and that the account books of a foreign invested enterprise be maintained in accordance with PRC accounting laws. Article 14
of the PRC Wholly Foreign-Owned Enterprise Law requires a wholly foreign-owned enterprise to submit certain periodic fiscal reports and
statements to designated financial and tax authorities. If a foreign-invested enterprise refuses to keep account books in China, the financial
and tax authorities may impose a fine on it, and the industry and commerce administration authority may order it to suspend operations
or may revoke its business license.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Second, while the enforcement
of substantive rights may be less clear than United States procedures, foreign-invested enterprises and foreign wholly-owned enterprises
are PRC registered companies that enjoy the same status as other PRC registered companies in business-to-business dispute resolutions.
The PRC legal infrastructure, however, is significantly different in operation from its United States counterpart, and may present a significant
impediment to the operation of a foreign invested enterprise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience difficulties in effecting
service of legal process, enforcing foreign judgments or bringing original actions in the PRC against our company or our management based
on U.S. or other foreign laws.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating subsidiary,
Helpson, is incorporated under the laws of the PRC and substantially all of our assets are located in the PRC. Additionally, substantially
all of our directors, executive officers and managers reside within the PRC, and substantially all assets of these persons are located
within the PRC. As a result, it may not be possible to effect service of process within the United States or elsewhere outside the PRC
upon certain of our directors, executive officers or managers, including with respect to matters arising under U.S. federal securities
laws or applicable state securities laws. Moreover, the PRC does not have treaties providing for the reciprocal recognition and enforcement
of judgments of courts with the United States, the United Kingdom, Japan or many other countries. As a result, recognition and enforcement
in the PRC of judgments of a court in the United States and any of the other jurisdictions mentioned above in relation to any matter may
be difficult or impossible. Furthermore, an original action may be brought in the PRC against us, our directors, executive officers or
managers only if the actions are not required to be arbitrated by PRC law under Helpson&#8217;s articles of association, and only if the
facts alleged in the complaint give rise to a cause of action under PRC law. In connection with any such original action, a PRC court
may impose civil liability, including monetary damages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a Foreign Invested Company in China,
Helpson&#8217;s ownership structure may be impacted by the foreign investment regulation and its measures in China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Decree
No. 723 of the State Council of the People&#8217;s Republic of China issued on December 26, 2019, the Regulations on the Implementation
of the Foreign Investment Law of the People&#8217;s Republic of China came into force on January 1, 2020. On December 28, 2020, the National
Development and Reform Commission and the Ministry of Commerce publicly released the Directory of Industries to Encourage Foreign Investment
(Encouraged Catalogue) (2020 Edition). On December 27, 2021, the National Development and Reform Commission of China (&#8220;NDRC&#8221;)
and the Ministry of Commerce (&#8220;MOFCOM&#8221;) jointly issued the Special Administrative Measures for Foreign Investment Access (Negative
List) (2021 Edition), and the Special Administrative Measures for Foreign Investment Access in Pilot Free Trade Zones (Negative List)
(2021 Edition), effective January 1, 2022. As per these policies, the national negative list of foreign investment access was reduced
from 33 to 31, and the negative list of foreign investment access in the FTZ was reduced from 30 to 27. Industries listed in the 2020
Encouraged Catalogue are the encouraged industries. On the other hand, industries listed in the 2021 Negative List are subject to special
management measures. For example, establishment of wholly foreign-owned enterprises is generally allowed in industries outside of the
2021 Negative List. Also, foreign investors are not allowed to invest in industries that are expressly prohibited in the 2021 Negative
List. The industries that are not expressly prohibited in the Negative List are still subject to government approvals and certain special
requirements.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The majority of pharmaceutical manufacturing industry
including the segments under which the Company conducts its business is not included in the 2021 Negative List. Helpson manufactures and
markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located
throughout the PRC. The Company believes Helpson&#8217;s business is not subject to any ownership restrictions prescribed under the Catalogue.
Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#8217;s three
former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the
Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business
license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005. However, in the event the 2021 Negative List is
amended in the future to include any of the business Helpson is operating, our ownership structure could be subject to change to the extent
our structure is not given any &#8220;grandfather&#8221; protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because we receive substantially all of
our revenue in Renminbi, which currently is not a freely convertible currency, and the PRC government controls the currency conversion
and the fluctuation of the Renminbi, we are subject to changes in the PRC&#8217;s political and economic decisions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We receive substantially all
of our revenues in Renminbi, which currently is not a freely-convertible currency. The PRC government may, at its discretion, restrict
access in the future to foreign currencies for current account transactions. Any future restrictions on currency exchanges may limit our
ability to use revenue generated in Renminbi to fund any future business activities outside China or to make dividend or other payments
in U.S. dollars. Although the Chinese government introduced regulations in 1996 to allow greater convertibility of the Renminbi for current
account transactions, significant restrictions still remain, including primarily the restriction that foreign-invested enterprises may
only buy, sell or remit foreign currencies, after providing valid commercial documents, at those banks authorized to conduct foreign exchange
business. In addition, conversion of Renminbi for capital account items, including direct investment and loans, is subject to governmental
approval in China, and companies are required to open and maintain separate foreign exchange accounts for capital account items.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot be certain that the Chinese regulatory
authorities will not impose more stringent restrictions on the convertibility of the Renminbi, especially with respect to foreign exchange
transactions.</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fluctuation in the value of
the Renminbi may have a material and adverse effect on your investment. The change in value of the Renminbi against the U.S. dollar is
affected by, among other things, changes in PRC&#8217;s political and economic conditions. From 1995 until July 2005, the People&#8217;s
Bank of China intervened in the foreign exchange market to maintain an exchange rate of approximately Renminbi 8.3 per U.S. dollar. On
July 21, 2005, the PRC government changed this policy and began allowing modest appreciation of the Renminbi versus the U.S. dollar. Under
the new policy, the Renminbi was permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies.
This change in policy caused the Renminbi to appreciate approximately 21.5% against the U.S. dollar over the following three years. As
a consequence, the Renminbi has fluctuated sharply since July 2008 against other freely traded currencies, in tandem with the U.S. dollar.
It is difficult to predict how long the current situation may last and when and how it may change again. There is significant international
pressure on the PRC government to adopt a substantial liberalization of its currency policy, which could result in a further and more
significant appreciation in the value of the Renminbi against the U.S. dollar. Significant revaluation of the Renminbi may have a material
adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we receive from securities offering
into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount
we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments
for dividends on our common stock or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative
effect on the U.S. dollar amount available to us. In August 2015, the PRC Government devalued its currency by approximately 3%, represented
the largest yuan depreciation for 20 years. Concerns remain that China&#8217;s slowing economy, and in particular its exports, will need
a stimulus that can only come from further cuts in the exchange rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, appreciation
or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms
without giving effect to any underlying change in our business or results of operations. The income statements of our operations are translated
into U.S. dollars at the average exchange rates in each applicable period. To the extent the U.S. dollar strengthens against foreign currencies,
the translation of these foreign currencies denominated transactions results in reduced revenue, operating expenses and net income for
our international operations. Similarly, to the extent the U.S. dollar weakens against foreign currencies, the translation of these foreign
currency denominated transactions results in increased revenue, operating expenses and net income for our international operations. We
are also exposed to foreign exchange rate fluctuations as we convert the financial statements of our foreign subsidiaries into U.S. dollars
in consolidation. If there is a change in foreign currency exchange rates, the conversion of the foreign subsidiaries&#8217; financial
statements into U.S. dollars will lead to a translation gain or loss, which is recorded as a component of other comprehensive income.
Very limited hedging transactions are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered
into any hedging transactions. While we may enter into hedging transactions in the future, the availability and effectiveness of these
transactions may be limited, and we may not be able to successfully hedge our exposure at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to the environmental protection
laws of the PRC that may be costly to comply with and may adversely affect our manufacturing operations.</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing process
may produce by-products, such as effluent, gases and noise, which are harmful to the environment. We are subject to multiple laws governing
environmental protection, such as &#8220;The Law on Environmental Protection in the PRC&#8221; and &#8220;The Law on Prevention of Effluent
Pollution in the PRC,&#8221; as well as standards set by the relevant governmental bodies determining the classification of different
wastes and proper disposal. We have properly attained a waste disposal permit for our manufacturing facility, which details the types
and concentration of effluents and gases allowed for disposal. We are responsible for periodically renewing this waste disposal permit.
There is no assurance that we will obtain a renewal of the waste disposal permit when the current permit expires in February 2028.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China is experiencing substantial
problems with environmental pollution. Accordingly, it is likely that the national, provincial and local governmental agencies will adopt
stricter pollution controls. There is no guarantee that future changes in environmental laws and regulations will not impose costly compliance
requirements on us or otherwise subject us to future liabilities. Our business&#8217;s profitability may be adversely affected if additional
or modified environmental control regulations are imposed upon us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with PRC regulations regarding
the registration requirements for employee equity incentive plans may subject our PRC citizen employees or us to fines and other legal
or administrative sanctions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 28, 2007, the SAFE
promulgated the Application Procedure of Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock Holding
Plan or Share Option Plan of Overseas-Listed Company, which were superseded by Notice from SAFE regarding Issues related to Domestic Individual
Participating Offshore Public Company Equity Incentive Plan promulgated on February 15, 2012 (&#8220;SAFE #7&#8221;), or the Share Option
Rule. Under the Share Option Rule, PRC citizens who are granted stock options or other employee equity incentive awards by an overseas
publicly-listed company are required, through a PRC agent who may be a PRC subsidiary of such overseas publicly-listed company, to register
with the SAFE and complete certain other procedures related to the share options or other employee equity incentive plans. We and our
PRC citizen employees who are granted share options or other equity incentive awards under our 2010 Long-Term Incentive Plan, or PRC optionees,
are subject to the Share Option Rule. If we or our PRC optionees fail to comply with these regulations, we or our PRC optionees may be
subject to fines and legal sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. regulatory bodies may be limited
in their ability to conduct investigations or inspections of our operations in China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any disclosure of documents
or information located in China by foreign agencies may be subject to jurisdiction constraints and must comply with China&#8217;s state
secrecy laws, which broadly define the scope of &#8220;state secrets&#8221; to include matters involving economic interests and technologies.
There is no guarantee that requests from U.S. federal or state regulators or agencies to investigate or inspect our operations will be
honored by us, by entities who provide services to us or with whom we associate, without violating PRC legal requirements, especially
as those entities are located in China. Furthermore, under the current PRC laws, an on-site inspection of our facilities by any of these
regulators may be limited or prohibited.&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PRC regulation of loans to and direct investment
in PRC entities by offshore holding companies and governmental control of currency conversion may delay us from using the proceeds of
this offering to make loans or additional capital contributions to our PRC subsidiaries, which could materially and adversely affect our
liquidity and our ability to fund and expand our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any funds the Company transfer
to our PRC subsidiaries, either as a shareholder loan or as an increase in registered capital, are subject to approval by or registration
with relevant governmental authorities in China. According to the relevant PRC regulations on foreign-invested enterprises, or FIEs, in
China, capital contributions to our PRC subsidiaries are subject to the approval of or filing with the Ministry of Commerce, or MOFCOM
or its local branches and registration with a local bank authorized by the State Administration of Foreign Exchange, or SAFE. In addition,
(i) a foreign loan of less one year duration procured by our PRC subsidiaries is required to be registered with SAFE or its local branches
and (ii) a foreign loan of one year duration or more procured by our PRC subsidiaries is required to be applied to the NDRC in advance
for undergoing recordation registration formalities. Any medium or long-term loan to be provided by us to our PRC operating subsidiaries,
must be registered with the NDRC and the SAFE or its local branches. The Company may not be able to complete such registrations on a timely
basis, with respect to future capital contributions or foreign loans by us to our PRC Subsidiary. If the Company fail to complete such
registrations, our ability to use the proceeds of this offering and to capitalize our PRC operations may be negatively affected, which
could adversely affect our liquidity and our ability to fund and expand our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 30, 2015, the SAFE
promulgated the Circular on Reforming the Management Approach Regarding the Foreign Exchange Capital Settlement of Foreign-Invested Enterprises,
or SAFE Circular 19, which took effect as of June 1, 2015. SAFE Circular 19 launched a nationwide reform of the administration of the
settlement of the foreign exchange capitals of FIEs and allows FIEs to settle their foreign exchange capital at their discretion, but
continues to prohibit FIEs from using the Renminbi fund converted from their foreign exchange capital for expenditure beyond their business
scopes, providing entrusted loans or repaying loans between nonfinancial enterprises. The SAFE issued the Circular on Reforming and Regulating
Policies on the Control over Foreign Exchange Settlement of Capital Accounts, or SAFE Circular 16, effective in June 2016. Pursuant to
SAFE Circular 16, enterprises registered in China may also convert their foreign debts from foreign currency to Renminbi on a self-discretionary
basis. SAFE Circular 16 provides an integrated standard for conversion of foreign exchange under capital account items (including but
not limited to foreign currency capital and foreign debts) on a self-discretionary basis which applies to all enterprises registered in
China. SAFE Circular 16 reiterates the principle that Renminbi converted from foreign currency-denominated capital of a company may not
be directly or indirectly used for purposes beyond its business scope or prohibited by PRC laws or regulations, while such converted Renminbi
shall not be provided as loans to its non-affiliated entities. As this circular is relatively new, there remains uncertainty as to its
interpretation and application and any other future foreign exchange related rules. Violations of these Circulars could result in severe
monetary or other penalties. SAFE Circular 19 and SAFE Circular 16 may significantly limit our ability to use Renminbi converted from
the net proceeds of this offering to fund our PRC operating subsidiary, to invest in or acquire any other PRC companies through our PRC
Subsidiary, which may adversely affect our business, financial condition and results of operations.&#160;&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Compliance with
China&#8217;s new Data Security Law, Measures on Cybersecurity Review, Personal Information Protection Law (second draft for consultation),
regulations and guidelines relating to the multi-level protection scheme and any other future laws and regulations may entail significant
expenses and could materially affect our business.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">China
has implemented or will implement rules and is considering a number of additional proposals relating to data protection. China&#8217;s
new Data Security Law took effect in September 2021. The Data Security Law provides that the data processing activities must be conducted
based on &#8220;data classification and hierarchical protection system&#8221; for the purpose of data protection and prohibits entities
in China from transferring data stored in China to foreign law enforcement agencies or judicial authorities without prior approval by
the Chinese government.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Additionally, China&#8217;s Cyber Security Law requires companies to
take certain organizational, technical and administrative measures and other necessary measures to ensure the security of their networks
and data stored on their networks. Specifically, the Cyber Security Law provides that China adopt a multi-level protection scheme (MLPS),
under which network operators are required to perform obligations of security protection to ensure that the network is free from interference,
disruption or unauthorized access, and prevent network data from being disclosed, stolen or tampered. Under the MLPS, entities operating
information systems must have a thorough assessment of the risks and the conditions of their information and network systems to determine
the level to which the entity&#8217;s information and network systems belong-from the lowest Level&#160;1 to the highest Level&#160;5
pursuant to a series of national standards on the grading and implementation of the classified protection of cyber security. The grading
result will determine the set of security protection obligations that entities must comply with. Entities classified as Level&#160;2 or
above should report the grade to the relevant government authority for examination and approval. The Company&#8217;s management believes
that they are currently classified as Level 1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Recently,
the Cyberspace Administration of China has taken action against several Chinese internet companies in connection with their initial public
offerings on U.S. securities exchanges, for alleged national security risks and improper collection and use of the personal information
of Chinese data subjects. According to the official announcement, the action was initiated based on the National Security Law, the Cyber
Security Law and the Measures on Cybersecurity Review, which are aimed at &#8220;preventing national data security risks, maintaining
national security and safeguarding public interests.&#8221; On July 10, 2021, the Cyberspace Administration of China published a revised
draft of the Measures on Cybersecurity Review, expanding the cybersecurity review to data processing operators in possession of personal
information of over 1 million users if the operators intend to list their securities in a foreign country. As we are not a data processing
operator in possession of person information, we are not within the expanded scope.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>


</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">It
is unclear at the present time how widespread the cybersecurity review requirement and the enforcement action will be and what effect
they will have on our business. China&#8217;s regulators may impose penalties for non-compliance ranging from fines or suspension of operations,
and this could lead to us delisting from the U.S. stock market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Also, recently, the National People&#8217;s Congress released the Personal
Information Protection Law (the &#8220;PIPL&#8221;), which became effective on November 1, 2021. The PIPL creates a comprehensive set
of data privacy and protection requirements that apply to the processing of personal information and expands data protection compliance
obligations to cover the processing of personal information of persons by organizations and individuals in China, and the processing of
personal information of persons in China outside of China if such processing is for purposes of providing products and services to, or
analyzing and evaluating the behavior of, persons in China. The PIPL also provides that critical information infrastructure operators
and personal information processing entities who process personal information meeting a volume threshold to-be-set by Chinese cyberspace
regulators are also required to store in China personal information generated or collected in China, and to pass a security assessment
administered by Chinese cyberspace regulators for any export of such personal information. Lastly, the PIPL provides significant fines
for serious violations of up to RMB 50 million or 5% of annual revenues from the prior year and may also be ordered to suspend any related
activity by competent authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Interpretation,
application and enforcement of these laws, rules and regulations evolve from time to time and their scope may continually change, through
new legislation, amendments to existing legislation and changes in enforcement. Compliance with the Cyber Security Law and the Data Security
Law could significantly increase the cost to us of providing our service offerings, require significant changes to our operations or even
prevent us from providing certain service offerings in jurisdictions in which we currently operate or in which we may operate in the future.
Despite our efforts to comply with applicable laws, regulations and other obligations relating to privacy, data protection and information
security, it is possible that our practices, offerings or platform could fail to meet all of the requirements imposed on us by the Cyber
Security Law, the Data Security Law and/or related implementing regulations. Any failure on our part to comply with such law or regulations
or any other obligations relating to privacy, data protection or information security, or any compromise of security that results in unauthorized
access, use or release of personally identifiable information or other data, or the perception or allegation that any of the foregoing
types of failure or compromise has occurred, could damage our reputation, discourage new and existing counterparties from contracting
with us or result in investigations, fines, suspension or other penalties by Chinese government authorities and private claims or litigation,
any of which could materially adversely affect our business, financial condition and results of operations. Even if our practices are
not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm our reputation and brand and adversely
affect our business, financial condition and results of operations. Moreover, the legal uncertainty created by the Data Security Law and
the recent Chinese government actions could materially adversely affect our ability, on favorable terms, to raise capital, including engaging
in follow-on offerings of our securities in the U.S. market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We are not required to submit an application to CSRC pursuant to the
M&amp;A Rules, nor are we subject to the cybersecurity review. However, based on the recent promulgation of the Trial Measures, which
are set to be effective on March 31, 2023, we may be required to complete the filing requirements when we have re-financing or any additional
offerings in future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory
agencies in 2006 and amended in 2009, require an overseas special purpose vehicle formed for listing purposes through acquisitions of
PRC domestic companies and controlled by PRC companies or individuals to obtain the approval of the CSRC prior to the listing and trading
of such special purpose vehicle&#8217;s securities on an overseas stock exchange. In September 2006, the CSRC published a notice on its
official website specifying documents and materials required to be submitted to it by a special purpose vehicle seeking CSRC approval
of its overseas listings. However, substantial uncertainty remains regarding the scope and applicability of the M&amp;A Rules to offshore
special purpose vehicles. Currently, there is no consensus among leading PRC law firms regarding the scope and applicability of the CSRC
approval requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Based on our understanding of the Chinese laws and regulations in effect
at the time of this report, we will not be required to submit an application to the CSRC for its approval of an offering in a foreseeable
future and the listing and trading of our common stock on NYSE American. However, there remains some uncertainty as to how the M&amp;A
Rules will be interpreted or implemented in the context of an overseas offering and our belief is subject to any new laws, rules and regulations
or detailed implementations and interpretations in any form relating to the M&amp;A Rules or overseas offering approval. We cannot assure
you that relevant PRC governmental agencies, including the CSRC, would reach the same conclusion as we do.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Recently, the General Office of the Central Committee
of the Communist Party of China and the General Office of the State Council jointly issued the &#8220;Opinions on Severely Cracking Down
on Illegal Securities Activities According to Law,&#8221; or the Opinions, which was made available to the public on July 6, 2021. The
Opinions emphasized the need to strengthen the administration over illegal securities activities, and the need to strengthen the supervision
over overseas listings by Chinese companies. Effective measures, such as promoting the construction of relevant regulatory systems will
be taken to deal with the risks and incidents of China-concept overseas listed companies, and cybersecurity and data privacy protection
requirements and similar matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On December&#160;28, 2021, the CAC, and other
twelve PRC regulatory authorities jointly revised and promulgated <i>the&#160;Measures for Cyber Security Review</i>, or the New Measures
for Cyber Security Review, which came into effect on February&#160;15, 2022 and replace the prior Measures for Cyber Security Review promulgated
on April&#160;13, 2020. The New Measures for Cyber Security Review provides that, among others, (i)&#160;the purchase of cyber products
and services by critical information infrastructure operators and the network platform operators engaging in data processing activities
that affects or may affect national security should be subject to the cybersecurity review by the Cybersecurity Review Office, the department
which is responsible for the implementation of cybersecurity review under the CAC; (ii)&#160;network platform operators with personal
information data of more than one million users are obliged to apply for a cybersecurity review by the Cybersecurity Review Office before
listing abroad; and (iii)&#160;relevant governmental authorities in the PRC may initiate cybersecurity review if they determine the relevant
network products or services or data processing activities affect or may affect national security.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We believe that we are not <span style="font-family: Times New Roman, Times, Serif">subject
to cybersecurity review</span>, since we (i) are not network platform operators engaging in data processing activities that affect
or may affect national security; (ii) are not critical information infrastructure operators purchasing cyber products or services
that affect or may affect national security; (iii) are not network platform operators with personal information data of more than
one million users and do not need to obtain any permission or approval from the CAC in accordance with the New Measures for Cyber
Security Review. However, a<span style="font-family: Times New Roman, Times, Serif">s PRC governmental authorities have significant
discretion in interpreting and implementing statutory provisions and there remains significant uncertainty in the interpretation and
enforcement of relevant PRC cybersecurity laws and regulations, we cannot guarantee the PRC government will have the same analysis
and application of law like us. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On December 24, 2021, the China Securities Regulatory Commission, or
the &#8220;CSRC&#8221;, published draft regulations (the &#8220;Draft Rules&#8221;) on domestic enterprises issuing securities and being
listed overseas. The Draft Rules lay out specific filing requirements for overseas listing and offering by PRC domestic companies and
include unified regulation management and strengthening regulatory coordination. On February 17, 2023, the CSRC promulgated the Trial
Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Trial Measures&#8221;), which will
take effect on March 31, 2023. The Trial Measures supersede the Draft Rules and clarified and emphasized several aspects, which include
but are not limited to: (1) criteria to determine whether an issuer will be required to go through the filing procedures under the Trial
Measures; (2) exemptions from immediate filing requirements for issuers including those that have already been listed or registered but
not yet listed in foreign securities markets, including U.S. markets, prior to the effective date of the Trial Measures; (3) a negative
list of types of issuers banned from listing or offering overseas, such as issuers whose affiliates have been recently convicted of bribery
and corruption; (4) issuers&#8217; compliance with web security, data security, and other national security laws and regulations; (5)
issuers&#8217; filing and reporting obligations, such as obligation to file with the CSRC after it submits an application for initial
public offering to overseas regulators, and obligation after offering or listing overseas to report to the CSRC material events including
change of control or voluntary or forced delisting of the issuer; and (6) the CSRC&#8217;s authority to fine both issuers and their shareholders
for failure to comply with the Trial Measures, including failure to comply with filing obligations or committing fraud and misrepresentation.
Because we are already publicly listed in the U.S., the Trial Measures do not impose additional regulatory burden on us beyond the obligation
to report to the CSRC any future offerings of our securities, or material events such as a change of control or delisting. Despite of
the foregoing, we cannot assure you if we will be able to complete the filing procedure in a timely fashion when we are required to do
so for any offerings in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Holding Foreign Companies Accountable
Act, or the HFCAA, and the related regulations continue to evolve. Further implementations and interpretations of or amendments to the
HFCAA or the related regulations, or a PCAOB determination of its lack of sufficient access to inspect our auditor, might pose regulatory
risks to and impose restrictions on us because of our operations in mainland China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On May 20, 2020, the U.S. Senate passed the Holding
Foreign Companies Accountable Act (the &#8220;HFCAA&#8221;) requiring a foreign company to certify it is not owned or controlled by a
foreign government if the PCAOB is unable to audit specified reports because the Company uses a foreign auditor not subject to PCAOB inspection.
If the PCAOB is unable to inspect the Company&#8217;s auditors for three consecutive years, the issuer&#8217;s securities are prohibited
to trade on a national securities exchange or in the over the counter trading market in the U.S. On December 18, 2020, the HFCAA was signed
into law. The HFCAA has since then been subject to amendments by the U.S. Congress and interpretations and rulemaking by the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On June 22, 2021, the U.S. Senate passed the Accelerating
Holding Foreign Companies Accountable Act (&#8220;AHFCAA&#8221;), which proposes to reduce the period of time for foreign companies to
comply with PCAOB audits from three to two consecutive years, thus reducing the time period before the securities of such foreign companies
may be prohibited from trading or delisted. On December 29, 2022, the AHFCAA was signed into law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On December 16, 2021, PCAOB announced the PCAOB
HFCAA determinations relating to the PCAOB&#8217;s inability to inspect or investigate completely registered public accounting firms headquartered
in mainland China of the PRC or Hong Kong, a Special Administrative Region and dependency of the PRC, because of a position taken by one
or more authorities in the PRC or Hong Kong. The inability of the PCAOB to conduct inspections of auditors in China made it more difficult
to evaluate the effectiveness of these accounting firms&#8217; audit procedures or quality control procedures as compared to auditors
outside of China that are subject to the PCAOB inspections, which could cause existing and potential investors in issuers operating in
China to lose confidence in such issuers&#8217; procedures and reported financial information and the quality of financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our auditor, BF Borgers CPA PC, the independent
registered public accounting firm that issues the audit report included elsewhere in this report, as an auditor of companies that are
traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which the
PCAOB conducts regular inspections to assess our auditor&#8217;s compliance with the applicable professional standards. Our auditor is
headquartered in Colorado, and is subject to inspection by the PCAOB on a regular basis with the last inspection in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On August 26, 2022, the PCAOB announced and signed
a Statement of Protocol (the &#8220;Protocol&#8221;) with the China Securities Regulatory Commission and the Ministry of Finance of the
People&#8217;s Republic of China (together, the &#8220;PRC Authorities&#8221;). The Protocol provides the PCAOB with: (1) sole discretion
to select the firms, audit engagements and potential violations it inspects and investigates, without any involvement of Chinese authorities;
(2) procedures for PCAOB inspectors and investigators to view complete audit work papers with all information included and for the PCAOB
to retain information as needed; (3) direct access to interview and take testimony from all personnel associated with the audits the PCAOB
inspects or investigates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On December 15, 2022, the PCAOB announced in its
2022 HFCAA Determination Report (the &#8220;2022 Report&#8221;) its determination that the PCAOB was able to secure complete access to
inspect and investigate audit firms in the People&#8217;s Republic of China (PRC), and the PCAOB Board voted to vacate previous determinations
to the contrary. According to the 2022 Report, this determination was reached after the PCAOB had thoroughly tested compliance with every
aspect of the Protocol necessary to determine complete access, including on-site inspections and investigations in a manner fully consistent
with the PCAOB&#8217;s methodology and approach in the U.S. and globally. According to the 2022 Report, the PRC Authorities had fully
assisted and cooperated with the PCAOB in carrying out the inspections and investigations according to the Protocol, and have agreed to
continue to assist the PCAOB&#8217;s investigations and inspections in the future. The PCAOB may reassess its determinations and issue
new determinations consistent with the HFCAA at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the HFCAA and AHFCAA are not currently applicable to the Company
because the Company&#8217;s current auditors are subject to PCAOB review, if this changes in the future for any reason, the Company may
be subject to the HFCAA and AHFCAA. The implications of this regulation if the Company were to become subject to it are uncertain. Such
uncertainty could cause the market price of our common stock to be materially and adversely affected, and our securities could be delisted
or prohibited from being traded on NYSE American earlier than would be required by the HFCAA and AHFCAA. If our common stock is unable
to be listed on another securities exchange by then, such a delisting would substantially impair your ability to sell or purchase the
common stock when you wish to do so, and the risk and uncertainty associated with a potential delisting would have a negative impact on
the price of the common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PRC regulations relating to the establishment
of offshore special purpose companies by PRC residents may subject our PRC resident beneficial owners or our PRC subsidiary to liability
or penalties, limit our ability to inject capital into our PRC subsidiary, limit our PRC subsidiary&#8217; ability to increase their registered
capital or distribute profits to us, or may otherwise adversely affect us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2014, SAFE promulgated
the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and
Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37, to replace the Notice on Relevant Issues Concerning Foreign
Exchange Administration for Domestic Residents&#8217; Financing and Roundtrip Investment Through Offshore Special Purpose Vehicles, or
SAFE Circular 75, which ceased to be effective upon the promulgation of SAFE Circular 37. SAFE Circular 37 requires PRC residents (including
PRC individuals and PRC corporate entities) to register with SAFE or its local branches in connection with their direct or indirect offshore
investment activities. SAFE Circular 37 is applicable to our shareholders who are PRC residents and may be applicable to any offshore
acquisitions that we make in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under SAFE Circular 37, PRC
residents who make, or have prior to the implementation of SAFE Circular 37 made, direct or indirect investments in offshore special purpose
vehicles, or SPVs, will be required to register such investments with SAFE or its local branches. In addition, any PRC resident who is
a direct or indirect shareholder of an SPV is required to update its filed registration with the local branch of SAFE with respect to
that SPV, to reflect any material change. Moreover, any subsidiary of such SPV in China is required to urge the PRC resident shareholders
to update their registration with the local branch of SAFE. If any PRC shareholder of such SPV fails to make the required registration
or to update the previously filed registration, the subsidiary of such SPV in China may be prohibited from distributing its profits or
the proceeds from any capital reduction, share transfer or liquidation to the SPV, and the SPV may also be prohibited from making additional
capital contributions into its subsidiary in China. On February&#160;13, 2015, the SAFE promulgated a Notice on Further Simplifying and
Improving Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June&#160;1, 2015.
Under SAFE Notice 13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct
investments, including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks
will directly examine the applications and accept registrations under the supervision of SAFE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our shareholders that
we are aware of are subject to SAFE regulations, and we expect all of these shareholders will have completed all necessary registrations
with the local SAFE branch or qualified banks as required by SAFE Circular 37. We cannot assure you, however, that all of these shareholders
may continue to make required filings or updates in a timely manner, or at all. We can provide no assurance that we are or will in the
future continue to be informed of identities of all PRC residents holding direct or indirect interest in our company. Any failure or inability
by such shareholders to comply with SAFE regulations may subject us to fines or legal sanctions, such as restrictions on our cross-border
investment activities or our PRC subsidiaries&#8217; ability to distribute dividends to, or obtain foreign exchange-denominated loans
from, our company or prevent us from making distributions or paying dividends. As a result, our business operations and our ability to
make distributions to you could be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, as these foreign
exchange regulations are still relatively new and their interpretation and implementation have been constantly evolving, it is unclear
how these regulations, and any future regulation concerning offshore or cross-border transactions, will be interpreted, amended and implemented
by the relevant government authorities. For example, we may be subject to a more stringent review and approval process with respect to
our foreign exchange activities, such as remittance of dividends and foreign-currency-denominated borrowings, which may adversely affect
our financial condition and results of operations. In addition, if we decide to acquire a PRC domestic company, we cannot assure you that
we or the owners of such company, as the case may be, will be able to obtain the necessary approvals or complete the necessary filings
and registrations required by the foreign exchange regulations. This may restrict our ability to implement our acquisition strategy and
could adversely affect our business and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. regulatory bodies may be limited in
their ability to conduct investigations or inspections of our operations in China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any disclosure of documents
or information located in China by foreign agencies may be subject to jurisdiction constraints and must comply with China&#8217;s state
secrecy laws, which broadly define the scope of &#8220;state secrets&#8221; to include matters involving economic interests and technologies.
There is no guarantee that requests from U.S. federal or state regulators or agencies to investigate or inspect our operations will be
honored by us, by entities who provide services to us or with whom we associate, without violating PRC legal requirements, especially
as those entities are located in China. Furthermore, under the current PRC laws, an on-site inspection of our facilities by any of these
regulators may be limited or prohibited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our China-sourced income is subject to PRC
withholding tax under the new Enterprise Income Tax Law of the PRC, and we may be subject to PRC enterprise income tax at the rate of
25% when more detailed rules or precedents are promulgated.</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC&#160;<i>enterprise</i>&#160;<i>income</i>&#160;<i>tax</i>&#160;is
calculated based on the taxable income determined under the PRC laws and accounting standards. On March 16, 2007, the National People&#8217;s
Congress of China enacted a new&#160;<i>Enterprise</i>&#160;<i>Income</i>&#160;<i>Tax</i>&#160;Law of the PRC, which became effective
on January 1, 2008 and amended the&#160;<i>Enterprise</i>&#160;<i>Income</i>&#160;<i>Tax</i>&#160;Law of the PRC on December 29, 2018.
On December 6, 2007, the State Council promulgated the Implementation Rules to the&#160;<i>Enterprise</i>&#160;<i>Income</i>&#160;<i>Tax</i>&#160;Law
of the PRC, or the Implementation Rules, which also became effective on January 1, 2008 and amended the Implementation Rules to the&#160;<i>Enterprise</i>&#160;<i>Income</i>&#160;<i>Tax</i>&#160;Law
of the PRC on April 23, 2019. On December 26, 2007, the State Council issued the Notice on Implementation of&#160;<i>Enterprise</i>&#160;<i>Income</i>&#160;<i>Tax</i>&#160;Transition
Preferential Policy under the&#160;<i>Enterprise</i>&#160;<i>Income</i>&#160;<i>Tax</i>&#160;Law of the PRC, or the Transition Preferential
Policy Circular, which became effective simultaneously with the&#160;<i>Enterprise</i>&#160;<i>Income</i>&#160;<i>Tax</i>&#160;Law of
the PRC. On October 17, 2017, the State Administration of Taxation promulgated the Announcement of the State Administration of Taxation
on Issues Relating to Withholding at Source of Income Tax of Non-resident Enterprises, which became effective on December 1, 2017 and
amended Withholding at Source of Income Tax of Non-resident Enterprises on June 15, 2018. The&#160;<i>Enterprise</i>&#160;<i>Income</i>&#160;<i>Tax</i>&#160;Law
of the PRC imposes a uniform&#160;<i>enterprise</i>&#160;<i>income</i>&#160;<i>tax</i>&#160;rate of 25% on all domestic enterprises, including
foreign-invested enterprises unless they qualify for certain exceptions, and terminates most of the tax exemptions, reductions and preferential
treatments available under previous tax laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, under the&#160;<i>Enterprise</i>&#160;<i>Income</i>&#160;<i>Tax</i>&#160;Law
of the PRC, enterprises organized under the laws of jurisdictions outside China with their &#8220;de facto management bodies&#8221; located
within China may be considered PRC resident enterprises and therefore subject to PRC&#160;<i>enterprise</i>&#160;<i>income</i>&#160;<i>tax</i>&#160;at
the rate of 25% on their worldwide income. The Implementation Rules define the term &#8220;de facto management body&#8221; as the management
body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties
of an enterprise. In addition, the Circular Related to Relevant Issues on the Identification of a Chinese holding Company Incorporated
Overseas as a Residential Enterprise under the Criterion of De Facto Management Bodies Recognizing issued by the State Administration
of Taxation on April 22, 2009 provides that a foreign enterprise controlled by a PRC company or a PRC company group will be classified
as a &#8220;resident enterprise&#8221; with its &#8220;de facto management bodies&#8221; located within China if the following requirements
are satisfied: (i) the senior management and core management departments in charge of its daily operations function mainly in China; (ii)
its financial and human resources decisions are subject to determination or approval by persons or bodies in China; (iii) its major assets,
accounting books, company seals and minutes and files of its board and shareholders&#8217; meetings are located or kept in China; and
(iv) more than half of the enterprise&#8217;s directors or senior management with voting rights reside in China. Although the circular
only applies to offshore enterprises controlled by PRC enterprises and not those controlled by PRC individuals or foreigners, the determining
criteria set forth in the circular may reflect the State Administration of Taxation&#8217;s general position on how the &#8220;de facto
management body&#8221; test should be applied in determining the tax resident status of offshore enterprises, regardless of whether they
are controlled by PRC enterprises, individuals or foreigners. It is uncertain to us as to how it will be implemented and the respective
tax base and the tax exposure cannot be determined reliably at this stage. In case we are required to pay the income tax on capital gains
by the relevant PRC tax authorities, our financial conditions and results of operations could be adversely affected.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to distribute dividends are
to large extent based on the dividends paid to us by our operating entity in China, and its ability to distribute dividends may be limited
by the PRC laws.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we are a holding company with all of business
operations conducted in PRC by Helpson, which is our wholly-owned subsidiary, we depend on its dividend issuance to us to pay the dividends
to our investors. According to the PRC Company Law and Foreign Investment Law, our PRC subsidiary, as a foreign-invested enterprise, or
FIE, we may only pay dividends out of their accumulated profit, if any, as determined in accordance with PRC accounting standards and
regulations. In addition we are required to draw 10% of its after-tax profits each year, if any, to fund a common reserve, which may stop
drawing its after-tax profits if the aggregate balance of the common reserve has already accounted for over 50% of its registered capital.
The reserve funds are not distributable as cash dividends. A PRC company is not permitted to distribute any profits until any losses from
prior fiscal years have been offset. Our ability to distribute dividends may be restricted because of the above-mentioned regulations.
We may even cannot distribute dividends if we are suffering loss in certain fiscal year in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividends payable by us to our foreign investors
and gain on the sale of our shares may become subject to taxes under PRC tax laws.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the new EIT law and
its implementation rules, to the extent that we are considered a &#8220;resident enterprise&#8221; which is &#8220;domiciled&#8221; in
China, PRC income tax at the rate of 10% is applicable to dividends payable by us to investors that are &#8220;non-resident enterprises&#8221;
so long as such &#8220;non-resident enterprise&#8221; investors do not have an establishment or place of business in China or, despite
the existence of such establishment or place of business in China, the relevant income is not effectively connected with such establishment
or place of business in China. Similarly, any gain realized on the transfer of our shares by such investors is also subject to a 10% PRC
income tax if such gain is regarded as income derived from sources within China and we are considered a &#8220;resident enterprise&#8221;
which is domiciled in China for tax purposes. Additionally, there is a possibility that the relevant PRC tax authorities may take the
view that our purpose is that of a holding company, and the capital gain derived by our overseas stockholders would be deemed China-sourced
income, in which case such capital gain may be subject to PRC withholding tax at the rate of up to 10%. If we are required under the new
EIT law to withhold PRC income tax on our dividends payable to our foreign stockholders who are &#8220;non-resident enterprises&#8221;,
or if you are required to pay PRC income tax on the transfer of our shares under the circumstances mentioned above, the value of your
investment in our shares may be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face uncertainty with respect to indirect
transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February&#160;3, 2015,
the SAT issued the Public Notice Regarding Certain Corporate Income Tax Matters on Indirect Transfer of Properties by Non-Tax Resident
Enterprises, or SAT Bulletin 7. SAT Bulletin 7 extends its tax jurisdiction to transactions involving the transfer of taxable assets through
offshore transfer of a foreign intermediate holding company. In addition, SAT Bulletin 7 has introduced safe harbors for internal group
restructurings and the purchase and sale of equity through a public securities market. SAT Bulletin 7 also brings challenges to both foreign
transferor and transferee (or other person who is obligated to pay for the transfer) of taxable assets, as such persons need to determine
whether their transactions are subject to these rules and whether any withholding obligation applies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&#160;17, 2017,
the SAT issued the Announcement of the State Administration of Taxation on Issues Concerning the Withholding of Non-resident Enterprise
Income Tax at Source, or SAT Bulletin 37, which came into effect on December&#160;1, 2017. The SAT Bulletin 37 further clarifies the practice
and procedure of the withholding of non-resident enterprise income tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Where a non-resident enterprise
transfers taxable assets indirectly by disposing of the equity interests of an overseas holding company, which is an &#8220;Indirect Transfer&#8221;,
the non-resident enterprise as either transferor or transferee, or the PRC entity that directly owns the taxable assets, may report such
Indirect Transfer to the relevant tax authority. Using a &#8220;substance over form&#8221; principle, the PRC tax authority may disregard
the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of reducing,
avoiding or deferring PRC tax. As a result, gains derived from such Indirect Transfer may be subject to PRC enterprise income tax, and
the transferee or other person who pays for the transfer is obligated to withhold the applicable taxes currently at a rate of 10% for
the transfer of equity interests in a PRC resident enterprise. Both the transferor and the transferee may be subject to penalties under
PRC tax laws if the transferee fails to withhold the taxes and the transferor fails to pay the taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We face uncertainties as to
the reporting and other implications of certain past and future transactions where PRC taxable assets are involved, such as offshore restructuring,
sale of the shares in our offshore subsidiaries and investments. Our company may be subject to filing obligations or taxed if our company
is transferor in such transactions, and may be subject to withholding obligations if our company is transferee in such transactions, under
SAT Bulletin 7 and/or SAT Bulletin 37. For transfer of shares in our company by investors who are non-PRC resident enterprises, our PRC
subsidiaries may be requested to assist in the filing under SAT Bulletin 7 and/or SAT Bulletin 37. As a result, we may be required to
expend valuable resources to comply with SAT Bulletin 7 and/or SAT Bulletin 37 or to request the relevant transferors from whom we purchase
taxable assets to comply with these circulars, or to establish that our company should not be taxed under these circulars, which may have
a material adverse effect on our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We may be held
in default on our convertible note, which could trigger penalties that worsen our financial condition and potentially disqualify us from
listing on the stock exchange where we are currently listed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
November 17, 2021, we entered into a Securities Purchase Agreement pursuant to which we issued an unsecured convertible promissory note
(the &#8220;Convertible Note&#8221;) to an institutional accredited investor Streeterville Capital, LLC (&#8220;Streeterville&#8221;).
The Convertible Note was due on February 17, 2023. The parties are in negotiation in extending the Convertible Note. There can be no assurances
that these negotiations will be successful. The Convertible Note has a principal balance of $3,800,000 at December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Although
no event of default has occurred as of the date herein, pursuant to the terms of the Convertible Note, upon our failure to pay back the
Convertible Note upon due, Streeterville can, at its sole discretion, send us a notice which turns this into an Event of Default (&#8220;Event
of Default&#8221;), which would give us 10 days to cure. As of the date herein, Streeterville has not sent such a notice and therefore
no Event of Default has occurred. If an Event of Default occurs and is not cured within the 10-day notice period, pursuant to the terms
of the Convertible Note Streeterville can impose additional interest payments and other penalties upon us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Such
penalties, as well as other similar penalties that could be imposed upon us as a result of our ongoing negotiations to extend the Convertible
Note, if and when imposed by Streeterville, could worsen our financial conditions by consuming or tying up our cash reserve, cash flow,
and assets, as well as dilute our existing shareholders if Streeterville initiates conversion of some or part of the Convertible Note
into our equity securities. Thus, such penalties could generally and negatively impact the operation of our business and the public trading
price of our common stock. Particularly, it could cause the values of our shareholder&#8217;s equity and market capitalization to decline
further. As a result of such decline, we may become unable to satisfy the continuous listing standards of the stock exchange where we
are currently listed, which would further negatively impact the operation of our business and the public trading price of our common
stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>



</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price for our common stock may
be volatile which could result in a complete loss of your investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price for our common
stock is highly volatile and subject to wide fluctuations in response to factors including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated fluctuations
in our quarterly operating results;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">announcements of new products
by us or our competitors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes in financial estimates
by securities analysts;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">conditions in the pharmaceutical
market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes in the economic performance
or market valuations of other companies involved in pharmaceutical production;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">announcements by our competitors
of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">economic, regulatory and political
developments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">addition or departure of key
personnel, or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">potential litigation.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the securities
markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance
of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may issue additional shares of our capital
stock to raise additional cash for working capital; if we issue additional shares of our capital stock, our stockholders will experience
dilution in their respective percentage ownership in the company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue additional shares
of our capital stock to raise additional cash for working capital. There is no anti-dilution protection or preemptive rights in connection
with our common stock. Thus, the percentage ownership of existing holders of common stock may be diluted in their respective percentage
ownership in us if we issue additional shares of our capital stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A large portion of our common stock is controlled
by a small number of stockholders and as a result, these stockholders are able to influence and ultimately control the outcome of stockholder
votes on various matters.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A large portion of our common
stock is held by a small number of stockholders. For instance, Zhilin Li, our Chief Executive Officer, holds 16.31%, and Heung Mei Tsui,
a member of our Board of Directors, holds 11.00% of our common stock, respectively, as of the date hereof. As a result, these two stockholders
are able to significantly influence the outcome of stockholder votes on various matters, including the election of directors and other
corporate transactions including business combinations. In addition, the occurrence of sales of a large number of shares of our common
stock, or the perception that these sales could occur, may affect our stock price and could impair our ability to obtain capital through
an offering of equity securities. Furthermore, the current ratios of ownership of our common stock reduce the public float and liquidity
of our common stock which can in turn affect the market price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are likely to remain subject to &#8220;penny
stock&#8221; regulations and as a consequence there are additional sales practice requirements and additional warnings issued by the SEC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time we have net
tangible assets of $5,000,000 or less and the trading price of our common stock is below $5.00 per share, the open-market trading of our
common stock will be subject to the &#8220;penny stock&#8221; rules of the SEC. The &#8220;penny stock&#8221; rules impose additional
sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors
(generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). For
transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of securities and
have received the purchaser&#8217;s written consent to the transaction before the purchase. Additionally, for any transaction involving
a penny stock, unless exempt, the broker-dealer must deliver, before the transaction, a disclosure schedule prescribed by the SEC relating
to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative
and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited
market in penny stocks. These additional burdens imposed on broker-dealers may restrict the ability of broker-dealers to sell the common
stock and may affect a stockholder&#8217;s ability to resell the common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that our common stock will qualify for exemption from the &#8220;penny stock&#8221; rules. In any event, even if our common stock is exempt
from such rules, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person
from participating in a distribution of a &#8220;penny stock&#8221; if the SEC finds that such a restriction would be in the public interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders should be aware
that, according to SEC Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud and abuse.
Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related to the promoter
or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (iii)
boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (iv) excessive
and undisclosed bid-ask differential and markups by selling broker-dealers; and (v) the wholesale dumping of the same securities by promoters
and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices
and with consequent investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are responsible for the indemnification
of our officers and directors under certain circumstances which could result in substantial expenditures, which we may be unable to recoup.</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide for the
indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney&#8217;s fees and other
expenses incurred by them in any litigation to which they become a party arising from their association with or activities on behalf of
us. This indemnification policy could result in substantial expenditures, which we may be unable to recoup.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have identified material weaknesses in
our internal control over financial reporting, which could affect our ability to ensure timely and reliable financial reports, affect
the ability of our auditors to attest to the effectiveness of our internal controls should we become an accelerated filer in the future,
and weaken investors&#8217; confidence in our financial reporting.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As directed by Section 404
of the Sarbanes-Oxley Act of 2002, the SEC adopted rules requiring public companies in their annual reports to include a report of management
on the reporting company&#8217;s disclosure controls and procedures and internal controls over financial reporting. We became subject
to this requirement commencing with our fiscal year ended December 31, 2007 and a report of our management is included under Item 9A.
&#8220;Controls and Procedures&#8221; of this Annual Report on Form 10-K. As set forth in such report, our management has concluded that
our internal controls over financial reporting were not effective as of December 31, 2022, and there existed a material weakness in our
internal control over financial reporting as of December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are taking appropriate actions to internally training related personnel,
such as Chief Financial Officer, to remediate such material weakness; however, such measures may not be sufficient to address the material
weaknesses identified or ensure that our controls and procedures are effective. We may also discover other material weaknesses in the
future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in the implementation
of such controls, could cause us to fail to meet our periodic reporting obligations or result in material misstatements in our financial
statements and affect the ability of our auditors to attest to the effectiveness of our internal control over financing reporting to the
extent we become an accelerated filer in the future. In addition, substantial costs and resources may be required to rectify any internal
control deficiencies. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information,
the market price of our common stock could decline significantly, and our business and financial condition could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>There is substantial doubt about our ability to continue as a
going concern.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our auditors have indicated
in their report on our financial statements for the years ended December 31, 2022 and 2021 that conditions exist that raise substantial
doubt about our ability to continue as a going concern as discussed in Note 1 to the financial statements. The Company incurred recurring
losses from operations, has net current liabilities and an accumulated deficit that raise substantial doubt about its ability to continue
as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To alleviate the conditions that
raise substantial doubt about the Company&#8217;s ability to continue as a going concern, management plans to enhance the sales model
of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic
alternatives to accelerate the launch of comprehensive healthcare products. In addition, management believes that the Company&#8217;s
existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund
its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives
raising substantial doubt about its ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to generate
enough cash or obtain additional sufficient funding, we would need to scale back or eliminate our business plan, reduce our operating
costs and headcount, or discontinue or curtail our operations. Accordingly, our business, prospects, financial condition and results of
operations could be materially and adversely affected, and we may be unable to continue as a going concern. If we are unable to continue
as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited
consolidated financial statements, and it is likely that investors will lose all or a part of their investment. Our financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not anticipate paying cash dividends
on our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not rely on an
investment in our common stock to provide dividend income, as we have not paid any cash dividends on our common stock and do not plan
to pay any in the foreseeable future. Accordingly, investors must rely on sales of our common stock after price appreciation, which may
never occur, as the only way to realize any return on their investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restrictions on the Use of Rule 144 by Shell
Companies or Former Shell Companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, the SEC has
taken the position that Rule 144 under the Securities Act, as amended, is not available for the resale of securities initially issued
by companies that are, or previously were, blank check companies like us, to their promoters or affiliates despite technical compliance
with the requirements of Rule 144. The SEC has codified and expanded this position in its amendments effective on February 15, 2008 and
applies it to securities acquired both before and after that date by prohibiting the use of Rule 144 for resale of securities issued by
shell companies (other than business transaction related shell companies) or issuers that have been at any time previously a shell company.
The SEC has provided an important exception to this prohibition, however, if the following conditions are met: the issuer of the securities
that was formerly a shell company has ceased to be a shell company; the issuer of the securities is subject to the reporting requirements
of Section 13 or 15(d) of the Exchange Act; the issuer of the securities has filed all Exchange Act reports and material required to be
filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials),
other than Form 8-K reports; and at least one year has elapsed from the time that the issuer filed current Form 10 type information with
the SEC reflecting its status as an entity that is not a shell company. As such, due to the fact that we had been a shell company prior
to October 2005, holders of &#8220;restricted securities&#8221; within the meaning of Rule 144, when reselling their shares pursuant to
Rule 144, shall be subject to the conditions set forth herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1B. UNRESOLVED STAFF COMMENTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
are not required to provide the information required by this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. PROPERTIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no private land ownership
in the PRC. All land is either owned by the government of the PRC on behalf of all Chinese citizens or collectively owned by farmers.
However, land use rights may be allocated by the PRC State Land Administration Bureau or its authorized branches. Helpson was granted
land use rights by the PRC government for approximately 22,936 square meters (approximately 246,881 square feet) of land located on Plot
C09-2 in the Haikou Bonded Zone, Hainan Province, PRC in 2003. These land use rights will expire on September 10, 2063.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson owns two production
facilities in Haikou, Hainan Province, PRC, one of which has a construction area of 663.94 square meters and is located on the 6th floor
of Standard Plant Building B, Jinpan Industrial Development Zone. The other factory, located on Plot C09-2 in the Haikou Bonded Zone,
has two buildings with production area of 20,282.42 square meters, certificate number HK477872, and 6,593.20 square meters, certificate
number HK122889.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Helpson rents
offices located on the second floor of the Jiahai Building owned by Hainan Zhongfu Foreign Export Personnel Service Center (the &#8220;Center&#8221;)
as its principal executive offices. Monthly rent at this facility is RMB 5,580 (approximately $843). The original term of the lease was
3 years, from December 1, 2010 to November 30, 2013. On December 31, 2011, this lease was superseded by a new lease, for a term of nine
years, for office spaces on the second floor and the entire third floor at a monthly rent of RMB 20,000 (approximately $2,941), with a
5% increase every two years from the fourth year until the end of the term (the &#8220;2011 Lease&#8221;). On May 2, 2018, the 2011 Lease
was superseded by a new lease, for a term of three years ending June 30, 2021, for office spaces on the second and third floor at a monthly
rent of RMB 16,000 (approximately $2,319), and RMB 30,000 (approximately $4,349), respectively. The aggregate area of the office space
rented by Helpson is 1,686 square meters (16,812 square feet). On July 10, 2021, the 2011 Lease was further extended to June 30, 2023
for a term of two years and the monthly rent of RMB 47,600 (approximately $7,461).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that all our properties
have been adequately maintained, are generally in good condition, and are suitable and adequate for our business. However, we anticipate
a potential need for expansion and additional space as our production increases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Mortgaged Property</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 18, 2021 the
Company obtained a line of credit for RMB 10 million (approximately $1.54 million) with Bank of China. The loan bears interest at the
rate of 3.85% per annum. The line of credit was paid in full on the due date of September 18, 2022. On September 30, 2022 the Company
received a new line of credit in the same amount. The loan bears interest at the rate of 3.45% and is due September 28, 2023.The loan
is collateralized by the Company&#8217;s new production facility and the included production line equipment and machinery. In addition,
the Company&#8217;s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest paid on
this loan was $54,923 and $15,582 for the years ended December 31, 2022 and 2021, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The loans referred to above
are set forth in the table below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; border-bottom: Black 1.5pt solid; text-align: justify; font-weight: bold">Total Amount of<br/>
 the Line of Credit</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lending Institution</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Contract Period</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Properties
under<br/>
 Mortgage</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 20%; text-align: justify">RMB 10 million<br/> (Approximately $1.54 million)</td><td style="text-align: justify; width: 0.5%; vertical-align: top">&#160;</td>
    <td style="text-align: center; width: 19%; vertical-align: top">Bank of China</td><td style="text-align: justify; width: 0.5%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 0.5%; text-align: justify">&#160;</td><td style="vertical-align: top; width: 17%; text-align: justify">September 30, 2022 to September 28, 2023</td><td style="vertical-align: top; width: 0.5%; text-align: justify">&#160;</td><td style="text-align: justify; width: 0.5%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 0.5%; text-align: justify">&#160;</td><td style="vertical-align: top; width: 9%; text-align: right">3.45</td><td style="vertical-align: top; width: 0.5%; text-align: justify">%</td><td style="text-align: justify; width: 0.5%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 31%; text-align: justify">Helpson&#8217;s new factory: 20,282.42 square meters&#160;&#160;(Certificate #: HK477872) <br/>Production line equipment and machinery included in the facility</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. LEGAL PROCEEDINGS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent
uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. However, we are
currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse
effect on our business, financial condition or operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="c_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="c_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON
EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shares began trading on
the NYSE American (Formerly known as NYSE Amex, NYSE MKT) on September 30, 2009 under the symbol &#8220;CPHI&#8221;. Prior to September
30, 2009, our shares traded on the OTC Bulletin Board under the symbol &#8220;CPHI.OB.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2023 there were approximately 134 stockholders of record
of our common stock and an indeterminate number of beneficial holders who held our common stock in street name.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent and Registrar</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is Equinity Trust Company, with offices located at 3200 Cherry Creek South Drive, Suite 430, Denver, Colorado 80209.
Their telephone number is (303) 282-4800 and fax number is (303) 282-5800.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid or declared
any dividend on our common stock and we do not anticipate paying cash dividends in the foreseeable future. As a result of our holding
company structure, we would rely entirely on dividend payments from our subsidiaries, Onny Investment Ltd. and Hainan Helpson Medial &amp;
Biotechnology Co., Ltd., for our cash flow to pay dividends on our common stock. The PRC government imposes controls on the conversion
of Renminbi into foreign currencies and the remittance of currencies out of the PRC, which may also affect our ability to pay cash dividends
in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities Authorized for Issuance under Equity
Compensation Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="12" style="text-align: center"><b>Equity Compensation Plan Information</b></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Plan category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
 securities<br/>
 to be <br/>
issued upon<br/>
 exercise of<br/>
 outstanding<br/>
 options,<br/>
 warrants <br/>
and rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/>
average<br/>
 exercise<br/>
 price of<br/>
 outstanding<br/>
 options,<br/>
 warrants<br/>
 and rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
 securities<br/>
 remaining<br/>
 available for<br/>
 future<br/>
 issuance<br/>
 under<br/>
 equity<br/>
 compensation<br/>
 plans<br/>
 (excluding<br/>
 securities<br/>
 reflected<br/>
 in column<br/>
 (a))</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(a)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(b)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(c)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Equity compensation plans not approved by security holders</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;&#160;&#160;-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: justify; padding-bottom: 1.5pt">Equity compensation plans approved by security holders</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">13,540,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Totals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,540,000</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. [Reserved]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">`</p><div>

</div><div><a id="c_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. MANAGEMENT&#8217;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The statements contained in this report with
respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements.
Forward-looking statements can be identified by the use of forward-looking terminology, such as &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;could,&#8221;
or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes
to caution the readers that any such forward-looking statements contained in this report reflect our current beliefs with respect to
future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive,
regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products,
licenses and other factors, some of which are described in this report and some of which are discussed in our other filings with the
Securities and Exchange Commission (the &#8220;SEC&#8221;). These forward-looking statements are only estimates or predictions. No assurances
can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company,
and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These risk factors should be considered in connection
with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral
forward-looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are
expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely
on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&#8217; expectations or estimates
or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report
or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Overview &amp; Recent Developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are principally engaged in the development,
manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality
diseases and medical conditions prevalent in the People&#8217;s Republic of China (the &#8220;PRC&#8221;). All of our operations are
conducted in the PRC, where our manufacturing facilities are located. We manufacture pharmaceutical products in the form of dry powder
injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of our pharmaceutical products are
sold on a prescription basis and all of them have been approved for at least one or more therapeutic indications by the National Medical
Products Administration (the &#8220;NMPA&#8221;, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety
and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">China's consistency
evaluation of generic drugs continues to proceed in 2022. The supporting policies from central and provincial governments were constantly
issued, including polices regarding consistency evaluation for injectable products. We have always taken the task of promoting the consistency
evaluation as a top priority, and worked on them actively. However, for each drug&#8217;s consistency evaluation, due to the continuous
dynamic changes of the detailed consistency evaluation policies, market trends, expected investments, and expected returns of investment
(&#8220;ROI&#8221;) the whole industry, including us, has been making slow progress in terms of the consistency evaluation. </span>We
have <span style="font-size: 10pt">submitted application documents to NMPA at the end of 2021</span>, and passed the clinical verification
of the drug by NMPA in June 2022. We had completed the supplementary documents as required by the NMPA in early November 2022We had completed
the registration inspection and quality standard review of the Institute for Drug Control on February 2023, and are currently undergoing
technical review and waiting for on-site verification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have taken a more cautious and flexible attitude
towards initiating and progressing any project for existing products&#8217; consistency evaluation to cope with the changing macro environment
of drug sales in China. Since trial Centralized Procurement (&#8220;CP&#8221;) activities were initiated in 2018 in 11 cities (including
4 municipalities and 7 other cities), eight rounds of CP activities have been carried out throughout China by the end of 2022, which
significantly reduced the price of the drugs that won the bids. In addition, the consistency evaluation has been adopted as one of the
qualification standards for participating in the CP activities. As a result, we need to balance at least the two factors above (namely,
the investment of financial resources and time to obtain the qualification of CP, and the sharp decline in the price of drugs included
in CP) before making decisions for any products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we continue to explore the field of comprehensive
healthcare. Comprehensive healthcare is a general concept proposed by the Chinese government according to the development of the times,
social needs and changes in disease spectrum. According to the Outline of "Healthy China 2030" issued by Chinese government
in October 2016, the total size of China's health service industry will reach RMB 16 trillion (approximately 2.5 trillion) by 2030. This
industry focuses on people's daily life, aging and diseases, pays attention to all kinds of risk factors and misunderstandings affecting
health, calls for self-health management, and advocates the comprehensive care throughout the entire process of life. It covers all kinds
of health-related information, products and services, as well as actions taken by various organizations to meet the health needs. In response
to this trend, we launched Noni enzyme, a natural, Xeronine-rich antioxidant food supplement at the end of 2018. We also launched wash-free
sanitizers and masks, in 2020, to address the market needs caused by COVID-19 in China. With Chinese government officially terminated
its zero-case policy, now the responsibility to protect people from the impact of COVID-19 falls more to the citizens themselves, and
masks and sanitizers have been more and more popular. We have sufficient production capacity for medical masks, surgical masks, KN95 masks,
and N95 masks, which meets the personal needs for protection against the epidemic outbreak. Thanks to the green channel provided by Hainan
Medical Products Administration, we received the Registration Certificate of N95 medical protective mask at the fastest speed by the end
of 2022, when the infection of COVID-19 has surged in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will continue to optimize our product structure
and actively respond to the current health needs of human beings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Trends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a generic drug company, we are presented with
a huge domestic market. We believe that through further upgrades and better conformity with Chinese consistency evaluations, which are
based on European and American production standards, we will be able to export our products to overseas markets. In China&#8217;s market,
we believe that in the future, cost management and control ability will gradually become important factors in determining the competitiveness
of generic pharmaceutical enterprises. Although price control leads to a decline in the profitability, the CP&#8217;s winning enterprise
has a good chance of achieving price-for-volume in order to increase its market share and support its continuous innovation and transformation.
On a separate note, rising and advancing consumer demand in China drives the increase of discretionary consumption. With the improvement
of residents' quality of life, the healthcare demand is also changing. We believe that there is a large number of unmet demands in comprehensive
healthcare and internet healthcare sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Office of the State Council
issued &#8220;<i>Pilot Plan for Marketing Authorization Holders</i>&#8221; on May 24, 2016, allowing eligible drug research and development
institutions and scientific researchers to become Marketing Authorization Holders (&#8220;MAH&#8221;) by obtaining drug marketing authorization
and drug approval numbers from the State Council. This policy uses a management model of separating drug marketing authorization and
drug production licenses, thereby allowing MAHs to produce pharmaceuticals themselves or to consign production to other pharmaceutical
manufacturers. This policy not only transitions our production practices to meet the European and United States standards by separating
drug approval and production qualifications, thereby changing the existing model of bundling drug approval numbers to pharmaceutical
manufacturers in China, but also serves as a supplement to the ongoing consistency evaluations policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, demand for pharmaceutical products
continues its steady growth in China. We believe the ongoing generic drug consistency evaluations and reform of China&#8217;s drug production
registration and review policies will have major effects on the future development of our industry and may change its business patterns.
We will continue to actively adapt to the national policy guidance and further evaluate market conditions for our existing products then
adjust accordingly, and compete in the market in order to optimize our development strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations for the Fiscal Year
ended December 31, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue was $8.1 million for the year ended December
31, 2022, which represented a decrease of $1.5 million, as compared to $9.6 million for the year ended December 31, 2021. This decline
was mainly due to exchange rate changes, resurgence of COVID-19 in many cities in China, including Haikou, the city where our operations
and manufacturing located, and China's strict epidemic isolation and control, which made offline activities difficult to carry out, and
pharmacies and hospitals implementing strict controls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below are our revenues by product category
in millions (USD) for the years ended December 31, 2022 and 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Product Category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">CNS Cerebral &amp; Cardio Vascular</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.68</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-0.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-37</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Anti-Viral/ Infection &amp; Respiratory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Digestive Diseases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-23</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The most significant revenue decrease in terms
of dollar amount was in our &#8220;CNS Cerebral &amp; Cardio Vascular&#8221;, which generated $1.70 million in sales revenue in 2022
compared to $2.68 million in 2021, a decrease of $0.98 million. This decrease was mainly due to a decrease in sales of our Alginic Sodium
Diester due to market fluctuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales revenue of our &#8220;Anti-Viral/ Infection
&amp; Respiratory&#8221; product category was $4.94 million in 2022, compared to $5.22 million in 2021, which represented a decrease
of $0.28 million. This decrease was mainly due to a decrease in sales of our Cefaclor due to market fluctuation, and change in foreign
exchange rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales revenue in the &#8220;Other&#8221; category
was $1.06 million in 2022, which represented a decrease of $0.31 million compared to $1.37 million in 2021. This decrease was mainly
due to the sales decrease of Vitamin B6 in fiscal year 2022, caused by the implementation of centralized procurement policy, a stricter
drug centralized procurement policy, as well as market fluctuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our &#8220;Digestive Diseases&#8221; category
generated $0.40 million of sales revenue in 2022, which represented an increase of $0.03 million compared to $0.37 million in 2021. This
increase was mainly due to an increase in sales of our Tiopronin due to market fluctuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"></td><td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year Ended December 31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><b>Product Category</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">CNS Cerebral &amp; Cardio Vascular</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: justify">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">28</td><td style="width: 1%; text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Anti-Viral/ Infection &amp; Respiratory</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">61</td><td style="text-align: justify">%</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">54</td><td style="text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Digestive Diseases</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">5</td><td style="text-align: justify">%</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">4</td><td style="text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Other</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">13</td><td style="text-align: justify">%</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">14</td><td style="text-align: justify">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2022, revenue
breakdown by product category experienced certain variances compared with that of the prior year. Sales in the &#8220;Anti-Viral/Infection
&amp; Respiratory&#8221; product category represented 61% and 54% of total sales in the years ended December 31, 2022 and 2021, respectively.
The &#8220;CNS Cerebral &amp; Cardio Vascular&#8221; category represented 21% of total revenue in 2022, compared to 28% in 2021. The
&#8220;Digestive Diseases&#8221; category represented 5% and 4% of total revenue in 2022 and 2021, respectively. The &#8220;Other&#8221;
category represented 13% and 14% of revenues in 2022 and 2021, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2022, our cost
of revenue was $8.6 million, or 106.1% of total revenue, which represented a decrease of $0.7 million from $9.3 million, or 96.4% of
total revenue, in 2021. The increase in the proportion of costs to revenue is mainly due to the decline in revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross Profit (Loss) and Gross (Loss) Margin</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross loss for the year ended December 31, 2022
was $0.5 million, compared to gross profit of $3.0 million in 2021. Our gross loss margin in 2022 was 6.1%, compared to gross profit
margin of 3.6% in 2021. The decrease in our profit and our gross margin was mainly due to the decrease in the sales price of main products
and the increase in the purchase price of main raw materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses for the year ended December
31, 2022 were $1.1 million, a decrease of $0.4 million compared to $1.5 million for the year ended December 31, 2021.&#160;Selling expenses
accounted for 13.2% of the total revenue in 2022 compared to 15.5% in 2021. &#160;Because of adjustments in our sales practices and Chinese
national centralized drug procurement, we reduced selling expenses to efficiently support our sales and the collection of accounts receivable.
Especially in the context of the increasing impact of centralized drug procurement, like other players in the industry, we have reduced
the promotion expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general and administrative expenses for the
year ended December 31, 2022 was $1.9 million, compared to $1.7 million for the year ended December 31, 2021. General and administrative
expenses accounted for 23.4% and 17.1% of our total revenues in 2022 and 2021, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development expenses for the
year ended December 31, 2022 was $0.19 million, compared to $0.32 million in 2021. Research and development expenses accounted for 2.3%
and 3.3% of our total revenues in 2022 and 2021, respectively. These expenditures were mainly spent on the consistency evaluation of
our existing products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Bad Debt Benefit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bad debt benefit for the year ended December
31, 2022 was $93,851, as compared to $255,215 in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, our normal customer credit or payment
terms are 90 days. This has not changed in recent years. Due to the peculiar environment affecting the Chinese pharmaceutical market,
deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are common.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of net accounts receivable that were
past due (or the amount of accounts receivable that were more than 180 days old) was $0.03 million and $0.11 million as of December 31,
2022 and 2021, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates our accounts
receivable aging distribution in terms of the percentage of the total accounts receivable as of December 31, 2022 and 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">1 - 180 Days</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">2.28</td><td style="width: 1%; text-align: justify">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">3.17</td><td style="width: 1%; text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>180 - 360 Days</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">0.16</td><td style="text-align: justify">%</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">0.11</td><td style="text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>360 - 720 Days</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">0.13</td><td style="text-align: justify">%</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">0.24</td><td style="text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&gt; 720 Days</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">97.44</td><td style="padding-bottom: 1.5pt; text-align: justify">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96.48</td><td style="padding-bottom: 1.5pt; text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.00</td><td style="padding-bottom: 4pt; text-align: justify">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.00</td><td style="padding-bottom: 4pt; text-align: justify">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bad debt allowance estimate practice is that
we consider accounts receivable balances aged within 180 days current, except for any individual uncollectible account assessed by management.
We account for the following respective percentage as bad debt allowance based on age of the accounts receivables: 10% of accounts receivable
that are between 180 days and 365 days old, 70% of accounts receivable that are between 365 days and 720 days old, and 100% of accounts
receivable that are greater than 720 days old.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize bad debt expenses per actual write-offs
as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than
that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance
is lower than that of the previous period, we recognize a bad debt credit for the difference. The allowance for doubtful account balances
were $16.7 million and $18.3 million as of December 31, 2022 and December 31, 2021, respectively. The changes in the allowances for doubtful
accounts during the years ended December 31, 2022 and 2021 were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>For the Fiscal Years Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Balance, Beginning of Period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 9%; text-align: right">18,312,707</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 9%; text-align: right">18,150,493</td><td style="width: 1%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Bad debt expense</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">(93,851</td><td style="text-align: justify">)</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">(255,215</td><td style="text-align: justify">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,479,329</td><td style="padding-bottom: 1.5pt; text-align: justify">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">417,429</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance, End of Period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,739,527</td><td style="padding-bottom: 4pt; text-align: justify">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,312,707</td><td style="padding-bottom: 4pt; text-align: justify">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Loss from Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating loss for the year ended December
31, 2022 was $3.5 million, compared to an operating loss of $2.9 million in 2021. The increase in Loss from Operations was mainly due
to the decrease in revenue in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Interest Expense</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net interest expense was $0.42 million for the
year ended December 31, 2022 and $0.54 million for the year ended December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Loss for year ended December 31, 2022 was
$4.0 million, compared to net loss of $3.4 million for the year ended December 31, 2021. The increase in net loss was mainly a result
of the decrease in revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per basic and diluted common share was $0.
76 for the year ended December 31, 2022 and $0.74 for the year ended December 31, 2021, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of basic and diluted weighted-average
outstanding shares used to calculate loss per share was 5,256,855 for 2022, as compared to 4,612,926 for 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal source of liquidity is cash generated
from operations, bank lines of credit and the Convertible Note Payable. Currently the Company has not witnessed or expected to encounter
any difficulties to refinance those lines of credit this year.&#160;In addition to the aggregated advance of $1,425,123 from our CEO
as of December 31,2021, we received some temporary advances from and made several repayments to her in the twelve months ended December
31, 2022. As of December 31, 2022, the aggregated advance from our CEO was $1,121,273 for use in operations. Our cash and cash equivalents
were $2.0 million, representing 11.3% of our total assets, as of December 31, 2022, as compared to $4.9 million, representing 21.5% of
our total assets as of December 31, 2021. All of the $2.0 million of cash and cash equivalents as of December 31, 2022 are considered
to be reinvested indefinitely in the Company&#8217;s Chinese subsidiary, Helpson and are not expected to be available for payment of
dividends or for other payments to its parent company or to its shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company obtained various lines of credit
in details described under Note 7 to its condensed consolidated financial statements contained in this report which is incorporated by
reference herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued a convertible note to an institutional
accredited investor as disclosed in Note 8 to the condensed consolidated financial statements contained in this report which is incorporated
by reference herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although the Company obtained the convertible
note and additional lines of credit in 2021, there can be no assurance that the Company will be able to achieve its future strategic
goal to accelerate the launch of nutrition products. This raises substantial doubt about the Company&#8217;s ability to continue as a
going concern. Although our Chairperson and Chief Executive Officer had advanced funds for working capital during the year ended December
31, 2022, there can be no assurances that this will be the case in the future. We may seek additional debt or equity financing as necessary
when we believe the market conditions are the most advantageous to us and/or require us to reduce certain discretionary spending, which
could have a material adverse effect on our ability to achieve our business objectives.&#160;&#160;There can be no assurance that any
additional financing will be available on acceptable terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities was $0.41
million in the year ended December 31, 2022, compared to $0.25 million in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, our net accounts receivable
was $0.4 million, a decrease of $0.3 million from $0.7 million as of December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, total inventory was $2.9
million, compared to $3.3 million as of December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, net
cash used in investing activities was $0.40 million, compared to $0.44 million for the year ended December 31, 2021. The payments in
2022 were mainly due to the purchase of equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash flow used in financing activities was $1.77
million in the year ended December 31, 2022; compared to cash flow generated in financing activities of $4.60 million in the year ended
December 31, 2021. This change was mainly because of a convertible debt issued in 2021, and the payback of certain bank loans in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to relevant PRC laws, companies registered in the PRC, including
our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under the
accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty
percent (50%) of the companies&#8217; registered capital prior to their remittance of funds out of the PRC.&#160;&#160;Allocations to
these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans,
advances or cash dividends.&#160;As of December 31, 2022 and December 31, 2021, Helpson&#8217;s net assets totaled $(190,000) and $3,447,000,
respectively. Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson&#8217;s net assets that
was designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends,
was 50% of Helpson&#8217;s registered capital, which was both $8,145,000 as of December 31, 2022 and December 31, 2021, respectively.&#160;The
amount that Helpson must set aside for the statutory surplus fund accounts is (4,279)% and 236% of its total net assets.&#160;&#160;There
were no allocations to the statutory surplus reserve accounts during the twelve months ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chinese government also imposes controls
on the conversion of RMB into foreign currencies and the remittance of currencies out of China.&#160;&#160;Our businesses and assets
are primarily denominated in RMB.&#160;&#160;All foreign exchange transactions take place either through the People&#8217;s Bank of China
or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People&#8217;s Bank of China.&#160;Approval
of foreign currency payments by the People&#8217;s Bank of China or other regulatory institutions requires the submission of a payment
application form together with certain invoices and executed contracts.&#160;The currency exchange control procedures imposed by Chinese
government authorities may restrict the ability of Helpson, our Chinese subsidiary, to transfer its net assets to our parent company
through loans, advances or cash dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, we did not have any
off-balance sheet arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management's discussion and analysis of our financial
condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with
United States generally accepted accounting principles (&#8220;GAAP&#8221;). Our financial statements reflect the selection and application
of accounting policies which require management to make significant estimates and judgments. Please refer to Note 1 to our consolidated
financial statements, &#8220;Organization and Significant Accounting Policies&#8221; for the discussion of our critical accounting policies.
..</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
are not required to provide the information required by this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated balance sheets,
as of December 31, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity
and cash flows for each of the two years in the period ended December 31, 2022 and 2021, together with the related notes and the report
of our independent registered public accounting firms, are set forth on the &#8220;F&#8221; pages of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="c_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9A. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain disclosure controls
and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information that would be required
to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time period specified in the SEC&#8217;s
rules and forms, and that such information is accumulated and communicated to our management, including to our Chief Executive Officer
and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by Rule 13a-15
under the Exchange Act, our management, including our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness
of the design and operation of our disclosure controls and procedures as of December 31, 2022. Based on that evaluation, our Chief Executive
Officer and interim Chief Financial Officer concluded that as of December 31, 2022, our disclosure controls and procedures were not effective
to satisfy the objectives for which they are intended due to the material weakness in our internal control over financial reporting discussed
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Report on Internal Control
over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is
defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company&#8217;s
principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#8217;s board
of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and includes
those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of the assets of a company; (ii) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles and that receipts and expenditures
of a company are being made only in accordance with authorizations of management and directors of a company; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company&#8217;s assets that could
have a material effect on the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any system of internal control,
no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or overridden and
misstatements due to error or fraud may occur and not be detected in a timely manner. Also, because of changes in conditions, internal
control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide only reasonable assurance
with respect to financial statement preparation. In addition, the design of any system of controls is based in part on certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under
all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree
of compliance with policies or procedures. Therefore, any current evaluation of controls cannot and should not be projected to future
periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management assessed our internal
control over financial reporting as of the year ended December 31, 2022. In making this assessment, management used the criteria set forth
in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the report entitled &#8220;Internal Control-Integrated
Framework.&#8221; The 2013 COSO framework summarizes each of the components of a company&#8217;s internal control system, including (i)
the control environment, (ii) risk assessment, (iii) control activities, (iv) information and communication, and (v) monitoring.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on management&#8217;s
assessment using the COSO criteria, management has concluded that our internal control over financial reporting was not effective as of
December 31, 2022, to allow our management, employees and consultants, in the normal course of performing their assigned functions, to
prevent or detect misstatements on a timely and reasonable basis and to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A material weakness is a control
deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the
annual or interim financial statements will not be prevented or detected. Our Chief Executive Officer and interim Chief Financial Officer
has determined there existed a material weakness in our internal control over financial reporting as of December 31, 2022, with respect
to our lack of accounting financial reporting personnel knowledgeable in US GAAP. As of the date of this report, we are undertaking steps
to address the aforementioned material weaknesses by obtaining education and training for our personnel regarding the proper accounting
under U.S. GAAP and reviewing the processes to correct the identified weaknesses. Notwithstanding these material weaknesses, management
has concluded that our consolidated financial statements included in this annual report are fairly stated in all material respects in
accordance with U.S. GAAP for each period presented herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we are a smaller reporting
company, this Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding
internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Controls over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our
internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules
13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9B. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="c_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND
CORPORATE GOVERNANCE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Listed below are the names
and ages of all our directors and executive officers as of March 24, 2023, along with their positions, offices and term:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; ">
    <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 65%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President, Chief Executive Officer and interim Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heung Mei Tsui</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gene Michael Bennett</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yingwen Zhang</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baowen Dong</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our independent directors
hold offices until our next annual meeting of the stockholders, at which a successor will be duly elected and qualified or until his or
her earlier resignation, removal from office, death or incapacity. Non-independent directors will hold office for a term of three (3)
years or when their respective successors shall have been elected and shall qualify, or upon their prior death, resignation or removal.
Directors may be re-elected for successive terms. Officers serve at the discretion of the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets forth biographical
information regarding the above directors and executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Zhilin Li</i></b> is
the Chairman, President, Chief Executive Officer and interim Chief Financial Officer of our company. She has served as a director since
2006 and as the President and Chief Executive Officer since 2005. She was a founder of Helpson, and served as Chairman and Chief Executive
Officer of Helpson from 1993 to 2005. Ms. Li was formerly the president of Haikou Bio-Engineering Institute as well as the vice president
of Sichuan Institute of Biology. She graduated from Sichuan University with a degree in biology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Heung Mei Tsui</i>&#160;</b>has
served as a director of the Company since April 28, 2009. Previously, Ms. Tsui served as a member of our board from October 2005 to February
2008. Ms. Tsui has been a self-employed businesswoman engaged in strategic investments and was previously engaged in the pharmaceutical
chemical raw material import/export business. Ms. Tsui graduated from Hunan Financial&amp; Economic College in 1982.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Gene Michael Bennett</i></b>
has served as our independent director since February 2008. Presently, Mr. Bennett is Chairman of the board of directors for Bonita Healthcare
Ltd, Houston, Texas, USA, and Chairman of the Board of Redwood Senior Living Inc. located in Alameda County, California, USA. From 2013
through 2015 Mr. Bennett served as part-time CFO for Kang Jia Fu, Royal Traditional Health Investment Management Co. Ltd, located in Wuxi,
Jiangsu Province, China and advisor to Swiss Capital Asia, located in Hong Kong. From 2009 through 2013, Mr. Bennett served as the CEO
of American General Business Association, located in Beijing, China. Mr. Bennett was a partner of Nexis Investment Consulting Corporation
based in Beijing from 2004-2009. He was a partner of ProCFO Company based in California which provided contract chief financial officer
service for firms during 2000-2004. During 1998-2000, he was a basic law, accounting and tax professor at University of Hawaii, and an
accounting, tax and audit professor at Chaminade University of Honolulu, Hawaii, USA. In addition, he previously served as the chief financial
officer and member of the board of directors of Argonaut Computers in Southern California. Mr. Bennett worked as an accounting and audit
professor at Chapman University and an accounting, tax, and audit professor at California State University at Fullerton. He also acted
as chief financial officer and a board member of the National Automobile Club. Mr. Bennett graduated from Michigan State University with
an MBA in Finance and BA in Accounting. He obtained his CPA license from the State of Colorado, which is currently inactive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Yingwen Zhang</i></b>
has served as our independent director since February 2008. He also currently serves as a consultant of Shanghai Reseat Medical Tech Co.
Ltd., a medical device producer. He acted as Senior Consultant and Chairman of HSE (Health Safe and Environment) Committee of SINOFERT
Holdings Limited (HKG: 0297) of SINOCHEM Group from October 2005 to June 2009. He served as an independent director of a public company,
Chongqing New Energy Co., Ltd. (SH.600847), from 2007 to 2018. Additionally, Mr. Zhang was appointed as the Commercial Counselor of the
China Embassy in Malaysia from March 2000 through October 2005. Prior to that, from 1988 to 2000, Mr. Zhang was appointed as the Director-General
to Sichuan Provincial Foreign Trade and Economic Cooperation Bureau (the Commercial Bureau of Sichuan Province, China). In his early career
he was a chemical engineer and senior economist, and then became a senior manager for several chemical corporations in China. From 1983
to 1988, Mr. Zhang served as vice CEO and then CEO of a large nature gas-chemical state owned enterprise (SOE) in the PRC affiliated with
the SINOPEC Group. Mr. Zhang graduated from the Chemical Engineering Department of Tianjin University in 1967.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Baowen Dong</i></b>
has served as our independent director since February 2008. Mr. Dong participated on the expert team of the Sichuan University from 2003
to 2008, doing teaching evaluation and assessment work in Engineering and Medical Science faculty. In the past few years, Mr. Dong has
focused on the research of China&#8217;s Health Care Reform. Previously, he concentrated on biomedical and medical information researches.
Mr. Dong has had different roles in areas of teaching and research, including serving as a department head and a professor, at Sichuan
University from 1974 to 2001. Additionally, Mr. Dong was engaged in the field of communication technology from 1966 to 1974. Mr. Dong
graduated from Xidian University in 1966.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
among our directors or executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director or Officer Involvement in Certain
Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, our directors
and executive officers were not involved in any legal proceedings as described in Item 401(f) of Regulation S-K in the past ten years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Section 16(a) Beneficial Ownership Reporting
Compliance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 16(a) of the Securities
Exchange Act of 1934, as amended, requires our directors, executive officers and persons who own more than 10% a registered class of our
equity securities (&#8220;Reporting Persons&#8221;), to file reports of ownership and changes in ownership on Forms 3, 4 and 5 with the
SEC. The Reporting Persons are also required by SEC rules to furnish us with copies of Section 16(a) forms they file. Based upon a review
of the filings made on their behalf during the fiscal year ended December 31, 2022 as well as an examination of the SEC&#8217;s EDGAR
system Form 3, 4, and 5 filings (including amendments to such forms) and our records, we believe that, during the year ended December
31, 2022, the Reporting Persons met all applicable Section 16(a) filing requirements except for the following: (i) Ke Deng did not timely
file Form 3 after being granted 1,552,230 shares on December 30, 2022. However, the Form 3 corresponding to the transaction was subsequently
filed on March 9, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2008, we adopted
a code of business conduct and ethics for all directors and employees (including officers) within the meaning of the regulations adopted
by the SEC under Section 406 of the Sarbanes-Oxley Act of 2002. The code has been designed to deter wrongdoing and promote (i) honest
and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships,
(ii) full, fair, accurate, timely, and understandable disclosure in reports and documents that we file with, or submit to, the SEC and
in other public communications made by us, (iii) compliance with applicable governmental laws, rules and regulations, (iv) the prompt
internal reporting of violations of the code to an appropriate person or persons, and (v) accountability for adherence to the code. The
application of the code to the persons it applies to may only be waived by our Board of Directors in accordance with SEC regulations and
the Sarbanes-Oxley Act of 2002. A copy of the code is available on our website at <span style="text-decoration:underline;text-decoration: none">www.chinapharmaholdings.com</span> or may be obtained
by sending a written request to our corporate secretary at China Pharma Holdings, Inc., Second Floor, No. 17, Jinpan Road, Haikou, Hainan
Province, China 570216.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 1, 2008, we established
an audit committee, which currently consists of our three independent directors: Gene Michael Bennett, Yingwen Zhang and Baowen Dong.
Mr. Bennett, the Chairman of the Audit Committee, is an &#8220;audit committee financial expert&#8221; as defined in Item 401(d)(5) of
Regulation S-K promulgated under the Securities Act. The audit committee carries out its responsibilities in accordance with the terms
of its Audit Committee Charter, a copy of which attached as Exhibit 99.1 to our Annual Report on Form 10-K filed on March 17, 2009, and
available on our website at <span style="text-decoration:underline;text-decoration: none">www.chinapharmaholdings.com</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 11. EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Executive Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information concerning all cash and non-cash compensation awarded to, earned by or paid to our principal executive officer and principal
financial officer during the last two fiscal years in all capacities to our Company and our subsidiaries. No other executive officer received
compensation in excess of $100,000 during the fiscal year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SUMMARY COMPENSATION TABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Name and</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Option</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Non-Equity<br/>
Incentive Plan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Nonqualified<br/>
Deferred</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">All Other</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">principal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Salary</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Bonus</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Compensation</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Compensation</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Compensation</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; border-bottom: Black 1.5pt solid; font-weight: bold">position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ended</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">($)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Earnings ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; width: 23.5%">Zhilin Li</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 9%; text-align: center">2022</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 7%; text-align: right">225,600</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 7%; text-align: right">16,000</td><td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: justify">&#160;</td><td style="width: 7%; text-align: right">241,600</td><td style="width: 0.5%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">Chairman, Chief</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td>&#160;</td>
    <td style="text-align: right">225,600</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">16,000</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">241,600</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">Executive Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">President and interim Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Zhilin Li</i></b>. Hainan
Helpson Medical &amp; Biotechnology Co., Ltd., our wholly-owned subsidiary and operating entity in the PRC (&#8220;Helpson&#8221;), entered
into an employment agreement with Ms. Zhilin Li, our Chairman of the Board and Chief Executive Officer. Upon the expiration of the original
agreement, Helpson renewed the agreement with Ms. Li on the same terms as the original agreement. The new employment agreement will expire
on June 30, 2025. Pursuant to the terms of the new employment agreement, Ms. Li agreed to continue to serve as Helpson&#8217;s Chief Executive
Officer for a term of five years at an annual salary of RMB800,000. Helpson may adjust Ms. Li&#8217;s compensation based upon her production
and operating achievement and her technical ability and working performance. Ms. Li&#8217;s total annual cash compensation for the fiscal
year ended December 31, 2022, when aggregated with her compensation from our U.S. holding company level, was $241,600.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Payments upon Termination or Change-in-Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>PRC Law. </i>Under the
applicable laws of the PRC, we must pay severance to all employees who are Chinese nationals and who are terminated with or without cause,
or whose employment agreement with us expires and we choose not to continue their employment. The severance benefit required to be paid
under the laws of the PRC equals the average monthly compensation paid to the terminated employee (including any bonuses or other payments
made in the 12 months prior to the employee&#8217;s termination) multiplied by the number of years the employee has been employed with
us, plus an additional month&#8217;s salary if 30 days&#8217; prior notice of such termination has not been given. However, if the average
monthly compensation to be received by the terminated employee exceeds three times the average monthly salary of the employee&#8217;s
local area, as determined and published by the local government, such average monthly compensation shall be capped at three times the
average monthly salary of the employee&#8217;s local area. Except as described above, our executive officer does not have any other agreement
or arrangement under which she may be entitled to severance payments upon termination of employment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year-End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Discussion of Summary Compensation and Grants
of Plan-based Awards Tables</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of certain material
terms of our existing compensation plans and arrangements is set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 12, 2010, our Board of Directors adopted, and on December
22, 2010 our stockholders approved the 2010 Long-Term Incentive Plan (the &#8220;2010 Incentive Plan&#8221;). On October 17, 2019, the
Board of Directors approved the First Amendment to the 2010 Incentive Plan (the &#8220;Amendment No. 1&#8221;), pursuant to which the
term of the 2010 Incentive Plan shall be extended to December 31, 2029. The Amendment No. 1 was adopted by the stockholders on December
19, 2019. The 2010 Incentive Plan, as amended, gave us the ability to grant stock options, restricted stock, stock appreciation rights
and performance units to employees, directors and consultants, or those who will become employees, directors and consultants of our company
and/or our subsidiaries. On October 25, 2021, our Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment
No.2 to our 2010 Long-Term Incentive Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 500,000
(5,000,000 pre reverse stock split) shares from 400,000 (4,000,000 pre reverse stock split) shares to 900,000 (9,000,000 pre reverse stock
split) shares.&#160; On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended
and Restated 2010 Long Term Incentive Plan (the &#8220;Plan&#8221;) to increase the number of shares of common stock that are reserved
thereunder by an additional 500,000 (5,000,000 pre reverse stock split) shares from 900,000 (9,000,000 pre reverse stock split) to 1,400,000
(14,000,000 pre reverse stock split). Through December 31, 2022, there were 490,000 (4,900,000 pre reverse stock split) shares of stock
and stock options granted under the Plan.&#160; A total of 66,500 (665,000 pre reverse stock split) options were outstanding as of December
31, 2022 under the Plan. As such, there are 910,000 (9,100,000 pre reverse stock split) additional shares available for issuance under
the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information concerning cash and non-cash compensation earned by or paid to our directors during the year ended December 31, 2022.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="27" style="font-weight: bold; text-align: center">DIRECTOR COMPENSATION</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="27" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees <br/> Earned <br/> or <br/> Paid in <br/> Cash <br/> ($)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock <br/> Awards <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <br/> Awards <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity <br/> Incentive <br/> Plan <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Qualified <br/> Deferred <br/> Compensation <br/> Earnings <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All <br/> Other <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 16%; text-align: justify">Heung Mei Tsui</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">16,000</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;-</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">16,000</td><td style="width: 1%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">Zilin Li</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">Gene Michael Bennett</td><td>&#160;</td>
    <td style="text-align: right">16,000</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">16,000</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">Yingwen Zhang</td><td>&#160;</td>
    <td style="text-align: right">6,202</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">6,202</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">Baowen Dong</td><td>&#160;</td>
    <td style="text-align: right">6,202</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">-</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">6,202</td><td style="text-align: justify">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors will also be
reimbursed for all of their out-of-pocket expenses in traveling to and attending meetings of our Board of Directors and committees on
which they serve.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ms. Zhilin Li, our Chairman,
President and Chief Executive Officer, was also compensated for serving on our board of directors as set forth in the Summary Compensation
Table appearing earlier in this Item 11.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Engagement Letters&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 28, 2021, we renewed
the engagement letters with each of our three independent directors. Pursuant to the renewed engagement letters entered into on the same
terms and conditions as the previous engagement letters and for a term of one year, each of Mr. Zhang and Mr. Dong is entitled to receive
annual compensation of RMB40,000 (approximately $6,202), payable quarterly and Mr. Bennett is entitled to receive annual compensation
of $16,000, payable quarterly, and a warrant to purchase 5,000 shares of common stock at an exercise price of $0.45 per share. As of the
date of this report, no warrants have been issued to Mr. Bennett.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="c_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDERS MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
certain information as of March 24, 2023, with respect to the beneficial ownership of our common stock, the sole outstanding class of
our voting securities, by (i) any person or group owning more than 5% of each class of voting securities, (ii) each director, (iii) each
executive officer and (iv) all executive officers and directors as a group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2023, an aggregate of 8,458,094 shares of our common
stock were outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name and Address of Beneficial Owners(1)(2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amount
and<br/>
 Nature of<br/>
 Beneficial<br/>
Ownership</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent of Class(3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify">Directors and Executive Officers</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Zhilin Li <br/>President, Chief Executive Officer, <br/>Interim Chief Financial Officer <br/>and Chairman of the Board</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">1,381,000</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right">16.3</td><td style="width: 1%; text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Heung Mei Tsui <br/>Director</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">931,265</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">11.0</td><td style="text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Yingwen Zhang <br/>Director</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">0</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gene Michael Bennett (4) <br/>Director</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">0</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Baowen Dong <br/>Director</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">0</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">All directors and executive officers as a group (5 persons)</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">2,312,265</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">27.3</td><td style="text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: justify">Beneficial stockholders with 5% or more ownership</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Ke Deng</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">1,552,229</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">18.33</td><td style="text-align: justify">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Streeterville Capital LLC(5)</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">515,909</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">9.99</td><td style="text-align: justify">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than 1%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Rule 13d-3 under the Exchange Act, a person has beneficial ownership of any securities as to which such person, directly or indirectly, through any contract, arrangement, undertaking, relationship or otherwise has or shares voting power and/or investment power or as to which such person has the right to acquire such voting and/or investment power within 60 days.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise stated, each beneficial owner has sole power to vote and dispose of the shares and the address of such person is c/o China Pharma Holdings, Inc., 2nd Floor, No. 17 Jinpan Road, Haikou, Hainan Province, People&#8217;s Republic of China 570216.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the percentage of common stock owned by the beneficial
owners, (a) the numerator is the number of shares of common stock beneficially owned by such owner, including shares the owner may acquire,
within 60 days of March 24, 2023, upon the exercise of the options or warrants, if any, held by the owner; and (b) the denominator is
the sum of (i) the total 8,458,094 shares of common stock outstanding as of March 24, 2023, and (ii) the number of shares underlying any
options or warrants, which such owner has the right to acquire upon the exercise of such options or warrants within 60 days of March 24,
2023 (for those who have options or warrants).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of his engagement letters, Mr. Bennett is entitled to receive warrants to purchase an aggregate of 70,000 shares of our common stock (5,000 shares in each of year between 2008 to 2022 fiscal years). As of the date of this report no such warrants were issued.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the Schedule 13G filed by the shareholder on December 5,
2022, the number of shares of the common stock beneficially owned by Streeterville as of the date above was 515,909 shares, which is 9.99%
of the 5,164,253 shares outstanding on November 9, 2022</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="c_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ms. Tsui, one of our directors,
has made various loans to the Company. The balance of such loans from Ms. Tsui remained $1,354,567 as of December 31, 2022 and 2021. The
loans bear interest at a rate of 1% per annum and principal and interest were payable by December 31, 2022, pursuant to a loans extension
confirmation letter executed by the Company and Ms. Tsui in 2021. We recognized interest expense of $13,546 and $13,546 for the years
ended December 31, 2022 and 2021, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company received net advances
totaling $0 and $1,183,414 and repaid $223,013 and $562,659 of the advances during the years ended December 31, 2022 and 2021, respectively
from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer as of December 31, 2022 and 2021, respectively. On July
8, 2019 the Company entered into a loan agreement to borrow cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief Executive Officer
and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement.
The due date of the loan agreement was extended to July 10, 2021 and further extended to July 9, 2022, and further extended to July 9,
2023 on identical terms. Total interest expense related to the loan for the year ended December 31, 2022 and 2021 was $28,962 and $30,194.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Independence of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors has
determined that Gene Michael Bennett, Baowen Dong and Yingwen Zhang are &#8220;independent directors&#8221; as defined in the listing
standards of NYSE American.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Fees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate fees billed
by <span>B F Borgers CPA PC, </span>our principal accountant, for professional services rendered for the
audit of our annual financial statements included in our Annual Reports on Form 10-K, for the reviews of the financial statements included
in our Quarterly Reports on Form 10-Q, and for services in connection with statutory and regulatory filings or engagements were approximately
$100,000 for the fiscal year ended December 31, 2022, and 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit-Related Fees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not incur any audit-related
fees during the fiscal years ended December 31, 2022 and 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Fees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not incur any tax fees
during the fiscal year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>All Other Fees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not engage our principal
accountant to render services to us during the last two fiscal years, other than as reported above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-Approval Policies and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Sarbanes-Oxley Act
of 2002, all audit and non-audit services performed by our auditors must be approved in advance by our Audit Committee to assure that
such services do not impair the auditors&#8217; independence from us. In accordance with its policies and procedures, the Audit Committee
pre-approved the audit service performed by <span>B F Borgers CPA PC</span>, for our consolidated financial
statements as of and for the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="c_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART IV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="c_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The following documents
are filed as part of this report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following financial statements
of China Pharma Holdings, Inc. and Reports of Independent Registered Public Accounting Firms are presented in the &#8220;F&#8221; pages
of this report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top; width: 94%"><a href="#Fin_001">Report of B F Borgers CPA PC, Independent Registered Public Accounting Firm</a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 6%">F-2</td></tr>
<tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_002">Consolidated Balance Sheets - as of December 31, 2022 and 2021</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_003">Consolidated Statements of Operations and Comprehensive Loss - for the years ended December 31, 2022 and 2021</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_004">Consolidated Statements of Stockholders' Equity - for the years ended December 31, 2022 and 2021</a></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt">F-5</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_005">Consolidated Statements of Cash Flows - for the years ended December 31, 2022 and 2021</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">F-7<span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Exhibits</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See the Exhibit Index following
the signature page of this report, which Index is incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="c_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 30, 2023</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHINA PHARMA HOLDINGS, INC.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="width: 35%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="text-align: center; width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; width: 51%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="text-align: center; width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board, President, Chief Executive Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2023</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer) and interim Chief Financial Officer<br/>
(principal financial officer and principal accounting officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Heung Mei Tsui</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2023</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heung Mei Tsui</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gene Michael Bennett</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2023</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gene Michael Bennett</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Yingwen Zhang</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2023</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yingwen Zhang</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Baowen Dong</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2023</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baowen Dong</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="c_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit Index to Annual Report on Form 10-K</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Fiscal Year Ended December 31, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex3-1_china.htm">Amended and Restated Articles of Incorporation of the Company filed with the State of Nevada on March 1, 2023.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054913000005/cphi8kex32010413.htm">Bylaws
    of the Company (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on December 31, 2012).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390021061610/ea151262ex4-1_chinapharma.htm">Convertible
    Promissory Note dated November 17, 2021 (incorporated by reference to our Current Report on Form 8-K filed on November 23, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390022016151/f10k2021ex4-2_chinapharma.htm">Description
    of Securities Registered Pursuant to Section 12 of the Exchange Act (incorporated by reference to our Annual Report on Form 10-K
    filed on March 30, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/f10k2018ex10-1_chinapharma.htm">Offer
    Letter dated December 12, 2018 from the Company and accepted by Ms. Heung Mei Tsui for Ms. Tsui serving as a director of the Company
    (incorporated by reference to Exhibit 10.1 to our Annual Report on Form 10-K filed on March 28, 2019).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/f10k2018ex10-2_chinapharma.htm">Offer
    Letter dated December 12, 2018 from the Company and accepted by Ms. Zhilin Li for Ms. Li serving as a director of the Company (incorporated
    by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 28, 2019).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054915000090/cphi10kex102123114.htm">Form
    of Independent Director Engagement Letter (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March
    30, 2015).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054916000541/ex101.htm">Employment Agreement dated July 1, 2015 between Hainan Helpson Medical &amp; Biotechnology Co., Ltd. and Zhilin Li (incorporated by reference to Exhibit 10.1 to our Annual Report on Form 10-K filed on March 30, 2016).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/f10k2019ex10-5_chinapharma.htm">Loans
    Extension Confirmation Letter between the Company and Heung Mei Tsui confirming the extension of the loans (incorporated by reference
    to Exhibit 10.5 to our Annual Report on Form 10-K filed on March 30, 2020).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054910000706/cphi14a111210.htm">2010
    Long-Term Incentive Plan of the Company (incorporated by reference to the Definitive Proxy Statement on Schedule 14A filed on November
    12, 2010).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054911000554/cphi8kex101060111.htm">Form
    of Restricted Stock Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company (incorporated
    by reference to our Current Report on Form 8-K filed on June 1, 2011).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054911000554/cphi8kex102060111.htm">Form
    of Non-Qualified Stock Option Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company
    (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390019022241/def14a1119_chinapharma.htm">First
    Amendment to the 2010 Long-Term Incentive Plan of China Pharma Holdings, Inc. (incorporated by reference to our Proxy Statement on
    Schedule 14A filed on November 6, 2019).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390021059533/ea150670-def14a_chinapharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to the 2010 Long-Term Incentive Plan of China Pharma Holdings, Inc. (incorporated by reference to our Proxy Statement on Schedule 14A filed on November 15, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex10-11_china.htm">Loans
    Extension Confirmation Letter, dated December 31, 2022, between the Company and Heung Mei Tsui confirming the extension of the loans
    to December 31, 2023.</a></span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390021061610/ea151262ex10-1_chinapharma.htm">Securities Purchase Agreement between China Pharma Holdings, Inc. and Streeterville Capital, LLC dated November 17, 2021 (incorporated by reference to our Current Report on Form 8-K filed on November 23, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/ea169540ex10-1_chinapharma.htm">Technology Transfer Contract between Hainan Helpson Medical &amp; Biotechnology Co., Ltd and Chengdu Bonier Medical Technology Development Co., Ltd. dated November 28, 2022 (incorporated by reference to our Current Report on Form 8-K filed on December 2, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054908000562/cphs1ex141071108.txt">Code of Business Conduct and Ethics (incorporated by reference to the Registration Statement on Form S-1 filed on July 11, 2008).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054911000201/ex211.htm">Subsidiaries of the Company (incorporated by reference to our Annual Report on Form 10-K filed on March 3, 2011).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex23-1_china.htm">Consent of the Independent Accounting Firm.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="f10k2022ex31-1_china.htm"><span style="font-family: Times New Roman, Times, Serif">Certification
    of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="f10k2022ex31-2_china.htm"><span style="font-family: Times New Roman, Times, Serif">Certification
    of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="f10k2022ex32-1_china.htm"><span style="font-family: Times New Roman, Times, Serif">Certification
    of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
    the Sarbanes-Oxley Act of 2002.</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101*</td>
    <td>&#160;</td>
    <td style="text-align: justify">Interactive data files pursuant to Rule 405 of Regulation S-T</td></tr>
<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
    Document.</span></td></tr>
<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase
    Document.</span></td></tr>
<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
    Document.</span></td></tr>
<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline
    XBRL and contained in Exhibit 101).</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
                                            filed herewith.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="c_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CHINA
PHARMA HOLDINGS, INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><a href="#Fin_001">Report of B F Borgers CPA PC, Independent Registered Public Accounting Firm</a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-2</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top; width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_002">Consolidated
    Balance Sheets as of December 31, 2022 and 2021</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_003">Consolidated
    Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_004">Consolidated
    Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_005">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_006">Notes
    to Consolidated Financial Statements</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">F-7<span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 70; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="Fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the stockholders and the board of directors of China Pharma Holdings, Inc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of China Pharma Holdings, Inc. and its subsidiaries (collectively the &#8220;Company&#8221;)
as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217;
equity, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred
to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the two
years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
concern uncertainty</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company incurred recurring losses from operations, has net current liabilities and an accumulated
deficit that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters
are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that
was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material
to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication
of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are
not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or
disclosures to which it relates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Valuation
of long-lived assets</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 1 of the Company&#8217;s financial statements, the Company performs an annual impairment assessment of&#160;its long-lived
assets, including property, plant, and equipment, intangible assets, and operating lease right-of-use assets, or more frequently if events
or circumstances indicate that the carrying values may not be recoverable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditing
the recoverability of long-lived assets involved complex judgment due to the significant estimation required in determining the future
cash flows of the long-lived assets. Specifically, the cash flow forecasts were sensitive to significant assumptions about future market
and economic conditions. Significant assumptions used in the Company&#8217;s recoverability estimates included sales volume, pricing,
cost of raw materials and labor, marketing spending, general and administrative expenses, and tax rates, as applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
obtained an understanding of the controls over the Company&#8217;s annual impairment assessments for long-lived assets and tested the
estimated future cash flows of the long-lived assets based on our risk assessments. Our audit procedures included, among others, comparing
significant inputs to observable third party and industrial sources, and evaluating the reasonableness of management&#8217;s projected
financial information by comparing to observable average industry historical trends and projections, and other internal and external
data. We performed sensitivity analyses of significant assumptions to evaluate the change in the fair value of the long-lived assets
and assessed the historical accuracy of management&#8217;s estimates. We also assessed the Company&#8217;s disclosure of its annual impairment
assessments included in Note 1.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<ix:nonNumeric contextRef="c0" name="dei:AuditorName">B F Borgers CPA PC</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2016.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lakewood,
Colorado</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
30, 2023&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(PCAOB
ID Number&#160;<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">5041</ix:nonNumeric>)</span></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="Fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><span style="font-size: 10pt"><b>CHINA
PHARMA HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><span style="font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 10pt">ASSETS</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Current Assets:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">2,029,971</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">4,859,059</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Banker&#8217;s acceptances</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:BankersAcceptances" scale="0" unitRef="usd">13,784</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:BankersAcceptances" scale="0" unitRef="usd">91,362</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: -0.125in"><span style="font-size: 10pt">Trade accounts receivable, less allowance for doubtful accounts of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:TradeAccountsReceivableLessAllowance" scale="0" unitRef="usd">16,739,527</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:TradeAccountsReceivableLessAllowance" scale="0" unitRef="usd">18,312,707</ix:nonFraction>, respectively</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">421,531</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">714,475</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: -0.125in"><span style="font-size: 10pt">Other receivables, less allowance for doubtful accounts of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">27,149</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">32,210</ix:nonFraction>, respectively</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd">29,139</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd">29,564</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Advances to suppliers</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:AdvanceToSupplies" scale="0" unitRef="usd">444,637</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:AdvanceToSupplies" scale="0" unitRef="usd">471</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt"><span style="font-size: 10pt">Inventory</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,947,787</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">3,339,686</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Prepaid expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">77,697</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">58,792</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Total Current Assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">5,964,546</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,093,409</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Property, plant and equipment, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">9,973,065</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">13,280,559</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Operating lease right of use asset</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">39,046</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">127,958</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Intangible assets, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">1,807,486</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">147,841</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">TOTAL ASSETS</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">17,784,143</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">22,649,767</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Current Liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Trade accounts payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd">667,082</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd">926,749</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Accrued expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">404,807</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">298,452</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Other payables</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd">2,390,063</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd">1,884,161</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Advances from customers</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd">520,295</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd">210,028</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Borrowings from related parties</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">2,475,840</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">2,779,690</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Operating lease liability</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">40,445</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">85,282</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Current portion of lines of credit</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LinesOfCreditCurrent" scale="0" unitRef="usd">2,440,915</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LinesOfCreditCurrent" scale="0" unitRef="usd">4,328,936</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Convertible, redeemable note
    payable, net of issue discount</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermConstructionLoanCurrent" scale="0" unitRef="usd">3,800,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Total Current Liabilities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">12,739,447</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">10,513,298</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Non-current Liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Convertible, redeemable note payable, net of issue
    discount</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="0" unitRef="usd">5,250,000</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Operating lease liability, net of current portion</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">44,181</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Deferred tax liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" unitRef="usd">754,698</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" unitRef="usd">824,407</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Total Liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">13,494,145</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">16,631,886</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Commitments and Contingencies (Note 9)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0"><span style="font-size: 10pt">&#160;</span></div></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1"><span style="font-size: 10pt">&#160;</span></div></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Stockholders&#8217; Equity:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: -0.125in"><span style="font-size: 10pt">Preferred stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <span style="-sec-ix-hidden: hidden-fact-4"><span style="-sec-ix-hidden: hidden-fact-5"><span style="-sec-ix-hidden: hidden-fact-6"><span style="-sec-ix-hidden: hidden-fact-7">no</span></span></span></span> shares issued or outstanding</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: -0.125in"><span style="font-size: 10pt">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">7,490,896</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">4,733,956</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">74,909</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">47,340</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Additional paid-in capital</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">28,853,520</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">25,645,367</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Retained deficit</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">36,211,496</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">32,238,655</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Accumulated other comprehensive
    income</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">11,573,065</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">12,563,829</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Total Stockholders&#8217;
    Equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">4,289,998</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,017,881</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217;
    EQUITY</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">17,784,143</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">22,649,767</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>



</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="Fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA
PHARMA HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>AND COMPREHENSIVE
LOSS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Years</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Ended
    December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-size: 10pt">Revenue</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">8,104,092</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">9,641,925</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Cost of revenue</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">8,598,008</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">9,292,655</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Gross (loss) profit</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd">493,916</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">349,270</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Operating expenses:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Selling expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd">1,069,785</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd">1,495,007</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">General and administrative expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,893,269</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,651,024</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Research and development expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">185,858</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">318,964</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Bad debt benefit</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">93,851</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">255,215</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Total operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">3,055,061</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">3,209,780</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Loss from operations</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">3,548,977</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">2,860,510</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Other income (expense):</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Interest income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd">10,755</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd">3,035</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Interest expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">434,619</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">542,001</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Net other expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">423,864</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">538,966</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Loss before income taxes</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">3,972,841</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">3,399,476</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Income tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-8; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Net loss</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">3,972,841</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">3,399,476</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Other comprehensive income (loss) - foreign
    currency translation adjustment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">990,764</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">218,383</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Comprehensive loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">4,963,605</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">3,181,093</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-size: 10pt">Loss per share:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="-sec-ix-hidden: hidden-fact-11; -sec-ix-hidden: hidden-fact-10; font-size: 10pt">Basic and diluted</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.76</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.74</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Weighted average shares outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">5,256,855</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">4,612,926</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>



</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="Fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA
PHARMA HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Additional<br/> Paid-in</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Retained</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Accumulated<br/> Other<br/> Comprehensive</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Total <br/> Stockholders&#8217;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Income</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-weight: bold"><span style="font-size: 10pt">Balance, December
    31, 2020</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">4,557,956</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">45,580</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">24,452,684</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">28,839,179</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,345,446</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,004,531</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-size: 10pt">Stock option compensation</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">15,243</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">15,243</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-size: 10pt">Issuance of common stock
    in lieu of compensation</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">176,000</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">1,760</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">1,177,440</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">1,179,200</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-size: 10pt">Net loss for the year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">3,399,476</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">3,399,476</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Foreign
    currency translation adjustment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-15; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" unitRef="usd">218,383</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" unitRef="usd">218,383</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-size: 10pt">Balance, December 31, 2021</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">4,733,956</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">47,340</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">25,645,367</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">32,238,655</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,563,829</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,017,881</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-size: 10pt">Issuance of common stock
    for intangible assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares">1,552,229</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">15,522</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">1,691,930</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">1,707,452</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-size: 10pt">Stock option compensation</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">36,270</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">36,270</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-size: 10pt">Issuance of common stock
    for services</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">30,000</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">300</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">41,700</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">42,000</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-size: 10pt">Conversions of note payable
    to common stock</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">1,174,711</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">11,747</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">1,438,253</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">1,450,000</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-size: 10pt">Net loss for the year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">3,972,841</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">3,972,841</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Foreign
    currency translation adjustment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd">990,764</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd">990,764</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">Balance,
    December 31, 2022</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">7,490,896</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">74,909</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">28,853,520</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">36,211,496</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">11,573,065</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">4,289,998</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="Fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA
PHARMA HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Years</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Ended
    December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 10pt">Cash Flows from Operating Activities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Net loss</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">3,972,841</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">3,399,476</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Depreciation and amortization</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">2,700,533</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">3,087,820</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Bad debt benefit</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">93,851</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">255,215</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Stock and stock option compensation</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="0" unitRef="usd">78,270</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="0" unitRef="usd">15,243</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Original issue discount accretion</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="0" sign="-" unitRef="usd">250,000</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Changes in assets and liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 20pt"><span style="font-size: 10pt">Trade accounts and other receivables</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="0" unitRef="usd">170,194</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="0" unitRef="usd">545,534</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 20pt"><span style="font-size: 10pt">Advances to suppliers</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:AdvancesToSuppliers" scale="0" unitRef="usd">459,959</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="cphi:AdvancesToSuppliers" scale="0" sign="-" unitRef="usd">1,798</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 20pt"><span style="font-size: 10pt">Inventory</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">689,104</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">1,011,905</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 20pt"><span style="font-size: 10pt">Trade accounts payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" sign="-" unitRef="usd">187,734</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" sign="-" unitRef="usd">332,779</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 20pt"><span style="font-size: 10pt">Other payables and accrued expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd">692,190</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd">415,309</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 20pt"><span style="font-size: 10pt">Advances from customers</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd">339,659</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" sign="-" unitRef="usd">520,414</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 20pt"><span style="font-size: 10pt">Prepaid expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" unitRef="usd">24,722</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" sign="-" unitRef="usd">21,505</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Net Cash Used in Operating
    Activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">409,545</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">249,838</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Cash Flows from Investing Activities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Purchases of property and
    equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">401,964</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">438,055</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Net Cash Used in Investing
    Activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">401,964</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">438,055</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Cash Flows from Financing Activities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Payments of construction term loan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConstructionLoansPayable" scale="0" unitRef="usd">2,325,039</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 10pt"><span style="font-size: 10pt">Payments of line of credit</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="0" sign="-" unitRef="usd">2,140,921</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="0" sign="-" unitRef="usd">2,526,542</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Proceeds from lines of credit</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="0" unitRef="usd">564,965</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Borrowings and interest from related party</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd">28,962</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd">1,183,414</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Repayments to related party</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">223,013</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">562,659</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt"><span style="font-size: 10pt">Proceeds from convertible redeemable debt</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" unitRef="usd">5,000,000</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Proceeds from lines of credit</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" unitRef="usd">3,828,564</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Net Cash (Used In) Provided
    By Financing Activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" sign="-" unitRef="usd">1,770,007</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">4,597,738</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Effect of Exchange Rate Changes
    on Cash</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" sign="-" unitRef="usd">247,572</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" sign="-" unitRef="usd">8,439</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Net Increase in Cash, Cash Equivalents and Restricted
    Cash</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">2,829,088</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">3,901,406</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Cash and Cash Equivalents at Beginning of Period</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,859,059</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">957,653</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Cash, Cash Equivalents and
    Restricted Cash at End of Period</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">2,029,971</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,859,059</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Supplemental Cash Flow Information:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Cash paid for income taxes</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-size: 10pt">Cash paid for interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">141,797</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">218,232</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Supplemental Noncash Investing and Financing Activities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Accounts receivable collected with banker&#8217;s acceptances</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:AccountsReceivableCollectedWithBankersAcceptances" scale="0" unitRef="usd">503,383</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="cphi:AccountsReceivableCollectedWithBankersAcceptances" scale="0" unitRef="usd">601,021</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Inventory purchased with banker&#8217;s acceptances</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:InventoryPurchasedWithBankersAcceptanceNote" scale="0" unitRef="usd">575,713</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="cphi:InventoryPurchasedWithBankersAcceptanceNote" scale="0" unitRef="usd">565,079</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Right-of-use assets obtained in exchange for operating lease obligations</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd">168,606</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Common stock issued for intangible assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:ConversionOfOfficerWagesToCommonStock" scale="0" unitRef="usd">1,707,452</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Common stock issued for compensation</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">1,179,200</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="Fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA
PHARMA HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock-c0_cont_1" escape="true" name="cphi:OrganizationAndNatureOfOperationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Nature of Operations &#8211;&#160;</i></b>China Pharma Holdings, Inc., a Nevada corporation (the &#8220;Company&#8221;), owns <ix:nonFraction contextRef="c27" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>%
of Onny Investment Limited (&#8220;Onny&#8221;), a British Virgin Islands corporation, which owns <ix:nonFraction contextRef="c28" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of Hainan Helpson Medical &amp;
Biotechnology Co., Ltd (&#8220;Helpson&#8221;), a company organized under the laws of the People&#8217;s Republic of China (the &#8220;PRC&#8221;).
China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock-c0_cont_2" id="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Onny
acquired <ix:nonFraction contextRef="c29" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#8217;s three former
shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate
of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license
evidencing its Wholly Foreign Owned Enterprise (&#8220;WFOE&#8221;) status on June 21, 2005.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helpson
is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety
of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the
PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables,
liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription
basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the
&#8220;NMPA&#8221;, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="cphi:LiquidityAndGoingConcernPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2" id="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had cash and cash equivalents of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" unitRef="usd">2.0</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="cphi:AccumulatedDeficit" scale="6" unitRef="usd">36.2</ix:nonFraction> million. The Company&#8217;s
Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalRequiredForCapitalAdequacy" scale="0" unitRef="usd">1,121,273</ix:nonFraction> as of December 31, 2022
to provide working capital and enable the Company to make the required payments related to its former construction loan facility. The
Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production
of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt
about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate
the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, management plans to enhance
the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring
strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#8217;s existing
fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3" id="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Accounting Standards Codification (ASC) 205-40, <i>Disclosure of Uncertainties about an Entity&#8217;s Ability
to Continue as a Going Concern</i> management must evaluate whether there are conditions or events, considered in the aggregate, that
raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial
statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s
plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this
methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s
ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4" id="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company&#8217;s
current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is
not probable of being effectively implemented as none of the plans are entirely within the Company&#8217;s control. Accordingly, substantial
doubt is deemed to exist about the Company&#8217;s ability to continue as a going concern within one year after the date these financial
statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation id="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might
result from the outcome of the uncertainties described above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split </i></b>&#8211; Effective March 6, 2023, the Company implemented a 1-for -10 reverse stock split as more fully discussed
in Note 14. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consolidation
and Basis of Presentation&#160;</i></b>&#8211; The accompanying condensed consolidated financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and are expressed in United States
dollars. The accompanying condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned
subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helpson&#8217;s
functional currency is the Chinese Renminbi. Helpson&#8217;s revenue and expenses are translated into United States dollars at the average
exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains
or losses from translating Helpson&#8217;s financial statements are included in accumulated other comprehensive income, which is a component
of stockholders&#8217; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency
of the entity that is party to the transaction are included in the results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
Estimates&#160;</i>-&#160;</b>The methodology used to prepare the Company&#8217;s financial statements is in conformity with U.S. GAAP,
which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting periods. &#160;Significant estimates made by management include, but are not limited to, the allowance
for doubtful accounts, deferred tax asset valuation allowance, valuation of stock-based compensation, the useful life of property and
equipment, valuation of intangible assets and the assumptions used to calculate derivative liabilities. Therefore, actual results could
differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_14" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents&#160;</i></b>&#8211; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits,
money market accounts, and short-term banker&#8217;s acceptances notes purchased with maturities of three months or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_15" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy-c0_cont_1" escape="true" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trade
Accounts Receivable and Allowance for Doubtful Accounts &#8211;&#160;</i></b>Trade accounts receivables are carried at the original invoiced
amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain
individual customer accounts and an estimation of the overall economic conditions affecting the Company&#8217;s customer base. The Company
reviews a customer&#8217;s credit history before extending credit to the customer. If the financial condition of its customers were to
deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision
is made against accounts receivable to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense
totaled $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">93,851</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">255,215</ix:nonFraction> for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_16" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation id="_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period
the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">0</ix:nonFraction> against
the allowance for the years ended December 31, 2022 and 2021, respectively. Customer balances outstanding for more than one year are
allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_17" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" escape="true" name="cphi:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advances
to Suppliers and Advances from Customers</i></b>&#160;&#8211; Common practice in the PRC is to make advances to suppliers for materials
and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials
are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company
reviews a supplier&#8217;s credit history and background information before advancing a payment. If the financial condition of its suppliers
were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad
debt expense in the period they are considered unlikely to be collected.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_18" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventory&#160;&#8211;
</i></b>Inventory consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable
value. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials,
direct labor and an allocated portion of the Company&#8217;s production overhead. The Company writes down excess and obsolete inventory
to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in
process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of
business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written
down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost. Provisions for inventory
write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories are carried at this lower
cost basis until sold or scrapped.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_19" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b><i>Leases
</i></b></span><b><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211; </span></i></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>At
lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including
any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease
payments using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. The Company&#8217;s
incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal
to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset
based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the
lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#8220;Short-Term Leases&#8221;).
For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed
balance sheet. </span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_20" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">After
lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease
payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease
liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference
between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized
on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_21" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation
of Long-Lived Assets</i></b>&#160;&#8211; The carrying values of long-lived assets are reviewed for impairment annually or whenever events
or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects
the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset.
If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying
value over the projected discounted cash flows estimated to be generated by the asset. If there is uncertainty both in timing and amount,
the Company will use the projected discounted cash flows to be generated by the asset. For the years ended December 31, 2022 and 2021,
the Company evaluated its long-lived assets and determined that no impairment adjustments were necessary.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_22" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
Plant and Equipment</i></b>&#160;&#8211; Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses
as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during
the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other
depreciation was included in cost of revenue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_23" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b>&#160;&#8211; Revenue is recognized when a customer obtains control of promised goods or services and is recognized
in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition,
the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with
customers. The Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide
no significant distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in
exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of
the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they
are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration;
(iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies
each performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_24" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606
at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which
of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated
to the respective performance obligation when (or as) the performance obligation is satisfied. The Company&#8217;s contracts are fixed
price and reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company&#8217;s
performance obligations are transferred to customers at a point in time, typically upon buyer&#8217;s designated carrier or the buyer
picks up the goods at the Company&#8217;s warehouse.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_25" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts
with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The
Company has received advance deposits for orders less than one year. These advances total $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd">520,295</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd">210,028</ix:nonFraction> and are recorded as a
liability on the accompanying balance sheet as &#8220;Advances from customers&#8221; as of December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_26" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of Revenues</i></b>&#160;&#8211; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated
with the manufacture and delivery of products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_27" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b>&#160;&#8211; Research and development expenditures are recorded as expenses in the period in which they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_28" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit
Risk</i></b>&#160;&#8211; The carrying amount of accounts receivable included in the balance sheet represents the Company&#8217;s exposure
to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company
performs ongoing credit evaluations of each customer&#8217;s financial condition. The Company maintains allowances for doubtful accounts
and such allowances in aggregate have not exceeded management&#8217;s estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_29" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been
secured due to the state policy of protecting depositors&#8217; interests. The PRC promulgated a Bankruptcy Law in August 2006, effective
June&#160;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts
in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any
bank where the Company has accounts declare bankruptcy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_30" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:nonNumeric contextRef="c0" escape="true" name="cphi:InterestRateRiskPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b>&#160;&#8211; The Company is exposed to the risk arising from changing interest rates, which may affect the ability
of repayment of existing debts and viability of securing future debt instruments within the PRC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_31" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basic
and Diluted Loss per Common Share&#160;</i>-&#160;</b>Basic loss per common share is computed by dividing net loss by the weighted-average
number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive
common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_32" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company has potentially dilutive common shares related to the option to purchase <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:PurchaseOfCommonStockShares" scale="0" unitRef="shares">96,500</ix:nonFraction> shares of common stock
and the <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares">126,667</ix:nonFraction> shares issuable upon conversion of the Convertible Note Payable&#160; are excluded from the computation of diluted net
loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_33" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_34" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13,<i>Financial
Instruments &#8211; Credit Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments
within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial
instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting
model for purchased financial assets with credit deterioration since their origination.&#160;The pronouncement will be effective for
public business entities that are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including
interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning
after&#160;December 15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will
have a material impact on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_35" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, <i>&#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;. </i>The
amendment simplifies the accounting for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification
(&#8220;ASC&#8221;) 740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application,
among other things. The guidance was implemented January 1, 2021 and there was no impact on the condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_36" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020, the Financial Accounting Standards Board issued ASU 2020-06,&#160;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and
Contracts in an Entity&#8217;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics
of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#8217;s
accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#8217;s own equity
such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require
liability treatment. The pronouncement will be effective for public business entities that are SEC smaller reporting company filers in
fiscal years beginning after&#160;December 15, 2023, including interim periods within those fiscal years. Early application of the guidance
will be permitted for all entities for fiscal years beginning after&#160;December 15, 2020, including interim periods within those fiscal
years. The Company adopted the standard during fiscal 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated
through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be
adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><ix:nonNumeric contextRef="c0" continuedAt="_InventoryDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; INVENTORY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_InventoryDisclosureTextBlock-c0_cont_2" id="_InventoryDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_InventoryDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Raw materials</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">1,839,641</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">2,131,584</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Work in process</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd">557,146</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd">622,380</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">551,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">585,722</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; padding-left: 12px"><span style="font-size: 10pt">Total Inventory</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,947,787</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">3,339,686</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; PROPERTY, PLANT AND EQUIPMENT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Permit of land use</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LandAndLandImprovements" scale="0" unitRef="usd">404,427</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LandAndLandImprovements" scale="0" unitRef="usd">441,783</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Building</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BuildingsAndImprovementsGross" scale="0" unitRef="usd">9,391,433</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BuildingsAndImprovementsGross" scale="0" unitRef="usd">10,258,885</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Plant, machinery and equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MachineryAndEquipmentGross" scale="0" unitRef="usd">27,780,585</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MachineryAndEquipmentGross" scale="0" unitRef="usd">30,122,235</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Motor vehicle</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:MotorVehicleGross" scale="0" unitRef="usd">438,138</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:MotorVehicleGross" scale="0" unitRef="usd">337,375</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:OfficeEquipmentGross" scale="0" unitRef="usd">308,847</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:OfficeEquipmentGross" scale="0" unitRef="usd">278,892</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-left: 12px"><span style="font-size: 10pt">Total</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">38,323,430</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">41,439,170</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">28,350,365</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">28,158,611</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Property, plant and equipment,
    net</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">9,973,065</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">13,280,559</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is computed on a straight-line basis over the estimated useful lives of the assets as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_5" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="cphi:UsefulLiveOfAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: justify"><span style="font-size: 10pt"><b>Asset</b></span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 10pt"><b>Life - years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Permit of land use</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c31" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">40</ix:nonNumeric> - <ix:nonNumeric contextRef="c32" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">70</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Building</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c33" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric> - <ix:nonNumeric contextRef="c34" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">49</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Plant, machinery and equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c35" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> - <ix:nonNumeric contextRef="c36" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Motor vehicle</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c37" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> - <ix:nonNumeric contextRef="c38" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Office equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c39" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c40" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of
revenue. Depreciation expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">2,663,975</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">3,049,706</ix:nonFraction> for the years ended December 31, 2022 and 2021, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 - INTANGIBLE ASSETS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets represent the cost of medical formulas approved for production by the NMPA. The Company did not obtain NMPA production approval
for any new medical formulas during the years ended December 31, 2022 and 2021 and no costs were reclassified from advances to intangible
assets during the years ended December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_3" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="cphi:IntangibleAssetsUsefulLifeDescription">Approved
medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which
range from ten to thirteen years.</ix:nonNumeric>&#160;&#160;It is at least reasonably possible that a change in the estimated useful lives of the medical
formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas.
Amortization expense relating to intangible assets was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">36,558</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">38,114</ix:nonFraction> for the years ended December 31, 2022 and 2021, respectively
which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of
their amortization period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_4" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_3"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 28, 2022, the Company entered into a Technology Transfer Contract (the &#8220;Agreement&#8221;) with Chengdu Bonier Medical
Technology Development Co., Ltd (&#8220;Bonier&#8221;). Bonier owns the know-how of a technical invention and creation of an ophthalmic
oxygen enriched atomization therapeutic instrument, which has obtained a utility model patent (the &#8220;Utility Model Patent&#8221;)
and applied for an invention patent (the &#8220;Invention Patent&#8221;) at the same time. Pursuant to the Agreement, Bonier will transfer
the ownership of the Utility Model Patent of the technical invention and the Invention Patent application right of the invention to Helpson.
Bonier or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product
research and development, writing of registration materials, registration application and other technical services, with a term of ten
years. Effective November 28, 2022 the Company issued <ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares">1,552,229</ix:nonFraction> share of its common stock valued at $<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsStock" scale="0" unitRef="usd">1,707,452</ix:nonFraction> based on the closing market
price of its common stock of $<ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">1.10</ix:nonFraction> per share at that date. The Company recorded the amount as Intangible assets on the accompanying balance
sheet at December 31, 2022. The value of the intangible asset will be amortized over its remaining useful life of approximately <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">9.7</ix:nonNumeric> years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_5" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_4"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will pay a service fee of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap-sup:ManagementAndServiceFeesRate" scale="-2" unitRef="pure">15</ix:nonFraction>% of the net profit of the corresponding product sales revenue, which will be paid in cash annually
after it launches to the market, contingent on the successful authorization of the above mentioned Invention Patent.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_6" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_5"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present
and also at the date of each financial statement. The Company&#8217;s evaluation is based on an estimated undiscounted net cash flow
model, which considers currently available market data for the related drug and the Company&#8217;s estimated market share. If the carrying
value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying
value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment
loss was recognized during the years ended December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_7" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consisted solely of NMPA approved medical formulas as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_8" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Gross carrying amount</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">6,554,628</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">5,294,892</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Accumulated amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">4,747,142</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">5,147,051</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Net carrying amount</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">1,807,486</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">147,841</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_9" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IntangibleAssetsDisclosureTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"><span style="font-size: 10pt">Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="font-size: 10pt">2023</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd">211,939</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2024</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd">211,939</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2025</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd">206,055</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2026</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd">176,632</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2027</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" unitRef="usd">176,632</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" unitRef="usd">824,289</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" unitRef="usd">1,807,486</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; OTHER PAYABLES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_2" id="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
payables consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Compensation payable to officer</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" scale="0" unitRef="usd">951,506</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" scale="0" unitRef="usd">715,506</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Compensation and interest to related parties</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" scale="0" unitRef="usd">372,578</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" scale="0" unitRef="usd">327,033</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Business taxes and other</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,065,979</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">841,622</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 12px"><span style="font-size: 10pt">Total
    Other Payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="0" unitRef="usd">2,390,063</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="0" unitRef="usd">1,884,161</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; RELATED PARTY TRANSACTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
member of the Company&#8217;s board of directors (&#8220;Board&#8221;) had previously advanced to the Company an aggregate amount of
$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToOtherRelatedPartiesClassifiedCurrent" scale="0" unitRef="usd">1,354,567</ix:nonFraction> as of December 31, 2022 and December 31, 2021 which is recorded as &#8220;Other Payables &#8211; Related Parties&#8221; on
the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">1.0</ix:nonFraction>% per year.&#160;&#160;Total interest
expense years ended December 31, 2022 and 2021 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseRelatedParty" scale="0" unitRef="usd">13,546</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseRelatedParty" scale="0" unitRef="usd">13,546</ix:nonFraction>, respectively. Compensation and interest payable to the board
member is included in Other payables in the accompanying condensed consolidated balance sheet totaling $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" scale="0" unitRef="usd">372,578</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" scale="0" unitRef="usd">327,033</ix:nonFraction> as of December
31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received advances totaling $<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">1,183,414</ix:nonFraction> and repaid $<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" unitRef="usd">223,013</ix:nonFraction> and $<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" unitRef="usd">562,659</ix:nonFraction> of the advances during the years ended December
31, 2022 and 2021, respectively from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed
were $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedParties" scale="0" unitRef="usd">1,121,273</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedParties" scale="0" unitRef="usd">1,425,123</ix:nonFraction> and are recorded as Other payables &#8211; related parties on the accompanying condensed consolidated
balance sheets as of December 31, 2022 and 2021, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange
for cash of RMB <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="cphi:LoanAgreementToBorrowCash" scale="0" unitRef="cny">4,770,000</ix:nonFraction> ($<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="cphi:LoanAgreementToBorrowCash" scale="0" sign="-" unitRef="usd">738,379</ix:nonFraction>) with its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears
interest at a rate of <ix:nonFraction contextRef="c45" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.35</ix:nonFraction>% and is payable within one year of the loan agreement. The due date of the loan agreement has been extended
annually on identical terms, and is now due July 9, 2023. Total interest expense related to the loan for the years ended December 31,
2022 and 2021 was $<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseRelatedParty" scale="0" unitRef="usd">28,962</ix:nonFraction> and $<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseRelatedParty" scale="0" unitRef="usd">30,194</ix:nonFraction>, respectively. Compensation payable to the Chairperson, Chief Executive Officer and Interim Chief
Financial Officer is included in Other payables in the accompanying condensed consolidated balance sheet totaling $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd">951,506</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd">715,506</ix:nonFraction>
as of December 31, 2022 and 2021, respectively. As discussed more fully in Note 12, on September 9, 2021 an aggregate of $<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="0" unitRef="usd">1,179,200</ix:nonFraction> of
compensation was converted into a total of <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="cphi:CompensationConverted" scale="0" unitRef="usd">176,000</ix:nonFraction> shares of common stock at the market price of $<ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">6.70</ix:nonFraction> per share from the Company&#8217;s
<span>2010 Long-Term Incentive Plan, as amended. </span></span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LongTermDebtTextBlock-c0_cont_1" escape="true" name="us-gaap:LongTermDebtTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c0_cont_2" id="_LongTermDebtTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lines
of Credit</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c0_cont_3" id="_LongTermDebtTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="0" unitRef="cny">10,000,000</ix:nonFraction> (approximately
$<ix:nonFraction contextRef="c51" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="6" unitRef="usd">1.4</ix:nonFraction> million), of which RMB <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="0" unitRef="cny">5,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c52" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="6" unitRef="usd">0.7</ix:nonFraction> million) was advanced in April 2020, and RMB <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="0" unitRef="cny">3,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c53" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="6" unitRef="usd">0.4</ix:nonFraction>
million) was advanced in July 2020. The loan bears interest at a rate of <ix:nonFraction contextRef="c54" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.25</ix:nonFraction>% per annum. Advances on the line of credit are due two
years from the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral
in certain land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the
Company&#8217;s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest expense under
this facility for the years ended December 31, 2022 and 2021 was $<ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">12,063</ix:nonFraction> and $<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">44,629</ix:nonFraction>, respectively. The Company repaid the remaining
RMB <ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="0" unitRef="cny">5,900,000</ix:nonFraction> and RMB <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="0" unitRef="cny">1,600,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c57" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" unitRef="usd">0.85</ix:nonFraction> and $<ix:nonFraction contextRef="c58" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" unitRef="usd">0.23</ix:nonFraction> million, respectively) during the year ended December 31, 2022 and 2021,
respectively as per the repayment schedule in full satisfaction of the line of credit.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c0_cont_4" id="_LongTermDebtTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2020 the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB <ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="0" unitRef="cny">8,500,000</ix:nonFraction> (approximately
$<ix:nonFraction contextRef="c59" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="6" unitRef="usd">1.2</ix:nonFraction> million), all of which has been advanced. The loan bears interest at the rate of <ix:nonFraction contextRef="c60" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.05</ix:nonFraction>% per annum. The line of credit is due in one
year on the anniversary date of the line of credit. In addition, the Company&#8217;s Chief Executive Officer and Chair of the Board personally
guaranteed the new line of credit and pledged personal assets as collateral for the loan. On June 21, 2021 the Company paid the balance
in full. On June 25, 2021 the Company entered into a new loan bearing an interest rate of <ix:nonFraction contextRef="c61" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.17</ix:nonFraction>%. <span>The
Company paid all principal and interest on June 21, 2022 and on June 22, 2022 entered into a new loan for the same principal amount bearing
interest at&#160;<ix:nonFraction contextRef="c62" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.17</ix:nonFraction>% and due December 21, 2022. On December 21, 2022 the Company repaid the loan in full and entered into a new line
of credit for an aggregate amount of RMB <ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="0" unitRef="cny">7,300,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="6" unitRef="usd">1.0</ix:nonFraction> million) with interest payable monthly at a rate of <ix:nonFraction contextRef="c63" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">3.9</ix:nonFraction>%. The
line of credit is payable in one year. The Company received an advance on the line of credit in the amount of RMB <ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="0" unitRef="cny">3,800,000</ix:nonFraction> (approximately
$<ix:nonFraction contextRef="c64" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="6" unitRef="usd">0.56</ix:nonFraction> million) on December 30, 2022. The Company has RMB <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="0" unitRef="cny">3,500,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c3" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="6" unitRef="usd">0.44</ix:nonFraction> million) remaining to borrow on this line of
credit. </span>In addition, the Company&#8217;s Chief Executive Officer and Chair of the Board personally guaranteed the new line of
credit and pledged personal assets as collateral for the loan. Total interest expense under this facility for the years ended December
31, 2022 and 2021 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">53,283</ix:nonFraction> and $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">54,294</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c0_cont_5" id="_LongTermDebtTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company obtained a line of credit of RMB <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="0" unitRef="cny">3,200,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c68" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="6" unitRef="usd">0.5</ix:nonFraction> million) from China CITIC Bank in September 2020 and obtained
an advance of RMB <ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="0" unitRef="cny">2,343,340</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c69" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="6" unitRef="usd">0.3</ix:nonFraction> million), and the remaining of RMB <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="0" unitRef="cny">856,660</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c70" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="6" unitRef="usd">0.1</ix:nonFraction> million) in October 2020
under this line. The loan bears interest at the rate of <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="cphi:InterestRate" scale="-2" unitRef="pure">4.50</ix:nonFraction>% per annum. In September, 2021 the Company repaid the line of credit in
full. Also in September, 2021 the Company entered into a new line a credit in the amount of RMB <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="0" unitRef="cny">3,200,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c71" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="6" unitRef="usd">0.8</ix:nonFraction> million)
on the same terms. The line of credit was due on September 2, 2022. <span>The line of credit was paid
in full on September 6, 2022.&#160;On September 9, 2022, the Company received a new line of credit in the same amount. The loan bears
interest at a rate of&#160;<ix:nonFraction contextRef="c72" decimals="3" format="ixt:num-dot-decimal" name="cphi:InterestRate" scale="-2" unitRef="pure">4.5</ix:nonFraction>% and is due on September 7, 2023.</span> In addition, the Company&#8217;s Chief Executive Officer and
Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest
expense under this facility for the years ended December 31, 2021 and 2020 was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">21,528</ix:nonFraction> and $<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">22,258</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c0_cont_6" id="_LongTermDebtTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 12, 2021, the Company obtained a short-term loan of RMB <ix:nonFraction contextRef="c74" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="6" unitRef="cny">3</ix:nonFraction> million (approximately US$<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd">460,000</ix:nonFraction>) from Haikou HaiHongXin microfinance
Co., Ltd., with a monthly interest rate of <ix:nonFraction contextRef="c74" decimals="3" format="ixt:num-dot-decimal" name="cphi:InterestRate" scale="-2" unitRef="pure">1.5</ix:nonFraction>%. The company paid off the loan in September 2021. Total interest paid on this loan was
$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:InterestAmount" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:InterestAmount" scale="0" unitRef="usd">16,051</ix:nonFraction> for the years ended December 31, 2022 and 2021, respectively. This loan was guaranteed by Haikou Financing Guarantee Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c0_cont_7" id="_LongTermDebtTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 18, 2021 the Company obtained a line of credit for RMB <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="0" unitRef="cny">10,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c75" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="6" unitRef="usd">1.54</ix:nonFraction> million) with Bank of China. The loan
bears interest at the rate of <ix:nonFraction contextRef="c75" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">3.85</ix:nonFraction>% per annum. <span>The line of credit was paid in full on the due date
of September 18, 2022. On September 30, 2022 the Company received a new line of credit in the same amount. The loan bears interest at
the rate of <ix:nonFraction contextRef="c76" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">3.45</ix:nonFraction>% and is due September 28, 2023. </span>The loan is collateralized by the Company&#8217;s new production facility and
the included production line equipment and machinery. In addition, the Company&#8217;s Chief Executive Officer and Chair of the Board
personally guaranteed the new line of credit. Total interest paid on this loan was $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="cphi:InterestAmount" scale="0" unitRef="usd">54,923</ix:nonFraction> and $<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="cphi:InterestAmount" scale="0" unitRef="usd">15,582</ix:nonFraction> for the years ended December 31,
2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c0_cont_8" id="_LongTermDebtTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
payments required for the remaining terms of the lines of credit as of December 31, 2022 are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c0_cont_9" id="_LongTermDebtTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Lines
    of Credit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">2023</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd">2,440,915</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd">2,440,915</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c0_cont_10" id="_LongTermDebtTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company obtained a construction loan facility from Bank of China, dated June 21, 2013, in the aggregate amount of RMB <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="0" unitRef="cny">80,000,000</ix:nonFraction> (approximately
$<ix:nonFraction contextRef="c77" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ConstructionLoan" scale="6" unitRef="usd">13</ix:nonFraction> million). The loan facility was for an eight-year term, which commenced on July 11, 2013, the initial draw-down date.&#160;The proceeds
of the loan were used for and are collateralized by the construction of the Company&#8217;s new production facility and the included
production line equipment and machinery.&#160;&#160;The interest rate was <ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="cphi:InterestRate" scale="-2" unitRef="pure">5.39</ix:nonFraction>% during the year ended December 31, 2021. During the year
ended December 31, 2021, the Company repaid all the remaining principal payments due under the loan in the amount of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">2,325,039</ix:nonFraction> (RMB
<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="cny">15,000,000</ix:nonFraction>).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LongTermDebtTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Lines of Credit</i></b> &#8211; Based on the borrowing rates currently available to the Company for bank loans with similar
terms and maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2022 and December 31, 2021
approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&#160;</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; CONVERTIBLE NOTE PAYABLE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2021, the Company entered into a Securities Purchase
Agreement (the &#8220;Agreement&#8221;) pursuant to which the Company issued an unsecured convertible promissory note (the &#8220;Note&#8221;)
to an institutional accredited investor Streeterville Capital, LLC (the &#8220;Investor&#8221;). The Note matures <ix:nonNumeric contextRef="c79" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">fifteen months</ix:nonNumeric> after
the purchase price of the Note is delivered from the Investor to the Company (the &#8220;Purchase Price Date&#8221;). The Note was due
on February 17, 2023. The parties are in negotiation in extending the Note. No event of default has occurred as of the date herein. The
Note has the original principal amount of $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">5,250,000</ix:nonFraction> and Investor gave consideration of $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="0" unitRef="usd">5,000,000</ix:nonFraction>, reflecting original issue discount
of $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="cphi:OriginalIssueDiscount" scale="0" unitRef="usd">250,000</ix:nonFraction>. The transaction contemplated under the Agreement was closed on November 19, 2021 and the Company anticipates using the proceeds
for general working capital purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Note was convertible into <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="0" unitRef="pure">350,000</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction contextRef="c82" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">15.00</ix:nonFraction> per share through April 19, 2022. Thereafter,
the Note is convertible into <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:ConvertibleNote" scale="0" unitRef="shares">175,000</ix:nonFraction> shares at a price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cphi:ConvertibleNoteConversionPrice" scale="0" unitRef="usdPershares">30.00</ix:nonFraction> per share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" name="cphi:InterestAccruesOnNoteDescription"><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined
in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event
of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration
by 15% or 5%, depending on the nature of the Event of Default.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Agreement and the Note, the Company must obtain Investor&#8217;s consent for certain fundamental transactions such
as consolidation, merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change
of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor&#8217;s prior written consent
will be deemed an Event of Default.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
may redeem all or any part the outstanding balance of the Note, subject to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">500,000</ix:nonFraction> per calendar month, at any time after one hundred
twenty-one (121) days from the Purchase Price Date upon three trading days&#8217; notice, in cash or converting into shares of the Company&#8217;s
common stock, at a price equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cphi:PercentageOfCommonStockPriceOnWeightedAveragePrice" scale="-2" unitRef="pure">85</ix:nonFraction>% multiplied by the lowest daily volume weighted average price during the ten trading days immediately
preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note
provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding
balance of the Note with the Investor&#8217;s consent. At inception, the Note was redeemable into <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="cphi:NoteRedeemableIntoShares" scale="0" unitRef="shares">881,143</ix:nonFraction> shares based on the lowest
volume weighted average price of $<ix:nonFraction contextRef="c83" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.95817</ix:nonFraction> on the inception date of November 19, 2021. As of December 31, 2022, the Note was convertible
into <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:NoteRedeemableIntoShares" scale="0" unitRef="shares">3,836,070</ix:nonFraction> shares of common stock based on <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">85</ix:nonFraction>% of the lowest volume weighted average price of $<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="cphi:WeightedAveragePrice" scale="0" unitRef="usdPershares">0.9910</ix:nonFraction> on that date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
original issue discount of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="cphi:OriginalIssueDiscount" scale="0" unitRef="usd">250,000</ix:nonFraction> was fully earned at the inception of the Note, and accordingly was recognized as interest expense
in the accompanying statement of operations for the year ended December 31, 2021. Total interest expense for the years ended December
31, 2022 and 2021 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">250,314</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">279,979</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2022 the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">100,000</ix:nonFraction> of the Note at the lowest volume weighted average price of
$<ix:nonFraction contextRef="c84" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.113</ix:nonFraction> during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total
of <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">32,123</ix:nonFraction> shares of common stock to the Investor on March 23, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_9" id="_DebtDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
March 30, 2022 the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">200,000</ix:nonFraction>&#160;of the Note and related interest at the price of $<ix:nonFraction contextRef="c86" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.129</ix:nonFraction>,
which was&#160;<ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="cphi:CommonStockIssuedToInvestor" scale="0" unitRef="shares">63,918</ix:nonFraction> shares of common stock to the Investor on March 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_10" id="_DebtDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
June 9, 2022 the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">200,000</ix:nonFraction>&#160;of the Note and related interest at the price of $<ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.98</ix:nonFraction>,
which was&#160;<ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">101,010</ix:nonFraction> shares of common stock to the Investor on June 13, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_11" id="_DebtDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
August 3, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">200,000</ix:nonFraction>&#160;of the Note and related interest at the conversion
price of $<ix:nonFraction contextRef="c92" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.755</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">113,960</ix:nonFraction> shares of common stock to the Investor
on August 4, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_12" id="_DebtDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
October 17, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">100,000</ix:nonFraction>&#160;of the Note and related interest at the
conversion price of $<ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.12</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days
immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="cphi:CommonStockIssuedToInvestor1" scale="0" unitRef="shares">89,286</ix:nonFraction> shares of common
stock to the Investor on October 18, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_13" id="_DebtDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
December 1, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">100,000</ix:nonFraction>&#160;of the Note and related interest at the conversion
price of $<ix:nonFraction contextRef="c98" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.829</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">120,627</ix:nonFraction> shares of common stock to the Investor
on December 2, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_14" id="_DebtDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
December 5, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">310,000</ix:nonFraction>&#160;of the Note and related interest at the conversion
price of $<ix:nonFraction contextRef="c101" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.829</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">373,945</ix:nonFraction> shares of common stock to the Investor
on December 6, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_15" id="_DebtDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
December 13, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">90,000</ix:nonFraction>&#160;of the Note and related interest at the conversion
price of $<ix:nonFraction contextRef="c104" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.91</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">98,901</ix:nonFraction>&#160;shares of common stock to the Investor
on December 14, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
December 14, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion
price of $<ix:nonFraction contextRef="c107" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.829</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">180,905</ix:nonFraction> shares of common stock to the Investor
on December 15, 2022.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 - LEASES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain
payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right to use assets
when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions
or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing
the Company&#8217;s incremental borrowing rate at the initial measurement date. For the years ended December 31, 2022 and 2021, operating
lease cost was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd">78,092</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd">92,085</ix:nonFraction>, respectively and cash paid for amounts included in the measurement of lease liabilities for operating
cash flows from operating leases was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:CashFlowForOperatingLease" scale="0" unitRef="usd">82,015</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="cphi:CashFlowForOperatingLease" scale="0" unitRef="usd">98,845</ix:nonFraction>, respectively. As of December 31, 2022 and 2021, the Company reported operating
lease right of use assets of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:OperatingLeaseRightsOfUseAssets" scale="0" unitRef="usd">39,046</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:OperatingLeaseRightsOfUseAssets" scale="0" unitRef="usd">127,958</ix:nonFraction>, respectively and operating use liabilities of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">40,445</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">85,282</ix:nonFraction>, respectively. As
of December 31, 2022, its operating leases had a weighted average remaining lease term of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="cphi:WeightedAveragesRemainingLeaseTerm">0.50</ix:nonNumeric> years and a weighted average discount
rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="cphi:WeightedAverageDiscountRate" scale="-2" unitRef="pure">4.75</ix:nonFraction>%.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_3" id="_LesseeOperatingLeasesTextBlock-c0_cont_2"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum
lease payments for the Company&#8217;s operating lease liabilities were as follows for the twelve month periods ended December 31:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_4" id="_LesseeOperatingLeasesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">2023</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd">41,007</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-size: 10pt">Total undiscounted cash flows</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="0" unitRef="usd">41,007</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Less: Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivableWithImputedInterestNetAmount" scale="0" unitRef="usd">562</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd">40,445</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Less: Operating lease liabilities, current portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:LessOperatingLeaseLiabilitiesCurrentPortion" scale="0" unitRef="usd">40,445</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Operating lease liabilities, net of current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leases with terms less than one year for certain provincial sales offices that are not material.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 - INCOME TAXES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary
differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities
is recognized in income in the period that includes the enactment date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the &#8220;more-likely-than-not&#8221;
threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included
as a component of other expenses. Through December 31, 2022, the Company has not identified any uncertain tax positions that it has taken.
U.S. income tax returns for the years ended December 31, 2019 through December 31, 2022 and the Chinese income tax return for the year
ended December 31, 2022 are open for possible examination.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">25</ix:nonFraction>%.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no provision for income taxes for the years ended December 31, 2022 and 2021, respectively due to continued net losses of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Years
    Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">(Benefit) tax at statutory rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">25</ix:nonFraction></ix:nonFraction>%</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd">973,717</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd">849,869</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Prior year refund received</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Other, primarily the difference in U.S. tax rates</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" unitRef="usd">8,416</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" unitRef="usd">8,440</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Change in valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">965,301</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">841,429</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Income tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
temporary differences which give rise to the deferred income tax assets and liability are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Deferred income tax assets:</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Allowance for doubtful trade receivables</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">4,184,882</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">4,578,177</ix:nonFraction></span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Allowance for doubtful other receivables</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" scale="0" unitRef="usd">6,787</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" scale="0" unitRef="usd">8,052</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Inventory obsolescence reserve</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" unitRef="usd">34,921</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" unitRef="usd">137,549</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Stock compensation</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd">3,201</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd">3,201</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Expenses not deductible in current year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="0" unitRef="usd">1,087,328</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="0" unitRef="usd">1,187,760</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Advances for intangible assets impairment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" scale="0" unitRef="usd">9,782,172</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" scale="0" unitRef="usd">10,685,714</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Lease liability, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd">349</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd">376</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">PRC net operating loss carry forward</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd">5,036,114</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd">5,779,437</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">U.S. net operating loss carry forward</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd">1,849,800</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd">1,602,243</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Total deferred income tax assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">21,985,554</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">23,982,509</ix:nonFraction></span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">21,985,554</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">23,982,509</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 12px"><span style="font-size: 10pt">Net deferred income tax asset</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Deferred income tax liability:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Intangible assets</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" unitRef="usd">754,698</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" unitRef="usd">824,407</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had net operating loss carryforwards for PRC tax purposes of approximately $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" unitRef="usd">20.1</ix:nonFraction> million which are
available to offset any future taxable income through 2026. <ix:nonNumeric contextRef="c0" name="cphi:NetOperatingLossCarryForwardsExpirationDescription">Approximately $6.0 million of these carryforwards expired in December 2022.
The Company also has net operating losses for United States federal income tax purposes of approximately $8.7 million of which $5.1 million
is available to offset future taxable income, if any, through 2039, and $3.7 million are available for carryforward indefinitely subject
to a limitation of 80% of taxable income for each tax year.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221;), was signed into law on
December&#160;22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the
statutory U.S. federal corporate income tax rate from <ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure">35</ix:nonFraction>% to <ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure">21</ix:nonFraction>% for taxable years beginning after December&#160;31, 2017; limiting and/or
eliminating many business deductions; migrating the U.S. to a territorial tax system with a&#160;one-time&#160;transition tax on a mandatory
deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally
eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized.&#160;&#160;The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&#160;&#160;Management
considers projected future taxable income and tax planning strategies in making this assessment.&#160;&#160;Based upon an assessment
of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets
are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets
as of December 31, 2022 and 2021.&#160;&#160;Therefore, the Company provided for a valuation allowance against its deferred tax assets
of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:ValuationAllowanceForDeferredTaxAssets" scale="0" unitRef="usd">21,985,554</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:ValuationAllowanceForDeferredTaxAssets" scale="0" unitRef="usd">23,982,509</ix:nonFraction> as of December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education
surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementInputsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; FAIR VALUE MEASUREMENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueMeasurementInputsDisclosureTextBlock-c0_cont_2" id="_FairValueMeasurementInputsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows:
Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities; Level 2 &#8211; Observable inputs other than Level
1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can
be corroborated by observable market data; and Level 3 &#8211; Unobservable inputs supported by little or no market activity for financial
instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments
for which the determination of fair value requires significant management judgment or estimation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueMeasurementInputsDisclosureTextBlock-c0_cont_3" id="_FairValueMeasurementInputsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses fair value to measure the value of the banker&#8217;s acceptance notes it holds as of December 31, 2022 and 2021.&#160;The
banker&#8217;s acceptance notes are recorded at cost which approximates fair value.&#160;The Company held the following assets and liabilities
recorded at fair value:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueMeasurementInputsDisclosureTextBlock-c0_cont_4" id="_FairValueMeasurementInputsDisclosureTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair Value Measurements at</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Reporting
    Date Using</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,
    <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Banker&#8217;s acceptance notes</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CustomersLiabilityForAcceptancesNet" scale="0" unitRef="usd">13,784</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CustomersLiabilityForAcceptancesNet" scale="0" unitRef="usd">13,784</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd">13,784</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd">13,784</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation id="_FairValueMeasurementInputsDisclosureTextBlock-c0_cont_4"><ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair Value Measurements at</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Reporting
    Date Using</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,<br/>
    2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Banker&#8217;s acceptance notes</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CustomersLiabilityForAcceptancesNet" scale="0" unitRef="usd">91,362</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CustomersLiabilityForAcceptancesNet" scale="0" unitRef="usd">91,362</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd">91,362</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd">91,362</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 - STOCKHOLDERS&#8217; EQUITY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">500,000,000</ix:nonFraction> shares of common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> par value, and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">5,000,000</ix:nonFraction> shares of preferred stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction>
par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or
limitations as determined solely by the Company&#8217;s Board.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to relevant PRC laws, companies registered in the PRC, including the Company&#8217;s PRC subsidiary, Helpson, are required to allocate
at least <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cphi:AftertaxNetIncomePercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus
reserve accounts until the reserve account balances reach <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cphi:ReserveAccountBalancesPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% of the company&#8217;s registered capital prior to their remittance of
funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the
parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount" scale="0" unitRef="usd"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount" scale="0" unitRef="usd">8,145,000</ix:nonFraction></ix:nonFraction> at December 31, 2022 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2010
Incentive Plan</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 12, 2010, the Company&#8217;s Board adopted the Company&#8217;s
2010 Incentive Plan (the &#8220;Plan&#8221;), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board
of Directors approved the First Amendment to the 2010 Incentive Plan (the &#8220;Amendment&#8221;), pursuant to which the term of the
2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October
25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase
the number of shares of the Common Stock, that are reserved thereunder by <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">500,000</ix:nonFraction> shares from <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">400,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">900,000</ix:nonFraction> shares. On October
27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated 2010 Long Term Incentive
Plan to increase the number of shares of common stock that are reserved thereunder by an additional <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">500,000</ix:nonFraction> shares from <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">900,000</ix:nonFraction> to <ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">1,400,000</ix:nonFraction>.
The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its
employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries.
The Plan currently allows for equity awards of up to <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="0" unitRef="shares">1,400,000</ix:nonFraction> shares of common stock. Through December 31, 2022, there were <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares">490,000</ix:nonFraction> shares
of stock and stock options granted under the Plan.&#160; A total of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:TotalOptionOutstanding" scale="0" unitRef="shares">66,500</ix:nonFraction> options were outstanding as of December 31, 2022 under the
Plan. As such, there are <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:AdditionalSharesAvailableForIssuance" scale="0" unitRef="shares">910,000</ix:nonFraction> additional shares available for issuance under the Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022 the Company issued <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="cphi:CommonStockPursuant" scale="0" unitRef="shares">30,000</ix:nonFraction> shares of common stock pursuant to a contract with a consultant to the Company for services.
The Company recorded compensation expense totaling $<ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="0" unitRef="usd">42,000</ix:nonFraction> based on the closing market price of its common stock of $<ix:nonFraction contextRef="c124" decimals="2" format="ixt:num-dot-decimal" name="cphi:ClosingMarketPrice" scale="0" unitRef="usdPershares">1.40</ix:nonFraction> per share on
the issuance date. The contract also calls for the issuance of up to <ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" scale="0" unitRef="usd">90,000</ix:nonFraction> additional shares of common stock contingent upon the achievement
of certain milestones as described in the contract. At December 31, 2022 these milestones had not been met.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2022 the Company issued an option to purchase <span><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="cphi:PurchaseofCommonStockShares" scale="0" unitRef="shares">60,000</ix:nonFraction> shares of common stock at an exercise
price at $<ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">5.60</ix:nonFraction> per share, under the Plan to the same consultant in the preceding paragraph. The Option vests immediately and expires
on October 3, 2027. </span>The fair value of the options granted of $<ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="cphi:FairValueOfOptionsGranted" scale="0" unitRef="usd">36,270</ix:nonFraction> was calculated using the Black-Scholes option valuation model
using the closing market price of $<ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="cphi:ClosingMarketPrice" scale="0" unitRef="usdPershares">1.50</ix:nonFraction> per share, volatility of <ix:nonFraction contextRef="c127" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure">115.5</ix:nonFraction>%, risk free interest rate of <ix:nonFraction contextRef="c127" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.84</ix:nonFraction>% and an expected life of <ix:nonNumeric contextRef="c127" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.5</ix:nonNumeric>
years. The value was charged to general and administrative expenses on the accompanying Statement of Operations for the year ended December
31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 9, 2021 the Company issued an aggregate of <ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">176,000</ix:nonFraction> fully vested shares of common stock at the price of $<ix:nonFraction contextRef="c128" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">6.70</ix:nonFraction> per share, representing
the closing market price on that date to its Chairperson, Chief Executive Officer and Interim Chief Financial Officer under the Plan,
as amended, to partially offset certain unpaid cash compensation totaling $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="cphi:UnpaidCashCompensation" scale="0" unitRef="usd">1,179,200</ix:nonFraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on September 9, 2021 the Company issued an option to purchase <span><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="cphi:PurchaseofCommonStockShares" scale="0" unitRef="shares">6,500</ix:nonFraction> shares of common stock at an
exercise price at $<ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">14.70</ix:nonFraction> per share, under the Plan. The Option vests immediately and expires on September 9, 2024. </span>The fair value
of the options granted of $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="0" unitRef="usd">15,243</ix:nonFraction> was calculated using the Black-Scholes option valuation model using the closing market price of $<ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="cphi:MarketPricePerShare" scale="0" unitRef="usdPershares">6.70</ix:nonFraction>
per share, volatility of <ix:nonFraction contextRef="c130" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">118.4</ix:nonFraction>%, risk free interest rate of <ix:nonFraction contextRef="c130" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.75</ix:nonFraction>% and an expected life of <ix:nonNumeric contextRef="c130" format="ixt-sec:duryear" name="cphi:ExpectedLifes">1.5</ix:nonNumeric> years. The value was charged to general
and administrative expenses on the accompanying Statement of Operations for the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 23, 2020 the Board approved the issuance of <ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">200,000</ix:nonFraction> shares of common stock from the Company&#8217;s 2010 Long-Term Incentive
Plan, as amended for the partial conversion of unpaid compensation totaling $<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="0" unitRef="usd">864,480</ix:nonFraction> to the Chairperson, Chief Executive Officer and
Interim Chief Financial Officer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; RISKS &amp; UNCERTAINTIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_2" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current
vulnerability due to certain concentrations</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_3" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, no customer accounted for more than <ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of sales and <ix:nonFraction contextRef="c134" decimals="0" format="ixt-sec:numwordsen" name="cphi:NumberOfCustomers" scale="0" unitRef="pure">three</ix:nonFraction> customers accounted for <ix:nonFraction contextRef="c135" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">52.9</ix:nonFraction>%, <ix:nonFraction contextRef="c134" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">11.4</ix:nonFraction>% and
<ix:nonFraction contextRef="c136" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">10.4</ix:nonFraction>% of accounts receivable. <ix:nonFraction contextRef="c137" decimals="2" format="ixt-sec:numwordsen" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">Two</ix:nonFraction> suppliers accounted for <ix:nonFraction contextRef="c138" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">21.7</ix:nonFraction>% and <ix:nonFraction contextRef="c139" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">11.1</ix:nonFraction>% of raw material purchases, and <ix:nonFraction contextRef="c140" decimals="0" format="ixt-sec:numwordsen" name="cphi:NumberOfSuppliers" scale="0" unitRef="pure">three</ix:nonFraction> different products accounted
for <ix:nonFraction contextRef="c141" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">29.2</ix:nonFraction>%, <ix:nonFraction contextRef="c142" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">27.3</ix:nonFraction>% and <ix:nonFraction contextRef="c143" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">12.5</ix:nonFraction>% of revenue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_4" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, no customer accounted for more than <ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of sales and <ix:nonFraction contextRef="c144" decimals="0" format="ixt-sec:numwordsen" name="cphi:NumberOfCustomers" scale="0" unitRef="pure">three</ix:nonFraction> customers accounted for <ix:nonFraction contextRef="c145" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">52.1</ix:nonFraction>%, <ix:nonFraction contextRef="c146" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">11.2</ix:nonFraction>% and
<ix:nonFraction contextRef="c147" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">10.2</ix:nonFraction>% of accounts receivable. <ix:nonFraction contextRef="c148" decimals="0" format="ixt-sec:numwordsen" name="cphi:NumberOfSuppliers" scale="0" unitRef="pure">Three</ix:nonFraction> suppliers accounted for <ix:nonFraction contextRef="c149" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">24.8</ix:nonFraction>%, <ix:nonFraction contextRef="c150" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">12.7</ix:nonFraction>% and <ix:nonFraction contextRef="c151" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">11.8</ix:nonFraction>% of raw material purchases, and three different products
accounted for <ix:nonFraction contextRef="c152" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">20.7</ix:nonFraction>%, <ix:nonFraction contextRef="c153" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">17.7</ix:nonFraction>% and <ix:nonFraction contextRef="c154" decimals="3" format="ixt:num-dot-decimal" name="cphi:ConcentrationRiskPercentage" scale="-2" unitRef="pure">13.5</ix:nonFraction>% of revenue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_5" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Operations</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_6" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
from the New Coronavirus Global Pandemic (&#8220;COVID-19&#8221;)&#160;</b>- Although the outbreak of COVID-19 since the first quarter
2020 has been under control, and China has returned to normal production and social life in an orderly manner, China is still encountering
frequent resurgences in many of the major cities. For now, these resurgences have not caused material impact to our daily operations.
However, we cannot guarantee subsequent resurgence will not have any material effect on the operation of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_7" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Economic
environment -&#160;</b>Substantially all of the Company&#8217;s operations are conducted in the PRC, and therefore the Company is subject
to special considerations and significant risks not typically associated with companies operating in the United States of America. These
risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The
Company&#8217;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by
changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance
abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely
affect the Company&#8217;s operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all of the Company&#8217;s revenue is denominated in the PRC&#8217;s currency of Renminbi (RMB), which must be converted into
other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies
abroad require approval of the PRC government.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CHINA PHARMA
HOLDINGS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>YEARS ENDED DECEMBER
31, 2022 AND 2021</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b>NOTE
14 &#8211; SUBSEQUENT EVENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
January 5, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="cphi:InvestorRedemption" scale="0" unitRef="usd">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion
price of $<ix:nonFraction contextRef="c156" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">0.763</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="cphi:WeightedAveragePrices" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="cphi:CommonStockInvestor" scale="0" unitRef="shares">196,592</ix:nonFraction> shares of common stock to the Investor
on January 6, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
January 18, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="cphi:InvestorRedemption" scale="0" unitRef="usd">250,000</ix:nonFraction>&#160;of the Note and related interest at the conversion
price of $<ix:nonFraction contextRef="c158" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">0.763</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="cphi:WeightedAveragePrices" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="cphi:CommonStockInvestor" scale="0" unitRef="shares">327,654</ix:nonFraction> shares of common stock to the Investor
on January 19, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_4" id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
March 2, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="cphi:InvestorRedemption" scale="0" unitRef="usd">250,000</ix:nonFraction>&#160;of the Note and related interest at the conversion
price of $<ix:nonFraction contextRef="c160" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">0.575</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="cphi:WeightedAveragePrices" scale="-2" unitRef="pure">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="cphi:CommonStockInvestor" scale="0" unitRef="shares">434,783</ix:nonFraction> shares of common stock to the Investor
on March 9, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Effective
March 6, 2023 the Company implemented a 1-for-10 reverse split of its common stock. The reverse stock split was approved by the Company&#8217;s
Board of Directors through unanimous written consent and the Company&#8217;s stockholders at its Annual Meeting for the fiscal year ended
on December 31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of the
Company&#8217;s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock.
No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split
were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder&#8217;s
percentage interest in the Company&#8217;s outstanding common stock, except for adjustments that may result from the treatment of fractional
shares. All share and per share amounts have been retroactively restated for the years ended December 31, 2022 and 2021.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt">F-21</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-size: 10pt">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>




</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-10" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.74</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.76</ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-12" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-13" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-14" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-15" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-16" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-17" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-27" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-28" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-29" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-30" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-31" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-32" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-33" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-34" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-35" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-36" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-37" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-39" name="cphi:ConversionOfOfficerWagesToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-40" name="us-gaap:StockIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-41" name="cphi:OperatingLeaseLiabilitiesNetOfCurrentPortion" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-42" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-43" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-45" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-46" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-47" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c111" id="hidden-fact-48" name="us-gaap:CustomersLiabilityForAcceptancesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c113" id="hidden-fact-49" name="us-gaap:CustomersLiabilityForAcceptancesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c111" id="hidden-fact-50" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c113" id="hidden-fact-51" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-52" name="us-gaap:CustomersLiabilityForAcceptancesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c116" id="hidden-fact-53" name="us-gaap:CustomersLiabilityForAcceptancesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-54" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c116" id="hidden-fact-55" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001106644</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="cphi-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cphi:OnnyInvestmentLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2005-05-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:PermitOfLandUseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:PermitOfLandUseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:MotorVehicleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:MotorVehicleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-28</xbrli:startDate>
    <xbrli:endDate>2022-11-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-09</xbrli:startDate>
    <xbrli:endDate>2021-09-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-25</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-15</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-15</xbrli:startDate>
    <xbrli:endDate>2020-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-15</xbrli:startDate>
    <xbrli:endDate>2020-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cphi:HaikouHaiHongXinMicrofinanceCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAH97Uj3CrYpCI3iMnN+zBsiA7R8Hc0PMjB8aYKuSvZFd8JBtZoOjmWf0KXzrZWbYK6sWg9BSB1dSM2htVGPahyLguSlQDTSZpy8M79KgRfS+Awfcr2iB4Fa24FQGtzfVo0=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-06-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:UnusedLinesOfCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-19</xbrli:startDate>
    <xbrli:endDate>2022-04-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-21</xbrli:startDate>
    <xbrli:endDate>2022-03-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-30</xbrli:startDate>
    <xbrli:endDate>2022-03-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-09</xbrli:startDate>
    <xbrli:endDate>2022-06-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-03</xbrli:startDate>
    <xbrli:endDate>2022-08-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-17</xbrli:startDate>
    <xbrli:endDate>2022-10-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-01</xbrli:startDate>
    <xbrli:endDate>2022-12-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-05</xbrli:startDate>
    <xbrli:endDate>2022-12-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-13</xbrli:startDate>
    <xbrli:endDate>2022-12-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-14</xbrli:startDate>
    <xbrli:endDate>2022-12-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-31</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-31</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cphi:TwoThousandTenIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-03</xbrli:startDate>
    <xbrli:endDate>2022-10-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-04</xbrli:startDate>
    <xbrli:endDate>2022-10-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cphi:TwoThousandTenLongTermIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-23</xbrli:startDate>
    <xbrli:endDate>2020-12-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-05</xbrli:startDate>
    <xbrli:endDate>2023-01-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-18</xbrli:startDate>
    <xbrli:endDate>2023-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-02</xbrli:startDate>
    <xbrli:endDate>2023-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="cny">
  <xbrli:measure>iso4217:CNY</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>f10k2022ex3-1_china.htm
<DESCRIPTION>AMENDED AND RESTATED ARTICLES OF INCORPORATION OF THE COMPANY FILED WITH THE STATE OF NEVADA ON MARCH 1, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 3.1</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; color: Red"><FONT STYLE="color: Black"><img src="ex3-1_001.jpg"></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; color: Red"><FONT STYLE="color: Black"><img src="ex3-1_002.jpg"></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; color: Red"><FONT STYLE="color: Black"><img src="ex3-1_003.jpg"></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; color: Red"><FONT STYLE="color: Black"><img src="ex3-1_004.jpg"></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; color: Red"><FONT STYLE="color: Black"><img src="ex3-1_005.jpg"></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; color: Red"><FONT STYLE="color: Black"><img src="ex3-1_006.jpg"></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>f10k2022ex10-11_china.htm
<DESCRIPTION>LOANS EXTENSION CONFIRMATION LETTER, DATED DECEMBER 31, 2022, BETWEEN THE COMPANY AND HEUNG MEI TSUI CONFIRMING THE EXTENSION OF THE LOANS TO DECEMBER 31, 2023.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Loans Extension Confirmation Letter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is made to the loans from Ms. Heung
Mei Tsui to China Pharma Holdings, Inc. (the &ldquo;Company&rdquo;), the principal and accumulated interest totaled USD1,354,567 and USD152,577.99
respectively as of December 31, 2022. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay
the loans, both Ms. Tsui and the Company agreed to extend the loans to December 31, 2023, by which date the Company shall repay the principal
and accumulated interest.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lender:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Heung Mei Tsui</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Pharma Holdings, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li, President &amp; CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>f10k2022ex23-1_china.htm
<DESCRIPTION>CONSENT OF THE INDEPENDENT ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consent to the incorporation by reference in Registration Statement on Form S-3 (File No.: 333-251973) and Registration Statements
on Form S-8 (File No.: 333-251545 and File No.: 333-267989) of our report dated March 30, 2023 relating to the consolidated financial
statements of China Pharma Holdings, Inc. and subsidiaries as of and for the years ended December 31, 2022 and 2021 appearing in this
Annual Report on Form 10-K of China Pharma Holdings, Inc. for the year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>/s/&nbsp;</B><FONT STYLE="background-color: white">B F Borgers CPA
PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">B F Borgers CPA PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lakewood, CO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 30, 2023</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>f10k2022ex31-1_china.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Zhilin Li certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing
the equivalent function):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">all significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 30, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>f10k2022ex31-2_china.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Zhilin Li, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing
the equivalent function):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">all significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 30, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer and principal accounting officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>f10k2022ex32-1_china.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby certifies, in her capacity
as principal executive officer of China Pharma Holdings, Inc. (the &ldquo;Company&rdquo;), for the purposes of 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The Company&rsquo;s Annual Report on Form
10-K for the fiscal year ended December 31, 2022 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: March 30, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer and principal accounting officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification accompanies each Report pursuant
to &sect; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed
filed by the Company for purposes of &sect;18 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A signed original of this written statement required
by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $3 2P# 2(  A$! Q$!_\0
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M?_A<OB3_ *=/^_(I?^%S>)?^G/\ [\BO.-H]*-H]*'0@/VK1Z/\ \+F\2_\
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M 9NN*/RHH"X@..*6BBC05PHHHH$]0HHHH **** .F\ ?\CKI7_7<5]/R_?\
MPKY@\ ?\CKI7_7<5]/R_?_"N"O\ $=M'8Y+XH_\ )/\ 4QT^4'/XU\T'@_A7
MUEXETD:WX<O=.)QYT>%XS@U\L:IIUUI5_-:WD+12QMC!].U:8:21G6393HI
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M?\),H807!!Z?OC2_\*>\)_\ /"X_[_&N[@96A1E8,K#(8=_>I*.>0<D3@/\
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M &G=_P#/3^=']IW?_/3^=5Y8I8)#'-&\3J2I5QM.13!R,CD460[LM_VG=_\
M/3^=']IW?_/3^=5 <KG(Q0>!S1H%V6_[3N_^>G\Z/[3N_P#GI_.I;30M2O=.
MGU"VM]]K!_K9-X&VL_\ BQWSBBT03:+?]I7?_/3^=*-4NQ_RTY[=:J $L%')
M)QBC!VYP1]>IIVB.[9<75;I<[7ZKCJ>OK31J5TO DX/4'/-52-IP:0@@*65E
M##(W#&119"LRW_:=W_ST_G1_:5W_ ,]/YU3) ')I>@ST'\Z.6(^8M_VE=_\
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M'_ODT<T1692QCN*.?45=_LJY_N'_ +Y-']E7/]P_]\FCF0692Y]11SZBKO\
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M 'R*FHHNPLB$VMM_SPB_[Y%.6&-3\L:+]!4GY44[L+(****0PHHHH ***,T
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M!:6L-C9PVMO&(X84"(@[*.E3\T7"P44<T<T7"P4444KA8**.:.:=P"BCFB@
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MUSIHDFN]5DM)&/\ =!-1Z+X5TXZQ=Q/II:W_ +5-KYC+D!?[H]/K1[47*>:
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MVR?\*(O!,WE_Z??Q6<CRR1PM(-JGRQ\W/UJN:.X<K,677=1GC@AFNY&CM_\
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M-YX4EN8[2^CE\R 3?=<#L:R?#T$&E^*-'N;J\@V1W(+X;(0#J:Y^69[AWDE
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A6T,7AZ>>.-5EW8W@<XKO9$5B"1DX%%%>;5^)G=1V/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex3-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1_001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MUX<_\*_3O_CM(W_!JC^VQ_T3GPZ?^YOTW_X[7]:&,4 8H _DN_XA5/VVL?\
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MI[X'B/2O_DFF_P#$,_\ MM9_Y(K<?^%%I7_R37]>F,T8H _D-C_X-G?VVI)
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M+Y?^HYI?_P DU_7]BC% '\@L_P#P;>?MK&UC'_"C=5+9Y UO3../^OFJ[?\
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M .2:_L/Q1B@#^/>/_@W>_;2\MO\ BP7B;J/^8EIN3S_U\U77_@W@_;223GX
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M@A/\I*_LLQ1B@#^,T?\ !";]L(;C_P ,\?$CY>O^AQ__ !?->*_%C]COXI?
M_P ?ZAX7\7> _$GA_P 1:7Y?VO3[RVVS6_F1I*FX9/WHW1A[,*_N<Q7\W_\
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MGI;38!PSXCV*_G0^92_: _X)Y?L^_ 7]H?PU'=?LV_LXW'PJUS2+HZK=GP)
MFI>%;E+BTAAOYI-YCGL"]TJ3*(XFMP1,TC1+*8_7?VE;3]E;P-:?$S4OB?XV
MT_1X9'T_PYXSDU+QUJ, B$\<L]KILH%R-D<D5U++]G4!624N5V@$=MJ?Q;^
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MNOI:B@#YI_X<T_LF_P#1M_P5_P#"1LO_ (W1_P .:?V3?^C;_@K_ .$C9?\
MQNOI:B@#YI_X<T_LF_\ 1M_P5_\ "1LO_C='_#FG]DW_ *-O^"O_ (2-E_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\D_\ !<W_ )1A?$#_
M +"/A[_T_P"G59_:)_X*P:1^SG>7\=[\%_C]K5O9^)+?PG#>VGAJVL[34[^X
MNH[2W6UDOKJV$\<L\J*DD>58$OG8"U5O^"YO_*,+X@?]A'P]_P"G_3JC_P""
MW7Q0\*?#S_@G[XV76G^T>*/L,NL^#M/@TZ;4;RZU;3!_:%O)%%#&[JL3VZ-)
M.0(X4)9W1>: .FN?C5^U)XS5V\._ ?X;^%X0PVGQK\272Y9?^N.FZ?=QAO\
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M,%KH'P<\87VEZUXH3PMH6O7;P:?I>HS$WZ2.S2XE41OI[AA'%*0)X3][S$C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\D_\
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MFN76FV=QK&BQSQ6%Y)$&FLUF""41L>5WB- V.H4"M3&30!\6?MV^&?#.O?\
M!2/]C7PM=07D,U]?^);I;6T<0V=U:6%E;:BL,Z@?.B:C:Z7<(G \RU5C]W%?
M6/ACX/\ A+P5_:G]C>%_#ND_VX[RZE]BTV&W_M!WSO:;8H\PMDY+9SFKFJ>
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M\^/C7_PCM7_^1J .UKY5_P""+O\ R8-8?]CSXY_]3#6:]V'Q\T,G_CQ\:?\
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M=0A72;:4V'CC54NO)2_NMQ5M*$N0(X(CC[2^0&8^22H28'])_P#@L3^V\W[
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M@*O^Z\A@&KZ1NOV>/ %]\45\<3>!_",WC2,JRZ\^CV[:FI6/RU(N"GF9$?R
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M 6A_]@^#_P!%K7\&.W=$_<XZ'O7]Z'@,;? ^C?\ 7C!_Z+6@#6HHHH ****
M"BBB@ HHH- 'X3_\';GQP?Q/\?O@[\*TG6'3]%TRYU_4L%GW27LPMH6* ?\
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M "BBB@ HHHH **** "BBB@ HHHH **** /DG_@N;_P HPOB!_P!A'P]_Z?\
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M=B2S.Q/6@#[FHKY&_P"&R?VJ/^C,[G_PZ^B__$T?\-D_M4?]&9W/_AU]%_\
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MO0!YS^U]\>X_V6/V5OB/\2Y;"354\ >&M0\0?8D;:;PVMN\PBW8.T,4"EL'
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M4 %%%% !1110 4444 %%%% !1110 CGY37\<'_!QTS-_P6Q^/F[_ *#%H/\
MRG6E?V/L<*:_C5_X.(IC/_P6F_: 8]M?B7\K.W']* /ECP:AD\8:2OK?P?\
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M_!3C]FZY($7[0?P/DSTV^.]+.?\ R/5N/_@HO^S[+C;\=?@VQ;D >-=-.?\
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MHH ***,\T %%&>:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM"B@# /PJ\,$-GPYH/[QM[?\2^'YF]3\O7WJ _!;P<;IIO\ A$_#1FDSN?\
MLN#<V?4[<UTU% ')7GP#\"ZA$8[CP7X3G0@*5DTBW8$#H,%*H?\ #+/PRRO_
M !;GP'\OW?\ BG[3C_R'[5WE% 'F-S^Q1\&[Q]TWPE^&4S8VY?PM8L<>G,59
MM[_P3W^ FI%OM'P1^$%QO;>WF^#=.?<<8R<P]< #/M7L%% 'A\W_  3*_9ON
M)1))^S_\$Y&7H6\#:83W/_/'WK\L?VM+/Q%J/_!6_P :?LW?L\?L>_L-^)8_
M"7AFS\3F?QAX MX;A8I8H/-S+')&C?O)T"J(\X.23C(_;ZOP[^-'[-?Q,_:P
M_P"#G?X^:#\+/C9K?P)US2OAMI=S=:WIFE+J,E[!Y.FK]E:-I(P%+RH^X'(,
M0P.] '>_\$T=8^&?QX_; ^*'[.O[3'[%G[,/PX^*?PYT-?%(N-$\&:7-H][I
M@:!7EWR))MP;F%U82$%'8,$:-L_5NA_LK_\ !/'XB>*/#V@Z1\/_ -DG5M8\
M;)<3Z%9:;H^AR7&L+!N6<VRQ+F01E'#;.A1^X-<?^R7_ ,$;-+_X)X^#?CE\
M4O%?Q*\5?&KXQ>/O"M[8ZQXO\0)Y,GV)+<L((X_,D8 F*'<SR-D01A0@7!^%
M/^"&W_!//P;X*_X(C>)OVI/"OAF:Z_:.L_#WC";PIX@BO;IKG2FBMKRRC2VM
MU?R?,VB4@^6S%I>O0  _15_V+O\ @GA/\8O^$$/@#]E7_A.A-]E_X1Y;+1UU
M'SMV/*^S#Y_,W<;=N[MBOD3_ (+6_#C]F/\ 8$\0?"7P/\-_V8_V9O$'Q.^+
M6O+H\,'B2TBL=/T6V/EQBZNA$R/'&TDJ 2,RC"2'YB*^9O"G[)_[*,__  :O
M7?Q0OK7P@OQ9:TN+O_A)S<H?$2^)EOG$-F'WF090(/)Z&%O.*Y.^NU_;@^"E
MG^T#XK_X)/ZQ\7O"MAK'CWXI2V6F>.;C5+8_;?$-I&-+9(;TG#2?+<2,5?D-
M-)_>;(!]%_ +_@GK\,?$O[2'A/P=\1?V3?V2[?PA?> AXCUWQ3X8UZUE2"_+
MR,D=M:R3BZ>T:W$4GV@Q;#N;YR!6M_P3B_90_8 _X*E:'X^U;P?^S=X)TC3_
M  ;XJN?#=M'>.$O=62"&W=[T0PRGRX&>;:F6;(3)VDE1S-I\!_!M[_P=&7GP
MW_X1K1_^$"M_V=E\.'0?('V$:=\EL+7R^@B\AA'M_N\5F_\ !H3^S;\/-.^"
M/Q7^)5CX9L;?QY9>/=6\)1ZF6D^UVNDB*PG2R(9B @<!N1N)').* .^_X*E_
ML._\$_\ _@F%^S@?'WBS]F[PWKU]J6H1Z1X?\/Z4UQ'>:]?R@[84Q+A5"JSL
MQ!VA>%9RJM\)^*O WP?_ &3M=\&ZY^U1_P $S[/X0_"CQYJ,6F6_B?3_ !O?
M7TNBM,"X^U6Z3$APJ.YC?RI=B2;48H5/W)_P<GSK\*?VD/V'_C#XBM9V^&/P
MS^);/XJO5B,L.FB>6PDAED"@D*%M9SGU4#JP!^G?^"@W_!8O]G?]B[X.>$_%
M'B?6-+^)5GXQU2TBT+1_"L]EK=_J08EUO8(3*%>&/:#YJMC<\:J=SJ" <%+_
M ,&V?["_]EM?O\'=+CL9(Q*)SXCU)8E1@,,&^TX .00?>H;;_@V'_8?GC6:/
MX/K-'.BE&7Q+JC*5(X92+C!SZ]Z^=OV_?A7H_P#P4M_X.&/AG\ _C-)K'_"F
M]%^&DGC#2?";WLNGQZ]J;^<'+^4RR>:B*V0&W*MHX!"N^>4_9*\)P_L-?M]_
MMU?LR_#'5M2OO@'H?PGOO%T&CSW37T/A;5Y;2W#6R3.2REHYYLJQ+,(4W;FC
M+4 ?5ES_ ,&MG[$,]Q_R2>[C9@Q"+XHU1<C/4#[1VR!^54Y/^#5#]B60G_BV
M.M+D@\>*M3X_\C>_Z5\%_P#!%#_@EGX<U7_@DOJ'[6'B7Q1XRU3QEHW@;QOI
M_A737O@-(T6P^SZG9S*L;*6W/*]U+E750TA.,Y->3_!W_@G;X/\ '?\ P;BR
M?M4:A\2/'*?&+X<K=7?A?54\231V_A;R-5\I=/AB#81IF<ON!#^;<(0< *0#
M]-K_ /X-*_V+;L?N_!OBZUX_Y9>*[PX_[Z9JIW'_  :-?L:RC]WX?\>6[8 R
MGBF?/3!^\#UZ_P"<5\T_M(_%?QY_P58_:I_8/^ ?Q*\7Z]X,\!_%?X6VOQ#\
M90:-<_V;-XFU$VUS(UNS+@8(M1M0<+]I<A=P0KZS^PCX1OO^"9/_  7C\0?L
MO?#_ ,7^*/%'P5\8_#<>,ET+6=2;4G\'7J.R 1R,VZ-65.1@%ENH=P;8KT =
M=>?\&@G[(5S*S1Q?%&SR.!%XGR$.#R-T+'WY)Z54F_X,_?V5WBQ'X@^-MOP,
M-'XG@RN/3-J1SUKY3_X-V?V6O$W[2_P(3]J+XM?M"?$ZQ\-_!/Q+JSZ1I-QJ
MSSZ;!#!81RW5]<O*SEU#2@[",8M2&W*VT?-O[3/QCUCX8_!#PU\?_@EK?[8F
MM3KX\59OC)XVUW^S-%\5*]Q/BTMM.61C+%NA*%\! 8I5=%W+&@!]S_$G_@W6
M_8E^$?[2G@#X/ZE\6/VA+7XC_$]+F70M)M?$,$DLUO;PS337,CBQ,<486%E!
M<@LP 4'#$97P]_X-_P#]F/XC?MM_$#X#Z;XL_;.T?Q#\.M,M=6N]>N=;L8]!
MU".XBMI%2UN/LI,D@%R%8%%P8Y!D[<F7_@IW^Q?8_'C_ (.<?@7X?D^(/Q2\
M+K\1_ ]YJ4U]H/B!K._T!K>VU%1'ITNUOLL<GD R*H(9I)3P7->JZ;^VSX\^
M"?\ P6(_X*(7DOB+Q%XC\)?!;X3VGBO0O"U[JD\FE6US!H5C=/Y4!;9$TLB/
MN9 "3(YZDT 69O\ @T>^#>Z3ROCI^T]'$S95?^$ILFVCZ_8QGZTR7_@TQ^&M
MHP_L_P#:)_:<LQP6!\36K9/K\MLO;BOFSPK\(OCY\0/^"-6J?MU3_M8?&"Q^
M,WV>\\9VVF0:RB^%(;.WO'C^P'3]GE$LJ.0N/+#.L9C(!)]'_;._;P^-W[4W
MQ$_X)N77P_\ 'WB7X,ZA^T-87$_B*'29=UFI<6/F2_9I<QSB-7G>%9@R_,F0
M03D ]/;_ (-6]#L&_P")7^U;^U#8<< ^(XVY_P" HGM2Q_\ !L'K%C!ML_VT
MOVH+5PP*D:\^T#G/ D'/3G/8]<\1_P#!.37_ (J?LG_\%[/BM^S?KGQC^(GQ
M<^'<W@*'Q=I[^,]2&H7]G<E[;D2;0%.9IU(0(K*4)4E0:^X_V(_V;?BE\ /$
M_P 4[SXD?%R_^*-GXP\32ZMX:MKFV:$>%K!F<K8IEVW!=RC(P,(.* /BJV_X
M-K/&]BVZW_;L_:JMV[%/$,ZX_*?Z5')_P;E?&*)7%I_P4,_:FMP3\@;6KUMH
M]\7RY_2OU8HH _*$_P#!N[^T!'(?+_X*/?M.!.P?4M08_P#IRI9_^#?7]I6!
M?]#_ ."CW[0@^7'[][V3G_P8U^KM% 'Y-Q_\$&_VOK%S]G_X*/?%QAQ_K]-N
MI/YZ@:D;_@B5^VU:<6__  48\=,#Q^^\.RMZ#O>'WK]8** /R?'_  1M_;OL
M8MUO_P %$/$<C*W F\+L1CGN;AO;C'\J=#_P27_X*$VCJL/_  4 FD7&,R^%
M%8_J3_.OU>HH _*0?\$R?^"DEC$?L_[=FASMC@3^$HO3U\EJ@?\ X)^?\%2K
M';]E_;,^&]T5)R+CPY&HQGCI8M[?F>O?]8J* /RE_P"&)/\ @JO9^7Y/[6_P
M=F/\9F\.(.?3']G'/UXH?]E'_@K7;S?N?VG/V?YX^QDT$*3^']EU^K5% 'Y0
MI^S[_P %>+56_P"+[_LXW&T\!]) W#UXTT4V;X7?\%?-*E3;\2OV;=25@"2+
M': >>#FT0\<=*_6"B@#\H1H7_!7VQ4$:Y^S'?%B<AHG79CZ1KU_&G+>?\%?M
M/@+_ &7]E^^;^X3*K?HRCCZ]*_5RCK0!^43_ ! _X*_64&1X'_9=O&P/E$\H
M;GK_ ,O:CC_.:4_&K_@K]ISM_P 6A_9=U *<?+>RKN_\J*_Y%?JY1B@#\GY?
MVGO^"OFGQJS?LY?LVW^YA\L.K%6 _P"!:P![41?MC_\ !6R.3$G[)_P,DYQE
M/$4*Y_/5S_D5^L&*,4 ?D[-^WE_P59TR1EN/V-/A9=;03FV\46VWMQ_R$SD\
M_P ZFC_X*(_\%0K1F%Q^P_X'D\O&[R?&%H,]#Q_IS9_#-?JYBC% 'Y3K_P %
M./\ @I+:;OM'[".BR*KE,1>+[?/!P?\ ENW'OT[U7_X>\?\ !0+3F47G_!/W
M4)&9]F;?Q*&';T5O7J>.OH:_6#%(5S0!^4R_\%D_VZK9&DN/^">?B=U5MN(O
M$A+9Y[>221QUQCIZBHX?^"YW[8EN/]*_X)R_%)O+.&,.KSG/../]".?PS7ZO
M!<4UDW4 ?E-;?\%^OVGD:99O^"<?QP9H&V/Y5_<D!O\ P7'/X4A_X.%?VAH(
MMUQ_P3I^/\:YP2D]RW_N.%?JYM_SFDV?7\Z /RD'_!QQ\8+>W\RZ_8!_:*AW
M8V[8IF!R"1_RYCL#^5>T?\$Y/^"X+?MW_M6ZI\']?^!?Q(^#GBO3O#+>*%C\
M3 (9[=9XX>(V1' 8R':^W:=C#@BOO+9GU_.OSWTB07O_  =':P,Y-G^SA;IU
MZ$^('/\ [-0!^A5%%% !1110 4444 %%%%  W2OXN/\ @NU(K_\ !83]HC(;
M_D<[L<'TVBO[1F^[7\6?_!=&99_^"P'[1++T'C:^7\0P!_44 >'?!9/-^,?A
M%,D9UVQ' SC-Q'VK^[U&R#]:_A*_9_LFU/X[^![=%+-<>(M.B"KU8M=1#%?W
M:KT_&@!:*** "BBB@ K\[?@$OF_\',/[0$G_ #Q^$&@QCVS<H<?I7Z)5^=W[
M,H\W_@Y1_::/:+X8^&D_-E- 'Z(T444 %%%% !1110 4444 %%%% !1110 4
M9I&SCBOQB_9\O_VE_P#@X'^*GQ4\?>&/VB/%'[.WP(\#>)KKPIX1T_P?&5U'
M5I[<(YN;J19(RZE)878&1E)8HJJ%+, ?L]FBOAW_ ();7?[3'[+GP\^+FA_M
M=>(-%UKPK\.KHWGA?XCW-[;I)K6E*LSW$MVJMNB6%8XG#2J'_>NI9@BDU?@3
M_P '%'[.?Q[^,_A[PC8W/CS1+3QKJ3:1X5\3Z[X8GT_P]XHNE;9Y5I=,>6+X
M4>8J?,RCJ0* /NRC-?&_[:7_  7B_9Q_8%^+GB/P'\2/%&KZ9XM\-Z3;ZQ+I
M]OI$UPUY'.T:QQP. $>4^9NV%AA4=B0%)KY?\$_\'*'AWXF?\%;?#_PRMTU3
M2?@[JGARW6SDN/"5^FNZCKUZ\'D1S(P+0VRQR<.(PF26:0KC !^M&:,U^7D7
M_!4FX_9K^%?[<7CGQ#\>+?XH-\,=>N-)\+Z''X-N+-?!6HL+Y+/3976%?M2/
M.D2-/N9%$)9G4-Q\J?L??\%,?BQ\0?\ @EQXY^,GB#]N+^PO&T%_I>GZDFO?
M#@7&E>"II[ZXV1QM;V;FZ:X@AQE(V2+)!(.& !^]U%?./[4?_!4'X*?\$_/
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MQ0\<?!GQU<Z]+%/ITWPZ=Y+;2T:VB>6RNV9V7[7%*[*ZJ?EZ$^F+_P %O_\
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M&\^.'PPU?PC\0/V.?CIXB\*^(K;[+J&EW<'AF_M[N,D$!D35V((8!@>&5E#
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M6NK7P*W-[#:1QW%P"02'D W-D@=2>@H _*;P9\-?#_Q5_P"#NSXE-KVEZ=K
M\,_!ZWN[6.\M4GC@N&^P1>8H;(#>5<2KG&<2,*S_ !;\</!?[+__  =EZA>>
M/M6M/"-CXL^$VGZ#X=ENXG6+4KR>Z@BAAB*J1\S12H"<+F,C(/%?KP-*MQ?F
MZ%O +EAM:41CS"OINZXX'%8_B;X4>&/&OB'3=6UGPYH.K:IHKF33KR]T^*XN
M+!CU,,CJ6C/NI% 'XG?L<3*/V>/^"RUPWRLU]XN4@^HL-8_J:\^_;-CCT_\
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MC>!4\)^&4\$O:M8MX>72X%THV[9W0_9@OE>6<G*[<')XH _GQ^''Q>A\4_\
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M7[&WAS5O"'[)'PPTG7-<_P"$EU?3?"FF6MYJYBFA.J2I:Q*UP4F"RJ7QN(D
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MU0Z;;ZC%EL264DJ38D4YS;SIC?&PK?\ V??VM?$7QM^*/BGPSJ'PH\3>$/\
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M=YIOB:P\>VFHE_%EE9Z)K=EK)A%E!HD:F273]0DB@MUN;B>!$\Q;IB9?/5E
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M\$1=.F=,#?UK]$6Y%?G=^P [7G_!?_\ ;VF8?ZFP\#0#C_J#C_"@#]$:***
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MMT>*-0T6ZTZ^USXPWMO#/=69B::UCN+N1-C,H+(6F)X)'0T <M_P3;_X+?\
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M>7?AVQ\%Z!X;6/\ X2#1M12-8[OS4C EA=I-Z,7QYLLB.-V-X_?'2]0E\)^
M+>Z\17MM')INGK+J=V3LA5HX@9I"2>%!#'D\"@#\P?\ @X'_ ."U7Q6_8!^+
MWA'P#\"='TGQ!XHM?#EWXW\8K>:5)J$>G:/'((HG8(Z^6NY)V=R?E4(> P)_
M2;X#?''0?VAO@3X4^(7A^Z2;P[XPT:VUNSE9A\L$T2R ,>@*AL-Z%3Z5^"G[
M)US^U%_P4'_:,_:=_:7^%/P8^'_Q.\#_ !N.H_#JRE\8:U_9\EMH406(6]M'
MYJ':\(MA(Q&TR1,!@AJZK]@/XX_$?0_^#?;]L3]F_48KW3_BW^S58ZOI%Q9P
MS![B#3+EII9@CH3O"%-14,I(">6!P5H _7#X7_\ !5_]FWXU_&M?ASX4^-?P
M[U[QI).UM#IEGJ\<CWDJYW1P/]R9AM8XC9C@&NH_:7_;T^#'['$NGP_%+XG^
M"? =UJR&2RM=8U6*WN;M VTND1.]D!X+A=H/4U^6G[,VO?\ !/[PW_P3=_8K
M;QQHGA?6/&ETVDQZ+'X:MG;Q)%XH\I?M<DWV)DNMOVW@^82I<VYP<*1?^%&A
M?"OQ]_P<=?MB0?M'6?@K5I=*\(:6/"D'C2."?3+;1OLENUTT"W0,:_(ZERF"
M/,N>S24 ?KIX1^,?A/Q[\,;?QMHOB;P_JW@Z\M&OX=<L]0BFTV6W4$M,)U8Q
MF,8.6S@;3GH:XOX%?MW_  3_ &G?$U]HOPY^+7PX\=:QIJM)<6&@^(K34+F.
M-2 9/+B=F,8+ ;P"N3C-?C'_ ,%,/'/P7D_X-_\ 1;;]D^7Q9H_[.]]\5[73
M/&CL-25H+9@7N%7[42QMS<?9R?+)B,N /F+ ][_P5(^$?P/^ '[5G[!=_P#L
MJZ/X$\._$C5?'5BFG#P3'! VK^'9/+6:6[:#YIH74E3+-N+H]SEC\] 'ZT^-
M?VU_@W\-;CQ%#XB^+7PST&;P>\,>O1ZCXGLK5]%>;_5+<J\H,+2?PA\%NV:;
MXB_;<^"_@_3?#-YJWQ=^&&EV?C:-9O#T]YXIL8(]>1CA6M&:4"X4D@ Q[@2:
M_*/]D?\ 8Q^%_P"V/_P7A_;^NOB9X+T'QM8^&8M.MK&TUBS2[M[62YM622=4
M<%5F5;?"2 ;DW,5*DYKXM_9R_8J^&GB'_@U6^-_Q7UCPGI.L?$+3?$VS1O$5
MW;B34M'MH=0L(5M[:8Y,4+>?<LZ)A7:=BP)"D '],?B7XE^'/!>MZ3IFL>(-
M%TG4M>D:'3+2]OHK>?477:&6%'8-(PWKD*"1N'J*H?#'XZ>"?C9!?2^#/&'A
M;Q=%I=P;6]?1-5@U!;.89S'(86;8XP?E;!X-?A?_ ,%0]$T/XQ)_P2#T?XD:
MA-_8/BBQM[77KJ2Y:%[B&:'PZDBR3JRLBRA]CN&! =FR,9KUS2? 7P__ ."=
M7_!SEHF@_!G3['P7X#UGX1WNM?$O0M%4KI^G+;Q7DT4Y@7*QO^XLV"J 1YNX
M#]Z=P!^M<_[1WP]M?B.O@V7QYX-C\7,P0:&^MVRZD6.,#[/O\S)R.-O<5TMW
MXFTW3]4AL;C4+*"^N4:2&WDG59I54$LRJ3D@ ') XP:_E5_;K\,^'?B+_P $
MR)/C[\,_@7X5^&?@?6/B%G2/'GB3QQ=:Y\1O$>H&:X+@,!B)1Y,KNDLC,/*W
MJ7/[ROT:_P""H'P3TG]KW_@O;^PUX+\42WEQHOB3P/J=QJPMKR6UDU&".TO;
MF6!I(F601S+"T;@,-R2NI.&- '[!>&_B?X:\8Z-<:EH_B'0]5TZUE,$]U9WT
M4\$,@P"C.K%589'!.>:TVUBT73UNS=6XM74,LWF#RR#T.[I@^M?BE^Q1^PYX
M(T3_ (+5_MT?LQ^']/\ [!^#/C'X;6JR^'X&9[.QGNH;(":*-FX>-KF=T;.4
M+ *0 ,?-O@?XQ>+/VK?V$/@'_P $Z=2O[FW^)5G\8[_P3XVBAG9KBU\.Z-/]
ML>5AP/*19\1= PTSCH30!_2+',L\2R1L&2095E.00>A!K\L?#O\ P<7_ !*^
M*'CWXC:3\.OV,OB=\2M-^&OB:\\,:AJ>@:XES&TUO*Z9V"UW!F50^P9(W 9/
M!/Z@^&/#=CX,\,:;H^EVL=AIFDVT5G9VT0PEO#&H1$4>BJ !]*_G=_8*\+?M
MLRZ#^V)XT_93\<>$=-TO1_BOKCZCX7O=)@N]5UJZ1F=FLWF@=/,\ID"QLRAF
M7U(R ?KU_P $NO\ @KKX7_X*:MXZT6'P9XP^&?Q"^&-Y%9^)_"GB6#RKW3VE
M\P(PZ%ANBD5@RHZLO*@,I/UH+F,RM'O7S%&2N?F [9%?A[_P2N^)]K\-?^"2
MW[6/[8VB?$+5/'_[2/BS2[VY\8OJ>G163>%M2LX93!;K;+D;$\X2A^$=$C41
MH8V2OG#X _L\?&BR_9E^"GQR^!/PI_:FU3]HZ\U*V\3:YX^U/Q%:WFA^.;"8
MR27%K)$]^9&A?$>WS(59U\SS.64@ _I4WC->=?M7?M5^"?V*/@%XB^)OQ$U1
M]%\(>%XDEOKI+>2XD!DD6*-$CC!9F>1T0 #&6&2!DU^,?_!:;X%_&3PY_P %
M&?&'Q1^*GP=^+GQ\_9OO-%LX?#%KX,\87>ER>!'^SVXN)_LUKN83+.DK$RQ^
M5)O0E_EVIQW[9'BGX:?M4?\ !KQK7B3P7\4/C9\0+?X5>+;6T@_X3R]1-6TV
MYDGM(WTZ\$0V75O%#="2(EI I= ' C\M #]]?A?\1+'XL?#7P[XIT^*Z@T_Q
M-IEMJUK%<H$GCBGB65 ZJ2 P5P" 2 <\GK6XTF.@Y]*_&C]KKX=_#O\ 9-_8
M!_9C^$^H?%_]J5;GXB3P:K;^#? U^^J>)_'3M9V?F6(N)'0VUG$655B#A 9L
MA&*93EO^"*=EXW\<?M:?MA_LU^(/$'QT\"?#RW\/6ESI6D:YXQ%YXH\%^?RI
M@O8VDCMY6BF#$)NQB,-O9&) /UK_ &0/VU/AU^W?\--0\9?##6F\1>%K'5[C
M1%U+[+);PW<\ 3S&B$BJSQ@N 'P V"1D8)]5#@U_-[_P30\>^*O^"?'_  ;?
M_%?]I#P/XY\=1^,-6U";PKIFB7&JF;PSH#SZA9VYU*WL"NQ+T*S'S6)!.T%2
M,@^C?LO_ !;^-'[.G[1_[,_B;X;ZY^W%\3(?&%S8Z?\ %^P^)>AZM>^'9[>\
M6V#ZC8L\96)(B\KI)N9@D<>7*>8) #]_=XSCO7A?["G_  4*\!_\%#O#'C'5
MO ,/B&&T\#>)+CPMJ7]K62VK&\@5&?RPKON3#C#9!]J_.WX%:5\8O^"MW_!4
M[]JKS/VC/BU\(?"W[.^O1^%?"&A^"]5%G9M=QS3JMS?6K*T5["7M79XY5S()
M=F]$4*>C_P"#0Y]0N_V+OC)=ZM-!<ZK=?%C4WO9H5"QS3_9K3S&4#@*6)( X
M - 'ZF?$#QWI7PO\"ZUXEUV\CT_1?#]C/J6H74GW+:WAC:220^RHK'\*\9_X
M)_\ _!3'X1_\%-?A_K?B3X2ZY>:M8>'=073=0BO+&2QN;>5HUE0F.0!MC*WR
MN."5<#E3CX]_X.L?VSX_V?\ _@GM:_#6QUZWT'7OCMJ\?AN2[E:15L-(0K)J
M%P^P%C'M,4+J 2R7#@ ]*^2?^"0G[2WP&_8^_P""[=Y\-_@#XZL_%7P2^.W@
MS3["#R$N(5L/$%A;G9YPG1"9)O)NWRH(WZ@ -H!  /WVKB?^&C? [_'I?A;'
MXIT6;XB'2)->?P]%<B2_@L$DBB-S+&N3'&7FC52^-Y)V[MK8_)O]LWXK_M4_
MM1?\%W/B'^S)\'_CI??"WPE)X'LM9ENOL"W/]B*D-M*[VVW;(LLLSQH6,@PD
MLF.<"N"_9*_9,^*NC_\ !SWXV\-WW[0GB_4_$'@_X>Z7KVN^(IM(LVN?%&GK
M<Z0TFC2H%5([=]X'FH!(!&.Y)H _7C]F?]NOX9?M>^.OB/X;\ >()=:UCX2Z
MV_AWQ3 ^GW%J-.OE>6-H@TJ*LHW02C=&67Y>O(KU\U^+/PR_X*Y_$+]F[]G_
M /X*/?%#5+C3O%%W\(/B?)X?\'6DVFV]K%;F;4IK* 3- D;SK&98W/F,798B
M-P+9KWG]C#X$?MZ>&O%7P3^)6M?'WPS\4O"?CRTM]2^(OA37M'ATR/0;>Y2.
M7_B62VT1:26))" &\M&>,9&USM /M7X>?MM_#+XK_M,>,O@]X?\ %$.H_$;X
M>V\=UX@T=;2='TZ*01E&,C((FR)8^$9C\WL:]8K\3?@W^T=:_LE_\%L/^"F'
MQ8O+4ZG;_#[P-::J+02>7]LDAM+5HX-^#MWNBIG!QNSSCGQ+2O\ @X"^-WP<
M^$?@/]H#Q!^TY\'_ (AS>(M<B'BCX&:?H=O;WF@Z5,[_ .HG4B<W$2CD.?E)
MCW-* P8 _H>VC.:6OQ:_X*@_\%F?BC\&?^"J/B#X-W'QJTK]F#X::1X?LM0\
M->*+KP ?%,?BZZN+>&4-,S!C#;B5Y8?,B4A?(?=DGY?T6_X)5_&_Q]^T!^Q[
MH?B+XD>+OA+X\\133S0#Q#\.M0>[T?584VA)&#(OE7&2RR1J-H*@@+NV* ?1
M^**_/?\ X*@?\%&?C%X4_;H^%7[*?[.UAX3M?B=\2=,D\0ZEXF\2QM<6'AW2
MXS< ND*L-\W^C3-\VX8"*$8R;DH_L-?\%"?CAX'_ ."@WC?]D_\ :/\ ^$1\
M0>-=-\+CQEX2\9^'+-K&UUZPX#I-;LWRR*Q8#8%'[B4$,-KL ?HJ!CI2U^0O
M_!%;_@IU^VQ_P50\0>"_&M]X8^$^C_!/1]:O-%\9:G;P20WVI2K:^>@M87G9
ME$9DMDW D%I'/S!2J_I5^V?^TQI/[&?[)OQ ^*6N%&L/ VB7&J^4S%?M<R(?
M)@!YPTLQCC'NXH VO!?[2GPY^)'Q*USP7X=\?>"M?\8>%]W]LZ%INMVUUJ>D
M;7"-]HMXW,L.'(4[U&"0.M=J5!K^:W]A'1/%/_!,S]IW]DO]K3QEXHDU*+]K
M?4=6LOB&CW*LME_:UP)[25]I+$.)(+MMV2#"P.#C'ZG_ /!5S_@JC\5?V)?V
MW/V>_A/\,_ WA+QS-\:S?6;6NJW$]I/'<H\,4!6=&V10JTN^1FBD.Q&V\XH
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M (+O\'->C^(::O8+9ZY'JEEJ=G<W&F_NG*X:*Z@,>V6)Q@"1"#\Q  /W<O\
M2+753";JVM[C[-*)X?-C#^5(,X=<]&&3@CD9-6%&U<5^>?[2?_!9WXD1?M;?
M$7X4_LZ_L]WWQRN/@K917OCO5'\1Q:/;V4CH9/L5L'1C/<; P"@[BZ2*$;82
M;?Q _P"#A?X8^%?^"5_AO]IK2_#NMZU)XNU!/#VE>#5E6+4IM:\QTEL6D"L%
M">7(_F!#N0(0I+JM 'W^7 %.!R*_#?\ :7_;4^*7[1O_  68_85\._$SX/\
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M\=M:M+'X?V;+=0Z['?7RK9:9-:R-'-(+B3:/).T."V-H;!)()/K_ , _VO\
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M(YX]*$]ND[12S#"[HPX#$A>F<"NS\'>.=%^(>A1ZIH&KZ7KFFS'"7>GW<=U
MYXX#H2IZCH: /ABV_P"#8S]C"/4?$4LWPIFN[7Q"S,+*7Q!J M=)WR+(_P!C
M59E-N6*("5.0@V A25/T1>_\$Y?A3J'[1?PL^*TVBZC-XY^#6B2>'O"^H2:M
M=2?9+-[>6W9)$9RL[>7-(-\@9R6R22 1;_;C_;'L/V.OV6_B;\0K6QL?%>K?
M#;09==G\/KJ:6L]PB $!V"R-$K _>,9'L:U_V)/VCY/VO_V1OAU\4I=%_P"$
M;?Q]H-KKG]EB[^U_81.@<1^;L3?@$?-L7/H* .-U/]COP-^S=\<OBU^TEX1\
M%ZYXB^+7BSPXT.HVEKJ;F37EM(8S#:012-Y,<DAMHD!  W=>IKXH_P""1'[$
M7CWXG_\ !6'X]?MC?$WX27WP;B\711:3X/\ #.K-&VH)NAMXKN^D13^[=UM4
MR2!N:ZG RHRWUM_P5R_X*B>'?^"37[+,?Q'US0[CQ5=:AK%OH>E:)!>"TDU"
MXD621OWI1PBI#%*Y)4CY57@L*[__ ()]_MG:#_P4'_8^\#_%[P[9R:;I_C"S
M>9[&67S9-.N(IG@N+=GVKN,<T4B[MH# !@,$4 >S'D5X?^Q-_P $^_A_^P)I
MGCFU\ KK?E_$+Q-<^+-6.I7OVEC>SA0_E_*NU,*,+S]37M[D@<5\Y?!K_@IC
MX)_:9^%GQK\4?#'3?$WC:'X*WU_I%U;6VGM#/KVHV=H+B2TLHWQ([%F6%2R+
MND/RAEPQ ,OX4_\ !(;X0_!G]HSXR?$30[?7HU^/=G+:>-?#$MXC^'M5,I8R
MS?9_+W+(QDF)/F8'VB;  ? \!\!_\&R?P8\)>*/"]KJ?C[XT>+OA?X'UIO$'
MA[X:ZWXC6X\,Z7=ERX(B$8=D!9OE+Y;<X<L'<-]I?L>?M":A^U/^SMX>\=ZI
MX%\6?#6^UT3F3PYXFMOL^J:=Y<\D0\U,#;O"!UX^ZZUZ-JEZ--TVXN&5F6WC
M:0@=2%!.!^5 'Q5^T/\ \$1?#/Q+_:J\0_&CX<_%?XN? CQ]XVMX[7Q1<>"M
M3BBM=?5%51)+#+&X67:J_,A R-^W>68V=/\ ^"%GPAT3_@F1XM_9@LK_ ,61
M^&_'-V=8UOQ!->)-K6HZJ9H)C?R.R>69"UM I4(%*)CJ2Q]&_P""8?\ P4I\
M)_\ !4[]GR_^(_@W0O$GAW1]/UVY\/O;:XD"W+S01PR,X$,DB[")U RV<J>!
MQ7T<30!^=/Q!_P"#?2U^)'P>^$NGW_[0'Q>;XE?!'4;B[\)>/B]NVHV%O*(%
M%F8]NUH8Q;Q[/FW EP25<K7H_P"P=_P1:\'?L%?M.^,OBMH_CWXB>+_$?Q%T
M0:;XH'B2[ANAJ]V94FEOV=8U=97=6.T-L42,   N/L_-% 'YQ_LL_P#!O!X?
M^ '[-_Q2^!OB+XM>,/B!\"_B);31V/A2]T^WM9/#=R\T<JWT-TA9GN$:*,C*
M+&67)0Y(.G^S'_P0]\7_  D^,/PQUKQ]^U)\5?B=X0^"\1@\'^%'MX]&MK=!
MM$*7LUO(7O4C$<6%DQGRE4_N]T9_0FB@#\__ (G_ /!$+6H/VXO&_P 8/@[\
M?/&GP4L_B^D<?Q#T/2-)M+XZV!GS)+2>?/V.9P21*(W>-Y)&0@,5KU+_ ()"
M_P#!+?3?^"2W[/GB#X>Z5XPOO&EGK?B2X\0I=W=@MG);"6*&(0$*[[]HA!+Y
M&XL?E%?5V:* /CWXY?\ !)72_P!I;_@J%X._:%\>>)+3Q-X=\ ^&YM#T7P'?
M:$DUC#/*)=]Y)*\C+(Y,S'!A&/+BY^0&N?\ ^"B__!%'PG^UM_PJW7/AC/X6
M^"/Q!^$_BZV\4:5K^E^%X)%E\HAS!)#$T._,L<#@LQ \HC'SFON*@C- 'R5\
M+/\ @FC>> /^"O'Q"_:DN/%UK>P^.O!EKX47P\NEF-[!XOL>Z<7!E.Y6^RGY
M=@(\SJ<<^??$;_@EM\5O#_\ P65C_:D^%_Q,\,:'H_BK2=.\.^-M UC1WNI[
MS38)K8W$=K(IPCRQVL05CM*/N.6!Q7WM10!^=7P^_P"""&GS?!#]K[X?^.O&
MBZQH?[4GC"?Q7#-IEBUO<>'7-TUW;@[W99FBG\IOX0XC(X#<87[-_P#P2K_:
MRC^*GP7L_C!^T9HMS\*_@(D2:1IO@:*\TG4O%RP+$D$>JOE4:,)$BNH+AE#
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MUGX*O-/UOP9\,O%EVUYXHT9[:>2*Y2V:QACD:/RHY-Q()2U5R2%6OTP\*_\
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M'XLT\Z?K=EI5Q*(I8;B%F.QT0V#X4L&,TC9P1G]+/V/?^"<_PY_8C^('Q/\
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MKPOX!NO$5WI_C#Q1=^+KY]9O$NIEO+F.&.149(T C"P1X!!.<DDYX\/^%?\
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M;Z2K\JO^#IRPOO!7PQ_9O^+%QI=YK'@GX0_%G2];\4P01&4):[U(=QV4F,Q
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MZYT_Q-<+X/\ #]C"RFV=YFE\W?)&9&8E@,Q817+8KZ^_98_:9^.GCS]JG5O
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M?M2?&3XH>+-8T^_\?^"]9\"ZHWA"YTFZ1WG6Q;[*(!Y6%C22W<A]^^/:J;2
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MGXCTFUU#3[JWOK&]B2XM[FWD$D-Q&ZAD=&7(964@@@X(((JU0 4444 %%%%
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M\6.L^MO!?,NJZO<+/'/]HGN^7>4O#&,G@(@0 * H^BOA#\+M)^!_PG\+^"]
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MOPSH,/CZ+7='\1>$IVN-!\3>';M+/5]*9B&*I(R.K1EE1MK*<,@*E3DUYO\
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MCA92"7AN"C,3;Q;? K+_ (+.?\%"BK2S?\$_]4DASPJW]Q&XP0#D%2>_I[]
M:FN/^"XO[=6EP*US_P $[O&<F>?W&HW;\?1;1C0!]"_ C_@GM\1O@W8?!6^O
M+ZZ\82^&_#^IZ;J/AWQ#KINM$\+:M<6DR6^IVT";%FB5))[*2(EF6"\S%M*R
M^9O_ /!/[X!?$;X4?&J&2\\)^-/ /P_LO"LMA<^'?$/BVS\3Z;8:D9[;RD\/
M2B66\M=.6&&96AG>*,J+,);QF-L?*S?\%_?VR;&+=<?\$W?BLPX&8KK46Y/'
M0:8QJ+_B(I_:JMV99O\ @F_\:_,CR9/+_M5MH!(S_P @GID$9[XH ]0\>_\
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MYL;G'!-@ >>/K5>?_@Z+\4M&\5_^P[^T)''("K*UE,P8'*D$-:CN",?6@#]
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MDA@TAM6U-U"R!U BB,$6Z3B:ZM]Q8;J^I?V?_C7H?[2/P.\'_$#PS,UQX?\
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MB((,-KCOOV^7URISGR^?7>_K34_9^DB^YX\^(B\ '.J1OG&W^]$>NWG'7<:
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M.?$';/\ S#;@5[I7S]_P5AN6M/\ @F#^T-(IVLOPZUWGZV$PH ]1_9YB\CX
M^!T(V[/#]@N/3%M'785SOPAMOL7PG\+PC)$.D6B GOB%!714 %%%% !1110
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MXTU+Q7I?@'X4W7P]FNM=N9+O6M8NIK_3[HWTTS9#;A9ON!.=SJ!P*X?]I_\
MX)O^*_C?J7[7EQIVM^';?_AH;X>:/X.T1;LS?\2VXLH-4C>2YVH?W;-?1E=F
MYOD;('&?H*7]GS5I+@R+\4OB4@+J^P7&G[>!C'_'GD YR0#UZ8P*)/@#K;*H
M7XK?$J/:P)PVE'=[?-8G]* .#T_]BLZ[^U-\6_$GBQ=!U[P#\3OA[HG@B?1I
M [27"6KZI]K6=2H7RI8[]5&UB3A\@8!/RSX&_P""+?Q$TGX2>)OA/XH\=:+X
MP^&7C;XIZ5K.O37=Q<1:OJ/@S2=,L[>PTF5HXEW71?3K&&659%WPQN^\O(5'
MW%!\!/$5O'C_ (6]\2F;;@,T>C-WSGG3\9[=.]3#X+^*(XV5?BSXZ;)!4R6.
MBL5]N+ 9_GUYYX /!?\ AV39_ ;]M'X7_%OX-QQZ2UA%J'AKQY:ZWXAU+4'U
MG0;I!-&+=KAY]LUO?0P2J@\M6628%AQ72_M6?L+6O[5'[;?P1\:>)?#_ (-\
M5> _AQHGB>RU32]?M5O#+=:B--%K)%!)&\3[1:SAF8J5WK@')QZ;/\$?&;N3
M'\8?&$8SP&TC1FP,Y_Y\QSVSTZ\'LVZ^#'CJ0MY/Q>\21< #.B:4P&.I_P"/
M<=: /,?VY_V$;/XF?L">+?A%\)?"_@GPG_;][IUU'IT%K'I.EOY6IV=S<%U@
MB(#-# XSL.X[0>.0?MW?L:WGQSUSX'7W@O1?"]K<^ _BMHGC'6;B9$M)?[.M
M$NA-Y3+&2\F98\(2H()^88P?3O\ A47Q"1 %^+&H-@G)D\.V#9&,?PHOU_\
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M[+_[3T9B(!SH.D-GZ;=2.?PIB?\ !3*]\K>_[-O[4$?S;<'PA:LWY+>'CWH
M^B[GP#H-['"LVBZ3,MO;&RB5[.-A' 2I,2Y'"$HAVCC*KQP*F7PII:31R#3;
M 20W37R.+=-R7#(R-,#CB0H[*7')#$9P37SI'_P4RC#[9O@'^TU W7!\ R2
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MSQZP/V<+2.%$A\7?$:'RV5@W_"2W,C<;."7+9!V<YS]YO4TH_9_FBB"Q^/\
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MU=7RC_P7&E$7_!*7XS;MVV32H(F"CE@][;J1^(.* /JY>E%(O3\:6@ HHHH
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M:&6\O&ALX828U@BQYC",&3"@'0P_\%H/AG#X@U#3=2\&_&30;KP_J.GV>O\
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MK8^#-4\*Z'\;O@@UI)8>+H=+,,&LQ>8/[0L+L)^]>TO(&D1P22C^7*OSQJ:
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M<A^&.@_VWH]C:7UU8PZK?QRVEO.\T=O*56<;1(]K<*#U<POG/-5_&G_!'O\
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MHUJT&T^8)0_RF/;G=NXQG/%>)?#?]N;]F']HO6='\$^%/BQ\$?&FI"2*72=
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M/P+\7/$7]F:-'XH\,P>);UH79;.SBDB\YF!D.X(J<Y;G YQ7S?\ #S_@FO\
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M=8^'-I;^$_@CIGB?4;/QD+V:WN_)U37"(H%@FB6W\Q4(DNF\SRQ'"/*D!.T
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M->FT+2[/P[%H\5V89EG_ +1_M6>>%[>*2\5[,((9W>-46-6DT?\ @FK_ ,%
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M#_Q-:*SCC_M7Q?\ VE):1LAQ^[C%MIT]X8X\*4U6UY(7% 'KFD_L@7FL?\%
M;KXU>))O#,\/ASPN?"/@FTL-/>*\L+6X>&>]EO)F<K+(9H@D*QHBQQ-)G<TC
M8Z;]H3]BSX>_M0>(M%UCQ;I^MMJV@V\]E:WNC^(]2T.X:UG:-I[6:2QGA:>W
MD:&(M#*6C)0';7JU% 'C7A7_ ()__"7P/\+M8\%Z3X1BL?#.N^$%\!WEC'J%
MWM?1%:\9;-6,I=%4ZA=X9"' E # (@7S[_@K!IEOHW[$&GZ;;IMMX?B!\/K6
M%,EMJKXPT4*,GG[J]37U-7RY_P %=V9OV6_#<(^]=?%/P#&N/;Q9I3<_]\T
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M\#XKW7_"FU\?-\31X-_L*/[>-8:[_M P_P!I>9_QX_VB3=^5Y'F;V*>;LPH
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M7AS0=2U];:UTF^']JQ:>#]LBLY&@V7,T# ++' 9'B+#>JC--T7_@JU\&]/\
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M_2OJ:OE[_@JI+_Q;?X1PMM\NZ^,_@F-]W3 UFW?^:CK0!]0BBA>E% !1110
M4444 %%%% 'B_P#P4=<)_P $]OCLS?='P[\0$X_[!EQ7\1-L^VWC'^R*_MS_
M ."DYV_\$[?CVV64+\./$62O4?\ $LN.E?Q%Q$K$HRO0=J /U!_X-!88W_X*
M\*S_ 'D\#:NR>Y\RU'\B:_J>K^6W_@SWMUF_X*WWK-_RQ^'^K.OU^T6*_P B
M:_J2H **** "BBB@#EOC?\6M+^ OP>\4>-M<\_\ L;PCI5SJ]Z(%WS-%!$TC
M*BY&YR%PHSR2!7R=^T/_ ,%!OBM\!;'QKI!\%Z-KWC3P[X3\%7-O::1:7%ZB
M:UX@U:]TUU:/ST>:U@>WB*JC))(21N0,"GT_^T_\$X?VDOV=/''@"XO9-,C\
M8:)=Z2+V-=SV3S1,B3 <9*,5;&>=M>76G['-W\8-8N/'7C.[G\/^+O%VF^"6
MUO2+%XKJTTR[\/:K)JPCAF(S)'+/,T;$@'8H(PQX .R^,?[45O\ LW^"/#\_
MB'P_XT\5:SJ5I)//;^$_#%S?&,6\2R74[JK.MO&N[A9)B[$K&GFN0#YWKW_!
M7/X/Z%=Z?Y<GCC5K'4(]'D74=*\'ZE?6<?\ :]LD^EHSQ0G$MUYD<<<8!?S9
M45E7<I/._P#!3;]FG6OVC?&/@5K'P?XF\6V'AN"_\ZTBTWP_K.BS-=B%/,FL
M=6OK:-KR 0[H)FCF2,3S HQ<@>?_  U^ 6N?"7X7Z=X5MO@M\?+ZUTG5O".H
MBY>X\(&28^'K73H($(&L@;9AIR,Q ^5I7"]!0![U_P /,/AS+X T+7;>S\?:
MA=:]+JD*:#8>$-0O-=LCI=P+;4FN;**)I85MIF2-V889I8@F\R(&M7?_  4N
M^$EOX^TWP_#K6KZD^I2:.@U33M OKS1;4:NJ'3))[^.%K>%+HR(D;2. 6=1Q
MD9^2_CU^R#K'Q8U33M8MO@/XZDUW3=4\2W0;QAX.\&>+--\C6[Z.]F5;637$
MVSPRQQ>5.KXV^8)(Y%;"]UH'PNU+PK\.-3\+VWPA^.%G;:E>^$[F%H]&\,1)
M9IH TX11+%:ZFL"++_9_2-$2+S2$0*JJ0#TCQO\ \%6O!-M\0+[0?#B7UY;Z
M7X>\2Z_<Z]J>DZG9:+)%HL<?VB2UNOLQCOHDFD$4K6S2,A&0K97/HFE_\% /
MACJ?QO7X=QZQJ@\2#5+G07F?0=0CTE=4M[1KV:P.HM"+070M5><0^;O,:,P&
M!7QM=?LZ^.K[1[SPUK6C?&&7P+IO@[Q5X-\.:;;^!-,^VZ9:ZVL0#W-TNL2"
MZDM8X_+3RXH0Z_?RV&/>^+]&CUWPY);WGPV^.U\EUXUUKQM-91^$H8Y+U;_3
M+_3S8^:+LK"RI>@B9CUB'R@$E0#Z._9X_;]^%_[4_CFZ\.>"]<U*^U:VTJ+7
MTBO=!U#3%OM+E?RX-0MGN88TN;25LB.>$O')M8JQ )J>#]O#X7W/QMF^'D?B
M"[;Q)#=W.FAAHM]_9LU[;6K7=Q91W_D_9)+J*W1Y7@24RHJ/E1M8#XX_8I\?
M?%CX=?M%0>)?B=X%^+VH:+X?^&MAX1T@P_#2+3IHI%NS)*LRVNH7GG3!(X-\
MJ&.$D?NXD^;=EW7PJUC6?VO;7XE>)-2^,6IZ?HOB36-=TFUO/A5XGO[R"WOM
M.O[);%/]->RMHK=;S*M;V<;S""/?ER[, ?8'A3_@IS\#_&G@C7/$=CX[MQHO
MA_3K/6)[FYTV]M!=V5Y(8;2YLUEA5KV*>8&&-[82B28>4N9/EKIOV4_VM_#O
M[7MCXVU'PKOFT7PCXD;PXEVZR1/=RI8V=S-OAD1)()(I;I[=X9%#I);N&"G*
MCXL\9>$=-3PSX%'A]OBI8Z_\-/"/AW0M&>^^!WB>XT^YO=&O8;J.6>.*WS]G
ME$9C*(VZ,N'5RR 'Z7_X)NV>I0>'_B1J&O7UYJ'B+Q=XND\2:@Q\ ZQX0L[9
MIK*UMT@MXM2C22<(MI\TRD[V.Y@C-MH ^DJ**,T %%&:*  ]*^6_V9YOM/\
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M[QCX?U7QUK^O7GC+X6V7PLNM4N+*VAF2UM!JBQW82-50S%=3(88"DP*< LU
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M -@NYK^)!%^1?E)X%?VP_P#!5AC'_P $R/VAF';X;^(/_3=/7\4,;,$7"]J
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MON8>=\:].?COLTC5G_\ 9: /J6,Y04ZFQ_<%.H **** "BBB@ HHHH ^>_\
M@K-.UM_P2^_:&93M/_"NM=''O83#^M?Q2@' QZ"O[4O^"O;;?^"6'[1'8_\
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M@+?\98:Y,?X1-\.]#*CKUVQJ3V[CI3Q^R[^T8GW?VI9&&?\ EK\-=*8X_P"
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MXB[8D=SN8$,?.-7TCXFZEX-A\/W?[%7P_OM M_#LWA2+3S\1+!X8])E\OS;
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MV$GC&'QS9I>WVED-I=I;S0B2/4;2">QE"3H[Q70C""0,7="KGF8_^"JOQ?\
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MJ:Q\1O$EMHFH^%K9;6?5(FFT?4+LPI+]I6U1XYK:/?*TS1+&DI!/!KA?'?\
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M_I^M?3!.*^9_VU9!_P -D?L>+_$?B+K)'X>#/$/^- 'TQ1110 4444 %%%%
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M4B^ ?PQ\':#X@\0?%SP%I6B>*=.76-'O9]6B$.IV98+]HA(/SQAF&YAPO.[
M!KYK^/'_  3$^(WC#X_W'CW0;S1IFC^(6M>(8=+L_'.K>$9Y=/U'0M*L/-%_
M8VLDL=W'<::Q,.QXI(KALRAN!TO[.?\ P3;\3?"S6HM0U:S\'1R-\/O$GAUX
M(]?U+7)H=1UC6Y=2E8WE]#YMQ&ZNOG3N$9Y Q$"IA0 >I_MA_P#!3KX3?L?^
M$M2;5/&'A*^\9+X?D\0Z+X6.MPV][X@B".T0A)W<3%&5&P=Y!VAL&NJ\3_\
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MP18O[12X&G)_;)NVG^S-&"HC"%:Z7_@IS\"_$'QY_P""AGP!7P+X@7PW\3/
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MVKL8_%/Q^CW*!@?&GQ:.1W_Y"/6I%_X)>^"$9BGC[]HZ/<,8'QM\6$+SV!U
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M)+47[7<":;#'&62.9HK@O*""/X:_1#Q-^S9\&_!/AVZU#6/"O@71])L_!_\
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MV.*+2XF8!BH>^V!F,3!0#Z6Q1110 8H(S110 8XHQS110 =*,444 &VC%%%
M!BC&:**  +BCI110 4$9HHH -O%8OQ"^'6A_%?P=?>'_ !'I=GK&BZDJI<V=
MTF^*8*P==P]F53]0*VJ* $"\4FP&G44 -V?YS2[:6B@!OE?-^E")LIU% '-^
M+/A1H?C3QIX9\17]B)=;\(33SZ3=K*\<EMY\+0S(=K /&Z$9C?<A9(VQNC1E
MZ(+QTZ]:=10 WR5_R>M,DLXI0NZ-&VG*Y&=I]14M% $/]GP^9O\ +3S" N[;
M\V <@9Z]>:;_ &7;AW98(5:1MSD(,LWJ?4U8HH @.FV['F&,_(8Q\HX4]5^G
M XZ<5%?^'[+5-+:QN;6UN+%UV/;R1!X77^Z5/!'L1BKE% &2O@/0X_%*ZXNC
MZ4-;6'[.-0%I']J$7]SS<;]OMG%79=&LY]4AOGM;=KZWC>&*X,8\V)'*ET5N
MH5BB$@'!*+GH*LT4 8[?#OP^]]]J;0]'-T+[^U!,;./S!=^5Y7VG=C/G>62G
MF?>VG;G'%-U+X=>']8UJ;4KO0](NM1N;!M*FNIK..2>6S9MS6S.1N:$MR8R=
MI/.,UM44 </\&/V:/AU^SC!J47P]\!>#/ L6M2K/?IX?T6WTU;UU&U6D$**'
M*@D#.< G'6NGA\(:3;>*;O78]+T^/6[^TAL+G4%MD6ZN+>%Y7AA>7&]HXWGG
M95)(4S2$ %VSHT4 >?V'[*'PQTOX[W'Q0MOA_P"#;?XC7D)MY_$T>D0+JLR%
M%0AK@+O)**J9)R54+G Q6#\1_P!@3X)_%[P!X=\*^*/A7X$\0>'?",DDNBZ?
M?Z/#-!I9D.9!"K+\BN<;E'#X&X' KUZB@#RSXI_L0?"#XW>._#/B;Q=\-O!O
MB#7_  <D4>C7U[I<4DVGQQ2>;%&A(_U<<GSJARJM\P /-,UG]AWX1^(?VD;3
MXOWWP[\*W7Q,L458?$3V2F]4I&8DD+=#(D9,:R$%U0[0P'%>K44 &W->7_M$
M_L9?#/\ :PU#0;OX@>%K?Q!>>%Q<KI5P;JXM9[%;@1B=4DAD1ML@BCW D@[%
M]*]0HH \+\0_\$T_@=XC^#?A[P"WP]TO3O#?A&^DU/1$TFYN=+O-)NY-_FW$
M%Y;2QW,<TGF/OD64,^X[BU;6@_L+_";POX0M/#]CX%T.'1;/PQ?>#$L65Y('
MTB^D26\M75F(D6>1%>1WW.[;B6)9L^M44 >%_#'_ ()O_!_X1>&-0TG1O#%\
MUOJFHZ/J=S-J?B#4]6O))=(N4NM,3[3=7$DP@M9T#Q6X<0J2XV8=PQ\4_P#@
MG!\(_C)\89_'6O>']4FUS4);.?5(+3Q%J=CI6O26A4VSW^GP7"6EXT>Q #/$
MYVQHI)5% ]THH !THHHH *^4?VR")?\ @I/^QS&W\.K^+)E^H\/3K_)S7U=7
MR?\ M@2;O^"G?['L?'_'SXQE]P!HH7_V?]10!]84444 %%%% !1110 4444
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MC$44\P=3'%*ZN_F*54[AD _)7QS_ ,% _C-\0_\ @GC\?)]:^(GA;XI:';^
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M"_[+FI_$G6_AO:H;JVO+J"[9)D@N8[AHP\TMO'(ESLE,<&8MK%C)7Z"_$?\
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M?CA_PM..Z^*(\7-^T;/I-NL^KZD]A%X9GQ;3VZV3.;86+@&;?Y?^L".'&U0
M#]'JY]OBEH"?%)?!)U*/_A*)-*;6UL-C[S9B80F;=C;@2,%QG//3'-?CG^RK
M9?'A1XEO]+\=>-+K]H)O OBG_A,?#R>%?$RR2:Y]@F-HMQ=ZA?OI"F&_$ LY
M+&! \9"1J('D*_2'_!,$>!==_;UU;6/A?JOQ@\1>$?\ A55G;7NH^-I=;N5B
MU8ZD[7,4<NJ#>+EOEDN(XSL$A!VABXH ^_\ XC?$O0OA)X7;6O$FI0Z3I:W5
MK8FXE#%1-<W$5M GR@G+S31H.,9<9P.:W<U^2?[7GBJS\5_M.>+/#WC+QA\7
M(_BQ:_&_P>WAGPI876JR:!<>$!?Z.Z3FRCW6!LRRW4DMU*HD6[@"%UVHC4?V
M=OBY\6M9_;CLX=3^)EU;_%R'QSXB@U[P)-JWB2\:72T%_P#8X'TQA_95K8B#
M[#+!?QH@8[,R2232*0#]6_B;\4O#WP:\&W'B+Q5JUGH>AV<D,,U[=/LBC>:9
M((E)]6EDC0>["M\'-?C4/B5X/^(O[%EY'9_%SXT>/_B9J&D>$)/B=H7B'5KK
M4-(\,:X?%.CI<1SPW"E=*U 3O=1)9VS1Q^3"Y,1$<4E;\'[8.O77_!2[PJN@
M^//$T-Y>_&.[\,>(/#NK_$F]U*^M]*WW=HL<_AN&SCT[3+-G2W>VN'D-Q('M
MV\R5I7% 'Z[54UW7K'POHMWJ6I7EKI^FZ?"]S=7=S*L4%M$BEGDD=B%5%4$E
MB0  2:_'[Q1\1/'GPR_9$_9CUCQ!\9O$\'AOXU:;=:YXU\4>,?B=J7A6TBU!
M+&V;3=.35;>WG;38FC>Y?9&L7VF2S!DE9V99OHSQ5>^(OC__ ,&ZWQ(N?%/C
M)O&VLWOPT\3O#XC\/W%[$VMPVZ7ILY%EDMK6:X\R&&%9)! D=T&=U5HIER ?
M=&B^/]#\2>(]2T?3]7TV^U;1XH)[ZS@N$DFLXYPS0-(@.560(Y4GA@IQG%;#
M-M&:_)7XFW%WH>I?'SXM?#7XV>,(-+^&/@_P%J/A^73=:BOK3Q)BWD?[1J-Q
M(LCW\4T+^6 T@7YY7Y<H\9\7_P!OWQ'#_P %(+&QT'XI:Y:V_P#PN/3_ (=W
M7AS5_%^EV*R6<LT=I<P6GA^""2[>/][YR:A<SP2%S&R QLB2 'ZNZ=XCT_6-
M,^VV=[:W=GEQY\,JR191BK_,"1\K*P/H5(/0U4T7X@:#XCU1;'3]:TF_O&L8
M=4%O;W<<LIM)BZPW.U23Y,ACD"R8VL4;!.#7P[_P3J\&Z>/^"*?BCP]I'C#Q
M3KEY'8^+;"^NY-7^V:MI5[]IOED@$FW,<T9VL$*Y#/NP=W/S3X/TOQ!H/[/6
MI^-/AG\</$VB+\+?V1_#'B2TU#2WT_4)=9O;=_$<T$5W-/!(K6D+PRQ-#&(V
M;A2X,>" ?LA17Y5_M,_MR_&JP_;+^(QT/QSH7A6P^&OB#PYIVE^'-3\6Z-IN
MFZI:WEEIMS*UW936DM_=?:I;NY@ADMKB(JT2*JEXY WMG[/?[2_Q.\??MNV_
MP,O/$%Q-?_"?Q+XEUGQQ>RVL)EU7P_*J/X:@9E150RIJ<9+Q@,S:'< @!SD
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MT1J/A;P)XX\*^(D\/^=HOVR]TG7_ #;&UOH)[;,1EB/DWD:/%+DJZ-AG0JQ
M/KFC-?F9X!^.W[2%]JOPMA;4O#?B+Q=K/QM^(NAVUJ=8O=-T5]-L4UB&)+[:
MDCR0VTEN?)B5"<);9*N&D'6:O_P53US3O!%M\1I/A[?2>*=-\ :G=7OAF+Q7
M*--DU&U\3VVC36R#R_*<M.LABNVCWK&=I4!V% 'Z#T5^<?[?_P#P4"^/_A+]
ME;X\6OAWX?>&;37?A'X2V^,-<T3Q?,DVCZC>VK3PMI*RV:FY^R6TMK<S/,8"
M?,9(@[IS[#X._P""F>J^)?\ @HWJWP+N/!_AO1X-/OY+&+^T_%'V'Q'>P)9?
M:EU6VTZ:W2*[L'?,(:UN994*EGC0!P@!]=T5\^_M)_M<^./ 'QDA\ _"_P"%
MT/Q-\2V?AX^*M;6\\1QZ%;:=9--)!;11R-#+YUU<R07*QH0D8^SL9)$!7/D_
M[(7[2_C?]LS_ (*#:EXELY]8TGX)6?PK\.>(_#>GIJ\"K?RZP;R7SK^S^S&0
M7&V%X@JW.R'[%G$IN,Q@'VU17YT_$K]O#X[:!\4-:MH?"L>H0:7^T-;> M!T
MK1-6MVFU[3F\-379M9WFAC6WC$WV>ZDF+NX$DJ!2(5$O2_$W_@N5H?PM^&W@
MV75O".C^'_'WBG5/$6CW.A>)_'.F^'],TF?0KUK&_P!VJ7)6*4-<!%@$<9:5
M7W%8U5V4 ^\:*\X_9&_:B\,_MI?LW^$_BAX/DF?P]XNM#<VZS&,RV[I(\4L+
MF-GC+QRQR1DQNR$H2K,I!/H] !1110 4444 %%%% !1110 4444 %?)_[5:>
M?_P58_9+3_GGIWCBXZ>EC8)_[4KZPKY-_:>;?_P5U_91CP/E\,>/I\GVBT1.
M/^_GZ&@#ZRHHHH **** "BBB@ HHHH ^(_\ @X\<1_\ !$WX^$_] BT'YZC:
M"OX_7W%ON_K7]?G_  <D3>3_ ,$2?CTV<9TRP7\]4LQ_6OY!73+F@#]O/^#)
M*//Q[^/K?-\OA_2%]N;BY_PK^B"OYZ_^#(ZW9OB[^T)-GY5T?1$Z]S->'^E?
MT*4 %%%% !1110!X'_P44MII/@[X4N)MO_".:?\ $#PO>^(@V-JV$6KVSEVR
M.(XYQ!)(> (XY"3@&OF3]H?1?%>@?M5>,+?P/X3^+VD>)/%7C'2+F^\//X87
MQ)\,_B):K]A1]4NKN6U:/29TMH/+D*7$,BR64;B.X)3?^A/B?POIOC;P[?:1
MK&GV>JZ3J4#VUY97<*S6]U$X*O'(C JRL"00000:N(@08% 'Y3VO@+XT7G[0
MGQ"&K-\3KKQ!))XYCUJUM_"WB"72M;T>2TU(:/"E[<7S:0R'?IGD)86OVH/$
M8W1 ;EVF^$G@WXT>'?VJO ]EJ$WQ'T/4-/UCPS#I<5OX<\0W&EGPO'IFGK>6
MTDRW*:)"FX7ZSBZB^UQS$,BR'[-G]5** /R9U_P*?&W[,EQ9>*H_VL+_ ,?:
M3-HFK_%H3'7UTF&_M?$FESW<MEMP69+<7LELNC9B^RHLDBAUMF'UE_P4*UV'
M2]=^%\OB36OBWH?P<FMM2&MW7@;^UUU1]2,5L-*2Y?3E;4%@*F^.%P&N!;+)
MG<%;ZTH(S0!^;GAOPU\<O%WABV\6>*/$GQJTGQ7X8TOX<3VFG6\EQ9VMS<S:
MDRZJ;JSA7R+F62U=%NXBK)$59@(R PRH=4^+'PB\,>&/"OAB;Q5HZ_M >-/%
MO@JWVQM#+X5N_P#A+]5U)M7A63!C,FAMJLHD"L&>RL2 58L/TX[5RFK_  0\
M+:_\7=)\>7VDQW?BK0;&;3M-OI99'^PPS',OE1EO+21A\ID"^84)3=M)! /G
MC_@I!XW;P?X^^','BCQMX^^''PCOK;6&US7?"/G1W?\ :Z+:_P!F6LT\$4DL
M4,D;:@X"@"6>"WB;=Y@BD\)37_CIXJ\!7?C#Q!X[^)WAOQ'X+\)> =0ATB&Q
M2SM[R_NKR==1:]M##B22:W$236_"P.7*JC!67]*",TT)@4 ?G3^RE^T%\7/%
MO_!0*WT7Q!XK:/41XF\26GBCP?-J-Y='3](A:Z_LV=+ :0D-C'M6Q,5V;]DN
M5F<;IG<"/-_: ^)NH?#K_@H1\7O^$;^)7BKP[\1+S6/!J^%O!-OI\+:=XW+P
MP1W8D#V[272" LLS12K]CC43'9D.?TH$84]_SI#;JQ!V\KT/I0!^;VC?M6>(
M+7XJZM!K?Q\\4:7K?]H^,K;X@^&3I6GM'\*M%M$OCIFJ01"T,L14QZ<L$EP9
MH]0%ZSJDN%"3>#OC3\3/B[^S99^*/BA-<Z+\:O"OQ3\%I!X-72H;!?#*W&H6
M5H&BP9)7&HZ;?7CS2-*ZPB>XMAM-I*6_1DV41=FV+N?&XXY;'3/KBL#Q?\*M
M%\=>(O#>IZI:M=7/A2_.J:<#,ZQQW)@EMQ(Z [9"L<\NT."%9MPPP! !T:'(
MI:!Q10 'I7R;_P $DH_^*0^/<W5I_CMXV)/KMU-D'Y! /PKZR/2OE'_@D>K?
M\*W^-CL,>9\=/'I'N!KMRO\ [+0!]74444 %%%% !7._%KXIZ%\$/AEKWC#Q
M/J5KI'A_PW8RZCJ%Y<S)#%;PQJ68EG(4=,#)&20*Z*N+_:.\(WOC_P#9]\<Z
M%IMK'?:EK7A^_L;2WD*A)YI;:1(T)?Y0"S 9;CGGB@#R7]G/_@II\./B_P#
MOX<^,?%GB;P'\,[[XK0FY\-:'JWC73)KO4XC)LC$3)+MEE)VAXHMYCD)C)W
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MVT83P5\023Z?-X<']:^KJ^6/VA$$O_!7;]F7^]'X&\?MC'K+X;% 'U/1110
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M3P!9_"G6/C!X@^+UOJWA^;Q#-\5K'59?#OA[Q$;'4Q=3L)HQ)%*A+&2"SQ9
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M13RPL@MS<22-%;FWC4B?@[U C/9W?[7GQ;A\<7GQ&C\;>#?^$$M/C%#\*/\
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MAT;Q5\-=%^'N@W4OB:7QA$/%L>IVUU9V%G:S17ME,MD)9H@MPQ".EJYEC=&
M55=X;#_@KYKGAKX=R>+O'GP5U?P;X;\1>!]7\?>")E\1V^H3^(+/3K,7SVUU
M&D:BPNY+1EF2,M,N!(I<.A6@#[<HKXF\??\ !736_A)\8? /@'Q7\'SH/B_Q
MIID6N2:9=>.-+MI4M)K][2*&R:X,4>H:@JH9IK2%PT:E0KREUW?;(H ****
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MKF@'5=:T"SL-2T?4(+FXA@%Y:6[RV;S0@0EF@)@GVB1%5) H /EV_P#^"/\
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MQM< E20* .B^+'PLT#XX_#'7_!OBK3H]8\,^*+";2]4L9'=$O+:9"DD9*$,
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M^T6']EWLER\MG' [>9%]F=!T^\*^*O@G\6?$7Q3\2_#W6/%GQ-\2W'ACP?\
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M/@/6-)DUQO$5[K]^]_>W2:/8Z/ A,4<*Q06UG%'%'&J1@\[G9V=BQR /7**
M/E_P5_P34M_#_P"S[K_@75/'&K:S)KWP]TSX;/J?V""W>'3M.DU$VL@C7*F;
MR]0:-R3M?R5;:I)%<[HW_!)>UMOVMX_BIJ'C==3N;+Q'JWB"UW^&K/\ MJ5-
M1L[NT>PN=6;=<RVD$=XZV\*>4D2QQ*RR;%(^PJ* / S^QYKS?L->&?A*WCBV
M?Q!X/AT8:7XF.ACRFFTB]MKJQDFLO.PZYM(%E594W_O"ICW +B^!?V!=6\)_
M&7P_>W/Q ;4/AOX-\6:MXY\/^&/[%6*]M=5U);P2B:_$I\ZUB?4;]XHA"C@S
M1AY9!$ WTM10!X'\8/V,M1^*?[1$WB]?%D&GZ%>Q^%Y+S2CI9FN)+G0=8GU.
MW9+CS0JQR_:9(W0Q,P*QLK#!5O+?VA_^"3"_%KX@S^+],UCP#>>(+C5=8N?)
M\:^"E\1Z7#:ZDM@75(!<P.MQ%)I\+),) "LDJ/&P8%?LZB@#P'XA_L>:M#^S
M?\,?"O@#7]#\/^*/@[/IUYX;OK[0U?29)+6TDL9$GL;9X L,MK/<*$@>/RF=
M&7B,*?"_B#_P2>^)7CWX;VN@W?Q>T.Z76M1\2ZCXIMCHVI6.CWT^L72W"W$=
ME::E#YK6PWQ)%>23Q,)"[+O&3]Y44 ?"_C[_ ()+^)O$GA.PTZW\8^%[S_A'
MCX;U33(K_2[V*";4M+TB71YUG-O=I(+6>UE9T$;K)#-ABTJ QMZ=X$_X)[+I
MO[ OC3X-ZIJ6BV%]X^BU:34;[1;";[':W%\SMN6.YFEEG$>4#&:4M-L).W=@
M?35% 'R?H?[%?Q.\>?$>X\=?$3Q-X$/BB[UOPM.]KX<TRY@L$T_1)KRX5<S2
M-*T\TU_.<L=L:+&@W;2[;O[=?['OBO\ :AU5H]!U+PU9Z3K'P_\ %'@75DU1
M9FDB755L7AGA" J^V2R571]N4D)!R-I^DZ* /FCXO_L-ZS\0_P!HF[\:6.K>
M';:SO-4TJ^:TO+!KA66STK6+%A+&"JRAGU*$[2RAHX64L,KC._X)L_L=?$#]
MDR;Q;!XLUG2V\/WUEI-AX?\ #^GZ_J&NVFABT6Z$S6\^H(+FWMI1-"([$R31
MVP@.R0B0@?5%% 'Y_P#BO_@F[\8/&'[/\?PEDN/A39^$_ \1E\.:S;7-_;ZU
MXEGCUNRU.!+R2&))-.61;5EN9+:6:26=TG7;Y?EMVG[+O_!/KQ/X'^*WAOQO
MXJM=!L[ZP\6:IXFN;-O%FJ^*KN%YM%@TFW?[??J'GF$43@D1P*D;(@#E2[?9
ME% 'P7X<_P"";_Q#NOAS=:+JG_"%VSV.FG0;$Q7TTT5];IXI75DN9%,"^4[V
MPP8QO"R\;F7##2\9_L6?$CP+XIF\3:#X)^%_Q1O-6D\::7)HWBC4&M[/3[;6
M]::_ANLM;2B1&AV17=N%5I%6,*YV$-]Q44 ? VF?L(_&"7]MSP1XNU*U\$Q^
M%?!_C:?Q'.-)NK?2]+O+6?0[O2OW6FQ61N'O%6X0/)=7LBE(MJ?*52/R;5?^
M"6?Q8UCP+X=\/WOA.U-I??#O1_AW>QZ3XSM-/M_#TFFW-T&O<O82R207 N$N
MU^S^7/'+%M(W;)4_5*B@#A[+7]4\>^"?&5@NCWVEW6GS7>CV#WKX&IA85"7*
MD@$1L[%<G/*,<D8-?%5O_P $N=6^&7P9\.Z3X3\!^#573?AQX3T;Q%H-M-#9
MVWC"[TG5(+R[T^X8)ME6XA%U%YLP*.;AA)E'?/Z&T4 ?+W[,W[.GB#3/@3\:
M+74/!%C\/[/XF:K?WFA^!K75XK>/0()-+MK)HVN+(/#;275S#/=N;;>$:[+Y
M>7>3\O?LR_\ !.WQQ\,?!GAB'6O@MHU]X=\'_$;P]K^FZ-J%EX:C\0B"#3+B
MPN+F:6Q:/3[G[*TMJ\4^V&ZE2VE+(7$2G]0J* /S!\.?\$__ (H)X-O- TWX
M7V_A3Q-I/P^U?P[XR\6_V[:(?C3?SWEE*,S0S&Y/VJ."]=KF^2.6W:_9$!#2
M-5KXF?L"^._CMJ]K<?#?X4+^S;X5T^#77N/#9OM/AC\6O)'H16QNX-/GDBL;
M2^:RGMY7LY#(\4+-)M\W:_Z:44 9'P_ '@+0]NAGPROV"#&CD19TG]VO^C?N
M2T7[O[G[LE/E^4D8-:]%% !1110 4444 %%%% !1110 5\KZX^[_ (+:>%_[
ML?P0UCMZZ]I?_P 37U17RGJ8\S_@M_HO3]W\#;_ ],Z_99_]!H ^K!1110 4
M444 %%%% !1110!^;O\ P=@3F'_@B[XW7M)KNAJ?I_:$)_I7\H;G#5_5M_P=
ME/M_X(R^+E_O^(=$!_\  U#_ $K^4EN6H _H&_X,A;8I\./VC)MV?,U704QQ
MGB"]/U_B[\>G>OW8K\,_^#(RUV?!O]H.;_GIKFCI_P!\VUR?_9J_<R@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_.'_@ES^TI
M\7/A[^Q!X=TWP]^S=XP\<:/;ZQX@:VU?3?%F@VL=^K:[J#%UBNKN*1?F)&&
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M:-J$GB6'PA)X:O?"6H)XDM]4GM);NUMVTX1&?]_!"S1.JE'R,-][ !SNF_\
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M+J.NZ'/%JGB[Q=X1UO2-$U;1]+\,:C>_V6VHW-G&OF3Q6LD*OY%XLR1[MTQ
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M&L+X3?\ !*W5/AG\)]4\/W7Q%CU[4M2^%^J?#Z34Y- %MON;Z^O+R343$L[
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MZ_\ &1/VH_A]HL.K-XMUSXK> ?$T$FG2)%?VVBD>'(S?P-)\B_9VTO4V5B"
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MEJUUH7B^UM_%*VFG_$;3?";^&?\ A9,2:=9AKZ6U;.^2"3?9>>I,<@L@4"J
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MP:VB^'[.&\\02'7;1U\,^9")O+OG21D@=5)R'8 %6YXKOO 7Q#T'XJ>#]/\
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MOP^A\5W/Q"\,Q^'[G2M/UR"]2Z\Q+BSU"22.QEC"@L_VAX95C506<Q. #M.
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MRO\ @EUX2AW >=\1=//UQ97]?S%.S%OEZ5_39_P><'_C6;X']?\ A8ED1_X
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M 'H&K?M._#70/ NA^*+_ .(7@>R\,^*&2/1M7N->M8['5V<$HMO.SB.8L 2
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M1[/P##I[PM+!_I5A+J-NHE2>Y0:8X29KJ2-TB+23. ?=GBCXO^$?#/Q'\/\
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MRO)KSX:^ 9&UBSM9+&>&&R\9:I:Q6FHB&1PJ2B"QLEDW(" ^OW66).%O6O\
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MVJ/@WX3\&^%]?\->'=4'B2X\>_VE::?/>:1<:/<6MI)I[D7FU%\ZZ1FGMUN
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M>FW>D_%C6[#XEZ+?V&J6/BLZ)9R1_:+;1O['<36.!%)%/;%B\:E,/M9&0H*
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M?V3V/_)R/P0_\+.P_P#CM0>//^"FWPC\,^#--UC^S_'7BC3=:L;G5I/^$?\
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M_A!.<1_$_P 4H/P U'BI8?\ @CK\"[=U:.S^*D>U=H"?%WQ<JXY[#4\4 ?4
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MOQQH_@CQ=JEKXMMKVUT^;5FLEL9[,>2DEX@_M"U,ZNL#1"5=HE.X* ;GB/\
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MZ^WBZ\M;:/7SX5>RNO#^I6^K+JHM3>"R-@]N+OSFMU,B)Y674?+NZ4[X,_\
M!4#X"_M">-+#P_X-^).BZUJFJ6$^I6JI%<0PS1P*KW">=)&L0GA1U:6W+B:(
M9+HH!P ?&'[6G[,OB?P'XK\-^'])\1:5H?Q9^+?Q8\8:?HUK;W1EN[OP?X@0
M#5KM$7#![.&*UO"3\J26L8)S(H/U-\-O#=K=_P#!2B/3_">GP6/@OX'_  N7
MP?.+=-L$%YJ-W97-O8I_M6UEIL,A SM6_AY&[%>F_L^_ME_"?]K+7;^'X?\
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M% !1110 4444 %%%% !1110 5\L_L90J/^"@_P"V))CYF\2^&4)SV'AFP/\
M[,:^IJ^6_P!B1C<?MR_MA3_PGQIH4('^YX8TL?UH ^I**** "BBB@ HHHH *
M*** /Q&_X/8[A4_9L^!<?\3>*K]@/7%F!_[,*_G:\O-?T-_\'LTW_%B?@''N
M'S>(]5.,]<6L7\LU_/)Y6>[4 ?U3?\&CMJUO_P $<M#9EQY_BK67!SU'GA?_
M &7]*_3BOS/_ .#2F!8O^"-/AEAN_?>)=:<Y_P"OHCC\J_3"@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>/\ @K=<?9O^"7?[
M0C9Q_P 6]UM<_6RE']:]M^',7D?#W08^/DTZW7CVC6O!?^"QD_V?_@E7^T(Q
M;;N\!ZLN<>MLX_K7T+X7MC9>&M/A;K#:Q(?P0"@"_1110 4444 >?_M%^"_
MGC?PMHB_$&>QMM*T;Q%I>N6$EUJ)L8UU.SNH[FR.X.N\B>)&$9)#[<$$$BO&
M?BW^S]^S!\=OB5XJ\8>(+[P9/XD\<^$V\#ZU?0>)%M)-0TWS5N$4^7*H\Z.2
M-62<?O4" !@% 'J_[1+*/$_PO5MI\SQE %W=B+&^.1R.>/?Z=Z]+$8=1GK0!
M\?\ P]_9,_9O\!>)Y=>N/B1=>*/$TT^CWE]K'B7XES:K>WDFCW4]W8LYEG*J
ML4DLQV1JB$%@5ZFNX/@7X!*JR-XR\-;9/'7_  L-2?%40!U@ CS!^\YC^5OW
M7W>#QQQ]#M9QN?F123W(ICZ5;R+M:"%EQC#(#0!\N? ']F_X(_L]?$JTUWP_
M\5M8N]/T>.YA\/\ AF_^()NM \,QRE_.6SLS(%"JH=$$ID$**4B\M0174_$+
MX*_!_P"+7Q1G\9ZAXNLWU6:\\.W3_9]?@6#S-#O+R[L1MYX\Z[GWC/SA5'&T
MY]V;P]8OG=9VC;NN85Y_3Z_G5<^"M'8-G2=-^8Y/^BIR>OI0!P/PDTOX>_"/
M6/&5]H_BC3);CQ[XA?Q'J7GZO#*OVM[:UM2(AD;4\NVAPO/))SSBO-X/V-/@
MGJ?PM\%^#;[6[?6O#/@GPKJ?@VWL[C6XF6_T[4;>&WN5N&3:S,T:( R%"-Y(
MZC'T!+\-_#TY'F:%HTFTY&ZQB.#Q_L_[(_(>E5I/@]X2E3:WA?PZR\<'382.
M,?[/L/R% 'S-X3_X)T?#^">\NO$WQ<\=?$76YET:RL-5\1:_9SW>D6&FZG;Z
MI!90>5#&A66XMH#-+(KS3!$W2$JI'I7B;]ECP+XSMO'BR^(KH1^/_&6B^-]0
M,5[!^XO=*_LK[.D?RG;$W]D6V\-DG?)AER-OI3_!'P9)&JMX1\+LJXP#I4&!
MC&,?+[#\A4;_  $\#2(RMX+\)LLGW@=(M\-P1S\GH2/Q- 'BOP<_85T7X)?%
MC3]4T7XK>.$\"Z'?WVK:/X"_M"S31M,N;PS--B5(5O)K=6FG>.VFG>&-F^5<
M1QA*W[='_!/;P_\ MXW/V/7/B-XDT;POJ6G?V1X@\.6HT^]T_6;82O(K(MW!
M,;*Z&^1?M5J8IBI4;LQQE/<?^% >!"C*?!7A$JP(*_V/;X(.\$?<[^8__?;>
MIHE_9_\  <\C,_@GPBS2$LQ.CV^6)+$DG9W+,3Z[CZF@#YX^/?\ P3(TWXS:
M]K6JZ?\ %+Q)X<U*^\9P^.=,1K#2]7L=%U :6=,N EK=V\D<T<T&U\3AVBE7
M?$T>Y@U7X?\ _!)?PKX)M=#@N/B'XQ\1Q6>H>*I]7&J&Q;_A([+Q$(VU*PG$
M4"+%$TT,4JM;B-D*%00I*U]'O^SYX"ED9V\$^$6=U*LQT>WW$'J,[.A]*'_9
M[\!/U\$^$CSGG2(/8_W?4#\J /G+X,?\$\O&7[,WA7Q%<>'?C%JWBKQ)9^&)
M_#W@K^U- TBPM]%!\LQRW36MLC7LP\F%3+-GY%;Y-SLS>_\ Q^^!]O\ M >&
M?#^FW&I7&FKH?BC1_$ZO"@8SOIU_#>I"P/\ "[0A2>H!R.E6D_9P^'T3AE\#
M^$493D%=(@4@Y0]E]43_ +X7T%(G[.'P_B@\I?!?A=8\*-@TR$* NP 8V]O+
M3_OA?2@#"^$_[+VG_#3]G74_AQ/J5]JVFZQ-K+W5TRK!.ZZG>W5W*!MX4J;M
MT!_V03SFOG_X>_\ !*GQCX>T*\77OCYKWB#6K?X??\*ZT.]3PKI]K!I-FES#
M/#*]LWF1W3L((X[A)?W=PF5VQ XKZ9G_ &9OA[<Y\SP7X98L,$_V?'TQCT].
M*27]F7X?S%]W@_P_F0;6(M%!8?-Z?[S?]]&@#YC^ ?\ P1\M_@KX:TV$^,M)
MCOK?Q=JOBZY@\/>$H]"T))KWP_<Z(8;/3DGD2T15G%PVUW,LBMG 8%3]IW_@
MG'-+^S9IMOI]YKWBK4/A[\(9? &FZ?HUO!::EJ%S'<:3=0:C;//+Y*7$4NDQ
MR)!+F-W95:10"3]/M^SAX',91?#>G1HS;BL8:,$_-_=(_O-^=/O/V>_"-ZV6
MTME^8O\ NKRXCY.[)^60?WV_/V% 'RO_ ,$J? 'Q>U3XW?&GXK?%B3Q))-XY
ML_#VAZ0VN^&;?PS<O#IBZ@TC)I\5S=-!"9+\X,TS2/()G 2,QJ,;3O\ @C9K
M4/[8FF_%"\^('@F\;1?B%+X[@OY_ 7G>++^*4W0_LNYU:2].VUABNFBB6"")
M56*+<C!,'Z[;]G'PFTJO]CU)2F -NL7J@ 8/038["F0_LU^%;8KY:^($*]-O
MB34A_<_Z>/\ 87]?[S9 ..^,?[)<WQ5^,GB#Q6OB**Q36?ASJ'@)+1K#S?L[
MW4ZS?:]_F#<%VA3%@9QG>.E>7_%+_@F7J7CK0]'73?']MHVK>&_ WA[PWI%[
M_8OGI!J>BZK!JEM>R1&8!X&FMHU>WR"4+8D!P1]#1?L\>'8)$:.;Q2K1D%<>
M*=4'3;C_ )>.?NCK[^IRY_@#H;X_T[QH-JA1CQAJXX  [7/^R.?KZG(!\O:G
M^P%\8-?\4R?%[4/B'X!_X7U;Z[INK:?';Z!<)X3M;*QT_4K!=+:-IVNG$J:O
MJ$C76\.LDL>V/9%L;+B_X)4>-M2^'^KVNN?$3PWJGB37M,^(T-[?VV@RV-K]
MJ\5- \;1P^?(RQ6QA*D%V9UV\YR3]9W?[/VAW:*O]H^-DVG.4\8ZNIZ8[7--
ME^ .E2(%&K>-HU4,!M\6:GGYBY)),Y)/SG&>F%QC:N #Y5_:A_X)0ZG\=+K5
MM5M]:\+W6J66I>&M;T+3]5ANUT^XN-*TR^T^6"\:WD298IHK^4J\1W1LJ,5D
M *-0^%__  3;^)W[/2^!_&G@.X^#>E_$30=1UU]3T46NIKX>N;+5XM.BD"W,
MDDUW)=0?V59.)F"B95DBV0JRLGUVGP)L(4(37/&RYSR?$MZYY)/\4A]?T Z
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MDAW>+/!+(I7SA_PB=UND'RYVG^TOESAL9!QE>N#N .\S17 S>'OB85_=^+/
MP;8!\WA.[/S8&3_R$NA.[ [ CDX)+1H/Q06%?^*H\!R2 ?,?^$8O$!.T]!_:
M!_BP>IX!'4@@ ] S1FN%;2?B0 V-=\$]]N=#N_?K_I?^[^1]> Z;\2 B?\3?
MP2S;OG_XE-V,K\W3_2>#]WUZ'U& #NJ*X2*S^)0E;S+[P.R[OE"V5VIQ[GSC
MST[4B0?$P2?-<>!F7=_#!=@A<C_;/.,\^N.* .\HKA$'Q*20!F\#LOR\A;L'
M^'=W/;?C_@/O3!<?$Q"N;?P*W S_ *1>+SQG^ _[6/P]Z .^HKS]M1^)T<'R
MZ7X$EDR.#JEY&,8&3G[.W?/&.F.>U-EU?XH#.W0? ;<#&=?O%SU_Z<S[>M '
MH5%>?_VU\343_D6_ \C#/'_"2W:@_>QS]@/^Q],MUP,NE\0_$P!O+\)^!Y""
M=H/BVZ7(^;!_Y!IP3A>.<;CR<#(!WU%<!'XH^)B_?\'^"^H^[XLN6[_]@X=O
M\CK3HO%_Q%6;]]X)\-^7D#,7BB1VZCG#6:C&,]^U '>T5PG@#XL:MX@^(NI>
M&=<\/P:+J%AIMMJBM;ZD+V.6*:2:+!/EH596@;L000<]17=T %%%%  :^7?V
M%7\W]L+]KY_^J@Z6F<>GAG2*^HJ^7_V"(?\ C*']KJ;&=_Q.M$W#OM\,Z+Q^
M&: /J"BBB@ HHHH **** "BBB@#\-?\ @]NX^#/[/O\ V'M7_#_1K>OYZ&7)
MZXK^@_\ X/<)O^+8?L[1_-AM8UQB<\<6]H/ZU_/F$#4 ?U<?\&G-N(?^"+O@
MIA_RUU[6V/\ X'RC^E?I-7YQ_P#!J/$T?_!%/X>LRX\S5]<8>X_M.X']*_1R
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^8/\
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MB?G['$9_:.\%A&8ZVBJH#,6MIAMR%/.4]&7\Z .XHKB/^&D/ P90?$FGJ6Y
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M"(7/_"4>'<!=Q/\ :<'3!.?O=,*Q_P" GTJU'\1_#TK*%UW1V9L@!;V(DXW
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M!='!_F*_ QI-K?\ UZ /ZT_^#6"T%M_P1#^$\G_/Q>Z[(?J-9O5_]EK]#:^
M/^#76%8?^"&GP59>?,?7F/U_M_41_2OO^@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ^6_^"ULA3_@EC\:%&?WVAK!Q_MW$*?\
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MFD?L2:EIL7PS637M-F;P/\5_$'Q)N7%BR_;(]3_M_;;(-QVR1G68\N<AO(;
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MI9-"\7>=^[\2:.$Q@"31&8^_(N!_+L/QZBB@#ETTGQF"-VO^&6'?_B0SC/\
MY.5')H_CDXV^(O"BX/.?#MP<CG_I^'MS['UXZRB@#E8]'\;*1N\0^%FYYQX?
MN!Q_X&FG'2?&A8XU_P ,8[?\2"?C_P G/I7444 <O'IGC2/[VM>%YOIHL\?_
M +=-38[?QLC?->>%9%[XL[A,_P#D4X_7/MTKJJ* .95?&"AMS>&VYXP)UXQ]
M3WJ*X?QP)/W4?A7;_M2W&?T7ZUU=% ')F7QQ]G'[GPKYN[G]]<;=O_?/6G1R
M>--WSP^%]N!TEN.N.?X:ZJB@#E)Y_&R0CRK7PM))QD/=7"K[\^6?Y<^U*+WQ
MHJ'.F^&&88PHU*=0>F>?(/OVKJJ* .9DU/Q>@^31?#LG3DZU.O?G_ET/;_#W
MJ-]6\9JR[="\-L.^=>G&/_)*NJHH X^76O' ?]WX?\*LFX %O$5PIQW./L)]
M^,_C2QZWXV,;[O#_ (7#<; /$%P0QXSD_8>._KGV[=>!BB@#ETUKQ@BC=H'A
MUN.=FN3,1T];0#U_*F0^*O%!?;/X5MU7/+0ZNC_^A(O^?2NKH(S0!R7P2\,Z
MAX1\ 16>J1P0WK7=Y=/'#*9$C$UW-,B[CU(610>V0<<8KK: ,44 %%%% !11
M10 4444 %%%% !7RS_P2ZE^T?\-$38QYGQN\3 _\ -M'_P"R5]2L<+7RQ_P2
MJB \._'B4$'S_C?XQ8XY^[?;/_9* /JBBBB@ HHHH **** "BBB@#\"?^#W^
M1CJ'[,*_W8_%ASZ\Z+_A7X)R#Y^*_>+_ (/>9=WBO]FF/^);3Q,Q]LOI/^%?
M@^Z$M_\ 7H _KT_X-GH%MO\ @A[\"%5=H-GJKX]2VLWY)_$G/XU]V5\._P#!
MMK'Y/_!$CX"K_P!0R_;\]4O#7W%0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?*W_!:)?._X)^ZU#\W^D^+_!EO\HR3O\5Z0G'O
M\U?5"]/QKY@_X+#1>?\ L0/'C._Q_P" UQZY\9:+7T^O3\: %HHHH **** &
MR1K*NUAN4]0>]<#\+OV3OA;\#]3UR]\%_#;P#X1O/$^?[8GT7P_:6$FJYR3Y
M[11J9<DDX?/))[FO0** .3UCX#>!M?\ #ZZ5J'@WPI?:7'HS^'5LY](MY+==
M+<1A[$(4*_9F\J+,.-A\M/E^48P_ '[(/PE^%.CV^G^%OAC\/O#>GVTUK<PV
M^E^'+2SC26UE>:VD"QQ@;HI99)$;JCR.PP6)/I!KR'X9? OPGX]\$6.L:IHL
M=WJ%]YTDT\TDGF.6EDR20WN?SH Y;]M#]@;3?VJO!$>E:3>^&?##3:R=;U6U
MU3P5IOB31O$=PT*0^9?V-TF)ID2.+RYE=)$,2@EDRA@\(?\ !+WX*I^S)X(^
M%WB_P?X:^)FC_#\3O93^(])M9Y5N;B1Y;J542-8X1-)(Y:*)5CVD)MVJ!7HO
M@+P?IOP_^-.J:;H]NUG9R:);7#P":1T+_:+A=V&8C.!C(]J^4/VCO^">_P "
M_&W_  5:^$T>K?"7P#J!\8>$O&NN:Z)]&A9=8O$NM"5;BX&,2RK]IGPS@D>:
M^.N: /J'Q;^P[\&_B%\2O#7C'6/AEX&U+Q1X,A@M=%U*;1X6GTR*W8O;QQG;
MPL+DM&N,1L2R;3S78_$3X,^%?BS>^'KKQ)X?TK7+KPEJL6NZ++>6ZROI=]&K
M(ES"3RDBJ[C<.S$5\#_!;XA?%'X'?'#Q)KFD^(O"X^%VN?M$7O@R[\+'1&^V
MS1W:10"[6^\[]V\-R%VPK#L,2'+98;;G[ W_  47^-W[0_Q9^'.N>*?#<UG\
M._C(;YK&SN-'L-.A\.I';37$ M[X:E+<:A(!;F.:-K.%MTC2 1+"8V /KKX+
M?L-?"']G;XE:YXP\$?#OPMX8\2^(E>.^O["S$<C(\IFD2,=(4>4^8Z1!5=P&
M8$@$.^,_[$/PI_:%UK6M2\9>!=!U_4?$6BQ>'M1N[B(K<7-C%<BZAB,BD,/*
MN )8W4AXW&Y64U\P?MU_M^?&?X<_M/>,/!WPM\-SWEC\,?"NG>)-0QX576EU
MV:\:^,<$TS:C:?V?;*MBRFX5+@[I78A1#MD=K_[<'QRNO$/BSQCIZ_#[2_AW
MX&^(/A'PG=>'[K39[O6-3CUFVT$W2?;8[A886M9-9#)(L,@EV,I"A0S 'T7\
M*?\ @G]\&/@9J%G=>$_A[X?T&ZT_58M<2XMHY//DOX[6YLTNY9"Q::86]Y<Q
MF20LS"4DDD C(^('_!+OX$?$_P +Z-H^K?#[3_[.\/RW[Z;'8WEU8-:QWUP;
MF\M@T$J-]DFE8LUL28#P @  'Q=/\5_B9X-^!^K#5_&&D^)/%6K>+_C"?#_B
M*33;FVN/#*Z;%JL47EQK=E9<20,5#\1Q.B* 8Q(?2O"G[=/Q.^ OPL\*_#?5
M?^$7\4?$CQ5X7\$_\*_O?L=Q!#X@FU&0VFHO/$9W=_[/2%KR8K(N89$R5+9H
M ^F-;_X)P_!'7_BOH?C6;X=Z';Z]X=&G_8OL9EL[%6T_BP>2SB=;:9[4!1 \
ML;-"%0(5"KCN/B7^SKX-^,'C?PEXD\1:)#J.N^!9[FXT*],TL,M@UQ"8+@ Q
MLNY)(SM9'W(VU25RJD>;_MB_&[XC> _BK\(_!'PUC\'QZM\2]3U"RNM0\1P7
M%S;Z3;VMA+=&=(89(VF<,BJ(RZ!M_P!] ":^8_%?_!4OXNS_  D^']QI=O\
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M@!=5?3-_V<WB[0PDV_ZP"0@R .,R]_X)0?!._N&DF\,W#[_BHGQF*_;Y=O\
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M'4]-TN(3W$5OJ<\L-LZ@L P'DO(^#\D>UN=R@^B+K5I)J$MFMS UW"H>2!9
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MNF/\Z^V:^,_^#>F'R/\ @B_^S\N,9\.LWYW4Y_K7V90 4444 %%%% !1110
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MF?#JX=+=&674M0.GBW>,[_FM_P#B96^Y^",/A3@9 -+3?V+/A7I'B?4M9M_
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MPO);>8^:55&=$6.62,'?$LRE@%(8@&3X4_X)->$M)\5CQ!KOQ"^+GCCQ$?[
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MH?ABW[.'QXO/$UUI]UK-H;:3PT;6[TZVNX;26[21M74A/,N(2$<+*5D!V#!
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M!"(*K>?\;/!H.1TVZBK\?]\5]3"OE3_@JC,R6O[/,2KN^T?''PJI&.RRSO\
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M1F(506Y)QUK/MO!^DV>H7=Y#I>FQ75_(LMU,ELBR7+J"JL[ 98@$@$Y(!(H
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M'=58@DX^H:\#N_V#M)N-,FM5U[5(UN/BC!\4&8P1-MN(IXIA:#IB(^4J[N6
M)]J]\H **** "BBB@ HHHH **** "BBB@ )KY;_X(PR^?_P3K\'R;MWF:QXC
M?</XL^(-1.?QSFOJ0U\I_P#!$E O_!,CX:E3N$CZO)D]RVKWK?UH ^K****
M"BBB@ HHHH **** /YPO^#UN+'[8WP9DS][P9=+CTQ?,?ZU^*[JQ;Y0V/:OV
MG_X/7+>-?VQ_@S*&/G/X,ND9<<!1?,5/XEF_*OQ9<X;[M ']IO\ P1F79_P2
M9_9O_P"R=:(?_)**OI>OG'_@C];_ &3_ ()5?LYQXV[?AUH? [?Z#%7T=0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?*O_  5)
M4277[-R[0W_%\?#AQ]([P_IC-?50&!7RW_P4U19O$7[,\;?=;XVZ*3QW6RU)
MQ^JBOJ1>E !1110 4444 %%%% $-\VRRF;IB-CG\*Y;X [1\"/!.WYE_L"QP
M< 9'V>/ZUU[#<*XN+]G#X>PEBG@7P:N\Y;;HEJ,GW^2@!V@1;/CIXJ?YOFTC
M2A@CY>);_I^?\J_._P  Z5^S5:_LN_M*6O[0T?P_/Q+OO&'BIO'L/B,PG7[C
M?=W(T7[()?\ 22K:9]@%D+;JQ'D_O,U^D&B>!]%^'LIB\/Z/HNB_VE*#/]CL
M8[<3,JG!;RPNX@ @$YP*QO$O[/OA7QKX\TGQ5K7A+P3K'BC0V5M/UB\T*">_
ML"I!!AG<&2,@[B"K#&1Z<@'Y->)_#OCW2OAK\1+?QIX\URV^*VM?!CX+QW6A
M^($M95MM0;6Y;9[F2,QK/*T%WEI1YNTRWTRMD- (_;OVA?VL/CE^S1_PFWP]
MM_B+JGCG4C\4?#_A:R\6WFG>']/U?0]/U+0I+]XAYD=MI?FFZMU@ADN8R,WR
MJ5F<1JWZ$:]\,--\5WZWNK:/X;U34(X5MTN;K3$FD6-98YE0,V3M$T4<@7.
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M0M]Z);B!)@I^@?'X5TU9FCZ=%X6T:STW3["*UL-/A2VMK>':L<$2*%1%'90
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M/_@B*FS_ ()=?"<_\]+2^D_[ZU&Z;^M?5AKY9_X(GQF/_@EC\&>,>9HKR?\
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M7_!&,[O^"6?P+/3=X4MB1[G=7TCXBD\OP_?,>BV\A/\ WR:^=/\ @C;!Y/\
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MGKGP:^'$?AOP?X@@L]:U'1_MVK7MHTQFU": R2KN$;7EW,L*M=QR7 =8XH@
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MV664LJG>$8T ?8U)N%?(FN?\%7]-T[]L2Z^&5OX3>_TC3/%5GX*O=6AOY6U
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M_@JE:^+_ -HOPOX!TW0?#\L.J>&/#_B/4]:FUR]BLX6UF\^S6MM8L=.V7C$
MN&=[?>610,B7R@#Z\SS17AME_P %)_@7>CQ05^)7AT)X-B,VIR.TB1A!<BT+
MP.R!;I1<LL!-N9 )71/O,H-0?\%+?A'J'BOX:Z7IGB6/5&^*&L:CH>FR1021
M_9+JPMVFN8[E9%5X'3$:%)%5@95) 7)H ]]9@HR>**\]^!7[57PX_:;75/\
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M2QTNWMOM%RA&+E@B#=(I(_>'YAQR*_+CXR_\$QOBE>>#_!^C-X.\7:I::/\
M#Z#PEX5M] G\/SR>"+^#4M0D5_M6HEY-/4V\NFE+RP\R518A60F.(-]#P_\
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MO?+I5DVJ-J3)-"D<FGHEHEFLL5Q 7"JOF3R 'WUX]_90^%_Q4TS3;+Q-\.?
MOB*ST?4+C5;"WU/0+6[BLKRX=Y+BXC22,A999))'=P,NSLQ))S7.^ /@+\#?
M%'QMOO&/AWP/X!E^('P]E3PK/K-OH,$>HZ,T=G"\=JLWEAE"6MS$%V'"QR[
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M8V__  L/6-!T99M>GL%TBXTW3IP\"62R>5J5SO2"&.:X2Q/E&-A(P /IIO\
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M\5WEC>>%].TN+2_$262-)#?:;<6]W:73VY8JRBXMHF>+< R[EW#.1\Y^"_\
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M7/%VH:K>VNJ^(X_.\Y=$C\)ZIX<TQ8]R[GN46[BNY@Q5#/<WK*V"H/.?$/\
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M?Q(\3V<W@GX@-X#\%7U]I/B#Q_%8P2:#I%W9V)OKE9%68W?DQQJT;7(@,(G
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MP]\3O#?Q-\)ZG?>'$AL[-?"RW;#4(':%K/Q-XAU&ZR-^3MAO;-^,[C(5&2I
M^@[_ /X*0^'] ^)OACPKK7P^^*WA^Z\436NGQ7>I:'%#9VNI7-D;R+3G?SR9
M)B@$9D@$MNLQ\MI@P8#C_@G_ ,%5='\;?!W2?''BS0]>\*KJWA/2M=A\,+HD
MUYK-Q<:A?W-G:PV_E.WV@SR0@11K&&Q^\8A#A #YM\4_L 6O[+O[*O@O7+KP
MGX5\$1V/PQ73_BE<7.J0:=#XAN$UO0+HZ;?W8<*_VF"+5;9;B5C%&MRRNZ1N
M:]^_X(X:AX8\1P?'_6/!'@_3? O@W4OB0!I.D:=?6%Y:0+'H.D),4-A--:(3
M.)2T<$C(C[U)WAQ78>)?^"IGPL/ABQANM!^(VJ:IKAUBSN/"MOX,O+W6+-],
M^S#4(;NU1&\L1QWD#Y8E)8Y4,;2;T#;WPO\ V[?A#J'C_P /_#_P5#K,\&J6
M&GWUI<Z-X3O?[#L(]0MVN[))KB.'R;9IX09%$A4?,H8JSHK 'K_QAE\GX2>*
M&P3MTB[.!U/[EZ\B_P""3O\ RBR_9I_[)5X7_P#31:UZC^T%=MI_P(\:W"'#
M0:#?R+D=Q;2$5YI_P2OMOL7_  3"_9QAX_<_"[PRG'3C2;44 >]4444 %%%%
M !1110 4444 ?R\_\'B#A_\ @K/I6/\ EG\.]*#?7[9J)_K7Y2M$6/\ ]>OU
M/_X/ &S_ ,%<8<D?+X!TD#GH//O:_+(R;3]V@#^Y+]BVU6Q_8\^%$*-N6'P=
MHZ!CW L81FO3*\Y_8]C6+]DKX7(O"IX1TE0/;[%#7HU !1110 445Y[^TGX[
M^(GP]\"P7WPS\ Z7\1]>:\2*;2K_ ,2+H*);E)"TRSM#,&8.(U"%1D.3N&W!
M /0J*^1_^&MOVLH5CW?L@Z/*S?>$/Q>T\[..^ZU7Z<9Y]N:E;]K_ /:DBDVM
M^QZTB\'=#\5M(8?3YHU.1_2@#ZSHKY+E_;._:9MV'F?L:ZXZY S#\3-!?&3C
M/+CC^G/M3;;]M_\ :-E53)^QGXSCW*&.WX@^'F(SVYG'- 'UM17R./V^OCQ'
M"SR?L8_%3N (_%WAQV)''3[:*?\ \/ _C5#Q-^QG\9LYP?*\1>&I/_<@* /K
M6BODG_AXK\6HBRS?L:?'S<@!/E:IX:D4\XX/]IC/^?K3HO\ @I/\15!\_P#8
MY_:63:,_NSX;DSV_Z"PH ^M**^2X_P#@IUXPW'S/V/\ ]JM."?ETWP\W3_N+
MU'<_\%4/$-GM\S]D7]KCYR -GAW19,$XZ[=5..O)/ YS0!]<45\B3_\ !5W5
MK:)FD_9-_:[ 5MOR^$--D.?HNHDX]^E5%_X*_P FW<_[+/[8L(VEN?ARC=.V
M%NB<^W>@#[&HKX[3_@L-;;?WG[,_[8D?J#\+;AB/3[LI]1T_3!PZ'_@L;HSR
M[9/V>?VP86*AQN^#NJ,,'W52 ?8\T ?85%?(T'_!8?PO*?WGP1_:VM^N/,^"
MFO\ ;G^&W-6X_P#@KQX/<#/PA_:J5C_"?@EXDS^EK0 []LPM)_P49_8[C[+K
MGBJ<\^GARZ3I_P!M*]Z^/_QOTG]G'X/:WXTURWU"\L=%B5A::?")KR_FDD6*
M"V@0E0TTTTD<2 LH+2+E@,D?!?[0/_!0#1_B=^VS^SKXPTKX4_M+2:'\.[OQ
M%<:Y(_P;\2+);+=:2UM!A/LFY]TC@?*#MZG YKT3XZ_\%)O@O^T?\(=<\%^(
M/"/[2UGINO0"%[BS^$'BBWO+"16$D5S!(MB=DT,L:2(V#AXU." 10!Z8_P#P
M46NM)\1>'?#NL?!/XM:#XMUV_OH)=*O5TI4TVRLTLY;G5'NQ>FUEM$BO8FS;
MRRR;UDBV>:NRL#X._P#!8?X=_'"UUI]#\/>,+N>U\//XLT2RLFTW4[[Q5IBR
M0QF:V@M+R62!]UQ;$Q7HMI%6=695"2^7X=\*/VQO@AX2\9VOBCQ3XF_:L^)'
MB6*SU.PNM1\1_"37EBN(+Y;".2,6UII,-O B)I\ "P1Q@L\SOO>0M7E,/C+]
ME>W^%/B;P'?_ !$_:,F\-ZOH</AG1[&Z^#M]"NA64%Q;SQQ@)H:?;R#:VT;'
M4/M)>*-D?=YLID /KZS_ ."IZ^/O%W@72O#/P]\322:QX_NO OBE9;K2KO\
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M&.R*-=BI&IW""(>7$(XR5/LE% 'A_B?]@GPCXI^/<WCN;5O&,:7NKV/B._\
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MO$,WBF"'5DL/MBFY%XUB\8NH(%\M9'C58PQ=!UWA30[[XTZKX?\ "O@/Q_\
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M&-RW'PCTI\^OW)TZTV3]D[]KJ*Y5H?VO?#3Q[OF2X^#5FW'L5OE]OUKZ\HH
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MDK'^'MN+3P'HL2_=CL+=!^$:BMB@ HHHH **** #%%%% !0>:**  #;1110
M4FP>E+10 FQ?2C:*6B@!-HHV =J6B@ V\8I-B^E+10 FQ?2C8/2EHH 38,]*
MRO$G@?2/%]SI,VJ:;9ZA+H5ZNI:>\\0<V=RL<D8FCS]UPDLBY'.'8=ZUJ* $
MV#TI/+7TIU% ";!1L&:6B@!-@KDOCI\"_#'[27PNU/P7XRL)]4\,ZT(UOK.*
M^N+/[4B2+((VD@=)/+8H Z;MLB%D<,C,IZZB@"#3M-@TFPAM;:&*WMK=%BBB
MB0)'$BC"JJC@*   !P *Q_BG\,-#^-/PXUSPEXFL?[3\/>)+*73M2M#*\0N;
M>52KIN1E9<J2,J0>>M;]% '._$KX6:)\7O#EOI/B&T:_L+74K#5XHQ,\)6ZL
MKN&\MI-R,#\D\$3[<X;;A@02#T(7CUI:* $"A3T]JYKX0?"+0?@3\--%\(^&
M;.2QT'P_:I96,$D\EP\42YVJ9)&9VQD\L2>:Z:B@!KP)(#N16W J<CJ#U%-%
ME"(A'Y4>P *%VC  Z#'M4E% %9=(M4U,WHMX!>-'Y1G$8\PIG.TMUQGMG%3-
M;HTPD*KYBC:&QR!Z9_ ?E3Z* *&F^%M-T:SN+>ST^QM;>[=Y9XH;=(TF=_OL
MP PQ;N3R:H2?"_PW-X1/A]_#^AMH+'<=--A$;,G=O_U6W9][YNG7GK6]10!1
MM/#.GV-Y;W$-C9Q3VMN;2"1(%5X825/E*0,JF44[1QE1QP*O444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 !;%%?*W_  44^*GQ"\$^-_!.E^ S\1KC
M[5H?B#6[^P\#C1/[7OOL*V/E!3JT4D)CW7+*4C7S6>2/&5#*?//!_P#P4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !110>E '\B__!SO<?:?^"XGQNQ_#_8:
M9^FA:>*^!6# ^M?>7_!S)*)O^"WOQRVXXFT9<_31+"O@V7_6'K0!_?%1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4&BANE '\@?_  <E,1_P6W^/'_7]I>./^H/85\,-(H//
M6ON'_@Y E%Q_P6S^/;#MJ.G+S[:18C^E?$.,T ?TE)_P>L? 4E=WPG^,2\9;
M":;Q_P"35./_  >J_ /M\*?C'^,>F#_V[K^:DGY#^-(W /TH _I7/_!ZK\ M
M_P#R2GXR;?7RM,S_ .E=2#_@]3_9](_Y)9\:/_ ?3/\ Y,K^:,\4XG@?Y[T
M?TN)_P 'J?[/1;YOA=\:5^EMI9_]O:F'_!Z?^SGD?\6R^-_O_H.E<?\ D]7\
MSY[?05&>WT% ']-"?\'IO[-;=?AM\=/?_B6Z3_\ +"IX_P#@]*_9C+_/\._C
MTJ^HTC2"?R_M(5_,DYZ4$X7\: /Z<O\ B-'_ &7A_P T^_: _P#!)H__ ,LZ
M%_X/1?V72>? 'Q_7'KHFD?\ RSK^8L=*,_-^% ']//\ Q&?_ ++0Q_Q0_P >
MAG_J!:7Q_P"5&I8?^#S?]E:4_-X/^.L?'\6@Z<<?EJ!K^8'/WO\ >']:">:
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M^(WB&ZM\R:]K,GS)]Z]D;T_VJ]*\'>*=3NKZ-9-1OI%WD8:X=NR^] '\K/\
MP<57?VO_ (+4_'YMJC&L6<?'^SIEFO\ 2OBG?BOL3_@X'=G_ ."S'Q^+,2?[
..?AY)_P"G*VKXY% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex3-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1_002.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#\0?@-X3T_QO\ ''P7HNJQ
M2W&F:OX@L+&\CC8J\L$MS''(JD%2"58@$$8]1UK^IQ?^#47]BE6S_P *]\1G
MV_X2[4^?_(U?R\_LG1M+^U/\,E58F9O%VD@"4*8R?ML/W@_RX]=W&.O%?W24
M ?G+%_P:E?L3QJV[X<^(),C +>+]4^7Z8G'^33A_P:F_L3XQ_P *W\0'_N;]
M5_\ C]?HQ10!^<__ !"F?L3?]$VU[_PK]5_^/T?\0IW[$P'_ "377O\ PK]5
M_P#C]?HQ10!^<X_X-3OV)0/^2:Z[_P"%?JO_ ,D4?\0IO[$W_1-]?_\ "OU7
M_P"/U^C%% 'YS_\ $*;^Q-G_ ))MKW_A7ZK_ /'Z/^(4S]B;_HFVO?3_ (2_
M5?\ X_7Z,44 ?G./^#4S]B4?\TUU[_PK]5_^/T)_P:G_ +$RC_DFNO'Z^,-5
MX_\ )BOT8HH _.Q?^#5;]B-6)_X5?K+9]?&&K\<?]?-.'_!JQ^Q"'W?\*KU8
M^W_"8ZQ_\D_YS7Z(T4 ?G>/^#5K]B(-G_A5>K'V_X3'6/_DFIX?^#6;]AZ+[
MWPAOY.?XO&6M\#TXNQ7Z$T4 ?GO)_P &L_[#KL?^+/WRY[#QEKG_ ,F5&W_!
MK#^P^6S_ ,*CU$?3QEK7_P EU^AE% 'YY'_@U?\ V'S_ ,TFU/\ \++6O_DJ
MGC_@UC_8?!7_ (M'J/RC'_(Y:WS_ .3=?H510!^>;_\ !K!^P^RK_P 6DU)2
MHQD>,=:R?_)O_.:=_P 0LG[#^X'_ (5'J/0#_D<M;Y_\FZ_0JB@#\^9/^#6C
M]AR0K_Q9V\7 /3QEKG/YWE$?_!K5^PVKDM\&[M\C&&\9:[Q[_P#'Y7Z#44 ?
MG^G_  :Y_L,K)N/P5F88Q@^--?P?_)[-.3_@UW_895<'X)RM]?&GB#_Y.K[^
MHH _/]?^#7+]AI0W_%E[@[AQGQGKW'7_ *???OZ#WS O_!K1^PZKJ?\ A3]\
MP!Y4^,M<PWL?],K]!Z* /SZC_P"#6O\ 8;5V+?!NZD5FW;6\9:[@#TXO.GZ^
M]-3_ (-:?V'5A93\';QF))#GQEKFY>N,?Z9CCZ=N]?H/10!^>:?\&K_[#ZL^
M?A+J3*PX4^,=:PGN/]*_GFE;_@UA_8>.['PCU!=P'3QCK7'_ )-_YS7Z%T4
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M(** /YU9/^#);XE8VK\=O Q7MG0+H?7_ ):4T_\ !DM\3 >/CIX#Q_V KO\
M^.5_1910!_"_^R&8$_:M^%[7*>9;KXPT@RH<?.GVZ'(YXY''/'/-?W05_"[^
MR+>+IW[5GPQN&C$WD>,-'D,9;;Y@%]"<9P<9QC.#7]T5 !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?PM_LFJ7_:G^&:C=\WB[2!P2#_Q^P^E?W25_#!^R! +O]K'X
M6Q'S/WWC'1T^1&=N;Z$<!>2>>@Y/:O[GQ0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '\-'[%&H#2/VROA'=%E1;;QOHDI9B0%VZA <D@@_D1]:_N7 Q7\-G[#9V?M
MK?!UM\D87QUH9+1C+K_Q,(.0/45_<G0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK^XROX<?V$+6&]_;A^#,,Z[H9O'F@I("VT%3J, //7I[U_<=0 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7COQ4=AX]OL6^ER?ZOYID0N?W:]<L#7L5?//QQ\17UA\4M4AAL]'FC7
MRL//;,\AS$AY(<?RZ4 ?Q]_L!JS?MU_!3:6&?B!H !7J#_:5OTK^XJOX>?\
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M<U;3;"STZXU+3+>UO4T2UG%EIY=(\[7-O;QY 8Y 09;EF^VM9_9,^&/P!_:
MAOM'T+3M*T?QY!/JT.FV;+%I,FK%#;WMTEHA\L2O'+;R93D&)W4J=X?\^O\
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M/H$,EC8W]Y.EQ;-&(U8MH6I1R !2V0%_O-DE W!X'].5 '/_ !5^(_A_X/\
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M''_!17X7?M[^(_B'9_"W6I/$VG_#;5(='O\ 68$4Z;?SR1&3-I*&/G1K@@R
M!&/*%U(8^Z5\R?L-?LA:Q^S3^TO^T=K]QIN@Z7X5^(WB/2;[PQ;:6RJD%E:Z
M/;691H555AVR1, HXVXQBOIN@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX7_;'LHYO
MVC_$;-8PS$_9OG:!6)_T6'N1FONBOSU_;DU&:#]J3Q0JW,L:K]DPHEV@?Z)#
MVH _F*_X)RQFX_X*$? >,+N9_B/X<4+G&<ZI;5_;^*_B#_X)PVAE_P""B/P%
MAD61=_Q)\-H0@W,<ZI;=!W//2O[?* "BBB@ HHHH **** "BBB@#QG]O_P#8
MS\/_ +?/[)_BSX8^(8[=4UJV\W3;R2/>=+U"(^9:W2]_W<H4D C<A=<X8U_*
MSKMEXR^!VK^)/@[XJN-0T.ZTG7WAO]$N[C_1UO[8K#YA'W&8*"5DP=T,B,,H
MP)_L,K\S?^"\O_!$0?MVZ.WQ2^&EG;P?&#0[5(KFS#+"OBVVBSY<>]G6..[B
M#-Y<K@AU BD.T1M& ?ARL>M? GXL3:=8ZMINI77AK6;?5A;^&=2%Q'KFKZ:#
M#:O%>18DPD=S*%$)!E"XVEE&W]*/%/P+^/G[4'[(GA'0_&-]X5AGU1K^_P#%
M=M!;R)J>BPNUW]@GN;2;!A3Y;*9G6)GB$@>6*,*I/YA:9>:)X4UKQ1X;^(_@
MW6+7Q19Z;/INGVMU))I;:3JPGC,4\\+*"P5!(IA?&X2AE.,-7UU^P)_P4U^(
MGPI\0:;'XD\.ZK\6O#_@ZWCU.-%U-;+7?LEM)'+';K<NCM?VT9BCE2VER1Y2
M['0)@@'T#IGQ@N?V<M#\'Z'IOA"34/%OA[44\B\LM=AU/[1 %DCN7AC5D$/V
MI)?,MT+LY$2>9Y2G!^LK/_@KKI?@#X&_V1XYM_&'A_Q18P0V$TLEI;/:RW<I
M7RK=8FE64M('58MI)?<IZ=/G#0?VL?V?_C]X_P!'D\8:QX+N]6BUZVO-:UGQ
M%I]WX(\16$MO D;2QWMB1'(RWXD'F"XD*QR1J2PBRVS\'/V?/V<O!W[6OA/X
MZ+=Z=#XELM5-R9;_ .,^E7=CI2K:20QW4D$BL\AC;=&$Y:,JD@.[<% ,'X"^
M./#?B+Q;XL\2?'&'Q#H5Y)/LN6M'OK4VYBNYI?WV^?:OE?:3&D"PA1'$P='=
MG ]<_:(_:8U#5O!TVK?#/P'I^J>'?#D*2^'=&\00%=:\4*DT+3W.EP*3)/;B
MW=IS+)&P"Q3$+*05'$_%']OW]G7X4^,=6UZ[UKP/9Z]JJW-T-3\+6MQXSURT
MU"Z:.X>:*1XY+16BN%D3:Y2-@ZE2H)1?C7]J_P#X*H^)FUW6-+^&OAV^^%\F
ML6BSZAK]],E_XGU2&Z5;C?'<+E+>.7SF92ADEC$IB$RQHL2 'R/:Z!K'[4'Q
MHTGPSI=A9W4VO:S>Z[%!+#:VMW#?7B?Z3;27;;<QK]F41J[!8MQ50I<YOVOB
M7Q=\:;+P)\)=#LFUS^T-8?\ X1W1[>W3S_M=^T,;QL^W_EH4B#%LB-(W;  .
M<#QOJ/A^U\0:+IG@6W\37^I:A96%M+938NKVYU;9%YY@$0)D5Y&81HN7..<G
M)/[I?\&_W_!$*\_8YTRV^,_Q<L9(_C%JT$\>G:7-(DH\+VLVU6:0J6!O98T"
ML0Q$4;&,<F0L ?9?_!+W]A?3_P#@G9^Q=X1^&=K):W>JZ?"U[K]_;J0NI:I.
M=]S*"0&,8;$<>[YA%#$I^[7T'0.!10!\K?\ !;[Q=KW@C_@DQ\>+_P -F9-2
M;PM/:221*2\%I.R07<HP1@I;23/NS\NW/:OG+X__ /!/_P"$'[27_!47X)?"
MNQ^%7@:T\,?"GP38_$;7/$5MI$$6I:S#:NVE:%I/VM$$AME,$DSQ[BK):Q*<
M* &^QO\ @HY\>_#?[-7[''C'Q5XT\*7WC3P7LMM(\0:3:;3)/87]U%83MM.-
MR(ER69<@E%;!'6OG>3_@LC\)?V9;;XZ?#_3O"_C2^M?V4]'TK3U$<HO9O$B,
MT-BD%K++(9)7AN)(8)7E8D.Y)).: /&=,_8_^'?QD_;/_:W^,'A#P!X9\&R?
M O1=4\$^$[[PKX807U_XANM(>YUC5IK>+R9+RZC:ZCMH4\P!OWQ!#2AA\=VS
M>'?@I^P-\9K7X,)X$\9V/P]TGX<^*/#?Q(\+>"U\+ZK:>)AK$-NNBWQ1W>XO
MEBD+N&8S1_;IHY?G<8_<ZR_;"^%]U\1]:\#VWC;P=<?$+0+)]1U3PM::Q;S:
MM:!(_,</ K;MRKC/&0""< BO#OA1^V'^S7_P4[^ ?@SQ9>>+/"ME:^'6L/B9
M?>&KWQ/:6]SH4D3L;>;588IMNR*=DDVRG9YJ0L<D+0!Y+_P<&6FL:P_[/VFZ
MAK7@/0?A+J'BS4$\8W7CLW(\(F9=-F?3H]4%M-#(\+2K+L1I4B:<0[R3L!_)
MKX\?$/\ X3;Q=\+M<;3_ !I\/;[3_!7@@>&=#N]>UR;Q+\^KE97\""4E)T:)
M07&I&1D5PB'"!E_H ^(O_!0OX,GX9^&_$=CXI\%?$#P7XG\3P>&)]4TSQ#I,
M^FZ7,T4UPT]Q)-<(A2)+=G9(R\P'S"-E5BJ? [_@H9^S_P#M/?!'PK\5--\<
M>!X?#^J7TNFZ1=ZY?VEE<V]X" ;8+(^Z*=E$;B+B0H\9*C(H _//2_VH?B=X
MI_X+P?#3Q5XV^'_QNT^\DT'QQIVB^"3HT-I8#3+)5-E);.]R(KBZN,.TT\DB
M1*]Q9QJ0B>8:'_!8KXU?\+=^(&F>._& TOX8CP#\-]7UK3/A3\6+O4M*U+Q5
M/'>PF22RFT34UM3<2B.*WA0W$LVYR6MBA5Q^OT>O>%-9^(W]GK>>'[OQ=H]B
M+C[,)H9-2L;2=L;]N?,CAE:+&[A7,??;QE_$FQ^'?BCQ%8VGB^'P7J6K>'(F
M\164.L);37&EQQG:U]&LN6B5",&9<!2/O"@#\W/"?P"T7]HG_@I[XH\7?#WP
M[XP\)WGP3\'VOC36M,/B?4IO[=\9ZO:O<V>F75L]RUO'%9Q(DCPQK$6EG0-^
MZ&U_C&[_ &A]4\&_L4>+M8\!_%[X@7G_  FW[/6A>)_B%JNG^(9M3>P\7WOB
M.&V'FO+,!I@F26]@G$/EF.WB+K&QC7=^^_A_4O >D^-[S^R9_"5MXE\5"*^N
M_L;VZ7VL!8L13/M_>38A7"L=V$7@X%8/ASP-\'?!UGJ>GZ3HOPUTNW^)<LD^
MHVUI:64">*I),QR/*B@"[9]Q4E@Y.X@YS0!\;?\ !N;X^O\ Q5\'/C5I-QXN
MN_%5AX4^)-YING)%XDD\5:/I<'V:WD6'3M9E8S7T!#ART@0H[,-@R2WZ+UQ_
MPL\&^ ?@OX5M/#?@G2O"/A/18[J:"UTO1+:WL;5;@%FE1(8@J^8"K%P!NR"3
M73/K=G%<^0UU;K-N5/+,H#;B,JN,YR0,@=Q0!:HJM%JUO/M\N:&3>S(NUP=S
M+D,![C!R.HP:D2]CDC9E=&5>"0<@>N30!+135E5UW#IC.:#*/?\ *@!U%-\S
M'K^76EW?7\J %HH!S10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YI_\
M% /&^F:1^USXMM[B_6&:/['N0G[N;* C]#7Z5.I.,''//O7Y(?\ !3O5=2MO
MVX_'"6]P8X5^P;5\A6Q_Q+[;/)'K0!_/]_P3"L%U+_@I3^SO;L2L=Q\4/#,3
M'N =6M1_6O[<J_B3_P""5Q;_ (>>?LWE55F_X6IX6V@G )_MBU[_ /UC7]ME
M !1110 4444 %%#' K\?_P!K7_@J9^VYXK_X*U_%_P#9\_9F\$_#'Q19_"_3
MM-U)XM;C$-RT$]E9322--+=PHQ,MV%"*,A5!YP30!^P%%?D=_P --?\ !7ZR
MBWM^SO\  F[PQ78FKVZL<9&?^0F.#3Q^V7_P5PL\>9^RK\&+CGJFN0>F?^@K
M^'UH _6Z@C=7Y%2?\%!O^"KEAI_VB;]COX7S*I *QZLK2'G'"#4B?QQTYZ4+
M_P %'_\ @J='!ND_8O\  #=OEU?!_+[>30!]F_\ !1W_ () ?"#_ (*6:-%<
M>+M-NM#\:6$(@T_Q9HHCAU2",-O$$I=62XM]W/E2JP&6*&-CNK\</VC?^" /
M[4G[#7BN74OAW-)\6/!<<LS03>'6,.HVD;6\D'[_ $YR9"WDR2Q@VSSD^8QV
MC(Q]AS?\%0_^"FVG/MN/V'?#<W_7#62W;/:Z:H[?_@K=_P %'H)&CN/V#89I
M%/)BU615..N#O8=QW]>O8 _&WQQ\5;KX=_"+2_ ?B?PMXB\%ZYX=C^Q2?;<:
M:SO)=37$LDT,T4<V7!C41A@O^BPL02 1L6W[4WAG7_BTOC*^T..\LGB<RZ;+
M);S6S3WAC&J3%F<8:5/M/E]2@*[L[2P_6KQ9_P %?/V\-9T1[+7O^"==[K%K
M,,F&2ZFNX6YQ\R>4X_.O/Y/VR_VBKG59+N\_X))^$KF[9O-,_P#8\/F$\\[S
M9DEL?C^= 'Y@^&_V@H;[P4/!WA72_$7C;4HK75-#TI//CF9-,O9;61DDM+='
MDDN$DA9]P^4/*Q .T5];? +_ ((M?M??M\VMC:ZUHL/PG\"6<@\F;Q3;2:<T
M.V"*!GM[/YKQV98E8B0PQ.VY@1N!/V3X:_X+8_M:?##2Q9Z;_P $Q_'.E6]N
M"#%I5S<P0]L[4CTTC&?3-:,?_!PG^UE;0LUQ_P $U_C(S( 7,6IZAT)('']D
M$]NE 'UQ_P $T?\ @BO\(?\ @FCI_P#:.AVLWB[X@7$0BN_%NM01->JNT!HK
M5$4):PDY^1,LPQO>0@&OKX#%?D;)_P '&/[2UG(L=U_P3:^.\4C=%6[U!LCC
M_J$#U%%S_P ')7QZTJ-GOO\ @G5^T);1*,;P+]ESSP3_ &6!V/Y&@#]<J*_(
M\?\ !S+\5[*+=?\ [ '[1UFJC<Q^QWA 'KEK!?4?G4EO_P '.7C^2(2-^PC^
MTDJL@D4IIURRLIZ-G[(.#@X/?% 'Z-?MN_LZ_P##7'[(?Q'^&BW4=C/XU\/W
M>EVUU+GR[:X>,^3(^WDJLH1B!S@'%?%#_P#!%?Q[J&C_ +.=Q>^*/"$OB'PQ
MKEWJWQ@N_-NY%\6)=:[9^(9H[7<A,F-1LHE7[0%'ENS?> %><3_\'36L:;.(
M[[]B_P#:.M)-VS8VFN&W'@##0CGVJ#_B+&L;2X$=Y^R;^T1:R-P%_LU2Q/'&
M"H]10!Z5\+O^"+/CCP!^VEK/BR]U/P=KO@A/%WBCQQX?U&?7=8BUO3K[6K>9
M&A-B@%EM1YF1YB[F6)5!C#=/+O W_! WXK>*_@9X'\$?$S2_V?;[3OA;\-=0
M\(:7;Z/>ZM!'XOOKNYM)UDU25((98HK9K-)4:$N[3GS"%&4JPG_!V[X3BN!'
M<?LR_M#P-SQ_94);@XZ%A]*=#_P=Z?#&+S&NO@#^T);JI )_L:V;!/K^^&.,
M?G0!V_PX_P""3/QXU70O ,?C;6/AW<6OAGXX:-\1'TN>\.J7=MH]II=[97-O
M/J2Z?;/J5P[SQF/[1""D8*M,^!7BVM_\$!_C3_PH[X5Z#=:3\-]>?X?^'/$'
M@&]T>Q\4'3[35;34)HI4UM9I])N/)N'P\<\2Q>;Y<4)CGW95>V3_ (/#?@?$
M^VZ^#_Q^M7 RRG0[,E?_ "9%2)_P>,_LY0(QNOAW\>K7!Q\V@677_P #!0!]
MW?LP_L^:I\$?B@+23P3X-M-$T?P#H/ANS\6Q7K7GB+5I+194DM+J5XD>2"$;
M6C=L%C*Y*J>!XS_P6$_X)N>+_P!N3QC\)=2\#W5CI[6MY>>$/'3SW"P-=^#M
M4$/]IQH=I+3#[-'Y0'1I&[$FO H?^#Q?]EV15\SPC\=HMYP,^&[,@_E>U+#_
M ,'C'[)\GW]'^,T/) W^&[;G'TNS0!R-C_P0]^.'P_\ V5M1\3:%<^%;K]IS
MP5XLTBW\ :G+<JMK:^&='L/[$LK=YMH(,EE-<W4JD#=(R#8&4 7/#G_!!#Q]
MX-^"GQ5T6.32M2U;X7Z?9:;^SW/<W$+7%M'9ZQ+XA\V>7:/)EGO)(K1F^3$-
MN,D@AZZR+_@\,_9%9U5XOBM""<9?PU'@?E<&KUM_P=\?L<S.H;4_B)#GJ7\,
M-Q_WS(: ,/\ 92_X)I_'S]EGX\3?$+6O#FF_$/\ X0GPYJ?Q%T'1$\006G]L
M_$77K.UAUB#S6&V*!&M[L12NFU5O_E)^<!O[;7_!*#Q]^T+^T!^TM\3K?X<Z
M9=>,M<U[X;W_ ,--6758$OK :=]F_M:6"7S%,#1CS5).TR"/Y0WRUU]O_P '
M;7[%UP!O\6>,H>V'\*W1Q_WR#5V'_@[%_8GE<*WC[Q)&,]6\):A@?E$: ,_3
M/^"6'CC5_P!KCXAZ7K&D:A9_!?PA'XS\2?#V_P!$U^&QU+4=5\6V\:7<$/!^
MQO8L=26&5E"C[?&1D(U?-/PS_P""8'[0GAOX$ZAX;TCX)KHOP_M=;\-W_BK0
M)]2T[P_XJ^)NG68G&HZ3(^G7LEA-&^^WD%RXM);EHV27*[=OUI:_\'6/[$%P
MWS?%#6(.^7\(:MQ_WS;FM"W_ .#I3]ANX"_\7BN(RPSAO"&M#'_DI0!\V^/_
M /@FC\5+G]F(^9\//BC9^$H_B7?^(/!GPFTO5M/UVW\*:/<6@C$&J6DVHVL5
MPCW*F=+>VO<6AG<JY^8'T/\ :I\3?&'PQ_P1CN/A]XM\$/\ "#4-"\+^';G6
M=0B\:)::??12:SLO- M[^ZO'ECNGL8@#YERREKH0B8@ACZ]%_P '.O[#\XR/
MC9"N>?F\,:P,?^2M.UO_ (.-/V$_&>B76FZI\9_#VH:;?0M%<VEYX<U*6&YC
M889'1[4JRD=01@T ?!'P4\+>)OVD?&OQNU3X3^%OBIKO[/>C?$SP?+X@\#Z-
MXU6\U;4O#]OX?D\_3[2\CO98I?)N9());*"[W;-D(8% !ZI'^RA^U9\)_P!G
M_2/$/A?0_B(M[XKUCQ;\/_#OA/4?$9U'5/ /A'78H?[(O-1E#.&ETVZ@DEP)
M9'BANEC\T^60/J+X:_\ !>[]@7X9^%TTOPI\7O 7AG1H7>1-/T[P_>:?;HS'
M+,(DM57+'DD#)KJ(/^#AG]BVY'R_'_P<./XX+M/YPB@#ZL^#7PSL_@M\)/#'
M@_3[S4]0L?"NE6VDV]UJ-RUS>7201+$))I6YDD8+N9CU8DUTE?'47_!P'^QG
M+C;^T'X$'^\\Z_SCJ[:?\%Z/V.;PJ%_:&^'*[NF^^:/\]RC'XT ?7%%?*L'_
M  7&_9!N =O[17PJ&/[VN1K_ #J]:?\ !:/]DJ^/[O\ :.^#@YQ\_BFTC_\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ K\<_^"J9NO^&]/'GEZO>6J?\
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MJ[?P]ITNIZQJ+FVGENM(TFV%RGDI(]PF;A/*"""",C$@C; _X(Q_%[QY<_\
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MU7T_\>'OB>'Q[_P6'L[MHSX+_9LO%4E?,,ZA7QCGBZ5N<]P.AX'&?UMQFC%
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M#A+_ (* 39SY<VD1<#T##_V6@#]8**** "BBB@ HHHH **** "BBB@ HHHH
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MW\.#SVK+TSX]>!]:^(=QX1L_&7A6\\66>[S]$@U:WDU&#:,MNMPYD7 ()RO
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M "BBB@ HHHH _-G_ (-=1O\ V#OB)-G+7/Q>\2RM[G? /Z5^DU?FU_P:Q/\
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MQ6?B+6DOIYM1\1'[;I&^6[F=RTLDGVJYWN>6$S*?EPH_3WXQ?\$</V??C/\
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M'\-ZUH_CII-=O;+3K34;+PQ>7FF-<7<PAAC:YC0QJVXC=D_(N6;"@D>(:_\
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M[(7PK7Q>URWBP>#](&MFYSYWVW[%#Y^_/\7F;L^^: /2J*** "BBB@ HHHH
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M[5?_  4.D;QM<_%QM;\)274'B.[TX6=SXNC<7A^V)9XX20M&5"KMVO'CAER
M?=7_  1?_P""Z7AC]N/]ECQQXP^*7BWPGX6\7>#KF]US7],CAEM+'PMHGF[+
M4O/(-DF0IRV]G9C]T?*H]G_90_X+F?LO_MK?&0_#_P"'WQ/LM0\63-(MA8WU
MA=::VL!-Y8VC7$:+/\J,V$)8J"<8!Q^*'PA\1:+\8_\ @TE\8> /A]JMCK/Q
M$\(:P?$GC70K ?\ $RM-*36=XEF4+EHA'Y4N22-L;G^!@.^^'_B+PK^US^TE
M^PW;-^U=\(]4\1>%=0T^X\*:/X,^%=U;:KIL<0MB^F7[P32"W_U#1CS55%R\
MI CR0 ?NG^VW^UKX<_8:_97\;?%3Q3-;QZ7X/TR6\2&:<P#4+G&VWM ^UMK3
MS&.)3M.&D!P:^=O^"+W_  5TT/\ X*1_L<WWC;Q-KGA/1_&WAN6^O_%NC6LS
M0P^$[!KZ]%CY\DN!M-I;!S*3@[68A <#V#_@JSIUOJ?_  3#_:(6XM8;Q(OA
MIXBG2*6(2+YB:9<NC '^(, 01R" 1S7XA^%;S2/'/_!H!KFB_"C4O#M[X\\-
MF"^^)5GHXC_MI-,;Q#>21B\$:^;L"J9 9"!Y,4I!V9! /V6_9_\ ^"U'[+G[
M4GQHC^'O@/XR^%=>\7W+F*TL!YUO_:#@%BMO)+&L<[8!.V-F)P< X-?4>[*U
M_/Q_P5P^(7P#^-__  3 _9)\*_LQS^![WXT7'B;0(_!=CX72&/Q!I;K:2+,)
M?+_>P'[4T&_S2"TNUSN*EQ^^=YKL?A#P5)J6N74-O#I=D;G4+ECMCB6./=*Y
M/90 Q^E 'Y4?\%PO^"['Q@_84_:S7X>_ _PGX5\90>"?!:^-/'KW]G/=2:3;
MR7:PH&,4J"$*C0L68-Q=Q'IQ7Z=? _XVZ/\ '3X#>%?B'I<T4>@^+-#M=>MY
M'E4K#!/ LPW/T^4-@DXP5/2OY[OV%_B!^TY^V3XS_:J^-W@/]EVS^.'AG]I:
MZO\ PG+JFJ>*['1UTG3$#QBR@2XD5I%6*6V!?&TM;@9W*V.]_96_:8^(GB7_
M (-:_P!I;X3K'JEM\1_V>Y+SP?JT"RAKJUTE[M9+E7(;[L4#7\)VD@1V^!D"
M@#]DO@]_P4X_9Z_:"^*\G@;P1\:/AOXI\7*Q6/2].UZWGGNR%9V$ #8G*JK,
M?*+;0I)P!70?M$?MQ?!W]DB?3X?B=\3O O@*XU8;K*#7-9@LYKM<D%TC=@[(
M"""P&T'@D&OR>_9M\,?L!>'OV?\ _@GW<>)=$L;7XL:UI^ERZ!=>"[:2+4[G
M7EAM5N'U1K/%PZ_;_NF7<H??C$?F5)X1\%?#/XW_ /!R5^UY8_M+Z-X5U_3O
M#_P]MY/#-KXMLX[BPL='CALGGN+82AHXW5)"^]")!YMP5Q^]P ?L?X=^+GA?
MQ=\/$\7Z5XDT#4_"<EJ]ZFMVFHPS:<]NF2\PN%8QF-=K9;=@;3D\5R?P5_;3
M^$/[27B'4M(^'OQ0^'WCC5M(5GO;/0?$%KJ$]JH(4LZ1.S!=Q W8QDCGFOPV
M_P""@WB#X1^#/^#>WP;8_LGZY\0'_9]USXJQV'CB]U.6^CO((7C9IX'\U5_T
M=I1;DK"C0F3'5R^?5_\ @JO\ _A1^QA^V!^PGJW[)_A_POX1^)7B#Q5;6MK;
M>$42W/B;P_(8 TMX8B/M$3J65II6S(CRY9@I*@'[$>-/VF/AS\-[#7+KQ%X^
M\$Z#:^&6B36)M1UVUM8]):7B,7#2.!"7_A#XW=LU4\0_M;_"OPCX3\/Z_JWQ
M,^'VEZ%XL94T/4;OQ'9PVFLLWW1;2M($F)[",MFOR _9)_8P^&?[:7_!Q'^W
M!9?%#PGIWC31O#\-I/::7J>9+-;B2&*'[08<[6E2,R*CG)C\UBN"<CY-_81_
M8%^&/QB_X-Y?VJ/B=XJT!M>\9?#S7-7TWPI>WM[,Z^&X+.WLKI%M$W;8S)-<
MS-)@?O<J&SB@#^F:\\2Z?I][!:S7]G#=72-)!#).JR3*HRS*I.6 ')(X%9/P
M[^,/A/XO6-W=>$_$_AWQ1:V%RUG<S:1J4-]';3J 6B=HF8*XR,J<$9Z5_.W\
M8?#VG_'*;_@DGX>^('B#5(=%\7>&I='UF]&HRVT]Y9W$]I;FS:=2'$<\3"V;
M!&4F9<C.:^A/#?A?X>_\$JO^#E^;PO\ "5V\&?"35OA%=^(_B1HNFRS3V.CM
M:6E]<B7R5)V,B6UI*NX,0;MPN/. H _9YOC3X/3Q]_PBK>*O#8\3\?\ $H.J
M0?;^5W#]QN\S[O/W>G-=!+J$$$FUYHD;:7VLX!VCJ<>@]:_DS_;3\):1-^Q=
MX/\ CQ\(O@;XH\#^$=<^*!FT3XP>+_'<>J^-/$5\7OG\IH(=HBB22W)WN'</
M;#]Y(79S^F__  5-^#&G_M4?\''_ .RG\-?$6J>(+/PUXQ^'&H1>((=)U&73
MY-6M8HM5NGM))(B&\F<VZQRJI!:-W7(SD '[$>&_&FC^,M/:\T?5--U:TCD,
M33V=REQ&K@ E2R$@$ @XZ\BM%7#J"OS ],=Z_#__ ()U?LA>$OA!_P %Y_VS
M?V8?"*ZCH/P7\1?#$M+X?CO7FAMI;I=+4RQ^86.^,7MR$+$E0X&2 *\/TC]I
MOXA:!_P1LN?V(K+4-5/QX'QJ?X/I)'?2I=-9->F^:X67?E8B<PD$[1$W/% '
M]&+<BORT\1?\',^SXZ_$7P+X4_99^/7Q&N?AGX@N?#^K7GA2Q&J0120SRQ*[
M>4C>7YGE.RJ^"0#Z&OT<_9_^#6F_L[? WPAX#T5IY-*\&Z/:Z-:RSMNFG2")
M8_,D;JTC[=S,>69B3DFOY_?V(O''[9G@#]HO]N;Q=^ROHOP[\2Z7IWQ,U&;Q
M%IFM6[3:I?21W-\T8LHPZ;R$W_(6!9F4*"210!^O/_!,7_@L5\/?^"G5YXPT
M/1M!\7^ O'_P_E5/$'A/Q39BUU&R5F9!( "=RAU*,"%=&P&494M];^8OJ/?V
MK\#_ /@G+\8M0\+_ /!/W]L']OJ#Q]I_CC]H?Q5H\EAJNCV&F?88?!,R;%B#
MPG)D*J890^/+*VQ&YSYC5\Z_#CPW\:/#_P"SG\(OCA\#?!/[=WBC]I&^O[+6
M_%'BO5K>ZO\ PMXUTUMTLMME)I)+BW9H[(+YJE98U?<,[=H!_3V&!KB/VC/V
MC?!G[)OP5U_XA_$#7+;PWX/\,0+<:CJ$ZLRP*SK&@"H"S,\CHBJH)9F  YK\
M4O\ @N=\*OC5?_\ !2+5_%OQ!\(_M">/_P!G"3PK9_V#8_"SQ"]K-X1G,,:7
M%S<VBI(&D$XNCF18ED5XAYV(BE<9^TGXQ\/_ +4W_!J[XAU30?CU\5OBA<_"
M/Q-9IJ,FNJ^EWLTDMS:QC3=2@:6<W-K$EVLL+"9EWQQ8;,+( #][O@C\7M)^
M/OP<\*>.=#6\31?&6DVNM:<+J+RI_L]Q$LL>],G:VQP2,G%=07Q]?3UK\-_C
M;X3\+_LK?\$Q?V7_  #KW[4W[4%K=?$RWLO$[^$?##RZ[XL\4VLNF68.C:;)
M&8OL%A"?EBC?>F96^5]N!>_X('^*/B)^T3\4OVQO@#??$#]H3PCX+TF&S'AA
MO%VL,?'/@G[0]PH(F8LMO,4569$!4, 1R69@#]8_V3OVW?AK^W!H?BG5OA?X
MBA\5:'X1UR3P[=:K:HWV*YNXX89G^SR'B:-5G0>8N5)S@D#->L[N?K7\OW_!
M,OXR_$#_ ()]_P#!!GXQ_M%>!OB)XLL]:U/Q+)X%T?PS)(DGA_2;NY.FL^M+
M P.;Y85>-&;Y0-NY6[>Z?LT_M@?$[]FS]JW]F[5OA[\8/VKOC=I?Q*U.ST[X
MK:)\0/#&IMI%O]K:)?M>G/<0JEO"KW,K 1N<?9T+.R';0!_0:2,UXS^R[^WM
M\-_VP_B+\3O"_@74M0OM8^$&MGP]XFCN=.FM5M;P/,FQ&< 2#=!)\RY' /<5
M^<OB+4/CA_P5B_X+4?&[X9Z'\?/'WP*^&?[-MI806=MX+NC;W.LZA.H=9KKG
MRYT\P3;DDRGEQQ($!:1ZD_X-:](\2:1\:/VWH?&FIVNN>,;?XH?9=;U*V@$$
M.H7D<E\LTR1@ (KR%V"@# ;':@#];?%/B:P\%^&M0UC5+J*QTO2;:6\O+F4X
MCMX8T+N['T55)/TKPK]A/_@J;\#/^"E"^(_^%-^-1XJ;PF+<ZK%)I=WI\ML+
MCS/*.VYBC+*WE2<J" 1@XR,_,W_!T9^V*W[,?_!+G7O#.FW[:?XF^,E[%X.T
M^42",0V\G[R]D=B?EC^S))$S=O/7IU'P]^PE\2/@/_P3K_X+<_!'2O@S\2/"
M?CKP'\9/AY9_#OQ ?#5ZD\5OXA@$$<=U,BMP;F:&)@S?,6N)R,\T ?OX75:Y
M.]^/7@VQ^,VG_#N3Q'I/_"<:GIT^K0:&LX>]-G"T:R3M&,E(PTT8#-@,6P,X
M./RO_P""D/[4W[6'Q*_X+5M^RS\ _B5IW@?2O&'@"WU5KZ_TZ&1/#C(9YI[N
M.01--YD@AC@ ^8 SY 4C>O@O[(O[.'[16F?\'-GBOPWJG[0-AJ?Q$\*?#[3=
M3\4>*V\'6^SQ'HZR:1YVEK;;@D+.)8U%R#O_ '9;&YL  _:KX)_MC_#3]HSX
MG?$#P;X)\66/B#Q-\*[Z/3?%=C;Q2J^BW+O.B12,RA68M;3CY"V/+.<9&?3
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M) ? SX*?L>_$#X$>&?#FI:;\-?B9>7=_KM@=8N9IIIKF*&*0I/([2(-EO$
M<#;GDDD^K?%;]L+X4? ?PMHNM>-OB5X%\*Z/XD7?I%[JNN6UK;ZHNT/N@=W
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M: LWQDO5&/:6Y/\ [,* /UCHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^SAX=_9#_9\\(_#/PD=0;PWX*TZ/3-.-].)KDQ)G!D<!0S<GD #V% 'XR?\
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M#:>/M<^-GAG1M0\?7GB29]2A\0W2A;[S##*61%^TR&0 <Y1"2Q4&@#[,\/\
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MQ\#_ !1^S[\4/$5BVH>&[?4+T7]CKL:QO(R),(T"MMBE*D;D)C=-RN K<_\
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M!DV]<_XT ?B'_P ,,_\ !8BQ"F/]HSP7/N0D@ZA;':>./FTWKR>1Z'GIE/\
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M]=O? ^H0>*]-GT_^S/"EGH%W;.UK=YG%Q]J$%H6!MHI(9+B_EVE$WO7R*/\
M@S,^$K7:M8_M)^((E**=HTFP9SD+R&64<$,N./XAUR*>?^#.GPC8P?\ $O\
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M1Z#KSR/?#;GX'_\ !:C3%W1_&#X=WNUL;%M_#V6'KEM,7Z]<T ?ME17XDP>
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M*-YX)U;4;O4]0\&7/C?4)/#=^]U<27,\<MEYFQH7FE=VB/R.20P920=S4?\
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MM&_%#QSI?P=U?P7\,&^$/A32-6U73/%/AZ35YM>UV^M)+_\ LJ603P_9K6*
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M,NT%@H9<]"WW:X'X/>!_$'PQN_\ A&5C\-Q?#OP[H.EZ9X;6U$JZDLD"2Q7
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M)5=?-QZ?UK^NBOY(O^#7"VCN_P#@MS\)OO(B6>M.H)SDC2;K^M?UNT %%%%
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MR^.O@^Z\6:?X=E\4^'+7Q5JB,UOH;ZM;G49"L*3NJPJY9RD4L;MLR KJV=K
MD ^<9?\ @MO\ 895CF;XN0NH+A9/A'XJ!&TX)Q_9_;/7MFJMQ_P7,_9CLI?.
MNO$'C:RFM\1YNOAGXDADBSG"_-8 C.#QWYKZDT7XP>$?$GBJ]T+3O%/A[4-<
MTV<VUWI]MJ4,MW:2A=YCDB5BZ,%Y*L 0.>E:6I>+=*TC7+'2[G4K&WU351(;
M&SEN52XO!& 9#%&3N?8""VT'&1F@#Y%L_P#@NO\ LGW-HT*^/-2A@WX,<G@?
M7(UWCY\8-EC=_%CKWIVL_P#!:']D'Q#8W5CJGQ TV\M[EDEN;6]\*:HXE90N
MTNCVG+ *N,C(VCTKK]'_ ."K/PV\2_$;3?#.CZ?XMUK4-<\6WW@_2Y+&S@FA
MU.>Q;9?74;";/V6!\*TCA2Q(**ZD&OH^RU6SU&6;[/<07#V\AAF\IPYB<=4;
M'W2,]#S0!\B?\/N?V.8]>M)F^+'A>/5+6-K2U>31[U+B%&VEHD)MPR@[4)4<
M8"G'2J6B_P#!9K]A_2/%MQK-E\7/A?8Z]?1&*YOH[5X+V>,N9"LDGDARN]B^
M&.-Q)Z\U].^*OBWX/\)^.O!NCWMU9?VUX\OKFUT(1P^:;R>WM)KF;#J"%VPP
M/EF(Y 7J<5T(\&:)<W#7']DZ6\LJ[6E^R1EG!&,$XR01Q]* /DOP1_P5Z_8C
M\!/J$OA_XP?!W0'UB<WE_P#86CLGO)3G,LP5%+.>?F?GWJMK'_!3/]@WQKJ6
MEZAJGQ1_9ZU"]T.XGN]-N=0EL6EL)IW,D\L+2+F-I'R[LN"S')))S7UX_@#0
MI9)';1=)9YE$<C&SCRZC. >.0,G@^M5M0^%/A?5;$VMSX;T&XMF3RC%+I\+Q
ME./EVE<8X''M0!\FZQ^WC^P'X_L-5M=5^)?[+VHVVN06UIJ4-_J&DE+^*V!6
MVCE$G^L6$$B,-D(#\N*ZKP/_ ,%)?V+_  2EFOA[XX?LX:*NG:?%I%JMEXKT
MFU%M91$F*V0+(NV%"S%4'R@DX'->^7OP&\#ZE.TMQX-\*7$K')>32+=F)QMZ
ME/08^G%0W'[.GP_NWF:3P+X-D:X0QRE]%MF,BGJK?)R#D\&@#PC4OVWOV*O&
M7Q#7Q5=?&3]F;4/%$=M;VJ:K-XNT62]6&"X^TP1B4S;ML<_[U!GY7^88/-9W
MQ!^./["_QDDLF\2_$+]E_P 1-I^I3:M;F]\3Z-.8[N8IYTO,W)D\N/>#D/L7
M<#@5[=J'[%_P?U95%U\*?AK=!<[1+X7L7VYP3C,7L/RK)U+_ ()X_ '6 OVS
MX'?!ZZVKM'G>#--DP"-I',/3''TXH X32OC5^Q_'X2N-!L/'W[/JZ+?6MC8S
M6-OXETL02P66/L<6U9<;(=H$:CA0 !@5=^-'C#]E3]I^72&\;>+O@OXLDT)Y
M)+%[KQ)8N\ E4++'E9@6AE"J)(FS'(%7<K8&-?\ X=8_LQD<_LY_ GD$'_B@
MM*YS@'_EAZ #\*CNO^"5'[,%W<>=)^SC\!9)?[S^ -*;Z?\ +"@#.\5>'OV7
M?'GQ-TCQOJ>J_"F[\0:'';K:W:Z_;1QE;=MUMYD2S"*;R'.Z(RHQB;!3:>:T
M?CUX4_9S_:TL[.'QUJ7PZ\51Z?%-;1F778E8P3[/.MG:.52]O+Y<9D@<F.3R
MT+*VU<16_P#P2;_9:M<;?V:_@%\N,$_#[22>/?R*;%_P26_97BZ?LU? +"YQ
MGX?Z4>O/.8* ,V\_9+_9E\7>,8]>^R^$KB^AET^[6.V\2RQV@N+ 0BSN_LT=
MP(#<PK;P*MP4\T)$J[]HQ5CX2_LH^ M*^&_CO3O%FO>&_%FL?%#Q(WBOQ+J>
MEXT-;B]3[.EK);""<RVS6\=I:[)$F,OFQ&;>'<FK4_\ P22_97N=V[]FOX"#
M<"OR^ -*7@_2 <^_6LO4?^",W[)NIE?,_9P^"R[>?W7A&RA_] C% '=>$_V9
MOA/X7^%'BGP3;V=G?:#XX\[_ (2%=3UJXU2\UPRP+;NUS=W,TES,WDI'&K/(
M61(T52H50,OX>?L+_"GX=^-+?Q)IMOK6H>(H;FTNO[3UCQ?JFM7DTEK%=PVQ
MDEN[F5I!%'?72JK$@"8\<#' 77_!"S]D&\DW-^SW\-864;08--\CCGKL(SUZ
M]>GH*BMO^"$O[)-FVZ/X'>$U;.X8DNN.W'[WC\/K0!VTW_!-KX4O:+'IL/C#
M0I%FOY!<Z-XTU?3[E8KZX%S=6BRQ7*NMJ\P,@@!$<;%C&$+$GU3X8_!/PY\'
M+C7)/#VG_P!GMXBN;>ZO5$SR*SV]C;6$6T,3M5;>T@7:, E2QY8D_.:_\$)O
MV48[EI4^$&EQLW\*:MJ*H.W"BXP/P%._X<8_LMJCJGPQ>'<2?W7B75X]N1CC
M%UP/8<4 >N?#7]C7P?\ "KQQ#KVFG79KJSU?6M;L8;O4Y;BWTV;5Y(Y;Y(48
M_+$\R-*$)(1YI2N V!R6A_\ !-;P'X2;18]#U?Q]X?TO38-/@U#2].\13PVG
MB,6"QI:->C[[.BQ(C-$T9FC18YO-154<=<_\$-OV:90WE^"O$-IG/_'KXXUV
M'&>XVW@Z=JHS?\$)OV>WE+1VGQ0M6)S^X^)WB),#T&+WI0![I^T!^RQI?Q_U
M/2]4;Q#XR\&^(-)M;K3H-8\,:G]AO#977E?:;5RR/&R.88F#%/,C9 \3QM\U
M<AX(_P""<W@OX:>/K'5?#FL^,]$T&SOX-8D\+V^IAM+O-0AACA2ZED=&O68B
M*)Y(Q<B*:1#)+'([R,_GR_\ !#GX&P2AX;WXT6[ [AY7Q9\2IM^F+VKC_P#!
M&/X4APT'BS]H*UV@!?*^,GB?Y".XS>GF@#LO&'_!.+P?XK^&W@WPI'KOB_2M
M)\'>#=5\!*+:Z@DDU32-0M8;>>&X:6%SNS;6TJR1>6X>$#.QG1M#X@?\$_\
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M<[PM(PB\R1([@LK,XR] 'K'@O_@D'\-_AGX>^">G^&?$'Q"T+_A0?B34M?\
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M%%% !7G'[8;B']DGXI.> OA'5B3_ -N4U>CUY?\ MMR>5^QG\6V_N^"]9/\
MY(S4 <9_P28B,'_!+C]G1#U7X;>'P?\ P705]!UX7_P2_LSI_P#P39_9_A/_
M "S^'/A\?^4Z"O=* "BBB@ HHHH **** &RG]VWTK^*'_@L\PG_X*T?M',6D
M_P"2AZROS]>+N0>_'''MCITK^UZ7E#7\3W_!8/\ XFG_  5;_:0E.XX^)6OQ
M],?<U"9/_9: /I#_ (-6(5D_X+:?#-CNW1:7KK+CIG^S+@<_@37]:=?R7_\
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M2XNH7TQ;8WL9A@EAED9X0J1S1L2%=2?%_#'_  2DU;3=,T^[DO\ X=Z'K/\
MPM'P[X[O(- T.>"U6QT@_)9F:::2XN)VS(PFD*HOF;5C55RVBW_!//XA?#']
MK[7OC=X'\1>$;_Q'JWB76+DZ-K<<\%C<:1J6F:+;-&T\:2217,-SHT4JLJ,D
MD;O&0A82( =#^SE_P5R^&GQ0_9T\-^._%>M:7X<;Q//K$]O!IYN-6AM]+L]8
MNM-CU2>6&)A;V<@@C<W,_EP*TA7S#C-;7[<W_!47X<?L7?#KQO<S:QINM^,_
M!^A+K1\/QRR 'S0WV2.XN$C>*U-RRE8O.*F4C"!SQ7ROX7_X(9>-OA[X!NH8
MO$?@GQAKWBGPQ=^%=<2^O=:T'2+(2ZUJNI)>0V]A/NNHMFJRQR:?.ZJY52MR
M@WK)WG[0O_!,#XF3^!/CMX%^&EU\-9/"?QZT71K6ZN=>DN;.7PO<Z?I=MI;+
M!;0P2BXAFMK*V,>^:-K:3S&_?@A  ??EA.US90R,NUI$#%<YVDC.*FKGO UQ
MXDEO]>CUZUT>VLX-1,>B-8W,DTEQ8""';)<!T41S^<;A2B%UV+&=V6(7H: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KR;]O:3R?V&/C1)NV>7X$UQMW]W&GS\UZS7
MC/\ P4:NC9?\$]_CM,OWH_A[K[#_ ,%UQ0 O_!.>U^P_\$^?@5#_ ,\_A[H"
M_P#E.MZ]EKR7]@6/R?V%/@J@& O@/0P .W_$O@KUJ@ HHHH **** "BBB@!L
MO^K;Z5_$[_P5U8M_P53_ &D-S>8?^%F^(1G';^TI\#\.GX5_;&WW37\37_!5
MT^=_P5'_ &DF.[_DJ7B8<>VK7(H ^H/^#4B-F_X+1>!=JL=F@ZV6(/"C[$_)
M_/'U(K^L:OY._P#@U#9!_P %H_!.^)9&;P_K>PD']V?L3\_ED?\  J_K$H *
M*** "BBB@ (S1BBB@#'\=> ='^)OA2]T+7M/M=6T?44$=U:7"[HYU#!@&'U
M/X5K>7GKU]:=10 TQY]?SH\KGJWYTZB@",0X/5OS-*8?D"C^'WI]% #?)4+M
MQP>OO41TZ$F9O*CW7  E)7_68&!GUXXYJ>B@"N^F1,^_RXRXQABOS#&<<^V3
M],GUKR_2?V-/!.E_#;0?";6VJ7VD:'XAB\5M]MU*:XN-5U.*Y-VES>3,Q>Y8
M7.R;$A(WPQ<;4"UZQ10 #I1110 4444 %?(GAJ//_!>+QDW_ #Q^ F@+_P!]
M>(M:_P#B*^NSS7R;X1C\W_@N5\0)/^>7P+\,H>/77]?/]* /K*BBB@ HHHH
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M^',OC"/XM_#63PG#>+I\FM#Q+9_V>MRR!Q#Y_F>7YA0[MN<XYQBNF\>_M ^
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MM*L/"\MWJ.L:I./+O(;38;[=?,]S$(I4AN,S1"98FRR&OFGQQX#\>7&H02?
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M-@T+DJ([AT,B&-\D8;Y&SC!S7H^P5\M?L_7&H?#/_@I)\2/ NG7EUK/A;7_
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MYO\ V:OK0U\F?LUCS_\ @KS^U%)SF'PIX&AZ<8V:N_\ [-0!]9T444 %%%%
M!G%&:\S^)_AE?'/QO\,Z7<:MXHL+)-%U&^>#2M4GT^*>5+BP6-I6A968J))
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MXLU+P/X;URTO8;O4=9U6RENH,-IX"F*WN9K.:*W<2O(S[/-B@5MX /IF_P#
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M,9O /PZUGPS97%YIR:7);^"AJ.EV+R0RL+A)[QA=W6YS"DNR-U(SPM>HR?\
M!7OX2VO[1D/P]ENKR)+CQ8? L>NO>Z<MFVN!C']C^S?:OM^#.#;B?[+Y!F&W
MS,$,0#ZHHKQ?]J3]NCPG^RKXD\/^']2L]3\0>*_%$%U>:=HFF76GVUS+;6WE
MB:=I+^YMK=$5I8D :4,[. BL0V/+[_\ X+,_#.[T"XUSPSX:^(_CCPS8> [7
MXE:AK6B:7;_8]-T.9[Q'GF^T7$,@EA-A<%[=4:<[2(XY2KA0#ZXHKX;\+_\
M!4[6_B'>_$RX7P_JWAWP[X7^)7A7PGX7U$:+!>2>)+758]+D6(QF_4I-<"]+
M)*ZQ+##<0,Z-*LD0UOV%_P#@KMI/[07P3TW6/B1X;UKX;^(9? 5Y\2+DWEI'
M'I-UHUK=/!<3VLRSS%O(_<>8DA1P)XFVA9%H ^SJ*^8?VJOV^KOX5?LK_"CX
MJ>%]#U*;3?B%XH\,64NG7NCS7&JIINJ3Q*X2TA;S/M?E2#:GS%7."I((K:TW
M_@I/X%UC1G6UT/X@7/BJ'Q!=>%I?"47AZ5]<@U&VM8KR:)XP3$J+:SP3"8R^
M4RS1[79G52 ?0E%?,5M_P5V^#>M:+HM]HEQXT\31ZKI%QK]Q#H_A/4+RYT;3
M[>^ET^XN;N%8O,C6*[MYXF4*S@PN0I4;JZ/]N[]L.;]D;X9> _%%G:0W]EXG
M\<Z%X;NU>SN+J9;2_N1%(\$,/[QYPI^10K98@%3TH ]ZHKPO2O\ @HC\-M7\
M%3:I%)XK_M*WUQ_#,OAP^&;\^(H]32U^V&U.G"(W&_[)BXW!-AA(DW;2#4GB
M+_@HO\)_#W@30O$2ZYJVK:?X@LKC4H8M'T&_U.\M+6UE$-Y/=6UO"\UJEM,W
ME3&=$\J0-&P#J5 ![A17S_XX_P""HGP-^'OBS5-'U#QJ))M#L]/U/5+NPTN\
MO].TNPOHS):W]Q>01/;PVDBC(N'D6(9&6&:]*^-G[1/@W]G;0M/U#Q=K"Z;'
MK%ZFFZ9;0V\U[?:O=NK,MO:6L"//<S%4=O+A1VVHS8VJQ !VU%>'ZM_P4A^"
MNB^"_#&OW'CBV_L_QG=WNG:,D5A=S7E]>68<W5F+5(C.MU$8W5[=XUE5D9=F
MX$4WX9_\%+O@+\8O+;PW\5/!^I6\NBW/B%+K[:(;1["V56NIA/(%B/V<.OGJ
M&W09_>!* /<J*\?MOV^_@W<?#7Q#XQ;XB>&K7POX3O+6PUK4;NX^RPZ7+=21
M1VQF\P*4CF::+RY"/+D6165BO-16W_!0CX+7?@BX\0CXC^&8M,M=5CT*;SK@
MPW4>H21F:.S-LX$_GO"#*L>S<T8+@%!NH ]EHKYO^$7_  4_^%WC3X0WWC;Q
M-XJ\*>#-!_X2S7?#>EWM]K</V?6(M,OY+0WD+G:#$X1)&(RL8D&6Q@GJ_P!J
M_P#;K^&_[(G@G6K[Q1XN\*V>O:?X>O/$=CH-UK5O:WVL0V\3OB%';)#LGEJ^
M"N]@!D\4 >RT5S/P5^(;?%SX/>%?%C6$VE-XHT>SU<V,SAY++[1 DOE,P !9
M-^TG R1TKIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KYA_X+53>3_P $D?VCF]?A]JZ_G:N/ZU]/5\H_
M\%Q))(_^"17[13*5"_\ ""ZB",<\QX_EF@#Z-^$MI_9_PL\-V_7R=*M8\GOB
M%!70UG^%;/\ L_PQIT'7R;6*/\D _I6A0 4444 %%%% !1110 &OX@/^"@TJ
MM^WU\<BNT _$+Q >P_YB=QVK^W^OX>?V\99+K]N?XU2.OEO)X^UYF7^Z?[2N
M,CO_ #H ^]?^#/8R?\/:[[8I9?\ A7^K;R%!VC[38\G/3G XYY]":_J1K^7W
M_@S=M%N?^"K7B!F56\GX:ZHZY&=N;_3%_#[Q_.OZ@J "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ /-?)O[+),__  5A_:QD[0Z/
MX'@'_@)J+_\ L]?61KY+_9&<R?\ !5+]K]CT2#P3$/PTNY;_ -FH ^M****
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MIOA3QQXWTOPBD6EZO>W%QID=QJ\FGSW<A>W4.$2(RJB#+%@IQC<0#Z#\>?\
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M7'B^X\67]K=Z9=+X1NUETBWT=;!8$F%S&L=K9VDBS^:S^<DA*E)/+7!\0_\
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M:?\  'P_\8?%6GW*7]AX@U)X=(&F6$VD8^PRQZG/IGVQ]0"R1221+*85;,:
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MUC"TVIR3OIFK7NG3WT6IW1N]0M+B6WF22>SN9SYDMK*S0.0N8_E& #Q_5O\
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MVT^*SA*./L\<+6D,BMAW**(V+'=(WO\ 0 4444 %%%% !1110 4444 %%%%
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MQ_?>6/ D8;!/EY_M"#&1Z]<<]-WKQ_230 4444 %%%% !1110 4444 %%%%
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M*V<<9 -C0?VSOA3XI^,<GP^TWXA>$[[QE'<W%E_9,.H1O.US;C=<6ZX.&GB
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM?T:T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_#?]I/Q);^#_ (-6/A&Q7]HC2O&MEK6F:986NGOX>3PNUK&R>6P?;;WXN&:
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MU5T#Q)IOBO2XK[2[^RU*QFR([BTG6:*3!(.&4D'!!'![5\C_ /!5,^'5\<?
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M D$$$5)HVNV?B*R^U6%U;WUL7>,2P2B2,LCE'7*DC*NK*1U!4@\@T 6J***
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M+)90<LCN/M)"JI^@/^";G[+/Q<_9V\1>)IO'FJ:=9^%[S1]*T[2/#-MXMO\
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MZ\_;M^(6I:[^SE\/]8\#ZAK6SQ%\0O QCNM*,T4D^FW'B#3C/NV8<0O:M()
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M9!0,=1_:0D^7:L?AY,8^;)_M$_EQ7[\T %%%% !1110 4444 %%%% !1110
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M\(_#S1O&CVM[;?:?M>DW=OJ$,SV:2^="XD7RK>1MXE<&):^V_!OP5UOX'?\
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M6TWQU\;_ !0/%>O6<&F3WM]ILFIW$5MIMA*D,;2 6=G]BMY'*A(A#*[;%#$
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M&2T?;:Q_+_ ._M0!^^__  9 J_\ 9W[2W"^7YWAL$]\[=4_STK]ZJ_!K_@R
MY\/_ +2QR.;KPWQZ?)JG^?PK]Y: "BBB@ HHHH **** "BBB@ HHHH ****
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MO44 8/V_Q%O/_$MT<KVSJ,JD]?\ I@?;\SZ<K)J/B+>VW2M'*_PDZI*,]?\
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M3X:\/ZAKK>+M#76K#3[VZ>?PCJ[6F@_;2JPQW]R+7RK-BS#BX:,A2KD*C*Q
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M:1KMP588X]54_P# 1Z4 :PG'HWY4HG7_ "*PE^%N@HNU=*L5'RCB$#@;,?\
MHM/^^10OPQT9%55LU4*"%VNZ[01CC#>E &\LBM3MP-8;?#[375P5N/G!!VW4
MJ]=V>C]?G;GZ>@PV?X<Z;<,S,+W+'/%].N/O>C_[3?G[# !O;L4F[![5B?\
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M$KP7\1OB%XP\+PZ#,I\%P6-W=ZA>:.(M+O([R%IXVMKAALFVJI\S;]PD9ZT
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M4/[2'P\N=OE^//!<A;IMUNV.?_'ZN0_&WP;<G]WXM\,R=OEU6 _^SUY'<?\
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M$D&Z7]D&9=V"1#XBC)&.OWV[\8_'/:@#Y7UC]FWQY^UQK&@_!'2_#LFCZ'X
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M6AMK=1;V]O,T%O;W*--)*\NJR%E"(BQ^PZ)\,O@_^S-?:?\ #WPCI_AGX7_
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MU5Y7\</V&_@S^TSXJM]<^(OPH^'/CS6K6S&GPW_B#P[::C<PVP=W$*R2HS!
M\DC!0< NQ[F@#XO_ &%O%'Q$_9(\$^$?!EGXQ_8UOO#O]IQWOC#7%^(^H7OB
M#79)9E-_J,DLL/\ I-]*-[!I7"[E2/*QJH7I_!'P-TO0?V"OA7\*V^+'PIN-
M:\%?$#2_%>J7</B&/[+<VUKXE.KR)$3\_F&,  , -P() ^:O5=6_X)G?L9V'
MC*U\/WGP-_9S@\17L7G6VF2^%]*CO+B/D;DA,8=E^5AD CY3Z5:L_P#@D/\
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M^PU\-OV04U6X\':%)_PD'B*3SM;\2ZM>3:MX@UZ3CYKO4+AGN)L;1A7<JO\
M"HKP>]_X-V_V+;\[G^ ?A-.<GR;R^A]OX)QQ[=*;%_P;M?L9VP7R_@?HZ[>
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MM6?MJ+N''_%TY&V_3,!_7- 'VF7 [BEW ]Z^)Y?^"+UT@'V7]KS]M:U8=_\
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MQ N-+\!V'B72/$VN1:I9W8\2):2",:;8VQ1HGB.TA[>3HQ!X/&> #RWX6_\
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M+0UN);R>YFEMDFEN/WCRNS2RM--+(\SEI)'D9F9B<T =S1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH X/]J>^_LS]F/XC71X%OX7U.7/IMM)3_2N
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M/[2/Q"C/S_ 'X@?ZP*-FM:$WRG^+_C^Z#C(Z]>#CD ]GHKQ>7]J+QI;RHK?
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M"W4$5H/B1X#F#C*E->M6W9P1_'[C\Q4]O^T]\-;LKY7Q"\#R;\!0NNVK;LD
M8^?N6 _$4 =U17(P?M > [J(21^-O",D;8PRZQ;D'.W'._OO3_OM?45/#\:_
M!MP@:/Q9X9D5AN#+JD!!& <_?]"#^(H Z>OCWXHL9?\ @NK\($_AA^#WBB0?
M4ZII _I7V"C[UR.E?(/CY6N/^"[7PTQG%O\ !7Q"[?\  M8TH?TH ^OZ***
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MC>/44 +11N%&X4 %%&:,T %%&:,T %%&:"V* "BC=1F@ H(S1FC- #3&"?\
MZ] C^OYT[-&: &^7_O?G2[?K^=+FB@!NS_>_.@)@=6_.G44 )M^OYTFS_>_.
MG44 -\OGJWYT&/CJWYTZB@"-[=9%PPW>QYJ&31+.7&ZUMVVD$9B4X(Z=O85:
MS10!FOX.TF555M+T]@O0&V0XZ>WL/R%4YOA;X9N-WF>'M#?=UW6$1ST_V?8?
MD*WLT4 <P_P4\&RJRMX3\,L&()SI<!R0<C^#M5:X_9\\!WD;+-X)\(RK(NU@
M^C6S!AM*X/R=-K,/HQ'>NPHH X?4/V9OAOJR,MU\/_!%TK*482Z%:N"I#@CE
M.A$D@(_VV]37!_M(?LO?##1_@!X]U"'X<^!HKNV\.ZA,DT6@6JS(RV\T@*L$
M#!@Q9@00=S$]3FO=*\__ &LY5A_97^)CM(T*KX4U0EU'* 6<O(^E '3?#I0O
M@'1 J>6/[/M\*/X?W2\5\M^)IO._X+R>#XSM_<_ K6)%ZYRVO::#_P"@U]4^
M!HQ%X+TE5.Y5LH0#Z_NUKY2U@;_^"_'A_G[GP!U$XSTSXALO\/TH ^PJ***
M"BBB@ HHHH **** /DG_ (+P-M_X(]_M#?\ 8FW8_P#0:_C8) /05_9#_P %
M[I_L_P#P1T_:$8\ ^$;A<^Y>,#^=?QO#ISUH _IS_P"#-Q]0/_!+_P 3)>RV
M,EM#X]O5L$MY87DB@-G9,1*(R65_-:4XEP^TK_#MK]:J_(W_ (,RK;RO^"7W
MC*3_ )[?$>_/W<'BPTX=>_2OURH **** "BBB@ HHHH **** "BBB@ HHHH
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M3F>7(V^C?#C]DGQE\,OVF_!_C"UNO#%]HMG=>/4UJ*26>&ZAM]>U6RU*T>W
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M/]4TC4TUB]?4]4D\0V^KK:+-!]E"6PMWU1DE*RS&0(KKMP4;<U7]C7XJ:?\
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MZL8]$T^'XAVOBK0_MZ:D5O/"L6L>&M$T^+48QY>)7AN-)EC,:LC%+A'#<,M
M'UYI?[2/PZUGPIJ>N6?CWP5=:'HMQ]DU#4(=<MI+2PFR%\J:4/LC?<0-K$')
MZ5R/[0'P+^!OQ:LK'Q]\2-(\":E86%K 4US5IHH[.:T$GG0QS3%A'/;>8WF+
M'*7CW.6"Y8D_)?@7_@F_\0_&<4EUXZ\,Z:)K?6/!5B+*]UK2;^UNM*T;64OY
MBL5AI.GQ>7&BE85G661EDD7$()#_ $K^VS\$->\:ZA\,_$GAOP;H7Q"A^&^M
M3:C+X0U&[BLHK]);&>U2:W>5'A%S;F4%%DV*5>7#JP7(![+%\3O#,NMZ;IB^
M(M"?4M:@%S86HOXC/?1%6<21)NW2*55FW*",*3T!J;6?'VB^']4&GW>J:?#J
MC6SWD=BUP@NIHD!+.D6=S*-IY QP:^5?^">?[!VK?L\_&;Q9XN\5^&O"5C<:
MMH]O'HB:<R7*^&1+K7B'4)]+MI#&C+!!%J5I$&1(TD*-A J@#-^)_P"RMXIN
M?VK?%E]'\&?"/C0>+O$MCXDTSXC7VL0VUWX1AMM.@M_L@3 O/,62WE$20MY#
MC4)/-*+YJ2 'U%\'OCQX7^./PMTCQ=H&IV\FD:OI-KK2B5UCFL[>Y@6XB\],
MDQ-Y; D-C'/I72V_B/3[O2EOHKZSDL6!87"S*T1 ."=^<<$$'GM7YVG_ ()I
M>)_@]^S%X"T?P)\*_ T>MV/POT+P[XLL8K73G_M2\M=3TNYNE"3$6UU>)'%J
M$EO)=%H#.P\PE78-%^RW_P $U?$.H>)]&M?B5\,;&X\$P_%*]\;)H_B :'<0
MVEK-X373HS+9Z=%%8B47GFYBBA8*760R3/F:@#](O/0[?F7YC@>_?C^=!?:,
MU^-O[3GPS\-? 7X4WWP[^)'PQT'QOXNNOA59^&?!.E2:Q8KJ7A:Z_M#5E@2P
MAFE6:7S!/9!6TP3S%K=(941%C)]Z_9Y_87^(_@K]N/3M<U[1M:CU#3?&.M^(
MM0\=VFG:-#!K>FW$EV;6QEO1.VI7">3<6\)M9K=8XC;Y1P(HW8 _1K=30X(_
M^M7YS_\ !5[]F+XD?'']H#5KKPO\-+[7)H_".GQ^&?$FE:?IEQ=VM]!=WD\T
M3WE_= Z=LS RM9VIFF,I'GAE3RN@\1?L"?;?'X\77G@^Z76/%'Q>UJ3Q/JS:
ME(DQ\)7-AJ-L5+>;^ZM'4VV8H]HW%9"GF N #[X+C%*6Q7RC_P $L].\5>,_
M!&O>//'%U_:.L3-;^"=-U"*^^U6NMZ9HAEM5U6$J NV^NVO;H%5&Z.6 $L%4
MU\B?"#X-^*/C-^Q]JFH> ?AK\2M!\4:M\-?$MAX@\17>L>9%XY:[B9=/AM&^
MU.\DAE\J>*4+&UI'"T"M&)#$0#]:0P-<A\,?CQX5^,FL^)K'PSJ@U:;PAJ4F
MCZL\5O*L-M>1EEE@65E$<K1NK(_ELVQU96PP(KX!_:=_91^(GA/]IRZT/P;I
MOB72_#5Q%I%K\.-6T/P]?:ROA(HV;MC.NM6<%FRW+R7$S7=O*MU"ZQEKE4^R
MIR_Q!_94\??!NPCN+/PWXLMO .I>+_B%J6I:3I6B:WK]Q<ZE=^(G?2KU[73=
M2L[E4DTY'$4V]XHRX9E1I!)0!^JNX4;N:_.3Q+^RY\:(O@YXTUIM2^(6M?$W
M1_#7A#2K>_N+J[A:\M(RCZ[]FL[>^$;7LEJT\3M#<><TBH$N%?;('?L\_L_^
M,_BA)X;TK6K[XM1?#+4?B$UV=/6R\0^$VM;:'P_J"R^8UY?S:FEC->&T_=2O
M%$9H\HA60E@#]&=X_P : X(^M?G#%X7\3Z#8^%;#Q]8?M17[6&A0:=X$;PI<
M:I+<VVJQ:UJ",]_*K>29/LHTHB;6-UJT$<I8MNF#S_L60?&C_AM#08_%5_X]
MM]8AU77IO'27VG^(7TB]L!]K6Q2*6Y?^Q43S)+%X6TX>;Y<95D ,Q4 _1?>,
M9S2"13WKX3_:%UGQA!^TIXTA:;XT1?$)O$^C1_"V+1(]6;PH^CF'3_M/VP0#
M^S64W/\ :GVDWV9TAV&(KB$UZ9^RO:>*? G[(GQ!\;WW_"S/$GCC5=2\4ZG'
MIM_J,]Q?,D&I:B-/M+"VNBT%L#;K D2K$J/^[9P_4@'U 9%'>@2+_>%?DS\&
MOB!\6OB-!KFG:-XH^,6F>$?%B> 8K>^BG\0WESIEU-XFCMM9\G4-9M8I?-^Q
M2Q^<L,$5O&I&(P5D:O;OBI\1?BA^QWX7\5:KX?OO'WCC2?!?CRY\&:/IFL7#
MZA<ZE#K&D:;)IC&:;][<^3KUS%;K,S2-'!<7"DL(_E /OG>/6F374<$+222(
MD<8+,S'"J!R23[5\Z?M)>$_&&D_!_P""O@:U\;>-+/4-4\2Z7H/B+Q)H[(NI
M7<$=A<R7$CRM&PC$\ENH:0*"IERI5L$?)'AKX\?&O5_VA]7\)ZQXJGAURSUG
MQ#:ZWX6O;^[N0?#44=XEFZ60T<)'N@%E,E\=282RR%7=_,^SJ ?H5XA^#'A;
MXE?%OP-\2)?,O-8\%V.H0Z'=6]V?LY@U%(!.Q53MD#+;Q%6[<D=:\U\2_P#!
M/?X;:W\<?^$NCU#Q%I?B^Z\1WOC&46>L>6UV]SIECI-W$\14[K5[>RLU90,A
MU!#+N(/P[>_M8>// 6J_#GPEX9\8^+/#=[H3^ -!;0[NZACDDTN[ATJ&^N[7
M31I4IEM5CN9]U[=7L8BGCE4 >3'')UG[-7Q)\??#CX"?#.W^'_B?Q%XV;P'\
M+;GQ!J>F7-K93:CJUU8:S9)>Z,TQME:.7R%O+=(\HRR^6S%BF2 ?34O_  28
M^&]GX9T'2-%UCX@>$['3_#.D^#M9&@:^VGR^,M)TR(Q6=MJ4B)YC[$>13) T
M,K)*\9<QG8/I^"!;:)8XU5(U&%51@*!T 'I7YG?'W]O+XN:7%X5\57GC27X5
M^ /B1H^I^*_#]WJEWHOA\VD?F6L6G:7*^HV%V&G-H/MKVY"W$DM_.D;F.U"+
M]#?'?X\^-O _[+OP-U3Q3XVT[X677BZ[TVU\?^+[2SB>T\.;])N;B1HS?0M#
M;QRWT4%NLMU%M03@%0[*  ?5U!.*^(_V5?CM\2?VA_C9X'T]/BA=W/@S3;?Q
M1?G4[/1M._XN-9V6L6-K873R& K%"T4MRC-:",3%5FC9$9147[:_[7_BSX5_
M&#XCVEK\4=(^&]YX#\.V6J>#/"M]I]G<-\3[R5)W:(></M$R--&EHL5BR2QR
M$NS-O1  ?<&X4M?G#\"O#OCKXB>,OAKH&C?'+5O^$HT[Q)\38]4UNXTO3=1O
MM/CAUB",:>81&L,3YDMYLR1LRQNR($22/R^5\0_\%1?C;>Z=HMW8R:38ZI:>
M!/"?B"PL)/["LM/\;WNIV:37'F-J&H074<#W#&UB%C'*T<B,29F(@H _4BD+
M@5X5^QKXQ\=?$V?XB>)/%GB:QU+1H?&6NZ%H6D6FE1VJZ5:Z=J=U9H7F#,\T
MCB'+$[0.,*#DGY?T+]L+XF^%?A;\%_&OBCQ%X#U3Q-\1?A?)XFEUR[T3[#I_
MA-=0U/PG;;V47'SVELFHS3REI$+_ &=,O$H)H _15G"]:7.:_/75/BU\6/BK
M\:?!7A2U^*?@G4-<\*_&ZZ\-VOB73-"?[%<6/_" S:E)%<6<=Z4DN%ENF',N
MP,L;^6"H6NV_X)J_'SXE?M&?'3QAKWB[QAHUSI'_  B^E1#P[9:6\,5O>Q7^
MK6<MW [7#E$F-DTC1E"?WL2^8?*RX!]J$X%(K;OPKXL_X;2^(VH_$31[ZXUK
MX9_\(+XG\8>*_!Q\-"QN8O$&F#1['695F:Y^U;7DD?34>2,0)Y<<\>UB3O.+
M\,?^"D7B;P]\-/#?AJ?PK8W/C)?#FD^,X;2V^TO%/X2.D)>W=Y'YLCRR31SQ
M3:<,R.QGGM97!5V4 'W=03M%?GGI'_!37XV:C\+FU2#PGX7N-0\2:7H-_H%Q
MJ/AW4]#TVPFU'6],TTVTK33R/?1F/43+'<VXC!^SMNB&^,'W;3_CA\2-:_9K
M_: AU;4/!]I\0/A;+J>D6>L:18W$>FSR+HUKJ-M<M:RRO)&RB]16C$[@F(L&
M^;:H!]+ YHKXEN?VU/B]X$^#&M:Q]C^'OB#_ (4[X!TOQ7XTDO9+JQNO$+S6
M<UW-%9(GF+;$0P?+)+YJRS.R;8E0M7VEI=\NIZ;;W"K(JW$:R!9%VLH8 X([
M'GI0!8KX[T]UF_X+]ZP-IW0?L_V7.>"'\177_P 17V)7QOX;B\S_ (. O%\G
M&(O@!HR_3=XAU/\ ^)_E0!]D4444 %%%% !1110 4444 ?$O_!QLRK_P11^/
MFX9']C6H_'^T+7'ZU_'R&;%?V _\'(4_V?\ X(F?'ML;LZ39)C&?O:G:#^O_
M .JOX_'&6H _J,_X,[K9;?\ X))WC!=OG^/=6<GCY\16BY&#[8YP>.F,$_JM
M7Y7_ /!GS'''_P $C6**JM)XXU=G(.2QVVPR?0X ';@#ZU^J% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\Q_\%I)!'_P28_:*
M)S_R(6JCCWMW%<O^U?\ M*>-/@SX7^&7A7P#K>EZ1KE]X5N-;N1=^'H=3_T2
MSBM4:1Y+K4M/MK>!6G4.QE>0[EVH%5V'1?\ !:^;R/\ @DM^T*?[W@C45_.(
MC^M>C?$VW^%5OX*\.S?$S3_!^HR>#=&E\6V0UK3X;Z;2X=/C@^TW\"NC.AA\
MV'=)&-RF1!U(H ^4?"G_  43^,WQ+\$1_$+3KSX:Z3X5T3PGX"\2:KH4NAW5
MW>ZE)KH#7<,5X+Q5MT1'0Q,89CNSN! ^;V_X,?M=>*/B/^U;??"6YBT2/7/
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MX:^)?'OA56T"[U"/0(GO+$:=-$AMA<&,?\>TOE)A6)1DVC!0@ 'S[>_\%/\
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M%\8H/$UUXH\<6FBR6-O8ZQ/+I[:=;-8G5+&\MT>SM4@B02P+N62[821O(P<
M^S/C)\;/!GP?^&U]XF\3:GIT>DV.GW.KH&=)9+V*VMWNI#;QYS,XBC9P$R<#
M/O3_ !]\8/"OA"/PW:>()X;>U\:2S6MJ;J(?9SLLYKR3SF;Y47R8)"2_&0!W
MK\]_&O\ P2W^(6A?L]^(/#:?"[X?_%/4?'7P]N/#5E'XAUJSC7X=WSWFKWK?
M9W73XXC"S:C;JOV." ))I\(VB,))%]1_MZ?L_:M\5K#X.7%K\,?#_P 7M/\
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MS0OB VF^ 'A^(WC#P;X82?Q%;O!>O<Z?8ZY,]YX=EN3=P3370T<VEIN,L:7
MM1NN%P&H ^X/V5OV'O O[)7@S^Q]!M9-2F_MF7Q =0U*VM%N([R2U2RWP1V\
M,-O:JMI%';K';0Q((EV[?F8MU7@_X5_#_0/B7-J&B^#_  WI?BC1=.&F?VE:
MZ%';7,-E<3O<FVCN!&,Q/,&E:-'*^8=S ,P)^:?^"7]EJGP%^T>#]<\/Z_X1
MM_'EW?:SX9\-W&AP:1;:):V$-A;W3):IJ-^;:.:2>-U03;"PD?RX3)^];^U'
M^S-XF^//[3R6>I:-XFNO &I>,O#DU^UCJ4UG#<6%OI&L_:-[0R(_D_:9;5)%
M& ^]0P92: .\\-?\$Q? >F?M9R?%[4;[4O$.O1W%]<VL%_I^G!H'O(IH)%EN
MX[5+R\B2"XGABBNIY4BCDVJ/E0K[MI/PO\,^']5TV\L/#^BV-]H^F?V+I\]O
M811RV-AF,FTB8*"D&8HCY2D)F-#CY1CYT\'_  Z\;?"'_@G+\2O#.D^']?U;
M7=%NO%EIX3T5]9N+>]GT\:E>C2X(KP2>>H-IY C82"0+L"LIP1\F?";X*>-?
M"MQJK:QX-^-TWP0U+5-'OM6T#0].UG1;R[*V>KV\SV]G)J=SJ7DK=_V8\T8E
MC=]D4@A:)69@#[H\$?L\?LY_"WP+XP\5>'?!'PMT'PZ]XVH>)-1L=(M;>V\_
M1[R2;S)V5  ;.[@ED&>(I8V88;)KM;7Q#\-4M_$RQW'AGR_$#S7FN1$1XU0K
M8VWG22H?]=BS-J&.&'EF,'C K\SOB)\$O&,?[&'B;0]?^'G[1FI:;K'A'Q3;
M?#W1-)GU"76--UJ[UC7Y)6UDVTX,DDUI<:7LDNGE@=5N0&+2XE[S]H7X(^,Y
M_C4?$UUX?^+M[JGAV/Q1I7@^YT<:JT%A/+X1T46F(K5O+2![N"^59)5\KSU*
MDAB@(!]E1?\ !/WX&:I9^#)%^&OA*XM_!-K#!H!:TW):6\<IG@BP3B2..5C)
M&DFY8W8LH5B37M2X7CGGUKX&N[?QQ:_M%V\-]#\<YOB>OC311H=YIZ:O_P (
M6OA/=8&]2X;_ )!F[[*+X3?:1]K-T28OE\@CJ?V(?A3XY^&WQ$^$FKZQJGQ:
MOYO''@O7;[QE#XFU;4+ZTLKY+O37L8C!<,T5E+''/=1HD:QET1]WF%"P /LJ
MRU:UU*>YCM[B">2SE\BX6.0,T$FU7V.!]UMKHV#SA@>A%?(_@A5N/^"\GQ$D
M_BM_@7X<B_[ZUW6F/\A7E/B'P]/\*_C#\9HWN/CQH?A'6OBLFH^-[S1(O$-W
M<MI4WAY&M)=.DA20K;M>ILGDT[][$L<,<ACC4 1?\$S=3\1Z[_P50^+5QXAF
M\2W<-O\ "_08-"NO$MNUOK=SI']O:^;)[N-T2193"%_UJ+,5"-(/,+T ?HW1
M110 4444 %%%% !1110!\,_\'*=Q]F_X(C?'AO[UAIJ<C^]JUDO]:_D#=<MW
M_*OZ\O\ @YJF:'_@AW\="NW)@T=3N]#K>G@_C@\>]?R)@XH _J6_X-"(/)_X
M) VC?\]O&6L/_P"/0C^E?J-7Y?\ _!H@BK_P1[TUE^\WB_6"WN?,C_H!7Z@4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RG_P7
M(E:'_@D5^T$RYR?!]VO!QUVC^M<7_P %&_V99OBIXQT?6M.^'>H^+M;O/@_X
MS\(:?JEA COINH7=K9M:+*[.IB61([Z-),$!YMI*[P:Z[_@NI(J?\$C/CR&.
M%?PRZ'/^U+&O]:]H^,?[47@G]G6;2M/\2WVI+?:A;274-GI>CWFK726L&P37
M<D-I%*\5M$9(P\S@1J74%LD"@#XT_:8_8Y\7_">Y\7Z1\,O#_BK_ (5K)>>%
M=0U;38KB^UPZW%%#J\6H%;8ZA;SW+^8=(DN(TN$:=8B2)R6C?T/X1^#_ (H>
M _\ @F!X^CMM+\8>*/$FHKJESX9\/72W/AG4K&RE(6&T@!O[B[MU51)+%&]X
MLZJZ1 P$*$]-_9]_;9G_ &D/VL_B!X-\/:-I]QX"\":=ITR^)Q)>DZU<WMK!
M>0FU/V46<EM]GG4^8ETTA."(]C!ZZ&?]OSX0V6IZM:W/C*UL8]'CO))+V[L[
MJWTZ\^QL4NTM+MXA;WDD#@K)';22.C AE!&* /@_X0_LJ^-O'?QCT>/6/#7Q
M N/AK9_$CPMXFT)+S2]4\/VNG"+3=<AO;B&SN;^YN[6,3):*ZSO&69HW\O9(
MDDG0:C^S-X^^'?PAN/#/A/2/B=H.EZVWC"6]BTO5-0CN$DO?'FFF&2.59#)%
M*=+6XD25"&$;2R#EW)^R6_X*%_!^#PCJ&L77BJ33ETS5;70[C3M0T>_L]96^
MN4\RVMUTV6!;QY)H\O&%A.]$=ERJ,1R=Q_P58^#NG?$BUTVZ\7:+%X9U7PI9
M^*],\1)<--:7D$U[=VDVX(A,"6SVR":64JD33JLFQAB@#QSXO?LJ>)(_B-KG
M]BZG\;;'2[#XB>$_#FCIIGC/6(X(?#S66GKJ3KB?YT?S+E9;ARTBM'N5T=-U
M>4?M-6WQ8\'^!-/\'V$?QNM6L[3QE;>%-:BN_%6MW%W=)K]\FFVC1Z9<0R><
MMDED8KS5KH0&*5=N[;.3^C?QP_:(\$_LW^&;36/''B+3_#NGZA=BPM7N"S-=
M3F.27RHT0%W8112R$*#A(W8X"DC@;#_@H5\+S-XBN+_Q1HECH6D7UC8Z=JJW
MR7%OXB-WIL&HQO9B+<9E$$X8[-WRJS\*"0 ?*?P7^&?B#Q!\5M<LI;WXS>&_
M$WQ1\4:)J7B?4K>?6+.)=/N/ 31&ZAE<"TAD34XI4*1[7BD@@5D1! M6/B7X
MQ_:2\8?LWW_CKQ)I?BKPG<6>OZ=X7US1M.N-128Z/IXG74M9MTTP/> 7FHE,
M/;1F86$*,FT2,U?7ES^W?\&;27PO')\3/!:MXUM(;_1!_:L9_M"WF<QQ3+@\
M1O(&16; +HR]5(&W\-OVI_AO\8O'&K>&?"OC7PWXAU_0_,^W6-A?I/-;B.3R
MI"0IY"2?(Q&0K<'!XH \"_9#T#XE?%_]@CQE;1>-->TO7]9O]1D\#:QJ<.J)
M=:3"OEFT$IU*.._N(%NDEYN4#R0,%)=<2/Y?XB^-_CCXB^'O#'Q-^,,GQA^#
M_P +_&D]]]LT/PX+X:EX8-G'%#I]O>M8Q-<QQW4SZM<O/$J;MNF0NX"[9/M2
M_P#VEOAWIGQ>@^']UXX\)6_CJZ4-#H$NK0)J4N4W@+ 6WEB@+!0,E?FQCFCP
M+^TW\-_B?X!UCQ9X;\?>#/$'A;P^91JFLZ=K=M<Z?IWE1B67SIT<QQ[(R';<
MPVJ03@4 ?G2E]\4O!&I_$7Q5#?\ Q0;XI:]\,=(C\-OJ"Z@KWVA6OB768Y+R
M>"*WEB75H=%N;*X:+[,TZSW$A6V:1Y(S] ?\$ZOBSXZ^(7P9^*VKZ)K"^,]+
MLY=O@J._U;5-6WWRV9:6W_M#4;&PDN+=IO(((618WDG7S^/+A^AM*_;(^$.N
M?#6^\9V7Q1^'=UX/TNX%K>ZY%XDLVTZSF(4B.2X$GEHY#*0K$$AAZBH?'?[8
M_P +_ GA_3[^Y\>>"9)-=L)=2T.V_P"$DT^&7Q!#&I9C:--,D<H[;]X0$_,R
MC)H _.?XE?%6Z^+7[/MY9V_Q5^,OB#2;7PQ::S\6KG4+>>PG\%ZO;ZOI,JA/
M]%C-G)L_M3S+6(,JPVRN44!7D]D^'&C^./A9XLO?&G@SQAXOUM?%WQ6\1V-G
MX8N1 VBWUM_8U_-;DYC60M+=V=O)]H:8<RE<A&Q7VTGQL\&R_$H^"QXK\-GQ
MDMN+IM _M6#^U%AV[O,-OO\ ,V[>=VW&.<TWX9_'7P3\:!?'P=XP\+^+/[+D
M$-Z=&U>"_P#L;G.$D\IVV,<' ;!X- 'YE?L]_M9?&7XJ>#M6L[7XJ7LEY>V/
MAZS\03PZA_;&J^%]7U'7M*LMR12:)9PZ=((9=2#V5PTK Q1E8U5)'?U/XW_M
M4_&']C3XDZEHLEWXI\=>$?@W=)XNU^]N=/BN-3\8>'M346-A8J\42K]I@U"6
M^D/E*K&+2H"V?.*O]D^-_P!K#X;^ +7QA_:'C;PPMYX!TFXUO7M/BU6"2^TN
MT@C\R266 /YB*%*\L ,NOJ*\N_95_P""H7@']K/Q%J6GZ'I^M:1#H.@0>(=8
MOM3O](-GI"3L?*@G>VOIBLS1@2G:&C53M:19 T8 /F7X[?'/XP?!3PI''XD^
M*WA7P;J-GXPL]+\6W\U_8>%QJ<\GAC3+HPV^J7&G75I&8YY+DHERB/<)'&BS
MH(V5N7TK_@I7\6OB1\3M(&E^(+KPG>WEQX;A\*>%_%=]I.GW/C"SN;>S:[NY
MK&.REN[WSI7OD6;3YDAB\A'VHH?=^F=[\6_"5AX3TW7;CQ+X=AT/6'CCL-0E
MU*%;2]=\F-8I2VQRVTE0I).#CI6!X2_:;^'7Q U#QD+'Q-H4TWPUU<Z#X@DE
MN4C&CWA2)C&[N0%SYJ+G."P9?O*P !XS^WQ\4?B-X2^,W@W1_A[KVK64T/@?
MQ=XPET/3K&UN)O%=WI7]E?8K!FFBD:..62[='\G9(P<A74X8?-GPQ_X*%?$S
MQ%X&U:\'Q4\/7>@M9Z(FO^*);[0M4D\ SWFI0V\UR(K")8;>$0-/B+4=[PO$
MKNTB+*!^A/QP^./A7]GOX9ZUXU\4WL-II7A[2KS59G3$EQ+;V\#7,PA3.Z1O
M+B+;$R3M%0^+OBAX1^&7BW0/#NHQPV-SX^DO&@(M0MO.\-N9YVG?&U<QCJ_W
MCQ0!\>_ C_@HM_9GQ#L1XF^-W@_Q1\-5^(&O>%T\8W$5CIMC?PVFBV%S;P/<
MIM@-P+B2ZS)%L68QOL14 1<#X9_M=_$3XV:#X)OO#_BK1M!U[XEZ;X#6Y\1P
M^'[:>9[>_E\02S,B.H5BT-J@B#@K$SLVP[F5ON'PQ\#/!/@E?$26^E:=]GUK
M5D\07\%T%FA@NDMK>WCD1'RL06*UA"A0 -A(P235'XJ_%WX>? BWN'\1W6EZ
M6^C:!?>*/)%KNE33M,5&N)T55)_<B=< ?-^\.T'YL 'Q-HG_  43^,EI^T!K
M-I:V\?BQ= \4>(_#LG@UYM L[C4K32HK[R;F 1WK:H+R?[)#<[39-$\5R0D2
M*8YJZ_\ 8R^.>H?%?]NS0=3U?XR>!?B7%>_"!=5,?AZ".Q@TB:^U.TPC(MQ*
M&20H$@\S]ZOER LY<8^U+/P!X=D\8'Q3%HND+XAN+86K:M]BC6^>#.1$9MOF
M;.AVDX!'2N<U_P#99^'NOV=Y"?".@6/]H:G;:Q=RZ?9QV4UW=P7L-]'+))$%
M=S]IMXI&R3O*_-F@#SS]K/XU>)O#7QU\"^!=!\=>$/AK;^(]#UK7KK6]>TY;
M[SSI\FGQK:0H]Q"@R+YY9&)9@D&% RSIY+_P3C\1Z_\ M*_M4>+/B]XJU.VF
MO+_X>>%K>PTBVCN([71ENX[BYG, :9D:.=U697,>\H\:ER$RWUQ\3O@YX3^-
M>A1Z7XR\+^'?%VEPSK=1V>MZ;#J%O',N0LBI*K*'&XX8#(R:U[#PUI^DZG<W
MEK96MM=7J1QW$L42H\XC!$88@9;:"0,]!P* /SD^ OB[XU_$+Q;\&+6U^+6G
M2>(+_P 6_%2*XO\ 5=&N+RW^PV6LR6T4#VJ7L8E>-EC\HM(%AB;8%.T$S?#7
M_@JQ\:OBUX>T3Q/H_@O1WTNQMO":ZS9?V?!':ZA-JUCI]W-*M_<:K"]G'_IS
M) #:7 =[?;O=G*1_?7ASX'>#?!WB&ZU;2/"OAW2]4OKRXU"YO+33H8+BXN;A
M8UGF=U4,TDBQ1!W)RPC3).T5R?CW]GGX-^"FTGXA>(/ G@.WN/A+I3OI.MS:
M%;M<>%[&WB=BMM((R\,<<>\A8\  G YH \[_ &M+WXE:A^VA\&=!^''BK0_#
M-UJ'AOQ7>:C_ &W87.I:?-#"^CJCFTAN;;S9EEG159I $268@$G!\G^&?_!2
MKXE?$SX'R_%A;/P#IGAGPO+X7L-9\,R6US+J^L7&JV>E7$DEK<^>J0 G546V
MB>"4SF$ NGF@I]KV>D:'XQO=&\416EC>7<5C(FFZB809HK:Y\IY%C<C<J2>5
M"S+QN\M,CY17&1_L8?"./Q[X:\5+\-? P\2>#+.#3]"U0:+;_:M(MX$*0102
M;,QK&A*H!]P$@8H ^)_B]^U3\6+G]C'XUZ+X-\2:+I.H> ?AWK_BR\U_7;J[
MEU2]-SJ6OV]LEC/',AM6MTTUBDS>:%9H(U10I8>J^'_^"AGCS5_VA[C1=/\
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M[+X;\4:IXI\/R:LNO&>\DU"?5$2*X@,5ZU[<7DQ#.\3_ &I@RDHIH ZWPO\
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M V/V-_V.8?V0+3Q%8V>NS:UINJ1Z-;V:3VWERVD6G:/9Z8 [!B':3[(9255
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M0HQ/V?=JT2@%FE<6Y>1V=RU>;:!_P5W\5:[IFJ>((/ASJ-UX9N-+\1WVE_\
M$CUNS^PG2K2\N(C=:A<6B6$Z7(LRA%K*S1231J/.7?(OJO[37Q9^-7@K]B+1
M/$EE_P (/HGQ.U+Q-X9LYX8)+BZTN""^UVQM9( [1^8Y,-P8V<(/O.RA3M(
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M>=<>/PU+H5\WB&&X\/V=BLENFN1S)(]I<03QDWQCE,=U)(DTCED?]1MHHVT
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MAE3(N/G<4_VB/V:O%UC\!_'OA7Q%X)^,/B_PZ/!WB;P]\,=+T"\O;B32+_\
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M\37FMVNCZ7;ZUJ*+'=W\5I&EU=(OW5DD W.!@8#$@8J&\^&/AO4/'-GXHN-
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M?0['3_\ A$-$/AS1O)4C^S]./V?-JG/^K_T2WX.?]4O/7(!\?ZS^T!^T!/\
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MV_\ "5?LYWV5^_Y$:[3QQ_J%YYSTQQ^%1[_^"Q5B,[?V<[S[O!\L?7NO3O\
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M>(/B?X^M?A19ZA97%EX3L[T6<T.FV3W02TEDM0X;'[N,R22;&R%9OO#XE_\
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M?6T%J-3C61\VME$JH5"D%&#/Z1K'Q\D\)_L4_$;6_P!G3XZ_M#?$[XB0^&-
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M'(S;)Q^E 'A,'_!7']E6X7*_M*? 4<X^;Q[I:_SG%3?\/8OV6?\ HY;]G_\
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M ,L?8?E0!V]M^TK\.KW/D^/O!4NWKLURU;'Y/5Q/CKX(D;"^,O"K'IQJUO\
M_%UYG/\ \$N?V9[H?O/V=_@6_P!? >E_3_GA[FJ<G_!)O]EV565OV<_@?\P
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MR%,8Y'F%QDX[YZG\*B_\$H5A"^7^T?\ M8HPZL?B,[[N>X:$C\ACCZY -?\
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M** #I1CBBB@!-HI0,"BB@ Q0!BBB@ QS2;1Z4M%  !B@C-%%  %Q2;>:6B@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 %%%% !1110 5\A?\$FD7_A)/VL)%.5F^/VOG/NMCI:']5-?7M?'O\
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MS_@BZRS?L;ZM.NUOM7Q+\=R[E/#9\5:H,_I0!]9T444 %%%% !1110 4444
M?AG_ ,'M]PW_  IO]GV,+PVNZPV<=Q;6_P#C7\]+\-\O2OZ$_P#@]OE/_"I?
MV>T]=<UH]?2WM?\ &OY[3U^7[O;% ']N/_!,N%H/^"<?P#61E9_^%>:"25S@
MYTZ ]Z]PKQW_ ()WQB+]@#X&JJA57X?:  !V_P");;U[%0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM_\ M*6)+6TDM_*M;JVGU.16NUG8M! J*BF5RF"O[!OQN^)GPQ\/:?XG\+_
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M30O\T<@SAE;D'(-:6U'7G!5N!WS7Y@C]G#XO>'OVW;=[S2?$"ZW'\7;:_P!
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MMO03+M^.W[/\T8ZF3X6WZD_@-6_K4<OPT_;JMB?)^+W[-%SQP)OASJT?./\
M9U4]^_\ ^JOJ.U^)_AN]\=3^%X?$&AR>)K6 74VD)?Q-?PPG&)&@W>8$.Y?F
M(Q\P]:T]6UNST#2[B^O[JVL;.U0RSSW$HBBA0=69F(  ]3Q0!\@W'@C]O@03
M+'\1/V49F(/EE_!.NQYZXSC43C/XX]Z]I_8'_9@'[&/['G@'X9?:+2[N/"NF
M"&\GM?-^SS74CO-</%YK-((S-)(5#L2%(&>*])_X3O11J>GV1UC2UO-6C\ZQ
M@-W'YMY'C.^)<Y=<<Y4$8K6!R* "BBB@ HHHH **** "BBB@#\#?^#WP?Z9^
MS!_N^+/YZ)7X*J-HQ7[S?\'O=SNU?]F.':?W<7BI\]CEM&&/_'?UK\&0<B@#
M^ZS]GI/+^ G@E<A@N@6 ! QG_1H^U=A7)_ 1=GP.\&KP-NA6(P#D#_1XZZR@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:Z+(N
MUE#+Z&G44 -CB6%0JJJJ.  , 4[%%% !1110 4444 9^@>%-+\*6LL&EZ;8:
M;#//)=21VEND*R32-NDD(4 %V8DECR3R<UH$9%%% %'0O"^F^%XKB/3-/L=-
MCO+F6]G6U@6%9YY6+RRL% W2.Q+,QY8DDDFD\,^%=+\%:-'INC:;8:3I\+.\
M=K96Z6\,;.[.Y"( H+.S,2!RS$GDFK]%  .*RX? ^BV_C"X\11Z1ID?B"\LH
MM-GU-;5!>3VL3R210--C>T2233.J$[5:5R "Q)U** "BBB@!"H:E(R*** &B
M-0<XZ4NQ0V<<TM% #?)7/W13@,"BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HH;D5^?\ \ ?^"R5]KWB3Q=>>/K#0]/\ "/@_P_KGB36KBQTG5K*;
M0+:QU)K*US)>1K;Z@+LQW 1[5\*]NP.0<J ?H!17S!\&O^"M?PH^-F@ZY>:6
MWB"&;09K2RDM)+:&>2]O+F[%G':6LEO-+!<S>=);AO*D9%%W 2PW';E:9_P6
M)^$^EZ,S>(-0OK:XTGP?8^+M<N[;3Y&L=.BNK&*]B0[CYP\R.5 C&/RR[K$9
M!*?+H ^M#TKY7\>_\$^[SXX_M+>.O$/BCQ1K6G^!M:O_  ]?0^'].2P\G6GT
ML),IN)I+9[N';<QQ\6\\>5C/]YB:-G_P6!^'/Q"\.:'=> ;77/&%UJFO:9H5
M\EM9.UMX<>\U:'30;^XB\R.')>9XCEDE\D@, P->W?&'X\WWPV_9Q\4>/-+\
M&^(O$E[X?L;N[A\/J(K&_O3 7!&;AT1%.PON+<QX*AB0I /S?C^"OQX_9L\'
M>._%OQ:3Q]-X+UW6_#MS?>&M#\=ZQ<7%P8$UK[;]DO8KJXN;.%IYM(G,CS0_
M:1:&%DB\Q86](_85_9S_ &G+?]H/X4^.?&7BCQVOA%O#.E&\L+[5_,AM[/\
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M@<G@8]3]:UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@>'K&RN-0NM5N+2VC@EO;E(DFO&5 IE=8D2-68@L1&BH"3M51@"_10 4444
M%%%% !1110 4444 ?ST_\'MTA/QF_9[3;\JZ+KA!]29[+_#]:_#<Q9/WC7[=
M?\'LMP#^T7\!X_EROAO56QCGFZ@']/\ /?\ $-R W\7YT ?WI^'-HT*SVJT:
M^2F%8@LHVC@XXS].*NU':0+;6ZQK]U  /H.*DH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/YR_^#UR_>7]K/X)VV&\N'PC?2@_PDM>@'\?D'YBOQ38J&_BK]I/^#UB7/[9
M/P93<,+X,N6QCD9OF[_A^E?BRQVM@4 ?WO6L'V6W6/<S!!@%B6)^I/7ZU)11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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KOU6_X/$[N6?_ (*SZ9$\DCQP?#[2_+1F)6/-U?$X';)]*_*Y/N#Z4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex3-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1_003.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M_@RP_9O)_P"2E?'/Z_VCI7_R!7[#T4 ?CO\ \05O[-^?^2E?'+;_ -A#2O\
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MX,E/AJ9?E^.GCY4QT.BV><_7/T[5^WE% 'X=_P#$$?\ #_SL_P#"^O&OE[2
MO_"/VF[.>#GS.F.V/QJ-O^#(SP&VW_B_GC+IS_Q3EKR<?]=:_<BB@#\+9_\
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M@70Y_P"_E,_X@E?B:6_Y+GX#[\_V'=__ !=?T744 ?SJC_@R?^* BV_\+R\
M_,02?[#N^/\ Q^J4_P#P9-_%H0-Y?QL^'32 _*ITJ\53QW.3C\J_HWHH _G!
MF_X,G?C!Y_R_&;X9M'C[S:=?*V<>F#W]_P#"G?\ $$_\8(DW1_&CX:&3/0Z=
M? =..<?TK^CSK10!_-Z__!E+\;)1(S?&+X6AE'R 6E_AC[_)Q^M49O\ @RG^
M/*W9$?Q9^$+0[B [+J*OMYP=OD$9/'&>/4U_2A10!_-=8?\ !E9\?6A/VCXK
M?!^.19!M6,ZC("O.22;=<'VP<^HJ.;_@RM_:"+_+\5/@V5W=3)J0.,CM]F/;
M)^H [Y']*M% '\S<W_!EK^THEK(T?Q(^!TDZM\B-J&J*K#YNK?820?N\;3U/
M/'S4[3_@S%_:B>^6&X\;? F&WP29X];U23!QP-IT]3R>/:OZ<** /YH;?_@R
MR_:.DB7SOB;\$XY-ARJ7>IN-W&!DV8XZ\X[=#G S[;_@R[_:?>[59OB!\!8X
M<\NNL:L[ ?[O]G#G_@5?TW44 ?S*0_\ !F1^U$MV4;QU\!O)8/\ O5UK521P
M=N5_LX=3@<$XSGG&"A_X,O\ ]I^2WC=?'WP($DB!I(WUC51Y;<?+D:<<]^>.
M1[YK^FRB@#^96/\ X,P/VGWB=G\?? 9)2<!1K&K,I'?)_LX?RJB__!F;^U)_
MPDK6:^,/@C]A\MI%OVUK45C)W*-A06)<,02PX*X4@L"17]/%% '\R,O_  9=
M_M0".)H_'WP%:1O]:K:SJRA.>Q_LX[N_I3;G_@S'_:D6Y54\<? >1&W9?^V]
M579QGD?V=GDY'&>F?:OZ<,<44 ?S#VW_  9I_M5227BGQ;\"4$!"1LWB#4L7
M.5!W)C3B1@DK\X4Y!QQ@FOK'_!FM^U=I@7R?$WP/U'<&)%OX@U!=F!D ^9IZ
M=>@QGIS@<U_4!10!_,+I_P#P9I_M67UOF7Q7\"[-E.S;+X@U(L0,\_)IS#GZ
M_A3Y_P#@S-_:J3_F</@/)N)!VZ_JG'YZ:*_IWHH _F(B_P"#-?\ :LMD;_BJ
MO@2W.<#Q!J?/_E.I)O\ @SB_:NNE"_\ "2? Y-Q R?$.HD*!SD_\2_\ #BOZ
M>** /YA6_P"#,G]JI2P_X3#X#MM'4:_JG)_\%M5F_P"#-K]J_P"7_BH?@BV4
MW'_BH;_Y3G[I_P! Z]^,CWK^H.B@#^7$_P#!G7^UMM4_VE\'?FSD?\)'=?+_
M .2=59?^#/K]KJ-EVR?">3(R2OB6;Y?;FV'-?U,44 ?RPO\ \&@O[7R#[OPL
M/;'_  DS_P#R/5.?_@T9_;"AF95T_P"&L@'\0\4#!_.(']*_JJQ56X>-9FW=
M?K0!_$/_ ,$[8O,_X* ? F/?Y>[XB^'AOW;=N=3MN<X./K@U_<%7\07_  3?
M"-_P4,^ 9D5FC_X61X<WJJ[F(_M2VR .Y]J_M]H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@L_Q.\,QDCKSJML/0^OH?H:_MUH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KX9_;$M[J3]HWQ$T>@R7B?Z-B80NV_P#T6'N#CCI^%?<U
M?%O[6FH-!^T%X@4:NUKC[/\ N@T0V_Z-%_>.>>O/K0!_++_P2MDV_P#!3S]F
M]CT'Q4\+'_RKVM?VV5_$C_P2T;_C9I^SG\N?^+I^%S@INW?\3>U[=_IWK^VZ
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^G^"?B5)XNNO#-W/<S:;+I L5LX],$K6I:9WW7$TDLD2@/*%52H& #L_B?\
M\%1C\$=&^&\/C7P[X5\':U\5/$%]H^@WVK^+?)\+3V\%O]HAO#JGV7*BZC:,
M0Q- K,[LIP4.?7;_ /:QM?AC^R5K_P 6/BAHMU\.['PE8ZAJ.M6,]PE]):PV
M<LR;XGCP)Q.L2R0[0#()HQ@,<#QOXB_L:>._C!\*K#P+X^\$_!?QY\,;=[BQ
M/@:_O+EX[+3XH+*#3)(-0>T\TWD/DWCO(8X_^/L(K#RPY/AU_P $K[>R_P""
M16K?LM>)/$5U/8ZOHVJZ5#?QRR7W]AQW=W<7-I#$\I22X2R\V&-&DV&5;<96
M,-L4 L:#_P %36T:P^".O_$#X=ZEX%\#_M#7\&F>$M6;5HKVXTZYNX3<:=#J
M]L$06DEU$,*()+I8Y3LD9/OU9^"__!334/CEJ_CB'1?A?JUS:_#SXGS?"S6&
MAUJW:ZDO8&B^T7EK RJ9[6&&59WPRS"-9"(FV&O/M>_8%^+/[2GA+]FOP#\3
MU\(:3X3^ 6M:9XCUK5M(U66[N?&-[I,!AL!! T$?V6*5R)YM[LR$>4F\9EK8
M_P""=W_!,V^_9[_:#^,GQ'\=:7H8\5>+/BIXA\9>&=1TG4Y9VCTC58+>-K*Y
MC:-$#JUN')4,2VW#X#!@#V;]HC]N/3?V>?VIO@O\)[KPYK&L:W\<KC4K;1;N
MTFA6TL6T^!+FZ-UO8.J^0^Y#&LA9E92$^4MYO\,?^"Q7@7XJ:M\8/#MEX/\
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MZ4M% #=B^E'EKZ4ZB@!NQ?2@QJ>HS3J* "BBB@ HHHH **** "BBB@ HHHH
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M/X5^"U^&Z3S? ;Q=HUK:^)K0ZA##9RWV@PQ2^2K!YL!)6P67>%E^8$LP^_\
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MX//6LW6/A9X9\0Z=:V>H>'="OK.QN1>VT%Q812QV\X)(E164A9 23N&#R>:
M/C:?_@HOK7A[XYQ^&K[Q9X5$<GQE@\*K:W=HMO>/X>E\&IK?G>5O$@?[27"R
M%>5 C(9OFKS;X7_\%2?B?X]T6:WL?$W@#4;J^U;X9-INI3:6GEW-EXFO3;7;
M+:Q7GF1H%036Z3.+A5E591N(V_HM-\-O#MSXI_MR30=%DUO,9_M![*)KK,8=
M8_WI7?\ ()) O/ =@.IK+TS]G_P'HD4*6?@KPC9I;M"T*PZ/;QB(PS//$5 3
M@I-))(N/NO([#!8D@'R'^SC^U!\3/BG^U-\']-\2>._#ZZ?/:?$[3-:LM/TQ
M;6W\076@>*+#2+2X5&G=XI6@E+&,.ZJQDP"'79I?'?\ :S\<? W]M;Q_H_\
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M68FAE2*2)7B$^QY%BE)D;[!U']E#X9ZMX'UKPS=> /!T_AWQ'J?]M:KICZ1
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M%VMW/B/7]1:/RSJ%].$0L$R=D<<,4$$:DL5BMXP69@6/?4 !&:*** "BBB@
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M>/O#FK7]OI>O64VAW$EI>6%]8/!>)*D:2;50\2;DD1E9&96W#!SG%?\ 9_\
MCQX=_::^$&A^.O"4UY=>&O$D'VK3KBYLY+1[F'<5$GE2!756P2-R@D8.,&@#
MLJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^$GM[F"]AU 2SK+#/!8G3HY4Q)A7^QD0%@ 61$#%MB8@E_X)X?!V7PP^B_\
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M_%B;QTNDVX\67&D1Z#)J66\U[%)GG2#&=NT2N[CC.6//-=(T2L>GZ4 ?DO\
M%;0/C!\/?^">OPS_ +";]IR^^)NM?".[\37]_<#7]2FT[Q1!INE(MI):0A98
M;PO%-Y4=RZ6W_'T3#=2R[3ZYJFE>)O"'QJ^*M[X7L/C!I5]XE_:!\#:L9H['
M7#:W^A7%CHBW; NK0_91Y=^EPORK $V2^6J1J/T,\M1_"..G%+M'H* /S/\
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MQH\O_!:+X @-&I&NW!RXR,#3[HD?4]![XK^Q2@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7\<__  <FK&/^"W/QZ\MAM_M*PSUZ_P!EV>?US7]C%?QR_P#!
MR2^__@MQ\>_NC_B:6(^7VTNSH L_\&[4+2_\%I?@$,MQK=TW#8X&G79]ORK^
MQ&OX\/\ @W542?\ !:?X";O,^76;LC9'O.?[.N^OH/4]J_L/H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHS10 4444 %%%% !1110 4444
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M)4 9(%?&I\-^,]#^&%QK6H1_M#:IJGBKXQZ[HL]O+/KLUOHNBIJ>LR:9.UE
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M-(\3_$J3P;KNO^%?!^N:?#-X8,\7Q#>8R+KT.V.(*MPI54=$>+[("LY79NH
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MEMX7U3PG?OH'@G4=D<C7>ER2^$)=74RW+RHIN3Y,.(8H)4$,R.\J/(L:^_\
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M(]2TBU;3? LFI^/M'B6V\1SQR:V^DP2V9-W;I&(T4W-O,\3;I'C54.%:1E4
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M:RZA=:EIFG3P6L\UO'#$Y:>2ZEEBAA?8LOV61O-4%-WTU;7'VFTCD 9?,4,
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M\*-*E^+L?C:1;B;7+?2&T.V9Y2T5K;/.L\HC3HK2O'#O8?>%O$/X!7D6D_\
M!,_X7V>F>*M.O-/U#5M'\3:'J7AB'3[R[S;Z#I.H7!N;RRL0BJT,<EP5DW$L
MZ^3 JLJ0QJH!/^PU\7]0\<)XT\,>+M<U[4/BCX*OK6+Q=I^H65M:6^ES75K'
M=0"Q6V:2,V;1R?NV,TLOR,)6\P,!SG_!0+Q-\0OA2GA'7O"_Q&U7P[9^)/&_
MA+PB=,M=)TZ>**&]U=+:\G,EQ;RR-+)#.JK@JD9A4[6);/H'@/\ 8\TGX?7$
MU]:^)?&MQKVIZY::YK.M3:C&M_X@:UMQ;06MTT<2(UJL*JOE*B E2Q)=G9MW
M]H;]G72OVD?#WA[3=8U'6]-A\-^(M.\3VSZ9<)#(]W83K<6X<NCAHQ*BLRX&
M[:!G&00#YJ^)W[7'B[]BG]I_6]/\7:EXT^)W@O1?!-AK-_-9Z=IELVD"[\07
MMN+R95\CS#';?9XV6(,76U=UB5BP/L?@/]O+PY\1OVAF\ Z7HGBBZC_M#5-'
M37HK'S-+^WZ:0MW!(RDO!A_-C225521[>158G9OF_:!_85\,?M':]XNU#6=8
M\56$WC3PS9>%;X:==0Q+#:6M[)>QM$'A?;(9)9%9F+ HV, @&IOA)^Q/I'P5
M^.OB;QEH?B[QY%I7BC4;G6Y_!\FIQOX>M=3N<?:;Z&+RO/5YFWNT9F, DEDD
M6)7;< ##^(7_  40\.?#GX]ZAX#N_"OCBX;2-?\ #_AW4-:M[2V;3+*?7#LT
M]B3.)71YRL+&.-C&S!G"H0YY[5O^"LWP_P##2^.EU30?'.GW?@&RLM4N[ Z;
M%+?W5G=ZD^FQ3K;),98SYJ"3R9UCF,4B,L;$E1UOQ#_8&\/?$CXD^(_$UYXD
M\6V]QXE\2^%O$\]M;RVHMX9_#\Z7%I%'N@9Q#+)&IF!9F89"-'FO,M/_ ."-
MWA?3-%U#3T^)OQ3DLK[28]%5)I=+D:W@CUW^VXSO-CNDE$YDC:28N\D<KEV:
M3;( #N?!/_!2OPCXI^(=OX:U#PSX]\*WC>)[WP9>7&LZ=!%9Z7JUMI\FIBVF
MECG=2);")KE)8O,B"E5=XY"(STG[+G[=_@/]K[7=8T[PC-J3W&D:=8:R#<PH
ML=[I]]YQM;J)D=P _D29BDV3Q_+YD2;UW8^I_P#!/CP_KGC.XUB]\2>);M;O
MXAS_ !%GLY!:>1+<2Z&VAO8G$ ;[+]E=CU\W><^81\M;?['?[)VH?LE>!T\-
MR_$KQQ\0-%TNVATW0+?Q#]DSH6GPAA%;JUO!$T[A2J&:<NY6)!D?,6 &>#_V
MZO!?CKQMIFAZ;;Z_.WB9=3'AF]:S6.R\5R:<Q6\BLY6<#<A5BIF$2S(CR1&2
M-6<>._"W]N?QIX2_X)WZS^TMXXTW4->T?4?#%IXHTWPA8:3!9ZAI>]6,D0G^
MT.LUN0\!#NJRHL<K%7W+&GH'P<_X)_0_!_7?#HA\8:EJ7AOX>WVJZEX(T>ZL
M8O\ BGIM069&#S A[B."*YN(H%;85CF(=I2J,MNX_85CO/\ @G(W[/,_BS4)
MK=?"/_")P^(38Q+<HJQ>7#<- N(V9<(64;0^T_=SP <M\.?^"@]O:_M;^._A
MWXW-[IZCQ3I.@>%A%X?NO+MGO-"M]16VOKI/,MUG>1KA5RZ@[%7&2I?T?X"_
MMX?"W]I?Q_?>&?!GB2/5M8LM,CUQ(A \:WNGO/);+=PLP >+SHI$X.X85L;)
M(W?B]1_X)]W>N>.KCQ!J'CRYN[Z\\>:!X]N2=(CC$UQIFF0:>T.%< ).(%D)
M !1F( (QC5_8A_8QU[]CCP]_PC<WQ(OO&7@[0K8:5X4TRYT:VLY]%T]7S%#<
M7*9>\DBC6.%)6"?(GS*[DO0!=T__ (*.?"35=6UVQM]:UR2X\/:M+X?N WAC
M5(XY]3BN)[>2QMW>W"7%PKV\K&.$N1$HF/[HB0UKC_@IQ\#X?!6D^(X_&GVS
M0]:TNTUF&\L]'OKI+>TNKLV-O+<".%C;^9=J\ 68(_F1R J/+?;QOC?_ ()O
MZQKGPAFTG2?B%:Z5XKTSXFZG\3?#NL2^'$NK.QGOI[MYK&ZLY)B+J$P7]W 6
M$D38D1UVLG/B'[6?[.OQ$T_]H#2&T?P_)XNNM-\'Z=9Q-)X$FG\/>+;^'4KC
M4%@F:QU2TCLHHKKR&5+Z.:.-&+*TA:<2 'T_IW[=/A/PK<>-IO%'B>SN;71_
M%]SX:TZRT?PSJTNI0/;Z9#?3V\T"QR2W$L<9EF::"/R1$T8SN#9N>&_^"@/@
M#Q!XC\?6#R>(;,?#_P 0VWA>9Y/#]\SZO?3V4%ZD=E$L)DNCY4X.V)68JC2
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MY:>!;;3)/A_XTTWQ+-X3U/6+:2X\3001W$<\7F1LULC1M/'<VWF2 //9Q[S
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ME>3^//V+? _Q/^!WCCX=Z]#K&I>&?B)>7-]K:3:K.;F>2>19&V3[O,C52B!
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M+A"V&.EW'H#COR< >M?ULU_)9_P:L$_\/LOAK@?\PK7-QST_XEEQS_*OZTZ
M"BBB@ HHHH **** "BBB@ HHHH **\O^*/[9?P[^#/C;_A'_ !%KEQ9WT<EA
M'>2Q:7=W5GI)OIS!9_;+F*)H+032@JIG=!T/ ()Y_3_^"C'PBU76=>T^W\1:
MM-=>&];_ .$;O57PSJNUM4^VR67V*!OLVVYN!-$Y,4!=A$!,1Y)$A /<**\-
M_P"'D'P8_P"$4T'7%\9>9I'B**:>TNDTB^:..*&\CL9I;C$'^BQQW4J0N\_E
MJC[E)!1MNEX?_;Q^%7BSXNMX#T_Q4LWBL:CJ6CBT;3KN.-K[3XQ+>6HF:(0M
M-'$PD\L/N:,%U#*"P /8*"<"OG_P/^W_ .!M)^!7@GQ-XV\8:&)O%&D:5J/]
MIZ/I>H_V/=G49##:>0\D19?/F!2..4B5C_#S796W[9?PQN]8\16 \9:3#<>%
M;*?4]1,Y:&*.UMYC!<3QR.H2>.&93%(T+.(Y,(Q5B 0#D="^&?B:+_@IEXD\
M<3:#-'X-NOAKIGA^SUC[7;E9+Z'4[^XGA\D.9@/+N("'*!25<9X&[Y!D_P""
M>OQ6TOP/=7GA7P2GAGQUX@\$_$S2M4U%-6LHI+NXU+Q-::EI-K/,DSMMFM4N
MT210XM3<MD(217VC^R/^U6O[3VL?%SR(;,:7\._&S^%K*6"&>.:ZC72=-O6:
M>*9%>.99;V2,IM'^J'K6K+^VY\([;P;_ ,)%)\0_"D.A?\(];^+?[0>_1;?^
MR)Y/*AOMYX\AY!M#],T <A_P3L^%I^&GPGUJX_X5_P")/A?_ ,)-K4FLR>'-
M9U*QNI;*9X84E:.*Q)M+:)WC)$4)^8[I6"O*RCXN^&_[*6L?'G4O'6H>!_#/
MB+2O$5OXO^+&B:MXEO-8:/3M<TFYN-7L[32(AYS':-0>RF52D:P?V?.PVF5?
M-_02U_;)^%NL>!;CQ%8^._#%YH]OJTN@-=0WRL@U&-2[VF%RWFB,&0J%)$8\
MS&SYJX7]CG]JOX>>)/V<?A5K\L'@OX<ZM\8M)M/$T'A^PGBCBDNM1 E)4JD?
MF/+,Y42LJM,_0%CB@#Y1_P"&<?BA\;O%,-SX@^&?Q(T#P[JVH_#6*_MKC6X8
M;B:#3X]3BU:246MX2JJKPI( Q,J/&0'Y"2?#;]G?4-<_;"\70_#VR\=:5K7P
MX^-,$%CKC:S=S:#I/A^/PII/VJQDCDG:.19F<)Y7EF1I)$D#8B+)]\?#[]IS
MX<_%R778_"OCCPGXDD\,Q)-JZZ7JL%V=+1VF5&F\MCY89K:<#=C/DO\ W37@
M?PM_X*(_!*S^)6AW7AEO OAWX?\ Q<\/7WCU_&LEY!H\>KW\5[8::%N(GC0R
M3RI/"1++)YFV%4*8P5 /&O"WP,^)-S\+],9M)^+'@W6T^&MQX?\ B9<VG_$R
MN->\2&^T\6^H6\3S 7ZJ4U661XBADM+L1 [C''%D7/P[^,&N7WP_TOQ;X-^+
M6D:+JFDS6&E3_#6Y6&/P[K4&OW5P-0GCOY))M.M[VT^Q2(DC2K:Q":U8;?E;
M]$7^+7A>/XA1^$F\0Z&OBJ2$W"Z.;Z+[<T8&XL(=V_&WG..G/2JFN_'KP/X8
M\:6_AO4O&'A33_$5Y<0V=OI=SJ]O#>SSS*[0Q)"SAV>14<JH&6",0" : /,?
MV\U\3)X7^'\VDZ;XBUCPI!XTM'\<V.@++)J%QH9MKM"8XH?W\R)>M822Q0Y=
MX(YEVN"8V^?? /P:\63?'+]FR[\0Z'\0-2T_P_X]\;7^B7M]#>2S>'/#\MG>
MIIL.HRD[HBRRPI"+G,FP1H_SJXK[/N_CYX'L1JWVCQAX4A&@QF;4_,U>W7^S
MHQ(8B\V7_=J)%9,O@;@5ZC%:FF?$?P_K5Q9PV>MZ/=2:E9+J=HL-[%(UU:-R
M+B,!OGB.>'&5/K0!X%^V/X&FN_VO/V:?%3:'XKUC2_#.OZQ%=W&CP7EU'ISS
MZ3.(9;F.WR%B+H4\V1=@+A"1YN&^._A%X:^-'[.W[*.D:;X=TWX[^<OP9\%W
MNLZ:NG7]U<65S;ZP(M8MM.ADV+!J"Z6TRBUMS%+($A8 R 2'](-%^.5G=:]X
MF.HC2]+\,Z%!8W%KX@EUJS>UU)+E"^X*LA>%5.U0TH42;P4W#FM'2/B-+J'C
MG6-/ET_[/HFEZ99ZG#KC7]J]M?"<W&]%C60RQ^4L",9)$6-Q,-C,4DV@'G_[
M!UO?#X M--KWQ"URSO\ 5K^\TJ;QIHT^E:I:6<L[/%;>1<_Z4(8=Q2,W7[XH
MJ[LC:3XU_P $W]7T_P"&G[%_@'X,^-O!?BBV\?>$773=;TR\\-7LEM?:C#>M
M-)JZ7;1?9I;>:<"]%RLI :4 D3 QC[$@UZQNM+BOH[RTDL;B/SH[A9E:*1,;
MMP;."N.<@XQ5AKJ%;E83)&)F4N(]PW%1P3CKB@#\P/%_Q;^.$O[-6NZOH.I?
M%Z'XF0_"SQ?)\1-,FL+U_P"Q_%$$:?V:=*C>,QQG[69DMDM 4N+1EE;S"JR&
M[^V/XD\??"/XL>+?"/A7XZ?&1_$%K\+8?%W@:QD@AN)?$7BB?6-0^RVDR"SP
M8I'-O;FU(11;JQ.U8'D3]-&F5752RAGSM!/+8ZXKP'PUXX\'ZW^WEXCNM%\(
M^,-4\2Z?90^!O$/BFWG#:/I,D-NNL06,T#3AE8Q:@'%PD!0O.(C+N^0 'B]A
M\9?B9K/[0UK8MK_B2Q\>V'Q0N=*U;PH;8#16\&-;RM'J$89 OE+ L5PMYN)-
MZ7M2S K /!?'G[3'QC^&'_!//X>^*&^*GQ6UKXD^//AQK/BZ.2\T6VMK2UU>
MRTNV,5D$@TYI6G67S)!92(%G*W<DDJ)"L;?=;_\ !0?P;<PZAJFFZ/XTUOP3
MH^M_\(Y?^+M.TL3:/;WZW7V.1%.\7$T45Q^[EN8(9+>-@^Z4".0IZ#\"OCMI
M/[0/A?5=6T>UU2SAT?7]4\-W,=_$D<@NM.O9;*XV[68,GG0OM8'YEP<#.* /
MAO3_ (Y:KX9^)WQ;U#1?'GB::ZUSXU?#GRK>]MA-;KH6IV>@B18%G@/EV\GF
M:@ T9!0P.<JR.Q6^_;(^)MQI%UJFG^.-0C\66K>.K'QMX0DTZS8> (=/M=0E
MTR_C4P^8H66#3HTDG:2*[341( PV!?T9JC_PD%@OB/\ LO[5;?VHUO\ :OLW
MF+YQA#;?,V_>V[CC/3/% 'RM_P $X_C5XX\>_%#QAH/C#QY<>.([?P5X,\36
MS7-A96LMA=:E:7;7D:?9HHP86:WBD42;W0RL-Y4J!YU^TU^UAXZ^&WQ9^/%O
MX?\ %?AVR;POXH\-6]M83W6E:+J-Y:3:))=W%G:7MW!);F[=HVEC-Z"C+'+$
MKQ;ED3[[Q7C'[5?[9GPH_95>PM?B-=ZE&VKV]QJ"0V'A34O$!6WM=AEGG6QM
MI_)C3>N'F"*3NVDE6P ><_M??%C7-=_X(Q^./B%X=\3^*="UYOA1/XCM-;_L
MZ/3=5AD&F?:?-EMV5UMI&P?,11F+<^QE*JP\]OOVU_%@^(6J)X?\=:;JMUX9
M^(/A;POI'A PV<\GC?P[J<6G"76TDC432$K=WUU'/;$6Z)I<JLK!)G7Z%MOV
M_O@_KWC7P_X47Q0TNI>+X=/-@DNCWJVL[:C;2W-E;RW#0B"&XG@AD=;>9TE(
M ^3YE!];'AK37U.WOS8V?VZUB,,%P8$\Z&,]45L95?8'% 'SK_P4D_:KU3]F
M+2_AO!;>)/#7@+2?&OB*;2-2\6^(;F.TTW1 NG7=S KSRQ2PPM//!'&K2H5(
MW(,.Z$>!ZI^W;\7-$\87$EY\0?AK<6/A.#X6R:K;:7I6ZQU>3Q%JTVG7YBN)
MI%EBMWC5;B!BF[.SEDSN^R/BY\??AWH7CG3_ (>^*#-J>J>(#9@::GA^[U6W
MC6YFEBM7NWBADAMHY9;>54>X:-&:)@#E35WQ]X]^'_A+QKX=T;7AI_\ ;7CS
M51HVFQ-IQN6OKV"TEOEAD=$98V2WADE4S%0 ORG) (!\?7'_  4;\>+XX^*=
M\?%7P_TWPS\,;?QU)XB6[LUO8]"72;EH=(E1;>X%U-YL:RR72;"5:!T7ROEW
MMT/_ (*2>,+?0M<T_5-?\-Q_V5\6[3P/-JZ)97NHV.EW/AN/5TF:WM9WMIKE
M;AC"PA9U6%)6P[1,Q]U^&W_!-KPKX'^+H\6:GKFJ>,&M+Z]U#3K76-+TEI+.
M2[2>*;S+V*TCO;I?*N9XP+F>3<LF7\Q@K#&_:J_9K^$OQ(\9>"?AQ'KGA?X>
M>+-0N)-8TG0U\/Z7=6OBE+6T-LRR65U \-S]GMR-I3$L**-I5"00#RO1/V^_
MC1>>)_!OA36KCX+^%?'W_"&^'O&&JZ?K>I-IMKK:ZAJMS;7EM9_/<.SVMO;H
M,PO)_I5W;AOD=5;W_P#X*#^+O^$+^'OP]N#HOAG78[SXH>#M.,&MVK3QV_GZ
MY:Q"YAVNFRZA9EEA<[@LB*=K5+\"OV:O@WX0_LCP?8Z)X4\1^(OA#>R7UO<7
M>B6?VSPY=WY>X>:W"0I'9F;>[!;98UV\ 8KU[QC\/?#_ ,1;2SM_$&C:1KMO
MI]Y#J-K%J%I'=);74#AX;A%=2%EC<!E<893R"#0!\G_L[_MP?$_QY^T;X3T/
MQ%!X!F\(^,/$?C_P[;1Z7:7,.I6?_"/:I):V]P\DD[QMYL<3I)&(P0VQP^&,
M:;7[?G[=OBC]EGXA:78>&8O!^K6]G;Z3J.MZ==>8^HI:7NN6NE^<6\V*.WAQ
M-+Y;_OY))8]HAV([U[]I'[/G@#P_KNG:MI_@KPA8ZIH]S?7NGWEMH]M%<6,]
M\<WLL4BH&CDN2 9F4@RD?.6KE?%GPF^"?[5WC?6X_$'A7X>_$#Q!X.'_  CF
MJC4M+M=1N-)$JV][]CD\Q&*!E:VGV'U1N] 'A?PZ_;B^,'CGXS6/A]M-^&L.
MG^*M;\?^%]!<1WOGPW>@7DL%I<W.9-IAE$+K+$@# A760;C&GI7[!?[7VN?M
MA^$(-8N]-TO26T72;73/%=E"LGG:-XMC>6/5M+RSG"VC(@^9<GSD.X\BM[XP
M_!CX9_"'X=7WB&SA^&GPIU;23J=SHOB^\T>PBA\,ZGJ:F.>^7S/+0R3RNIE!
M=3.?E8DFM7]C[P_X9\,_!N.W\.>+M(\?2S7UU=ZYXBT][5DUC5II3+>3NML3
M%&[2.?W8_P!6NQ>=N2 >!>)OC5JWP7_;4^.-QI=WILEYK-UX%T:SMM6N+F:-
M'N$OQ*;6TBR\]QY:EA#'Y0?RRSR(B,XR(O\ @JOXT_X5-\.O$DO@+18+KXI>
M!]8OO#VGM?3>9?\ BW3YHUCT$'9@&\C,K0D;G!MY<JRH6/T]\0_V0/AC\6-5
MU2^\1>"M"U:^UJ]TW4;ZXFA_>W-QIQ)LI2P(.Z'<X4@]'8'(8@U/AM\$OA#X
M*;2? _A?P_X-LI/AG>G7M/T6S2%I/#$]ZMXHNDAR6MS,LUZJMA05:4+P"  ?
M+OCW]K_7/VU? 7P)U'PG_94/P[^*'Q"T_1+O;?W5O-K-D?#=[J5U;N\:AXC%
M>PF%E5MV^S='P"ZCI_A/^V+>>)OA7X3\"1Z'=Z?'K7A;Q_:#4CXEN;R_LSX7
MU.'1XY/M#HLTTEP)?.,K.LD;J!ER=X^B9_V2_AW-IW@^S3PO9VEGX!UF3Q%X
M?M[.66UATS4)//\ ,N42-E4NWVFY!W @BXE'1V!Y+2_V&O@AX:^*=Y>6OAO3
M[/Q5K5IK4IC76+E9A;:I+&VJ&"'SL0Q33[)'\E542N7&)'9B 4_@-\9M0\!?
M\$O_  -\0-4D_M_5-*^&.G:[>/J>JQ6/]HSII4<SF>\N&$<.]@2TTK;5W%F.
M :XKX??\%)-<^)>I2>%-.\"6<7Q%;Q->^'+2QU'4;O3-.O!:Z-::NUQYEQ9I
M=(&AO8(U1K;<6+.,QC?7NVN_L_> _$'P!?X/ZAI%G<>!;OP^?#9T*2X<B33!
M +?R0V[S2HBPN[=N'!W9YKS?6O\ @EM\&/$&CWMK<:-XH^U7^NVWB=]5C\9:
MS'J\>IP6:6*W<5\MT+F*5[5!%(\<BF9<^9O/- $W[-_[2'CSXM?M0>/O"OB+
MPOHOAC1?#/A;PUJT5LNI_;-2MKW48[N2Y@G9$\EA$T/EAHW93Y6X$^9A*_Q*
M_;U_X0+QIXD6'PK+J7A#P/XST;P)XCU9+\)=65_JBV#12Q6OED2V\7]J6'FN
M94<>9*51O*'F>D> OV8?!7PQ^)MQXNT#3+C3-8NM!L?#4JPZA<?8VL;(R&U0
MVQD,/F1B5U$NSS-K%=Q7BLW7?V.O ?B/XMW7C.XT_4%U34KVPU34;6'4[B+3
MM4OK H;.\N+57$,MQ#Y4.V1EW?Z/!DGR8]@!D_L@_M1>(/VHK'Q%J6H?#^Z\
M&Z'H^K7VBV-[/K$%Z=7N;'4K_3KS;'& T:))9JRL^/,6<8 VG/ ^./\ @J1H
M/PM^,/BCPSXB\,ZC:VGAW1]=U<7=I?07DTPTF2R22&2)2([>6X^W1-!&\V\H
M5>580Z$^[?!+X'>'OV>? 3>&_#$-]!I1U"^U4I=WTUY(;B\NI;NX<R3,S_//
M-*^,X&[    'C^K_ /!*GX0^)/$NN:AJECXHU*W\0/XD-YI=SXEO7TUX_$&P
MZK"MOY@18YI4\X ?<D.Y2N%"@#?$O[8/Q$T#XV?"?P=??"ZWT1O'/B^_\/:G
M<WFNK-"EK;Z)-J:75DT<>9@Q0QMYBQ%9+>5 &5DF',? W_@HEHFB>!_!\&OV
MOCJ2U\6:-XGU^QUO7Y+*66:32K^47&F-]F"J;A83OA5$(>&!\LSQL6]'\)_L
M!^#_  KI?@57UKXA:UJWP_U\^(]/UO6/%-W?ZK<W!M9;0QW%Q(Q:: V\K1&(
M_*1SC<69FQ_\$[_AO)\+?A[X0O++5-4TGX9>*#XOT-KR^9[B*_,MS*3)( #)
M&QNY@T9^5D;:V5X(!YSXL_;NUCP!\6=6TVP\.^+-:U"\^(?A;P9>Z/J]SIUM
M9^&UU'2X;N26T>'YY@%<AUF<MYV[9^Z"[O4?A+^VQHOQ>\<W'ANU\/\ B;3]
M=TWQ9JGA+4K&]B@2;3Y+"V6Y>]<+*W^B31S6C12#+,+ZW)5=YVTO'W[ OA7Q
M[XV\2>(+C7/&%CJ7B/Q7HOC)Y;._BC^P7NEV\5M"( 83B*2&(+(C[\[W*E&(
M(;^S3\"-6@^/'C_XN>,?"/A[PAXQ\71VV@16>EZN^JJ^G6,DPANY9FBA47%R
MKQ[T5/ECMK5&=S& H!S?[?'[0?BCX=?$?X8^"?#^H:MX1L_'+ZQ-J_B^R@TZ
MX/AZUL=-FG\TQWK%"J2F*63]VY,4+JOS.*AU3_@J'X0^'7@*ZU+Q+X?^(5C-
M9^'-.\46D4NC0-=^)-,N[N&R%Y:00W#GY)KB RP2&.>);B/,664'U#XX?LIZ
M'\??B7X.\1:YJ&L+%X/M]4M!I4#0"QU:+4+;[+<)<AXFD*^5D+Y<D9!8DYXQ
MY7>_\$L]#UGX51^%]2\?^/-3DTK1-/\ #.@:K<M9->Z!IEG?VU\L"'[/LF>5
M[*T2:6=7>1+:/[K[W< ]>U_]HV'PE^S'JGQ/U;PKXST^UT71[C6[S09=/C;7
M(88$9Y(_LZRE6FVH2$60[N,$D@5Q>C_\%"O 7CKQ5JWAO0[C5+S6K.P\/:A
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M#_Z] 'Y_K^UG\4/ASX'^'/Q!T+Q]#\</ ?B[7]6\&0/H^C(L-S<7YW^'[LW
MC7SD@ND_L^:YC*0L+I9&0-#(]7?BE^T)\0/A1X\^,OA_3?&WA.\\4>$=.^'\
M"7FJ/INBW.IRW#7AOK47DD/DQW-W%!)]F%RIA6:Y"+Y8D!7[Q^S1X4;5PHP!
MV%0W.AV=['(DUK;S)-CS%DC#!\=,@]<>_2@#\_?A#_P46\6?%WX\^ _#MO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ2Z-X#\,> KRZOM-T?0]%N=1E'VFXMK2&V>ZD=^-[* 69I&[DDLWJ:Y[X/\
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M6-KKVM?%G6O#G@#]HO1K2TN-VI2.FEOX,MXU9C;H#/;MJCN&D 9!-))DKEJ
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MMX!-Y,R0V]PL@$,F-D3* \A5/^"H6H>//V?/AW\*]5L?$'Q*NOA'X2FM]/\
M'.H^&[]F\60G[38):ZK((XFDOHU1+M9X8URSW*2&.5$95 /JGX-_!.U^%7[-
M_A?X;SWC:U8^'/#EKX;:YDC\AKZ&"V6WWLJGY"RKDA3@$\5\]V'_  2XOE^"
M\/@W4OB+'JB>%OAOJ_PN\%Z@^@>7<:)I>HI;PO+=XN,7MREO9648<>0I,+L4
M+2''FFO?M=>/AX[UOQ-I'Q _MWP_X!^(?PW\ 645K;P#3_%]EKL>C-?:DZJ#
MNDF&N*\)C<+&;)-H*M*']&_;^^//CG2_C+?>"O!OBF\\$_\ ",_"3Q)\2#J$
M$%O(+^_LY;6"R@E\Y''V9&DF>9% 9]T0W* <@'O][\&=2E_98D^'L6KZ/+JG
M_",'P^FI7^B+>V$LGV7R!+-8-)MEA;J\!D 925W#.:\!^'/_  2VU7X86_A2
M'2_B):QV?A.U\6VMAILFBW$]CIT6M16Z6]M9K+>O+!:V9M]PA:20/YKJA@0(
MJ^7R?M]?$GQQ>7GQ(L]3.BZ#X3\6_#KPO)X12VB>'5(O$%MI4^H22EE,WFJ-
M<A$)61%5M/Y#;Y WU!\#_B1XDUO]MSXX^$]4UR75/#_AJQ\.7FC6;VT,?]EF
M[AO//C#HBO(&:!'S(6(S@' H \7T#_@E5XQT+QC\*=0F^*/A_5[/X3MX7;3(
MK_PE+)+;#2],ET^[BM6%\$MX[L2F?(1Y5DPKR31HB*3?\$K_ !5X>^#WP3TO
M1?&7P\U+Q-\)K#5]!O'\2^"&U/0=?TW5)H9+@&R-V)(;A#;6SI()VW%)%8;)
M2!Z1^TU_P4HT7]E[XG^(O#^J?#[XC:Y8>#=%TCQ)XAUW2(+"33]&TS4+N\M%
MNI!)=),ZPR64K2K'&[K'EPK*I(R_&W_!63P/X)M?&NH?\(G\1-9\/^"=+U[5
M)]9TK38+FRO!HEQ]GU"%&\\&.42++Y0F$8F%O+L+$*& -#X5_L/Z]\-OVNX_
MB!:>(-'T?18M-_LN^T_1+>>RC\4PI:6]O:&^LQ)]C2XM3$^RY@B1S$T<.%CC
M&:_[4W[$?BCXT^._B5/H/B#0+7P_\:OAZGP\\4VNJ6DDTVG0QM?".]M"IQ(_
MDZE>(T$FU&80MO 5E?T+Q1^UYIGPX_9@UKXK>,/"_BWP7H^A)-+=Z=K,=I#J
M$427!A69]MPT$<<@VR!I)E"1OND\O:P7P'XJ_P#!2F_^$'QYL_$VI:'X\F^&
M<?PMU3Q;JN@V5AIMU<::+/5H8'U9ITGV20?97DD BGD$D.UXT9LB@#W+]GS]
MG/7O@]^T3\6/$EYJ&E7GAOQL=%&BV\7F?;;)+'3UM'%PS#:Y=EWAEQ@'!!QF
MN>TS]G?X@? W]J;XC>-OA_)X1USPW\6FLM2UK2-=OKFPGTG6+:UCLOMEO-%!
M.)H9K6"V5X&6,J\&Y9<.5$_C;_@I%X'^'7Q<U;P;K&D^,+*_TW2M7UB"XDT^
M-8=5@TNWAN+HVR&7SV79,!'*T2PRLCJDC%:Y6_\ ^"P7POT/P=INN:MI?CK0
M[;4[--96#4=+CMKR+2'>!(]4-NTWFO:NTXVB-7F/E3'RL1L0 9_Q6_8,\:?$
M3Q9\3M-N=8\+7_A3XR7GAO5]9OV\^UU+0+S2Q:)-]B@"RK)'*EE \.Z>-K:9
MY9/WV0M9?@+_ ()^>,O"GQ3\,>(;JW\ 7<6A_$CQUXVG47,WFSP:W%=)9Q@M
M;?ZT?:$6;)VA8@5,G"C[.$JE=P8%?4&OF^\_;AN[3_@HIH?PG>QTU?!7B/2-
M1LM/UH3YN9_$U@MO=W&GA<X\L:?<>8&QDR03KQY9R ?/^C?\$K?B#:? N/PW
MJ%K\.]0U"W\ _#7P@CO>S/#))X:U66]O6):UW"*:.0+&,$DH P48([SP[^Q7
M\1_A;^T._P 1=)TWPCK%O!\0/$VLKX<;4&MX[G3=7L;&W2[60PE(KZ*2R;*%
M2K17EP!)N8AM+1?VROB'/X_T?3YKC0)+6^^/^H_#F;;IS*S:/%I%W>1!#YAQ
M.)($#2$$,-^%7(Q]%?$O]HGP[\*_&^A^&]0_M2[UO7XGNK>STZPEO)H[:.>W
MMY+F18P2D*2W< 9\84.6.%5V4 ^$=<_X)$^,O#_POUC0-+T_P?KUU'\-O"_A
M/1KRZNS$UG=:?XBO-5N(8F:%GAM8H[F*.W(.?]%C!5< C[9_:Y\!7?Q4^"UU
MX>B\$^%?B-I>L7$%OK7AOQ"ZQVFJ:>S_ +]0S(Z"9!B2/<N"\:C<F?,7@OAG
M_P %,? _CSX7-XHNM(\::0SZGK]G#H[:#<W>JRVVBWKV=[??9H$=_LZ.J!G
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M"O$5KK%U\+I-6U[P]\.M.EDM]9U%K5KOPWK\^HW;11-:B.TMIH9CY%O;QK'
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M=\3O"^L>'8-7M?$6@W6DW4CQ0WL.H126TSINWJL@;:678^0#D;6]#7YT1?\
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M](,@ /KK7_\ @FY\"_%&KZYJ&H?#/PO=7GB:35)-3F>!MUV=3"C4 V&X6XV
MR*,*[%F(W,Q/M5C8QZ9I\-M#\L-NBQ1@L6VJHP.3DG@#DDFOE+XJ?M87'AS_
M ()[_![QNWBGQ%X7N/'K^%K275M;L+2ROR;_ ,C<+YCNM=/:3)$LRI(L1=A%
M&[F,5\JW?_!1;XM>)/V7[?Q);?%S3]-USP[\#?&OCG4#9Z?82IJ.L:%JT=K:
M^9YT *QRXDBF14C+?\LQ"V30!]Y^*_V1O@GH_A#P;X3U#P]X;T/2]+\0SZGX
M9LH;Q],9=5N5NFG^SF.1'=YH[B[#Q D/')(K*4R!CZ9^P-\ ],\-ZE\-;?PW
MI2V^I>"+;PC=:-_;-TUT/#UO-.;:)0TYECCBFGG,<R%71W.UP0,?*WQ+_:HM
M_CK^VG\+='\1^/-*TO6/"/QVM=,T_P #'[&C2Z>WAB^GM-67>GVM_M,LSF.9
M)/(9&6((9$=CI_\ !27XTZO\ /VP?B%X\\)>+O#_ (5\1?#_ . R>(76]M8)
MWU2*+79#';2B4@K;2LDL3,H#AID\MT.X. ?2VO\ _!+;X(^)O!\VB77A.^\F
M;Q(?%_VV#Q'JL&J1:L;9+5[R.^2Y%U')) BQR%)0)1G>&+$GTGXB_LV^#/BE
M\+=.\&ZMHT?]@Z+-9W.EQ6EQ+9S:3-:,KVLUM-"R2P21,B[71@0 1D@D'XW_
M .&]O&'CG]O^7X6^&?BAX76U\37OBSPW9PSV-FC:#J&G6-G-:&&!G:ZN&61[
M@S/.5CF5OW,:HJRMFZ?_ ,%._'FJ_LQ^$_&NI7NC^#H9M;T?X9>,M0UJ,:;:
M^&O$R-=1ZY<>?)#*D<"7$5O:0221O")IB74JA! /KZ/]B_X?QR^#9ET[4UF\
M!:_<^*-*F&M7HE;4[B.:.>ZN6\W-U(Z7$Z'S_,&V5@ !@"O^T+^R5X/_ &J-
M3MSK&K^)]/O-,6.VNQH'B"XTUKNV\Y+C[-<+"X!5FC!#8$B MY;IN)/AG[0W
MQ[^(T'_!&_Q1XYF\?>$;'QY9Z;,K^*_!,QN-)9$U$V_VBWDN(T^];C+2*H57
M+M$VT(QX'P[\7O$WP7_;K^(VJ>%]8\%WWAGQA\5O!_AC78Y-.+WNL&\\,6?^
ME17$4RQQL,PR+^ZD#@.,@%2 #ZHE_8$^&;?$;0O$<.BS6)\/KIIM]*M+J2#2
M99=,1TTV:6V4[))+59&$1/3;$2&,,)CJ_%'_ ()_^!OC#I<%KK][XQO/+&MV
MLUPVOW!N+S3M8N!/J&ERR$EC92%8D6(8,201+&R!:\W_ ."9?[:GC;]LK2=.
M\4:UJGPNN?#/BGPI9Z[:Z9H>HO+K?AZ_::2.ZLKJ$YQ'$/*CW/MD$\=PI&-H
M3E]9_P""AOCW1?B1X^\)ZI-X1\.^)+77K&R\(VE]H5Q=6NO6%SK_ /9\5S9W
M=O>M'?326Y2-K>3[&UM>;O-(M_G ![]XG_89\!^+/C-;>-+BVOH;B*YTS4)]
M*MYQ%I5_>Z;O&G7<T ',UL),(0P4^7 75S!"8^F\!?L\Z5\/_CGXX^(%KJ6M
M76L?$"#3[?4+>YEC:T@2R25(!"BQADXFDW99MQ;V%?#<W_!4OXS^(?@1IOB3
M2;/X6Z?JJ_"KQ[X[OTOM/N[JWEO/#.LVEBJ1""^PL%S#+(2!)*8W*L))57:_
M>:[_ ,%&?B-\/_B)JG@WQ!I?@F37-4\4^&M%\/7EE')%;6<6L:;>7HBNDN;N
M(3SQO830(RS0"9KB#"(<H0#T+XE_L2ZE\>_VV_'FO>*+C5K+X9>(/ _AOP])
M96.H0+'XCDL-2U:\G@NHS$TR0XO8%S%)&9%\U&)4XJUK?_!+WPKK.@?%30(?
M'7Q.T_PC\5HM3%UX;M]7B;2M"FU-F?4)[&*2%C&\\CS.5D:2.-[B5HT0L31\
M6?VK?B1\(O\ @G)<?$S4?#/A'_A9FDI;V][HL>J-<:2UV=1CLI$6>$NR@[F;
M;ES&WR,6*DGA/$_[27C7X#?%/XF:AXF\)^$]4\>>'_!G@YKV^T&YU![.2/4=
M=U6SW&WD8DQ6L:-<$1)YTO[Q-QQ'M /J_P ?>!;GQK\.;K08?$&J:/=7$"0C
M5;6*WDN$*LIW%)8WA;?MPR-&59688P:^=[7_ ()%^ M)^&FL>$],\0>*-'T/
M7/ >N> )K6Q2RA@M[35]0EO[R6",6^V%_,FD2-% ABB*JL8V@CR?XJ_'WXN>
M.OBI\'?$%IH>BZ-XBTGQ)X\TS3!>7=[:Z/K^GV6FW"6VHRP#+M%.T,<B)EMJ
MN&25U^9^@^'/_!0CXH>/;CQUXPT_PM::YX;M/AIX%\8:1X:TNRGO-6LI-:-U
M)>NP1BUYY$,3R>3"BO*MND<8WNQ(!V_B'_@E)H_B#XCZQXD/Q)\>QR:Q<:].
MUJ8]/EBA_MC3$L;I5=[8RE5,44L09R(_+6-<1Y0[NO?\$[L>+/AWKGA?XG>.
M/!.K>#?"MOX'U:YTN.S<^*]&A*.D$ZS0NL,RR*[I<6XCDC\^8*0&XU;#]L?^
MU?V&[3XM:7=>#-<DU!(4MIH=0N+72YI);Y;->981<K(&< VOE&X,P-NJM(5S
MXAJ7_!5OQ]=^$II=!^&.@W^KZ;HWC[4[U-4URYTJ,?\ "*ZG;V3E4:UDE472
MSJRJX#1LVUL@%B ?8W@3PAK7A6UUN/5/%%WXBDU#4[F\L'N;."$:3;28\JS4
M1*OF)$!@/)F1LG<Q[>$^+/\ @FGIOB/X8?#^SM_$JZ7\0/ ?BN#QE_PF]MH=
ML-2U;4 \YN7G7IBZ6XF24 X*2,%"C;M\U_:)_;%\2?&Z[\,Q^#;*XT'P]X5^
M*?@#2=>ODUV:TU!Y-2;3+][;R(5V36QM=2M(I%ED <SRG;^Y7S/7?VO?VQ?&
MWP%^)MCX4\%?#?3_ ![J=]X-UGQ@OVKQ)_9"B/3)[&.6W_X]Y<O(MZOEGH7
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M'K_05OKK5I-)A,$%Q;7GG(MHTT0CCG4PRAEB'E^4QWCD_ /_  4_U#3OV?\
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MGK5KX)L=7T/2O!?B[1=0URY>SVZ7<WZ6 LU*2-Y[!O(N 3&C!-_/WCCZCHH
M_,30_P!C[XWZQ\"=<TJ\^$VH:/J+?#'X8>$X[<^(M*FEU&_T+6;F74FW+<;
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M*NJ:DOB;4F\%ZSXTM_B)<^%GMHVB77(5C*S1W'^L6!IX8;EH<',T>0P1GC8
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M /IS]I[]KF']F3X;> O%6IV>EQZ5XJ\2:3H>J7%_JBV4&B07I(>[:1D*L(B
M2K% 5W'<,8/3Q_M;?"X^#?#OB+_A8_@,^'_%QQH6J#Q!:?8]9.]8_P#1YO,V
M2_O&5/D)^9E7J0#Q/[7'[._B?XW?"#X>6FBKX;;7O OBS0/%<MAJ,\JV-_\
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MOID7GR F.&:,6\?F85HUC!PHH ^M[O6+6PO+6WFN;>&XOF9+>)Y KSLJEF"
MG+$*"Q S@ GI4Y?!K\N;?X+_ !HO[CX=:YIW@_Q OC;PO#X^T7PMXCABU2WL
M+B^NM+M3I6J7.GZA,\VFP33PS(8+DO$DD1P=DT0/8:M8?$C2/!6N^)/AUX>^
M-7_"#MH'A23Q;X9U.ZU#_A(KB[AU56UR/3S<R"9[S^R_,29[5PEQ(L8AD:;<
MR@'W?<_&7P_9_&BR^'\EY(OBK4=&N/$%O:&VEV2V4$\,$L@EV^7E9+B$%-V[
M]X#C'-+X%^,/A_XD>*/%VCZ/?-<ZAX%U1-&UN)K>2+['=O:6]XL>74!\V]U
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M80W5]IT<QF6PE= S0[R!N*9VDX&2#70T %%%% !1110 4444 %%%% !1110
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M^)5U235/"?AC4/[7NK?4-0:ZTN";[9<6P7[//+N4[Y(A&FQVR4V+@C KS/\
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M-]V\5_LB_ /X87VN>--<\)^!?#TNL2:A'J>M7I2S5VUF2.*]4S.P"&[E\L,
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M+-X]T:1M)U76=9.OS^%';4+*]OKRYNX+[3I(KZ*6PO;22Y;RYUE<,-P="&(
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MK'PTU#2+358]+UBZTV2S@U..S65;2=H2BSB!V*L%<A_+9B#C!)ZT >(_$/\
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M+VX@C:,R)&3Z'9Z-\:=4^),;:(OQ TGXGZ;\0]=:ZFU66\D\+WOA)[&].F*
MQ-CM7?I";8\W2W4,[-E3<,0#ZS^)5[\-_@M8:*VO:5H>FV_B+5]-\.V.W2!(
MD]Y(XAL83Y<;! &PB,^$3( (R 8=6C^%[?%^^^']YHOAN3Q5XXTF7Q%?Z?)H
MRM_;=G:SP0//.YC\N;RY;F!=KL7'F*0,<U\&ZK9>/OBW^RCX=O/!>A_&[2_B
M3<>+O!":E:?$C3]2O=)TG7K*\DFO;M87Q-]F60(UQ<P,+-D6#R3N61:J_&&+
MQG\6O#&E>*-&T7X_^#?%WAWX">-Y&+#4FUFU\4#4-)DAM#=)'_I.^YMI9(8H
ML13Q1KMB\G]V #]-/$G@S1_&/AZ72=8TK3=6TF;:LEE>6R3V\@4AE!C8%3AE
M4C(X(![5YG9^-/@G<_"K5/BO#'X)_P"$6\,7^IZY?>(?[,C5;"\LS+:W]V7\
MO>LT?D2Q/(/F(C(R17SQJ7C[XH>)/C[?)!=?$#3_ !OI_P 2O#W]D6*6=XOA
MS4?!<\%C]O=T*_9-PB.IN[R8N(KN&-%(0Q(_SU\:O$/BRS_9&\?>#=5TOXKZ
M+X5\7>'_ (LW^@_V%H>II/JGB"?Q%JDUI!=+!"9522QF62!)E$$ZS2D[V2/
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MTEJSG]\\[I(7(CEB.=PRE>::-^VU\5;RS\#^&=2^-%[X-DOFUW3_  OXHO\
MP9_;!\<ZGI_BR_L$L[B.W2-'F.FVMGMBC\HW'V^65#F-"H!^F'A#X6^&_ &M
MZ]J6BZ+IVEZAXJO5U'6)[:$1R:G<K$D*S3$??D$4<:;CSMC4= *\JT?]D#X
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M",>6O@JV5GV\J3?)@9QWP>,CIT../Z0* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK#^(NO:SX<\*377A_18_$.K>9%'!8R7@LXY-\J(SO*5?8B*
MS.<(S$(0%)(% &Y17R%JG_!2KQ99_L[?$CXD+\*[&31/AOK'B'0[O9XK!:6X
MT>^:SE<AK4;896BG*,-S J@=5W$I[_)^U3\,(? UWXH;XC^ U\,V%_+I=UJY
M\06@L+:[BR9+9Y_,\M9DVMNC)#+@Y Q0!WU%<=\9_BY%\*O@+XJ\=6MJFN6_
MAO0;O7H[>&Y6-=02"W><(DN&4;PN V".0>E9WP__ &H/!'CKX6MXJ'BGPQ:Z
M?8Q0?VPS:Q;M'H=Q+%'(+:YDW;8I0)4^5]I.Y3CD4 >A45YEJ7[3.FP?'[X?
M^"K"WCU:S^(GAS6/$EEK=I>1R6J0Z?)IJ8&,^8)1J*,KJ=H$9SU%9WPV_;*\
M*_$KXG?$?0[:]TJ/1_AS!IEQ<Z^NK6\VGW*WD4K_ 'U;$9C,15MY_B4]#0!Z
M]16+'\2?#LKV*KKVC,VJ)')9 7T1^UK("8VC^;YPX5BI7.0IQTJUX=\5Z7XO
MT[[9I.I6.J6F]H_/M+A)X]R\,NY21D=QVH T**S_ /A*M-?5;BP74+%KZTC$
MT]N)T,L$9Z.RYRJ\CDC'->;_ +,?[5UC^U3IEWK.A>'];M?"+P176C^(+E[<
MV>OPO-<1$Q".5I(V3[.'*2HA\NX@/4NJ 'K%%>5^'?VP/!_C;XM^&?"N@W3:
MY#XJT36-=LM=L989=)\O2[ZRL;F(R[]QD,U]$%VH48(YW_=#>G?;H1<^3YD?
MG;/,V;ANVYQNQUQGO0!-136F5#RP'X^O H\Y2>O^>E #J*Y_XG^/O^%9>![_
M %S^Q]>U[^ST#_8-&LS=W]SEU7$4607(W9(S]T$]JT]+\16.M75]!9WEK=3Z
M7<?9;V."59&M)O+23RY #\K^7)&^TX.V13C##(!=HKC=,^.&BZO\=M9^'<8O
ME\2:%HEEXAN0]LRV[6EW/=01%)>C-YEG,&4<KA2?O"NPWT .HJKI6LVFNZ9!
M>V-U;WEG=1B6&>"0212H1D,K*2"#Z@UD_%?XG:1\%OACX@\8>()IK?0/"VFW
M&K:E-#;R7#PVT$;2RN(XPSN516.U02<<"@#H**IZ#KEOXDT2SU"U8R6M] EQ
M"Q4J61U#*<'D9!'!JT9%!^E #J*X3PS^TCX1\9_%_4/ ^EZA-?:]I<5Q+<&*
MRG:S4V[P)<1"ZV>09HFNK</$'WKYHRO#8T?%GQH\-^"/&WA?P[J6IQV^L^,M
M0FTK1[81/(;NZALY;Z2(LJE8V%M#++^\*Y5.,D@4 =512!LUE>./'>B?#/PI
M?:]XCUC2_#^B:;'YMWJ.I726MI:)D#=)+(0B#) R2.M &M17&_##]H3P3\9=
M1O['PQXHT?6-2TJ&"YOK"&X O;*&??Y$LL#8DCCE\M]CLH5PC%2<&NRS0 44
M9H)Q0 44UI M9MOXXT6[\977AV+5],D\06-E#J5SI:W2&\M[69Y8XIWASO6*
M1X)U5R K-#( 258  U**-W%&: "BL^[\6:78>(;/2+C4K&#5M2CEFM+*2X1;
MBZ2+;YKQQD[G5-Z;B 0N]<XR*OL^Q<T +163HOC[0_$<]G'I^LZ5?2:A!)=6
MJV]W'*US#&ZI)*@4G<BNZ*S#(#,H."16MF@ HHS2;QC- "T5%;7L-X&,,D<@
M1BC%6#88'!!]P>H[5+0 44;J,T %%&:* "BD+A12"0$T .HHI"X!H 6BDW_+
MFD,JA<T .HH!W"D9MHYH 6BC.:,T %%&>:* "BBB@ HHHH **** "BBB@ HH
MS10 4444 %%%% !1110 4444 %%%% !1110 4444 5=:8KH]V5)5A"Y!';Y3
M7\&$TKW,\DDC>=)([,SG/SDDDG\:_O-\0/Y>@WS=-MO(<X_V37\%T$N^%6;+
M%AN)QUS0!^T__!DW:J_[6/QLGVMNC\(V29W\#=>$G([_ '1SVP?6OZ-J_G,_
MX,FXF/[5?QO<,OEKX3L5*^80S$WC8.W'.,'G(QD<'=D?T9T %%%% !1110 4
M444 %%%% !112-TH 7-%?)W[.WQ3^*O[:OP)USXG>%?%^G^$?MVNZI8^$?#\
M^EPW%D+;3=0N+'&IRLKSF>YDMI69H&1;=7C41RM$YEZF_P#^"D/A+3Y=-N&\
M-^-9-$\077B"PT+6$@LFLM<N]&ANY[BWA_TKS5:2*POGA::...1;5R74-&7
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M3:IH/A?Q5HOB#Q)ID-BUV[17%GH]T8I+@SNB1K((#%/)"6W1I(&Y3#D P_\
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MY&!E?#/QMT?QE\;?%W@"&VU./6?!NGZ;J5^\]OLM9H;_ .TB'RGS\^#:3!N
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ME2)8V#M(D"RD'/,G17$;!NXU;_@I;\'O#WP\O/$U_P")-0L;#3[W5+"ZMI]
MU&/4K633%\R^\RR,'VE5AC*N6,>"LD6TL9$#9'[0G[ MU\;_ (D>-M<M?',^
MA6?CC3O#-K=:>=(CNEAN-#U=]1@G60R*VV19'A>,\ $,&!&*Y/X@_P#!,G7M
M7\=W'C#PO\3H?#OBR7Q?K&O+/>>$[?5K"33=4M[*&YTV6VEE&]E;3[25+@.A
M#Q8*,K,I /J[PMXGT_QMX9T_6=)O+?4=)U:VCO;*[@??%=02('CD1AP596!!
M[@U?JGX=TG^P="L[(W$UT;.!(#-*J+)-M4+N8(JJ"<9(50O/  XJY0 4444
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M+8201)Y]PR@YD8 R2L,\ECUKX_C_ &)_&_PN\?:A/HOPMN9_A@/$WA#7-?\
M"T&HV,B^,((= OK'43Y!G*33P7LFF7$HG*FY-AE6F;;N^O;']O[X,7WAEM87
MXD>%8=+6ZL+,7-Q=_9XY'OU+V)3S N]+E06AD7*2@$HS &MKP/\ M<_#+XE?
MV%_8/CCPUJW_  D^FW>KZ4+6]1S?VEI*(;J:,9R5AE(CD[HQ"M@G% 'QG_PQ
MM\9O#?AW08?!FEWVAWFG^$_BG;>%_M&IVJ_\())J]W9S:!I[.)F;]VD+*I@$
ML=L$6/.R.,MQ:?LZ?$>&/QWXD\$_L_\ C3P%X<U"3P+<ZMX.2_T9=1\46]BN
MI)JEO"))I[:5T:XM9&2XVK=>0X+;IBU?H]KGQJ\)^&_A[9^+-0U_2[7P[J$<
M,UIJ$DX$-TDRAHC&?XMZG("Y)'/2LD?M4?#5EW+X\\(,O]F66M KJL)W6-[+
MY-G=#YN89Y2(XY!\KM\JDGB@#XQ\!?L,WUOXUAOM3\)?&:'P_P"%_A1<1>&U
MN?%<,FM:=JK:GJ<\=O&T$ZVZWT=M<Q)#E6@A!CB$C"+-?0?_  31\"^+/AU\
M"M8TGQ9I,%C-;Z[*--ODTV329=?LQ;6RK>S:>\THLIV=98WC1@DC0M.$3S]H
MZWP3^W7\)?'GPZU3Q99^./#]MX<T?6K[P]=7]]=+:0I>6<LL4Z9D(X4P2L&Z
M%(R_W>:Z2?\ :<^'-IX[L_"LGCSP9'XGU"6*"UT@ZU;"^N9)83/&B0[][,\(
M,B@#YD^89'- 'RWI/PQ^(VH_M(6]Q<:;XOT_QKI/Q3O=3O\ Q(996T75_!,D
M,X@M5;=Y.U8I+6W%H )ENH&N-F"\S>H_\$K_ (5S?"']D*UTF[\.:SX4O&\2
M>(;U].U-9$GBCGUJ]G@;:[-M5[>2)@ ?XN0&W"O2_@W^U+X ^/OP:F^(7A;Q
M1I&I>"[=[U9=8^T+':Q+:32PSR.[$!8U,+MN; V8;H<UN0?&;PA>>8L/BKPW
M(T-K:WSA-3A;9;W3;;:8_-Q',W$;_=<\*30!\ ^'OV6]3O/$6@>'9O!?Q&TN
MRM_VG_$7B+6KJW:]MD;3+K2M>,%[%<QR;UMG^V6<;2Q,HWS&,D,D@7'^#FG_
M !D^U_"'P]XX_P"&A]/BF\,Z$OA[5=*L[BZFL]4L-6O3J-OK,LK;8?/L_P"S
ME::]5TF@68*PEX?[:_96_;'\-?M+?!NW\3R7&E>'=0CM9KW5-%N-5@FNM%@C
MN)X1+/MQLC;R'8.RA< \G!-=%=?M2?#F#Q'X-TE?&GAFXU#XB37,'AN*WU"*
M?^VFMD9[CR2A(<1A"&(. Q5?O, 0#C?^"A?BKQ3X(_9\AU;PSI?B?6;6QU_2
MI?$EGX:CEDUJ;1/MD?V_[(D/[YY!"6)6']ZT8D$9#E37R#^U)XW\=>&_ _A=
M/ANO[2R1V&E2>(]%OM2TO5[^ZN8_^$E@D>TEM88TD69;(D(-29G6S"1_9Y97
MF9/T/@^+7A2Z\.WFL1^)O#\FDZ;.;6[OEU&%K:UE&W,<DF[:KC<ORD@_,/45
MIW?B+3K.[L[::_LX;C4RPM(WF57NB%W'RP3E\+R=N<#F@#\]_P!G7Q3XR\:_
MM81ZEI_C3XO:Q#IGQ6\<:5XKTZ[>^D\/V?AB&*_^SI'N01+-#??8%A,+-<#=
M+%_JXV6/SWP)XC^('@CP7IWC;Q19_'Z[\:ZI^S;X5CNIK6'5A>-J::A<)JXD
MW03);72++ \Q$)N51GDAC>517Z3?"'X8^#_A#I6I6OA.&&TM?$FMWNO72K?2
M70NK^[E:XN95,CL07<LY1"%&3A0*Z2P\0Z=JNEQWUK?6=Q93!F2XBF5XGVYR
M0P.#C:V<'C!]* /S[_9B\2>-/'7[0/P;7Q.OC?5V\*_$CXA6T-_J7A_4[5+7
M3OLDIL5>2Z4OY)AN(UADGD8N%V!BRE5]E_X*L?$_Q5\*_AAX?U+PKJ>I136]
MQ>W=YHEA=W.FWOB:&.PGQ:V=_%!,L-\DKQ3P0S)Y5T\'E/\ *QQ]6XR* N*
M/SJB^(6I_"_]I?XG6=]K?Q"T/PGX@^,>GIXPU2YN+S=H6CW7A"TEL1%.P9+6
MWFU1!;R2V[ 0CY"T0(9:VD_M3_$&QU#PMX6\>>/OB!X3MM:L=5;P!XGTOPP+
MRZ\;7%MX@N8+,747V=D>>724L9%B(B29;R>; **8OT> Q1B@#\_OV3_C[?\
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M"TH(<?1B?L\> X_B)#XO7P;X77Q5!''#'K TN$7RI&C1Q@3;=_R([HO/RJ[
M8!(,?@?]F[X?_#/6M,U+PYX)\)Z!?Z+I\VDV%QIVE06LEE9S3BXFMXRB@I%)
M,!*R# 9_F()YH \Q_:O_ &K_ !%^S]\=OAMHJZ?9V/@OQ=J-GIE]XBN],N=1
MMH+ZYO[>VM[&0V\@:Q:=9)1#<S1O \XCB8QE@3\V?LU?MC>-/V:?AC/I.H:;
MX,D\,7&G?$OQ)H5WJFNW<,MO+HWBAXECO;AXY-L$JZA$JB-'>,08_>%PJ?<O
MC/\ 9[\$?$7QYI?BC7?"NAZMX@T7RA8W]U:+)/;>5,+B+#'_ )YS*LJ9SLD
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MJ^ H?!_A#3?%FE>.O!^EZA.VLSW6G:EHVMRW"B2W?[,KQW DL[B%E>-@JJ)
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MZ;X3UDZIX@^&,4DTD)LM8UN$_P!JQ3M'\\,/G+<"-XQN6/6+D#/EQA:NF_\
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M-6U:UT'2[F^O;B&TL[.)IYYY7"1PQJ"S,Q/ 4 $DGH!7+7G[0?@?3OA!IOQ
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MF^I7#ND:PP"1E,LC/)&H5,DM(@ RPSX1^VM\;KSX=_&_P/X>UCQU??"OX?\
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MASXL>%_C#_9]_I6HZ#<6L/AJ:3P9K4\B.$NG348"!+-!<6UPL=Q&803&X<@
M_1[--$H+8Y_*OS[\+_\ !6#Q_P"(/#7PEU(:5X+N[G7[KPCIWBW3[""X8:?)
MK'B*?0Y+D3R3(L$1:$2VT0%S-+MF$BQQH)FS_@K:^7^T3\&Y(Y&B!_:"^***
MBR, 8A:Z\I3&<%=R*V#P"HP.!0!^BU!.*^9_VZOVK/B-\!?'NCZ%X!TGP7J#
M:EX(\4>+)IM>>Y'V=]'%@RQJL)&]9OMFPY*E.'RVWRWX_2?^"D7BGQ=IK>+-
M+\-Z"O@_0_%OA3P;K>ERS2MK#2Z]:Z3*MY!)E8UCMY-:M!Y31LTR0S,KQDHI
M /LC=Q0#FO#/^"?/Q-\<?%WX$:EK?CW4]"U75E\9>)M*@DTJP>RACM;#6[VP
MA38TDA)"VW7.<8!W,"[?)G[%/[=WCSX,_LR>%=#UK1]!U"VN? ^I>)-"UO6O
M%5U/=7+V_B"'3F2^>2%Y&9_[0@>)(FEFD,9B&Z1TH _2:BOB_P .?\%4[_0]
M)\%:]XZ\-:;X9\#ZQXT\3^ ]<U^6:X@_LN]TMKS[%-]FDC\Q8[];*0".0B2*
M9HH?WK2@KTWA']NSXD>+/BEI_A>V^#LMY-H5]H6D^/7@UZUC?PQ<ZE8QW;R1
MK*R^?#:K<6P<@[IB\PB#-#LD /JJBOG7_@H)^W)J7[$?@Y=:LO"ECXKM[?0-
M8\07<#:M);W9BTZ."1XH+>&WN)I"Z2N3.R);P",>=*GF1[N?UG_@HOX@TK]I
M*X\&K\.+.3PS;>.M+\"OKQ\2XN#-J.AIJMO,+,6I^56=(9%,PVAUD0R?,B@'
MU517SS^Q_P#MP:A^U3<6=C+X/M_#NN:4-7M?&FG?VS]LD\(W]EJ36,%JQ\A/
M.^U"*YF1_P!V/+A# .'4UR_[2'_!276OV?/C7XLT$?"S4->\(^ %\.W?B/Q%
M;Z[!&]E9ZQ<3VRS16C1EYG@EA+/&&7,>Y@VX"-@#ZNHKY,T[_@IAK5TTC7/P
MIU:QAU3QKJ?@'PXXU/[<VM:AIUQJB7DC0VEO-/#;QPZ7+)YGENQ+A=F!O.EX
M0_X*07GCGQCX?T6Q^$OQ%6^F715\46<VFS+>^$9-4W[%FC6(QLMOM62=FECV
MQ2*Z"0AD4 ^H:*^+&_X*\:A/HDU]9_!/Q??(^A^*]<LA'KNEK]IC\-ZJNGZB
MI+2C9DR1O$3DN6*D(%WUTDW_  55TO\ X67)IMO\./'-UX1L]<\-Z%?^+4DL
M18V$NOV]G)ISM 9Q=,IFO[>&3;$?+9@QRF6 !]7[J*^0?AQ^VMXD^*VJ_#^X
MUGPYXB\,:EJGQ(\8^$['2-&U"RN;/6#HL.K1+%>R3 .JR&PED4P[,311[F\L
MG=T7AK_@J/X,\5_![POXRM=%\1_8_%&FVEREFT<7VO3[V[U+^S;?3;A=Y"7+
M7*72L 66/[#<;B-JA@#Z<HS7G/P0_:)@^.'P4F\96_AWQ/HIM9+VWFTG5;,6
MM\LMK+)$X0.PCD1S'NBE#^7(CHP8 G'B_P ,O^"A5A\<M;^$OB0:3\3/A_X7
M\;Z9J>N:=!JNF:;);^)-/BTNUO5N9?+FFN851;D^6J*CN\,@==NS> ?5V<45
M\2?&S_@J!_PE?P776/ >G^+-!U.SO?AWKK276GVEVNI:!XD\0VEE$(T625C+
M<6WVY0@59(WB&2N4+]KHW_!4'2O$'Q$\,Z3#X#\9:?IE_9^*[KQ!>WWV,2^%
MW\.W4-I?0R00SR-<,))T8-;&561D,?F%F\L ^IJ*\]_9P_:'T_\ ::^&T'BO
M1M+UC3])O=DED]Z;:1=0A>&.:.>"6WFFADC99 N5D)5T=&"LI%>1_"O_ (*9
M:=\0OA__ &I=?#[QY9:]/J/B.*V\,VD5IJ.J2:?HFH/8W>H$0SF,(LH1?+WF
M5Y'V0K/PS 'T]17G.N_M5>!="_9HC^+S:];W7@"XTB'6[;5;=&>.ZM9U1H70
M$ _/YB !L8+#=MP<<_XE_;I\%^ K"ZD\26OBKP_<:?X7UCQC=6MYHLWG0Z;I
M-Q';W\H\L.LAC:6)E$;-YT<BO%YBG- 'LV:*^4O!W_!2?P_H'[4?COP/XVU*
M:SL?^$OT3P[X/N[;PWJ'V5CJ>D6%U;P7MXJ/;Q3S75S+'$)6B+?NTVYP6])\
M+_M[?#3QEX636M-U'7KK3;NXMK73)8_#>HL=>>X\[R?L"B#=>*5MIW)@#B..
M%Y'V(-U 'LE .:^=]8_X*7_"G5K673=#\3:M_;UYX3'BVS:7P5KEQ!:6$L%[
M)!=W*I;*8X\Z?=*T;O')OA,7RRNBGS_X:_\ !4C1?#WQVNO#/Q$\1:''X?U/
MP[X)OO#>N:7X=U2*WO[O7!=QDW3$2K90RSP0+!]J,.#,(V9GYH ^R**\U\(_
MM>_#OQU\8I_ .E^(DG\5PK?,EH]G<0QW?V*9+>]%O.\:PW#6\TB1RK"[F-CA
M@I!KS/\ :5_;:U+X:?M*VOP[T.3P_I#:3X6E\=^(-6\3:??KI::7;W<$4\27
M,*B.&3R&N9!,QD57BBC,9\S*@'TM17BWB#_@H?\ !OP?X/O-<UKQQ9Z'8:=J
MT>A78U2SN;&YM;Z2W-U%!);RQ+,CR0#S$W(!(O*[J[KQ+\>/"7@_X?Z5XHU+
M6K>UT/77M(M-N"CLVH27146T4,:J9)))"ZA452QSTH Z^BOFG]K_ /X*9^!/
MV=OV1M3^)GA_7?#7BBXN/#<WB/PW9M?/'!K<,;1IN\R-',:&26./<R@>8ZID
M$\=!^T'^V]H_P=^-OPV\ Z;+HVM>(/&OB^W\-ZC:-?-'-I$4MA=W@E 5&5Y=
MMO&?)9D;RYA)R,!@#W:BOG?PG_P4-\(ZE::7I.H:_P""/^$RUSP]KGBJPAT[
M69+G0I=.TV[:W:9M2:!$11^[\TE#Y1$W#+&&;O/"W[4GA-])\$VWB/Q-X-T?
MQ5XTTVRO+?3+;6TNHIY;E,HMM,RQF:-W$B0R%$,VP[5SE0 >F45Y[HG[6GPO
M\2^*+[0]/^(G@F^UK2[:[O+RP@UNV>XM(;27R;J61 ^Y$AE!21B $;@XKF?'
MO[:OAW2HOA[=^$[C1_'.E^./&L'@R6\TS5HVCTN66VGN#(VT/O91"H,1*'$R
MMG'4 ]HHKC_B)\2[CP3XM\%Z7;VNFWG_  E6L/ITQN-6BLI;6%;.YN#-#$XW
M7;AX8T,,?S!96D)VQMF*+]I#X>R^%;K75\=>#6T2QN_[/N=1&MVQM+>YP#Y#
MR[]BR<CY"=W/2@#M:*Q;7XD>'[V\6WAUO1Y;AKQM/6-+V-G:Y6/S6@ #9\T1
M_.4^\%YQCFFCXE>'FM-4N%US1VM]$E,&HRB^BV:?(,928[L1MR.&P>: -RBH
MK2]AO[6.:"1)H9D$D<D;!ED4C(((X((YR*X3XV?M'>'?@E\,H_%%Y<+J%K?:
ME8Z)IT=G+&YU&_O;R*RM;='+!%+W$R(79@J LS$!2: /0**Y_P"%GC.^^('@
M6QU;4O#VK>%+^YWB?2=3:%KJS=)&0AFA>2-@=NY61R&5E/&<5T% !1110 44
M44 %%%% !1110 4444 %%%% '!_M42"']F'XCNQ557POJ9)/0?Z)+UK^%NU3
M_18_O?<'3Z5_<[^US<1VG[*'Q.EF_P!3'X2U5WXS\HLY2?TK^&&U5_LL>.FP
M=_:@#]W_ /@R'&/%?[1G][[+H&/INOZ_H"K\#?\ @R#CC9_VDY/+_>9\.*'V
M#@8U/(W=>>./:OWRH **** "BBB@ HHHH **** "@G%%5=:AN)](NDM3;BZ:
M)Q"9U+1;\';O P2N<9 ()&: /+M4_;L^$>G:EX6M(_'WAG4)_&6OIX9TH6&H
M170N+][9KM8248A<P+Y@+$ AX\9+J#UN@?'[P/XIU76['3?&'A>^O/#,3SZO
M!;ZM!))I<:.Z,\ZJY,:JT4JEFP T;@G*D#Y'^#?_  3Z^*7PTT[P##'JF@VV
M@^!_'EGKFD^&;KQ'=ZLGA;23H%_I5U;6>HR6JW$RQ27QEMH)U(2. 1^=&K@1
M8]S_ ,$Q?B5XK^!?A/PC=:MX/T'6_A)\.KSP'X<UVVFGNH_%9^U:9+;3:E;>
M7'Y,#II$1N(!)-N>]G"L%CS, ?2OB;]M7PW9?$OX<Z3HMYH?B30?'UYJ]C-K
MMAK,,EMHTFG64EW*)-NY6/[IT;YU\LCFO7=!\06/BG0[34]-O+74-.OX5N+:
MZMI5EAN(V&5='4E64@@@@D$&OB+]I']@[XL?M3:%X1U:2U^'GPO\76.JZUXD
MU"/PYJ$UY:KJ$NE):62W3O:Q#58)98D6[CECA62V;R<.%WM]D_#&YUZZ^'VC
M/XHT[2=(\1&SC_M*RTNZ:ZL;6<*-ZP2O'&SQY^Z613C&0#0!"?C/X1_M?6-/
M_P"$H\.G4/#]NUUJEJ-2A,^FPK]Z29-VZ-%[LP %<'^Q_P#M4R?M=^!(_&%C
MX=_LWP;K5G::IX;U5-6M[T:O:W"NP61(_FMKF+:OFPMN5?,0+(YWA/#O@A^Q
M1\0/ E_X#@UC2_#LD_P=D\3M8Z];:D?M/CR+4A.L,-U&8\P>:TT=Q<L[2_Z1
M:QE?,#%D]Y_83^$.M? +]B_X6>!?$=MI]KK_ (-\*Z=HFHI8W!N+9I[:W2%W
MCDV(65BA8$J#\W(S0!B^)/\ @H!\/].\=^']&TG6-/\ $$.I>,[WP/J^H6E_
M +7PS?VFDWFIS"Z9F& L=F\9VYVN<,1M;'KTOCG187TM7U;3%.N8.F@W<8_M
M#Y0W[GG]Y\I!^7/!%?&FE?L/^,=0^-=@NN>"_"M]X-TOXZ:O\19;B;4(I_[3
ML+S0;^VBD-JT6!+'=7<2%&8DB)G!^Z#Y=\)O^"=_Q,\(V'P@T/Q5\+]'\7^'
MX?!?ASPYJ"Q>/I],'P\O]&U.ZO([J-;?8;V%O/@=%B*OYEE&AVHV] #]&_'7
MC?1_AGX*U?Q)K^HVNDZ%H-G+J&HWUS)Y<-G;PH7DE=NRJJDD^@KR[X=_ME6_
MC[4O!._X>_$S0]'^(4CIH>KZGI]K':R?Z-+=1M/''</<6HEAB8H+B&,[BJ,%
M<A:O_MR_LUM^V#^QU\3/A:FIC1IO'WAV]T6&^:,R+:231,J2,HY90VTL!@D9
M'%<%\0Y?C1^TA^R%XP\%2>!?^%8>/O$'@_4=+_M637[:XTNTU*2UDBB:TDMG
M:X:(RLK!Y(H'2/)QO 4@'T98ZS9:G;--;7=K<0QN8B\4JNJN#@J2#C<#QCJ#
M4L=S#)C;)&VX9&&SG@'^1'YBOSZ^(W["/B#XN7NH:I#\&[7PGX;\3:Y\._M_
M@AM0TTPVPT;4YI]4U'$,QM]KV,L5H C>;/%;A73;M4<KX+_8MTWQU^UC\0K?
MX;^!;'PSJ'PS^-^B7%AXOL+BUA@\+Z;:>%-$^T:?' )!,1/&3 T*Q^5(+A6=
MOW0  /TQ1T=F56#,AVL WW3C./R/ZTIVCC],]:_,75_V$?BCXG_94U;2;7X8
MW7AWQO#\%M<\!>)1#K5CCXC>(9I+3[%J*SBX!?9)#>W0NKHQ2H=0*\L9 O2?
M&_\ 8O\ %?A?]J;P7?\ PS^#>I:3X5\+Z[X1U>'5-+U2P\YX?[5O9M8BE-U=
M>;"RK=.TD=JJBY$\C232X6( 'W*/C+I6KZ[X=M='L]2\26'B"]OK$ZOI,:76
MFZ5-9>8)1=2AOW9\Z%X5P&/FKM..M=CL7_ZV:_-/P;^Q#\6/!/PG\$^&_ 7@
MN7X;>(O#-S\4K>VU:">R@T^PN=3^V'1K\I!,6>%FFM]O[LR1^5AD10";7C;]
MDSQWXT\%7T_A/X<^,_ FC:Q;_#^UUOPO_:T<-U=:G8>);:ZU6_26*XY>+3EF
MCENE</>93F0QJ: /TB*J3T%1WEC!J,!CN(HIHF()210RD@@C@\<$ CW%>#_\
M$\?A7K'P5^'?COP[J.CZIH6EVOQ!\03^'K2]N/.5=*EO#+;M"?,<K"V]F120
M5!QM7H/'/%GPM\<:K_P4KUK4O$6B?&"XT&WUC3M=\'Z[X?O+#_A'8=+BTI+>
M^TV^5P;I=UR;R0VZ*PN#<6[#:8]\8!]O[1CWZ5F:#X+T?PN]X=-TO3=/^WR&
M:Z^RVR0_:9#U>3:!N8^IR:_.*P^%GQB^%7@;QY86?A'XM>)K*6STGQ'X31=;
MG&H6OA2;7%NM5\)/(\JLNL16_G!96D9Y(9H8$F#0;WU/B]X#\::@_P /=+TO
MPC^TUH?PM\4:9K$6EQZ)J4=QXD\*:U<ZG#=6L]]Y\S&U@$1E2W9Y'2TCC\N4
M()"B@'Z!6/PW\/:+I%G8V>AZ/:V6GS_:K6WALHHXK:;)/F(H4!7R2=P /)YK
M@_V=OV8O"?P>\1^,_%>C77]N:I\0M>N_$$^K7$5I)<6ZW/DAK2":&)&-JI@C
M*JY=LC)9B!CXX^"O@/Q%\4?VPM1NM+U3XO75YI/QG\36/B*:[UK5&\-#PN=)
M>.6T56D%IDWTEKY*Q 3Q2J[+LBC8#Z3_ ."2O@^]^'7_  3<^#'A[5-!\1>&
MM:\/^%+#2]6T[6X)H;RWOH($AN<K*2P3SDDVD?(RX9,HRD@'L%M\"?!-EH6J
M:;#X/\*PZ;KES]KU*T32;=;?49]P;S9D";9'W '<P)R <U)K/P4\'^(_%<>O
M:AX4\,ZAKD2P*FHW.EP37:""3S8 )64N!')\Z<_*QR,'FOS^\5:]\5KC]JCQ
M=)"OQX\&Z!JUA\0]$O;VWT/5-<&FS*^GG1]3BP?LLJ^2EQ+:16D:LJ%H7DDN
M&.[ZL_X)PZKXKU7]GJX_X3#1[[2=4M]<OX(Y9[S4;B#585D 2\MDU'-Y;V\O
M+)!.SM%\RJ[IL8@'J.D? WP3H-S!-8>$?"]E-:B[6"2#2K>-H1=OYET%*H-H
MF?+28_UC<MD\U1\,_LS?#?P7X5M]"T?P'X-TO1+._BU6WL+71K:&V@NXMHBN
M%C5 JRQA$".!N4(H!  KXU^,7A[XDZU^UIXLN;/6OC=8:2OQD\,Z3I\6G3ZC
M'I0T&YT&V74S&JKY7V5K@SAYQG[/,H:-X7.6\I^*WQ;^,7@[X"Z-8:;=?'^/
MQ%X9M_$%[I.I2Z5JUZU];V7B_P JTBGBBA\RYNGTE8COO'9&@<L(KAW=D /T
M[\-?#/PWX,T&\TO2-#T?2]-U*:>YN[2TM(X8+F6=BTTCHH"LTC,2S$$L22<D
MFO.];^%/P/\ V;-"\(PW7A;P'X3TZ'Q'9V_AI$TJ&%8=9N%%E:_9PJ?)<-&1
M"K+@B/Y<A1BO,OA%9?$BP_;E\8^!-2U3Q-J'P_T_4+?XE:3K-Q?.66TOK66R
M3P](I(<1Q7L%W=J&&!&(4()!)U?^"K=G-=?LX^&&CN-<T^WL_B+X1N[[4=)L
MS=7&DVL6MVDDUUM$<@18D4L9&0JF-QX% '=WG[ WP.U*336G^$?PUF;1K:*T
ML/,\.VC?8H(KLWL<<?R?*J73-,H' D9F'+'/2Z1^S-\//#^NZ;JECX)\*V>I
M:-JE]K5A=0Z9%'-9W]\K+>W4;!05FG5W$CC#2!VW$Y.?SN\1_%WXS^#=)\/^
M%=8^)7Q2\->$]?F\36WP_P#'3^"+WQ#JNIW<6I0#1TOH;4Q,SFV\XP"\40WD
M89I1O\LG]'OBYXGNO!/P,\3ZU'_:AOM(T*ZO5&FZ>MY?>9';NX\BV)*RRY7Y
M8B<,V%S@YH 9X_\ @)X)^*NN0ZEXD\+Z#KFH6^F7FBQ7%[:)-+'8WBJMW;!F
M&1%,J()$Z.%&<XK$TK]CSX6Z'XWTOQ'8^!_#MGK.BVUK9V=Q;VHC\J.UC,5K
ME%PC-!&2D3LI:)20A4'%?GM\/OV__&FD_#/7-0U;QSKS^$;?QEX.D>ZNA.UY
M-H=_I EO5AU"2U@16DN(9I"RA4C83012(6C([7X)_&[XQ?%+Q+X+M=+^-UUX
MXU#3_AAJOC"XM=!MM*FL/$NK6NKK';Z=+<K9KC,>;:=8A&Y9&93'R6 /O;X8
M?!3PG\%H-;C\*:'IV@Q^)-7NM?U-;./8MY?W+^9<7##^_(_S$CJ23U)KR7XA
M?L0_LZ^ ?A1';>*/"?@_1/!^CZ._AR*34;QK6UL+*YOXKHP+*\@\O=>I!(K!
M@XECB*D,J8^0?!O_  4 \86G[-FF^/I?C=-KGA'5M>T#3/&>K2^"Y+&;X922
M6=T=0CG<QN(_,ODLH'1H3]A$[,6"NA3F?VN_VGO$6O\ P"U+P'\1?B]!>7$/
MACPEJ^BW=OX=M]*MOBGYWB$K>W:0SQ/)B**&T4I;-'M\TSX$<L:Q@'Z)Z'^Q
M/\*_#OP_U+PO9^"=(A\/ZQXBA\67E@P=X9]5BN8;M+LAF/SBX@BDXP"RDD'<
MV3Q-^Q1\+_%_[1>G_%K4?"=G/\0--MXK6/5EN)XO.2(LT/GPHXAN&B9V,;S(
M[1$Y0KQ78_%^[U33_A'XIN-#DGCUJ#2;N33WAB6:1;A87,15&#*S!PN%*D$\
M$$<5^<5A_P %3_%OQ%\ V>I^&?BSX76%_#/PCO=0U,Z?9W%GI=[KNN36.M,_
MW%V"$1%E+CR7W -&<A0#[N_:,_8R^&_[6;69\?:!)K?V'2]2T2/R]4N['?8Z
M@D2WEM)]GEC\V*7R(&*ON >"-UPR*PSIOV$_AO9WK:E8Z#<)K$6N6'BBWFGU
MO49(_P"U=/L%L+*X=?M'SJELB1M&?DD"@N&8!J^5OAE^V+\2M4\51^ ?%7Q<
MTG0])%WXT30_B>^CV$$?BS^RGT[[-$4=?L@\H7E\)O*5#,-+D,9CVS%<SP__
M ,% OC-X@\5>']:U;Q)X=\+6JCX4G6/"+:/'NCN?$TK6^I6C7$C^;'Y882Q\
M!U:,!MR[@0#["_9*^ NM?"/2/$GB+QK)X5O?B=\1=0BUGQ=>^&[&6STR>YBM
M(+*!+>.9Y)O+CMK:%<R.S,YD;Y0P1?/=*_9!T'X[?M?_ !$^)&L:OI/B?P?K
M%OX<TZSTW2M=GD@>\T:>\N2-0@CQ#(8[BYB=$+-S'AQ@[:](_;OUVZ\+_L3?
M%[5+'69/#UUIG@S6+R/4D"[K%H[*9Q(-W&5VYR>E?$'@_P"/WCC]E7P-XNU#
MP7JW@&Y\._#'X.>$O'.L6$/A-6U#Q%/=V&I68FN+BVF0B&WCT^SFW+$[M# T
M:E00] 'V!XZ_X)R_#/X@_![_ (0F[M_$MKI\/BR?QS87UEXAO+75='UJ>XFN
M);VTO$D$T#M)<W.0C!=MQ(N K$4MI_P3L^'.D_&?P_X\T_\ X2[2]<T33K72
M[I+3Q/?QVOB6*U>22U;5(O-Q?R0R32R+)/N<M*Y<N#BO$/B1^V5\4OAUXUOO
M">E^+/!?B2%?&?@73-.\4RZ0'@O+77KB:&[LFCBG2-KB%(4N$='R8KN$%#_K
M&N?LE_ME?%3QE\?_  #X<\8:]X$U[1_%=SX_T.7^R]'DT^Z%QX:UM=/BO%+7
M,H83QEFDB"@1L4PS<E@#UFP_X)M?#G2M(M;*&3Q0D-GHGB;P^A.L2%FM?$%V
MMYJ88D99WG1'5CS'M 7 &*XGX*?\$Y?^$<^//C[5O$&I75UX#N=8\,ZAX;T>
MWUIIHKQM%TNTMH)=1B,"XFBN[43*(Y620QPM(,QA1UW_  4!^(GBSP'?_!&U
M\+^*K7PG%XG^)VF:/J\LUJLPO;(VUY<-;99UV>8]O&"0<D?+T)!\-\'?M2^/
M-%?0O#O@.W^%GA6;QCXZ^)MI?SOH5S<0>;I-[>&&\$27D9::5XLS[I &:4LI
M0*$8 ^B_!O[!?A/P1XWT77+36/%TDGA[QGKGCG3[.?45DM+:^U=+E;N-5\O/
MD;KR[=4W95[ACN("!<OQ)_P3/^&6M_#/X@>&+2'7M!C^(7BK_A.+C4=*U)K?
M4-(UI9HKB.\L9<'[.T=S%YZKAD\R24E6$C _/WAS_@JK\0M-^%$GB;Q)8> P
MOB+P%\//&>D& 2VEKX??Q1J,NG217DTLY2>&V:,3";-N'#&,A,"6OK;]E?Q[
MXV\?_#>\D\?6?ANQ\2Z;J][I[_V)>K<6UQ!'*?L\S*'?R)G@:,R0^9)L?< Q
M!% &UX ^#_\ P@_PB_X167Q-XI\032VTL-SKFL7<=QJEW)*#OF=A&L0?GA4B
M6)< +&% 6O+;K]A2S^'_ ,-/AK:^#M;U^76_@CX0O_#7@Y-2U&.&WO3-IZ6D
M7VZ6.W,GR^3"?,A"E2I;:WW3YS9_M>_$;0/VI/'7@V\UGPK=QZ]\5;3X?^$F
MGTF2&#P_#_PBJ:]++<;;C==.ZB2%4S%NE=3N5<1K[M^QQ\==7_:%^#<VK^(-
M,M=+U[1]>U?PUJ*V3,UC=7&FZA<6+W-L6RWDRF#S%4EBFXH68H6(!\P_LJ?\
M$X/%-I\.X?"?BF^\6^%O!UG<:#JSZ?<W'ARXU&XU31M1L[^R:.XT[385-F&M
M CB??-(-NWR,.9?9M#_X)S:5X5^(%KXFT;Q]\0=)U>UU3Q7J7G12:>Q8>(9H
M;F[@&ZT.(H;BWMY82/WBF(*[R*6!\M^)'QX\97_COXEV?BP>'_$WA;PW\=?!
M7A#0;"V^UZ1/ID5S_8ER)WFAF)N)(YK]'*/B.3RG5AY;>6*$_P#P4J^,E[=L
MMCX!^&[1ZA:^/9--:;7[U2K^%]5^QL\P%M]VY0@!5YC8%B6#;% /I']D;]D+
M1/V0M#\3VFBWDMY+XPUDZ_J;"RM=/M3>-;P6[O#:VL4<$/F"W6638F9)I99#
MR^!Y_P"%/^"<#?#/Q9;^(O"?Q*\4:-XBLK_Q,]G=S6%C=1V^GZ[?C4KJP,1B
M42+%>*)H97)D4_*YDC)0XWP9_P""AOC+]H/XE6-OX5^&JW7A73[[0M/\3W4V
MN6D=QHW]JZ):ZLMPH>1&D2'[=:P^6L9:8O*R,ICV/UW_  51U[5O"_[&&KZA
MH,]_#K%OXA\-"U^QZB^GR3%]?TZ,PF9.5217:-\@J5=@58$@@';I^R_IOA;]
MDVQ^$OA.YAT;1-)T.W\/V37UA#JL36L*I&8KB"4".X26-6253MW+(^"I((\"
M\0?\$@H)_@[I7@_P_P#$?6/"=G:^%?%G@VZ^PZ3!-"-,U^XBN9+6SBF9Q9P6
MLD$,<"!I-D"^7G.V1=*7_@I1XE\!7XB\??#_ $7PU9^'_B9'\.O&6J6OB9[S
M3] %W86][INHQ2-:1F:"<WEG;NL@A:&6X&=R@FOI/X-^--3^)'PNT/7]4TM=
M#O=:M$O38>>9VM8Y/FC5FVK\_EE"RXPK%E!8#<0#Q6+_ ()\>?\ $74+R]\;
M7E]X5UKQ#X=\8:EH[:9''<W&KZ)!916DBW*, ENS:=93/#Y)8R1$+(J.R5Y_
M8_\ !)C5/#1OM?\ #OQ*L_"?Q 'B+3_%FFW^B^%EM]"M]5@M[ZTO+V72FN7C
M:;4;749X[MH)(%D*0.%5T+/Q-]^UW\9/&'Q-^&&M?V/I+ZM%\0OB%H$7A[3_
M !/-9:3J]EI-MJ%O!]LE:V))66U5@_DRD,^X*H)5?5/A'_P4]O/CUJG@O_A$
M?A?XBUK2]:L?#5YXBG@N6:;PS_;=@M]$=H@,,T=O%+ TSF:(A9<QI(59: .N
MB_8H\0W'B7XC:OJ7Q%?5M1^(7PZL? <US<:*JRV\UM)JLWV\[)E1MTFK38@5
M(U1(HE#<%CQ,/_!,"\#/I-QXXL[SPCKOAOPCX?\ $EDVBE;J\'AZ5Y8FMI?/
M*PI<E]LJNDK*H.Q@Q#+Z7_P4B_:#U[]F']CGQ1XK\+-90^)&N--T33+N\B\Z
MUTVXU'4+;3X[R5,@/' UT)BA(#^7M)&<C&^).G7W[%V@M\2=4^)7CSQ5X;\/
M:5+:ZOH6IFVNG\1:C<36\5G-$^R,6LWG,8MB%+?%QDHNP, "#]E7]A/5OV:?
MC/XJU7_A)_#>K>#]0UC5M:T2R7PG!;:YISZG>27EQ;W&IARUQ;QS2S>4HC23
M#J))) @%0_M8?L#:E^U#\4_$6L2>+K?0]+UCP&WA.TC@T\RWFG7RZC%J$-]O
M,FR2-98(@T!0;U4_.,X&9X]_X*2ZK\-O%=QX0U#X5ZY??$*'Q)IOA^+0]-UB
MVDAO$U*QO+JRO(KJ81(86>PNH9 P5HVA<X9=I;-D_P""LMKX5\<7%MXQ^&?B
MSPEX2TOQ->^#]6\3S:A8W=IIFIV^E_VGY;Q0R-,T30+*OFJFT.BJ?O\  !>U
MG]@CQ;X]^+VC_$;7_$'A./QBOBS0-:U>+3]-G73YK+2+:_ABMX@\A<3/)J,\
MOFN2% C3:P3>WK7[6GP=\6?&CP/H.G^$?$%CX?NM-\16&J7XO897AU2RA<^?
M:%X72:(NI!WQL,[-C9C=U/E7C?\ X*D:;\+O!VK:IXC\ >+;&ZM_#FG^,-)T
MZ&6WN+G6M+N[Z"R+)APB7$,ES 98&8G$J;&D).-G4_\ @HE#X-^)O@OP?XL^
M'OBCPGX@\::A;:1;V5]?Z=+-%=7$%Y-'@0SN)80+/:\\99$>XC3+$2; #YXD
M_P""1/Q6\+?LY:MX"\.^./ANJ^,OATWPXUZ2[T:\C@M8+;4=2N].N[)%E)5O
M+U6ZCFB=MNX0LK'RR']5N/V$?B98_M*PZM9>)/!EUX!_X6M%\4V6\M[D:S!(
M^CRZ=<V"E?W3H&998I6((5C&5PBL<GX<_P#!3VW\2>!?A3\1O'6G^*O ]IXL
M\">)?&$GAZP2SU*QNK>TO-*AB\R8?Z0;I?ML"0I%LCD:YFW_ '8POIGB'_@I
M'H7@?4[K1=>\#^/-/\86/B31?#EQX?CAM+FZ3^V/,&GWBR)<&![61X9XBZR%
MHY()0RA5WD \Q^''_!/?XH?#[P]X5A&K> [JZL?!OCWPQJJF:[2/S-<U2+4;
M*6 ^4251H4CF#@%0Q*;\ &C8?\$T?B"GPUU3X>W>H>";KPCXV\/>#K/6M16Y
MN8]3T"^T6*VAF:QC^SE)XG6TAD@:22%H9F=RKCY3]6?LT_M":7^U!\'['QCI
M.G:QH]O<W=_IT]AJL21WEA=V-[/8W4$@C=T+)<6TR;D=E8*&5B"#7G/Q,_X*
M3^!?A)\7-8\&ZYI?BRWU+2]-U74X9/L4835$TVR2]NQ;HTHF8"*3"2M&L,CI
M(BR%EQ0!X7XO_P"":/Q,U"PNI-*;X51:I<:M\3M5\W4!/>6TK>)(YQIPG@>U
M*SJADB2YC?Y3'%A?-&%J]\-O^"?OQ<\/^-H=4U63P*T5Q\6]%^(MV3XHU+4K
MH06_AZ/3+R+S9[,&243Q*\0Q'&8S@" *L8]@\$_\%-? /CK3K]HM'\;:?JD,
M^B6]AH^H:4MO?ZXVL1-)IQME,FS$HCFW&5X_)^SRM+Y:*6K:_P""?_QS\1?M
M#_ W6O$7B99X]0M_&_BC1H8)[)+.>UM;'6[VSMX98T9E\Q(H$5F#$,REL\T
M2?M7? KQ+\8?'WP;U70(/#\UO\/O%MWX@U(:G>2V[2PR>']7TQ(HA'$^XM-J
M,;-EDPD;8).!7RG_ ,.Z?C%IG[.;>&=-6SL]0T?65OO 4K>*8;G4/ \:Z*UB
MMM<W,FG>5J]@)))K7R;J)YOL,H^=I%5$^L/$G[=_@?PG\;6\!ZA!XEM]4:2]
MMK>Y.DR_9+ZZM-/34KBW@;[\K+:2"0.J&)F5XUD,J-&.0\.?\%9/@_XC\!W?
MB5;CQ?8Z+8V/AS59+B_\,7UK_H.ON\6F7@$D8)MY)HY(FE'RQM&2Q"$,0#R1
M?V%_BY:?M%6UQ_9?@-_#,OQ:LOB7<ZW;:M):W%L/^$,&@3Q6]D;9PLD5S%YR
M9EVM'(BY!#E.*^$7_!.'QYX/_9E_L'Q#\.;73?&^AVGA[P\?$G@WQY)J&H:X
MNCW+W%IJT-MJR?88UBE=I3:7 ;S#<3J6553S/T'\#?$G2_B)<:Y'IC7$G_"/
MZI+H]V\D#QHUQ&B-((V8 2*OF!2RY =77.5('G_CK]N7X<_#GQ#XVT_5M0UB
M/_A7%A<:AXDN[?0[VZL]*6WLH=0EC>:*)D,PM)XIA$"7=7^4,58  X+XA?LV
M_$;QS_P2KM_ABO\ PA^E_$G_ (0_3],N+735:PT">XMTA\ZQ01J3#:3K&]N=
MBD)'*<*0 *\>^)_[$/B3QY8^(M9T_P"$]KIVD>+/B1X$\2+X&N;C2_\ B50Z
M/=VTNIZ@RK*UHL]Q!"8 D,C&1(8=Y7>X3ZJO/VT/AY::WJVEKK%Y<ZOHUQ8V
MLVGVNE7EQ=S2WMJUW;)!$D1:X+6\<LI\H-L6*0OMV-CR/_AZ+X-TK]H&WM-1
MU[3U^%_B#P1H/B?0]9AT>_>=IM3U.ZL4-R51A;V^Z*W'F3I$L;S;78$C !]6
M6D"6T"QQJ(XU "H!@(!T 'I4E(OW:6@ HHHH **** "BBB@ HHHH **** "B
MBB@#S']MF9K?]C/XN2+NW1^"]99=OWLBQFZ>]?PVVJL;6+I]Q?Y5_<)^W[>#
M3_V$/C9<&!KH0> M=D,(SF7&GSG:,<\]/QK^'FW3_1X_]T=_:@#]^_\ @R M
M=NA_M*S8(!N?#:#T)V:F3_,5^\]?@Y_P9!0,/#/[2DV[Y&N_#B 8'41ZD<^O
M<>U?O'0 4444 %%%% !1110 4444 %5]5U.'1=,N+RX;R[>UB::5MI;:BC+'
M R3@ \ 9JQ5/Q#IDVLZ%>6MO>7&FW%S!)#'=P*C2VK,I D0.&7<I(8;@1D#(
M(XH ^>],_P""D.@^,+GX03:#X5\57FA_%_5Y+'3]8F6VALX+1='EU47V_P X
MB2)HH]N%)92DP<*\>QMC2O\ @HS\-=1L&N[BXUS2[*Z\/KXJTB>]TJ6,>)-+
M>XCMDN;%0"\VZ:>U01%5E)O+;Y,2KGB?!G_!*;P[X'O]'OM/\37UC>6?C9O&
MFH16.EVEGI^HR3:,^D7MNMHB^5;K=0N\DKPA6,SNXVEN(Y/^"4VDZO\ !W3/
M!NK^/?%6H0^"_#'_  B?@?4DAMX-0\+6J7EC>6\Q<*5NKF*72M+ DE7:ZV8#
M(QEF+@%_QG^W\-/^.'P_L[>"ZTGPMJ2^)[7Q)I^K:+/%K4=]ID=H88;8;\2E
MVGPJPK-YYDB\MNH*C_@H%'X%_:\\8>#_ !D)K#PO'8>##H9A\/W;7.F7FN7&
MH6HCU*=6DBC#W,%K%&2(]KRE3OY89/QF_P""7%Y^TMX<\'?\+&^*WB#Q-XI\
M'V^K26NOQZ1:6-Q9ZC=K;?9-0LDB 6TFL9;2&6';NW/YF\L)&%;GBS_@GSK/
MCG7/%&K:I\2;BZU;Q2W@:6>Y_L&&/$OAK4CJ.\HL@4F[E)#@;1&N0@] #LI?
MVVO!_BRYU'1O#>JXUVXTW5+OP]=7VG3KI>NR6&4N/LTWR)<K#+MWK&X9DW.A
M* N/'?%O_!3'4/#O[%'PW\50KI%Q\3O%6C^"=5U:RBT>]NM)TL:[>V5LWFF)
M\VPD\ZY$'FRGYH@6W@'=UO@?_@G++X/T[0]'D\;-J'AGP##K<?@>R?2-MQH1
MU&*6!?M$_GDW:VUO/-#$H6(E'S(9'57'#3?\$EO$&B^%=/T/P_\ %S^R])N-
M%\'Z=K\%QX62\_M*Z\-SV\EK=VY-ROV;SHK=8IHV\Y3A&4H0V\ ]D\9_\%(O
M@Q\/=9\2V&L>-+>SE\):;JVK7[?8KF6-K?275-3,+)&PG>T9E$L<6YT.<CY6
MV^F?"'XOZ!\=/!,?B#PS=7%]H\MS<6D<\ME/:>8\$SPR%4F1&*;T;:X&UQAE
M+*03\Q:Y_P $O_$^I?#GXU>![?XJZ?%X+^*%KXDCT6WF\%6\FH^&9=<EFFNA
M+>K.CWD$<US.\4>V%QO57ED5 *^H=.T?Q/%\0EO+K7-+F\-_V2D#:;'I;1W!
MU 2$O<BX,S 1-&0HA\LE2"WF-G  .DI"N:6B@ Q6?I'A32] O;ZXL=.L;*XU
M2;[3>26]ND3W<NT+YDA4 NVT ;FR< "M"B@ (S1MHHH 3:*4C-%%  !BC&:*
M* $VB@ID4M% '.?#SX1^&?A,NM+X:T33]$7Q'JUQKNIBTB$8OK^<@SW,F/O2
M2%06;J2,FNCQBBB@ VT444 &*0C@XZTM% '%_!O]GOP?\ HM>7PGHL6E-XHU
M:?7-5E\Z6XFOKN9BSR-)*S/CG"H#L1?E4*.*[)DW'/>G44 -V9'?\Z"F13J*
M .#^._[/&A_M!Z1H]OK%YXETRY\/ZB-5TV_T+6KG2;VSG$4D)(E@=2RM%-*C
M(VY&#\C(!&S\+OA7I'P?\'0Z'HRWGV6.22>2:]O);V[O)I&+R333RLTDLC,2
M2SL3T P  .CHH 88%9=I&Y3D$'G.>M(UJC.K%0S+T)Y(J2B@!NP%<5Y[\=?V
M:]!^/7@[2=#OY+_2+/1]?TKQ) VE>3"[7.FW\=_;HV^-U:(SQ*77'S L,C)-
M>B44 95YX%T74=)M=/N-)TNXL;%D>VMI+5&AMV3[A1"-JE>Q &.U277A'2[Z
MXDFGTVPFDE=)'>2W1F=D^XQ)&25[$\CM6C10!7U32+77-/EM+RW@N[6=2DD,
MT8DCD4]0RG@CV-4=(\":+H$TDECI&EV4LL"6KO;VJ1L\2 A(R5 RB@D!3P,\
M5K44 <OHWP2\&^'/#]EI.G>$_#.GZ5IMXNH6EE;:7!%;VMTIRL\<:J%253T<
M ,/6I](^$GA70-0L;RQ\,^'[*[TQKA[.:#3H8Y+1K@[K@QLJ@H96Y<KC>>6S
M70T4 8_C7X=Z!\2M-@L_$6AZ/K]G:W4-]#;ZE91W445Q"XDAF59 0)(W 97
MRK $$&L9?V=_ "WMO<CP/X/%Q:37UQ!*-&MM\$E\,7SJ=F5:Y!(F(P9<_/NK
ML:* .!N/V5?AC=Z!>Z3)\._ SZ7J6AP^&+JS.A6OD7.DP[_*T]TV;6M8][[8
M2-B[VPHR:Z#X9_"WPW\%_ VG>&/"'A_1O"_AO1XC#8Z7I-G'9V=FA8L5CBC
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M^T?#^6#<D>5J&!CL!SSWR?2OW<H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BB@G% !11FB@ HH)Q10 449HS0 449HH ***,T %%&:* "BC-% !11
M1F@ HHW44 %%%&: "B@G%% !11F@'- !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >(_P#!3&7R?^"<'[0+\#;\-O$9R1D#_B5W-?Q'Q?+$O)^Z.]?VR_\
M!4YY(_\ @F7^T,8RZO\ \*V\0X*KN/\ R#;C/Z5_$T@9D7[W2@#^A+_@R,TN
MUB^#?[05\H_TRXUS1X)3YF<QQVURR?+VYDDY[YQ_#7[F5^(/_!DKH[P_L]?'
MK4/*41W7B;3;=9 OS.8[1V()[X\T'';<?6OV^H **** "BBB@ HHHH ****
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M ."M'Q'3X?7VOQ?!?PW/''X+\8>,K6$>.G1I8_#6J)8W<$A;3\(TZRQ/"PW
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MGL[E@P5 K?3GCA]:7P?J7_".?V7_ &\;=QIYU+?]C68J0C2A/G*!L$A2"0"
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M-5T;4]9U2?P9K=E_;UCJUS>16]O;1NS&"^3R8$6,>?\ :)965%0JP7U[4_\
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M:NUX-,U$Z7I-WIUY:WKQ0[XD9;V1H)8TD*M%$63@K0!]/:/^U5X?USXL>#]
MM+JSU#2/B-HT^L>%-<L;I;FSUC[/L:>$,O <12QRH02)$6;H8CGT+Q3XKTWP
M1X?NM6UB_L]+TNQC,MQ=W4RPPP+ZLS$ =17QKXW^!/B_PIXH^#EOX/\ "O@_
M3=0^!&B>(O%TUGI-A=6OAI-8OM/N;.STR 0Q//)&SWES+(T<1EVPHY16F1#Z
MQ^UQ\$O'/[6/[&>EZ?86_A_PW\1H;G0/%<>F:O<2S:0NI:?>VNH&PN985,AM
MVE@,32QJ6 (=5) % 'HD_P"U-\-K71-!U*;Q[X/AT_Q1(\.D7$FKP)'J;I,D
M#K"2WSE9I(XF ^Z[JIPS 5C_ +0/[6GAOX*_#WXB7MGJ&A^(/%OP]\,7_BBX
M\+1ZQ##J$T-K;&?:R_,\2L#&-Y0A?-0D89<_('[1_P#P35^+OQ<^#QT'P]X=
M^"/A5M=\/:^NK:9INMZC:6]KK%_J5K>(_P!M6R-Q?02>0S3*ZP(9W\QHI@J(
MO7^(OV)?C!KG@7XV>"[C0_@YJ&G^)(?&=]X,\5W%[<_VY%/XA29OL,R_9"+:
M.&6<QM=1RRM);VUN@@!SY8!];_!OXU^'_C?X474M!U;1]2D@$<>HV]C?Q7;:
M7<M$DC6TVP_)*H=<JP5L$' S6)X1_;$^%WCGPSKNN:;X^\*RZ+X9UB;0-3U"
M34X8;6TOH6VR0-([!=P8%>N"5.,XKS_]D/\ 9CU[X#_'3XF:Y>:5X8T?P_XH
MT?PO9:5!I%TTD@DT[3WMKCS8S#&J!6,:1LI;?'&N0F M?/\ XX_8+^+5MJ4U
MW;>#_!?C+2;+XC^,=7F\/3>,KW1%\1Z3XA+.MT9X("8+FV$K0-$XD62)[G#
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M[7O%UZVG:#HFF6S76I:Q.D;2R"*(?PQQ*SR2.5CC499AD9 /EJV^/WQ"U_\
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M#=<M[>&]\)>&+R.SU%]7MTGTJ"18+U]P:Z4%3MF;>^9!\QW-SR: /C#]GO\
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M'O ?BKPFWAGPA:ZJUUXLU2&7PEJN@/(ZR6EM'$L5_$S.)(3)Y#1S&1F&UMI
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M: /T\7IQ12+TI: "BBB@ HHHH **** "BBB@ HHHH **** /G/\ X*]R"/\
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MV+QHQ9 8RP =<W+G2]$L&ALY;72X?MC>5%$T4:^>R[Y=JJ1\Q'SO@=/F;U-
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M+S;^0ZU#>PQZO"J3JI73'57C2.2,E0-KJSCTZY_;OUK1?$5W<6'A/3;OX?\
MA?XAZ5\+M7G.IRG5X+R^^PP1WB1&,JT*7>HVL11GWM$7GW8 C;T>Z_8J^#GC
M;2Y)%\#^&)]/U+PB? ["RC$5O<: S%_[/ B(0V^6?"CH)) #AV!TXOV/_AW#
M\5O^$V7P[&OB(R6]Q)+]LN/LUQ<V\/D6]W+:^9]GENHH<1I</&TRHJ*' 50
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M=SQ_C7\7J?=K^S+_ (+DWAL?^"0W[1$@56SX'U!,$X^\FW],Y_"OXSPIQTH
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MB5X'7X2PZMI]G=:;X!^*?_"1VLNI7=B=;L-"'A"?2(XKJXM8DCO+B.YF$*R
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MI  /D7]MKP9\0/$GQ?\ BVOA_3_BDVE:CIGPU33;G0I[R-#)!XGNWU8VK1.
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M'5[<RK=P6J'YF$$D,T3.< O#(!D!6< ^)_#V@_M!QZYI.M>,;SXTR>-M%O\
MX/IJ$6FB_P#[%N)I9TA\3NMO;@VLL7V=Y_M04-#"RAQL;:Q]A_X)[7'Q"U[]
MH/Q'>>/-1^,5CXDT[^V-/\1:-K&@75OX4NG_ +39["[T^\F9K>95MODB%CC,
M+_Z0HD5#7T-^RY^U'H_[3/P]?6H(?[#OX;_5;*?1[N[ADO+5+#5+S36G81L1
MY<DEG(RMTP<9R#7H7ASQ1IOC#1(-2T?4+'5=.NL^3=6<ZSPRX)4[74E3@@C@
M]0: / /VI(KQOVZ_V96O%F;PJE]XC/\ TR76_P"R3]AW?[7V3^UMOOG'-2?
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M]YJ@6T348+J?1=5CGGTZ5&8*"9[7RG)R5PW!-=!XI_8T^$7CCPQI>BZS\-?
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MQXE_?CP_!KXM]$TW6+N$QRZG;IY$CQ3NV7.[S85D9I1"9#FO8/AIX5U/PO\
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M(MUMK.ZE<PF2WE,*11S?9V19DB12!B@#ZE!R**11@4M !1110 4444 %%%%
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M+0[SX8^,-%\9:QXB_L'2=+OQ]E@U5%TXZC+>17,RHK011))&^%++.@3!#*Y
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M2]2CU2!OAI>11:W<(L<T4=G)H\^L+J";'+/;_9K:9,[0YF0Q!2V,@'._%_\
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MG3Y+A8[AX1<1R,TME>^6RL&;?##M>569@#SW]I#]@3XU?M,Z=X,UZWL/A/\
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MBXF5X@(5<JZ,KA2"  ?)-_\ \$K?B?J?P[FM]+T/POX9\3:IX0^(NDZC>+J
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M6X5BRS1Q%-BR!B2' !!).:T_&G@'0?B-I26/B#1])URRCE69+?4+..ZB609
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M?\/=7\*7WPMTK6O#MQ:SS6LNA/+K6EZ0#JDDTOE- 1JT=SYBF (+.Z0DA?-
M!]A6/[#3>+?VM_B)XX\775Q<>'-:UCP[K.BZ59ZO*+>YN-*MP8I;RW\M5W17
M865 KNK&&%F&8U M?\.Q_AF?">N>'BWB5O#FJ66MZ?8:4=2)M?#46L!Q?C3Q
MMS!O$DJIRWDI*Z1>6C%*\F\9_M[?&CPEJ]EX)'ASX9O\0[C2O$VOVSS:K%%I
MNJ6FF7-DEM"^Z\ LYI8;U7G8377V81AO+E63";O@#]NOXE>)?VL-/\,WVB^!
M8?!-]\3M5^':R6[W+ZH5M_#3:W#=ARWD\-%+"Z[3O$BNI385< [GXR_\$S?
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MQQJQT3P_H^E"(W>J72VT]W(JM/)%!&J6]M/*S2RHN(]H)=D5OBGQQ^Q)\2M
M^+OA3Q'X1^$^FP>!_"WA/1+*[^&YU2PN]*UR)=:OKB?36EN) 4GL8KNWNX#Q
M:F>V,62@C9?I;_@H!\!M+_:4^&OAKPWXB^'/B#QKH;:NE[+=Z#J<>G:]X.NH
MH96MM4LIC/$RS1R'RR87+[93\KIO4@'KOPE^)MC\9? %GXAT^SU>QM[QYH6M
MM4LWL[RUEAF>"6.2-^599(W7C*G *EE()Y+5OVI=+LOB%XV\+6?AOQAK6M>
MTT2:]MM.LXYFNH=4FDBAE@S*-R1>5,\N[:42)R W&?SW^+/[-WB[XEZO\-O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVCN-1O([:.69\[(E+D!G;!VH,L<< UXK_P $V_B!/\1O@UKE]=^-KKQG<?\
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MSPIK\>A7MCYZ^/(]2NKB*ZEL8VD%P8W2W_T=82SPR2J9O-0A2S_@D_\ '_\
MM+QUKWPN2>W\*V.B:WXSUS1]+-O!(/&5M+XNU))+ZUG1R(XK.;=;R0;1)ODC
M=BL;1[P#[YHI%Z4M !1110 4444 %%%% !1110 4444 %%%% 'Y_?\'1ES%!
M_P $._C(LC;7FGT!(A_>;^WM.;'_ 'RK'\*_DD'2OZSO^#J"98O^")'Q2#9^
M?4-! P,_\QFS/X=#7\E^#VH _JX_X--T1?\ @B_X,VE2QU_6R^!T/VZ3KZ\8
MK])J_-[_ (-0(98O^"+/@1I&A9)-;UQH@@^95_M&88;WW!C]"*_2&@ HHHH
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MS@'LM=_90^%OBK1]<T_5/AKX!U"Q\46EI8:S;77A^TFBU:VM!BU@N%:,B6.
M8$:/E8_X0* /CY?%/Q:\1?M WGC#0=/^%MY\?;;X#W\5O!9SS:CX?U*]M]=;
MR8 ZR12B.1HG4KYA\B25E+2!"7^GOV./VGX?VQO %QX_T)K>3P#K!MQX<F-L
MT5U.!;QF[\XER-T5TTML4"J4DM90=W!K4^(W[,UC<^!Y;?X<S:+\*?&%OHUO
MX>T;Q1I/ANPN;S0]-BGCE%E#'-&8_L^$*B$CRU+;@H8 UV'PN^'&F?"'X>:3
MX9T=9%TW1K=;>$R-NEDQRTCMQND=B69L#<S$]Z /@']G3Q'XE7]JB_F:Y^']
MY\6/'7CGQWHFD^,-1T6[VV&DZ5/ ITYXDOE-V3LM?)B,D8ABM[EQO;?OXW]H
MKXS:A^TU\)_B3X\U#29/#NJ:O^RWX@:]M+:]=H(+RWU&9/,MY/E+1>;%))%+
MA2T;H3C.!]U>"/@/\"_CK\)X;_PWX5\!ZSX1U[69_%$%UI5E"D%UJ<C/'/J"
M21 '[1(?,2292'<,ZL65B#TGB;]D_P"&/C&WNH=4\!^$[ZWO?#H\(SPRZ;$8
MI-&#[QIQ3&W[*&&1%C9[4 >*:Q^V[XIT_P 97-]I^E>'[KP+H7Q/LOA7J-DR
MS#7%GN/LT U!&W^7L6ZNX3]G,99K8&;S02(J\VU'_@K1XH\$>(['0?$7AKP[
M'KEGX@\1>"=?AM1<>7IVNP++-X>C!9MWE:M;QJT09=Q>2-5R76OKR+]FCP!%
M\4F\;+X3T7_A*G\IFU'R!YKR11&"*9NQF2$F)9B/,6,E P4[:T-2^!_@W5]0
MNKNZ\+Z#<75]J]KX@N9GLHVDGU&U2*.VNW.,M-$D$*HY^91$@!&!0!\I7/[4
M7BKX4_%KQEI/AOP;X3N/%'B;XSZ;X(U*XN==OOL<SS>$++4/MX1ED\LHJ)%]
MGB"(0A;)D=G.5K7_  55\?6/P%\)^(++X:Z9J/BK5O">NZVVDQW\YAU[5-*U
M*#3FT;376%I&GN7D>6$NA;:JKL;+O'] 7/@7X%W7C^6X=_!;>)&\=Q7\G_$T
M3[0?%*Z?LCROF9^W"P  C(W>0!\NP5Y;\=_^"6-AXU\4>&V\%W7A'PMX;\.Z
M5/I=KIMSIFJ-<::UQ=R74]Q:W=CJ5G,ID=P6CD,B[HU9#&2^X ]$_;*^-'CS
MX2:9\(X?"J>'5U#QA\0=(\/:U]M\R2-;*59I;A(&"G#MY.T.Z\*Q. Q!7YQ^
M"G[>GB#]E[1_%T?B[P_)J_@>'Q!\6=;MM736Y;G5D30M<O9_LWV>:,*L)MRT
M41$QV>0@VA&&W[$\5?LU^%_B)\*_"_A/QA'>^+K7PK-I]Y:WNI7<GV^6]LMI
MAO'FC*,9BREG((#[W# JS*<VS_8D^%UE?6=POA&QF:PNM<O(HY[B>>$R:V[/
MJN^)W*2+<NS,ZNI7+,0!DT 1_LP_&GQG\7F\11^,O B^#VTN6T;3;J#41>6F
MMV\]NDADCW)'*ACE\V([T"ML5T9@Q"_"_P"RO\=_&^I?M@_#WP=:^+?B'IM]
MJGQ+^(+7M_XLU][[0?%GA[2M4U"T71["&229C?V^+.1<+;.L-M<2%IUR#]]?
MLT_LF> ?V0/ K^&_A[H;:'H[R"3RI+^YOG4*H6.-9+B2218HU 6.(,(XQPJK
MDU@M^P'\*1X!M_#7_"-W TRQ\52>-[)AJ][]KT[6I+A[B2]M[CS?.AD>669F
M$;JK>=*""KL" >8:=_P4/\<^./"_B_Q!X.^"NL>)] TG2==U#0+P:G]F76[G
M2KU[4V+[H#Y4UT(II(-@E'[O;)Y9(-2WO_!3>#Q)8^'YO GAA?&B>-GAB\,2
MP7TBPZH_]CG5;HL8X)&5(HFMX@55RTLS*P3RG(]8^#G[%'PZ^ ?Q5\3>,O">
MD7VEZOXMNKB^OH?[8O9M-CN+B027,]O922M;6TD\BAY7AC1I&&6)YKG/%_\
MP3I^#6L?!#PG\._^$?E\,^'?!NLR:SX:.@:U>:'?Z+?S23R226EW;2QW$3R&
MYN P20;EE88QC !YWK7_  4M\8Z?J/B(0? GQ9-;^#_!.E^,_$$#:G&=4TK[
M?;7KQV)LHHI)9+B.XLGBE$6_:C>8N\@1E$_X*J?VWX8T&^\'^!9?BA>:AH\O
MB2ZB\#:J==MY-+759-/BELIX8"EQ/*(9YA#-]GV>1)&[I(-M>R)^Q-X%LG\3
M2Z>GB31[KQ7I6E:+>7.G^([^WFBMM,+M9"!UFS \;22$O'AI"[;R^:Y75?\
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M)]+LV\/Z)XEL5U?19;"36++6)6@L&MA+@2&2=3%R0 V&)V$.?2OV<?V;K?\
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M @].A!H O455N]<L["]M[:>ZMH;B[)6"*255><CDA 3EL>U>9Z'^UAIGB_\
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M>[CCFF7GE48@L.#R!V-:H.: "BC-&: "BC-,GN([:)I)'6-%ZLQP!^- #Z*
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MDT >L>-OV9=+\<?M"?#WXC3:UX@M=2^&]GJ5AI^GV\D)L+Q+](4F-P'B:5F
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MB-K#>-/#MEXI6\CTNW^Q:-8W,]Y;"2[E^T84QSV4L;B/S,ET9-Z%G7N/B?\
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M8U]'?LY_\%!]:^,/Q;\!PZEH^EV?@[XO-XI3PHT*2"_M/[$O5@1[IBY21;R
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MA;XQ:3=7WA77M(\06EC<FSN9+"Z2<6TX57,4FTY1]DD;[6P2LB-T8$@'@_\
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M'+X3\3:!:M/K7A/R+KPY<:FFA7VIWZ7$EQ*E[8*T=NEY:S.CP26J.KGS'5Z
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M6%C/;H;B%;BY:2-!L8S?1^C?M,67P]_8[\(?$;QU>1JVI:/HK7<MLBJ+J_U
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MI=7*1 37*QY"*[=6";FP#TW'U- &A1110 4444 %%%% !1110 4444 %%%%
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M7W@O398==32DO'62:.9SI>/[.=)5<21R6V 8Y(V5U/.[/->%_P#!2:_NK?\
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M7O!EIX.A\(6'BU[VYUY(M2LHKJ2<*]U:,H$%N4A&V=I<.XF0*/+W'Y_^"/\
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MBD6/:D;W+E<Q]0#[ \$?%&T\2^$?"MYK$<'AK6O$]A#>1Z+>7]O+<PR/&KO
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MOV'QA9ZI\0KSPT^FZP;FQL8-3:[ETR8:=(LDLJ(D=RR^4\ZM"S-$K%T5HV8
M.A.;XD^)OA?0_C=X=\&7DCQ>+_%.CZCJ&E[;-V,EG9R6BW7[\+M3:]W;'8S
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MT>."TU6*RET]X((YC;2/J/V<33QK$J)YT1EDDF06ZNX!]O\ Q8_9U^"\5O\
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MWO(2LOBC5X_WL4OR;BDVU&8$HQC89*J*76_VKOBSK7[2<F@Z5\2O#-CHM_\
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M$G-O<J%FMRRAMC@$@,N<$ G!!H MT444 %%%% !1110 4444 %%%% !1110
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MW$"TMO),'V+*BC+(2&4#) '->"_MT_L1>/\ ]HGQM\3YO"]QX1&D_$GX3_\
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MFLI=6]Q<O:F2RA9W'GFWC+V[W+)$(<KY='P%\??'M_8Z'XW\2^-/'4/C"'X
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MOVQO'G[7&E:3XFUSP[X5TWP5XS\*VGB?P_=:=JT,UW"\LKK-8RQ+/*TOD*8
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M0!'&J +&!TVCH/PJ*7POIL\5Q')8V<D=U)YTZM I$[X WN,?,V .3D\"K]%
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MC_9UOV'%>R4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'X9_P#![;(%^#G[/JX7<VO:P<X&
M1BVMN_X_I7\]+'8V.OOTK^@W_@]P91\-OV=1GYO[8UT@>H\BSS_2OY\B=O&
M: /[@O\ @GP2?V"O@CN7:W_" :#D>G_$NM^*]@KR?]@UU?\ 8=^#3+'%"I\"
MZ(1''G8@_L^#@>P[>U>L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %!HHH _!__ (/=K\IX1_9O
MM0IVR:AXBE+8Z%8M.&,^^_IWQ[5_/ZRMGY6XK]]/^#WN7%O^S*F]?FE\4ML[
MMA='&>G;..O<=>WX&;V7_P#50!_<M^QC!]E_9 ^%46(QY?@_2$ 1MRC%C#T/
M<>]>EUY]^R9IRZ1^RS\-;2./R4M?"NEPK'G/EA;.( 9P.F,=!7H- !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^!G_![\^VX_9A'MXL/_ID']:_!$G!^[GWS7[U_P#![[*K
M:G^S'&)%,BQ>*W*9Y4$Z* <>^#_WS]:_!<(,?=% ']T?[+EJUC^S1\.X)%"O
M#X9TV-@#D BTB!YKNZXS]G.R_LW]GWP+;_O/]'\/:?'^\.7XMHQR>YXYKLZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>_\ Q?GXS\,<?\5MJ7K_ -=JTM+_ ."CG[0WDR_\7X^,WW!_S.VI>O\ UVH
M_L0HK^032_\ @HY^T-Y"_P#%^/C-T'_,[:E_='_3:NGT?_@HU^T(VDR?\7W^
M,W^HS_R.NI?W3_TVH _K4HK^3FT_X*,?M"'3P?\ A>WQESO'/_":ZEZ_]=J[
M*S_X*#?'QD7/QO\ B\?WF.?&.H__ !Z@#^I2BOYB=/\ V^OCL\\.[XU?%ILR
M*#GQ?J'/S#_IM3O^&^?CMNF_XO5\6N)\#_BK]0X&3_TUH _ITHK^:.Y_;O\
MCBNF7##XS?%;<I;!_P"$MO\ (X_ZZUD6O[?/QU9WS\:?BT?^YOU#^Z?^FM '
M].=%?S3Z)^W=\<)6BW?&3XK-F;!SXMOSD9'_ $UKMKO]MCXS*ECCXN?$X;[/
M<V/%-]\QPW)_>]: /Z(J*_G/U;]M[XT1^)9HU^+WQ06, 84>*K[ ^]V\VN]\
M*_MC?%ZX73_,^*GQ(D\R]5&W>);T[AN;@_O.E '[YT5^&NB_M;?%:6&;=\3?
MB$VT1XSXBO#C+X_YZ5V7PV_:B^)E]&_G_$3QU-^[C/SZ]=-U#YZR>PH _9BB
MOR+E_:4^(P63_BOO&W DQ_Q/+KC$D@'\?H /PKK!^T%X]_M&S7_A-_%^UF7(
M_MBXY^7_ 'Z /U(HK\OA\?\ QYYJ_P#%;>+ONG_F,7']^3_;]A^506_[07CU
MI'SXW\7_ .LQ_P ABX_N_P"_0!^I%%?FCX=^/'CB=]2W^,O%;^7)$%W:M<';
MEGSCY^^!7H7PT^+OBR_UFW6?Q1XBF5IHP1)J4S @D9ZM0!]V45\C^%/B3XBN
M;>,R:]K4G,GWKZ4]"N/XJZ:^\=:XGB#4$76-5")"2JB[DPI\MSP,^H'Y4 ?2
M5%?*&C_$;Q!+ID+-KVLLQ5LDWLA)X_WJZ/0/'&M37=F'UC5&#&;<#=2'.' &
M>>U 'T917@>I>,=8CUB15U74E43D "Y?&/FXZUCZMX[UR/5K-5UG5E5H4+ 7
M<F">.O- 'TI17B-[XLU1/!5O,-2U 2L1EQ</N/ [YK/T?QEK$NJWBMJNI,JF
M3 -RY PPQWH ]^HKRG6/$6H11Q[;Z\7]RAXF8<\^]:ECK=XYAW7=T<J,YE;G
M[WO0!Z%17->&;Z>XGF$DTLF'P-SDXZ5IRSN$?YF^]Z_[1H TJ*R8[B0J_P"\
M?[H[_2KL#DLO)^[0!9HJO:NS2=3]T=ZL4 %%%% !1110 4444 %%%% !1110
M 4444 ?SD_\ !ZW*K?M<_!1/FW+X0O&([8-[Q_(U^+"\CD5^SO\ P>JG/[:7
1P<_[$JX_]+WK\793\YH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex3-1_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1_004.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#\K?\ @BE^PCX4_P""DO\
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M9@-O7Y"7#8!)&&P1O:E_P9U_LBWGB/3;R&7XHVEG9B;[181^(4:&_+KA-[-
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M?^#-?]DU](U:W75OB\D]\ZM:W0UZV,NF@*H(C'V78V2&)\Q6/SD#&!C]9**
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M5_T4GXY?^#'2_P#Y J:Z_P"#*K]F6>"V6/X@_&Z%H8RDCKJ>F$W#;V;><V)
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M[1EC9S;$*KIW@UKE=^7W F2\C. OED'&22PP, G;_P"(&K3O^CF+W_P@5_\
MEA7[XT4 ?@=_Q U:=_T<Q>_^$"O_ ,L*/^(&K3O^CF+W_P (%?\ Y85^^-%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYVO^"ZO_*5
M+XI?]PG_ --%E7]$M?SM?\%U?^4J7Q2_[A/_ *:+*@#Y*_X-.M,DO_\ @MC\
M/98VM56QT?6YI!+<Q0LRG3IX\1J[!I6W.IV1AF"AW(V([+_6U7\F_P#P:/\
MA%_$G_!9[PK>*+HKX?\ #FLW[^5$KH UJ;;]X2P*)FX'S*&.[8NT!BR_UD4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^
M=K_@NK_RE2^*7_<)_P#3195_1+7\[7_!=7_E*E\4O^X3_P"FBRH ^5/^#2SP
M[+K?_!:?P5=1K<E='T'6KN0Q6LDRA3920_O&4$1+NF7YWPI;:F=SJ#_6A7\C
MG_!J3M_X?=_##=MW?V=KFW/K_95UT_#/ZU_7'0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?SM?\%U?^4J7Q2_[A/_ *:+*OZ):_G:_P""ZO\ RE2^*7_<)_\ 3194 ?.G
M_!GSXQM_#'_!82WL9I+I)/$7@S5M/@$44KI(ZF"Y(D*2HJ+LMW.Z195W!%$8
M=DEB_JPK^4'_ (-#M;L]*_X+)Z)!=74%O/J7A76+:S22WGE:YE$22E$:.5$C
M81QR/NF66,JC*(Q(\<L7]7U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_.U_P75_Y2I?%
M+_N$_P#IHLJ_HEK^=K_@NK_RE2^*7_<)_P#3194 ?+7_  :1^,KCPQ_P6@\)
MV,-IIEQ'XC\.ZSITTEU;":6U1;5KD20,?]5*6MU0N.3')*G1S7]95?R=_P#!
MHO!X;F_X+,^'&URXU2'5(?#.L/X>2U"F&>^\@!UN,J2(OL9O&&"I\Q(N<94_
MUB4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9^"8_"<FI>'_ !UH/B6['B&8I;&SL+Z.ZF2,?9K@&=UB$<;%%,3R"975X4!
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MOP=UZXT^V30I-?:YU*.TU/1DU=K@Q2FSD0-MMH85EN5F:%T\TI&LTD;(>O\
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M&FC:+X/N?%VDC37:>'7(4M&N8#&\2N3'*NPB158!6W<@5YIJ/_!/'7[O6_\
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MB&8W*""VD0-</]1?LD_!G5OV=/V:/!'@+7->T_Q1J'@[28='.J6.E-I<-Y%
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MRF8V,^FVPW@%6B /I:Q\5:7J>OWVDVVI6%QJFEI%)>V<=PCW%FLH8QM(@.Y
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MB#P+H\VEW'Q8M=;^$=Y\3%\$M\=+*+3YI?#=O<Z'%?6S7)CL_P"RY&_M69+
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M^!-?TO5_'/\ \')O_*;GX]?]A*P_]-=G0![9_P &>7PP'C[_ (+ +JQ^P_\
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MEP7^C2:BMK/#]M<B]FG2&TBE>2.,'4+:0PN2(9/,?BK_ ,%-OC)HUYXD\/\
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M;K4-'OK3P=?^.VO;BQE336TNPECCO7%UCRO,@,]NSQE@RK/&V,-FL_2/VV_
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MX8:E/$(KF2)68ZGI4>)%5@)5VR,=CAE#!6QN167^H>@ HHHH **** "BBB@
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M/_*4WQ]_V2K4?_3OH]?T_5_,#_P94_\ *4WQ]_V2K4?_ $[Z/7]/U !1110
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MJVY5P]4_X*!_MP6CVOV;_@GNUVLL"23G_A>OA^/R)#]Z,9B^;;_>X!K[SHH
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M ,')O_*;GX]?]A*P_P#379U_8Q7\<_\ P<F_\IN?CU_V$K#_ --=G0!]-?\
M!E3_ ,I3?'W_ &2K4?\ T[Z/7]/U?S _\&5/_*4WQ]_V2K4?_3OH]?T_4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7\<__!R;_P IN?CU_P!A*P_]-=G7]C%?QS_\')PQ
M_P %NOCU_P!A+3__ $U6= 'TU_P94_\ *4WQ]_V2K4?_ $[Z/7]/U?S _P#!
ME3_RE-\??]DJU'_T[Z/7]/U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_&7_P<%Z+-H'_
M  6;_:"@GL4T^23Q+]I$2ZI/J099;>&59/-F =3(KB0PC]W 7,,9,<:$_P!F
ME?QS_P#!R;_RFY^/7_82L/\ TUV= 'TU_P &5/\ RE-\??\ 9*M1_P#3OH]?
MT_5_,#_P94_\I3?'W_9*M1_].^CU_3]0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?QS_\
M')ZLG_!;KX];@5_XF6GGD>NE65?V,5_%]_P7NU#PMJ7_  6._:&D\'M&VDKX
MMGBN#''+&/[01$34.)0&S]N6YR1\A.2A*%20#[#_ .#*G_E*;X^_[)5J/_IW
MT>OZ?J_F!_X,J?\ E*;X^_[)5J/_ *=]'K^GZ@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?Q!_\%8O^4IO[2W_ &57Q1_Z
M=[JO[?*_B#_X*Q?\I3?VEO\ LJOBC_T[W5 'ZC?\&07_ "<E\=O^Q:T[_P!*
MI*_HVK^<G_@R"_Y.2^.W_8M:=_Z525_1M0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q!
M_P#!6+_E*;^TM_V57Q1_Z=[JO[?*_B#_ ."L7_*4W]I;_LJOBC_T[W5 'ZC?
M\&07_)R7QV_[%K3O_2J2OZ-J_G)_X,@O^3DOCM_V+6G?^E4E?T;4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM._]*I*_HVH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1HD4_*1F5>1P#_0Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?P=_M._\G*?$+_L9M2_]
M*I*_O$K^#O\ :=_Y.4^(7_8S:E_Z524 ?M=_P8[^';*?X@?M#:LT.K?VC:Z?
MHMG'*L8^P^5))>.ZLV,B;=$A49&5W\'&1_0M7X!_\&-UK>&+]I.9;R-=/4^'
M4DM3!EWE/]IE9!)NX 4."NTYW Y&,']_* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^#O
M]IW_ ).4^(7_ &,VI?\ I5)7]XE?P=_M._\ )RGQ"_[&;4O_ $JDH _=/_@Q
MJ_Y%W]IC_KY\-?\ H.JU^^-?@1_P8V6$;Z;^TK=;IO,CE\.1!1,_ED,-4))C
MSL+?*,,1N R 0"0?WWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OX._VG?^3E/B%_V,VI
M?^E4E?WB5_!W^T[_ ,G*?$+_ +&;4O\ TJDH _=/_@QJ_P"1=_:8_P"OGPU_
MZ#JM?OC7X'?\&-7_ "+O[3'_ %\^&O\ T'5:_?&@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_@[_:=_Y.4^(7_8S:E_Z525_>)7\'?[3O_)RGQ"_[&;4O_2J2@#]T_P#@
MQJ_Y%W]IC_KY\-?^@ZK7[XU^!W_!C5_R+O[3'_7SX:_]!U6OWQH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OX._VG?^3E/B%_V,VI?^E4E?WA33+;Q-)(RQQQ@LS,<!0.
MI)K^#7]H36+7Q#\??'&H6-Q#=V-]X@O[BWGB;='-&]S(RNI[@@@@^AH _=O_
M (,:O^1=_:8_Z^?#7_H.JU^^-?@=_P &-7_(N_M,?]?/AK_T'5:_?&@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH @U-TBTZX:21H8UC8LZJ&*#') ((./3!^AK^";XF7MCJ
M7Q(\07&EW#76F7&I7,EI.UNELTT)E8HQB152/*D'8JJJYP  ,5_>SJ<\=MIM
MQ)-'YD,<3,Z8!W* 21@\<^]?P3?$S7]/\5_$?Q!JFDV*Z9I>I:E<W5G9K&L:
MVD+RLT<85/E4*I"X7@8P.* /WN_X,:F!\/\ [3"Y^87'ADD?\!U6OWRK\*/^
M#'BWU!?@S^T)-)=:LVE/K6C);V\D4HL8IA!=F5XG)\MIF5H1(JC>JQP%LAH\
M?NO0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 4O$G_(NZA_U[2?^@FOX$*_OO\ $G_(NZA_
MU[2?^@FOX$* /Z*O^#'O2K"'X&?M 7T:Z5_:EQKND07!COM]\88[>Y:+S;?>
M?+BW23>7)L7S&,R[G\K"?NE7X;_\&0&HZ;+^SG\>+2+6I+C6(?$FFS76D&&Y
M"6,#VLHAN0[2FW8S,DZ%8XDE7[*#(\BM L7[D4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%+Q)_P B[J'_ %[2?^@FOX$*_OO\2?\ (NZA_P!>TG_H)K^!"@#^DS_@R.\2
MW=U^QE\9-'?PU<VMC8^-(+R'Q W^IU.2:QB22S7Y1\ULL$<C?.>+]/E7J_[8
M5^.?_!E%_P HU/B1_P!E,NO_ $U:97[&4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+Q)_
MR+NH?]>TG_H)K^!"O[[_ !)_R+NH?]>TG_H)K^!"@#^G#_@RB_Y1J?$C_LIE
MU_Z:M,K]C*_'/_@RB_Y1J?$C_LIEU_Z:M,K]C* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"EXD_P"1=U#_ *]I/_037\"%?WW^(^?#U_\ ]>\G_H)K^!"@#^G#_@RB_P"4
M:GQ(_P"RF77_ *:M,K]C*_'/_@RB_P"4:GQ(_P"RF77_ *:M,K]C* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^:_5.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \-_X*??\HU/VAO\ LF?B3_TU7-?PZU_<
M5_P4^_Y1J?M#?]DS\2?^FJYK^'6@#^K;_@T"_P"4.NG_ /8WZO\ ^A15^HU?
MES_P:!?\H==/_P"QOU?_ -"BK]1J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PW_@I]_RC
M4_:&_P"R9^)/_35<U_#K7]Q7_!3[_E&I^T-_V3/Q)_Z:KFOX=: /ZMO^#0+_
M )0ZZ?\ ]C?J_P#Z%%7ZC5^7/_!H%_RAUT__ +&_5_\ T**OU&H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /#?^"GW_*-3]H;_ +)GXD_]-5S7\.M?W%?\%/?^4:G[0W_9
M,_$G_IJN:_AUH _JV_X- O\ E#KI_P#V-^K_ /H45?J-7Y<_\&@7_*'73_\
ML;]7_P#0HJ_4:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'RS_ ,%NK5[W_@D9^T1''?:;I[?\(-J+&:_QY) B)*#*M^\<
M HG&=[)@J?F'\5-?VM_\%K_$EOX3_P""2G[0UY=:59ZU#_P@VI0"VN@#'OEA
M,22X(/S1LZR+QG=&N"#R/XI* /ZP/^#1'2I-._X(UZ%,\EI(M]XIUB=%AN$E
M>,"98\2*I)C?*$[' 8JR-C:ZD_IY7Y_?\&M\2Q_\$*O@>RJJM(=>9B!]X_\
M"0:D,G\ !^ K] : "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'R/_P %Y?\ E#K^T-_V)]S_
M #2OXNZ_M$_X+R_\H=?VAO\ L3[G^:5_%W0!_7E_P:PZ#8Z1_P $,_@W<6EG
M:VMQJD^NW5[+#"J/>3#7+^$22$#+N(HHDW-D[8T7HH _0JO@#_@UQ_Y04? S
M_N/_ /J0:G7W_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?(__  7E_P"4.O[0W_8GW/\
M-*_B[K^T3_@O+_RAU_:&_P"Q/N?YI7\7= ']?O\ P:X_\H*/@9_W'_\ U(-3
MK[_KX _X-<?^4%'P,_[C_P#ZD&IU]_T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R1_P %
MY1G_ ((Z_M#?]B?<_P UK^+JO[+/^#B"\T>Q_P""+7[0$FN7#6UDV@11QNLT
ML.;IKRW6V7,1#'=<&)=I^1MVUP4+ _QIT ?U^_\ !KC_ ,H*/@9_W'__ %(-
M3K[_ *^ /^#7'_E!1\#/^X__ .I!J=??] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQM)-8OI+1U#\^4ULT+1D?*8FC*_*17W50 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? G_!
MT*T2_P#!"SXZ><DDB[-" ".$(;^W]-VG)!X#8)&.0",C.1_']7]?O_!T=_R@
MH^.?_< _]2#3*_D"H _LX_X-_(+RW_X(T?L^+?:Y:^(9CX85ENK>\^U)%$9Y
M3%;%\##V\92!H_\ EFT+)D[,G[$KYE_X(OL7_P""2O[..23_ ,6\T8<_]>D=
M?35 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!\ ?\'1W_*"CXY_]P#_ -2#3*_D"K^OW_@Z
M._Y04?'/_N ?^I!IE?R!4 ?VP_\ !%W_ )1*?LX_]D\T;_TDCKZ;KYD_X(N_
M\HE/V<?^R>:-_P"DD=?3= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\ ?\'1W_ "@H^.?_
M ' /_4@TROY J_K]_P"#H[_E!1\<_P#N ?\ J0:97\@5 ']L/_!%W_E$I^SC
M_P!D\T;_ -)(Z^FZ^9/^"+O_ "B4_9Q_[)YHW_I)'7TW0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ? '_!T=_R@H^.?_< _P#4@TROY J_K]_X.CO^4%'QS_[@'_J0:97\
M@5 ']L/_  1=_P"42G[./_9/-&_])(Z^FZ^9/^"+O_*)3]G'_LGFC?\ I)'7
MTW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ? '_!T=_P H*/CG_P!P#_U(-,K^0*OZ_?\
M@Z._Y04?'/\ [@'_ *D&F5_(%0!_;9_P1XT2Y\.?\$J/V=K.\6-+B'X>Z+N"
M2I*O-G$00R$J<@@\$U](5\Q_\$6_^42?[../^B>Z-_Z21U].4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'Y0_\'D=]/:?\$C].CAFFACNO'^EQ3JCE5F06UZX5@/O+N56P
M<C*J>H%?RPU_4S_P>5_\HE-'_P"RAZ7_ .DE_7\LU ']RO\ P3CTG^P?^"?'
MP,L_M5S>"W\ :$BS7&SS&']GP8SL55X&!PHZ>O->SUXK_P $V[?4K3_@GG\"
MX]6NK:\U)? &AB>:WB,4<C?V?!R%)XXQ]>N!T'M5 !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!^3G_!Y7_RB4T?_LH>E_\ I)?U_+-7]3/_  >5_P#*)31_^RAZ7_Z27]?R
MS4 ?W0?L _\ )B'P3_[$+0O_ $WP5ZY7D?[ /_)B'P3_ .Q"T+_TWP5ZY0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?DY_P>5_\HE-'_[*'I?_ *27]?RS5_4S_P 'E?\
MRB4T?_LH>E_^DE_7\LU ']T'[ /_ "8A\$_^Q"T+_P!-\%>N5Y'^P#_R8A\$
M_P#L0M"_]-\%>N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'Y.?\'E?_*)31_^RAZ7_P"D
ME_7\LU?U,_\ !Y5_RB4T?_LH>E_^DE_7\LU ']T'[ /_ "8A\$_^Q"T+_P!-
M\%>N5Y'^P#_R8A\$_P#L0M"_]-\%>N4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@_['E_\ T@N*_FKK^E3_ (/;?^3(/A!_V/+_ /I!<5_-70!_?Y1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?BO_ ,'MO_)D'P@_['E__2"XK^:NOZ5/^#VW_DR#X0?]
MCR__ *07%?S5T ?W^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XK_\'MO_ "9!\(/^
MQY?_ -(+BOYJZ_I4_P"#VW_DR#X0?]CR_P#Z07%?S5T ?W^4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'XK_P#![;_R9!\(/^QY?_T@N*_FKK^CS_@]Z\:V=A^RY\#O
M#KK)]OU3Q5?:E"PDB""*VM!'("I<2DEKJ+!2-D&#O9"8Q)_.'0!_?Y1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?A'_ ,'Q4>I'X3_L[M%K%C!I"ZOK8N=)>[5;F]G,
M-EY-PD/WGCA43H[CA#=1@_ZP5_._7[_?\'SG_-KO_<U_^X6OP!H _O\ ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#\ ?\ @^<_YM=_[FO_ -PM?@#7[_?\'SG_ #:[
M_P!S7_[A:_ &@#^_RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _ '_@^<_YM=_[FO\
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M ,>H_P"'BG[07_1=?C)_X6FI?_'J /[F**_AG_X>*?M!?]%U^,G_ (6FI?\
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A )M=_P"YK_\ <+7X U^_W_!\Y_S:[_W-?_N%K\ : /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex3-1_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1_005.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M2NRZ;\1D#'*J/%$F$'H/DS^9/2D'_!H;^QV,_P#$N^(^?7_A*'X_\<K]0:*
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MOCD!QP-0TK_Y ]:=)_P99?LVLWR_$CXYJ, ?\A+2CSC&?^/"OV&HH _'./\
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M_!D[\(A<LR_&CXF>468J/L-AN"_P@G9R1W.!GT%?M;10!^)Z?\&3WPG4-O\
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MPG,&[9_Y>?7./PZ4T_\ !D=XQ\],?M!>&1'GYS_PBD^X<\8'VGT]^M?T+44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH 1ONGZ5_-Q_P7OO--A_X*R_%=9VG\U?[(W;;H(/^0-8]L'%?
MTD-TK^:S_@OOK5Q9_P#!6OXL1I);*J_V. &SG_D#6/\ LT >'_\ !I_!'<?\
M%G_!<DF[='X?UMXP(]W/V-AR<C;P3SSV&.<C^L.OY-_^#4NW63_@M)X!9P&\
MO0M<9249MO\ H$@ZCA>">3D<XZD5_610 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 #?=-?S
M1_\ !?Z?5E_X*X?%H06]K)#G2-C,.2/[&L>M?TN-TK^9G_@X#OWC_P""NOQ<
M475E& =(^5KHJ5_XDUCU&[B@#R'_ (-1-26Q_P""T7@>%D9FO/#^MPIB0J$(
MLG?) ^]PA&#QSGJ!7]8E?R<_\&I<<;_\%IO K21M(\>A:VT3#_EDWV&0;CR/
MX2P[_>''<?UC4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%%  WW:_ES_X.%[I5_X+#?&(>78G
M$ND_>;!_Y ]CUXZU_46_W:_E^_X.$9K-/^"P/QA$C?/YFDYP%Z_V/8^] 'GO
M_!J+<^1_P6C\#H5MV\[0=;3+KEE/V)V^3T;Y<9./E+#OBOZQ*_DQ_P"#5:1E
M_P""UWPWQ]V32-<!]?\ D&S'^E?UG4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBFA\T;N>A_*@!U%-,@%!DP>AH =13?,'/M3MV!0 44!MU-9PM #J*0N :6@
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MQX\,_&+5-=L-"O+M]1\,7$=KJME>Z=<Z?=6,DD8EC#Q7$:/AT(96 *D'()H
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M7_AV'Q1IOQ*FT_3_ (<:[X)O[G3/A;XJ6^\_4]52^,T'_$N(55C4 DL&\P9
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M\*>'_$FH?#NWAELYCK2:@!X5C730R7-AJ33O#?6=Q,RPO83J9HKAI;A2$7%
M'VD6Q7!_'7]HSPW^SSI%C<Z_)J$L^J-,MCI^F6$NH:A?>3!)<3F&WA5I)/+A
MBDD;:"<*  695;A/VZ;;Q!+;?#&6RT_Q/JW@VW\9PGQO:>'C.;Z72VL;V.)O
M+MSY\L":@]A)-'$"QC1B0R*ZGP#X;_ _Q;-^T#^S5=>*-+^(.I6OAK6O']UI
MU_=RWTC:+I$T\AT6'4)=V5D:R,4:BY)E.P))EPU 'W4-=M/[+M[Q[B.&WNO*
M$;S'RMQE*K&N&P0S,RJ%/)+ 8R<5A_"CXQ^'_C5HNI:AX=OI+ZUT?6+[0;MG
MMY;<Q7EG</;W,6V158[)8W7<!AL9!(()\3_X*@>!9/&?P8\"W TGQ+K%KX=^
M)?A36KV+0TO)KN"V@U: S3^5:?OI5C0EV4*VT+OQE 1\S:;X1^+OP\\3:IJW
MPYMOB/9^)_$GB/XM&"QO([Q-#,SO<W.BR26\P%K&LMP()(IW ,AF=0[*Q0 '
MZ6[J-W%?+_\ P3(U:^\5>"_$&MMK7Q@O--U;[ W]D_$#0+W2KG0+Y+8)>00_
M;LW$P9PC2,K/;>:6\ESF0#R__@HA\<_$G@?]JR/08_'WB+P+X?;0M U"+5[>
MSU-=-T#;K4[:I+<26]K+:S&?3H6B"W4D8A,:L"GFF5 #[OW8HW"OB#X2?$GX
M@?$/XX^%[1M9\;V_B"\\=^*]&\=://'.FG6/AJ.'4?[)N[5M@BBSLT=H;F$[
MYS=3;BY#B+@[_P".OQY^'7[*GB+4_$U_XNL[[X,ZO:^ O%&O_P!D27KZ[9?V
MQ;M?^)H;2#$LJKHYMY-T 5HWN;T(,VZD@'Z-[A63X[\?Z%\+O!VI>(O$NLZ5
MX?\ #^CP-=7^I:E=QVMG8PKRTDLLA"(H[LQ %?#GPU^(WC;XC?$[X/\ AO3O
MVCO$^I>%]7\,>+?$\NMZ=X6L]-EUNWL=9T@Z<C"^AN7V+;SWEN9C@W,<#2@9
M)D;Q_P +_ML_%*P_9#\0:[K?Q>N->U+5/V=/"OQ$AFU'2-)1+#6+FYN8+H1Q
M"V"/'*4ACDBF5RKGY=A<!0#]60X-*&S7P?XB_:L\?:'^VYK%@OQ-$GA/3_CC
MI/P^@\-/ING>1+87OA"VU&2-IQ$+@RK>R.\;+("-KH_F# 30_P""6?[8?C#]
MJ_QO?W&O?$CPCXDL8/".FWEYHUAJ.C7%U9ZU)=78O&ABLG-U!IZQ+9B)+Y%N
M 92)"7#*H!]H7OBW2].\06.DW&I6%OJNI+))9V<EPBW%VL>#(T<9.YP@92Q4
M';N&<9K0+8KXX_X*+SWEI^UG\#9M,\?:+\+]2CT+QDUOXCU/3X+R.T*V=E(5
M5)F5"VU#(P).8X)>!C>GGNB?\%"/BUXE^&]]K5X=(\/>._"&A^!]3E\"R:?M
M?Q:VL1VS7AC,F9XPTTMQ:0",_NIK1O,\W)C !^A(;-0W=_#80&6>:*&-2 7D
M<*H).!R?4D#\:_-7XL_\%7O''A37_BA_PC?B_P !ZM9Z5X-\8>(-!:^L8X5M
M[W1=?M=.C@:W6X%P83'/)'(\Y1I)8'DB58MH:]^W/\:/&6O>'_&'PO\ &?C/
MP/-<_#W6? &IW\G]@'3V\3IJ7BN(Q2P12W4@@C@2".%65Y2\T<K-L!5  ?I%
M2%P#7F7[9WQ\N/V6_P!E;QY\0K73X=3N/".D3:A'!,S)!E1]^9E!*PIG?(PY
M6-'/:OE']M+XR_$S6?A#\8_AG>>(/#[7N@7G@<1>)M/TJ6&WU6QUW5EL[C3Y
M;87)VNHB?>5F(DM[R-2@)+L ??44ZS*&4AE8;@0<@CUH$@)_'%>6:AX MOV9
M/V6_%%GX!M=#\-S:3INJ:M9QI8O)IMM>R":YDD%MYH(A,[,_DK(JJ&VJ5 %?
M#'A']I7XG?#'Q]I?Q0EF\+^*=3F^!_PWU/Q5+>+/:_VH+_7-3AE%O%&[)#<&
M.5G,Y+)N@1?)VR P@'Z>9HKYM_9L_:^\:?'OXTWT*^$])M?AU_;'B3P]%J!U
M.V6^L[W1M2:PVM&+AI+C[3Y5Q*5\B$VPC16,PDWK])4 %%%% !1110 4444
M%%%% !1110 4444 #?=K^5O_ (.(9[@?\%C_ (S;5N"OGZ5@K;DC_D#V/>OZ
MI&/%?R5_\''%[;I_P6C^-RLWS"[TO/#?] BQ]J -;_@T\TV.^_X+.^#YGW;K
M/P[K<T>!W-H4Y_X"YK^KZOY3?^#2CR/^'Q^@>=,T<@\*ZSY"@-^]?RDRIQQ]
MW>W.1\OKBOZLJ "BBB@ HHHH **** "BBB@ HHHH ^8_VX/"^M>'OVF?V?\
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MTJ>^\/OJ]AX@^'W]FA;_ ,)W<&J/%:2&18(WAA>U7 \^28761+"RJDBG[,H
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M4:M\8M5NM)\+W%QJIATF22WLKNZD:6:*.5E :T,!54+++( 0-K"H/VCOV_\
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M3H6B_P#"17LPUFWD,>GE8V2Y"JY9HW$T(1@"',T07)=<@'A_[9?PC\9>.O\
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M,=HR JL<<L:^GAX&T+_A*8M<_L?2_P"VK>U^Q1:A]DC^U16^=WDB7&\1YYV
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M7]CX&\,V_@G6O"WB:]UC1M(U2%;AULKVTT:#4(3<3&11,6>219(88=L2F/\
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MW4XA6ZN46.YNHH-_DPW$R*!)-&BR/SN8[FSI?#_]G#P3\+?@=%\-=#T&WL_
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M+8-X2\!6'P_^)UE"\LT7B2PL8X+FTBMW*KN6/4(9%S*B[[:_NU*@O@ 'T_\
M#?6/ OAB4_#_ ,)WGA>SF\&6<%N?#NESPK)H=L$ @0VR',,>S:$!4#&,<8JS
M\2O&^I>"[?3/[)\+ZKXHNM2O1:&*RDAB6T3RI)#/-)*RJL8\L)P2Q:1  <DC
MY5_9]_9$^)'P&^)7BS7+KPAX(\5:EX5D\6:AX'\13^+]1COM<_MO46U/^SY[
M5H6M[!?.\N.:=?/W^1$ZQC+ ?8$][>6OAUIX[-;C4$MS(+5)@JR2A<^6'(
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M^/?V@_%OQ F\*W'A$:;X^^#NL_#F7^U[JX@DL[RY=C!,!'#('A(F??G#+Y0
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MRC+D??\ >I* -HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ QD4@0 TM% !1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ HQ110
M8HQ110 8HQ110 8YHHHH **** "BBB@ HHHH **** "BBB@ HHHH &Z5_'=_
MP<HW,R_\%N_CR/.DXU#3L?/T']DV5?V(MTK^./\ X.1M_P#P^V^/>\$-_:EC
MU.>/[,L\?IB@#WS_ (-";6.?_@KY$[2.K0^"=7=0 ?F.ZV7!X/&&)YQR!SV/
M]4%?RP_\&@B;_P#@KPK+N^7P-JYZ9S^\M.OIUZU_4]0 4444 %%%% !1110
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M **0N!1NH 6B@'-% !12;Z3?D?RH =11GB@'(H **** "BBB@ HHHH ****
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MB"*2V?38]%D=KLX593=?;XVN-XD"_9QY>W^.@#Z0^)/[,E]\0?VP_AO\4/\
MA(+.WT_P!H&NZ%)HCZ29GU-=4:Q9Y/M'G*(_+.GQ87RGR'DR>1MX7]HO_@G[
MJ'QJ^+FN>,M+\96OA_4'TWPM'X>MSHK3PZ3?:!JE]J-O--BX7[1!,U\\,D(6
M,A%!60-@B/\ 9UTOXG:'^U=\1/#-]\4-<^('@JV\.64EQJ.IZ9802^'O$<TD
M[26UD;>%$,(M3#*T$XF:+?;_ +Q_-85YGH?[;_Q(N/V%/V78],:\\4?%KX\:
M5:-<ZI:V%J9K6"/2WU#4-0CMW:*V:;8BQQ1NR1B6YC+*RH8V .^@_8%\7>&O
MC%;?%K1?&GA^/XI7&M:IJ6L"XT67^PM1M[ZPTVP:U2%9_.B,46CZ:ZR^8S.\
M,N0%FPA\#OV$->_8_;Q#JW@SQ%I>H72_#2Q\*:7!<:*S.=4M+O5;\WC(+A$,
M,UQJDG^C*R!%15$H'3VK]E+XQ:!^T!^SMX/\9>%=<U3Q)X?\1:;'=V>I:E"(
M;VZ!R&,Z*B!)0P974(H5E(  %>A4 >7^+?!?C?XG? CPC9WTWA_2_&4-[H&K
M:Z$662Q$UI>6MW=PP8);:[0R1HS$X# G.,'P_P".O_!*.U^(?CGXH:EX3\87
MG@G2_BIX?NTO](BLUNK*T\1R75A.NMQQL1\T@L(4N8 52?RU8X=I&;[  Q10
M!\]_";]G[XC>#/BMXF^(UY<> X/%WQ"O=$M?$=G:K=3:?;Z5IT$\9^S2$1N]
MY(]Q(P>1 JIY<9#>6';J_P!KWX):]\=_"7A'3]!GTBWDT'QMH/B:[;4'D59+
M?3K^&\>./8C'S'\D*,X R23V/K-% 'F?C+X.ZEXZ_:=\&>*+^XLW\+>!],OI
MM/L<OY[:S<[(!=GC:!#9FZB3DD_;I<@;5-<K^U'\ _&'[0'Q=^&%M"WANT\!
M>#?$EEXPO[N2YF_M9KRR\XQ6\< C,3Q2&2/+F5&38WRON 'NU% 'PWHW_!.K
MQQ'\0=+U34[7P%J-KIGB3XF:RB37<LC>7XCF=[# :VP'$<CQ3C.%!.TRY(KQ
MGP?^PSKGQ#^)'B[X.W6D>#+O5O#/@+X4Z/K/B=[J3[1H4VER7DTL]AFWWRR8
M@4QG?$5=XRXVY%?J5BD"X- 'YG?&#_@FC\<OBHOQ2ANM%^&DG_":>#/&_A&U
M,>ORVUEMU76X-0L)%LTLA' /+64S,6DE:9I'>20E:^OOV4OV>M0^ WQ7^.6H
M_P!BZ+HOAWQUXJLM;T*TTMU55@BT+3+"3?$J*D4AFLI#@%@5*$D'('NE'2@#
M\[?V>?\ @GU\3_V??B+\/_BQ:>'=*OO&&F^*O%T?B?PS>Z]]KM6T?7-:O-0B
MU#39I 8K34+=)XDD6-(Q<QF6-W&(V%.Y_8$^+$WP;;2_^$+\-WGC3P7X-\::
M!<ZE?:E&VG_%N353FW2[\MQ.J3N!<W'VC9Y4X"1LZ.\B_H]M [4FW- 'YN>"
M?V-/B[X0\>-J^J_"U/&'@[_A9M]XENO"FHZ[I#3:G;:AX:LK%;]HXTAL?-M;
MN*Y5X=JC;<RO'YK(CR?07_!-Z7Q;\"?@]\+_ (%^*O USHNH>!?A=H\M_J=M
MJ5O>V$%XC26DE@?+;>KA85E1R-DBLX4YB:OJ+;GM2;!F@#X^7]E;Q'KG[2'[
M5'BG5O#OBZ'3_&ECI4/A5]-\5/8C7/LND/;R*([>[C$;>>Y4&X"9!4Y ''SW
MX=_9.^,?ABT_9_A;X1Z]!K7PP\._#.RNM5L=6TZ>4_V=<M!K-FSS77[A8X7=
ML6:J+J.4F624(L0_4;%)M'I0!^8WQ'_9*^.%[9Z+-X8\&ZI#-HNL?$_4;S3K
MR]MA'XBTS4==M[RTT<W G,EK_:%C&\23QG=;L%#;!D5Z%XG^"WC[Q1\5]::Q
M\%^+] \1W'C#PCKOP^UY72.S\)^'8(].75-)F\N5HH"BPZLDL #+<_;8BAD(
M#0_>^T4N* /SO^'>I?$3]GWXRV>O:YX!^*\GA/X87GQ3U+5;B*:.:UU&QGU-
M;_2(K827(\\&T 6'>%6-LQY3#8]L_P""EMEJGQ__ & X1X3T7Q7J5UXCUOPI
MJ4%OINGE]3M;5=:T^[FF\EE.QX;>.20AU.&3!5C\I^GKW3K?4K22WN(8YX)E
M*R1R(&613U!!X(/H:D6,** /SY_;&^''Q \'_M5>,_%&AZ3\7OB):Q? O5-(
MMY].1;&X:\FU>TF^RVMU:VZ,MP8(Y)-JAI"$"H1(5!C_ &;M+^*6C_%;P?8Z
MM9_%4^&]+^+7BB2>5],U+3[-O#]QX=FEM<1/+(ZVHO94$*R.S12 (-CJR+^A
MF*0* .E 'Y7?"JS^+OPA^"FCRZS9_M%ZU<>(/A5X2N/$L$TVLW5U#K \0QV]
MY_!+- T=G,YN8;-4GEM8V9<2!9A,$^-'CGX3W5A?ZI^T1IMYX=\$_%0V\VGZ
M;K6E27M]:ZU;-X;P#YDK2?92[6Z-+(\R1F-FG7>'_4RC% 'R+_P4.D\0?$+_
M ()R>&&2R\07'B74_$/@2^N$MM"N+J[MWBU_2KNYFDM(TWJ(8XII)%95"B-@
M=O2N/^*W[)OB+X2_&GPK9Z/\2OB59ZE\?_B=J&J^.M=\-64=F+>T3PO=6UK"
MH6&6*UBCDM-/599,N\K99V9E"_=6*39Q0!\$?"CQS\4/C1\0/#NBMXN\=^'_
M !QJ>L>+-#^(NE_9RMKX5T]$O1I.H6H>+R8F1TTTV\B<7<=S*\@E*N8\RP^/
MOQL;]AQO%'B&^\3>'?&7A'7_  I\.=122QBE_MV^L_$EK8Z[J\49B;=:WD3R
M%' &R*)Y%*C#U^A/EC;CGGB@0*IXR.W6@#\U=7_:P^.'A/Q[J6K:%XN\1>-K
MZX\:_$OP]I'@RYT:R2TNHM,TZ[N])B1H[>.=F%Q;V\22&7$B7.T[V(>M#Q/^
MW[=:5\%_#?C#P[\<M>USX9^)O%5AI7B#QIJWA>"Q/@,2:1<L;>65;(QIYNI1
MVB2M+;G[(UYY3,FY#%^C7E#_ &OSIK6RNI5E4JW4$<&@#R7]DSXY6OCSP1I/
MA?6/'&B^,OB1H/A[3+_Q'+9V#:9)<+=1,8;TV;_- EQY;N$.,'(PO"CY-\+_
M +.$O[6W[8O[0$6CZSX3T_2/!WQY\+^++F^AMS<ZTLVF>&_#\C6]LX94@\Z:
M"6WDE)8A&NDVL6.W[XT_P)I>F^,K_P 016J_VSJ=O%:7%T[L[M#$7,<2[B0B
M!I';:N 6=F.2<UJ0V<5N[-'&BLWWBJXS]: /S3^%7_!2KXA>-/AU#XJN?B5X
M+^RZQ>Z+HWC#2HK9'U+X-7]SJ_V:]^UHUM$+>.)9/LP2^,K>9%]HWR0K(#UF
MM_M;?%JZ\9^'?!47Q7\+^&=/OO'?B?PK!X\U#0[6XBURQM-$34+>Z5"\5OYU
MO<-/:R&/$;M92G:O*C[VD\,Z=+;WD+6-FT6H9^UH85VW65VGS!C#Y7@[LY%>
M?_$K]D[PM\5?B1X \1:HLRP_#EKXZ=H\4-O_ &7="[MOLT@GB>)BP5,E C(
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MJ\1ZYX(\$^'?"^K>+KEKO5[G3K-87O9&=G8G' !D=W*KA2[LY&YB2[3OV5?
M&D?%.Z\:6OAVWM_$5Y>MJ<LR3S+ UZUO]F:]%OO\A;MK?]T;@()3&2I?:2*
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M"^DZ/K;E-2CU&WFM]3^VK%&)HU$;3Q/83I*L32Q*VT+*YW;?H"O&OV:/V%/
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MDVEIJ9N+B!Q:;3=PW#7-K'\K//YXB*%I5XB?3OB_\-OAY>:Y9ZY\>-+U+6_
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M?QBO_#-UXAL9KZ?P=J\>O:.R7L]O]CO8TDC2;$3J'(261=K[E(=@0037644
M<[9?"S0[#XH7WC2.R_XJ34-*M]$GO#*[9LX)IYHXE0G8F)+F5BRJ&;*AB0B!
M<3Q!^S5X1\4?'32/B-?:?=W7BG08!#82/J5S]DMV"7$:S"UW_9_/6*[NHQ-Y
M?F!+AUW8.!WM% 'AX_X)U_"A?#\NF_V'JS6LND>(-"8/X@U"1FL]=N?M6JQE
MFF))GG <N<NA V,H&*X[X6_\$\K71/VD?'GB;Q%)]L\+WNJ^'-1\,Z7#K=U*
MF[2-.@MX);Z!T5&FBN(O-C8/)N*Q,_S11[?J&B@#Y;L/^"/_ ,'-(\/7FEV<
M?CBWL;O3(-%6$>++]X[2QM]4&J6UM"CR%8XX;@80 <1LR<ACGVSX9_ /1_A'
M=^-KC1;C4X[CQ]KLOB/4Y)KGSC'>26\%N6A# A%$=O$ F"H*YP<G/<44 ?._
M@_\ X)D_#GP%X4^%6FZ3<>*K6[^#-W>7'AC5O[4W:C;PWA8WEG-(R$3VL^1O
MBD5@3'&<@HI&;>?\$J/AUJ'PMF\&S:KXV?0+316\.>'(/[4CW^#=.-[;WJVM
M@_E;O+66SL@!<F?]W9PQ',896^FJ* /E^#_@E5X2TZ^74;#QY\5-.\0#6-<U
M8ZQ#JULUV\>M) -3L2'MFB^RSRVUO/M\O?'+"C1N@4+7=_LS_LOZA^S1J$>B
MZ?XP\0:M\/M"\(:%X5T#1M3N(KAK$Z=#) ]T76&,B2:,P!_F8,T18!,[:]EH
MH \/N_V%-#O_  K\>='F\5>,9+?]H6:>?7G\RS$FEF;2X-*86)%MA +6VA \
MX389-W.3GAY_^"5GA\>/O#^OV_Q$^)$,GAV7PS/%;%M,EAN'T*-XK?>SV9D5
M98Y'\V.-TCWLTB(CL2?JBC% 'QWJ?_!'#P;J_AOP[:W'C7QQ-JG@[3-7MO#^
ML%;!+[1;[4-;AUG^U('2V4)=07$")'@>6T)D21)!(^>YM_\ @G_ /'.I7$WC
M+6;GPGX@\5Z7X\U?P_)96X2ZUVP^RO'<1SJH:&&2XLK6YD@ (,T7RLB/)&_T
M710!\8V'_!-7QM\$=*U;6?AS\7-8C\6:-X=\1>'_  /#>:+8/8Z*FK:I;:DA
MN-ZDW'DRVX1G)!:+HF]<O[M^U3^SK?\ [2_PY\/:'#X@M_#\FB^+-"\5/<'3
MC>+<2:5J5OJ,<(3S8]BR36L89LDA"P R01ZQ10!\Q_M+?L">(OCS\9_%GC'3
M/B6WA&;Q%X.TWPG#;P:(T_D+::M_:3&5Q<H9H+D-);30 1EH)642*?F/->"?
M^"6M[X&_LB&T\?6:V.BZWXRUFUMH_"\=O'%_PD,<@\E5CG556VDFD887]XI"
M?)C<?L&B@#XXL_\ @F)XI\,>'=.M-%^*%G;R67A'P/X0N$G\..UKJMMX<FO9
M)%N42[5VAO5OI \*.FWRHP7D0R(W*:5_P2"\3:#\$-:\$VOQ \,BUO\ X8>(
M?AO:31>&I+=;0:GJ;WB71C6Y((BB;RS$I7<PW J/EK[RHH \1_;._9?U3]JC
MX?\ @O08[SP_;V_A_P 8:+XGU2'4]/:\MM3AT^Y2Y:U";P%,C(!N?>%'\+'I
M-X__ &7)-1^-/P5UKPNOASP[X8^%5_JEY/I,-AY7GK=Z?-:*MN(RL<6UIV=B
M5.>0,$DU[110!\E_L[_\$[=8^'<WPST7Q=JGA_Q%X4^"VB:OX=\./#!(M_K-
MG?+' JWZM^[!2UC$;A"RS28EQ'M"5F^!?^";GB3X:?LV^$_ ]MXIT_7]2\,>
M/=!U:/4]45XW7PYHFIQ2Z;IP*(=TT5C;PQEB K323R$Y<D_8U% 'PAK_ /P2
MV\;^+_ *^';K7?"6DK?:/\4=*OM2LO/FG@;Q9J'VNUFCC:)1(;<;4D5W7?M&
M#CBKOQ._8W^.7Q97P;X\UC0?V?9/B5H6IW8UKP[;W>I6_A[Q'9W.FK82SRZ@
M+4W0O%6./RRUNZQPE[?<X/FU]Q44 >1?LV_\)-X+UW4OA_=>$_#FA^!_ NBZ
M-I_AR_T;[1!;71%J4N+5+:6,"*.W,<83RI9D\N1%+"1'1?+?V<_^"?']@^+O
MBIX@\?:#X*?Q-XD\>ZSXI\)ZSIMS+J%WHD-[:QVJ2@SV\0@NUC1@3%OP'(#X
M)S]6A #3J /SQ^#G_!._XL_#_P"&'@>ZU#PQ\.5\<?">[\,V:O:^*]3OXOB)
MIFBK=QQK,;J()I^S[8]U;0!95CNHQF14PPY'XD?LD#PU^T]X%\+Z[\/O GC?
M4OB)8?$_Q'!X,O;V%M/T9-0GT0K$LDT6&!D)EG\M/E>ZNFC$NQ1)^GE,:WC>
M59#&ID7@,1R/QH _/+X@?\$\/BUH7PMU#0M MM(\47'AKX>_#/0;+[9KTFFQ
M^,;GPSJ=W>7]I),@,UNMQ%,BQRMUD^_A,EOI?]FWX%-\-/V2M3T-/A]'X0O-
M735;\^%XO%$NHR6\M])+-+"=0?/EO+*[,QB_=1M(=FX+N;WDC-% 'S#_ ,$R
M/@5XN_9N^$?B?0_$>C?V9IBZS')H'VRUTR#Q!>6:6%I"#J9TT_8YKE&A,"3Q
MX:2&"%I 'S7SO^QO^P[\5/V9?&_PH^)5]X/UC7+NPOO$NB>)O"&IZW;7S>&8
M-2U>\OK?7M&\RY:W@F,4T4%W%$ZM+"WRJ7BQ+^DV*0J#0!^2'C7]F+Q3\*?V
M3_&%]\2/A_XZM_&VGZKX<\.ZSK<'B:R_L_XC,_C*QE@NK%+>2.9KB59)"9K_
M ,F2W-UY*.Z%W3VKP1^RMXK^!_Q!\'>)/#/PO\32^![7XJ>(=0LO!UM?6:W&
M@Z+J'A_["08YKA88[2;4XI+GR$D/EK>1ML4JR)]W>-?A_H7Q(T%M+\1:+I.O
M:8TT4[6FHVD=W;M)$XDC<I("NY'564XRK*",$5K+& /QS0!^5'@G]A+XF:K\
M/?!EGKG@KQQI_P 2H?AA\.=)T#Q(-97R?"FN:3<7AU&:\DBN""T:SJS963SX
MG>)22[)7M_AKX/\ Q T+XKZ#>V_A7Q58I)^T3K_B"[N%=%MVT>?0;^V@O)E2
M7Y[5KA[3"N"VY0Q1=H-?=.T>E&T>E 'R)_P2^\/^(+739KSQA\/_ (F^"?'U
MIH=EHGC2[\0ZH)M*\2ZS;O*T^H6*+/()_->21S=;8]T36\>/W92+D_@SX+^)
M%Y\=O"TVMZ?X\L_%>F^-_%8^(6H3&\;0-=\,S1Z@=+2V<GR9<!](\F. "6!H
M;D,%+2^;]T8H"@4 ?#_[,'[+_B;Q#_P1#U?X8Z'9Z]X!\;>+/".OZ5;Q:ZES
M:W.EW]U]JCB=UE)DC7+HV5['<!DG/HGP9^,&C^*OV4/#WAO_ (5IXZ\-ZSX;
M\-K:R>'M0\'WD:^')[.S,81)6C\B4(R!(FMI)3*"IB#C)'TX!@4A0&@#\IOA
MGI'Q6^!/[%]QI&DO\=+.2W^"WPJN[6V-EJKS:9K*WT]OJMK:1B,_9Y$M$LEN
M+6$+L0;G129'/I>K>+?B9X/^/FJ^)H]?^-E]:_\ "W/$NA1:%!9S7%F- 3PE
M<W,1MK>6$0M_Q-(+86TTA*&27RE8J[*?T/VTFWZ_G0!\6_\ !);XP^,/B'KG
MQ$T_Q-J7C;4=+M[/PYJNB?\ "16E^98DNM+7[3BZN[>%IF:YBE9U142.3>$C
MC3"U]IT;:* "BBB@ HHHH **** "BBB@ HHHH **** !ONU_%;_P7"VR_P#!
M7G]HIHYI+A?^$YU$;VSD$2D%>>RG*CMA1CBO[47^[7\4W_!;%E;_ (*Y?M&;
M%*+_ ,)]JHP<GG[0V3SZG)_'TH ^X_\ @S+=%_X*F^,MV_<?A9J07;G&?[4T
MCKCMC/7C..^*_IW%?S$_\&94)E_X*F^,F'_+/X6:DS'_ +BND#^H]*_IVH *
M*** "BBB@ HHHH **** "@T44 ?-_P"U-^U5XG_9#_:$\"ZIXJFT./X">*HY
MM#U/4DTZ9]2\/ZZY4Z>9I1*5-G<XE@&(-RW#6ZE]LORSZ?\ '[QAX(U;X9P_
M$+6=-TC5/&]YK=^-#L/"MS)*^GP64MU;V,DXN76&]@B$;ROADGD25(T088=S
M^UM^SE+^U)\)X?"J>(KKPRL.NZ1KOVNWLXKJ1GT[4+>_BCVR?+M:6VC#'KMR
M!UJ'X[?LSS?&KXE^ _$B^(I]'E\"C5C'!%9I,MX]]I\EF&8L05\KS"X SN(
M) H Y+X=_P#!3GX3_$WPE>:UI]_X@M[.WTS0]8M5O]!N[.;5[76I?(TR2T21
M T_VBY!@78/]8,' ()V?#7[?OPW\6>*?#NAVEYK@U;Q1JVL^'[&VFT.[B9]2
MTF.26_LBS1A/-C6*4C#%9/*?RV?:2/GK]H#_ ()WZY\-/V>UM?#NHZ_XWN+3
MP-X.^'LEK9Z/:2726FAZ@]V-12&6XA$LC^80T231NH :)PZJ#T_PC_8LU[XY
M_LS6GASXA23^&+K0_',?BWP_JVDZ8=!UIU,@EO)+F);RZ,<]V+C48))!/YC1
M79<K')P #UW1O^"A'PJ\2> =!\2Z=XAFOM+\5:7INK:.8].N/.U&+4'G2S2.
M-D#>=(;:XS$0'002,ZJJ,1A7O_!5KX#6/AG2=9/CI9]+UK0D\36]U:Z1?W4,
M>FM>?8FN9FCA80I%<YCE\TJ82#YFP<UPFL?\$GH/"WPAO]%^'?C0^$]>L?B+
M-\1?"UW>Z+'J>F^'VD6=&TC[$SHLFG>5>7R")'C,9NW="C@&M'XU?\$W?$'Q
MITOQ-#>?$;3;>Z\4_"^7X>7,\?A-42*>:]:YFOHXH[E%$95C&MOU7"L9G.[<
M >X_M!_$#7/AGX3CUS3[KPGH^AZ2)[_Q+K'B*>2.UT;3H;>65YP$*[B'5 =S
MJJH78DX /S3X"_X*8^,K/P9\&_%WQ'\*Z1X(\+_%;5M=,4+P7LVL1Z/:Z=<7
MFGW)M5#.ES<K 9&M@)62.5%_U@8+ZW^W/^R+KW[8_AGP?X='BG1]-\'Z7K,6
MK>*= OM&DO+7QDD WVUG,R7$;1VRW(CFDC^<3>4B-\A=7K^(?V7?B)\1/C#X
M)\7>)O'/A>X;P1JNK7UG96'AR6WC\F\TDV$46]KIVW)))-,[MNWAPBJ@7=0!
MUUA^V[\+-4UKPSI]KXRTVZF\8VFFWVD20)+);W,.I+*VGLTRH8HC="&7R5E9
M6E,;!02,53\&?\% ?@S\0;O5H='^(WAB\;0]*OM<U!_M/EQ6EC8W!MKVX=W
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M&NFK\A_AQ^V7J7@[Q9\#?'&HZY8V-IX@^#^FVWC#QMIEKIT+>%;.ZUXQK?\
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M?V_PWN/&6@?![XL:O%JL-A'=R6ESH&NZ=90[)DFP+:X18Y)XD8*[Q(5=0H
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M?CI9:M-X=O+B>30;T:=J5M=V,]C=6$[017"I+#.B2*6@GAD4E<,DJD$@UV%
M!1110 4444 %%%% !1110 4444 %%%%  WW37\4O_!:L+%_P5N_:,$;+M_X6
M!JQ^4YY-RY/IWS]/?K7]K+?=K^*3_@LK*VH_\%8_VCI+A?*D'Q%UN,*&W_*E
M[*JG( ZJ <=1G!R1F@#[N_X,P$9O^"H7CPY^5?A7J (]2=6TC_"OZ;J_F/\
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M7=M);+=W2FY=)'C23>4A$"/(-V%7$8^@:* /EO7O^"=^K:SK6O7G_"<VL?\
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M#/"'@&RTRWT7PWHNEQZ+%=0:?]FM51K&.ZE66Y2)L9199$1G"D!BJD]!7/\
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M1Y-'\%Z'JFF>%=*@TN2.YMIM2BL4N'NIS*5F16LBR!$C;%RP).Q20#'\#_\
M!2;X9Z7\// \GC;X@>%T\2>)O"^A^)I7TFQOQILMKJLGD6M[&9(R\5I+<9C5
MYRNPE!)L+#/7:?\ M[_!W4_C'-\/X?B#X?\ ^$P@N;ZSETUY6C>.>RC$MU"7
M8!!)'$?,*;MVP,P!521\\V__  2H\76?P$;P6OCGP[(__"G_  I\+UNWTB?'
MFZ+=W$K7A7SONS13[?+SE70$LP.T4_A-^R=X[^-WQ)^(DVI3V_A'0?#?QEUW
MQ?H,]WHDXU*ZNSI!TZUF59P(9K/-S++YB[A*(UC^Z7- 'T=IW_!0'X,:GX3_
M +=7XB^&X=)^V6-@+FZF:V5IKZ(360'F!25N(B'A8#;*IRA85T$/[1F@^-OV
M<M0^)/@.^TKQEHL>E7>I:=-;WACM=1:W$@:(RA',?[R)HV.QBC*P*DC%?)OP
MG_X)>?$SPWXDM=4\1>+/ U_=W.M>!]<U:2VM[Z26\GT$S?:',DTCEFGW1LA(
M CQLQB-2WN_PC_9H\6?#7]COQQX$N+SP[>>)/$6H>*]0LYHWFCL4;5]1OKV%
M96V%QY?VP(Y53G82.N* .<_90_X**WG[0?Q!\%^&]>\%6OAF\\=_#.T^)]A-
MIVOC6(+"SF:%3;7I,$#6\V;A#&VUXY0D^UP8F%>M:5^UU\,-<\.:IJ]GX\\+
M76F:)-;6][<1ZC&R027.W[*O7)\_>GE8SYNX;-V:^2_AA_P22\2_!GX<'POX
M5UCPKX=T?XF?"V#X??%&UL?.CCDU"UTO[!::]I?[KBXV,Z2Q2!%E1826#QEG
MZ/Q7^Q/\8/&4]EXLE3X7Z;XXM=*\)^&[NSL=2O$L-2T_2M0N+N[DBN_L8FL9
MY!=2+;^5%(]O\^)LR!XP#V/]I_\ ;]\!_L\?LJ:Q\4;;Q#X3UZUB\/7VOZ!:
M'7H;6/Q2+6 RF&VFPX9G;9&"J, \L:D98 ^TZ-?/J6CVURZ>4UQ"DI3.=A89
MQGOC./PK\X(O^"5?QL\&?L]>(O!VBS?"/4Y/&7PW\3?#N\CU+6-32'1OM>JZ
ME>V%];2FTFEE+QZ@$N8Y K![:%Q--LY^Y/@GXS\8:[XG\8:1XE\-V&CZ7X;N
M[:ST74;2ZFE368C:Q/*Q2:&(JT<I9,IYD; KA]ZR(@!Y7J'_  4<71OV4?BI
M\5;OP'K'V7X5>(]3\.W>E0:A;R7.I/I]X+2>:!V*H$,FXH)"K%5Y"D@5[E'\
M7= EU^YT'^VM#_X2RQLOMMUH@U*!KVU3:K;GCW;E3YU^<@+\P.<$5\6^.O\
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M^ 7B'PEI?B%M;-]XXO9]-T:'3=&NM2>[N8;:2Z>+;;QNRGR(9I 6 !$3 '.
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MR/'WCK3_ (:^"-8\1:HTZ:7H-G+?WKPP//)'#$A>1EC0%W(52=J@L<8 )P*
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M@!:*3=2>8* '=:*16W=*6@ HHI"X6@!:* VX<44 !YI N*4G% .: #%&***
M#%&*** #;FC%%% !1BBB@ QS0%Q110 8HQ110 ;:,<444 )MS0$P?_KTM% %
M/1?#UCX=2X6QL[6S%Y</=S^3$$\Z9SEY&Q]YF/4GDU<QFBB@!-GU_.N3A^"7
MAZW^.%U\14MKI?%=YHD7AV6X^VS&%K**>2X1/(W>4&$DLA\P)O(;&['%=;10
M FWZ_G2,@=<&G44 1_9D$83:NP<;<<8],4UK*)E4;%PIW*,?=/J/2IJ* //?
MC-^SCH/QI;P>=0DO;&/P;XFM_%5M'8^4B7=U#'-&$G#(VZ-A.Q8+M8D*=PQ7
M97/A;3KV"*.:PLY8[=&BB1X598D9=I501@*5X('!''2M"B@#/3PMIL>M?VDM
MC9KJ7DBW^UB%?/\ +!R$WXW;<]LXJO:_#_0K&>TDAT7289+!94MGCM(U:V64
MYD5"!\H<\L!C=WS6Q10!C^"?A]H/PTT%=*\-Z+I/A_2XY&E6STVSCM+=78[G
M8)& N6)))QDDY-8]G^SYX#TVV\0PV_@GPC;P^+M_]NQQ:/;HNM[RY?[4 F)]
MQD<GS-V2[$]37844 9NE>$-*T'PQ!HMCIFGV>C6MN+6&P@MTCM8H0NT1+&HV
MA-O&T#&.,5Q.C_L>?"GP_P"#=4\.V7PY\$VOA_6[<6E_IL6C0+:7< .X0O%M
MVF(-R(\;03G&:](HH XF?]FWP#<:T^I-X-\-&_DU:WUY[G^SX_-?4;>+R8+P
MMC)GCB^19#\RJ H..*P]2_8F^$NK>'3I%Q\.O"4NEM8ZGIGV4Z>GEK:ZE+YV
MH0J,<+<R@22 8WN QRP!KU*B@#C?A#^SUX(^ <6L)X+\+Z/X93Q!>#4=2&GV
MXA^VW B2$2R8^\_EQH"3R<9.223V5%% !1110 4444 %%%% !1110 4444 %
M%%% !7\2?_!4:YAU#_@IK^T9/&/W<WQ0\3.FX%3@ZM=8X[?2O[;#R*_B4_X*
MB2^;_P %,_VC&\OR]WQ0\3-M4<+G5KKC@XXH _1K_@RKY_;X^*WK_P *^Z<<
M_P#$QM?Q_+_"OZ4:_FS_ .#*E0/V[/BW^Z9F'@) ),<*/[0M\C/O_P"RU_29
M0 4444 %%%% !1110 4444 %!.!110!^?_[;_P"RGXO^-_Q)_:6A_P"%;_$K
M6M/^(7@71/#GAF\T#Q5:Z7:7]Y!'JA<7,;7T2M;I+>0AUNH)(Y$$J^7*IV/D
M_%3]G;XS:E^T;\+M:OOA[=:EK_@J?P.VH>+/#5Q9K97RQ+<PZOLCN+B-[6W1
MYW)MK6)!+$P:1I<+&GZ+8HVB@#\]?V?_ -B3Q1\2_#FD^&_%7AWQ1X#U"_\
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MGK-@9KM[8Q7[3^7)&P:.;[.R^4Q&0P4@C:#6;\#OCG=^&?C?XT\">'_%6B>
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M/!/</ DEO:0/*4CC55758-H550"U^UEJ4MI^WWX'DLYKBZM[?X/^/;Z[T_\
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M5_P[XI^%?@63XF:/KW@GQUX@\)0^,-9LH]!U&33=$TUY;R)=2N+EH0MI:/\
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M/B%XB\-Z[H5MJNJWSF$"^-TEJ;JZCME>XDA@GB66X%NCW$D3.44R$CR+2/\
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MG_@R<N73]K/XUPB'=')X0LG:7?\ <(O2 NWOG<3GMM]Z_HVH **** "BBB@
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M^ 'A.TU:_P!(U[6EO;L644&E0([*WE2S%Y997C@MXECA<F6>6--VQ-Q>1%8
M^7/V3_C=<?LZ_L<VO@/5/"/Q0U3Q5:IJLS7-G\,?$%OI<DUY>75U& #;/*L:
M^>JM@,1M.!TKR/P18ZOJ?[-'P'^#7CK2_'EG\/\ X.V_AZ36#X?^%WBVZOO&
M%QH@@>SB'F:=&EK;-<V\,T@_>R/Y>Q2@)DKZ>@_X*R_"N^@T:ZM+7QM>Z7K6
ME>%];34X- F:RM++Q#<2VVFSSR?\LU,T11P1N0G."%<JSQ9^VY<>(OVROA)X
M)\'_ &]O#6O:]XCT37;Z?2&^QW\VF6$S216UT6&V2"\C$;#;B39,%8^4^ #Y
MT^#<]OX+^.'@/7O$N@^+KS3O"FL?$+5KI8OA9XPFN(SXCUE-0LWMU?1@GF0H
M'BE)9<%\H6!(KROP1X6UCX;?!.STF'1=(A\=?#.?1K?P?XC;X6>.O.\::?IF
MJQ7L,.L;])9K/S%0,ZV_V@?:W$ZE0@C;])_CM^V3X)_9R\5:;I/BB76+=]0D
ML8VNX=-FFL[(WM\EA:^=,J[5\RYD5 H+,!N=@J*SCFM _P""DGPQ\3_$FZ\)
MV,GBZ;6;6\UW340>%M1\J\O-&9A?VEO)Y.V>=0I=(XRS2J"4W8H ^(OV@-:3
MX\QS/;B/P/<^*/AOXG\*:K;Z5\.?%Z6>F:CJ.IVNH1M$AT9/ML$TD,B7;R?9
MWD,TCA"7*!_Q)UOP]\>_C,?'6N6>E:3<:KXJ\$:CK?AR?POXDN+);70OM[W%
MTLDFCH)KJ3[<D*J8U4PV<&Z13^[3]#/@;^U9X,_:/T[1+SP;J%SJ]EXA\,V/
MB^RN193Q1/IUZTBVTC,Z 1R.89<1/B0>6^5&TU7T?]L/P'KOB+Q%H]OJ5X=6
M\*^*(/!^IV3Z?<QW%OJ4\,=Q$@1HPSQ-!*DWG(#$(MTA<(C$ 'YO_'*71_&\
M/QTT[PCJECHOA7XE^&==T&WT'4K+4Y;!KV[EL(X+NS+:7Y^FQR6MM-]LMM[P
M/+%;-&F0\@Z=O'/P[TG]I2X\2:7K7A/2_"H^.%A\0[>-;:ZM5M=*@\&+HD[B
M/[,%2;[6C2% 0&C<L6#';7V[X/\ ^"A?PI\=Z)>7VFZ]?S?9(]+FCM7T>^BO
M-0BU-7;3I+6W:(2W"W CE*&)6XBD)P$8AUE_P4)^$NHVOAZ>+Q-,UOXF^Q_9
MI3I5ZJ6IO-0;3;5;LF$?8VEOE>V5;CRR98W7&5; !^5'[)6N_!GQM^R]X1UZ
MW7P?X;C_ .%7:UX.U?\ L768=+U3QE)?:K:S1LLZQE(S:1VLLB&ZP!/=>7CR
MPSM]F_ ;]M/P+X+_ &&?$7A'7OBQ\'-1\=-%K\=A%?7EKI5OJ)N;FZDLWU);
M'9$EQ.)HVNGM0JF665DQD&OI#P?^WW\(/&/CV^\+Z?XRT]=4TLZNER+BUN;.
MTADTF;R=3B-S+&D'FVKX,L8?>B.DA'ELK')U?]N3POXOO_"]KX-\5>'8[J^\
M8V'AO4[37K'4+.Z*W-G)>)%!$8E=9Y;=5EA>4"%T#G<<4 ?FE\')/ >H^.-!
M_P"$LU3X.KX5_P"$T\(>)M2L;KQEH#V^GQV/AR[TR[06L+)$J13_ &=51-YD
MA"DL[;U&!XYUOPO8?LLZIX)N+_X.^-+'5/A3XG\&>&=%'Q#\/@> ]7EU2_N;
M"95N+M8DAELY[!!);L\D)T^)-@4[E_733_VV/A7J4VLQP^,],:70K>&ZN$V2
MJUQ#-=-:0RVP*9NHY;I# CV_F*\N$4EF /5Z/\5/"7B;X9IXWCU735\+K9R:
M@VJ7G^BPVUN@8R22M*%,2H$;?OV[=IW8P: /)-:_;E_9M^)?PQNO#OB#XP?!
MN[TKQ!ICZ;J>GW/B_372>&:(QS0OB8JP*LRG!(.:^,/AA\7O#_PR_P""=7Q(
M\+ZY\6O@C\2?B%I>AR> O"NG_P#"Q+&(Z[X=TV66#37G=+V'_2[B&2664>=#
MYI:*-WCVDC[YB_;.^#,OA&XUZX\>^#].TNUU2'1;B;4[M+!K:^F020V\B3['
M222,B1%8 NA#C*D&M_PS\7/A[XY^#O\ PL#1-6\.ZSX+^R3WPUBR*7%J88=X
MF;<@/W#'(K+]X,C*1D$4 ?E5X1^+WACP.]Y8^(/^$<^(WPLG\;>*/-\(+\1/
M"4%X;?5K&P:SU2WA348;.-()EU.%HU>)XCJ#2H'96<]Q=_%?0U_;9\&^(H[G
MPU+X?\.^(H;?4+W3/B)HNI+K6BR>";FP82WEWJ"W3I'J1B3[,L<<>^-KI_.E
MF5H_J#PU_P %)_@[XK\>>#H[I_ ^@_#CX@>![?Q=HOB77-0@L#>337Z6:6)M
MY4"AR74Y\TMN+*4&W<?<&U3X1W_Q+;P6TOP]F\7K"TYT0_9&U#RPJL[>1_K,
M!71CQP)%)X89 /S!^%4>K_!GX*:7'I-[;ZE/)\+/AU_PF^E0^/=-N+CQ5?Z=
MJ<I\06".;XA[Z33V$7+K',FR'S-N OJOQ$U;5/$6DZ*WP5;6/!=Q>?#CXA1:
M3!J'C&V9M"U._N-.GTN"5ENI(;1R4O3;(&9;6/:F8L&,?1OQS\1^%? W[1]G
M\.],^ _@GQ9J.J>#=1\91W4QL+)9(;"YMK::W/F0D"0M?0E"S",AI-S)MR7_
M  SUS]EOXU_L_> ?B5>>#_A3X=\/_$:QAOM%3Q3HFFZ==2F4*WD[91AI58@$
M(S G!4L"K$ ^6/&%K<ZW^R7<7W@>/XQ:7=ZIXGDU^#P7XWMX;N">:/1)[:33
M7@T>6.XT^TFDVR172.P34$6XVE2#)^BGP?\ B-+XULKJQN/#^NZ+<Z''9PSR
M7J^;:W;RV<-P?LMSG%U'&9/*:48'F1N.U<#=_LY_LU+XX?PS<> _@:OB7R&N
MWTF31-+^W>3C)E,)3?LV\EL8QWQ70>(OVA/AS\&_@3J6M:'J_@U] \)V!BM+
M+3M4M+:U!CM?.@LXB&$4;/$$V)P-K*0-O- 'R9\??V>O&"Z1\5/C=\'/#>M1
M_$A;S6_#_B;PS>:;/IB_$S1%WK&J++&IDO(-_F6-VH97!D@):.7]WMO%X]U_
M_@HMJ?AS7M0^.&BZ78ZKIE[X5DT/2[G_ (1G5M ;0HH+ZVNKQ9!:V[+?M>R.
M)%2[#+9M"S?*!]??!WXJVOQ<^"OA;QLEO)I5CXHT2TUQ8+EQOLX[BW2<([#Y
M<J'P3TX-<[\<?VI_"OP3^'&E>(6O+/6$\2:Q9Z!HD=K>1"/4[^ZG$$48E)V*
MBN2TC\[$C<X8@*0#XK^&7PX_:2L/'?@3P[JM_P#$:7P]9WVL_"'6=5O-:O?M
M.J6$-X=2L_%ID60B.5].M&LO/8"1KN\*9\L1DZ$L/Q&^#W@77/B=X6L?%SWG
MA7X_ZV][X3=KC3HO&VDZI>#3458Y-B3%)KBVNH)#N1O(95)\S(^J?B#^U^/A
M5\/?ASK&O?#GQQ'J_P 1=6MM @T*V;3I;S3+Z>.218IW>Z2':!#)\Z2,/E'3
M(%<%XD^*7PS^.WQ7FUS4?AQXLU/XQ? $I<6_A74#':ZG8Q:BR(E["AN1I]W"
MPB9EN%EE$;VTJJRRJ5H Z']I:7QQ^SI_P3ZU"3P[=>)_%GBSPWIUB-1O;)6O
M]9O+<7, U.YME?<9+D6INY(4P?G6-0I "GPC3?$%[\9OBQ\%=%\!_%SX]6_P
MY\;:EXGU(ZE>6SV=W<6\4%G-;6HEO+3[0+5)C.D3W($L@$RAY$"-7WHU_;Q*
MP>:%?+!9P7 V 8))] ,CGWI1<V[JC"2-A-]PAL^9QN&/7CGCMS0!^8WPX_:^
M\<WOPD\7>)O%7Q ^)%CXHTVXT[0O''A>'PG=:?#X-U*3Q!#"TPOYA-'#9M;2
MO&\MHDG^B*+E0)4#-E^#_P!H+XE7^M>$_%5OKOC#Q3\0O#OA#XMZ#X>TJ6UN
MH['Q#K&FZO;_ -D6\UO)%&99GL5W!GV/(D()8-YF?T^\,^,]'\:6]U-H^I6.
MIPZ?>3:=<26LPE2"YA<QRPDJ<!T<%&7JK J<$$5J?+GOZ=Z /SF\"_MN7U[X
M-\(Z\OQTU+6/A'XV\<V.DZAXM_X1\Z=<^#1_8\\AL9[BYB**;C4H;9)&>("W
M-T\&Y2\9B])_80^(>N?#/_@BE9^*O!-C-XV\3:#X7U[5M%LY8&\S7+R.XOI8
M4:.,(Q,T@7Y4"D[\+C(K[0&W/OBC"@GWZ\4 ?E3IG[3NE2^*?B_XW\'?&;3_
M (BPZM8_!R/^WM0M],FCECN_$%[!<0M&D*Q(0EP\FW;YD#O@,I10O=^,?VWO
MB)X$\(>,/'&K?%[3;3P/:_&J]^&=]=SV%C:V/@338;R8)=W%VMO+LE:1;>R\
MV=6B1;J)V4.#*?T6-O;^7M\N/:QZ;.#U_P 3^M<A\8OBMX5^#7ANQNO$_P"Y
MTW7M8L?#T6VQDN4EN[^XCM;:.18T;:KS21IO<! 6&2 : /C[P/\ MO\ B2^^
M(_@OP7XN^.W@30=<N/#6@ZYH6I:?H\<FF_%=[C6;VUO$M(YL2W#&TM;0(MB8
MR)=0$X$D#0I7,?LO?M7>)Y?#GA/P+J7QKFTR;Q!K7Q.GOO%VL#3KBYLK[1_$
M+1VFE,7B6"/-I<273QLF\PV9\HQ1CY?NS6_B%X9T[Q;X9LF@.H:AJEY=:9IU
MQ9Z?+>0V,\,,DD\<L\:,EIA(67,K(&90@RQ"ULZOX"\/^(K+[-J&BZ/?6_VG
M[<8KBSCE3S_^>V&!'F?[77WH ^#OAO\ MK_';XSZ7K6N6OBSX7^$;SP]\'O"
M_CJY\-ZKI_DV[ZOJ]IJZ&"6\DN UI:BXMK693(C/A@C$ L3YK\5/VKO&%WXK
M_P"%L>&=6BTOX@_#'X,_%&YU)/&?ANW_ +2A?2-9T63^S;F.SN%MW*M"(GN;
M>1HG4LZ*C-A/T\UKP%H/B.WU*/4=%TF_CUB#[+J"W-G'*M]#C'ERA@?,3'&U
MLC':O,]#UKX*^(_B;-\.=/T?PC=:UI^F7=@;&/05-JEHCPF[LUE\KR#L:Z@:
M6W5RR^<I9!G- 'S3\2OVM_&W@SXR>/IO!-C\+='UW6/%OPVT"34;S0))IY[?
M6%6*07<D5S$]Q)$928264*C; N6\RH=+_P""BGQ>\,Z;X8?Q9'X4.BZ/X[U+
MP5XL\6Z+H,MS92M;:Y;V%I=-9?;3<6=K<QF[@:=#<K!>QH' B# _37[1O[$/
MA#]H;PWI.E26>DZ'9VOB31O$&I1VVCVLJZZFF2B2"SN5="'A^4+SRJC"X%=9
M)^S#\-IK[PW=2?#_ ,$M<^#HA!H4G]B6V[1HQ(DH2V.S]RHDCC<!, ,BMU4&
M@#SG]M3XU_$?X;^._@[X5^&MQX'M=6^*'B._T":Y\3Z?=7T%D(=#U+44E2.W
MN(&8B2R4,I;YE8@%"=X\;\ ?\% OC/\ %3P;XK\5>&?"?@?7-)@L]=M-&TF*
MYBAUJ/6=.U9;);-XGO\ _26>$F1HV%FT<WDP[F$RRK]D>)_AQX<\8:]H>JZS
MH>CZIJ7AFX:[TB[O+..:?2IG0QM+ [ F)V0LI9""5)!."17F/@;]G?X!_&[1
M?$GC+PUX/^&WB"S^*!5M;US3-.MI!XD-O.=K2SQC,Q2>+<&+'#H&SD T ?-V
MM_\ !5OQ5IWPH\6>(K&/PCK4?AWX9:SXUC>?1]1T9VO].URXTZ73[BUN)3+;
MR 1"&2,EFBN4DPTB;0;.N?$/QM\-OVPO%=AX+U/2]-MO&GQ^T;0-96]LGO/.
MLSX&L[Z5(<2J(B7M\DC.=QZ<Y^E_&?[!_P &?B%H>EZ;KWPQ\%:S8:+;7ME8
MP7NE13+;PWD@ENT&X'/G2J)')R6<;S\W-)+\!/@M\2_%7B/1_P#A'_ VM:UI
MNMZ;XBURP1(9KBRU**!5L;J>('=%*+>-%C+ $Q* ,IQ0!\QZ#^V;XT\!--H?
M@'P9X(M=0\1^*_B9/>OJ>I7[VZ3:)?,%N?XW_P!)<C>BE4C+_(-J[3U-E_P4
MN\:>--:\&P>&OA[:SS>*-'\%ZPNFW=S<?:KJ'Q TXGF@DBB9!%IRQ&2;>O,:
MR',?[OS/H$_L:?"\3^<O@K1$F635YA(L;*ZOJP_XF3A@<AKGK(>K'GKS7@'Q
M _X)22:[\>+?7/#NN>&_"WAFPL=+TG2?[.L-3L=>\-V%A"L<5I:W5KJ$,$L8
M969#<V\A3SI$;S8PD:@';_\ !37Q3XKT7X6?#_3?"UY96L?BSXC>&] U@7$L
MT1NM/N=0C6: -%\P611L<9&Z-G7/->:_L^?MD>-M!@\,?#_2? ^@VUOJWBO7
MO GA"[U?QM>ZI/<G0[G4UO+B\DDMC*(_)L8Q$H>21GE8-LCCWGZC_: ^%'@3
MXE>&--O?B##8MH_@G5+?Q5:W5Y?264.E7=GN>*[:170+Y62V7.T=2.*YZ;]A
MOX8W?@BWT*/0[N"PM?$MSXRLYK76[^WO;'5KF66:XN[>[CG%Q"TKSS[UCD5&
M6>52I5V4@'SSXX_X*W>*-!\!2ZMIGPKLKN\T7P-XN\7:_:7WB9K06%QX8U2'
M3M3L866UD\X/(\I@F.P2;5WK%DX]Y_9A_:IU;XX_$SXD>%=>\)Q^%]4\ RZ;
M+&(=5&H1WUGJ%H+FW=F$<?ESKB1)(QO160%9)%(:E\1_\$]?A'XJTAM/O/"\
M@L9/!VH> 7A@UB_ME?1M0D26]MSY<ZY>>2-'><_OV89,F2:Z[X;_ +.7A/X1
M^/O%7BC0[74+?7/&D&GV^L7-SJUY>BZ6P@-O:X2>5TC*QDAFC56D)W2%V^:@
M#YO^*G_!6H_";Q#\4K&Z\!K?_P#"OO"OBGQ3;_8]?69KR/0;F"">"=U@,%O+
M,L\<R(DLTD:.HG2%R$KH-6_X*4ZEX)UW5K'Q-\,K_11X;\?Z%X,URX.MPW$.
MDVNLPV[66I2,B8VB:YBMYHQQ'(0PD>+,@V+_ /X)7?!'QD^OW4^F>(KZT\66
M_B*VO($\8:M]B:#7YQ<:O%#$MT(HH[BX!E*QJ CLS+M.,,_:0_8?E\=Z;XRT
M/POIOA^\T?XZ20Z7\3[CQ+JE_<R_V7'I_P!B$FGP@M&MWY2HH),:AL2MO92&
M /:_@K\3)/C!X @\0_V:VFVM_<7/V --YOVRT2>2.WN@=H^6>)$F4<X25>37
M655T;2;;0=(M;&SMX[6SLX4@@AC7:D,:@*J@=@  /PJU0 4444 %%%% !111
M0 4444 %%%% !1110 &OX;/VTKGSOVROB\_S+O\ &^MMC9MQG4)^PZ?3M7]R
M9K^&/]KEXYOVL_BFR.DB-XQU@JZ<*P^W38(Z\'ZF@#]=_P#@R56$?M$_'K<9
M/M'_  CFE[!M^79]IGW9/KG;@?6OZ):_GG_X,DC(OQL_:#7;"$71=&W'/[P-
MY]W@#GIUSQUQS7]#% !1110 4444 %%%% !1110 444'F@#S3Q7X4^$?A/XG
M:"NL:'X#LO&'BS6Y=3TE[C3+87^IZI;V+B2YC8IO:XCLXW4R@[Q$I7.WBLSX
M;_ KX%_%GPO\/?&GA7P/\+M;TKP_"VH>"-8L=!LI8](CG;S6FT^41_N!(WSE
MHBNX\G)YKY$A^,^H?$__ (*$> ;7Q-XD\867BGP7\3/%]C>>''TTQZ9HFE+H
M6HII5\C>205FM3%,L[R$22W=PG(B5(SX'?MA_$C4;_\ 9B;4O%E]XJN/&W@7
MP]-K>AV5S:V6N+JT]O?-/>W5G):8N;&9XMDSV\D+V36>_84=Q0!]J>)/V0_A
M5XQ^%FH>!]5^&O@'4/!NK7\FJ7VA3^'[5].N[R24S/<O 4\MIFE)<R$;RYW9
MSS536_V)_@]XCURQU34/A;\.KS4M+BL(+.ZF\.6;36D=@^^Q2-_+RBV[<QJI
M 3^' K\^_"G[?'Q.\<? _P 5>)_#_P 4O$VJ>([7X#3>--5TIO#]I&?"_B>"
M]"W4"0&U\U#!ME@:VE,I"(K'+.)&[#XZ_P#!1/7KGQ/\1+/PC\5FL]-F\;2:
M=X/OX[*T73YK=?!EOJ:0_;9+:4-')>O-)#Y<4\ETZ"%"(]SJ ?3WC[X!?LR:
M)\/_ !EX)\3>'OA/9^'H[2PO/$FE7\5K'#96WG2"P>96(\B)9O.,'W51S(8\
M,6)ZSXBZ]\%/A)X"L_A7XHU;X=^$?#NOZ:=%LO#-_>6NF6U[92 P&UB@9D#1
MNK%-BCYAN SS7PGXR_:HU/5]%\>_%'3_ !!H2>)M6^ 7PLO[B^CMK:ZM7N+K
M7=:-PGE2AXMK?:=NT@E!,I&#M-=!^T5XFC\'_M#?M2^(#XITR_OO#?BGX86\
M-EK>GZ;?VVBB>[MERJ2PEHV,=W<>7(S%D,K.IW $ 'VK??L7?"_4H[M9O!^F
MLNH+HZ7 #2+YRZ1)YFF X8?\>L@#Q_W6&[KS72_%GX(>%?CC8Z+;^*]&M=9A
M\.ZO;Z]IPF+*;2]MRWE3*5(.0&=2IRKH[HP9693\5>)?^"BEQ:V7QKUBX^,V
MB^&?$/PNE\7V>J^ IO#L.HW^@VEC.8M+U?R?,AN!#)"D5R99Y/LTW]H1HK1A
M03@_"W]L?Q9\5?VA/AGI&L_%JQM=/T/XTZQX5NO[.OM-FCUZW;PV;_3K2[FC
MA6*2?S)FB585C#LAP)'B66@#ZOT#]B?X)^,_"5HMCX=TCQ#X?CL-;T:.-M2G
MU&PGMM4NA+JL#JTKQRB>YCW2;PQ#Q\;2O'=? ;]G?PC^S+\/X?"_@K2WTG1X
M',@26\GO9Y'P%W23W#R32$*J(-[G:B(HPJJ!\%_##]N?Q@_[._E:7XK\"^!;
MS0_A[K7CK2[F+1+>/2_%U]!K6HP26RQ A5BB%O ;A;<B9GU.-]R$8D]"\*?M
MK?%+5?VBK8:CK'A32/"[?$W1O!-QX6GTW_B:6JZAX2MM6D@DN/-!%Q!=S$#]
MV-R+(&'W2H!]!0?\$_\ X3VWAVUTG_A&9)M,L]$UOP[':W&J7D\9L-9F6?4X
M&#RG>)Y41BS98%%"E0 *J^#_ /@G;\*_ VH6=]8:7KS:E9ZYI_B3[?=^)=2O
M+NYU"QLFL;:>:6:=GF86S-$PD+!UP&#;5V^BW/Q,TOQ7\'[SQ1X5US1=5TV3
M39KW3]5M9TO;";:C%9%>-PLB!EYVN <$9'6O@K1/^"@WQL/PC^$O]I^.?@3H
M_BWXM?#F3XE:5J6OQ3:'H3M':Z4W]C^8TLQFVM<W,\LR%)/*9"D8$3E@#ZPC
M_P""=GPI'AV'1Y-#U"ZTF'1/$/AS['<:Q>2Q36&O7"W.JQ2;I<N9Y55M[$NF
MT!"HXJIXW_X)M_#'XA?#JZ\/ZE#XH>YN-0L=63Q%'XBO8O$=G=64?DVDT&I+
M(+F%HHFD1=C@;9Y\Y,TI?Q37?VQOC3J/Q_NM!T;6/AK8Z#/\7W^%]HEQH=U<
MW$$<GA5-96[:072!Y(9E:/R]B"5223%P!S_@W_@I?\3?B1^SG>:U8R?#O2O%
M?@OX3-\1]4:^MIVT[Q1-#>ZC:36]MB=6M8%_LPM))F9HCJ%KD$*1* ?7_P ,
M/V5O"7PA^(LOBK1UUHZU<>'[/PS-->ZO<WOGV=K-//$9/-=O,G,UU<2/.Y,L
MC3.69B:S/C=^QCX+^//C"[UK66UZSO-8T-O#&M+I6I2V4?B#2R[2"SNU0_O(
MU:2;81M=!<3JK!97#>/^&?VZ_'-[^T?JGPWU;1] T76-271?%_AU+VRG@>+P
ME/ TFIR7H\YMMU:7%O<6K2 +&DEW8%D/FE:\%^*?[9/BK]K#]E[QUHOBB'PS
M+:6:?"[Q5I&J:#!<6=O?1:QXD4?NEEG>:2W0V*-%/(EN\Z2Y-O&,;@#[X^'W
M[.WA_P"&GQ8\8>,])?4X]4\<16$&HPR7;/9Q)91-%;K!"?EA"H[ A,!B<D$\
MUP_B3]@?P[XB^(/Q%\1+XN^(VDW'Q4:S_P"$B@TO7/L4=PEK;?9HXXGC036Z
MF'Y6:&1')^;<&R:V_P!J[X^W_P $8/ .FZ/'I:ZU\2/%UMX2L+S4P[6.FR2V
M]U=--*B,C2?N[21$C#IYDTD2[U#$CPOP7^W;\7?B-\:_!GP[TGPKX#BUJXU+
MQ98>(]0O[B[ALFBT'5-*MGN;%4#LWVBWU D1R-^ZG0HSN(V+ 'H_Q,_X)E_#
MGXBZ!=Z-;S:_X4T&X^'_ /PK2#2]!GAM;33])$Z3 0(T3[)1Y:Q[B2-F1MS\
MPWO$7[$F@ZQ^U+'\6+'Q1X\\/ZO<VMK:ZYI&DZJ+?1_%(M&9K5[Z QLS21;F
M4-$\6]#Y<GF)\M2?M ?'KQ)X6^-/@GX;^#;3PX?%'C32]7UJ*\UZ65;*WM].
M^R*\82+YY9I)+V  !@$C6:0[M@1OBG]H7]MSXA?M1?LT?%/6+."'PSX5N/@]
MX4\7:7I,5Q+;:KIVJZEJ=[$T;WL9PR;K J&554H5;:0S"@#Z8TC_ ()2^$=$
M^#?BOP##X^^+#^%-=(&B6$VL6\T7@6-;Y+Z.+2U:W("1SQ0[!=BY*)"D8(CR
MIZ;2/^"?'AG1O&MSJ"^)O&$^BW'BK_A.AX=FEM&TR'73$%:^4?9_-R9\W?E&
M0P_:B90@^[7F]Q_P4;\<P^*M6\!KX!T*Z^)D'C75O"FG6UIK#OIM['9Z):ZR
MDOF21QR>8\5[!"8PI(999!E$VGM/V>/VN/B5\=?VA-6\,7?PUT#PKH'A?3M)
MN]>GN_$YN-4L;C4-,^UBVC@AMV@F,,X:%W%PJE=KINR44 R_&W_!*KPMXY_9
M=\ _!V\\9>,;CP3X$TW^RTBNHM.FNK]5>![>Z,OV4&WOK;R=L-S;")XQ-*>6
M*LOJW[2_[,\/[25KX-27Q)K/AR3P;XEA\20M806MQ'?/';W-OY$\-S%+%)'M
MN6D7<A,<T4,BD-&*Y_Q/^U'XBN_VB]:\#>#_  MH^O1^"?[#E\3R7FN"PNK>
M#5)Y8UEMHS&RR""*&29A(\?F;6CCW.,5XG>_\%<]0T?5?%%O<_#VTG31;/3-
M3LY[+7&FM;R&[\0G17B%Q]G\F2:+,<I-N\T6YGBWAD+$ Z'P;_P24T?P1\)I
M/"=M\0O%EU%)X?\ "'AQ;NZM+$RQV_AO49;^RP(X47<[3O'(2#E N-K@NW1_
M#S_@G2OP[^/6A^*[?XB^*KCP]X7\4^(/%>D>&9[6S:VLY]:2=KR'SQ&)FA6X
MN;B6(;@4$I3+*%QSOQ5_X*C'X6Z=XBN+WPC96-GX?\>WW@:;6-3UA[31+=X+
M2"X@FN[P6[K9BY:X2%#,!"L@PTPRN[M/A+^W!J?QC_: NO#6D_#GQ%-X-M]7
MUOP^_BQ-WV>TOM*E$$PG5HU18I9DN(HFCED8M -R('! !G_MC_\ !/23]K?X
MBVNO-X^U;P_'96.GPVUC_95KJ,-E=6.JQ:E%=V_G@^2\K1+%/LYFCB@!9?*&
M[-@_8?O?@GXDTWQ[I^L:QXNO/!/BGQ?X\A\/V6FVL5UKLVLQ3'[#%)+.D<;Q
MM*RH[LH?*ARHRQ[CXT?MDV_P@_:?\#_#2XTNQBF\;)')::AJNI_V9#?L9C%)
M;6+/$T5U>1*!,]L9(Y#$RF,2'<%^>OV2_P#@H5XH\'?"!M+\6>&/$'BF\ATS
MQAXCTG6[S7+19M:@TKQ*]B\,[2LB6R1QW=F5ED?'EQR$JI15< ][_P"">_[.
M$/[/'P;U KX?U#PI<>,-<O\ Q$V@7UY!=R>&X;FXDEATU7A+1+' K\11.\4;
MR2*CNOSM=G_8JT9/VS=2^,EKJE]9ZAJ_AV#1[K388D%M)>VYN8[?53G/^E1V
MMY<VP;',4NTY 4#R31?VS-3_ &A_B[\"YM&FU3PM9W7Q$\3^#_$6G6UP)K+5
MOL.BZE(DJ2/$CR0F2&":)BD><\J1@UV7[#?Q!\4?$3_@EIX'\3^(?$VI7WBS
M5?!)OKK77$1NFG:%V%Q@IY>\<-@H5R/ND<4 >/\ @O\ X) >-O _V36K7XQ:
M0/'VC67AN2PU]?!A5KW5M';4T?4-24WIDOFOK;5KN.ZW2)*[RF194PJ+V'[0
M?_!.3XB?'[Q%X=U/4OBQHFI7&BIH-XRZMX1:ZM[35=,UU=6:[L(DO8UMEN%
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M;=^&_BSQWJ/P9N/"GAN;7X_!_P 0K/Q!JT,%[;6K064-G>1,R^<Z!V\R>+"
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M_P .YO#?CS2].U;P_>7%NY@O'\M5N(Y5>W>-P5:.5)51D=&#JX4J0<4 >/\
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M!M&^&OQ'DU%-#T/P[=MX2\02PW&-%2/[!JT%ND+NN^,?O5@=(Q*F?D.T,0"
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M W?C34=56.]&WPXFL3R7-E86:,F98;82_9@1Y86.%"J@$(ONW[/_ .UYX/\
MVM? .IZ]\.[S5+[3[6%6@O[_ $&]L;6X=E?!B,\<7GJCHR2",G8Z.C%6! \4
M_9<_X*\_#GQ]^RYX?\5^/_$EKH?BF'PAHOB;Q-;0:%J-O:VZ:@R0"XM!)&S3
MVB7;&!YHGE2%@!(Z]: ,?_@K;^RO\3_VF=/NK#P'X7\/ZW:ZA\/?$.A?:Y-4
MATW4;;4;A[*6TB\Z6-\6CM;,SB+8YEBM]SK'OKU_]OGX):U^TK^R_:>&[7P[
MINL7\_B?PQJM[IEU<QB%;:SUJPO;M=[@*Q$$$P' WD@< UZ-K'QW\/Z+X5\:
M:PSZA<6?P_,ZZR+:PFGFC>&V2ZD2*-5+3L(I$XB#98E1\P('SOX1_P""K/A>
M\^*GA]_$-Q;^%?A]XN^'F@^,=*N-3TZZAU."XU/4)[01W0 9(K=2MNOG,HC#
M3 F3:R$@'D?A7_@G9XN^&7Q8M->\,?#/PO87%K\2_'.KPSIJ%O:QKHFHZ+>P
MV4+M"1-';37\T+M!%S&P,FT, :\M\+?!+Q-\&9+/0?%WA>S\*:SXN^('PDUW
M2- &KZ3+<PMI^H6-MJ1@LK)CY<-NL!7S?GW1!=TKL' _2C3OVI/ >K?%]? =
MOXBM9/%3M<I%9F.14N9+98VN88IBHAEFA66-I(HW:2,,"R@5#XH^,?PUT;XM
MQV&KZCHL/BK1H),75S;X.FHUN]S)&UV5\N%FMX7F,;2*QBC+E2HS0!\7WO[%
M/Q.U;1IK>;P/-%XQ\/WGCR76/%$6I6")\2[#5+74X]/LS^_\W+2W6G2%+M8X
M[=M.VJVP1DP>*?\ @FYK%I\&?"_A?PY\,(8/[4^ ?B_PUXC^TZC9S1GQ/J5M
MH2P+=%YV,\DDEA<9G7S$5E#%QNR?IGX[_M[:#X5^ NN>+OA_=Z+XQU#P]K.A
M:9>:=-<26K0QZGJ-I:I*RE/,"M#<F:)MNR;:-K;26'JFC_'SP7XA^)MQX+L?
M%&B7?BJUCFFETN.[1KH)"T:S$*#\WEM-"' R4,T8;;N7(!\3^ _@Q%/^U%X#
M\*^%M-T3PQI_C3P1I4/Q6\$/?VC:CX3.A207>FNT%J\D2-<_:WM)0&"O$8G4
ML8Z^AOVZ?"FO>(M8^%=PGA_5/&/P_P!,\4O)XXT+3T$TUW92:?=Q6\SV^X&Z
M@@O'MI'MU#L?ED"-Y.#U"_'GX*?#_P"-?B?2E\5?#;1OB'<0BZ\16W]HV5OK
M$T=K;1R+)=KN$K+#;3Q,#)D)'*A&%89OZM^V7\)?#_A.SU[4/B=\/].T6_\
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M ,&1$2GXH?M#/B/S!I6AJ#L^<#S;W/S>G3C'/X5_0E0 4444 %%%% !1110
M4444 %(QXI:1N10!\R> _P#@H3=>(_%'Q;\%:UX/M_#GQ*^&]K>ZMI>DS:TT
MFG>,=-@4@7EG>FV0[%F_<3J(&:VD9-P=71F]2T/]J3PE_;/AWP]K>OZ#I/C+
M7H+8_P!D+?\ G>5<SP&=;592B!I&59&16"/(B%@F.GE/QT_8!N_VA_@YJVGZ
MEKMOX8^(&G>(]6U_P9XLT.!OM&@-=M(!%(LG^NAE@D,%U!D1S1DXVL$=*'B'
M]@WQ+K'BSQ1HO]K:#+\//&'CO0?B'<3R"9=<TF\TP:<QM;<;3$\4DNDVFV1F
M5XHYIUVO\A ![C^T7^T)X=_9O^&NI:_K^K:-IS06ES-90ZA?K9K?RPV\DYC#
ME6*@)&S,X5MB*S$84UB_!3]KKPO\3?AO\--1U34M$\-^)/B5H&G:U:Z!+J:2
M7$;W=I]I6!"0AD;"S;3M4R""1@OR,%XW]L;]FKQ]\3OBIX;\8?#^^\)->6/A
M?7_!FI:9XE-PEHUIJHLY#>0O CM]HAFL(5\ME"R132@NC!37D?P4_P"":/C#
MX6_%3PJVJV7PA\9>$1I/A>75KO5K"YDUGPWK&B:=#9QRZ2I0QO"Y@22-I7B>
MWD>5\3;M@ /JC_AJ;X9B;6(S\0O!*/X=GAMM4#ZY;+_9\DTS01++E_D+SJ\*
MY^](CH,LK*+7AK]HSX?^--4T6QT?QSX.U:\\26GV_28++6K:XDU2WVLXF@5'
M)ECVH[;DR,(QS@&OD.T_X)[?%O6_V3H_AGXEM/@GJEQX3;PUH6B:S#'=1W?B
M31-'UJTOE.I,ULQAF>"V*FVB\V$SSRR;U5@B]+)^P9XRT_\ ;&\:^(H-!^$^
ML> =?UBV\7:#?:M+?G5?"VJ0Z'%I MTT^-?LDT)2 ,LWF1O&EU<1^7)D$@'T
MK8_M*?#O4_"NI:];>/?!=QH>CS);W^HQ:Y:O:64K[2B2RA]D;,'0@,03N7'4
M5J6_Q<\*W6OZ3I,?B;P_)JGB"T.H:79KJ,+7&I6P7=Y\$>[=)'MYWH"N.<U\
M"_#K_@F7\8-+\+:Q;^(K/PG:ZGJFE>$4M]0\)>.;O3[[0=1T>&^B>ZTYFTS[
M-;QKY\/E6OD?9_):6)HB,F3L_@[^P3\4/"_[0VA:EXZTGX<^-M%DD\/>)+C7
M+36M2TL^&-;TW1[?39DLM'C46DL,C0,\$F8O*%U<!XV78A /KKQ;\4'\(_$;
M0]'EL86TS4[&_OKW5)=3MK=-,6V$)&Z&1Q+(K^:V7C5EC\OYRN]<[GASQIH_
MC 71TG5=-U06,H@N/LETD_D2%5<(^TG:VUE;!P<,#T(KYP_;P_93\6?M!?$#
M3M2\.Z7H%Y;6WPW\:>%I'O[OR9#=ZM;V,=J@'EMF$M:OYC$_+E"%?G$W["O[
M)NJ_LT_%+QI>R>&]!\.:'K?A7PGIMO'I<L>)[W3[2YBNWD1%4 YDA17.2ZQC
M., 4 =E>_MX> Y_&W@G3=%U*V\1:;XP\0:QX9EUFQO(6L=&O-+M+JYN4N&9@
M<#['-'E00& S@'->N-XAT]);16OK57OANM5,ZYN1C=E!GYN.>,\5\3>&_P!@
MSQ5<>-/!FG^(O /@_4O"7A?XL^-_&%VLES!<PZK8:K!JS6;M;21A?,#ZC%$4
M;=M\EVSC8#P7P;_X)X_$SPAK'P;TWQ;\.])\6:)I/P^\%Z#<7J^-Y=/F\ ZM
MX?EGE>14B3-Y!*TD4B&(JS/$8Y L;!E /T;O-4M=/CW7%S#;KMW?O)0O&0,\
MGU('XBE-[#N8&:,,I"D;QD$]!^-?,/[=G[(<G[3/QK\"ZA>^ ]'\;^&]"\(^
M+M-O(M1-LT:W5_;V26L?E3'YUD\F92?NH2A./O+X-K_[&7QGL/ ^BZ7#X#_M
MG4-4\ ?";3M6OAKUG&;34O#FO2W>J+*SR!I9C;S(8Y5#)((74NI$8< _1._^
MRW=G-#-,!')$PD"S&-@IX)# @KC/4$$'OFN*^'7Q/\-P?%?7OA/H^EWFEW7P
M_P!!T?4BODI'8_8[YKV"U2!@Q)*G3IPRE5VC9@MNX^*K'_@FUJ6K?$NQU77O
MA+I^HV]YXM^)%YK3SSV,WV_2]3DGFTN&5?-_>Q.S0%86R(98PY"$!ZY5_P#@
MG3\1O&'@/PWI6O>!-4'C9OA1\.O#FB^+3K-J[^!M>T2YO7U"Z>43F82*+B-U
MD@647*AXF8*[!@#].E$+-M7:S+@X!Z>G'X4CVT#3;FC4R8V[C][!.<9]/:OS
M:^(/[''Q.\5^$_VC+6Z^&OCJY^(FH:!XYTS0?%-MXITZ+2?&-OJ\KRZ7$D0F
M2Y%S OV6("Z6.*U%JWE2L'"GZA^.?[.FK>#_ -@#Q1X.^#>DWFBZY<VC7]MI
MJ:HT-Y>22W*W5_;"[>1C'<7*M<1B4R +),&WJ!N ![%\5OB7X?\ @AX(O/$N
MNNUK8630V^883+--+/,D$$,:*"S/)-+'&JCJSKTZUP7BS]K_ ,!?#KX5^'?&
MWBK3?%7AJS\6:[!X>M+6\\+7TNIC5)IVLX8);>"&216>5/+23!C8-&5<JZ$_
M+?Q>_9$UKQO\)OB!#H_PHUR/P+XF\<>"-7T'P)<"QCFT=['4+236+^.'SO)M
MX9;>,(8DD+/)#.X3]_N;WK_@HU\/_$'BSX=?"^U\*^$]5\2+H7Q0\+:S>6NE
M" /96%C?QW,TVV22-=B+"!M4ECD *: .JL_VJ/AEXALO%$VGVNI:KK7PQC2[
MU+0(?#-Y_P )#IBS ^5)%I[PK=,LVU]CQQE9/+?:QVMCTK6/ NDZV+UI;&&&
M\U*/RI;VW'DW?"/&K+,N'5U61PK AEW'!&:^#_VV_@5\4/V@/&WQ9^*7AGP3
MXO\ #<FF_"UO 'ANUMKF*U\1>);V?5[>]>YC\F<^3;6XMU6,2NKN;BZRBI@R
M.^-GP/\ B/8K\?\ QYH6D?&*^U6'XF:>MII=CKDSS:KX/$?A^;5H])L[F5K1
MVEDM+W:K(KR#SH494F (!]'? ;_@G[X4^"E]:W.H:MJ7CRYTK33I&FR:_INE
M(]C:$PED)L[.W-PS&VMR7N/-8&)2""7+>TZ-I>D6#Z@NGV^GPO=7+2WPMD13
M+.57<TNWK(5VY+<D8[8KX O?"?BSPQ:> - OO#O[5'B+X=^(=#U!?#<\&H"#
MQ-X5UE]4:XB.HM;&)+:$VKQ1VK7&Y+:&"2&4*9"IA\'?#[Q1\(O&NN6>K>%?
MBU9_#G4OC1XGO?%HT5=6FNKZ"\MWETF\@^R,UQ)IX+*)3:XV3-!O 6*4* ?=
MDOP3\$7"^'Q)X1\+O_PB<[7.AAM+@/\ 8LK=9+;Y?W#GNT>TFJ=Y^S3\-]5L
MM9M[CX?^"+BW\17"W>K1R:':NFIS+*TRRS@IB5Q*S2!GR0[%LY)-?$GPF^%G
MQ>O/&L*>//%7Q^LX?"7PKN+[3[O3I[]Q=7::MJ?V$W$,?[B^U5---EYL#DM/
M)CS$8A=OO?\ P3>N?'W_  SYXFM/%5CJ_P#PD&EZY/:V&IZQ=:TUMXCB%E:-
M%?0P:MF_LX7=F1[:1Y!'-'<;)'1E:@#W76/A3X3U_P"'$O@V_P##?A^\\(SV
M?]GR:'/812:;);8V^0;<KY9CP,;"NW Z5F+^SO\ #M-2BOE\#>#EO(=3AUJ.
MX71K<2)?PQ>1#=AMF1/'"!&LGWE0;00.*^#OA?\ %;QOJ7P+\(>(+R/]IRPN
MI]5\/Z5\:+36K:_B?1G1;S[?/I?R^<J/>26@GDTUC;I9*K1B)P[50^)$7QFU
MGPW)8P^,OC9I_AVU\,?$S4?#MY8"[AU&_M[>?3V\/"[E,32M<C-V+<.1/<0Q
M(7\PO(& /N31_P!BOX,^&C;M8_"OX<6+6<D$]NT/AVTC-N\%T]W"R$1_*8[F
M1YD(QLD8L,-S5KP_X>^&-M>>+/ACIFD^%H_MUH^M^(O#T-G&L-W#JLMRLEQ<
M1!=DGVJ2&ZWELF1E<MG.3\)_'7X@_%+XEQ?$C1XKKX@>)O\ A)OA/JAMX=";
M4M'NO#>J'PO;3>1-:&,03Q37$@D@N[9TG2[GDMF1T1O+3X]^+-:\4_!CQAI.
MEZ[\5/\ A!='\$?"?6M.:&#4H;R&,>(KS^V)5_="Y=_L,=J\\;!G\L1DKM."
M ?>_P8_9C^'/[.:WK>!/!GAOPE_:D5M#>/I=DENUVMO$(8/,91E]D8"@MD_B
M<UXSI7[#?PC\ ?M:M#I-K\/]#TGQIX#U[2K[P#:Z'%"WB&&ZO[.74;UV60*\
M(+PQ/%Y. ;HG>-VVO+]1_:1\:1?M:'P!)X@\?6\-U\;X;)(_[(F$<?A6Z\$F
M>/,_D;4MVU82;9&82+.C)N 0J/'_ (+_ !Y\=> /V#_AT/#_ (T\=-J]C^S/
MXRUJ_DU'3VN;^U\3V+:6('8W%N9&N4N)-0C$3[A(86!60H30!]Y:%^P#\&O"
MN@2:;I/@'1-+AEU"UU8S6/F6]VM[;6_V6&Z6X1A,LZP9C\Q7#E7<$D.V>J\*
M?LX>!/ ?BBUUK1O#&EZ;J5EH2^&89+=#&L>FK*9A:A =GEB0LW3.6;GDY^']
M>_:R^('P1\-?$1=9^)NLZIH>A^)/ <T^LZO8VEM<V]AJD<#:G!;3I!%;1KM5
MG5IA^[WR)YBLT>WVKX(?$KQ1\5?^"8WBW7O^%EV_C?Q5-H_B+[+KWAB]L[F:
MS*M=?8H4EM4\K[9!!]F60A6_?K(1N!6@#HO"W[ G[..C:AJ?@G2/"?AF+48=
M-TE[[28-5F-];V%KJ$E[IA=/.\V.WBO(I&@Z(IA9$^5-H]"TO]D'X=:-XQL]
M>MO#JPZM8>)KWQE;SB^N3Y>K7ELUK<W6TR;<O [Q[2-@#MA1DU^;L/QYU?X?
M>%-/^(O@OXH2?VAX9^ GPWNKB_FAM+T>(]^N7L,L5S))$6\LK+(C^5LD#3(=
MZD8;Z<_9H_:Y\4?&+]NCQ-X5O/B/X;MKKPOK_B'1M9^&LVFL-5L].MY$&E:I
M%\BRQQ2PB.5KF222WE^WB) LBH% /;_BK^SI\(_BK\56U;Q-;Z?-XDN+&#2K
MZ :W-:+J]K#,;B"WO+:.58[N-))79$G1POG2 #$C!NP\"_ SPO\ #KXC^,/%
MFCV-Q;Z_X]GM[G7;A[^XG6\EMX5@A812.T<6V)53]TJ@A1G.!7Y]?\%"M)\*
M^.?VQ_VD]'N/%?P/\,ZQ=_ G0;#[1X\M$NDCDEOM?(9,31NC(OE,2%D8,]LP
M4X"OI/\ MQ^//"/P TVUT+5M2\&>)O!GP4\)>,_#'A3Q7'#>:Q\0K^Z%Q'<:
M;>/)&)Y9MUK;6I-J(IEN+[S'#!XXZ /L3P_^PM\-O"_BBSUBQTG5(;S3?$&L
M>)[-?[>OVM[/4-6BECOY8H3,8T643SMY:J$22:2155V+5SFF?\$Y/@[\-O$'
M@GQ#8Z?K'AU?AKX?L?#=B+?Q5J-M9W&E:>6:QMM03[0$OH[9G=H_M7F;2S9)
M!(KY:^,O_!4KQ1X+^)_Q6MM$^(WA*[M=%\'?$J\L+6^MK.W_ +(U?PVUDMI$
MEMYANB%$MR9S=2 W)C:6"*&W",_+_P#!2+]HOQ=J7[%_Q:^'GC[XI>!+>?5O
M@I/XWL[Q]'@L;;Q8U]+<PG3[9)IG#16<<40+QN9FDU"S<E0ICF /T&^+W[*_
MA;XV_$CPGXNUA_$$'B#P.EY'HMSINN76G_9/M<:Q7!*0NJ2,R*%RX8K_  X/
M-<7%_P $\_AEX)TSPW-H+>(/"&H^%+[5-0@UZRUZ?^U+J7575M2-U<SM(US]
MJ=8V<S%F#PPLA1HHRNQ^UQ\==2^$LWPNTO2K_3]'_P"%E^-;?PI+K5W#Y\6E
MI+9WERK(I8*9II+6.VA+Y02W49*R'$;_ "SXP\9:]^V!\2/V<?#OCZ3PGJ6B
MWGQ \<^'M:TN?2A/HWC>VTNRU6SBO!;22ME71 _EDR*DC,065%) /?=3_P""
M7WPOOO%NFZEI[>*M!AT>+PY';:9I6O3P6*'0IS-IKM'DEF0,T;;F*NIR07 <
M6V_X)T^!].\ _#_0M-UOQIH=Y\,]4O=4\/ZY9:L$U6V:]>9KR%I&C9)(9EGD
M5D9#@!"I5T1UXK]HGX/^#O%G_!1W]GCP[JFAZ-J&EV_@/Q@$TZ[A2:"2*!]#
MBA!B;(;RUGEVD@E=[XQN)KQ3X!_$2XT7X\KX:T&33?&WP?L_C\GA_P  ZKX@
MDN-6DTI1X4N[K4(],NC,"T=IJ,5S;1E_,2-&GA7B-2H!]>1?L+>#8?V-M$^!
MZ77B(>%?#=C8V>E7YU$MJ^GO8RQS6=U'<%?]?!-#%(C%2N8P"I7(.?J_[ ?A
M_P 02Z?>WGBGQA-KT'C6P\>:AK(DLH[K7+^RMTMK=+A5MA"MNL$4<?EP1Q9"
M;BV]G=OG/P/_ ,%$?CEXA^%/PJFN(?A#-XN^-NEZIK/AB.WM9[>PA6PMXV-I
M,;G48S+-.\R29B?,,4-Q^[G*[J]2\(?MG>.OBYXG\36_A^\^$NAQ^";ZPT76
MM.U/4)[ZZ^TWOAZ'58KFTFA=$N8O.NX(XX=B?:8X+EUGB.U0 >O?';]ERW^.
MGQ'^'WBE_%?B?PUJWPUO;S4-).D_8VCDFNK.6R<S)<6\P<"&:4*!MP7R<D#'
M''_@G%X/_L<JVN>*KCQ!J'CG2/B!KWB*YN()M5\2ZAIDL,EK'<N8A&ELJV\,
M0@MXX42-2(PA9B?GWX<?\%)OB=I?[&=KXLO(?"_BCQ#\/?@CX8^*_BWS[>:T
MF\3KJ4-U+);V:I)LAD$>GW/[XAT>:1%$4:AL>D^)OVQOC)9^)OC)=Z1X)\.Z
M[X4^%_BF+PO%%I,-[J7B&[#P:/=R7JV2E1<+!:W]VS6\+^=,]N@CQD@@'4>)
M/^";EE>_"7P_H>A?$3QKX7\3>#_&>J^.-!\5V263ZAIU[J=U>W%Y$89(&MIK
M=UU"ZB\N6)OD9#DL@:MCP_\ L/W7A#]HA/'.B_%3X@6-CJEIIZ>*="+6DUOX
MNO;%/+M[ZXF: S0RM&$25;9HHY4BC5EV@AK3_M3:QJG["FF?%3PGIEG\1]4U
M#2++4H[;PU!<S0WJ221+<2VT$BK<OY4;2R_9BHG8Q&+ D-?*7B7]O3Q58?%.
M_P#C-X1_X1WQQX?T_P"#5KKFKVD&M7]GI;PPZ_>Q2M:VTT&^.^,<<ZLLR1ND
MD'E2$[05 /<O W_!+N/X5:781>'?B9XDT^XMM'U7PM<7$MA:3?:M%O+N2ZAM
M-NT*);2263R;@@L?-D\P2 @+T?A[_@GOI?@'PC\2-"\,ZS9V>D^/8=%LHM,U
M30[?5M.TVRTVRMK 6;P2G_289K6V$;B1LCS&*E3@CA_B'^W'KGB?XF>-/AP=
M'M[?2[[P]XQ%AKNC:G<^=ITVCK:PD-<JB1F>0W;L5MI"]J\ C=O-W+'7_8-\
M9Z]KOQ\\&6^I>(->U*"Z_9Y\(:G<6UUJ4T]NU[)<7HDN_+9BGGR!0'E WN(T
M#$[5P >H?LL?LO>)_P!E*;PUX1TOQ<^I?"_P[X>O+7^S;NS4S+J$VHM<PM;S
M,[2QVT%O));I Q95C2W"L2K$Y]M^P&(?B#JTG_"7--X U?QY;_$D^'9=,#7%
MMK$31S@1WGFY6U:\ABNC%Y6_>'7S/+<I7G/[;'[<.I6_A_\ :0^&]G%/X-U_
MPC\--?UO1;\W]QI^L:BL6D1S1:GIA$:QS0I//)$[P3F2WEM4WJOG+MWOAM^W
M_P"))/%%E\.=4\"V=K\0KK5-.T72(Y_$;36-]'<:'<:N;FZN1;%XI$ALKI7B
M2.8&7RPLC([2H >S_LI?L\S?LT?LR>&/AS<:\WB$^&[ Z?\ VF+,6;7*[W(;
MR@SA6"L!]XY*YXS@?-\O[":?LX_L_P!C9^-+'7/C]:Z%\/8_@YI.A>%_#T6G
M7,^CW<T$4SW(FO"KNRP6?F3B2)8E@DD5!O;'6>$_^"B_BKXI^,O"/A?PG\)_
M[0\3:]:Z\VK6]_XG2QM?#]SHFMVFD:BCS?9Y&FB$ET98I(X]\B1X,:,Q"\I\
M%?\ @JAXP\7_  ,\!:O>?"J\\6>,-?\ "NG^--=TGPC)=7?V#3K^ZE@M_LV;
M;$DY%O=-Y4SPIBV;$S,P! /H;X,?LZW'@7]D:P^'NL:U>:IK5WH3V>N:W._G
M7.I7]Q$1=WCG #,\SR.  % PH"J !\_ZS_P2J\6>(/@O>>&;SXG>&_[0OOA5
MH?PS:]C\'2K#'_9M[-<"\$1U DB2*7RS#O&'0/OP?*'??!/_ (*(S_%GX^Z;
MX-N_A[JFAZ9K.M^+/#FGZTVJ07"7-[X?OVM9\PJ Z0S*KNCL=P:-D9 "KMPO
M_!1K]L'X@?#JV^-WA/PO:Q>'X/!?PE7QO8^);*\\S5!>RW=Q#% D$D1C"_Z)
M("23NWCE,<@'9_L_?L&:U\#OVH/$WBAM;\ ZMX1U3Q!JOBK3%D\&1KXJTZZU
M-GDNK4ZKYI#6HEDF=,0K+MD6(OY<8#87[5O_  3<UK]IGXQ>--4MO%MOX%T?
MQOX;OO#>JW.BFZ^UZU:W&DSV4<-]:-)]DG>WN)A<Q70"S*D7V?[CLXW-4_X*
M5P:+?:WH-Q\./&2^.]*\47/AJ'PY$T5[-="'2;?5_M?F6QE58C:W4"D#<5GD
M"'Y?WM=)^T/^V3J/PS_8FL?BUX=\$ZYJ%]K"Z/\ 9= UI/[)OK)M2N[:V5;J
M.4J8Y(6N1OB)!W(5W ?, #SWXJ_L)>/OCAH?BC6M=UGP7:>.O$EMX,TN3[%%
M<_V8UOH&M-JLDS;AO$ER\TZK'@B %!YDV&9M;]F;]B'Q/\$_VE?$&N:PWPQU
MSPK'KNN>(/#>KKH4B^+K1M7NI+JYLIIV8QB)))I )8_GE18594"'?H>*_P#@
MI[X4\)>(/$%JOA'X@:MI_AE=:BOM3T^PAFM8;O2;)KR\M7;S0(VVI+"DDFV)
MYHF0.-T9?'\5?\%9M#\$>$EUC5OA)\9+&%O!FJ_$(0R6FD^?_8>G26BW-V4&
MH'!V7D4JPG]ZRAQL#@(0"C\;OV ?%GQ3'[1LVGZGX2T?5/BEJGAS6_#%[+!-
M<>3-H\5D4@U!5",8))[(*WE2$B*=\88?-G:=^P;XPO/$_@?Q)=>'/A3H>J60
M\5ZEXAL-(N;N2W?4M6L(;5)%GF@,ERS&(F::18VVR !'V_-[]^S[^U/I?[0G
MB/QEH]KH/B;PYJW@B[M;:^M=:@@C>>*ZM8[JVN8C#+*IBDBDZ,5D5D=712,5
MC>'OVZ/"GB;QOHNCVVF^)#9^*M4U30?#NMM;Q#3/$&IZ<)VN;."3S=ZR;;2\
M:-IDCCE6SF*.P"E@#YMTC_@G5\4OAUX1\-V^@6OPYN+G1_!/PY\*WD37LD'V
MJ3P_?WD]])#-]D<V\C1W8:"Y5&E1HFVB)F65,OP]_P $R?B=I/P+E\+S6?@<
M7D?PL^(7@*"5-;N;A&N-=U6*ZL79Y+8.8EBB/F,VYPS='.37N/["_P"T=XQ^
M*G[*_P#PO#QU>:DGA_Q)X?7Q!%X<BT..2ZT41BXEE%JUJTDMU&\/D*D;JTYD
MBD(8B58TV+3_ (*6>!;W38)(])\92ZE/XR;P!_9-OIBW5]#K0TS^TQ:N(9'C
M3-L02Y?9&V5D,91]H!X]K_\ P3[\:KX_N;O2-!\&V6DW/B_X;ZVD,-_Y(MX-
M!9#?N$%OCS L:QQ ']XH4$QA<5Q7BS]B/6OV>_A]J'C37/#?A;3]+T?0_BW<
M>)I])OY([J:'7]26^L )(;?S6Q#&$D8#,+*I7>%R/IWP=_P4G^&OCG2;.^LY
M/$,=OJ7@6]^(5L;G2I(&DTVSF2"[0*V#]J@FD2-X,;E9T[,I/9?M"?&"3X:>
M&_!EXFK6_AUO$GBK1]%S?:+/J'G?:[E$-KMBD3[/)(#Y:SN62-V!*OP* /F/
M_@CW?:7?:SXVOH]-T"_\07VE:'!J/B'PUXCTS7M&NDLK,64-LLMBB)'.%B\U
MD9<D3*1A%15C?]F/XU:[^R=\</A';^$M#T6X^-'BWQ6S>(+[6XKBST?1]:NY
MB;CR(U,LUREM,VV#"(9  957+#V[P#_P4@^$/BRZOK6SU35-*MM+TO6]:ENM
M2\/WNFV1M]'OA9ZH8Y98E21[>XDC#HF6Q*I /..D\+?ML>!/%7BG3]"6XU[3
MM=U36+G08--U+0;VSNA?0:?_ &FT+))$-I:Q_?HQ^5ERH.\%* /E'XE_\$X/
M$'B#XA:MI)\ VGB/P'/\1_ ^I)]OO[1C?:1I>D)87<TT;,"S#R]C1D9E1R,$
M%EJBW[ ?Q$M/BQ\5M,T?P3=:#JD=KXBD^&WQ.L_%JV>G:9!J&BBPL=.?386^
MT?Z$4MHEC:/[.$M(YT<2HB5])ZW_ ,%2_@;X:T'2-4O?&DT6FZYX<TSQ?;77
M]@ZF\*:/J,S06M],ZVQ%O"TJE7:8IY)9/-\O>N<#XM_\%+/"_A74_ FH:'J$
M-UX9O_'MUX'\6B]T74H=5TF>+0[W4XXX;,Q+.\TA@M]BB)_-CN4:,,&5J /(
M_!_[)6K:YKWP5\:']E^Q^']UX5^(EOJOB'P\-<TS4)(D_P"$;U#27U*%5F-J
ML,<\U@W[IEN)EM5E>+S(T6N!U']A[XO:K^RAK>EQ>!-8TOXD6GP0\4^!O%=[
M'JMFP^)_B2YBMET^_CE%P"[&>.ZNA<W/E20B\,8Y>54^W%_;Y^$,G@WPMXAC
M\=:3-H/C*UM+[3M2A2:6U6WNIEM[::XD5"MHDD["%6N3$#*&C^^K*,?6?^"E
MWP7TJR\520^-K74YO!ND:SK>I6EA9W-Q<+;Z1+Y.HB-%C_>2P285XTRXWHV-
MK!B =5^SMX+TWX(V,/@/P[X'UCPWX?L]/36OMTUREQ;37MW<3R7-ON,TDK7"
MR9ED)RA\]=KMR!ZA7/\ PL^(MC\7/ASH?BC2UNH]/\06,.H6ZW4#0S*DJ!U#
MHP!5@#@@UT% !1110 4444 %%%% !1110 4444 %%%% !7\(_P ;YGG^-OC2
M1B69]?U!B0-H)-S)V[5_=P3BOX1?BTZR_%KQ8RO\K:W?$94H<?:)/X<<?3M0
M!^V7_!D-%_Q6_P"T4VX_+8Z"NW/'W[_FOZ"*_G]_X,A;;=XK_:,F\M6VVF@1
M^8<[AEM0.WICG&>N>*_H"H **** "BBB@ HHHH **** "@C(HI&&10!\/77[
M2?QHTO\ 9R_: ^)6F^+/#VKS_!;Q=XC6TT/4M'BM[76=)TI?-:TDN(V5X;AX
MUD1;GE%;8S1,NX'LM-_X*0^'=!O?$'B*\;X@:WIE]<>$K'3M!M/#T,DFG3ZW
M:++;"%D82SK*TB"0RX\IU(4;<D;EU_P30T/6?!7C3PKJGQ!^(VH>#?B)XFO?
M$OB/0A-I]M;ZM]LD62XL))8;1+C[%)C8\:RAGC9D9V5F!U_%O[ &@^)OB;JW
MB6/Q%K^FMJOB;PYXF^PVT5H+6U?18PEO;Q@Q;A#)@%P26!'R,@XH S(?^"I7
MPLM_&*Z+JUUJOA^:**X&H2ZC!&JZ-<V^F+JES9W:)(\T,L5H69G:/R-\3Q"4
MR@(9/$__  4,M=%UOPCID/PX^(_]H^*O&%AX3\C4-.2P^R?:["34([O>\FR6
M+R(9 1&S/'(C1RB)E(J/5?\ @G1I^M>.OBJ+GQ]XVD^&WQ@@O#KW@-7MDTW[
M7>67V*[N(I_*^U1K+%\YA$OE^<S28R<4W2?V#?$A\&>![77OC3XZ\6>(O 7B
M>R\06&N:E8Z?YCPVUO<VGV1H(X5A)DMKN<23E?-:1E?("(B@&AKO_!3#X8>&
M-#U#5M0N-?L]%M_#&J>,=.U!])E-OXBTO3<&]GL"N3/Y:,D@3 :2)UEC#Q_/
M7J_P:^+EC\;_  4NOZ98>(=.L9;F>WBCUK1[G2KJ412M'YHAN$23RI-N^-RN
M'1E8<&OG36?^"56GZ]\#9?A[=>-M8G\.Z/X0U[P5X0$EC$]QX9L=6A^SN6D+
M?Z3);6H^S0,P0+$6\P2N=X^C]*\*Z]9^.[6_F\1M/HL.CK92:2MA%&DEX'#&
M\\[)D&4^3RLE1G/)YH Z>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ II
M13VIU% #?*7'W11Y*Y^Z*=10 WR5'\*T>6*=10 WRUXXZ=/:CRUIU% #3&I'
M3WH\L4ZB@!HC &.WI2E:6B@#B/CI\ M%_:!\/Z;8ZO=^(M,FT6_75--U#0]8
MN=*OK"Y$4D.])8'4D&.:5&1]R,LA#*>,:/PK^$FC_!WP])INC_VA(MS.UW=W
M5_?37UY?SLJJTTT\S-)(Y5$4;FPJHJJ%554=-10 WRUS]T?E0(E!^Z/3I3J*
M (S:1,P)CC)4Y!*C@^M1SZ5:W-W#<26UO)/;[C%(T89XMV-VT]1G SCK@58H
MH HOX6TR2[DN&TZQ:>4LSR&W7>Y951B3C)RJJI]0H'0"JVO> -!\4PV\>J:+
MI.I1V:LMNMU9QS+ &7:P0,#M!7@XZCBM>B@#,\6^"]'\?^'+G1]>TG3=<TF]
M 6XLK^U2YMIP&##?&X*MA@#R.H!JI)\+?#,UYH=PWAW0FN/"Z&/1I381%])4
MH$*VYVYA!0!<)C@ =*WJ* .3^(7P$\"_%N^ANO%7@OPGXFN+:%K>&75M(M[V
M2*-CED5I$8A2>2!P:M77P@\)7UGH-O-X7\.S6_A643:+$^FPLFCR*C1A[8%<
M0L$9E!3!"L1T.*Z*B@#SWQ5^R9\+?'/PRTSP3K/PV\!ZIX-T6X6[T_0KO0+6
M;3;&969A)%;LGEQL"[\JH/SM_>.;EU^S9\/[WXTP_$>;P3X4E\?6^GG2HO$3
MZ5"VJ16IR#"MP5WA,,PQGHQ'0D5VU% 'E^D?L5_"?P_:^'8+#X=^#[*W\)PM
M;:1#;Z7''%8PM,MP8E50 4\]$F"L"!(BN & (T=:_9;^'^OZ;K%I<>$]'\GQ
M!K<7B74/*A,+W6J1>7Y=ZSH0WGKY,0$@(8"-1G %=_10!QNK_L^^#=:^$UKX
M%E\/Z?'X2L5M5M=,MU:WAM?LTJ36YC\LJR&.6*-U*D$,@.<UR^H_L*?"/5M,
MO[*X\ ^'9+75-"7PU>QF XN]-6Y>[^S/S\R&XEEE.<EGD=B26;/K5% 'BI_X
M)X?!L^-+[Q$O@;38]:U*35I9[J.XN(V+:I$(M1VA9 $%PJJ7"@ N-_#_ #5U
MWP^_9G\$_"OQ5::WX?T.'3=4L/#5EX/MYHYYF\K2;-G>VM0K.5VQM+(0Q&_Y
MSECFN\HH \C\=_L,?#/XG:CXHNO$&AWVK2>,M-U#2=2CN-<U!H/LU_!%;WJ0
M1>?Y=J9HH8U=K=8V.&.<NY:OK_[!'PO\2ZU=:G<Z'J2:K>7NF:D=0M]?U*WO
M+>YTZV>TM)H)H[A9(&6WDEB<Q%?.2619?,#L#[)10!YGX#_9$\ _#+QSX?\
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M:CT7XF?#J;P_\/?L?A6\\*:GHVF^'H5L]:@DECFM9)!&T>UK65&*8!RLTRY
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M);27MD+FS\0F[MYK&QMP693&TLNHPM&X!82+%Q7<>+OV-_A/X^C\%1ZW\-_
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M-]6_#7XQ^&?C3\)=)\<>%=8MM<\*Z]8)JFGZC;*S1W5NR[@X7 ;I_"0&!!&
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M%(@9)%(P58'@@@D$'BN"\>_LZV/C[QWX-U.77/$6G:)X-#LGAK3[B.WT;5)
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MX-\0Z/>W?E>(M#\40&6PUO3FAE22 D1R;7$C0R F-E/EE2/FR/D7PW_P2/\
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MA_&A55OM0\9VYD/."GV"+9[==_Z>U?M50 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<9^T5>0Z?\ O'%Q<#=;P>']0DE&&.5%M(3POS=,].?3FOX4+:-C;1X)^X.WM
M7]UG[25Y-IW[/?CNXM^+B#P[J,D1W*OS"UD(Y;Y1R._'K7\*=L3]FC_W!_*@
M#^CC_@R?L+>/]C_XT72S;KJ;QG;Q21>9G8B6$11MN.,EW&<G.W&!MY_:JOQA
M_P"#*:Q2/]B#XO7(C823>.UB9]IPP73K4@9Z'&\\ Y&>>HS^SU !1110 444
M4 %%%% !1110 4444 %%%% !1110 5F^+?&6D> = N-6UW5-.T72[, SWE_<
MI;6\ +!1ND<A5RQ &3R2!6E7S9_P4_\ "NA^+O@=X=M]6^(*_"W5[;Q;IVH>
M%_$]S!'<:;INLV_FSVGVZ*4B.2V=HV1E=ERSIM97VL #Z#\,>+-+\;:)#J6B
MZEI^K:;<#,5W97"7$$HZ?*Z$J?P--T_QEI&K>)=1T6UU33[G6-'CAFO[&*Y1
M[FR2;?Y+2Q@[HUD\N3:6 #;&QG!K\Y?@W^WGK7@G1? TWB2X\#?#'2M;\1^.
M-!\1:IX6$<OA?QCK4%JEW#JNF2S(S[IYQ=,L669YH[A#YQ 8\3X6_:F\?7GB
M)?B5H'Q!T:Q^)'B_X8?"?7%\/_V;:2_\+(N+J;4$NK1$8>8L;&X=0]L5,#NC
M,VQ2A /U1\.^+])\7QW;Z3J>GZHNGW<MA=-:7*3"VN(FVRPOM)VR(W#(<,IX
M(%:).!7YO?%+]M_Q;\$OM6CS>-/!OPUT7Q/\6/&6@#QGJMM::7I^ER6]N9]/
MMIYC;R6XDFE,A,LZ;YA;,GF"616KT'P!^V5XD^(WQN_X0;7?C!X1\&>.-+31
MHX?#=CHBNWC:SO-#6XFU73H[G-R%%]+,(WPT4":<XGCDWEE /N#=QF@'(KXV
M_9H^*GB#QA_P0]T?QA8?$O5/$GC*;X5R:J_BI);6\O;?5%TYI9,E4,32PSAH
MR'4L&C(<ELFO*O"_[?OCFQ^ U]J'AWQOI7B#4OAEX-\':SI]A?)!>7/Q/745
M5+B3[0F"3+.);* P8*W=NYE,H<1@ _1[-%>#_MZ?'V_^ O@WP>FE^)--\-ZE
MXN\2QZ'!+=6T,LMSFSN[EHX'GDCMH9 +;>TMP2@BCF"JTK1*?DC0/^"HWQ>\
M8?!_PSXZL=:^&,=C#\.OACXRUNP33))_M=WX@UB[TW4[:.<76(47[.3&2KLC
M@*VX!B0#]+Z*^6_@A^TM\1/$_P"USXR^#WB0:.NL>"]=EUV:]M],DBM[_P (
M7-K_ ,2QD)D8"[:]::!VZ'^S+HB-0\9K+_:[_;8\;?#7]J%_AWX+D^'=A>Z3
MX6L/%S1^+K\V4>OP3:E+;7,,$N\%/(A@)+HDI$MW;97;E7 /KBC-?%.H?M[_
M !(\,?&CXR>"=4?P#%=?#GP]KOB_P]?QZ9=M;^+["WA00PQ_Z1A;BPNB8;\*
MS9,EOL6(RN(N7A_X*"?'C1K/[!J-K\([[6M:MOAUJVD75E87\=C:0>)M3ETZ
MXM;A3=.[RP-"\T4J%%E3(,:E<T ??U&:^-_ '[:_Q<\4?%77M!_LGX;:A'\/
M];D\)>*,WW]DM-J":!'J"75MYUS))''/=2!$MWB<BWW3&X8QLIY.?_@J'XXT
M/X5V_B'6-,T_1X=&UZXT;QK-?>$+^&7P!,MK83P0:I9I=22PPR?:I&.HV[7-
MLL)M92NV5BH!]Z49KQ7]M+X[^+O@=I?P\@\%V'AR_P!7\<^,K3PL?[;>9;>V
M2>WN9#./*^8LA@4[>C#*Y4D,/G;PE_P4J^+VL7>AV^H>"_ 5FVBZ'XIUGQO-
M#>7DR[?#7B"+2]1_LM0F9C/"SRP+*1MD78[$#) /O.C=S7Q7X@_;^^+6C> K
MR\T_P1X3\5:YK'PM'Q5\+VFDW<YANH(9;;[;I<C99I)Q#=PFWG0*D[%@8XPO
M/07O[6ME\=/''P7U[1+.QU[P#XL^)?\ 97A;7;+5[JV-W$OA;4KQ[TI&5CN(
MQ-%=6OD2YC#)YF/,C3: ?61D _+-.!R*^&-(_;TU+XW>#O#_ /PD7AN+1_$F
MD_%#PQH.M^&(]4U+1=8\)2W<H*K>)M072+)M*%6:TO(B6!(!6M+Q#_P50USP
MY\)K'XA_\(7I5]X-\9^'_$VL>$3%JCI=^=H]I<WB6]^/+*Q?:K>TG?,>XP.G
ME,')WT ?:M!.!7A'[)/[5/B;X[?$'QUX9\6>$M-\*ZIX0MM&U&$6&KG48KFU
MU*T::,.S11%)HWBE1E 92 I5CGCF]/\ V^M1U;Q[H+1>$;1O _BCQ_J_PTL-
M475&:]@U73S>Q&6XMA#A+66YTZZA!5V=/W+LNUV$0!],B52:!(I;&>:^1_\
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MFCVNO>*_$7@>YU.;50NFZ?JVDVUQ=HIDDBCD:WNH+69XYFB0C9AD!*!LV/\
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M"Y,:.Y W-@#(/<5VRR9'/4=?:@!U%(K;UR.E+0 4444 %%%% !1110 4444
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ML7QZU34KOP#\1H? <GBV+52R:S*-+N=.MYX;E5>W@)AOE@.JHI;RD5F9?(!
M/T;TW1[/1[);6SM;>UMUW%8H8Q'&-Q+'"CCDDD^I)K)/PH\+?;M$NCX;T#[5
MX90Q:1-_9\/F:4A4*5MVVYA!4 83 P,5\%_$37_'&I^$/$E]\/?$_P ;[7P'
MJUY\.$M)[V#57UO3M0EU\1:\L7VF-IUB&E&%KA64P1/O*@-YRCT+X+7OC'X>
M_P#!0Z/P4NM>/_'7@FSL9+&&]U&\U.*?PZ;;3+)=E^MPAM-3@N'(FCOX7%P+
MF>6)PZHY0 ^J/C'?>$O#OPWU37O&\>DGPSX3@;7[VXU*V6>#3TLP;@W6TJV&
MB$9D# ;E*Y'-9^@?!WX=^(?"D<FG^$?!\VCZU:6S!4T>W$-W;HWGVX*[,,J,
MV] 1\K'( /-?%'[9WCSQ[+\?OCGX;MSXL\:>$]2\#:[;6]II<>HVZ>$YAX9C
ME%M/9F(V^I6]S*ZO#<VK_:$N;A[<JX5O+RO#WQ0\:? T:IX9OO$7Q:O_  Q]
MK^'ZPW,MK<QI827UA<"]B>XBM6FM[)I+:VWI:H#'-.L0:V25FC /J[PEK_@G
M]D_Q5XXE\=?%:;7/%DND3>+]8U#Q$]K;S:5X=M9I1$H6WBBB2SMFEF 9E+LT
MDC,S$\=E\8=.^%>K:CX%\0>/+'P3>7MKK-O%X/OM<M;>6>WU.YP(18O*"R7$
MFT$>7AB$S_#D?FFWQ!\6?&G]D/6M<\8-XEUKQ5=?LC^*].U2\O- N[.YO-0^
MU&V9&B>)6%P[P_ZK&]CR 003]B?\% [1_$7P-^"%GIVI7NEOJ'Q)\(B&_LK=
M)9K5!<*YD59$= =JG#2(54D$@XQ0!ZY\6OV1/!?Q'^%&I>&['0?#GA^Z?2]7
MT[1]3MM'@:;P])J<4L=U<6PP-CR-*SOM*^82=Q.35;X4?L3?#7X8?"/0?"0\
M%^#[RWT?^S;F5QH=O"EY?6$4<=O>F,*0LJ>4A0Y)CP-I& :_/;XU_M__ !"^
M%7[.6GF'XD^)E\4>&K'Q??6FHZE9I%#K%OI'BD6=O+-Y=J[7ES]@"!H-D4)A
MGDN'=2(V'TI8?%[XR:-^T3\4_ =C)KGB>/P^#\2_#&HS6T<=OJFBW6GS1V>@
M%P@"R#58)AD_O3;QJ2VYMP /I#7/V4_ACXG^+-WX\U+P!X.O_&U]I+Z%<Z[/
MI,$FH7%@ZE7MGF*[VC925*DX*DCIQ7)ZK^S#\ _#VM>%?"]]X3^'MGJ<S7<^
M@:7<1P1W5[L2W-UY,3'?.JQV]IY@ 90D$(8;43'E?_!*']HW4OVG/"&L:]-\
M7K;XH64^GZ6]U:+X>?3[CPKJYA<:A9S2$*H<R!3]D*>9;E3D[)8U'RW\/O&M
M]X@MOA#8K\8]8L_&.B^)_C"EQKE])87FL:0UI<WN(L7$)B4I$;>4B6)\1G"A
M4*% #]"/VK_V6X?VHU^'MO>:A96NF^"_&%IXJNK6YL&NAJ8MX;B-8%998S"V
MZ=9!+\^UHA\IKHO"7[-?@'P#XBT?6-#\):#I.J:!HDGAS3KFVM5C>STV25)I
M+5,=(WEC1V'\3("<D5\)_LS?\%%O'_Q]^,_PMT74OB=X-\*:SK&@^"_$*>&K
MG3][_$#3=2TA9]1NK*)8#*["[DG4207"QVHTXM-&8V<GT3_@IK^TQX^^#'QC
MDT?PO\6M'^&MG'\*?$'C"UBOM(L[\ZGJNG7E@MO HF!D995N7B>.(%V!'E[9
M,-0!]2?!G]F'P#^SP;S_ (0GPOI7AS[;%';N+1" D,;R/' @)(CA1II66)-L
M:F1B%&34=C^RQ\/=)\+>!=%L_">CV>D_#.<77A>S@B,<&BRBWFMMT2*0,^3/
M-&<YRLKYZFOE/PU^VQ\2/%/CV.:ZU2UT'Q9I7Q*T?P5JGPIDM[9KA]-O;2UD
MFO4D*FY:6-)[B_699/LYM[&2(QET>2N//[>7QO\  OBS2O"FLRW.J:IIOBG7
M?A/K^I)H$<=N?$%X#=^%-0CV(5\F2S-O]H4,8XFO(=^W#T ?7GA_]@KX4>&=
M*T^QM?"JF'2=4TW6+-Y]2O+F>WN-.!%AMEDF:3R[<,WEP[O*7<V$^8Y%_8+^
M$ZVGBBW_ .$1M_L?C*#4[;4[3[==?93'J1SJ @A\WR[7[2WS2FW6,R-DL223
M7R1XF_X*-_$AK#XU:AIOCCX5Z=J7PMTWQU;W7A/4)VGU_3YM(CE;2]1>R6"-
MDAFC@6>5Y)VAD2^@$1C8!']=_:T\9_%#X;_\$B/BEXLN?B58KX^M_"5[KMEX
MET71H].CTU&B$R)'&\LH&R,E/.+[L'>-K &@#Z$^&_[/'A'X2^,M;\0:#IDE
MEJ_B.SL+#4;AKVXG^TPV,30VJE9)&5?+C9AN4!FR2Q8\UA^&?V,_AWX.^+EY
MXWTS0YK37+S5)]<9%U2[.GQ:E/ UO/?QV1E-M'=2PNZ/,D8=@\F3EW+?/NK?
MMO\ C:3X@:[/H>M>&=6T[P9\4/#'P\N?#WV,?:M;L=5BTTOJL<ZR_*P&H27$
M013$8;&16RQ9XND_X*'?M._$KX$^.=-TGP#K'@O28[CX>>+_ !A<R:[HLVHL
M9]&73GA5!'=0[8W^UR!\@D  @YX(![[\$OV?_"G[/'PHL_!'A+3I=/\ #&GF
M?R+.>^N+YE\^5YI<RW#R2MNDED;YG/WCC P*\K@_X)E?!&'P'<^"QH.K2:-<
M^$4\$2V4GBO59'&AI=/<1VBL;DNB)(S!74AU3]V&" (/#M"_X*$?$Q=7U#0]
M:UKP&FL:SJ/@[_A'Q8Z'.9F36["ZNY-.CB>[\N6X3[%*R7$TT$7EERPRBH_E
MOP1_;_UCQ?\ M+_#WQWJ%GH>@ZW\8OACX0TK6/$\%I]KT#PY<RZUKBQB=%G$
MG^F21_9;<F0QQS31AY#E$F /O#X=_L/_  Y^%7QWU_XC:%I>I6/B+Q-=/J-_
M"-:O'TM[Z2,137R6#2FUCNY8U5'G2)78;LGYW+-^/_[$/@']I?6=6U#Q5:ZO
M->:OX?7PT\MKJUQ:^1;+>1WT;Q"-@$G2YAAD64#<#&HSMR#Y)^S[^W)XP^,O
M[1/B&&1?A]IWPZ\-^+/$O@W4X+G5!#K6ESZ4Q$-QCS&\P3I#/.\;Q0B.">WD
M#N%8OZY^V!\:]:^#W@SPZ/#<VC+K_BCQ%:Z%80WMO)=2WCR)+*T5K KQ++<&
M.%R/-FAA15DDDD58R" 96E?\$\_A?8^"M6\-WFEZEKVCZSXQ@\>SPZSJ]UJ!
M35X9H)UG1Y7+*IF@5V0':V^0$%7*U:U3]A7P6?!WB'1="GUSPC:^+O$M_P"*
M];;1[I =6O+Z*2&\6=)HY8Y(95D8F-D(#!&&&4$?"/QD_;$\=^,OAC:_'CP^
M^D^#?B-<_LLZQXAW^4;RRL;H:GITC;8S)M."LOEEG<(7!/F $/\ 5=I^U_\
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M20RAT=7AEM[J>-UP&P^596 8>/ZC_P $FOASKGPXMO"NH:MXTOM+L] UGP]
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M$+P#H?@FW\-VFOR-I#2V-U=327DERMH"H"79BA7R2VR!=Q7<%C]^M_C'XL^
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MB^'XU\.^-+J[O-=L[R[N-0&K37<8CNI)WN'=W:55 ?+?,22>68G\_P#]C?\
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MJS^*'BCQ')X5OO%%]I=CKFBZS \(9[N&V9H+V$$?*8I8RDDR[LL" #[+UO\
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ML+C0K"5X;U7E6+38KSR8UE6.-6^SM)$LK  'ZE$CWX]NE!.,XY]J_+F3X/\
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MU@VKWNJP>0)&8V5U#)J%U$LX:0%)<F,LJL.6\5?M=?%3QQ\<?#]I;Z5;6?\
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M>@4#H!6C10!CWGP_T*_\76OB"?1=)GUZQB,%MJ4EG&UW;QG=E$E*[U4[WX!
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M+NCN8)$*21L.ZLK$$>AK2HH ^;_B#^PH- ^!EQX#^&,F@Z78^+(H/#GBJ_\
M%WV[Q)?3>'%M9[<V=M+-<;P\:R_N4F9X$,L[&-FE<M] >$O"NG^!?"VFZ)I-
MG#I^DZ/:Q6-E:PKMCMH(D"1QJ.RJJ@ >@K0HH \>M?V&?A_8?%B;QI;VNN0Z
MW+XK'C90FN7@M8=6_LY]->XCM_,\I/,M998Y$"A9-Y+ D CDK+_@EA\)='U;
MP3?:?;>+]+N? MB^DV[V7BK4+;^V=.>YDNO[/U+9,/M]H)Y97$%QO0>8ZXVN
MRGZ.HH 1!M6EHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X*@7*V?\
MP37_ &A)&8*%^&OB/J>YTRX K^)./<L:CC@#M7]LG_!5.!KG_@F5^T*BN8V_
MX5OXA.X '@:;.>_'.,?C7\3:$F-?< T ?T\_\&:\>S_@E5XB;<QW?$34C@MD
M#_1+$<#M_CDU^L]?DW_P9MO"W_!*;7EC9FD7XA:GYH)'RG[+8X_\=QUK]9*
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M+FUKP^^KK\7H[6+Q3#>:A<RPWXM8Q';%$,F+=X@ 4>#8RLJL#N4, #Q/]O\
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M\&?'R^^),6J>(KKQ!J7AJQ\*7"75XLEJUG:2S2PD1A!B7S+B9BX/S&0\8
M/2Z*16S2T %%%!.!0 44UI54]>^*-_- #J**1G"]: %HH!S10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!\Z_P#!7FX:V_X)9?M#N@RW_"O-;'3L;*4'
ML>QK^*D?=7Z"O[3O^"QFKIH?_!*?]HBYD+JJ_#W68\IU^>TD0?\ H7Y5_%EL
MP!] * /ZE?\ @T"+?\.B(MW3_A-=8VX';_1_SYSUK]2J_+__ (-$K=H?^"/F
MFL?NR^+]98>P\R,?T-?J!0 4444 %%%% !1110 4444 %%%% !1110 4444
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MWKX.?";QE\.GT&/5_'%KXAM+73KI=8BC\/PZ>NHZA+-$\=S$(WQ;PQ(LT8@
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M5D^)_'.C^#+*WN-4U*QL8;N]ATZ!IYE037,T@CBA7/5W=@H4<DFM02*3C<*
M'44;L?SII? ]?3WH =17G/P0_:=\/_M!7-\WAZS\0-IEO#%=6>K7.FR0Z;K5
MO(\L:SVDY^21=\,@*DJX&Q]OER1N]SQ9^T9X5\%_$GP?X3O+Z1]8\<ZO=:'I
M:6T+W$?VRVL)M0EBFD0%86%M!(X$A!. !DF@#NJ*3> .M9'Q ^(&B_"KP7J?
MB/Q)JECHF@Z+;M=7U_>S+#;VD2C+.[-P * -BBO._AS^U1X)^*?CF/PUI=_J
MD.OSZ4VN0V&IZ)?:7/<6*R1Q&X1;F&/?&'EC4E<X+C/6O0C(H/WA0 ZBF^<N
M?O+^='F+C[PH =13?-7^\OYUS[?%;P^GQ-L_!IU2U_X2;4-*FURWL!DR2V44
ML4,DX.-NU9)XEZYRXXZX .BHIHD4C[PZXIP;(H **P_&_P 2=!^&UKI\VOZQ
MIVCPZKJ-MI%F]Y.L(NKRYD6*WMTW?>DDD8*JCDDUMJVY,T +17(W'Q]\$6EW
M<6\OB_PS'<6NN1>&)86U2$2)JLL:2QV!&[/VIXY(W$/WRKJ<8.:ZY3E: "BB
M@,": "BJ;^(]/CU^/26OK-=4FMVNX[,S+]H>%65&E"9W% SHI8# + 9R15R@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^0/^"^Q7_AS?\ M";HS(/^
M$3FX Z'S(\'\#S^%?QP.<-7]D'_!?1U3_@CC^T)O9E7_ (1.89#;>?,CQS[G
M''?I7\;[\-0!_5S_ ,&G);_ARYX)S,\@_MW6]JD$"(?;Y?E'J.IXXRQ[YK])
M:_.G_@U0L/L?_!$SX:R?:(YA=:IKDH1>MO\ \36Z38??Y=WT<5^BU !1110
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M\2^'M5GUV:_TVZ.F:JNG2I,R6JQ-*%D2;RX)9@DFZ"5HG5C7?ZK^V-_PJ_\
M:L\9>%_^$;N[GQMK^L^&/"VF6UQXON)=&N[JYTR_OR41X=MDD4%G>,[Q1.]P
M8XLJ"5"@%O\ :4G^)'[3OP3\0^ M<^!/C#3['7HT0:EI'C'11=Z?/'*D\%U
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M>#VT;_A'YM-OLW45U8^1Y!@EWDF16B^5MQ)8$Y)S7PKX1_X*"?%KXI:CX?\
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M\5CQH?@=X6\-^!M8BO(6/P_\6V$<Z7DUQ*LQ,#?:#8W'VF/S!-%;O&<E$CE
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M;'X>ZS;^-?@QK'Q6\.1VUK=+#H4^G"P=M/OG\\FX21-2A02QB!EEMY04PZA
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M1110 4444 %>8_M&_':;X4ZCX$\.Z5#'<>*?B9XA7P]HXE4M!:E+6XO;JZE
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M4KKP/\.T\;?'#2K.T\.SMJ'VE[0_V%::?/%+<M:J\<<<\#,K(I\Q-A*HWR@
M^F?A1^U1HOQ(^*OCSP;=+;Z#KG@G7QH45M=ZA"TVLC^RM/U)KB",'<8UCU!%
M/!(,9)P"*WO'O[1G@/X8?#S4O%FN^,/#FF^'=)TTZQ=7\NH1^3': [?.R"=R
MEOE!7.YB%&6(%?+?B?\ 8 \0>.OVJ]>\27OA7PK;+J?Q0\/_ !(L?& N5DU3
M2[33M*L+272T7RQ*))9;.:,[7,)M[^8E@^8W\=?_ ()G_&C5/@7J_@N[\)>
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M=M_P0\^.C2E0K6^CQC<F[YFUO3U7CUW$8/8\]J_D/W,.U ']?G_!MC/<S_\
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MEEL&A=(U?:TH;.T9.W8?\$Z_A[H5CHZZ3<>,M&U#0M0UC4+/5K+Q)=IJ4?\
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MK;3:@KH&MXY7B9PS#Y8629]D3*YK_M'?L!6W[1?C#XBZI=>,M<T>+XC^ H?
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M]GFD^T0&&#/FL)!MBXR=QZ#@YY[&OS8^(/['GC+P'^S7KVH^+- L]#U3X9^
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ME)]^OZRO^#K&RDNO^"*?Q$='VK;ZOH4CC^^#JELN/S8'\*_DV>/+4 ?V0?\
M! /3_P"S/^"-?[/<?F2R[O"T<NZ0[B-\LKXX[#=@#L *^P:^1?\ @@GJ7]J_
M\$<OV>90DL>WPC!#B1@S'RW=,\=CMR!U (!YKZZH **** "BBB@ HHHH ***
M* "BBJ>JZ_8Z$D;WUY:V:2N(D:>58P[GHH+$9)P>!0!<HJJ^M6D5^+5KJW6Z
M9/,$!D D*YQN"]<9XSZT0ZW9W)D\NZMY/)D\F3;*#Y<G38?1O8\T 6J*P+_X
MG^'].\5Z/H4NL:>NL>((YY].L_/4S7D<.WSI$4<E$WH&;H"ZC.6 .S;:C!>Q
MEX9HYD4E2R,&&1P1D4 3-TK\Z_VX)[[X4?M5^,/&OPQU2ZNO'&HS:!I'BCX6
M^)M#EO-%^*MLIA^SSZ7*J;X;ZWCGD1IXF>*-K=#<1HB"2OOSP?\ $'0_B#X>
M@U;0]6T_5M+NI)(8;NTG6:"9XY&B<(ZG#8='7CNIJ3Q-XMTGP9IBWFK:A9Z;
M:27$%HDMS.(D>:>5888P2<%I)9$11U9F ')% 'PA\+/B59^"?C1^TKJ.L>-I
M-(T>[^,<5P/#3^'DU"7Q;;1Z'H=HT=JK)YDGFW$1AWQ[D5[=AP Y'1_L;>,/
M"'PMTCXY?#7XN+''\0/$GC[Q#?:SIVI6KRS^.--U"X<:=)9Q[=U] =.-M:!(
M0_EFV>(A2F*^IO@K\>M&^.T7BPZ3;ZK:GP9XDO?"U^M]"(BUU:E0[QX9MT3!
MU*L<$@YP*[8.O3IU/6@#Y1^,&G:%I7_!3O\ 9UT6WLK6TMX/!7C?=:+"/+0W
M$NBL%? V[IO*N6PQRYBE/.UC7SK\>=%@U;Q5^TG;Z9IGV[P;X8^-?@&\\9Z7
M86AE6X\,V>E:&+P&% ?.MH?)<RQJ"#':W"8.&6OO71/VE=!\4?&._P#!>FZ?
MXBU&?2KF;3[_ %6VTYY=)L;V*W@N7M)IUSY<OD7,+@N C%BBN9%=%A^,G[5W
M@_X$>)9])\0R:M#>6OA+5_&S"VTZ>Y4Z;I9MENV4HIW2J;N';$N7;=P* /C[
M]M/QAX;^//[1FI>)/!.L>'];\%^%O@EXQT[XE:O97$=QI=W%>QVC:/I\TZ$Q
MRS!DOIDC)+11RN<+]H7?U'PD\ ^*OV3?VB_A7\%9K?5_%GP=DUN?6?AIXF?_
M $QO#EM#I-^'\/WL[$N1$D@:RG.XR6X>)FW0!I/L[P;XBTWQKX,TO6-/4_V;
MK-I%?V^^(QDQRH)%+*>A(89!Y!JY>ZK8Z1):I<W%O:M=2BWMEED">=(02(T!
M^\VU6.T9. ?0T <)^U?XQ^'GP\^ NN:U\5'T5? NEB&YU$:N4^QNRS1F!760
MA&)F$056X+%<UX-_P34\=?"7P1X%\03>%O&?P]F/Q2^(VHWT6F^&M5@NM'L=
M5N+-+G^R;.6$F&6X2RM1<3K"2OG/<N,!A7UU*L=PFV15D7K@C---C:DQ_N8?
MW;;H_E'RG!&1Z'!(R.QH ^=?^"Q%]86'_!*7]HQM1DM(X)OAQKL"FY953S9+
M&9(L;N-WF,FT==V,<XKQGXL_M=>-OAW^T#XFLO#WQ$\,V?@?P'K'PPTVVT-=
M/LY%NH/$&HC3[N*2?=O51;LMQ"4VL&3.6C^4_9'Q0^&FB_'KP<FFWFJ:[!I_
MVA9Q/H&NW6ESL\98;3/:R(Y4-D,F[:2O(.*\XB_8!\)POD>,/C0W*L-WQ)UM
MP"I^4\W)Z=L],#% 'Q/??MSZEXF^,^C?%RWU[1?$'Q \(_"SXJ7(^'WV>$7/
MAJ^T^^TGRM.FCB O"Y6W42HY+2,CO$$4J@]+\ _MI?$GXF>*_ASI'A[XV?!W
MQ#H?Q(\93:1IVO:#Y>O20V:^%KS498I2([6$74=Y;*Z*J,4AFC696/,GT/I_
M[!/A62(WNF^/?C!%)> R?;8/'VH223;MN6WM(V[(1![A5]!46G_\$]= TAK;
M[#\0/BY9PVLCRPPQ>*'\N-WSO=04)5FRV2""=QSD'% 'Q[I?_!3_ .,VD?LQ
MZEXPO_&/PUU+6-4^ ,7Q1TU(]%\BVTS4(KI+=U9?M):6"?S #EAY<B';P0@]
M8NOVC_%FI?M!Z+X+\:3_  ^\97'A/]H*W\)6FI2:"L4L,,_@Q]:CEMT::3[/
M=P/<R6XE!9FBW @%F)]DO_\ @G3H-];>3_PL#XH+ ;7["T1U.UDC:#?O$162
MV8; V"$^[D X)R2EQ_P3QL9]16]_X6E\5/MT=S]M6X-SI<DBW &T3@M8G]Z%
MX#_>QQG'% 'RM\ XK/PS\:_ OC[4]*\'>/O&6K?'?XF>&H]9N?#\,OB*PM+6
MW\0R);V-RKADD*Z7!#A@_P"Y8HH1>OHWP\_X**>)/&7[/OA/QG;_ !(^$NO-
M\3!X7.DV&C64DU_I=WJ;3?:M-"?:/*,FR+9;R74D(66&Z,PVQA*[CX9_L5^#
M?&R7%WX4^+_CY_\ A%_$%_:^;:66@HVF:O&S0WC(6TK(N,[E>09+<_,15ZU_
MX)<:#%H&I:=:_$KQG%I>M:DNM7]JOASP@]OJ%\KK(MW,C:*5EG5T5A*X9PR@
MYR 0 ?,-E^WO\0/V@O@YXT\3>(-0^'VI:&G[.6M>)+OP9<:;]ITC6=02[U*W
MGWF.[W20O'8HK1B1PJ2R!7^<N?=H_P!MCQ?X>&I'P]IOA&#PS\-_'GA7X<ZC
MX=-C,NI7L.J6VD'[;9RB8)&L9U:(Q0F%U>.SFS(&<>3=\5?L)>"_#_B[P[X1
MU/XS>(;36_%5GJUCHNF3^%O!+2W]M)BYU2*&-M!.8I"RR3H,*[,&8$FK$?[#
M^AW/QTM[6#X\^)F^)7AS1[2]@QX6\$-J^FZ<'N(+9U(T,2QP _:HX\$*,RA>
MK @%#]G?]N/XF>-_CWX3TOQ9;_#U?!_B_5OB!I$#Z9:W=O>V7_".:RUE!<22
M2SO&5FBCD\Q @VNJ.'PYC0_;)^#7AI_VP?V<9&MY;U?B)\0]2&N^9?2O'J5O
M%X1U>2*W9=VTVZR6MO*L6-@>,/C<23UG@G_@F;H_AKQ%IMQJ7C*\\3Z3I[ZI
MNT?4/!7A."UN(]3##44+VNDPS1BZW S&.1#,5&\MR#ZQJO@+X7>(/B-X7TF\
MTWP7=^+OA_:_VCX>L76!M0\/6[+]F\^VB_UD$;*#%O0 $ IG&10!\?\ A#XA
M^(OV1_VS?B)IOA6RTK4/!%[X_P# _@R^CU2\O+K4U2ZT2VMUD@=F*@Q?Z.[&
M3>909 =C ._M/[!_[8_CC]K5=+\2:IX7T/2OA_XS\,Q>(O#E];ZI;27BR>>8
MYK*6*.YF:4Q(\&^8I!Y<IDB:(,%)]1B^#GPI^(GC;6]0CT+P;K/B"VUVQU35
MYHHX9[J'5;.%5LYKC;EEN(8M@C+_ #(NW& !5KX/_LJ?#7]G[Q/XHUOP/X&\
M+^%-6\:7AO\ 7;S3-/CMIM4G+,Y>5E +$N[MZ;G8]220#QO]M'Q1JGBK]L/]
MG[X4W&I:EHO@7QZVOZAKDEE=26<NNS:?:126VDF>-E=8Y1-/<.B$&5+$J28_
M,5K'B;59?V7_ (\:'\.?A_?276N?&![_ %;3[/Q-J=Q>:/X:BTVU@^T1VR;C
M,OG-/ RVZ,J*#<2C&W8_M_QC^!GA#X_^&+?1_&6@:=X@L;&]BU*T6Z3]Y8W<
M1/E7,$BD/#,FYMLD;*X#, <$YXVW_9M^$7Q1\*1:/::;HNLV_A'7)9A<VFIR
MRZAI>JK$89F>\CE^T)=>3)Y3[I-YC8(WRX% '@'@'_@IM\1OC-JNFCPQ\.?"
M=I8VGP__ .$U\2-K?B&XMY=/DBOM1L+JUM1%:R"X7SK M%*WEAXR68(2JF#X
M<?\ !5#QUJ5SX8TKQ?\ #GPOH^O?$S1?"FL^#3IGB.:]L&76FEC>*_EDM8FA
MEMS;R2!8UD6965%8,":^@/B3^S3\/O"'A+6M2TNS\+>!=9N?!G_"O[#5Y$$-
MKINGL76UM?*WHGE)/*"L8*DEMH8;JP/@E_P3B^'?PY_9KTGX?ZSHECK\L>B:
M'I6K:EONH9;Z72$3['- S3/-:B"96F@2*4>0[DH0Q+$ \^TC_@H?\1_%GQ9T
M3X<Z+\-?#,WCAO$6O>'-;DU#Q)/9Z5:-I<6GW0NK>1+2:66*>TU")E4QJT<W
M[MB5!E'%^/\ _@JOX[U?P/XTM_"?A7PO;>(-/T_0M1T349=1GO-)GBU/Q ^C
ME//6!8YY8PJR"6V,UN6<KN81_/\ 6>A_LI> _#7BSPSKUGH<<.M>$3?MI=ZU
MW<231/?[?MDDC-(?/DF*(7>;>Q*@YR :\_LO^"5WP)TSP]J&DV_@AK?3=3T3
M_A&Y8$UW4E6+3Q>_;XX(?](_<"*Z_>0F+:T!XB*+Q0!R.G?M;WWAC]J3QEX%
MTWP_)>>-O$7C2'P_9KJ/BB=]&/V?PQ::K//&#"QM$$3K'Y,,;F29O,) 9V7D
M?$O_  5YUK3O!UYK6G_"6:XA\-^#=2\7>)(KOQ(EM+IK:5K,VDZI90@0/Y\B
M2V\KP.?+295.\P':'^@-?_8/^&?B+4+N^FT748=6O-:MO$)U.UU[4+?4+?4+
M>Q&GQW$%PDXD@;[&HMV$;*LD197#AB#1\2_\$Z_A#XK\.:AI-UX9N8]/U3PG
M)X(NX+36]0M5FTF2X-S+"?*G4^9),S.]Q_KW+MND(8@@'M,MR8;)I=LDFU=P
M11\[\9P!ZFO@Z?\ ;^\4?M*V_P "_$7@W26TO4KKXJR>&M2\,P>)S#)D^%-8
MNWT[7$>!);*:VN8X6FA,,I7R4DB\\.@/W=/I4=SI+64A=H9(C"WSMN*D;3\V
M=V<=\Y[YS7C?@S_@GW\-O GB71]<MK7Q%>:]H>L0Z];ZIJ7B34;Z]DNX=-ET
MN%YI99V:=4LIIH@DNY?WLCD%V9R >5:'_P %9;36/#/PGUN3P'?V.E_$Z/PX
MKQSZO"]]I\^M:D=,1$MXE?S(K:YV>=/,UO&5FB$)FE8Q+SGP6^-WC35OBU\,
M;>[\7:Y>6NK?';XB^';RWFE5H[O3;.+7GM;5_ESY=NUK!Y8!! C .[K7IFE_
M\$GO@GH\&DQZ=IOBFQMM%M=$LK>&W\7ZKM(T;4)-1TUI#]H+2R07$LI5Y"S;
M7VYP%QW7AO\ 8C\!>%_&/A_7M-BUJ&]\-^*=:\9V0.L7$L U+5UN%OI&C9RK
M(XNIRL>-D9E)0+Q@ =^W=\2H_@_^RAXP\137'BRTCTVVB+7'AJ:VAU6W#SQ1
M[X'N%:)2N_)W*WRAL M@5Q%G_P %(M)7X]R>"[SP3XJTO2[?QGJ7@67Q)<7%
MC_9\=]9Z&VMERBSF?R7M8YAO\OY75 1\S%/7_P!H;X&:)^TQ\(-:\#^(IM2A
MT7742*Z-A<&WN,)(DJ[9 #M^9%SQR,@\$UPH_8$\$GQPOB![OQ%-=_\ ":W?
MCR2&6\62WGU&ZTE](F1T*'-N;.1X_*S@$[@<\T >%Z;_ ,%(=0'[29\3ZGI?
MC+3OAGJOPOT;7-!T!HK.XN-9O-5UL6=A+$D;&1+B42PQM%))L17C/#"3'H&L
M_P#!4:PT#2=&\[X0_&.37=8@\23II TNSLYD30S#]ID#7ES LD,ZSH]O*I*R
M+D-Y;XC-/2?^".WPNTSP5J'AV;7OB9J&FW'A>V\'Z:+KQ/*TWAW3[2]%]8?8
MI54/'-:7"1M#*S.ZB&,,7 KL)_\ @GOH.I/X:N-0\<?$G5]5\-Z-KNB?VGJ&
MIP75WJ::O%!%<37#/ 5,D:VT/E")8XTV8*,I*D Y>U_X*Q^$Y_#MUJ3^ /BE
M"JV_A/4+"W:QL&N-7L?$MX]EIMW BWAPGVB.1)(Y2DR;"?*8$9N^&?VY[#XQ
M_$#X6PZ?9_$3PI=ZYXG\3>'+_P .W>GZ6YDO-(M[I9K:]F$\JQKNB\Z&2TE<
M.0@=E4N!97_@F7X.,>FHOBCQRJZ7I/@_1[=1/9<0^&+Z2^TTG-KRS7$KM,>C
M@X4(  -SP=^P+X;\#_$;P_XFM?$GBR:\\.^+/$'C&WAN)+5H9;O6DE2YC<+
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M'79_$E_::OX"O=/TI-,2&WTY$:WO (X=\4KRQ>6UW/O24 *W _"/_@G+X_\
M"_[,<_AW7OA_HND^-M+M/#?AR/Q)X0^(5VVJ:S#HUT9[75HEO;<V]H\$K&=;
M.19ED,TR.X7&\ _0S2=7M=?TNWOK&ZM[VQO(EGM[B"0213QL 5=67(92"""#
M@@U7\0^+=+\)0P2:KJ6GZ;'=3I:PM=W"0K-*WW8U+$;G.#A1R:\4_8MUGXB^
M$=.TWX9^//#.BPW'@KP;H;S^)=$*V^FZKJ$D<T=U;1V:0QQV_DF%& B9D99@
M0D(VH?,?^"MW[+7Q(_:E\)IHO@/PWHNK1ZCX'\7Z!/>SWUO:WFGWE_8P1V2H
M\\<BK;2M'(LKPA9PRVX61(C-N /KO_A)M.&IK8_;K(7DC.BP>>GFLR*KL N<
MY575B,<!@3P17%_\-(Z*_P"T[;?"N.UU";6KCPY=>)/MT;0/8QQV]S;6\EN^
M)#*LX-W"^UHPI1LAR05'R7X1_83\76O[0.F_$2X^&^AZ?XBF^,.F>*Y]1BU*
MUDO;'15\'PZ5<CSP S-]M$^Z-?\ 6J^XYS@3?\$YOV3/B1\&_CUX$U3QI\-M
M.\-W7@_X5W7@?Q!XIM]8M+QO&.JKJEK/]OVQ_OV2Y$=Q=;[@+(KW,JNNX[G
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M^+-6^)?C:9/$=Q?6VVPTF\\/W%OI\TB1W#[K5]06RD6%4+!X_,:-6+.WJO\
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M-N0R^1%B0%6R@^8')(/UR?S-0OH5C)&D;65JR1EBBF%=J%E*MCCC*D@^H)%
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MJVM>!/$'@OP%XMN?$OA*]M;.XN/#GB72DL6%K=&2)F81FY9@8V$<\3PR*=K
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MUM3E\)/XZUS1]&>TO7\/:.9ID@G=VG03-*MO<%(HMTDGV2XP@(16 ,'XL?\
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MOH;0ZF[PNID)>YDU""3RW3[%]DC=MHW&32@_:5\::1\/;[Q)K?QNUQK;Q/\
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M+IM*@,SWUK'Y5K=%]N3-#& D<GWD484@52;]E'X7R:7%9'X?^#19PV&H:5'
M-(@$<=IJ#B2_MU7;@17+@-*HXD8 L": /D'XX>'O&WC_ /:9\6S>&M%\&>+-
M2^&GP;\->,? GA?4K*Y"6FL?VAJDBI;S1W*-"\QT^&$R*!N18T<,BN'^I/V/
M_P!J"U_;#\ 3>/O#C6UQX!U@P_\ "-W8A>.>]00I]I>0,>/+N3+;[< AK:3[
MP*FK?Q/_ &;;;5-+U;4OA]>:/\-?B)?:;::-!XNM=!M;^\M;&WF61;8QRC;)
M$%,BHC';&92P&>#V?PS^'^F_"?P%I?AO2D9-/TF 01EMN^4]6D?: "[L6=B
M 68G S0!\]0?MM>-O$G[1/B[2=!\+^')? /PY\3R>%O%%_J>KPV%S8D:-%J*
M7P=Y?]6TMQ##Y7D$E"\PD^7RZX'X0?\ !3[Q?\1?$MGX3O=#\+Z=KWB35_#N
MF:'K$J7-OI<HU31;[5'D\B5A/*J?V;<Q1$F$SF6%ML0)KZ:UG]D+X6Z]\<V^
M)U]X!\*7GQ ?3&T=]?FTV.2^DM&1HVA9R,LIC=T.>=C%<[3BO./"G[ ?[,/C
M_P"'/B7PQH?PZ^&NJ^'9&MO#^MV^G1PS+%-ICL8+:5XV+1SVK.=H++)'D#C
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M)V*N,8=#&FU@!@V)_P#@F7X D\.>)M+M]2\9V5KXITO0;";R=9W-:3Z+Y/\
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MK0\*QR1FQB-?1E?.?_!(33'T?_@E?^SK;R- SQ_#K0\F'.PYL8CQG'K7T90
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M&_"%IX@_X0G5]0\4Z9JFHOIMN]EKTVE6S*Z6DOF&96BNT=,M&B2^7)M9U7)
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MQ6'3[FP=K33]3N+.)IH+@F6.<K#\X8+\V<*HXH ^=_#7[ OBSPO^T]8^./\
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M@6WT^XU19K5XX1'?)*\!CD(VR9$$@;;]TK@\T ?GC^SM^V1XETS]G73=$O\
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MSW?C?QTUWXJTCPSI-Y=RSVMQ<'^PM3N-3MKC<\!S++/=3"7(*%&"HD85<4_
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MFG>&]:N?&82ZB\.:I!H&I1?VI;W\%V^YVOI(X[JUGBF6Y\RWF7:T.Y0#]#-
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MM;NWCNKL1&U@+QN5$LPG@\M"=S^='M!WKGY!^#?_  3"\?>"?@[X'\+:Y8?
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M1=!&I:#K&DZ]I_GS6IN].NH[F S0R-#-'O1F7='*CHRYRK(RG!!% 'A?A?\
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M;2*R%_H3P;XMT_Q]X1TO7=)NDO=)UJSBO[*X0%5G@E0/&X! (#*P." >>@H
MTJ*** "BBB@ HHHH **** "BBB@ HHHH **** /Q[_X//=2^S_\ !.SX=V^Q
MF^T?$. Y!&%VV%Z>>_?M7\TA=E/"YK^EG_@\_(_X=Y?#CU_X6%#C_P %][7\
MT^[;WH _N$_8'@FM?V&/@O%<*RSQ^!-#60,NU@PT^ '(['/:O6J\M_8<M)+#
M]BSX0P3,6FA\$Z+&['J6%A #W/?W->I4 %%%% !1110 4444 %%%% !7SO\
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M>^+4\4:!KGB70(]9LWA@MKC3;33+NS,L9FMXM)F6S#B5)-T2S@A^* /6)_\
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M!!(K\_-/_:\^(WPE\6Z.GB+XHZAKOPWO_&/BK0-%\77>D6,;>*+5-#@O-/\
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MP9N+'QU/XAETWQC8O'J^F36-CIUG<1Z?.H>*W-W(;J:5@KX-K:L0H9BZ=/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _"?\ X/=K:1_AU^SG-^Y\F/5=>1LK^\W-
M#9$8.?NX5LC')V\C'/\ /FT6X]Z_H"_X/>;LCPS^S9!YBA9+WQ')LWD%ML>F
MC.W&"!NQDG(W# .3C^?\OGO0!_? C[USC%.ID!S&#3Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH _ G_@]]?\ XF'[,*_)C9XK88;YB<Z+V].!SGG\.?P4/)[_ )U^]O\
MP>_<W?[, Z?+XL.?QT2OP3. ?O8_"@#^^"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_A;'A7SC'_PDOA_S NXK_:,.X#IG&[I7\'0MH_E_=I_WS2SV\:QQXC3G/\
M#0!_>4GQ(\.R_=U[16^E]$?_ &:HXOBGX9N!^[\1Z"_)'RZA$>02#_%V((_
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M"K5I^U'\3;#=Y'Q%\=0[LY\O7[I<YZ])* /[PLT9K^$.+]K#XIP3M+'\2OB
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M ?*+;,^(KSY.(NG[SCJ?S-=@/VH/B9YEW_Q<3QU\L<!'_$^NN,R '_EIW'%
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3,^Q2<+N/)QC)K\GT^Z/I0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex3-1_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1_006.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MV[)=Z8][923W,I#[76X^SCRP,IE?+;.SJ,\?L/10!^2?_$&5^RA_T,7QH_\
M!]9?_(='_$&5^RA_T,7QH_\ !]9?_(=?K910!^2?_$&5^RA_T,7QH_\ !]9?
M_(='_$&5^RA_T,7QH_\ !]9?_(=?K910!^2?_$&5^RA_T,7QH_\ !]9?_(=9
M?A?_ (,NOV9]/.I?VMXT^+FI?:+^6:Q\C4;.U^QVK;?+@?\ T9_,=<-F3Y=V
MX?*,<_L!10!^2?\ Q!E?LH?]#%\:/_!]9?\ R'1_Q!E?LH?]#%\:/_!]9?\
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M*B@#^>W_ (@<-:_Z.0TO_P (F3_Y-H_X@<-:_P"CD-+_ /")D_\ DVOZ$J*
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M*?3!T_ 4^@!@Z?@*<O3\331T_ 4Y>GXF@!&^]^7\Z5>GXFD;[WY?SI5Z?B:
M$;[WY?SH7[WY_P Z&^]^7\Z%^]^?\Z '4444 %%%% !36^]^7\Z=36^]^7\Z
M !?O?G_.E;I^(I%^]^?\Z5NGXB@!%^]^?\Z5NGXBD7[WY_SI6Z?B* &GI^!I
M],/3\#3Z &'I^!I],/3\#3Z &'I^!IR]6^M-/3\#3EZM]: $?^AI5ZM]:1_Z
M&E7JWUH '^X?I2?Q?C_2E?[A^E)_%^/]* '4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO?E_.E7I^)I&^]^7\Z5>GXF@!&^]^7\Z%^]^?\Z&^]^7\Z%^]^?\Z '4444
M%%%% !36^]^7\Z=36^]^7\Z !?O?G_.E;I^(I%^]^?\ .E;I^(H 1?O?G_.E
M;I^(I%^]^?\ .E;I^(H :>GX&GTP]/P-/H 8>GX&GTP]/P-/H 8>GX&G+U;Z
MTT]/P-.7JWUH 1_Z&E7JWUI'_H:5>K?6@ ?[A^E)_%^/]*5_N'Z4G\7X_P!*
M '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA^E "?Q?C_2E?[A^E)_%^/\ 2E?[A^E "?Q?C_2E3[@^E)_%^/\ 2E3[@^E
M"?Q?C_2A/Z"C^+\?Z4)_04 *W5?K2TC=5^M+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7\H/_!QW_RFA^-7_7;2/_3-85_5]7\H/_!QW_RFA^-7_7;2
M/_3-84 ??_\ P9#?\FM?''_L:K'_ -)#7[?U^('_  9#?\FM?''_ +&JQ_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRM<Y&^.5FN877+REE9MY1P5KZ\H **** "BBB@ HHHH **** "BBB@ HHHH
M*_E!_P"#CO\ Y30_&K_KMI'_ *9K"OZOJ_E!_P"#CO\ Y30_&K_KMI'_ *9K
M"@#[_P#^#(;_ )-:^./_ &-5C_Z2&OV_K\0/^#(;_DUKXX_]C58_^DAK]OZ
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MC<U[<S)'*9$BDE)154*J][X-^"8\ ?LXZ5\.M,\1:Y:)HOAR/P]9ZW%Y"ZE
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M('S'.7XE_9G^'/C37M>U76/ /@O5-4\5::NC:U>7>B6TUQJ]BI!6UN)&0M-
M" 1&Y*C XXKXS^,D?C3P?]L\"VGC/XPZAX?\9_&^#38+Z>ZNXI[2QO\ P[%J
M"6LNHP1B[L;!-3DPAB (;9:L\4+.4\#^%_[4_P ;OBI\.X?&7B#XC?$OPS?>
M&_V:-)\>7L,6CM#;7'BVUU#4% FM3 &D\]8T26UCVBXCDC(&/)< 'ZR7GPT\
M.ZE\/6\(W&@Z//X5:Q&F-H\EG&U@UH$V"W,)&SRM@V[,;<<8Q7-0?LE_"RV\
M/WVDQ_#?P''I>I"R6\LUT&U%O="R %F)$V;6$ 51$"#Y84;<8KXA@_:,^(EE
M>^&?'OA/XP^-/&-QXT\8^-=%\.^#]4\.V\6D:Y;V]GJDFGQJ?LL,\"QW\-G'
M'/+,!(DJ1EVWJ])X'^.'COQ9X(^']OJO[0GQ ?5/B-XH\/V;R6'P_71&TMY=
M,O(=0T_?<17*JXECCEE#$?9IQ"H8>:(R ??WQ+^$7A7XT:#'I?C#PUH/BG3(
M9A<QVFK6$5Y#'*%91(%D4@,%=ER.<,PZ$UQ_C#X,?!KX<>*])\;:YX1^'>CZ
M[;W6GZ3INMW.DVL5Y'.S"TL;>*8IO#9E$42J> ^U< FN+_X*+>,_&'P/^ &A
M>//"NH^)+@_#_P 2Z1J/B#3M,MXYIO$6CM<QVU_#(I1B%2&9KDF%?,)MMJ@;
MJ^29/$?Q@U#X$76A^.OB!XSM]>\-^./#?@O[?=:';7L4^M7_ (IT[4X+MHQ$
MJNECIS6-N)-P@>66Z5M[(IH ^WOB1^RQ\'=8O/!EKKWA/0+=M/M[_P ,^'+:
M%6LXT@O;<O>64<<)53'-#:EGC8%2(<XR!69\:?V)_@1XW3QC-X]\)>%[I/BQ
M?Z5#KSZM<LJZY>6K"/3E&^0 3(<)$(]K<[1G.*\&^!/[7WCS4O$=MX=UGQ9)
MKFK>&_CAXH\#P126]I;7GBW3;+0+[4(4F6.)5$B3>0-\"1C$<>X$L=W'Z7^T
M'-^T3^QE-KUG\>++6?$^L:QX!AU2VO\ 0XEA\ >(F\061G@:$F+9(A:-6L9V
M$J&U+,W[TT ?7^O_ +(/P7\.>*/"_CS4/ W@G2;[X5Z;)!HNJO:Q6D7AZR0,
M[!3\L:11@NX+#$99V&TDDM^$_P"R?\&]'T;P[K7@GPQX9CTFWNK[Q!H\^CRY
ML)I-3CQ<W""-O*E6>-L D,NP@+@8KAOAM\8+SQ9^SS\?--U[QGI?C>7X;ZGK
M.@3:NL-O9N8X].AN6CNDB/E)+"UP\3,%0$1!BH)-?+W[+W[2OB+]BW]DOX3^
M#'^(UK\0/"]_X'\ Q:?KT&F6ND/X/TS49Y[%]5961PUI#%':?-<IQ(V9'P^U
M0#[I\,?L:?"_P9X8L]&TOP7H]CINGO;-:Q1A_P#1DMKL7EO C;MRV\5PJRI
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M;Q!:^(IO$ANX/%-['/;7DUE':,IV2C]S]GCA @8&,>5&VW(!K'_:Y^*/Q#^
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M$\<B;')&WTSXO_MJ^/=*^$NCW'A/7O U[K7QMU75+CX9ZCJ972=.L-+M]/\
MM5J]P\C2I=^=Y+2[D:)VM[D,J PL:^GO _[/O@7X93>)Y/#G@WPQH,GC:[>_
M\0/I^F0VS:W<."KRW)10978$@L^2<GU-<Y=_#_X._M-?#;PSHEUX=\#>-O"6
MGN+[0K"XTN"\T^S>PD%N'AC9"D;0.?+  !3E>.10!\L?$S]IG7/VH/"T=GK#
M>!=#G^%WQ8^&^EZI;"Z^V6VLWMW<:#J33V%P&4[<Z@BVQP?,$,A;<' 3TO\
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M<?VU_;UQXH\^34KJ51J,UC_9\DXC:0H";3]T%"[%7[J@\T >5Z5_P4"^P_\
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M^'=U\/[WP=XFUF?6DM=>6Z@G\-37+0R78A$(87<<MQ]MNMLCQ,);PJ'\M54
M&[;_ !W^'OQD:'X>^)/['OM8\269L=5\-7MO]NM1,]J9KC39V*&!IEA#LT#G
M>8P6*;3FO,_A/_P4'_9/^%?PD5? _C/X=^&/!=CILNN6]OHMA]@L6M?W4DTT
M$442K)M-S$9!$K,K2?, <XO>"?V2?'VE>*]:T'7O$VCZYX#OO&&G^/+35DB^
MQZY;W=NUK/+8F&.,0^5+>6IF:?S"QANIK;R@ DH\P^"_P9\8_L8K^RE\)=)G
M\.Z]XN\(_"_6?#]S>WD=Y#I4KQ'1%D=)8XF^<-&9$BDV&6.&4 QGYD /I#Q)
M^V]\)?"5UX4COO'WAU/^$X^PG19(KCSH;P7S%;)O,0%(UN&5UA:0J)3&X0L4
M;&2__!1;X'G4=<LX?B9X7OKSPW=1V&I6]E.;N:VNI+V:QCM=D09FN&N8)8Q"
MH,AV9"[2"?G3X8_\$?M8^ WA[Q1\./"?B:U;X7?$?P]HMEXBOKF]NH=>TJ^T
M]$AEETX1Y6-+F-?,&95:WGWNF\.%3T76?V1/B-'\./!(TF+P+;^(/"/QBU?X
MBSVSW&8M4L;R[U>984NWLWDM;G9J42R21Q%FCBFB#A)F- '?W7_!0_X4_P#"
MWM:\#Q^++"VU/1_ L'Q$DU>Z4IH"Z/-++$ETU]_J0@:/<<N,JX*EL/MZWP]^
MTSX'&M:'X7U7Q]X!;QQJEO;?\2RTUB'S+N:6 3#[/$S^8R.F708)*8/(YKY\
M_9S_ &-OBM\"OAAXBT^33OA7>W>N?#U] 32EU._;3;?4(]4UBZMH#)+ TDEG
M]GU79)(RF0M!PF'R-#X2_L8?$7PWX2TOP5X@F\$W/A5M7\,>+9]1MKF=]1TN
M_P!*&G22V4<3PA+F%Y]-C$=R7A=8IV4PYB4N ?0WP\_:(\ ?%S48K/PIXX\(
M^)KJ:Q&IQPZ5K%O>226I8*)PL;L3'N(&\<9(&>16OX_^(WA_X4>%KC7/%&N:
M3X=T6U>..:_U.[CM;:)I'6.-6DD(4%G954$Y+, .2*^"?@Y^Q1\2O^"=7PE_
M9VU?1O".B_$34O@;\+_$GAC6]+T"[:UDU?4KZ?19H9(,P%I%?^SIE9RF\,\9
M*[2S+]/?MF_#;Q;\9/A/X1NO"VGW,>LZ+XAL=9GM4N+.#5+6$Q2PS?99KA);
M:.ZC6<D,P(PCA'1RDB@'>:C^TK\.='ATZ2[\?>"[6/6$L9;!I=;MD%ZE[(8[
M-HB7^<7#@K$5R)&!"Y-87QN_:9A^%GQ-^'OA/2]/LO$VN>-/$46CWEA%JT-O
M>:19M:7=RU^8GYDC06N"ORDAOE+-A6^.O!?[ /CR'X,>/--U[X-^#[KQ--\&
MXO WA^^;6;.^G2_@O]<\M(YWAC9(WAO;*X,A";60H$)0$][-\!OCA\+OCU=:
MEI/@'P)XNT!?B>_Q 76UU\:+JE[:7FEWUB]E<0M#,LD]B)D593,J2PK JK'M
M?: ?8_C+QOHOPZ\.SZQX@U;3=#TFU:-)KW4+I+:WB,CK&@:1R%!9W51D\LP
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M^.7[0FF6?B#5?B#X?N;:/5;BW6QMK!O-MC!NMPT+1-$)8IU(:1)60/)"RQ@
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MF2Y_5JB@#\L_CA^VC\3_ (0_ML^-/A7=?%7Q'=^$?#>L:?/)>11:/8:TQO\
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M^)=>\1:IJ'PZ\$WVI>+?+76KN?1;>2;51&8G3SG*9DVM!"PW$X:&,]44C/\
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MBNFQ7;C/9>!O^"??A'X?_%KPGXPTZ\U*UO\ PE=:Y+'!;/Y-O?P:E,LJVLZ
MXDAMC'$8E/"O&),>82QQ]8_8%U35/!/ARUC^(4EKXB\$_$O4?B3X?U9-#C:.
MSEOI+]KBSEMVD*S1,FJ7T6_<KA9$((= Y *OP@_;7U#XU?\ !0"'P9H[1_\
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M]U!#<V\PVO%*@=''H0>#^-176A6-_?PW4UE:S75OCRII(5:2/'(VL1D=3TH
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M?3_&GCQ;:#P%X=^',KM+9"2YTS1+R2YM-Q%L,2,DTMO*RX#QR$X$@$@VIO\
M@FAX8N?C_=?$&Z\6>,+B\NOB';_$QM.)LULQJ5OH[:/$@*VXE\A;4J-I?)=
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MG-=#I7C6T\9^ (?$'A>XT[Q)9ZE8B^TJ:UO%:UU)'3?$4F7<NQ\KAQD8.>:
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M;/2+&]O4M/&.J6]C]HMKZQ>>&&.RM+5'8A%DCF R&#LW:0_M(:UX!^&_PO\
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MQ^_X+ Q^+O#WQ'L?B'I_BGX V>H6EQ;);Q0VH;6W9H(HXU61 I8,T<[/-&7
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MK^-;_@OQX6OK/_@L?^T"LVGB-I/$[3*$MKE R/#$Z-AQDEE8,6'RL22ORE:
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MO3]#L=>\":#I7B#Q_I&D:OX3:UUI[JP9;]3OBO&,22QO;,,L41EE5TV%6WA
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MBCWY+.CQLWS$D^\UF^$O!VC^ - M])T'2M-T72[0;8+.PMDMK>$=<+&@"K^
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MC]IKP='HO@7QE)I>@?&/_A-;O6[/4K=+-M&G\-S03H@:X#LS7^ T)3:'VO\
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MKP;X(T?X<>&;71?#NDZ;H6CV*LMM8Z?;);6\ +%B%C0!5RQ8G Y))ZFOB_\
M;B\=_$"#]K6QU+P???$S2[/X>ZYX M[]+*&\DTK4K+5-=F@U2-+2*%X[P&R
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M1'<M,'48+'(8L.*Z;PQ^Q9\*?!7QTN/B=IO@+P[!\0KJQ@L)?$)MO,U"2*"
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M %%%% !1110 4444 %%%% !7\6?_  75_P"4P7[1'_8Z7O\ Z$*_M,K^+/\
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MZ6W@X:4=1W><"8!=9&W:)B!GR^: /?\ X]?&;1OV5_V>/%_C_P 0+JEUX?\
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M.Y\%3/LC\JZLKU7G6929;F*UN+<ND\$Y4 ]H'_!,3X0KX:TK1QI7B+^S=%\
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M0AC.+6*WB=HFB65;:$.K[>?-)_\ @BO\-)/A5/X/77_&<6EW'@+Q#\.6=;F
MSC3-8U2/4IF!,1'GQ.GEHY!&UCN5B :[7]@K]K;QQ^U!#%=>,/#/A7P[;:OX
M!\*^.-,CT?4Y[YT35TOO,@F:6&(91K(,I4'B4J<E-S5/VY_&?B;P[\?O@98?
M#^W\.ZM\0]4O==.G:9KOB&XTK3WM8](F,US,L,<S31Q3M9(0L3.IN%PR!F)
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M?[1G[._B*XUR+PZ8?&'C3QA\5O%EMK2>,;'1;&/1_AK#IXAC5@DKDJQM&G1
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M7* "BBB@ HHHH **** "BBB@ HHHH **** "OXL_^"ZO_*8+]HC_ +'2]_\
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MX7\/^%;+P)';2P:O#+J&E6E[;O'<>:DN^UO3;P!UDC+&"X",C-M#5Z#^R_\
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MGX#MO'VEZKX6M=3O8O%.HW)\3:?HLCVR7$L]Q$[6X%K(TL5JBNL>YH_,.05
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M&S7]XBO/*S:G?-IKY6\)_P!*VD(WS!% /UBTZ>#Q'JNM0W&BW%O_ &?.-/\
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M6NW^C:>QU>+4&U-;.[FM)9B(U'D_O8'PA+<$'/4#TR@ HHHH **** "BBB@
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M%U!&G98A)));;1;QN7R84C5MVP&@#SS3/^"A&K?#/]NKX\>#?&=GX@U7X?\
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MOM)TU[5?#&J3S>?JMNMQIRA8K=]WVF-LQD9!967AE91VG@K]G:Z\#_L=:?\
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M/& ?;]U\$_!E]'$DWA'PQ,L$%W;1*^EP,(XKHDW4:Y7A9B29%'#Y.[-1:?\
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MMG=)K=UJ5FVGQF26!;;S99$CB+7$C_NL!C)DYXKBO^"=/[17C#]HOP;\4O\
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M_91M2_\ 2+3Z_6ROR3_X,R?^44'B+_LHVI?^D6GU^ME !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M_%G_ ,%U?^4P7[1'_8Z7O_H0K^TROXL_^"ZO_*8+]HC_ +'2]_\ 0A0!^\'_
M  9D_P#**#Q%_P!E&U+_ -(M/K];*_)/_@S)_P"44'B+_LHVI?\ I%I]?K90
M 4444 %%%% !1110 4444 (W3\133T_ TYNGXBFGI^!H ?3#T_ T^F'I^!H
M<O5OK2/_ $-*O5OK2/\ T- "KU;ZTC_T-*O5OK6)\1]9UO0/"%U=>'=#A\1Z
MRAC2WT^6_6QCFW2(KLTS*X140LYPK$A, $D"@#:_B_'^E*_W#]*^4_ W_!1;
MQ%XT_9ZUSXC3?#?3]&T;P_KVH>'[R6X\4QM%#/8:\NCW)9O(4A,+<SHV,%8
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M (*<^,&^$'@S1$\7^'/V;-2U7PAIZVJM&VLKJ,T-KA691N8%8,[EQ$?+W*G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K^+/_@NK_P I@OVB/^QTO?\ T(5_:97\6?\ P75_Y3!?
MM$?]CI>_^A"@#]]/^#.;PAJ'AO\ X)%W-[>0K';>(/'6J7]BPD5C+"L-K;EB
M <J?-@E&&P<*#T()_5BOR3_X,R?^44/B+_LHVI?^D6GU^ME !1110 4444 %
M%%% !1110 C=/Q%-/3\#3FZ?B*3&?UH =3#T_ U\V>)O^"K7PQ\&>$I]:U;3
M_B#I]FNFZKJMMYWA>Z#7\>ESRPZC'&-N!-;F%V:%RDC(-R*XK:\1_P#!0SP=
MX1\+1ZQJGA_XB6-E;:4NN:V9/#<^_P *V3L DNH*,F E,RF+YI5C1W9%"F@#
MWM>K?6D?^AKRWP#^U[X4^)7BN\T;1X=<NKW3_%EYX-O-MB6CL[VULA>NTKJ2
M$A:!HV1VQO,T8 ^85S>A_M^?#MY_!^DQ:OKNN:QXNLX]1MK:+1Y#?P6<U^MC
M'=7-LJ"2&$W+B(NR )M8OM"LP /=UZM]:1CAOPKP)?\ @H'X)T;X9:5K4<?C
MKQ+?:M::CJT>CV/AJ>;7(K.SO/LUS++9H@:-8962+! =CC <[L6+S_@HY\*X
M?BS'X-AU#Q!>ZD^J:5I#7MMX>OI='ADU2V%QI[MJ B^RB.<,B(WFG,DBIU-
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MPT>2:VFAD6XM9M2OI[*T9Y,E&6XG188T5=P=&R2&7 !\!_#3_@FK\<+'X:^
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M%/\ 8LNM6#W^B:3_ &E)X<-U9(3-(1B2.%Q T9:-69F:-=IW<?&^H? +XK?
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MDL6 &<BH;SXA^'].U<:?<:YH\&H,746TE[&LQ*>5O&PG/R_:(,\<>='G[ZY
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M=CT 4 G+*#H^&=<N-8T6.YU#39M%N))I8A;3SQ2/M61E1]T;,I$B*K@ Y <
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M_B-XSF31M!N_$>E:]!8V%M.41H5DN+2*\FD@0(90DIA,7EG'U!_P4T\6>+_
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M^SN?#NM?V%;^-OBYH?AW7(UC1S?6,\-W(]L'<90-)#%DJ S %> Q%<_^SO\
MMZ>*OBO>_#O6KW3+.31?B=XZ\2^"1H,5DT&K>$FTQ]4,<]XYF<$B/2F2>,HI
M66]BVD!-K_47C#P#H?Q"M+.WU[1]+UJ'3KZ#4[2.^M4N%MKJ!Q)#.@8';)&X
M#*XP5(R"*XF[^'OPE^ 'C63QA-I/@OPGKWB[6(K'^U'@AM9M1U*\<1)&K\9N
M+AV"G;\TK$9W&@#S;XY?MA:[X _:DTOP?H_]G7=G#J&B:?JEN--GN%MHM4G>
M%+FXN\QPV\BO&%BMP97D#LQ4*RM'\C:3_P %N/C5'\%=0\8:CX)^%C06WPLU
MSXG10V]W?K(T>BZPVG75FP8$!K@/ \<@8B$^8&64!2?T.\7?LJ_#?Q]X^F\5
M:UX(\-:IXCN$LDEU&YL4DN)197*W5GN8C+&"X198R>4<97!K#_X8Q^"O@CX=
M7FE_\*W\#V/AFWT*_P!%N+7^R8?LR:5=2_:;RU*[<>1+*OFNGW689()H X35
MOVQ_'?B_]J;7/ ?@#P/;:UI/@?Q7;>%_%FI7MW%;KI27&@IJB7JDS!W7S;RP
MA$20LSXN3N7:F?'/!'_!5?XC>$]/\,W7Q0\,_"_1U\=_#O1_%NC+INM7RQ6%
MY>ZQI^DK'>SRV^U;:675+24/&&>%5F1UDVI(_P!E:M\ ?!'B+XEP^-+SPOHE
MQXKBMELTU9K5?M?DJ)-J&3J0OFR;<_=\QL8R:HV?[+'PWL/"MOH<?@?PS_8U
MIH4WAB&Q:PC:WBTN9D:6R"$$"!VCC+)C:=B\?*, 'B?_  3:_MY?C%^U='XE
MNM-O=7A^+,*32Z=!+;VA_P"*3\.E1''))(R_*1D%S\V2, @#IOVK?VR-6_9_
M^*&EZ!IVE:+J7VR+2KGR'FGGO[J*YUB"PN7$,$;_ &>&WBE#_:)R(WDEBC'2
M1EV/ /[,'PEU_5-!\8> K/3]);1==>]>]\.S?9AJES:6LVD/!=M&1YRQHOE,
MDF<-:Q@_ZL8L?$G]F3X/_MP:)8>)M6L+/Q?INL:2MI!J.F:U<P6^IV)F2XC5
MGM9D6=$F198R^[RGRR%6)) /*/"/Q4USX)_$QH--NO#MGX/UKXM>(E\5S:RU
MQ)-:V4>B3Z@9;:7?MC*SP*6$@*"-F"[, 5@>%O\ @J;X[\1?L_?\+)_X4SJ&
MG^&/&.J^$HO =YK.IVVGIJ=IX@OK*QC-VD$EW-"\$MT9"XC*31;"NQBR#W[Q
M)^PO\+?&?VQ=8\-S:M'?>)T\9217FKWT\2ZHH9?/1&F*QJR,R/$@6)T.QD9?
MEKF;;_@G7\ _!FA3^%[7PK9Z%;>*O$%OX@^R6NN7ME-?7]G.]] (BDZR>5!,
M9)TMXR(8SEA&N* /=O#LNH3:!8OJT-G;:HT"&\AM)VGMXIMHWK'(R(SH&R S
M(I(P2HZ5\6_M3_MC^,/C%_P3L_:%\7^&?#LGAWP;'\-?';Z#XFMM?\K6;*_T
MJ.ZLPTENB@P^9+%--#+#-(R+"OF")V"CZ>^$OP&C^%7Q,^(7B2+5;RZ_X3[4
MH-1DL#+.;6R>*!82Z))+(%DD"KO,8C0B./\ =A@SOP?Q _8;^ ]N/$S>(-"T
M[2[?XH0WWAS4()->NK&VU$:JT;7MM;Q+.D<,EXT"&46ZH\[*2VXEL@'&^!_V
MZ-?\$?#R'3_&'A?2]*UBQAT:*WNY/$#75G<0WNG3W$4L\@@\X3&2SFA,444Q
M9WB*EU9BG/\ AW_@J]K_ (T^&^F>,M!^#6J:YX5D^'GA_P"(NIWD/B*U@DL;
M34I+Q)(8XIE1I9(%LWDYV!TS]QPL;?0-_P#L>_#[4/$DFL-H^H1ZE(;!DN(-
M:OH6M396]Q;6QAV3 0E(;NX4F,+O\TE]Q (Y[P%_P3V^&7PW^!EU\/=-L=>_
ML.^\/67A>YEGU^]FO9M/M'G>"'SFE+*%:YG)";0WFL""O% '"?$__@IY:?##
M4DUFX\'S3?#2QM/$C:_XB;5H8+CP]=:)=M!-;36D@#%IU7=#A\L652%#*Q]8
M_99^./BCXXZ'XGF\5^ -6\ WGA_7IM)MDNS(T6L6ZQ0RK>0&6**0QDRM$<H!
MO@DVEEVL?D_X)_\ !)WQ5I7Q2\0:AXKU"2TL?%7BC5-9\40Z=XWU*^\.^,;6
M\NKAI()O#]Q%]FB,]O*J/NFF$+%C&20A'V+^SM^SUI/[,W@!O#>B:MXPUBP^
MU274<GB3Q!=ZW<P!@JK#'-<N[K"BJJI&#M4#U)) /"?%'_!5W1?#_P"S^GQ6
M@\#>(M2^'FIZ1X@UC0]6MKJVD_MF/2K6YO<*BL?+%U:65W- SD B)5?RV<"N
M^\5?ML#X:?L"ZU\>O%O@G7-!L=#\,2^*[CP]]JMKC4EMDA\]8RR/Y/FE,94.
M0IXW'&:HZK_P34^&.JZ-KVCPKX@L= U:/4H[;1[35733_#KZC \%[)I\."+5
MY8YIQA/E3[1-L5/,;/IGQQ^ GA[]HOX">)/AKXK6\OO#?BS1Y=%U-4N#%<3V
M\L9C?]XN"K$9^8=Z /"[[_@J!;^'?BMX<\"ZM\./%2>,-4DT<ZOH^ES1:M<^
M&X-5N7M[.:X\C<FU6BEDFP^(HDW@R XK2T;_ (*=^&=3\47DEQX/\;:;X#L]
M4\0Z!)XQGAMGT]=3T1KP7MN88IGN54I8731RF(*YB*_*S(&]%/[(GAF#XN67
MCBSO_$VE^(TTVRTG5+BQU1[=?$EO9NSVHOD7 F:-I)<. K%9I$)*,4KQG]CW
M]AVYO/@[X@T?XL^'[VQ^T>/?'.M6VD+JR2VM[8Z]J%[*DLGV=S^\%I>R1#Y@
MT9DEQU!H U;3_@JMX3O3XG_XH_X@6EOX;U"YMQJ=]HD]CH]]9PZ>U_\ ;X[Z
M9$A6)D4PA9&5_/\ W>W&','[&_[7^J?M,_MB^.DL-6O[KX:ZI\,O!'COPQI]
M[9003Z=_:_\ :IDW%%WY>.UMV*.[[7W[2 <54\9_\$CM#\9?#GP[HLWQ8^+S
M:EX7FN!9:S=:E:7UQ]CELGL4LGAGMGMGCAB<-&[0F59E\[S#(S,W:?LB?\$]
M-!_8Y\:G6-#\5>+-:C'@?0/ 4=KJS6TBQV.C+.+23?'"CF7_ $JXW$L5.\ *
M BX $^(?_!2#P;\-/'UQX=O_  _XV:[C.NK!(EE;QI?'2+);RZ\I9)TD960N
MD<A01N\3C<!M9HO"G_!2[P3XG\8:IH<WA_Q]H-]I&I>'[&==:T==/!AUQGCT
MZ\7S) 3 \\;P$8$J2C:8QUK/^(O_  3)T#XC_$?4/$UQXU\7V]]?W&MW)9(-
M.DE7^T].;3VA,\EJTS6]O&\C0PE]JLXW;PB!9/VL_P!F"ZU?P9XN?1-%USQY
M<>.?"]AX .A)J5II5OIL$<UP8]4-XR>?$\#7+R%XO,D4HC1Q%U!H ]U^'?Q
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MMZ;K%O+JOPQ\56NIRZ=KPNTE>4Z+*865KB>VAV20R$EKF))1)&YA=W[K4/\
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M  G\/ZEI^C)I.GV<-EJMWX9-Y=WKK);M*TGVY6"QES&A1DVMT'Z2!LG'<44
M?#?[0/[7,E]^V1I/AWP9\:9M-?08K#5];\/R3Z;'9ZPUW;%=)T>R66T:>YEO
M[J6*266*<>3!&%^1IT=>3^"W[:7C\W:ZWXD^+GAZ[\!^(M<T.SUVY>P\F\^&
M<MQINIB]M;AI+6".WWZI;V4$:7(DEMS,?.9A)'C[P^(_Q*TWX7:%%>ZC]HD>
M\N%LK*UMTWSW]RX8QV\8)"[W*D#<RKGJP'-'PL^)%C\6_ 6F^(-/M]2L8=0C
MW-::C:M:WME("5>">)OFCE1@RLIZ%3UZT >6_P#!/+Q+9^*_V?M4NK'4H=6B
M?QUXO;[2B[-X?Q'J4B$K_#NC=&'JK*1P17P;_P $Y-,^-D/_  3B^'/A[X5_
M$V6SUCQ5\--2FTC0[O2+%E\&:MILL+0,LIBWB*[EF,=PET)F'VE&A,0C(;]9
M*Y'X@?":/Q3X*\1:7H.JWW@74O$G-SKF@V]M'J*.<*95:6*1#*4&T.Z,5&",
M$ @ X']BOXJ:U^T/X9UGXD76L+<>&/%DMNOA_1X?)DM]'2W@6*[Q,J+))(UX
M+A6$G"^0H4 $EOFGPT_B3Q?XJTJSTSXK6>J^-6_:3\11B36(4U2X\'VB:)K,
M4=@+=9(]A-C )8=P50MU'(R2C)D^\_"WARV\'^&=.TFS\[[)I=M':0^;(9)"
MD:A5W,>6; &2>2>::/"&DKK)U(:7IW]H--]H-U]F3SC)Y0AW[\;MWE )G.=H
M"].* /SW^&?_  4O^)OQG\4^!_#.E^-O@?HEW'8)J5YXDU>YEM]*\?I'XBU#
M2;J'3;<C>)4AT^.5@LV4DU*W#*% #_4__!0>;P[#\#M!/B-]'CC_ .$^\(_8
M#J#1+B[_ .$@T\Q^29.!-PQ4K\PP<=Z]8L?AOX=TN>PDM= T6WDTN6:>R:*Q
MB1K22;/FO&0OR,^3N*X+9.<U@?&CQMX$\-6>GQ>/%TQ+&;5M.LK&35; RVK:
MA>7!M;..-V0IYSS,$&#E3*F<!UR ?!WA'_@H+^T!\8=1\9>%O OB+X;>(O$5
M_P##K5_'GA+5(/#LDEE<3Z?KD=G]F@B6\,D]I<0F2&.27RI1,C.59-JUZI\%
M/V^_%'Q__:-U[2?#_B+PS_PBO]G:9\3/#US<Z:T-EJO@BZTET1I+HR;[>[DU
M@3!F>(K%!9O\C,U?6NA_";PKX8UZ+5-,\-Z#IVI0VTUG'=6MA%#,D,LJRRQA
ME4'8\B*[#H64$\\UA_$CQIX!_9YTK1;K7(=.T2UUR^L/!]@T&EM());F;RK6
MT(AC;9$9'(&[$:[B21F@#E/V,?VA;[XX>&M;L]>FBC\5>&9K.+4M/,2K<6/V
MBQM[E/,DB9K:=7:21HYK9VB:+9R)!(H\;\1?MH_$+Q-\(?\ A)XT\-Z3H_BR
MT\7:7;V%J\_]M>&[K3+>^D@EE=@$$ZFSDBN82F(IC&$D<!B_T9X2TCX<?L_>
M,[/PGH.EZ#X5UCQY)=ZK%9:=IXM_[4>W2%9YF,:[<HCP+\Q'R[0O P-;2O@7
MX+T/4/$5U9^%?#]K<>+FD?6WBL8T.JM(H60S8'SEU #$YW8&<T ?/7[&?AK4
M-&_X)->%O$VCW&EZ3\1?%GPHTW5+SQ!'8F1KK4O[$C$-Y<(7W3R*=A8LX9]I
M^89&/FRV_:H\>?!'XS?$CXJ6\WAOQ]JGA/\ 9S\#^(M;AB$Z#6?+U;7GN8;9
M%DDV7$D'G!7=V'G+%E"K-L_0^X3P'^S?\*M)T:1?#O@_P;:O9^'=.LRL=K8Q
M&XE2UM;.-.%'F221Q(@')=5 YKG--_88^#&B^ =0\*V?PK^']GX9U;38M&O=
M+@T*VBM+NRBGEN([:2-4"M$LT\T@0@C?*YQECD \]^&_[7?Q ^)W[7;:/IWA
M?09/A';ZKK'A6\U-[ZWCU;3]7L$C=-T?VHLZ2[;K]RMN'6/[/-N*.P6K^V[\
M)O%'BOXO:5XE\+NWCY=%\+WFG:M\,1XE.BSZG;W-U;.FI6<@=46[C:V:-3<$
M1,K,HDB.XM[AX=_9Z\"^$/B%_P )9I?A#P[I_BC^SUTK^U;>PCCO#:JL:+"9
M -Q4+#$N"?NQ(.B@"/XD?LY>!_BYKJZMX@\-Z??:PFGR:0NI*&@OELI)$EEM
M1/&5E$$C1IOB#;' PP8$@@'Q[\'/VR/B)X>NO$U];ZUX?F^$NE:+X&\.>$9/
M%=NUKK46HZC$BS7&H$3^9<3CSX08(T!GD:-(W0K+(U[X4?\ !17XC>,=-L_B
M)KUKX9TGP+X5\&^.KSQ5H4%A.NHWNJ>&M52QN'@FFE18(7V[XTE4L@DE23)"
MR+]%>,OV!?@WX^U>YU#4?A[H/]I75AIFF&]M$>RNH8--G^T6"Q2PLCPM;R@-
M&\95EVJ <* &>'?V)_@U\'M.T.^M?".BZ38>!8]=N+%[FYE:VTZ/5I//U5G$
MKE"DS L_F9"C(&U210!J_LV_'#Q-\;D\17FN> KSP3I4-S!+X<FN=8L;^37M
M.FMHY%NV6TFE6$^:9DV%F!5$8,=Q5>'M/VR_$4?C9KB\\(Z2O@2X\<2> +2]
MM];$FJ+>+,ULMQ-;-&J+ URC)MCEDE"/')LQN"]]^S'^S-\-_P!F#P#)IGPQ
MT'3]#T'6)SJ9%I<27*7!D&X,LDCN?+ /R(K;$7A HXK%L_V2_@[\/_CC<>+(
M]$TO2_&/C;5GU8J^J31QZEJB6GE->16;2^3]L6V1@9XXQ*$WG=AF) .;_P""
M;?AG7M2_9[T/Q]XRNEN/&WCC3TN]5:RU>^NM.F4SSS0R)!<'9#+LGVOY2*IV
M*H^1(U7Z&KBOV>? ?@WX:?"32]%^'\T<WA&S\R.P,6K3:I$@#L&1)I9)&*JX
M9=N["X*@#&*[6@ HHHH **** "BBB@ HHHH **** "BBB@ K^&S_ (*1:C-J
MW_!0WX[7%PP>:3XA:]N8*%SC49QT  [5_<G7\,O_  41_P"4@/QT_P"RA:__
M .G*XH _I^_X-1/^4(_PU_[">M_^G2YK]'*_./\ X-1/^4(_PU_[">M_^G2Y
MK]'* "BBB@ HHHH **** "BBB@!&Z?B*9*GFQ,IW ,K#*DJ1]".13VZ?B*8Z
MLZ,%;:Q# '&<4 ><^(OV6_A_XI^$.G_#[Q+IK^)M!@O5O[2/7]1GU*]-Y'.;
MI+A;F=VG,T<F75P^Y , A1BH?#/[*/@'X<?&'5_B!IUC>:=K6M7LFHW4?]KW
M0TLWTT4=M)=K9&3[-'<R1QJC2I&'?<^22[%O#_@K^T+\4K[X=_!WQ%X@UWP/
MXTU;XC)J<\%A9:1_942M%IEW=0QQ3-/,5):%$D?###N< 8%>>^)OCM\7_C?^
MR/K?B;4[OP'<Z7XA\/\ @KQ+X?MKG3+C3UTK5;S5(I9K&YE\UVFMH0+4>:L2
M.1(>IZ 'UAI'[&'PS\/^"O /AW3?"MGINC_"W51K7A>"TEDA_LF[V3HTB,K!
MFWK=7"N&)#B9]P.:\]U/_@DU\%;C1=/TNRT?Q-H&CV/AFV\(S6&B>*=2TV#5
M=,M79[2"[\F=6N/(,DNQI"6"S2*25;%>2ZG^UYXS\#?MR>#?!OQ \>>%8=.\
M-:EXN;4[RRMO[&TF]M8-%TF^M'O6FN)3"\"ZE(A&XI)L,OR% *]T_8^_:S;X
MXZWXH\,^(+BUM?&WAF'3+^_T^"%/L<$&HVSS6YM;N.62.]@<P7!25?+<H@+Q
M(2,@&U\+/V*O"OP?^(UKXDT;5/%WVBQO->O(K6ZU=[BV)UFXMKJ\1@X+.@N+
M99(PS$QEW .TJJWOVA_V2/"_[2=OJ2ZW>>)M-FU3PU?>%IKC1M6EL95M+N2"
M20J4X$JM;IM?&0'D4Y5V%<%^V+\2?C3IOQ:T?PC\)=6^&.AMJ7@_6?$,]]XL
MTV[O?)GL;C3TC4+!-$/+=;ME8DY3[XW8V'Q;X#?\%&_C/\4O 7C'XK>(/"GA
M+PS\-_!/@32/%[Z"\<JZQJ-Q?:&M]-9-=2RJELMO-M/FO;D/'.!\IC9B ?67
MP,_9@\,_L\^)_'6J>''U=9/B%KA\1:M!<WK30?;F@BAEFC0_<:00HS]<L.,#
M '$WO_!.?P)<_M%1?$I=0\50:A%XN'CPZ5'?I_9<FM#2/['-V4,9DW&RPA02
M!,C=MSG/EU_JWQ*^.[?#_P .^/+KPC:PW'Q,FMIK>RCAU*+7M";0=1N88[N&
M.X9(I=\;C(9E/E12J ?E',>)O^"DGCCPO^Q6WQ/\!^ O"L'@73X[+2=&35=5
M\ZX2;_A)O[#,,L=O*Y 6 I(&W[A)%(CA6.$ />-+_P"">_AG1!HYL?%GQ"L;
MC3;2?3KZXMM4BAF\06<NH'4/L]XRPC<B323*AC\MUCN)DW8D;/=?M%_LT>'_
M -IW1_"]GX@FU6V'@_Q1IOB_39;"=89$OK";SH"VY6#1[OO(1AAQQ7C?C[]L
M7XG>'_VE/#OPY\/^"-'\1?V+=Z.OQ UR2]M]/L--M-2%PL=S:K+=^?N22W5?
M*>)O.,NV-]R,*X?1?^"D?Q*^'/P.T/QE\4O#/@'2H_%G@Z?7]+CT:^O)A!=C
M5-.T^UBG+Q_ZNX_M:T<E2#"5D5BP_>  ^CH?V4-!@\=P^(EU;Q'_ &A#XEO/
M%BYN8_+-[<Z:VF<KY?\ JXK9BL:]CRQ8US.N_P#!/7P7K_POD\*R:OXRMK5?
M"6C^$;.]M-4%O?Z7'I<SSV=[;S(@:.]29ED\X9&Z*,A1@@^:_&3]M7XP?"&W
MN/!]MX0\%^-OBT[:GJFG66AZC%%IEUI5D^GJQN6N[J&2TN,:C"[X\Y8T7<=P
M=,^B>"/VM=:US]LEOAGJ^DZ7HUG?:7J.LZ0\[S"XU6RMGL8X[FUF56MKE7:X
MF,D0D2: +$61ED5V /6OA;X#N/AQX,M]+O/$6O>*KZ/+W&JZQ+&]U=R'&6*Q
M(D48X "1(BC&<9))\?\ "7[ ]KX6\6Z/XDF\::_JGB31[;Q9"M]=65D?-?7[
MRWNIG*+$ OD-;1)&JX!0$2;SS7(_%?\ ;Z\6?#W]M[3/AS8^'-+UKP[=>(+#
MP_>W,=O>*^D_;=+N+J"YN+P*UK&6N8HH!;$><5G20#:R[N!T3_@JA\1OA/\
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M !%^#OQ'^&MO+\1M"U[X;_"M]5M-&L;W0YFU^;3KFV6.TBGO_M.QGM3NB!6
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M<KG@^/W'[>EQHG[#O@SQ]J5GX=A^(WBCP?9>(V\.?:Y?LXD>".6Z5)%1V\M
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M,VT"^&)4U+04O2[6^T>1/9:C>R2F4 QBU\R-HE5P/8O#O[:NL?M8_M8MX/\
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M.TM;6#2GT?8UC)#&D#_,\IB<MN, !:,TOVD?VR?BQX&^,4D>@^-O \?@N_\
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M!G0.FFO(I?<A?S7X8?L:_'3P-\&/A-:^'_#/Q#T7QUKOA/XC0^*)9->$-O\
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MZ?O^#43_ )0C_#7_ +">M_\ ITN:_1ROSC_X-1/^4(_PU_[">M_^G2YK]'*
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M_98\!^!_B7HGBW1=!_LG6/#GAF/P=IHL[VX@LK328W#QVBVBR"WVJP7:QC+
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MZ4 "]6^M+2+U;ZTM !1110 4U_Z&G4U_Z&@!U,/3\#3Z8>GX&@!R]6^M(_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?MF>%;G7OV?O$FH6?B+Q1X;O/#>EW^KV\NB:BUE)-+'9S^6LC*-S1JS*^T$
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M/^P3K'C6ZCMFLDL;V\UR2ZO])MK.[AO(+2">0,ZPB:"$L&+-((T#LP5<<?\
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M "2K;E(W(X7F/#__  4-^"?BSPM?:UI/Q*\,ZII>GS6<#SV<YG$[7D\MO:&
M(";A9YH)TC>$.LA@EVD[&QYCJG[#/Q&U7]H2Y\:R^+O"<B66A^,-%TU);2]+
M30ZU>)=VT;PI.MK!]G:*%))HXFFN1""S!F)KE?%G_!,SQUH7[1?@_P")G@OQ
M%X*AO/A?X8\.Z-X;T2\LI[>QOI-*L]=LG2X,1/DQ30>(;P(T:,8'M[=MDJ[X
MR ?0G[$?[0]S^U-^S[#XRNFT5VN/$&OZ5%)I7F_99X-/UJ^T^&1?- <,\5JC
M,"!AV8#C%:UO^UG\.+SXEZSX-A\7Z3/XH\/PW,U]IT3L\T0MHX);A1@8=XDN
MK=G1"SH)X]P&X9J_LC?"+Q)\$OA#<:+XLU'0]6UF[\1:YKLUQI-M+;VI_M+5
M;K4?+5)&=AY9NC'DL=P0-QG \YT3]D_QMI7[6.B>.9-0\.S:+I?B76[A[:.Y
MN;<)IE]8*8FBM4'V<7@O=PFD?<TJ$R"12S0T <_^QC_P5#TG]I7Q3X/TW6%T
MW3;KXL^&Y?&O@VST^"\FDM]*A:VAFCOYGB6$3B:<$-"S1,-P!PJ23^N>,/V[
M?@S\/=)OK[7OB;X+T6STW41I-Q->ZI% L=VUA_:*0Y8C+/9$7"8SYD;*R[@P
MS\E_!S_@E_\ %R'X-?!OPKXJUCPCH+>%_@CXB^"'B:\\/ZM=375I;7L>G+:Z
MKITCV\>ZX!TZ,M'((Q&9"5=]H![_ .!'[%GCKP5%\(9M8^'/P/\ #^H>'?&#
M>(_%C^%KVY6&[\C1+O2;6=!-:[IIB+E) KL@@2W2-7DP' !]8^-OB3HGP[^&
MVK>,-6OXX/#>AZ;-K%Y>Q(UPL=I%$97E41AF<"-2V$!)[ UX+^SI_P %.O _
M[0_QIO?#4,MCX>TR\\)^$O%7AJ\U?4([2[\0C7X[^6*V2V?!$T:62Y56<L9>
M@VY;V_XU?#UOBS\&?%OA.*Z73W\3:+>:2ER8O,6V,\#Q"0ID;@N_.,C.,9'6
MO@3X-?\ !*OXG:=\+O%-AXXT7X;ZAJ&I^#?AEX-AM++Q%=M%=1>&;V:6^F^U
M&S26V\^-T,0C5G1T&7!57H _0S_A/]!_X3O_ (1;^VM)_P"$F%A_:ITC[9']
MO%GYGE?:?(SYGD^9\GF8V[N,YXIWB[QSHOP_TR.^U[6-+T.SEGCM4GU"[CMH
MGED.U(PSD LQX"]2>!7SG\#?V,->\ _M9R^,/$6F^%M:71;GQ-)H/BX:MJ)U
MK[!K.I#4O[*DLV8VZQP32RH)3)("EK;[(H=[JGH7Q_\ AWXZU+XS?#?QAX+A
M\,:M#X9;4;'5])UN[FLTEM[R*+;=6\T<<H2XADMT4;HCNBN+A0R$\@&%^QA^
MW]X3_:M^!WP[\2:A>^'_  =XH^(]I->:=X6NM;ADU"58YKB,^4AV/,,6TK95
M. C_ -TFNQTC]LGX2ZWX$;Q1#\2O Z^'H]7E\/OJ$^M6]O;QZC$YCDLV:1E"
MSJP(\LX;H<8(-?$_[-__  2^^+7P:^!OPKL-1_X1NXUCPB/!IO\ 3[#48H8+
MF2S\1W&HWTD\KVCRR_9;:8BW2.5$9KBZ!&2I>;XY_P#!/SXI?$+XBPKX@^&_
MA[XE?#>34/&?A^Y\+IX_N] 6_LO$.NPZNNL7,D,8W)!'$;9K4!Y-Y$BEAM"@
M'Z.5YC\9/VQ_AM\#?A1\0O&6M>+-%FTOX6Z<^I^)(K"\BNKO34".R1O$K;EE
MDV,L:-@NW KT$Z7_ ,4\;&%FL3]G\B-HFW&W^7:"I/7;V)]*_/3XE_L!_$CQ
M?^P[XD\%V/P[T73?&FA?!/6_A#:SVVIVVSQG/=O:);WXE9]\<"FVGNBMTQE5
M]0E +/O>0 ^Y?@?\0];^)GAG4-0UKP]#H*QZI<P:7+;ZG%J%KK>G!MUIJ$,D
M?1)H61MCA61@X^90KMS'PP_:AF^+WQ%GT_1?"=W/X5M;_5='E\3'5K+[.FH:
M=>SV5Q9_9Q(;CS1)!(P^3&U&)*D -Z=X<EFG\/6$EQ9OI]P]O&TMJ[J[6S%1
MF,LA*DJ>,J2#C@D5\@^#_P!G/Q]?W_PEU.^\!+X?N/ 7QT\5>+KJWCU&RF:X
MTG5(O$*17Q=)  W_ !-X"\0#R9B<8/#T >Z?LQ?M8:3^U'\*[+QAI>GW.D:1
M=7VNV$@U&XB2:W?2M4GTV5RJL04>2WD<,#\JE=V"V!Z9)K=G%%=2->6JQV/_
M !\L95"V_&[YSGY>"#SV-?G?\+?V$?B7X%^$5IH>O?#K2O$$,'A?XO:)?6ZW
MEG))>C7]=34].A#/*%:&YA5HW1@-DFPN54$UP/QY_9N_X8=\=V>H:5X)T/3=
M#\76WPWT73;*_P!1LH],UO5-,M_$IU1-2-U,HFVZ<8%,LS[C)]F=6F>'RF /
MU4MKF.]MHYH9$FAF4.CHP974C(((X(([TTZC;K?K:F>'[4T9E6'>/,9 0"P7
MK@$@9Z9(KYW_ ."5?PV\-_!O]C[3?"7A.UOK;1=!U2_2)KF^L;U9?-N'N?W,
MEG-- ((Q.(8T5\QI"J$ K7COBW]E#XA>)?VD/'T%QH,DWB2^^).A>/?"?Q/^
MSVYBTC0H&TX7FB##>?'(+?3[BV\L*8Y_MZ2$@^:4 /JCX.?M'V_QK\>>)M-T
MOP_K2Z'X?GFLH?$+M VGZC=6]W<6=W;(%D,J2PS6[9$B*&1T="P/'9:[XSL?
M"AN)M6FBTG3;9(2=1O)XH;1GED,:Q!F8$/NV#! !,J!2Q) \9_X)U^#F\$_"
M#Q;#-\/M0^'=UJ7Q!\3ZS+;7MI;V\NJI>:M<7=O>D0NX.^VF@3YR'4PE"H""
MO-/V\/@;J7Q9UWXL6LWPQU3XA^'K[PYX-O$TDQ6TMKXAGTS7[N\NK2)+B58S
M<&W>$ R;%8%5+_+@ 'V*DBRQJRLK*PR"#P13J^1?ASX&\?77[>7A3Q!>>"O$
MDW@Y]%U.X\_7[N"VG^'T\H@'V&W:TG>'4(+G&%BE0FT-L[)(5G"C>_;@^&.L
M>.?CG\-;S6?".M_$#X0Z?IVLP:UH6C2_Z5%J\RVHL+Z2+S8O.ACMUU&'AF*2
M7<3[#@21@'TU/+Y$#R;6?8I;:HRS8[#WJIX;UG_A(_#NGZ@;.]T\WUM'<?9;
MR/R[BVWJ&\N1<G:ZYPPR<$$9-?#7[%W['GB3PK^UE\2-5\<Z+XLOUL?AYX<T
MK2-<U34)GEGNU.MP3>3,LF/M:Z:^E0W,L.W=-&S@LQWM\D^-;SQUX-\):;X3
M^)%U\;H;#P7\(? UU<_$;3=*U&ZU+X<:G;;Y=70K9L9!+/;21?:#<3I,BL'V
M21(" #]F/#?B ^([6XE-CJ&G_9[N>TV7D7EM+Y4C)YJC)S&^W<C=U8' SBM"
MOS[TWX=P?M"?$[P/X7UJS^.UOX;M?'GCR/4)+8Z_I=CJVGWL5Q<6_P!HO%9"
M]B\<\?DN) /-C2*,A=RGR3P)HOQ0U#QM\%Y;?2/C=IVH:+-\/]#BU#6K'6))
MAIUI=LFLEMMN(X(ITC9+E[R1II@8Y&V0%* /TL^ ?Q]\,_M,?#:+Q9X1NKJ\
MT>2^OM-+7-G+9S17-G=RV=S$\4JJZLD\$J'(YVY&00:T_'/Q7\,_#&\T&W\1
M^(-'T.?Q5J<>BZ.E]=I;MJ=](CNEM"&(WRLL;D(N2=IP*\;_ ."7_P .;KX8
M_LE0V=Y'J5O-JGBOQ1KOD7^F3Z=<6Z7^OZA>(C0S*L@VI.H#%0&&&'!%<E^V
MA\%O$O[<UA\0/".A:9H>EW7@^S6T\-:QXCTF]@DT_7)(X[B/5;"?#02+#F-%
MD2-GCEAF&=CE6 /K%FV@D\ <DUD2>-;2+QM:Z"8M0:\O+&748IELY6LS'&\:
M,IG"^6LF94(C+!F7<0"%8C\\M.T?QG_P4+^+FO:[XK\/_'#PCX;U+X!16U_X
M*NKC7M TV/Q1/<72W4.$,,-Q,D(BC^4D,DH.T\[=+XK:-\6O#_@>QN/A;<?&
M!;"U^#6FV$6BRPWZJ&_MNU75YT>Z(FCUB'31<"V1LRR;AY?^K 8 ^]/$_P 2
M]%\'>+/#>AZA=M!J?BZZFL]*B$+L+F6*WDN9%W %5Q%%(WS$9VX&3Q6]7PC8
M?&#3Y[7X3Q_#W4?BIX@B\3>,]?U/P7<>,]/O,(J>%]0\N-9[Q%G%JUS<H(3>
MMO8M(BL41 /'_!_QJ\::[\/HM9T[XN?$H6]]=V,^O:%XG\-:MH%O;:S;Z=,N
MHZ:NJLUQ/8RFX-M<81)+$30I"GF)<2(0#]3JAO[^#2K&:ZNIH;:VMHVEFFE<
M)'$BC+,S'@  $DG@"N7^ 7B74O&7P,\&ZOK&EZ]H>K:GHEG=7FGZV8CJ=E,\
M",\5R80(_.5B0^P!=P. !P/S=\=_%/7/C9^PK\4O%%CXK^(7B+6_%'P,\5:=
M\1O#FN6=U;QZ+KT5B8;86]C(J+9RM.;J!8H(S]I38_SE [ 'Z4?#/XT>%?C)
M_;7_  B^N6.MCP[J+:3J1MF+"UNEC20QDXY_=RQN",@JZD$@@UU%><?L>6]O
M9_LE?"^*U:9K>/PEI2(9G=Y"!9Q ;FD)<MQSN.[/7FO1Z "BBB@ HHHH ***
M* "BBB@ HHHH **** "OX9?^"B/_ "D!^.G_ &4+7_\ TY7%?W-5_#+_ ,%$
M?^4@/QT_[*%K_P#Z<KB@#^G[_@U$_P"4(_PU_P"PGK?_ *=+FOT<K\X_^#43
M_E"/\-?^PGK?_ITN:_1R@ HHHH **** "BBB@ HHHH 1NGXBL[Q5J6F:/X9U
M"ZUJ6SATB"WD>]>ZQY AP=^_=QMVYR#UK1;I^(JGK>B67B32;BQU&SM=0L;I
M&2:WN8EEAF7T96!##V(H _,32?VEO&GPF_82\-^*/@WXV\+Z#X3\$_ $?$6Q
M\-G0[3RM5EMYO,B#R,R-;V\D2-!*JA67=\K1NI->V6?[=>J^+?B;XX%MXUL=
M)\=>#9=6ATGX5&.VDD\8:='I;W=CJ4>X?:<3.IE6XC<P&-&@V&0%Z^O+?X3^
M%;2T:WB\,^'XX'LFTUHTTZ%4:U9B[6Y&W'E%B6*?=)).,U<TSP?I&B:C]LL]
M*TVSO/LJV7GPVR1R>1&?W<6X#/EKDX7H,\"@#X_\<_M->-H+26/P-\7_  GX
MDT/Q%-X2FTGQ1)H]O>P6DFKZRME<6Z^5,D<B-!();="?-CV_,\RG(S?V@?VJ
M_BU\!?%OQ&ETWQQX4\8W7P_U/PEIEAX,ET6&VU'Q&^JO'%+'YRSADDF+2FWV
M1X5K>0,)5!"_8UK\*_"]GI3:?#X;T&*Q^V#4/LR:?$L/VD8(GVA<>8" =^-W
M YK!\+?L_P"E>&/BYXP\82W$NJ7WBZXL;OR;NUMBFEO:6S6Z&!UB$O*NY)D=
MR"[[=H8@@'Q3XH_X*E>-M)\ VOB;3-2\.W>J>()?&.GZEX5N886F^&DVCZ;J
M5W#)?M#(SY$MG9Q3)*4!-\NUES&&[CXB_M@_$7]FOQG\/_#GBCQAX?\ &6K'
M_A'9O%5WIVBV^E:3;V^JZI]AEN9)KBY!2%%#M;I;^;*QAD:8!,&OL!_AKX<F
M?6&?P_HC-X@ 75";&(_VD , 3_+^]&"1\^>#4&O?"/PGXEO;.YU+POX=U"XT
M^)8K66YTV&9[9$.55"RDJJGD 8 H ^0/V*_VI_&VL_#;PA>>)O&&F>+KG7/C
M7XW\+7+WEE$EX;*Q?7OL=O:"-U5) +"WQE6)CE*]P]8GBG_@H/\ %Z;X)>&/
M&GA:[\ ZU+\0/AKK?B=(ETR6XTOP;JFG-:D174BW"3/&QN'M)4*B1+F($;5#
MQC[EE\!:'/>QW#Z+I+W$-Z=0CD:SC+I<E-IG!QD2%>-X^;'&<5,GA#2;>*Y6
M/2].C6[,C3A;9 )C(V]RW'S;F)8YZGD\T >:_L\>.?'6L>-O'OA7QQJ'AC4M
M2\,36DEKJ&AZ5-I\3174+2"-HIKB<EHR-N\. PP2H.:^2_A!^W#^T!XD\>Z3
MX+\0:EX%M]?N;+5/ M_=QZ9Y=O;^.(-4$D*Q!ILO&- \W4&A;!=(XRC9DV5]
M^:=X,TG2?%6J:Y:Z;96^L:S%!!?WL<06>\2#?Y*R-U8)YLFW/3>?6GKX0TE+
MW[0NEZ<MQ]K-_P":+9-_V@Q^49LXSYAC^3?UV\9QQ0!\F0?%GQOXM_:C\(PW
MVK:+X7\,Z?\ %GQ#X.UK1;"TC,7C"W;PW+=:=-<RLS$31[%#(O#L4RJ^6%KS
M'_@C#^T)K/@+X&_LZ?#34UT2X\._$#P?X@U'0I8HYX]0LKC2]45)X922T4D3
MQWD;(5\LIY+*0^5(^T--_9,^&&D6S0V_P_\ !\,+^('\5L@TF':=7=61M0QM
M_P"/DJ[@R_?^8\U8\$_LQ_#OX;7WARZ\/^!_"^BW'@_3YM)T*2RTV*%M(M)G
M#S00%5'EQNRJS*N Q )SB@#Y?\?>*/&'B/5]?TV[\3>%]8\4:!\>K&W\-&]M
M76/1;.6QM7CC:%93(Y2&XF!V-'YN7R8P[$87@_\ X*4?&KXOQ6.F^%_"/P?M
M=;\,RZH?&,VM^)I[2TGM]*\17FBWTUBC(KI&PL7F$DI<0M<6\;AMWF5]=C]E
MWX;CXFWGC3_A _"/_"7ZAJ%OJMSK7]E0_;[B[M[9[6"=IMN]I([>62)6)RJ.
MRC )%.E_9G^';2Z3)_P@_A7S-!U2[UW3F_LR'=97]U*T]U<QG;\LLTKO)(PY
M=VW')YH \\_;:^#VJ?%?4?"<VAW7AO7-6\/1:E?P> O$.H26>F>,<P)&&D>/
M<R26[O&4E:&=(S.28PYBEC\._9N_;8U_7=$\._#_ .#7@?7]<MO T>ACQ(WC
M'65NKFVMKK6M3TS4[=;^:Y5II].DTVYS*%N!,8UC&"ZN?KOXM?L[>!/CS-I4
MOC3PCX?\3S:&TKZ=+J-DD\EB95"R>4S#*;U50VTC( !S45[^S=\/]0U?PWJ$
M_@SPU-?^#8#;:'<-I\9ETJ(,K!(6QE5#(C8'&5!ZC- '@_Q*_;:^(&G?"CQY
MXX\'Z?\ #?6M+T>37],T?3+_ %26TOAJ.D7[6<L4[)Y@E68PW#XC1&@"Q!_,
MWLR6K+]KOXNWGQ_B^']G\._#WB+5?"VJ:9_PF\FDZU +?3=+U)[OR;B$W$T5
MQN@BBA=MUNRW!BNDC\ME3/J5K^Q)\);7QWXV\2K\/_#;:U\1K=[/Q)<2VOF#
M589!&)8W1B459?*C,@55\UHU9]S &M+Q%^RO\._%'Q]T;XI7_A'2+CX@^'].
MDTNQUPQE;J*V=U<QD@@.%9<J7#%-S[2N]]P!\;_$?_@I7\6OV<_@5XEUO6O^
M%9^*-<\-R^+/$?D$7-B=3T?2]<FLTM $>0VL@@C9C>S@PAA#%LE9I)4[+XE_
M\% OBYX"\9?'/6_^$3\ W7PP_9_\2V^F>(V@N;Z;7I],>ST;4Y[Z&,(L.;>P
MOKMGC+?,\2X8*A\WV/XB?\$TO@;\5[#7+37/A_I]S:^)6U ZO##>75K'JGV^
M:.XNA.L4JB4//&DH#Y"2+O0*Q)-KX@?LG1:-X<^)'_"M8])\/^(OB]=FX\5:
MAK$U[J$=R6M/LAGCA,VU)5B6%%";$VQ*I&%7 !K:+^TM#_PH+QI\3-1LK>X\
M+^&_[5U"P?1+H:A-JVFV2O\ OD!"+YLAAEVQAB/N?/R<>$?M/?M?_$31OAM\
M2O NK>'=!\)^.K_X6ZEXV\-SZ=KT]S''!;216]Y'/,ENODW$!N[4HT1D60R-
MM90A8_5_PZ^'FD?"KX=:#X3T.SAL=!\-Z=;Z1I]I&BK';VT$*Q11A5 4*J*H
MP !@=*\XT7]@3X2^&OA=K'@VR\*-#X>UK3$T2Y@_M6]:5=.0Y2QBG,QE@M5.
M=L$3I&H9@% 8Y .<\?\ P(D^"G['FC_#WX8VOAWPU?+?6W]F^')]?N+6QU/_
M $G[=?:3;W3*TJ)- EXB;8_D0YV*BD+\R?!3]J_QW\&?CSX/\&Z<_C_7-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9
M3MC;'H:_@M^-_C'4OB'\:?%_B#6+C[9JVN:W>ZA?3E GGSRSO)(^%  RS$X
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M[02!@4 =%16?%XDCE\5S:1]FU 30VD=X;AK206C*[N@19L;&D!0DH#N564D
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MY0N_L_\ _8O/_P"E=Q7V=7QC_P &\O\ RA=_9_\ ^Q>?_P!*[BOLZ@ HHHH
M**** "BBB@ HHHH 1NGXBFGI^!IS=/Q%9'CS6%\.^!M:U!XK^9;&PN+AH[$H
M+J0(C,1$7*KYAQA=S 9QD@<T ;%,/3\#7SIIG[=5OH6NZ#H-EX*\=:YH?V7P
MMYWB6ZNK' BUMWMK261#.)I)!,B"4+'QO=AG: S1_P %%]-L? ?BK7-0\!^,
M?M'AJQT;4QH5@UI=ZU/;:K=2VMJKP&9%AN1-#*)('DW(%ZL<J #Z/7JWUI'_
M *&OEW0?^"F4P\76OA'7O@K\6-)^(%SKQT-O#]NNF7K0[[&>_M[HW2W:VQMY
M;>VG^=9#LEB:)]K;0V2/VWK7QC>K\1[;_A9&C>#6^'VLW=_X=N+""TU72+O3
M]7BL[ES;S?*+F)O/1MTCH5B!0'.7 /KE>K?6O,OVT?@GJ_[2G[)?Q(^'>@ZQ
M!X=U;QUX<OM!M]4F1W73_M,+0M-MC96+(KLP 89('.*S?$'[9WA_2?$NN6.F
M^'_&7BRW\-ZY_P ([J]]X>TY=3BTV_%@;]X9(HI#<?)"80S+$5$EU$@)._9Y
M7^T-^V5K7B/P+X;U#P39^/O#>K:+\1?#.F:YI2:587U]J%G=B"XN;,Q^;(@'
MDS-'(ZR(\+Q2,"P3#@'<>//V3M<\??%S]G#Q--K.CVL?P2N;[4-2MH[:1CJU
MQ<:'<Z6J0,6_=1JUT\A+AB0BKQDFO*_!/_!,WQ/I?CSP/JVO:M\,]<L=%\+:
M5H6IV]UX8DNIK2\TR^N;JUO]/DDF*JQ6Y93'-&X21(Y5)VE&O?$']N^XU+XC
M?#KQ)9S>,/ _A/PKK7BNQ^)7A_5])MS<P1:;HT]T#-L\TJH86MQ%+!*5ECG3
M[PD&WW3]G']JG0_VFXO$BZ1INL:9=>%[N"TO8+UK696,]K%=1/%/:S3V\BM%
M,A^64E3]X#(R >ER2K!'))(RJB#<S$\* .:_*+]E[]A[Q5^V[_P1_P!%T*Q@
M\+Z->P^"_&WA_P /7>H"XBU#[=JUY>6Y6YS#NM[01G>R*)&E86\F5$>Q_L[X
M=?\ !2#1]<^#K>(?$G@SQ?X?\16NCZCXAOO#%C FMZA:V%E>BSEG'V5G5P7W
ME$XDD$$^Q&V<]]XO_:CT^U\-_"G7/"]C+XQT'XKZS9Z?8ZCI]Q$(;>TNK*>[
MCOB78;XML*\+EB) 0#C% '!_'G]D?Q'\6+WXC>&86T$^"_C!X7BT75M2FGD&
MI^'+B&*2%7M8A&4F0I()(\R1-!,C.-_F837^$W[*6L?!S]HCXC>,(=6M]?T'
M68DO?"NBWC2++HM_-!''J>ZY8OF.ZDL[.7.PF-VN"!^\;?QWP._;\L?!,.I>
M&_BG=>*(;S1]0\4_\5GJ&@#3_#^I0Z7J&H,T$<Z'8)8;"U,C @ K#(0S,K@>
MQ?!;]JSP?\?+CQE#X?NKR2X\!WT=CJL5Q;-"R&2TBO(I$S]Z.2"9&!'.=RD*
MRD  ^<?#?[$7Q.T?4/ACJMOH?PVTOQ!X7MM*L]3U./5I[J:2SMM6NKVYL7CD
MLS#<Q/&8/L\FR&:TGEFD1R!MDWO@S^RY\6? MK8W6K:=\-;R3Q1HFK:+XHT=
M]0N;FUT<W.IWU_%/:2M;K]IB87IAFMY(H2XCB82?N]K=)\+_ !U\>/BI\+?
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M'PC_ &7/ 'ACQ!IOA?1]<T'1;:SOK+PY9+8Z5;RI& RV\"DI$F?X$)522%)
M!K+_ &E_A'KGQL\;_"G2X?M$/A'0_%$7BCQ%-#=>2TYT^-IK"V(#AF5K_P"R
MS$;67%H5;&Y37KG\7X_TI4^X/I0!\<^ _P!DSX@_![]OB]^+]C9Q:HOC(>(X
M_'&;J+RKJSB:#_A'TTZ %?+O/L\4,,TCX63R)?,9L6["/]JW]C7XR_%/XZ:;
M\1/#?Q3:S\/W.M^#FG\#3^#[&XFL;&QUFSN[I5OVF#KAA-<2;5);R40;@B5]
MD_Q?C_2A/Z"@#YS_ &?_ (:>+/#/_!1S]HKQ+J^AS6?A7Q5I7A.+P_J@C@6+
M43:6U\MRF4/F%XY)E&90#M90I*K@=E^Q=;:I:_"W7/[8\/ZUX;N;KQCXAOXK
M75(DCF>WNM5N;J"0!'<;6BF0\D$'((!%>MMU7ZTM 'A/[>OPYN/''A+X?ZI#
M\/7^* \$^.-.\1/H4*V9N6,23Q1W$/VN2.$202SQS9+J0L;%22 I\)_8D_9G
M\::%\7_ ^M>(O!/B3PS\0/!>H>)+/QUXVO+Z!X/B/97$]RUJRI',Y=)YY;>]
MB1U!T\6\EJFU)?G^[** "OB'XK_LX^//B_\ L\^)M2\5>!_L_B#XD?$6/4_$
M%OH]XD?B'PSH6G3M'I-SI=Q$V&U&-;.QNE)=##)>7++\\:QM]O44 ?+OP'^&
M?Q0A_P"">7_" Z7_ &?\*_B5>:;K-MI6OP:%#Y%E)]ME6VU2ZLU<QI>W4<B7
MDL09U$\D^6.,'S?]FW]C[]H7P+HGQ%\+ZU/\#K'PW?>---N[>QTO0=1M=/U[
M2(M%MX;F,JUY+)'YMRD ;S&DWFVN_,$BW0V?=5% 'YJ^,/V9?VEO%?\ P3AU
MR'7+7X>:IKVG>%/&\<OA*ST_4K4W6JWUS>>5<6QW.9#';R31V\;1?.;A7W*2
MH3[N^$GQRL_B'XN\3>$;F&^L_%W@462:U#+IUQ:VMQ]IAWQW5D\J@7%H\B7$
M2R*3^\MID.&0UWE5[+2+33)KB2WM;>WDNG\R9HXPK3-_>8@<GW- 'B?[7VJ7
M6A?%O]GZ^AL?&%]9P>/9HM3.AV5[=Q6UM/H&KVJRW:VX*K +J>T'F2C;&S!L
MKM+#XJL?"'Q:^%'[/_PWD\"Q_'R\\2>*/@;:6?C*WN([Y[BQEM-1T2*46ANE
M MM8@TZX\0?9T!5YWBB9A-($9OU)HH _,_Q!\$M2TO\ : _9[O/AGHOQMG\)
MV^K>,KW2AXDL+W_BD(I_"D=I;6T;3H)[&U^V92-+PJWFF8H3%Y;5R_ABX^,G
MC>'X2Z'KFO?M$>%=<B^%7A3PKX@,GAKQ!>:;J/BNTU>WDU)KRZMG0PJR6LD,
MM_$X$L.H^8LTJ1.C?JQ10!^:]G\,?C]\8/!VMZ+H.I?&'PK>+^SCX5O?#,NK
M:]>AD\8VU_JD[075Y(D)EN)1%9Q7;/''+)!(/,5"5QUW[2GQ;\6>!/V=O"?C
M;7H?B-\/M!^*7BN>_P#%5P++6M:NO!4#PO'I4<EG:7B75G%)Y=MYR6YV+=2X
M>-4D<#[ZHH \S_9<^)/_  D_PXTGP[K'B"_USQ_X5T+25\4MJ>F)I>I/<SV:
M2?:9[6,F*%IB)&*PL\2.LL:L3$P&/^VMXNN/!O@+PW<W&HZQHO@Z;Q+:6OB_
M4=)\T7UEIDB2JI1HE:2.-[PV44TJ -%;S3R!XMGFI[$(469I-J^8RA6;'S$#
M.!GT&3^9IU 'P)X!U>Z3]K3]F#0]6\0>./$5K;ZGXZN?#-]?RS2Q:AHZ6JQ6
M,M[*''GR>1*R6\MRCO/&DLID+Y>7[1^.FB7'B;X)>,=-M5OFNM0T.]MH1932
M0W)=X'5?*>,ATDR1M9"&!P00<&NJHH _'?X3:+XN\&?#OX6^*_#^N^+/"FM_
M#+]BRWNYKB&))KA-9BEM9HK*>.YCD9P9[.='MU ("A#L!0'ZT_9X^/7Q!^+_
M .VMJS:MXEUCPS;^'_%>MZ++X&?2OMEIK_A_[+;2:/K5M<*H$,;Y\UYRS*7N
M&MB ZK7VI10!S/QH\2:?X.^#OBS6-6O+;3=+TK1KR\O+NY<1PVL,<#N\CL>%
M55!))X !KX]_99^%?B+X?Z/^S[X+G74[_P"',L>G^+?"VIO&ERGA^=-'F6;P
M\Z*%:&V59'N+6=BX5?,MB$$5OYGW+<6\=W;O%+&LD<BE'1QN5P>"".X/I2QQ
MK#&JJJJJC 4#  ]!0!^8/P]_;'^+7Q-_9B\1?%4_%I=2NOAN-!\8^+_ ?AG1
M%BUKP]'8W#S>(=%O?M2$QR2VKRK';,8Y@;"/8S"1W.U_P4)_:@^+7[+OP@BU
MJS^(VM:3XBM?!/BCXHKH5Y8Z<LT5U#/%>VNE7,DA4W-A:P226+0VL9N&^6>2
M6(*IK]'DTNUC2X5;>W5;MBTX$8 F) !+?WB0 .>PINI:%8ZRT;7EG:W1A#",
MS0K)LW#:V,CC*D@XZ@XH _-']M?]M'0O'?[1GP7\/:SXDM=(\=>!?VC/L\GA
M2YM6^U:=I\>B:[#8WPMP!/<PW8:"99%PK&Y\I"2FX_1'_!-W]L2^_:-U"\T[
M6?%T/B"^D\(:#XEM(98=/@NS'<_:X)[@QV4DL<<<DUMD1M([1,6C9B5./JA]
M)M9;T7+6MNUP,8E,8+C&X#GKQN;'IN/J:;IFA6.B[OL=G:VGF?>\F)8]W+-S
M@<_,S'ZL3W- 'RG_ ,%QS:W?_!-3QIIT^K^'=%GUC5-!L[2XUR_CLK$3'6[%
MAYDKD!4 5G8YX5&/8UYJ/VGIO@A9_';Q'JTMCX/^,3>(/#^B:YX>CU/[-HND
MZ;<ZL;#3_$5O(]O/&Z7<-V9Y;IH&"-$MO,%-HS5]T^./A_H/Q.\/2:1XET/2
M/$.DS.LDEEJ=G'=V[LI#*3'("I*L 0<<$9J7Q!X+T?Q9IU_9ZII.FZE::K9O
MI][!=VJ31WELX*O!(K AXV!(*-E2"01S0!\*Z1^T1\<M!D^%)U+Q_:>+M+^(
M)\1^")]:\):);WVG:?KPNG_L>\DE^S@R*D(GBG,<:VWF6C,64 J_HOQ1^/OQ
M"^$WC7Q1IFE:AX7UJ[L?%'AS37:YAM['5+VR;3#<WPMTR$O;YO(FD2',7[II
M%3YHUW_56B^&].\-:-9Z;IVGV6GZ?IR+%:6MM L4-JBC"JB* J@#@   "L+Q
M5\"O!'CN'4H]<\&^%=9CUBX6[OUOM)M[A;Z98/LZRRAT/F.(/W09LD1_+G;Q
M0!\?_ #_ (*-^*/VI/BIX.T[PGXL^&JV&CG0'UM]3>;1?^$^M=1T^22ZN]+L
MKB-KJ'R;@(($,CB0I.CM]UUY']C[X[M^T]_P49^!/Q O/&/A7Q)JWBKX(^)[
M^^TW1[%+9O##OJ?AI_L$FYC<8C+,N+D!_,2=@%#^5']X2?!'P7+XLT37F\(>
M%VUSPS:'3]'U$Z5 ;O2K8XS!;R[=\4? ^1"%X'%0^%?@!X#\"^.]0\4:'X)\
M(Z/XFU:2>6^U>QT>WM[^]><Q-.TLZ()',A@A+EB2QAC)SM7 !1_:@T:Q\1?L
M^>+M/U'Q:O@.SOM.DMW\0/)&B:46^597\PA&0,0&5B RDJ2,YKXI\&7_ (D^
M!%]XDM8[>U\!_%*W\9_#NP\9S^![=M0\'Z]8WNJFS1+.TGS_ &6TMO([7(VA
MXR\!\V9661OT&U_P_I_BO1Y]/U2QL]2T^Z7;-;74*S0S#.<,C @C(!Y':L+2
M?@;X)T#P7-X;L?!_A:Q\.W$XNI=*M])@CLI9@RN)&A5 A<,B-N(SE%/4"@#\
MYOC[_P %>/B2_P (?C%<^&;[P=!Y/PIU3QSX5UG1X)+I-+FM=9.EX26;Y+^(
M@^8L_DPKNC8!74AJ]^^$/[:OQ U/XB>)O"/B#5?!%UJ'AGXQQ?#J.\@TJ6S&
MJV<OAF#55=8&NW*SK-.3E78-'"PVJ277WZW_ &/_ (3V?BC4-;@^&?@.WUC5
M]/O-)O[R'0;6.:^M+ME>Z@F94!DCE9%+JV0QSGJ<QK^QE\(1<Z/.WPM^'<US
MX?BMH--N)O#MI+/8I;1"*W$<C1EE\J-51,'Y5  P* /A+]FK_@IQ\=?'7[&7
MP372K7PO\1/C-X^\$W?Q$NI-1%MH=A<6-M>P0RVA+7**C8G;=<1JPB"1DV[!
MB5^L?V:_VO?$WQ?^-%WX9\2>&]/\+^?!J6HZ5''<27\>J6-O/:PPW5I?PJ;2
MY5O.9IH]T<UNTD*%) 3)7>^+_P!CCX3^/=.TJSUCX;^";ZST/5WU^QMY-&@\
MJWU!P0]R$"@&1]QW,0=W&<X%;?@_X">#?A_XUU'Q%HGAO2]+UC5?,^TW%M%Y
M>XRN))F5!\J-+( \C* 9&56<L5! !C_M4_$WQ5\(_@S>ZUX,\-KXJ\0+=6MO
M%8><J.(I9XTGGCC9E^T20PM)*MNK*\QC$:LK,"/DW0/VS_%WC#7->^,'@&Q\
M!^+-/L?AM_:7B)9-3U+38C_9FIZPCVT$$MKYJ71\N:-Q.B&%X]I$HP1]H?&#
MX*^%?C[X-_X1_P 8:+::]H_VNWOUMY]P$=Q;RK-!,K*0RO'(BNK*00R@BL;_
M (95^'@\/:QI(\*Z:NG^(-$'AS4H5WJ+W3P\[F"0[LL&>ZN&9L[G:9RQ8DF@
M#YB^*_\ P4CU:[^*5U\-9O#^BK:^,F\:Z+I^HZ/K,E[)IHT?3O.22XE2(0QW
M4CI<K)9[Q/;_ +DMG)IW_!*JSGUW3?A)X@O-2UJZOIOV=?!:W EOY9(;R27[
M2S3S(25DG'E@"5LN%=QG#&O=+O\ X)W?!*_\5-K<WPX\.R:H6NY!.T;YCEN[
M;[+=3H-V%GF@^2290)''WF)YKM/A[^SQX)^$^JZ?>^&_#MAHMQI6@6OA:S^R
M[D2VTNU)-O:(F=HCC+-M &1N//)H X?_ (*"W.L6'[-OVKP]&+C7K7Q3X:?3
MX'U.;3H;J8Z]8*L4TT2LRPONVO\ (X*L<HW2O&_$/_!37QUI>I>(_ >G?"O_
M (2#XU>!+RX&L^'M/O7_ +.U6T@M[&Z$UC>2(B_OH=2LQF50())"L@*KO/U9
M\6_A/H?QP^'VH>%_$=O-=:3J)B>007,MK-%)%*DT4L<L3+)')'+'&ZNC!E9%
M(/%>=_$#_@GW\*OBAI.@VVM:!>W%QX=U"74K?4H=8O+?4[B6;8+E;B[CE6>X
MBN!%$)H97:.588@ZD1H% /6_#>L_\)%X=T_4/(DM?MUM'<>3(Z.T.]0VTLA9
M"1G&58J<<$CFKM0Z?I]OI-A!:VL$-K:VL:Q0PQ($CB11A551P%    X %34
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M_@Q=*21K.?33%-;Q1WQD\T6YO;>WNG1E9V99$\P1R%!]+4P]/P- 'R5\;/\
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M"@!6ZK]:6D;JOUI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTB?T% "G@CZTWJ/P%.;JOUIHZ?@* 'XIN<K^ IU,'3\!0 _%,SD?@*?3!T_
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MX>>'X]:.I+H>CKJ+7_\ :ANA91^<;O[-]D^T[\;O.^S$P^9G=Y7R9V\5G_\
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M'EM\9H?%.K>,/#-S;0_$74?&OV.UT6:)I+:70'T:SM#(UPV)(E99))0N)""
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M?PGXC\(WNE_#_P"$U]\.GU+7))[>6^N+O5-!NGG\B*&15B6+2)<#>2S3(IP
M7KK?B3\ _P#AFO\ ;,U#Q3?V?A6;1_BU\4M*?PEX=2>&V-]+:^"-1M)D*R!8
M8Y)I%= ,DL%&3\RK0!]@W?[2?P\T[7/"NFS^.O",.H>.(%NO#MN^KP"37(7V
M[)+8;LS*V]=K)D-N&,YJQX3_ &@O ?Q \7-X?T'QIX3UK7EMI+TZ=8:M!<W0
M@BF\B27RT8ML2;]VS8P'^4\\5\=^(_\ @F]XZ\/^(M+M?#MGX<;0;?5]!\3?
M9;'51H]G'=V/CJZU^2TF"6KS2VT5MJ,HMHU81+) ^^/<\3+V'P!_9$\0?#+X
ME?"G7E^%_@W0;O3O%7CF^U^_L[RW6ZTW3]4N[RZM-ICB!G>9FLQ)&I"H4)W-
MY:A@#V#QG^U5<_#SQM\4+'5O"_DZ1\,O#FG^*Y=135(R=0T^Y>]$S"-E41R0
MKI]TVUGP^(_F7<2OI@\?Z(+K2[=]5L(;G6D62Q@EF6.:Z#*7&Q&(8DJK' &<
M*WH<?%?[;W_!/7Q!^UU^TWXR\6KX%\,_VEX=\+Z%)X#UW6M16XLM2U72[S4K
MIM-O[)5+?V;>+J7D3'E]L<C!0RPM4GCO]BSXH?'W6?BQ:^)]'L=)L?CA:^&=
M:@U!=;^V77POU?3K=(IXK5UV-(L,MM%<VDT(7-Q<SM(B*3N /MS3O$>GZQ>7
M%O:7UG=7%H<3Q0SK(\/S.GS '*_-'(O/=&'4&O+_ (/?M@^'_C;^TU\2?AOH
M:1WDGPWTK0]4N-5M[R*XM;T:H;\)&FPDJT?V!MV3SYBX]_BOPQ_P2^^+MQXS
M\7:A=:9X(T&&_P#A=XW\$6FF6$R+HIO=0UZVU&Q>-5077V>X47#SFXEDD2:6
M?;A7 KUO]GKX??$#]GO]K3XB?$W6/A/I>@Z?\8K?P/X7L?#_ (;U6"\FTR6T
M.K_VA=3E8XHS%"+M9-R_,\*;L*^8@ ?2OCC]I'0?A_\ M$> /AG?0ZD_B#XC
MV&KZCI<D,*M:QQZ:+4W'FN6!5C]KBV@*<X;.,#-3X*?M7>$_CEHGC'4K":XT
MJS\#^+M0\%ZA+JOEVR-?6<X@D,9WD&-I&4(206R/E!.*\:_;#_96\3?'[]OS
MX$^*!X;FU#P!X!TCQ!9ZS?6WB1]*NXYM3^Q)&8UA=)76);-BXW ,)DP&(('@
M?PV_X)Q?%>S\%76AW'@SPUH\.M_$OQMXE_M*]UU=7U3P[INJV+_8C#YPDAEN
M'N&2&9IA,8XU=H]S,KJ ??7QW^,</P.^'-YX@?3;K6OL-S90R6=K+&DP2YNX
MK;S3YC*-D?F&1NY6)@H9L*=Y_'&BQ6UQ,VL:6L-I=BPG<W486&X)4"%CG"R$
MLHV'G+#CD5^>G@O]AOXI_#K]DHZ3I/A&33_B1K_P?^%7@O5-7AOK2>:+5=.O
M+B#4+IEE=HIGTVWG%S\XVW(18PS8XZWX=_ 3QA=:=X9T7XC_  %T?Q%X?U23
M7_#7CVPL(-/6RUS6+EX-OC 1/.!);7\ NEF:7=>P-.$5'0RNP!]POXOTF*\N
MK9M4TY;BQDAAN8C<IOMWF($*N,Y5I"RA0>6)&,YJ7Q#JKZ%H%]?1V=YJ,EG;
MR3K:6H5KBZ*J6$<89E4NV,#<P&2,D#FOSO\ BE^P?\4M&^ OBSX?S>";#XO^
M)_B?\%="\':IXKGU6VTV"/7M';4?+N[V5Q]HD96U"UD@E2.20_87+F-@A;[<
M\ _'.\\>?!"Z\71^!_%=GJ%K;32IX?E:S:^OWC3<J6TJSFUF67@1RB81MN!+
M*,X ,'P9^V-HGC;PM\$=8@T'Q1;V7QWC6316F@@_XEA?29]5C6\VRMY;/;VT
MH'E^8-XP2,YKT_Q3J]SH/AN^O;/2[S6[JU@>6'3[1X8Y[Q@,B-&F=(PS= 7=
M5R>2!S7QY\)_V</%G@+X/_L56"^#_%4>K?#T6Y\4Q-K:M!H3IX-O=)/GJUPR
MR?Z1);HIA679F1P!N8MY)\*?V2/B/X>^&OCJ\O/A/JVE3:K\*O!&CVNAVUW:
M7%RNM:;K6LRS1"=[H_:I;:*6P<WTSJ]P%60_O-R* ?I;17YX:E^RKXIN/C/H
M_P 3O#OPO\>^&=9N?C!JVMFV;68/M,.C77AJ:QF\W_3'CMH+S5&BN'$&944!
M]JO&H7#^%O[+7Q+D^""^$=1^%_B[POH^M:EX UQM.T/4K?1X?#\MIKJ_VI:*
M8-0DN)6BT^U1IKQYY)+HNC@[RL<0!^C?B[Q39>!O">J:WJ4C0Z=H]I+?74BH
M7*11(7<A1R<*I.!R:\^^$O[8W@/XU:SX1L=#U&\\[Q[X0M_'/APW=A-:QZUI
M4PC)D@:10'DB$]L9HO\ 61"Z@+*!(I/DGPR^%UQ\*/V2_P!HCPCH_A'Q=I.A
MZ7J.OP^&-*N1-?3W]O+IL4I>R!EFEECFNY;ED&=S2.X"C@5\]VO[ 5UX-_X)
M?_#?Q3XS_P"%U>+/'WA?X8>%/#,'AO3=T.J^$8/.TB75+738-.C@G%RYLX%=
MY7DD462 .@,I< _3"BO@S7OV1H?#_C'Q?X7\.^#?'5IJ6G_V;KWP?UR"YO#I
M?AR-5B::W,LCG[+<_;Y+^>Z6X7==6UU''F<1^1%Z+^S3\ _'_A#XF_%CPSXR
MNM4F^%/ANZU*'P/'8WMS#/J.G:ND-Y+!\C!T&GN);2V*2EE5WVB)5A50#ZFT
MC4?[7TFUNQ#<6XNH4F$5Q&8YHMP!VNIY5AG!'8YJQ7YAS?!'Q[XF_9C@\0-J
M'[2FA^*[7X)>"!#&DNKR7FG^);:XN(IKDV63]IOUVI]JC<.DL2J9%992[>H>
M)1\:(?@=\8]6\(^$?'EO^T)I.F:S8"74-4GF\.ZT/MT;64^G12N+.2XDT]=\
M'EQA8)-T-P<D[P#[LKA_B/\ M&^#?A+=:U#X@U:2RF\.Z(/$>H(EC<7#0:?Y
MK1&<".-MX5T;<$RRC#, I!/F_P"S)XM\/?!^+2_#*_\ "V;>'XC:W=7?AJV\
M80W5Y-:J-.ANYX [JTMG!&PG54O&#&990A9&A!J_%+PQXE^(W[;"Z=H.J>*/
M"-K!X',-YKL'ATS6S$ZK9RM;P7<Z&V$[VZ3)C$C*)2X ,0H ]Z\)>+-,\>>%
M=,US1;^TU71M:M(KZPO;642P7EO*@>.6-QPR,C!@1P00:T*^'7^$OQ T+]I#
MQAH?@E?&G@V;X?:>FE?"J$6%P?!=]I8\*B&&#4)EE:*2.'5FW;2J7:M;QX,D
M+DIP3V/B2]^ MAK6G^(/C?X777H? FF>*+J>]O8]4M-?_P"$LM[/4EBBF#JD
M[J]PDH@0P21F$@-&8B0#[_\ %WQ.T?P-XH\*Z/J4T\-]XSU"72]*5+:21)KB
M.TN+QE9U4K'^XM9F!<@$I@9) J/XL_%WPY\#/!$WB3Q9JL&BZ';W-K9RW<RL
MR)+<W,5K I"@GYYIHDSC +Y. "1\-_".V\2?##XE>'=/L[[QMXB^'=O\8VC^
M&MSXC.IZO=FSF\#7JSS3W,R/=&S.L7-PBSSL44.%1A&(Q7??\$KO#_B#QY\-
M_$E]X^UKXA:IJNI6>E6'BSPGXR\,W6GVVE^((;5?[1N+5KHN)HKJ1HY=MLYM
M5 0HJLSY /LJO+/$7[:7PW\(_$/4O"^J:]=:?JVC2P1:@9]'OH[2Q\\D0M+=
M&'[.B.00':0(2",\&O*OA1JGQ"T/_@H=JUCKGB+QIXN\'ZQ8:M-IJ+8_V;I_
MAP"YM@D%Y;R0J)U'ER+:7EO+F4/<B6-\),/,?VR]9U;QC\6_C3H^ERZQJG@V
MXTOP]IOCW2-(T2>76;S0C_:4.I?V;,49'EC6[MGEC2.20P),L16>2-E /O:B
MOBKQ/^T1=_$_XF>+=1M?'7C;P6/"K7-WX<M=,T*YETSQ9H(T28^<YF4P^<FH
M&X8R PO&;&")@%D$DOS[X?\ VF?B[XM_X)U:CXB^&?Q$^)WQ"\8:U\"+/Q5J
M,\FAF:;0_$82R*&RD6W6-I+F.6^+6R^;C[$CJ%,A,@!^HNM>,--\.ZQH^GWU
MY%;WFOW+VFGQ-G==2I#).R+QU$44C<XX0UD>(?C5X7\+>+[OP_>:Q;CQ!8Z)
M+XCFTR%7N+U=/C?RVN!#&&=EW_* H)9@0H)!%?%WQ+\?6_[5/Q532[7XF^/O
M!>AS_%]--T3Q!I\ TZZLHYO!K;8;*:^M7C\N:]%S&&"-NE:2-&#,%KP_XD_%
MKXI>&KSXQ?$[Q!KB:/\ $CPK^RMK[0ZQ8V8M9XI[;6M2?1[V6)T,4$][;Q03
MB$<[S,$50JF@#]9;&\CU&RAN(MWESHLB;D*-@C(RK $'V(!%2U\6_!/]I36?
MB!^T-I?A?7_%'C+1?&&F6F@ZCH^CQZ:)+'QAH=SIEJ]]?,#A6\N]DN4EGW+Y
M!@@55+2[)=+]J#]H3QEX?_:*^('AUO$MSX!_X1/PAI_B;P!]FM!?+XVN?,N_
M[2MY;<HQN/+\FUA\F(K*BW9E&"4=0#ZCN/BAX;M?'5MX7DU[1X_$=XDDD&F-
M=H+N98U5W*QYW':KHQXX#*>A%5-7^-_@WP]XON/#^H>*O#MCKEG:"^GL;C4(
MHYX("RJ)&5F!52S* 3UW#UKQW]B;Q5I?B3XT_M#6JZQ;:AKUIX\M+R_T][Z"
MZN=$>7PYHZ& ^6 5C1XYHE8CYC$XW,5;'-?LN_#WX8^._P!GO4OA'\1= T>3
MQ5XLU?4]2\7>&/%%M$E]XCU#[:\L^HK"_-U SHCPW$0:,1Q1!&7RPJ 'U#IO
MB73M9L;BZL[ZTNK>TFEMYI8I5=(I(F*2HQ!P&1E96!Y!!!JQI^H0:M8075K-
M'<6UU&LL,L;;ED1AE6![@@@YKX8\!_&O7?A#XB;6$^*'AR#PMXB^+_BWPTF@
MM;V:11-Y6J7*"2X=C*UY]NMT**K(ICN4C,3N5D.1\2OVJ?B9K6CR>-M%^.7A
MGPOH/@?X5^$?&NK:,=&TV[36[R^EU!IQ-<2,&MX)XXK9 (\$95D8;B& /T$K
M-U;QAI.@:I96-]JFFV5YJ3;+2WGN4CENFR!B-6(+')' SU%?(_P4_;O\3_$K
M_@H!H?@.VNX]3\%:U;>-DN+B?3H[)X+W0]3TVUC@@B\QKA D5Z?,DN/^/@E)
M85CB(#;/QH\'V_AK]OG0?'GAOQ)X7\7>(=2FTGPCK_@C4+.SN+[3;3=<7,5]
M:7"1FXLY($EN+IDF)BGC5P"K^40 ?2^F_$GP[K.O-I=GK^BW>IH6#6<-]%).
MI7.[*!MW&#GCC%:$NMV=OH[:A)>6L=A'%YS7+2J(5C R7+YQMQSG.*_/?]MS
MX)MX3\1_&34O@W\,? ^G7GPU\!76H6UWINB"SO7U_79G&IW"21I&KSII<!D+
MJYDW7@!!+8KTKQSH7P_UKX]_%*/QE:Z3XH^"</ASPI%;Z!):13Z+<ZW)+J%J
MMJL6_P JZDFMWTQ!!(OEIMM6ZD,H!]C03I=01RQ.LD<BAD=3N5P>00>X-.KX
MYTKX8^ OA;\)_@[X?\,:IHNKVO@3XJ_V9IY@U%;X>&WGFNY&TF&;JJV\4RVP
MBX*QQ(A VX"ZY\;?$UM\:?B9XNUC0]-UR?X>^/-)\*>$/#M\9+&[@TVZM[".
M\U.V+!O/FEDO9V1Q'AH[1X58%G:@#[%HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .._:)\3WW@G]G[QUK6F3?9=2TCP]?WMI-M#>5-';2.C8((.
M&4'!&.*_@YOKV74;V:XF;S)KAVDD;'WF)R3^=?W;_M9_\FK?$S_L5-4_](Y:
M_A#H _LN_P"#>7_E"[^S_P#]B])_Z5W%?9U?-O\ P1U\&P^ O^"5?[/>G6]Q
M?W4?_"!:1=[[R7S9=T]JD[+G ^56D*J,?*BJ.<9KZ2H **** "BBB@ HHHH
M**** $7I^)I&^]^7\Z5>GXFD;[WY?SH 5>GXFANGXBA>GXFANGXB@!%^]^?\
MZ5NGXBD7[WY_SI6Z?B* &GI^!I],/3\#3Z &'I^!I]-(X_ TXG% "+T_$TM(
MO%+0 4444 %%%% #?XOQ_I0G]!1_%^/]*$_H* %;JOUI$_H*4]5^M(@Q^0H
M5NJ_6FCI^ IQY(^M(!Q^ H =3!T_ 4^F#M]!0 ^F#I^ I],'3\!0 Y>GXFF3
MP1SLN^-'\M@R[ESM/J/>GKT_$TC?>_+^=  OWOS_ )TK=/Q%(OWOS_G2MT_$
M4 (OWOS_ )TZFK][\_YTZ@ HHHH **** "BBB@ IL<:Q(JJJJJC  & !3J*
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M!0A\*Z7;ZNVH1Z;81W[.\C7*VZ"8LRHC,7QG++%&I.>1&@Z*,5+3X;>'=/\
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M(+B^M;_3KRQO=.%P@BMS;R:>+P326$<=LY-UMB<N\;&-8X3J3_\ !)KX?O\
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MF:/_ %:@'W@OBG3&@M91J-B8[V!KJW<7";9X0 QD0Y^9 &4EAP P/>LCP?\
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M)OB%K.GZMJVF^&;9;F:STN$37EUND6-4B1BH9RS@ 9&?K7R+XI_9]^+'A?\
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M%*J^0#D DD ^A)JQ5/3-&72II/*FF^SLD<<5M\HAME08 0  C/&<D]!C%7*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** //\ ]K/_ )-6^)G_ &*FJ?\
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M?\Z5NGXB@!IZ?@:?3#T_ T^@!AZ?@:?3#T_ T^@!%Z?B:6D7I^)I: "BBB@
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M?@K3M-DOK#Q%\0;Y[6YUEF\U+5;31K8-=.UQ(;,11W,MI(WV@J51U (!RO\
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M "C'_9Y_[)QH'_IN@KWRO _^"5/_ "C'_9Y_[)QH'_IN@KWR@ HHHH ****
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MA+X/\1>-O"OQ$\5?#W2;VS\ W0TG3KSQYIWA_7]7EU%+J*>VMGGGBDLF,=M
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MQLOQE\>:?*MYI7A:SC>T\!^#I@V]?L5@>;J6,Y N;O?(P"G:I4$?:"J$& ,
M< #M0!\O>+_%/P/_ ."0OPA.N>)]4UJ\UG7#(T^K7R3^(/%WC.Y@MVEE9F16
MEF9(8W<JBI!"@8A8D''3_#+]O.U^/'[#FA?'#P'\./B/XFL_%D"3Z'X9^R6M
MKK5\LER;>*1EDN!!%"W$WFM+M6!O,/\ =K@O^"W7Q6^'_P (OV -<U#XF:M%
MIO@VZUO1+36+=&_TW6--?5;4:A96RAT>1Y;+[2KHF=T)E!&TL1[%^RS\3/&G
MQ5T&[U/7_AO%\,_"ICA7PQI]U?B36)K;Y\27=JD8CLCY?D[8!)(Z'>K[2H%
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M.@ 7[WY_SI6Z?B*1?O?G_.E;I^(H 1?O?G_.G4U?O?G_ #IU !1110 4444
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M/PSX?^,&N>)-4N%TCPSXKU2:6>X9YEL;."V@D8*HR0BKO.U1ZX&30!YOI/\
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M17PV\=V7Q2^'>@>)M-6==.\1Z=;ZI:K,NV013Q+*@89.&VL,C)YH ^*?AO\
M\$WOB1\#_A;X9G\'P_"O2OB'\,M>T^2SO+:*2WM/B9I5C8W5C"FJDPO)83>5
MJ%VZ+;>=%#*2R@J^U-S]H?\ 85^+'Q3^$^H>$]/E^$CKX_\  VL>$?%$AM;S
M2]/THWES+<(;2UM\M/&?/>)RTL,C;/-W;I&5?M2B@#XQ^+?[%GQ0\9Z[X#M+
M:U\%2Z+X$^/:?$F"Z.J3Q7%WI$J7LDRO$8&5;J.:_>-4#E'2!6+H7VKNQ?\
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MG_.E;I^(H :>GX&GTP]/P-/H 8>GX&GTP]/P-/H 1>GXFEI%Z?B:6@ HHHH
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\U_P#!9#_E$_\
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ME_.E7I^)I&^]^7\Z !?O?G_.E;I^(I%^]^?\Z5NGXB@!%^]^?\Z=35^]^?\
M.G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!\U_\ !9#_ )1/_M'?]DZU
MO_TBEK^)>O[:/^"R'_*)_P#:._[)UK?_ *12U_$O0!_>=^S_ /\ )!_!/_8
ML?\ TGCKKJY']G__ )(/X)_[ %C_ .D\===0 4444 %%%% !1110 4444 -4
MX_.@\\_2C^+\?Z4J?<'TH 13C\Z"=P_(T?Q?C_2A/Z"@  P?SH)W#\C2MU7Z
MTB?T%  1_6E#9H;JOUIHZ?@* %VY'YTNZEI@Z?@* 'J,"BBB@ HHHH *-W/X
MXHIO\7X_TH ",'/OG]*%X/Y"E?[A^E)_%^/]* %;^5(O!_(4K_</TI/XOQ_I
M0 OWMM(!_04J?<'TI/XOQ_I0 X'(IH']!2I]P?2D_B_'^E #@V:;C&/PH3^@
MI6ZK]: $0\?K0PY_*A/Z"E;JOUH 13S_ )[TYAD4P=/P%/H :O6G4U/Z"G4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110!\-_\')W_*$7X]?]@W3_ /TZV5?QSU_8Q_P<G?\ *$7X]?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0G]!1_%^/]*$_H* %;JOUI$_H*5NJ_6D3^@H 5NJ_6FCI^ IS=5^M-'3\!0
M^F#I^ I],'3\!0 ^BBB@ HHHH *;_%^/]*=3?XOQ_I0 K_</TI/XOQ_I2O\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PW_P<G?\H1?CU_V#=/\
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M :.GX"GTP<+^ I] #4_H*=34./R%.S0 4449H ** <T9H **,T4 %% .:,T
M%%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCA==0UG1[63S 254WT;Y7!&&R@ZY&">.X_DGK^LO_@[<_P"4+WB[_L8=&_\
M2M:_DTH _O\ **** "BBB@ HHHH **** "BBB@!!]\_2EI!]\_2EH ;_ ,LU
M_"G4W_EFOX4Z@!!]\_2A>GXF@??/TH7I^)H &Z?B*6D;I^(I: $'WS]*%Z?B
M:!]\_2A>GXF@!:*** "BBB@ I!]\_2EI!]\_2@ 7I^)H;I^(H7I^)H;I^(H
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M2EH(R*0-EF'I0 C?ZQ?QIU(5RP/I2T -C_B^M*W3\12 [7QZ\TXC(H ****
M$7I^)H;I^(I0,4U3N)]C0 ZD'WS]*6C'- "/]P_2A/N#Z4A.6V^U. P* $/W
MQ]*6C'--=L,M "KT_$TM &** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /S._P"#MS_E"]XN_P"QAT;_ -*U
MK^32OZR_^#MS_E"]XN_[&'1O_2M:_DTH _O\HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&Z?B*6@C- !130W[PBG
M4 %(GW!]*6@# H **** $7I^)I::YV+^-.H *:O^L;\*=0%P2?6@ HHHH :?
M]:/\^M.IKC^+N!0AR* '4444 %-C^\U",2?PI0N#0 M%%% #?^6OX4ZC;\V:
M* "FR?>6AV(/X4I7<?I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'Y6_\ !X7H&N:M_P $C&NM+U9;
M#3-+\8:9/K%J<YU*!O-CCC'!^[.\,G) _=]<X!_E5K^I;_@\E\=7/A?_ ()2
MZ3I<-Y]GA\2^.-/L[B+[*)?M21PW-P%WE@8L-"K;@&)V[> Q(_EIH _O\HKX
M@^''Q9\57VM?!-9O$WB"9=6N;I;T/J,S"\ O64"3+?/A>!NS@<5[S^SEXHU/
M7-;T-;W4;Z\6;P387;K/</('F:><-(<DY<@ %NI % 'LU%%<C\?-2N-&^"7B
MN[L[B:UNK?2KB2*:%S')$PC)#*PY!'J* .NHKY#^&'Q+\1ZA^W_=:-<>(-;F
MT=;FZ46,E]*UL +9B!Y9;;P>1QUKZ\'2@ HK#\ 7<U[I=ZTTDDS+J=[&I=BQ
M"K<2!5&>P   [ 5N4 %%%% #3(H[TZBB@ HHHH **** "D8G;Q2T4  Z444R
M09- #Z*;'P*=0 4444 %%%% ";<-FD8MNXIU% !GY:;YB^M.HH ;O7UIU%%
M",NX4M%% !1110 4444 !&13<;%^6G44 -4MN_\ K4XMMHHH 8I53UI3(OK3
MJ* "BBB@"/<W^13D)(YIU% #63<:=110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?D#_P>D:I<67_!
M,?P3;Q2!8;SXA6:3+L4[P+&^8<D9'S*#QCTZ5_,#7].W_!ZE_P HT_A__P!E
-%M?_ $W7]?S$T ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>cphi-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 20:27:51 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.chinapharmaholdings.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cphi="http://www.chinapharmaholdings.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20221231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20221231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20221231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20221231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet" id="cphi_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals" id="cphi_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" id="cphi_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals" id="cphi_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3" id="cphi_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" id="cphi_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies" id="cphi_r_OrganizationandSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/Inventory" id="cphi_r_Inventory">
        <link:definition>008 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment" id="cphi_r_PropertyPlantandEquipment">
        <link:definition>009 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssets" id="cphi_r_IntangibleAssets">
        <link:definition>010 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/OtherPayables" id="cphi_r_OtherPayables">
        <link:definition>011 - Disclosure - Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions" id="cphi_r_RelatedPartyTransactions">
        <link:definition>012 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility" id="cphi_r_LinesofCreditandConstructionLoanFacility">
        <link:definition>013 - Disclosure - Lines of Credit and Construction Loan Facility</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable" id="cphi_r_ConvertibleNotePayable">
        <link:definition>014 - Disclosure - Convertible Note Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/Leases" id="cphi_r_Leases">
        <link:definition>015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxes" id="cphi_r_IncomeTaxes">
        <link:definition>016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurements" id="cphi_r_FairValueMeasurements">
        <link:definition>017 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquity" id="cphi_r_StockholdersEquity">
        <link:definition>018 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/RisksUncertainties" id="cphi_r_RisksUncertainties">
        <link:definition>019 - Disclosure - Risks &amp; Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/SubsequentEvents" id="cphi_r_SubsequentEvents">
        <link:definition>020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy" id="cphi_r_AccountingPoliciesByPolicy">
        <link:definition>021 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/InventoryTables" id="cphi_r_InventoryTables">
        <link:definition>022 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables" id="cphi_r_PropertyPlantandEquipmentTables">
        <link:definition>023 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables" id="cphi_r_IntangibleAssetsTables">
        <link:definition>024 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/OtherPayablesTables" id="cphi_r_OtherPayablesTables">
        <link:definition>025 - Disclosure - Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables" id="cphi_r_LinesofCreditandConstructionLoanFacilityTables">
        <link:definition>026 - Disclosure - Lines of Credit and Construction Loan Facility (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LeasesTables" id="cphi_r_LeasesTables">
        <link:definition>027 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesTables" id="cphi_r_IncomeTaxesTables">
        <link:definition>028 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables" id="cphi_r_FairValueMeasurementsTables">
        <link:definition>029 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" id="cphi_r_OrganizationandSignificantAccountingPoliciesDetails">
        <link:definition>030 - Disclosure - Organization and Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable" id="cphi_r_ScheduleofinventoryTable">
        <link:definition>031 - Disclosure - Inventory (Details) - Schedule of inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails" id="cphi_r_PropertyPlantandEquipmentDetails">
        <link:definition>032 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable" id="cphi_r_ScheduleofpropertyplantandequipmentTable">
        <link:definition>033 - Disclosure - Property, Plant and Equipment (Details) - Schedule of property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable" id="cphi_r_ScheduleofestimatedusefullivesoftheassetsTable">
        <link:definition>034 - Disclosure - Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails" id="cphi_r_IntangibleAssetsDetails">
        <link:definition>035 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable" id="cphi_r_ScheduleofintangibleassetsTable">
        <link:definition>036 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable" id="cphi_r_ScheduleofaggregateannualamortizationexpenseTable">
        <link:definition>037 - Disclosure - Intangible Assets (Details) - Schedule of aggregate annual amortization expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable" id="cphi_r_ScheduleofotherpayablesTable">
        <link:definition>038 - Disclosure - Other Payables (Details) - Schedule of other payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAH97Uj3CrYpCI3iMnN+zBsiA7R8Hc0PMjB8aYKuSvZFd8JBtZoOjmWf0KXzrZWbYK6sWg9BSB1dSM2htVGPahyLguSlQDTSZpy8M79KgRfS+ELARBWvSwOw7XHLqB7w6rc=] CSR-->
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" id="cphi_r_RelatedPartyTransactionsDetails">
        <link:definition>039 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails" id="cphi_r_LinesofCreditandConstructionLoanFacilityDetails">
        <link:definition>040 - Disclosure - Lines of Credit and Construction Loan Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable" id="cphi_r_ScheduleofprincipalpaymentsTable">
        <link:definition>041 - Disclosure - Lines of Credit and Construction Loan Facility (Details) - Schedule of principal payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" id="cphi_r_ConvertibleNotePayableDetails">
        <link:definition>042 - Disclosure - Convertible Note Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LeasesDetails" id="cphi_r_LeasesDetails">
        <link:definition>043 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable" id="cphi_r_ScheduleofoperatingleaseliabilitiesTable">
        <link:definition>044 - Disclosure - Leases (Details) - Schedule of operating lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails" id="cphi_r_IncomeTaxesDetails">
        <link:definition>045 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable" id="cphi_r_ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable">
        <link:definition>046 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals" id="cphi_r_ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals">
        <link:definition>047 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable" id="cphi_r_ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable">
        <link:definition>048 - Disclosure - Income Taxes (Details) - Schedule of temporary differences to deferred income tax assets and liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable" id="cphi_r_ScheduleofassetsandliabilitiesrecordedatfairvalueTable">
        <link:definition>049 - Disclosure - Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" id="cphi_r_StockholdersEquityDetails">
        <link:definition>050 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails" id="cphi_r_RisksUncertaintiesDetails">
        <link:definition>051 - Disclosure - Risks &amp; Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails" id="cphi_r_SubsequentEventsDetails">
        <link:definition>052 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfInventoryAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract"/>
  <xs:element name="ScheduleOfOtherPayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfOtherPayablesAbstract"/>
  <xs:element name="ScheduleOfPrincipalPaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfPrincipalPaymentsAbstract"/>
  <xs:element name="ScheduleOfOperatingLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract"/>
  <xs:element name="ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract12"/>
  <xs:element name="DeferredIncomeTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_DeferredIncomeTaxAssetsAbstract"/>
  <xs:element name="DeferredIncomeTaxLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_DeferredIncomeTaxLiabilityAbstract"/>
  <xs:element name="BankersAcceptances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_BankersAcceptances"/>
  <xs:element name="TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts"/>
  <xs:element name="AdvanceToSupplies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_AdvanceToSupplies"/>
  <xs:element name="TradeAccountsReceivableLessAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_TradeAccountsReceivableLessAllowance"/>
  <xs:element name="OtherReceivablesLessAllowanceForDoubtfulAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts"/>
  <xs:element name="AdvancesToSuppliers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_AdvancesToSuppliers"/>
  <xs:element name="AccountsReceivableCollectedWithBankersAcceptances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_AccountsReceivableCollectedWithBankersAcceptances"/>
  <xs:element name="InventoryPurchasedWithBankersAcceptanceNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_InventoryPurchasedWithBankersAcceptanceNote"/>
  <xs:element name="ConversionOfOfficerWagesToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_ConversionOfOfficerWagesToCommonStock"/>
  <xs:element name="LinesofCreditandConstructionLoanFacilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_LinesofCreditandConstructionLoanFacilityTable"/>
  <xs:element name="LinesofCreditandConstructionLoanFacilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_LinesofCreditandConstructionLoanFacilityLineItems"/>
  <xs:element name="LeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_LeasesTable"/>
  <xs:element name="LeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_LeasesLineItems"/>
  <xs:element name="OrganizationAndNatureOfOperationsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock"/>
  <xs:element name="LiquidityAndGoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_LiquidityAndGoingConcernPolicyTextBlock"/>
  <xs:element name="AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock"/>
  <xs:element name="InterestRateRiskPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_InterestRateRiskPolicyTextBlock"/>
  <xs:element name="UsefulLiveOfAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UsefulLiveOfAssetsTableTextBlock"/>
  <xs:element name="LinesofCreditandConstructionLoanFacilityTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_LinesofCreditandConstructionLoanFacilityTablesTable"/>
  <xs:element name="LinesofCreditandConstructionLoanFacilityTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems"/>
  <xs:element name="LeasesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_LeasesTablesTable"/>
  <xs:element name="LeasesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_LeasesTablesLineItems"/>
  <xs:element name="MotorVehicleGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_MotorVehicleGross"/>
  <xs:element name="OfficeEquipmentGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_OfficeEquipmentGross"/>
  <xs:element name="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable"/>
  <xs:element name="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems"/>
  <xs:element name="LeasesDetailsScheduleofoperatingleaseliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable"/>
  <xs:element name="LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems"/>
  <xs:element name="LessOperatingLeaseLiabilitiesCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_LessOperatingLeaseLiabilitiesCurrentPortion"/>
  <xs:element name="OperatingLeaseLiabilitiesNetOfCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems"/>
  <xs:element name="OrganizationandSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_OrganizationandSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="OrganizationandSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="AccumulatedDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_AccumulatedDeficit"/>
  <xs:element name="PurchaseOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_PurchaseOfCommonStockShares"/>
  <xs:element name="IntangibleAssetsUsefulLifeDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_IntangibleAssetsUsefulLifeDescription"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="LoanAgreementToBorrowCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_LoanAgreementToBorrowCash"/>
  <xs:element name="CompensationConverted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_CompensationConverted"/>
  <xs:element name="LinesofCreditandConstructionLoanFacilityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable"/>
  <xs:element name="LinesofCreditandConstructionLoanFacilityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems"/>
  <xs:element name="InterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_InterestRate"/>
  <xs:element name="InterestAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_InterestAmount"/>
  <xs:element name="OriginalIssueDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_OriginalIssueDiscount"/>
  <xs:element name="ConvertibleNote" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ConvertibleNote"/>
  <xs:element name="ConvertibleNoteConversionPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ConvertibleNoteConversionPrice"/>
  <xs:element name="InterestAccruesOnNoteDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_InterestAccruesOnNoteDescription"/>
  <xs:element name="RedeemOfOutstandingNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_RedeemOfOutstandingNote"/>
  <xs:element name="PercentageOfCommonStockPriceOnWeightedAveragePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice"/>
  <xs:element name="NoteRedeemableIntoShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_NoteRedeemableIntoShares"/>
  <xs:element name="WeightedAveragePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_WeightedAveragePrice"/>
  <xs:element name="CommonStockIssuedToInvestor" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_CommonStockIssuedToInvestor"/>
  <xs:element name="CommonStockIssuedToInvestor1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_CommonStockIssuedToInvestor1"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_LeasesDetailsLineItems"/>
  <xs:element name="CashFlowForOperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_CashFlowForOperatingLease"/>
  <xs:element name="OperatingLeaseRightsOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_OperatingLeaseRightsOfUseAssets"/>
  <xs:element name="WeightedAveragesRemainingLeaseTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_WeightedAveragesRemainingLeaseTerm"/>
  <xs:element name="WeightedAverageDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_WeightedAverageDiscountRate"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_IncomeTaxesDetailsLineItems"/>
  <xs:element name="NetOperatingLossCarryForwardsExpirationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_NetOperatingLossCarryForwardsExpirationDescription"/>
  <xs:element name="ValuationAllowanceForDeferredTaxAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_ValuationAllowanceForDeferredTaxAssets"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_StockholdersEquityDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_StockholdersEquityDetailsLineItems"/>
  <xs:element name="AftertaxNetIncomePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_AftertaxNetIncomePercentage"/>
  <xs:element name="ReserveAccountBalancesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ReserveAccountBalancesPercentage"/>
  <xs:element name="TotalOptionOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_TotalOptionOutstanding"/>
  <xs:element name="AdditionalSharesAvailableForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_AdditionalSharesAvailableForIssuance"/>
  <xs:element name="CommonStockPursuant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CommonStockPursuant"/>
  <xs:element name="ClosingMarketPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ClosingMarketPrice"/>
  <xs:element name="PurchaseofCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_PurchaseofCommonStockShares"/>
  <xs:element name="FairValueOfOptionsGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_FairValueOfOptionsGranted"/>
  <xs:element name="UnpaidCashCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnpaidCashCompensation"/>
  <xs:element name="MarketPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_MarketPricePerShare"/>
  <xs:element name="ExpectedLifes" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ExpectedLifes"/>
  <xs:element name="ConcentrationRiskType_Domain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ConcentrationRiskType_Domain"/>
  <xs:element name="ConcentrationRiskByBenchmarksDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ConcentrationRiskByBenchmarksDomain"/>
  <xs:element name="RisksUncertaintiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_RisksUncertaintiesDetailsTable"/>
  <xs:element name="RisksUncertaintiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_RisksUncertaintiesDetailsLineItems"/>
  <xs:element name="ConcentrationRiskPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ConcentrationRiskPercentage"/>
  <xs:element name="NumberOfCustomers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_NumberOfCustomers"/>
  <xs:element name="NumberOfSuppliers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_NumberOfSuppliers"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SubsequentEventsDetailsLineItems"/>
  <xs:element name="InvestorRedemption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_InvestorRedemption"/>
  <xs:element name="WeightedAveragePrices" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_WeightedAveragePrices"/>
  <xs:element name="CommonStockInvestor" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CommonStockInvestor"/>
  <xs:element name="ConcentrationRiskByBenchmarksAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="cphi_ConcentrationRiskByBenchmarksAxis"/>
  <xs:element name="ConcentrationRiskTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="cphi_ConcentrationRiskTypeAxis"/>
  <xs:element name="BankOfChinaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_BankOfChinaMember"/>
  <xs:element name="BankOfCommunicationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_BankOfCommunicationsMember"/>
  <xs:element name="ChairpersonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ChairpersonMember"/>
  <xs:element name="ChinaCITICBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ChinaCITICBankMember"/>
  <xs:element name="CustomerOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CustomerOneMember"/>
  <xs:element name="CustomerThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CustomerThreeMember"/>
  <xs:element name="CustomerTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CustomerTwoMember"/>
  <xs:element name="HaikouHaiHongXinMicrofinanceCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember"/>
  <xs:element name="HainanHelpsonMedicalBiotechnologyCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember"/>
  <xs:element name="MotorVehicleMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_MotorVehicleMember"/>
  <xs:element name="OnnyInvestmentLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_OnnyInvestmentLimitedMember"/>
  <xs:element name="PermitOfLandUseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_PermitOfLandUseMember"/>
  <xs:element name="RawMaterialPurchasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_RawMaterialPurchasesMember"/>
  <xs:element name="SalesRevenuesNetOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SalesRevenuesNetOneMember"/>
  <xs:element name="SalesRevenuesNetThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SalesRevenuesNetThreeMember"/>
  <xs:element name="SalesRevenuesNetTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SalesRevenuesNetTwoMember"/>
  <xs:element name="SuppliersOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SuppliersOneMember"/>
  <xs:element name="SuppliersThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SuppliersThreeMember"/>
  <xs:element name="SuppliersTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SuppliersTwoMember"/>
  <xs:element name="TwoThousandTenIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_TwoThousandTenIncentivePlanMember"/>
  <xs:element name="TwoThousandTenLongTermIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_TwoThousandTenLongTermIncentivePlanMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>cphi-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 20:27:51 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedBalanceSheet" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedIncomeStatement" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedCashFlow" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofinventoryTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofintangibleassetsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="cphi_BankersAcceptances" xlink:href="cphi-20221231.xsd#cphi_BankersAcceptances"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="cphi_BankersAcceptances" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20221231.xsd#cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvanceToSupplies" xlink:href="cphi-20221231.xsd#cphi_AdvanceToSupplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="cphi_AdvanceToSupplies" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LinesOfCreditCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermConstructionLoanCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermConstructionLoanCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermConstructionLoanCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAH97Uj3CrYpCI3iMnN+zBsiA7R8Hc0PMjB8aYKuSvZFd8JBtZoOjmWf0KXzrZWbYK6sWg9BSB1dSM2htVGPahyLguSlQDTSZpy8M79KgRfS+DvenC55/Sd3fiiB2sPJH14=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionPlanExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvancesToSuppliers" xlink:href="cphi-20221231.xsd#cphi_AdvancesToSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cphi_AdvancesToSuppliers" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConstructionLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConstructionLoansPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfConstructionLoansPayable" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndLandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovements"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_LandAndLandImprovements" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_BuildingsAndImprovementsGross" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="cphi_MotorVehicleGross" xlink:href="cphi-20221231.xsd#cphi_MotorVehicleGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="cphi_MotorVehicleGross" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="cphi_OfficeEquipmentGross" xlink:href="cphi-20221231.xsd#cphi_OfficeEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="cphi_OfficeEquipmentGross" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>cphi-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 20:27:51 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedBalanceSheet" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedIncomeStatement" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ShareholdersEquityType2or3" roleURI="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedCashFlow" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_OrganizationandSignificantAccountingPolicies" roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_Inventory" roleURI="http://www.chinapharmaholdings.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_PropertyPlantandEquipment" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IntangibleAssets" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_OtherPayables" roleURI="http://www.chinapharmaholdings.com/role/OtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_RelatedPartyTransactions" roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LinesofCreditandConstructionLoanFacility" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConvertibleNotePayable" roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_Leases" roleURI="http://www.chinapharmaholdings.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IncomeTaxes" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_FairValueMeasurements" roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_StockholdersEquity" roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_RisksUncertainties" roleURI="http://www.chinapharmaholdings.com/role/RisksUncertainties"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_SubsequentEvents" roleURI="http://www.chinapharmaholdings.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_AccountingPoliciesByPolicy" roleURI="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_InventoryTables" roleURI="http://www.chinapharmaholdings.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_PropertyPlantandEquipmentTables" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IntangibleAssetsTables" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_OtherPayablesTables" roleURI="http://www.chinapharmaholdings.com/role/OtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LinesofCreditandConstructionLoanFacilityTables" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LeasesTables" roleURI="http://www.chinapharmaholdings.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IncomeTaxesTables" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_FairValueMeasurementsTables" roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofinventoryTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofestimatedusefullivesoftheassetsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofintangibleassetsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofaggregateannualamortizationexpenseTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofotherpayablesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofprincipalpaymentsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofoperatingleaseliabilitiesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofassetsandliabilitiesrecordedatfairvalueTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_OrganizationandSignificantAccountingPoliciesDetails" roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_PropertyPlantandEquipmentDetails" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IntangibleAssetsDetails" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_RelatedPartyTransactionsDetails" roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LinesofCreditandConstructionLoanFacilityDetails" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConvertibleNotePayableDetails" roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LeasesDetails" roleURI="http://www.chinapharmaholdings.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IncomeTaxesDetails" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_StockholdersEquityDetails" roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_RisksUncertaintiesDetails" roleURI="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_SubsequentEventsDetails" roleURI="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_BankersAcceptances" xlink:href="cphi-20221231.xsd#cphi_BankersAcceptances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="cphi_BankersAcceptances" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20221231.xsd#cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvanceToSupplies" xlink:href="cphi-20221231.xsd#cphi_AdvanceToSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="cphi_AdvanceToSupplies" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_InventoryNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermConstructionLoanCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermConstructionLoanCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermConstructionLoanCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="cphi_TradeAccountsReceivableLessAllowance" xlink:href="cphi-20221231.xsd#cphi_TradeAccountsReceivableLessAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="cphi_TradeAccountsReceivableLessAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20221231.xsd#cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvancesToSuppliers" xlink:href="cphi-20221231.xsd#cphi_AdvancesToSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cphi_AdvancesToSuppliers" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConstructionLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConstructionLoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConstructionLoansPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:href="cphi-20221231.xsd#cphi_AccountsReceivableCollectedWithBankersAcceptances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:href="cphi-20221231.xsd#cphi_InventoryPurchasedWithBankersAcceptanceNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConversionOfOfficerWagesToCommonStock" xlink:href="cphi-20221231.xsd#cphi_ConversionOfOfficerWagesToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cphi_ConversionOfOfficerWagesToCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OtherPayables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility">
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityLineItems" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTable" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityLineItems" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityLineItems" xlink:to="us-gaap_LongTermDebtTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/Leases">
    <loc xlink:type="locator" xlink:label="cphi_LeasesLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesTable" xlink:href="cphi-20221231.xsd#cphi_LeasesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_LeasesLineItems" xlink:to="cphi_LeasesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RisksUncertainties">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_OrganizationAndNatureOfOperationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_LiquidityAndGoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestRateRiskPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_InterestRateRiskPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cphi_InterestRateRiskPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:href="cphi-20221231.xsd#cphi_UsefulLiveOfAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="cphi_UsefulLiveOfAssetsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OtherPayablesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables">
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTablesTable" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="cphi_LeasesTablesLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesTablesTable" xlink:href="cphi-20221231.xsd#cphi_LeasesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_LeasesTablesLineItems" xlink:to="cphi_LeasesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesTablesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfInventoryAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndLandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LandAndLandImprovements" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_BuildingsAndImprovementsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_MachineryAndEquipmentGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_MotorVehicleGross" xlink:href="cphi-20221231.xsd#cphi_MotorVehicleGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cphi_MotorVehicleGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_OfficeEquipmentGross" xlink:href="cphi-20221231.xsd#cphi_OfficeEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cphi_OfficeEquipmentGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OfficeEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable">
    <loc xlink:type="locator" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems" xlink:href="cphi-20221231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" xlink:href="cphi-20221231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems" xlink:to="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_PermitOfLandUseMember" xlink:href="cphi-20221231.xsd#cphi_PermitOfLandUseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cphi_PermitOfLandUseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_MotorVehicleMember" xlink:href="cphi-20221231.xsd#cphi_MotorVehicleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cphi_MotorVehicleMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfIntangibleAssetsAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfOtherPayablesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfOtherPayablesAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfOtherPayablesAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfOtherPayablesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAH97Uj3CrYpCI3iMnN+zBsiA7R8Hc0PMjB8aYKuSvZFd8JBtZoOjmWf0KXzrZWbYK6sWg9BSB1dSM2htVGPahyLguSlQDTSZpy8M79KgRfS+NdjjYGOSA14/C+YSQcnwg8=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnusedLinesOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusedLinesOfCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_UnusedLinesOfCreditMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:to="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_LessOperatingLeaseLiabilitiesCurrentPortion" xlink:href="cphi-20221231.xsd#cphi_LessOperatingLeaseLiabilitiesCurrentPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:to="cphi_LessOperatingLeaseLiabilitiesCurrentPortion" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:href="cphi-20221231.xsd#cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:to="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredIncomeTaxAssetsAbstract" xlink:href="cphi-20221231.xsd#cphi_DeferredIncomeTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="cphi_DeferredIncomeTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:href="cphi-20221231.xsd#cphi_DeferredIncomeTaxLiabilityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="cphi_DeferredIncomeTaxLiabilityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable">
    <loc xlink:type="locator" xlink:label="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" xlink:href="cphi-20221231.xsd#cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" xlink:href="cphi-20221231.xsd#cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" xlink:to="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomersLiabilityForAcceptancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomersLiabilityForAcceptancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" xlink:to="us-gaap_CustomersLiabilityForAcceptancesNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_OrganizationandSignificantAccountingPoliciesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_OrganizationandSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="cphi_OrganizationandSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_OnnyInvestmentLimitedMember" xlink:href="cphi-20221231.xsd#cphi_OnnyInvestmentLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="cphi_OnnyInvestmentLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:href="cphi-20221231.xsd#cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AccumulatedDeficit" xlink:href="cphi-20221231.xsd#cphi_AccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="cphi_AccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalRequiredForCapitalAdequacy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalRequiredForCapitalAdequacy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CapitalRequiredForCapitalAdequacy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_PurchaseOfCommonStockShares" xlink:href="cphi-20221231.xsd#cphi_PurchaseOfCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="cphi_PurchaseOfCommonStockShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsUsefulLifeDescription" xlink:href="cphi-20221231.xsd#cphi_IntangibleAssetsUsefulLifeDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="cphi_IntangibleAssetsUsefulLifeDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_DividendsStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementAndServiceFeesRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd#us-gaap_ManagementAndServiceFeesRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ManagementAndServiceFeesRate" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_RelatedPartyTransactionsDetailsTable" xlink:href="cphi-20221231.xsd#cphi_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="cphi_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_InterestExpenseRelatedParty" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_LoanAgreementToBorrowCash" xlink:href="cphi-20221231.xsd#cphi_LoanAgreementToBorrowCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="cphi_LoanAgreementToBorrowCash" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_OtherNotesPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_NotesPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CompensationConverted" xlink:href="cphi-20221231.xsd#cphi_CompensationConverted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="cphi_CompensationConverted" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails">
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_BankOfChinaMember" xlink:href="cphi-20221231.xsd#cphi_BankOfChinaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cphi_BankOfChinaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_BankOfCommunicationsMember" xlink:href="cphi-20221231.xsd#cphi_BankOfCommunicationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cphi_BankOfCommunicationsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ChinaCITICBankMember" xlink:href="cphi-20221231.xsd#cphi_ChinaCITICBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cphi_ChinaCITICBankMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember" xlink:href="cphi-20221231.xsd#cphi_HaikouHaiHongXinMicrofinanceCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionLoan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_ConstructionLoan" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForMortgageDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForMortgageDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_PaymentsForMortgageDeposits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_InterestExpenseOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestRate" xlink:href="cphi-20221231.xsd#cphi_InterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="cphi_InterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestAmount" xlink:href="cphi-20221231.xsd#cphi_InterestAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="cphi_InterestAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTerm" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ConvertibleNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_OriginalIssueDiscount" xlink:href="cphi-20221231.xsd#cphi_OriginalIssueDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_OriginalIssueDiscount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConvertibleNote" xlink:href="cphi-20221231.xsd#cphi_ConvertibleNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_ConvertibleNote" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConvertibleNoteConversionPrice" xlink:href="cphi-20221231.xsd#cphi_ConvertibleNoteConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_ConvertibleNoteConversionPrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestAccruesOnNoteDescription" xlink:href="cphi-20221231.xsd#cphi_InterestAccruesOnNoteDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_InterestAccruesOnNoteDescription" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_RedeemOfOutstandingNote" xlink:href="cphi-20221231.xsd#cphi_RedeemOfOutstandingNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_RedeemOfOutstandingNote" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice" xlink:href="cphi-20221231.xsd#cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_NoteRedeemableIntoShares" xlink:href="cphi-20221231.xsd#cphi_NoteRedeemableIntoShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_NoteRedeemableIntoShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAveragePrice" xlink:href="cphi-20221231.xsd#cphi_WeightedAveragePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_WeightedAveragePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestAndDebtExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_SharesIssued" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtWeightedAverageInterestRate" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CommonStockIssuedToInvestor" xlink:href="cphi-20221231.xsd#cphi_CommonStockIssuedToInvestor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_CommonStockIssuedToInvestor" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CommonStockIssuedToInvestor1" xlink:href="cphi-20221231.xsd#cphi_CommonStockIssuedToInvestor1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cphi_CommonStockIssuedToInvestor1" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="cphi_LeasesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_LeasesDetailsLineItems" xlink:to="cphi_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CashFlowForOperatingLease" xlink:href="cphi-20221231.xsd#cphi_CashFlowForOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesDetailsLineItems" xlink:to="cphi_CashFlowForOperatingLease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_OperatingLeaseRightsOfUseAssets" xlink:href="cphi-20221231.xsd#cphi_OperatingLeaseRightsOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesDetailsLineItems" xlink:to="cphi_OperatingLeaseRightsOfUseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAveragesRemainingLeaseTerm" xlink:href="cphi-20221231.xsd#cphi_WeightedAveragesRemainingLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesDetailsLineItems" xlink:to="cphi_WeightedAveragesRemainingLeaseTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAverageDiscountRate" xlink:href="cphi-20221231.xsd#cphi_WeightedAverageDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_LeasesDetailsLineItems" xlink:to="cphi_WeightedAverageDiscountRate" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="cphi_IncomeTaxesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_IncomeTaxesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_IncomeTaxesDetailsLineItems" xlink:to="cphi_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_IncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_NetOperatingLossCarryForwardsExpirationDescription" xlink:href="cphi-20221231.xsd#cphi_NetOperatingLossCarryForwardsExpirationDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IncomeTaxesDetailsLineItems" xlink:to="cphi_NetOperatingLossCarryForwardsExpirationDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ValuationAllowanceForDeferredTaxAssets" xlink:href="cphi-20221231.xsd#cphi_ValuationAllowanceForDeferredTaxAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IncomeTaxesDetailsLineItems" xlink:to="cphi_ValuationAllowanceForDeferredTaxAssets" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="cphi_StockholdersEquityDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_StockholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_StockholdersEquityDetailsTable" xlink:href="cphi-20221231.xsd#cphi_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_StockholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_TwoThousandTenIncentivePlanMember" xlink:href="cphi-20221231.xsd#cphi_TwoThousandTenIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cphi_TwoThousandTenIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_TwoThousandTenLongTermIncentivePlanMember" xlink:href="cphi-20221231.xsd#cphi_TwoThousandTenLongTermIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cphi_TwoThousandTenLongTermIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ChairpersonMember" xlink:href="cphi-20221231.xsd#cphi_ChairpersonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cphi_ChairpersonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AftertaxNetIncomePercentage" xlink:href="cphi-20221231.xsd#cphi_AftertaxNetIncomePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_AftertaxNetIncomePercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ReserveAccountBalancesPercentage" xlink:href="cphi-20221231.xsd#cphi_ReserveAccountBalancesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_ReserveAccountBalancesPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_TotalOptionOutstanding" xlink:href="cphi-20221231.xsd#cphi_TotalOptionOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_TotalOptionOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AdditionalSharesAvailableForIssuance" xlink:href="cphi-20221231.xsd#cphi_AdditionalSharesAvailableForIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_AdditionalSharesAvailableForIssuance" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CommonStockPursuant" xlink:href="cphi-20221231.xsd#cphi_CommonStockPursuant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_CommonStockPursuant" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ClosingMarketPrice" xlink:href="cphi-20221231.xsd#cphi_ClosingMarketPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_ClosingMarketPrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_PurchaseofCommonStockShares" xlink:href="cphi-20221231.xsd#cphi_PurchaseofCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_PurchaseofCommonStockShares" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_FairValueOfOptionsGranted" xlink:href="cphi-20221231.xsd#cphi_FairValueOfOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_FairValueOfOptionsGranted" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_UnpaidCashCompensation" xlink:href="cphi-20221231.xsd#cphi_UnpaidCashCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_UnpaidCashCompensation" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_MarketPricePerShare" xlink:href="cphi-20221231.xsd#cphi_MarketPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_MarketPricePerShare" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ExpectedLifes" xlink:href="cphi-20221231.xsd#cphi_ExpectedLifes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_ExpectedLifes" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails">
    <loc xlink:type="locator" xlink:label="cphi_RisksUncertaintiesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_RisksUncertaintiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_RisksUncertaintiesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_RisksUncertaintiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_RisksUncertaintiesDetailsLineItems" xlink:to="cphi_RisksUncertaintiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskTypeAxis" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="cphi_ConcentrationRiskTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskType_Domain" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskType_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cphi_ConcentrationRiskTypeAxis" xlink:to="cphi_ConcentrationRiskType_Domain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskType_Domain_0" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskType_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="cphi_ConcentrationRiskTypeAxis" xlink:to="cphi_ConcentrationRiskType_Domain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskByBenchmarksAxis" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskByBenchmarksAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="cphi_ConcentrationRiskByBenchmarksAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskByBenchmarksDomain" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskByBenchmarksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cphi_ConcentrationRiskByBenchmarksAxis" xlink:to="cphi_ConcentrationRiskByBenchmarksDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskByBenchmarksDomain_0" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskByBenchmarksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="cphi_ConcentrationRiskByBenchmarksAxis" xlink:to="cphi_ConcentrationRiskByBenchmarksDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ConcentrationRiskType_Domain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersOneMember" xlink:href="cphi-20221231.xsd#cphi_SuppliersOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="cphi_SuppliersOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersTwoMember" xlink:href="cphi-20221231.xsd#cphi_SuppliersTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="cphi_SuppliersTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersThreeMember" xlink:href="cphi-20221231.xsd#cphi_SuppliersThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="cphi_SuppliersThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerOneMember" xlink:href="cphi-20221231.xsd#cphi_CustomerOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cphi_CustomerOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerTwoMember" xlink:href="cphi-20221231.xsd#cphi_CustomerTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cphi_CustomerTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerThreeMember" xlink:href="cphi-20221231.xsd#cphi_CustomerThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cphi_CustomerThreeMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ConcentrationRiskByBenchmarksDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ConcentrationRiskByBenchmarksDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_RawMaterialPurchasesMember" xlink:href="cphi-20221231.xsd#cphi_RawMaterialPurchasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ConcentrationRiskByBenchmarksDomain" xlink:to="cphi_RawMaterialPurchasesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_SalesRevenuesNetOneMember" xlink:href="cphi-20221231.xsd#cphi_SalesRevenuesNetOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ConcentrationRiskByBenchmarksDomain" xlink:to="cphi_SalesRevenuesNetOneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_SalesRevenuesNetTwoMember" xlink:href="cphi-20221231.xsd#cphi_SalesRevenuesNetTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ConcentrationRiskByBenchmarksDomain" xlink:to="cphi_SalesRevenuesNetTwoMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_SalesRevenuesNetThreeMember" xlink:href="cphi-20221231.xsd#cphi_SalesRevenuesNetThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ConcentrationRiskByBenchmarksDomain" xlink:to="cphi_SalesRevenuesNetThreeMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskPercentage" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RisksUncertaintiesDetailsLineItems" xlink:to="cphi_ConcentrationRiskPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_NumberOfCustomers" xlink:href="cphi-20221231.xsd#cphi_NumberOfCustomers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RisksUncertaintiesDetailsLineItems" xlink:to="cphi_NumberOfCustomers" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_NumberOfSuppliers" xlink:href="cphi-20221231.xsd#cphi_NumberOfSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RisksUncertaintiesDetailsLineItems" xlink:to="cphi_NumberOfSuppliers" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="cphi_SubsequentEventsDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_SubsequentEventsDetailsTable" xlink:href="cphi-20221231.xsd#cphi_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_SubsequentEventsDetailsLineItems" xlink:to="cphi_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InvestorRedemption" xlink:href="cphi-20221231.xsd#cphi_InvestorRedemption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_SubsequentEventsDetailsLineItems" xlink:to="cphi_InvestorRedemption" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAveragePrices" xlink:href="cphi-20221231.xsd#cphi_WeightedAveragePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_SubsequentEventsDetailsLineItems" xlink:to="cphi_WeightedAveragePrices" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CommonStockInvestor" xlink:href="cphi-20221231.xsd#cphi_CommonStockInvestor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_SubsequentEventsDetailsLineItems" xlink:to="cphi_CommonStockInvestor" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>cphi-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 20:27:51 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross (loss) profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Net other expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used in Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash (Used In) Provided By Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase in Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfInventoryAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule of Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfInventoryAbstract" xlink:to="cphi_ScheduleOfInventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfIntangibleAssetsAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule of Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfIntangibleAssetsAbstract" xlink:to="cphi_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract_lbl" xml:lang="en-US">Schedule of Aggregate Annual Amortization Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfOtherPayablesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfOtherPayablesAbstract_lbl" xml:lang="en-US">Schedule of Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfOtherPayablesAbstract" xlink:to="cphi_ScheduleOfOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Convertible Note Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_BankersAcceptances" xlink:href="cphi-20221231.xsd#cphi_BankersAcceptances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_BankersAcceptances_lbl" xml:lang="en-US">Banker&#8217;s acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptances" xlink:to="cphi_BankersAcceptances_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20221231.xsd#cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts of $16,739,527 and $18,312,707, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" xlink:to="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_TradeAccountsReceivableLessAllowance" xlink:href="cphi-20221231.xsd#cphi_TradeAccountsReceivableLessAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_TradeAccountsReceivableLessAllowance_lbl" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TradeAccountsReceivableLessAllowance" xlink:to="cphi_TradeAccountsReceivableLessAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract" xlink:to="cphi_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables, less allowance for doubtful accounts of $27,149 and $32,210, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20221231.xsd#cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Other receivables, less allowance for doubtful accounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:to="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvanceToSupplies" xlink:href="cphi-20221231.xsd#cphi_AdvanceToSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AdvanceToSupplies_lbl" xml:lang="en-US">Advances to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvanceToSupplies" xlink:to="cphi_AdvanceToSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract0" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract0" xlink:to="cphi_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract1" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract1" xlink:to="cphi_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Advances from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Borrowings from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Current portion of lines of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermConstructionLoanCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermConstructionLoanCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermConstructionLoanCurrent_lbl" xml:lang="en-US">Convertible, redeemable note payable, net of issue discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermConstructionLoanCurrent" xlink:to="us-gaap_LongTermConstructionLoanCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible, redeemable note payable, net of issue discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 9)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 500,000,000 shares authorized; 7,490,896 shares and 4,733,956 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract2" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract2" xlink:to="cphi_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract3" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract3" xlink:to="cphi_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Selling expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Bad debt benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract4" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract4" xlink:to="cphi_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract5" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract5" xlink:to="cphi_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract6" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract6" xlink:to="cphi_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive income (loss) - foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock option compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock in lieu of compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock in lieu of compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of common stock for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common stock for intangible assets (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversions of note payable to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversions of note payable to common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock and stock option compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Other payables and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Advances from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract7" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract7" xlink:to="cphi_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract8" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract8" xlink:to="cphi_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US">Payments of line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from lines of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Borrowings and interest from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from convertible redeemable debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Proceeds from lines of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract9" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract9" xlink:to="cphi_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate Changes on Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract10" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract10" xlink:to="cphi_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract11" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract11" xlink:to="cphi_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract12" xlink:href="cphi-20221231.xsd#cphi_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract12" xlink:to="cphi_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental Noncash Investing and Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:href="cphi-20221231.xsd#cphi_AccountsReceivableCollectedWithBankersAcceptances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl" xml:lang="en-US">Accounts receivable collected with banker&#8217;s acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:href="cphi-20221231.xsd#cphi_InventoryPurchasedWithBankersAcceptanceNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl" xml:lang="en-US">Inventory purchased with banker&#8217;s acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ConversionOfOfficerWagesToCommonStock" xlink:href="cphi-20221231.xsd#cphi_ConversionOfOfficerWagesToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ConversionOfOfficerWagesToCommonStock_lbl" xml:lang="en-US">Common stock issued for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConversionOfOfficerWagesToCommonStock" xlink:to="cphi_ConversionOfOfficerWagesToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Common stock issued for compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Original issue discount accretion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Trade accounts and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvancesToSuppliers" xlink:href="cphi-20221231.xsd#cphi_AdvancesToSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cphi_AdvancesToSuppliers_lbl" xml:lang="en-US">Advances to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliers" xlink:to="cphi_AdvancesToSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConstructionLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConstructionLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConstructionLoansPayable_lbl" xml:lang="en-US">Payments of construction term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConstructionLoansPayable" xlink:to="us-gaap_RepaymentsOfConstructionLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other	Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndLandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandAndLandImprovements_lbl" xml:lang="en-US">Permit of land use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndLandImprovements" xlink:to="us-gaap_LandAndLandImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingsAndImprovementsGross_lbl" xml:lang="en-US">Building</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingsAndImprovementsGross" xlink:to="us-gaap_BuildingsAndImprovementsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Plant, machinery and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_MotorVehicleGross" xlink:href="cphi-20221231.xsd#cphi_MotorVehicleGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_MotorVehicleGross_lbl" xml:lang="en-US">Motor vehicle</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MotorVehicleGross" xlink:to="cphi_MotorVehicleGross_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OfficeEquipmentGross" xlink:href="cphi-20221231.xsd#cphi_OfficeEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_OfficeEquipmentGross_lbl" xml:lang="en-US">Office equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OfficeEquipmentGross" xlink:to="cphi_OfficeEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:href="cphi-20221231.xsd#cphi_UsefulLiveOfAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated useful lives of the assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:to="cphi_UsefulLiveOfAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of aggregate annual amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">OTHER PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Compensation payable to officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Compensation and interest to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Business taxes and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Total Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of principal payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTE PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xml:lang="en-US">Total undiscounted cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:href="cphi-20221231.xsd#cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:to="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">(Benefit) tax at statutory rate of 25%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">(Benefit) tax at statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior year refund received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Other, primarily the difference in U.S. tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of temporary differences to deferred income tax assets and liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredIncomeTaxAssetsAbstract" xlink:href="cphi-20221231.xsd#cphi_DeferredIncomeTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_DeferredIncomeTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred income tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="cphi_DeferredIncomeTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl" xml:lang="en-US">Allowance for doubtful other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory obsolescence reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US">Expenses not deductible in current year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl" xml:lang="en-US">Advances for intangible assets impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Lease liability, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">PRC net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">U.S. net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred income tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:href="cphi-20221231.xsd#cphi_DeferredIncomeTaxLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_DeferredIncomeTaxLiabilityAbstract_lbl" xml:lang="en-US">Deferred income tax liability:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:to="cphi_DeferredIncomeTaxLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of assets and liabilities recorded at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomersLiabilityForAcceptancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomersLiabilityForAcceptancesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomersLiabilityForAcceptancesNet_lbl" xml:lang="en-US">Banker&#8217;s acceptance notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomersLiabilityForAcceptancesNet" xlink:to="us-gaap_CustomersLiabilityForAcceptancesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">RISKS &amp; UNCERTAINTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_lbl" xml:lang="en-US">Less: Imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LessOperatingLeaseLiabilitiesCurrentPortion" xlink:href="cphi-20221231.xsd#cphi_LessOperatingLeaseLiabilitiesCurrentPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cphi_LessOperatingLeaseLiabilitiesCurrentPortion_lbl" xml:lang="en-US">Less: Operating lease liabilities, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LessOperatingLeaseLiabilitiesCurrentPortion" xlink:to="cphi_LessOperatingLeaseLiabilitiesCurrentPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PermitOfLandUseMember" xlink:href="cphi-20221231.xsd#cphi_PermitOfLandUseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_PermitOfLandUseMember_lbl" xml:lang="en-US">Permit of land use [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PermitOfLandUseMember" xlink:to="cphi_PermitOfLandUseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Plant, machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_MotorVehicleMember" xlink:href="cphi-20221231.xsd#cphi_MotorVehicleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_MotorVehicleMember_lbl" xml:lang="en-US">Motor vehicle [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MotorVehicleMember" xlink:to="cphi_MotorVehicleMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnusedLinesOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusedLinesOfCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnusedLinesOfCreditMember_lbl" xml:lang="en-US">Lines of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusedLinesOfCreditMember" xlink:to="us-gaap_UnusedLinesOfCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskByBenchmarksAxis" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskByBenchmarksAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ConcentrationRiskByBenchmarksAxis_lbl" xml:lang="en-US">Concentration Risk By Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationRiskByBenchmarksAxis" xlink:to="cphi_ConcentrationRiskByBenchmarksAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskTypeAxis" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ConcentrationRiskTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationRiskTypeAxis" xlink:to="cphi_ConcentrationRiskTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity method investment, ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AccumulatedDeficit" xlink:href="cphi-20221231.xsd#cphi_AccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccumulatedDeficit" xlink:to="cphi_AccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalRequiredForCapitalAdequacy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalRequiredForCapitalAdequacy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalRequiredForCapitalAdequacy_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalRequiredForCapitalAdequacy" xlink:to="us-gaap_CapitalRequiredForCapitalAdequacy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Bad debt expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Uncollectible trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PurchaseOfCommonStockShares" xlink:href="cphi-20221231.xsd#cphi_PurchaseOfCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_PurchaseOfCommonStockShares_lbl" xml:lang="en-US">Purchase of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PurchaseOfCommonStockShares" xlink:to="cphi_PurchaseOfCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Shares issuable upon conversion of the convertible note payable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expanse</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsUsefulLifeDescription" xlink:href="cphi-20221231.xsd#cphi_IntangibleAssetsUsefulLifeDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_IntangibleAssetsUsefulLifeDescription_lbl" xml:lang="en-US">Intangible assets useful life, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsUsefulLifeDescription" xlink:to="cphi_IntangibleAssetsUsefulLifeDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense relating to intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Stock issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsStock_lbl" xml:lang="en-US">Common stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsStock" xlink:to="us-gaap_DividendsStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Closing price of common stock (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementAndServiceFeesRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd#us-gaap_ManagementAndServiceFeesRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManagementAndServiceFeesRate_lbl" xml:lang="en-US">Service fee percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementAndServiceFeesRate" xlink:to="us-gaap_ManagementAndServiceFeesRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Received advance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Repaid advance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedParties_lbl" xml:lang="en-US">Borrowings from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LoanAgreementToBorrowCash" xlink:href="cphi-20221231.xsd#cphi_LoanAgreementToBorrowCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_LoanAgreementToBorrowCash_lbl" xml:lang="en-US">Loan agreement to borrow cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAgreementToBorrowCash" xlink:to="cphi_LoanAgreementToBorrowCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Aggregate Note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CompensationConverted" xlink:href="cphi-20221231.xsd#cphi_CompensationConverted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CompensationConverted_lbl" xml:lang="en-US">Compensation converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CompensationConverted" xlink:to="cphi_CompensationConverted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Market price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionLoan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionLoan_lbl" xml:lang="en-US">Line of credit amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionLoan" xlink:to="us-gaap_ConstructionLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForMortgageDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForMortgageDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForMortgageDeposits_lbl" xml:lang="en-US">Advance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMortgageDeposits" xlink:to="us-gaap_PaymentsForMortgageDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Total interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Repaid remaining amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestRate" xlink:href="cphi-20221231.xsd#cphi_InterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRate" xlink:to="cphi_InterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Short-term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestAmount" xlink:href="cphi-20221231.xsd#cphi_InterestAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InterestAmount_lbl" xml:lang="en-US">Interest amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestAmount" xlink:to="cphi_InterestAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Notes matures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Original principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Investor consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OriginalIssueDiscount" xlink:href="cphi-20221231.xsd#cphi_OriginalIssueDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_OriginalIssueDiscount_lbl" xml:lang="en-US">Original issue discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OriginalIssueDiscount" xlink:to="cphi_OriginalIssueDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xml:lang="en-US">Note converted into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Converted common stock price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ConvertibleNote" xlink:href="cphi-20221231.xsd#cphi_ConvertibleNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ConvertibleNote_lbl" xml:lang="en-US">Convertible note (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConvertibleNote" xlink:to="cphi_ConvertibleNote_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ConvertibleNoteConversionPrice" xlink:href="cphi-20221231.xsd#cphi_ConvertibleNoteConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ConvertibleNoteConversionPrice_lbl" xml:lang="en-US">Convertible note conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConvertibleNoteConversionPrice" xlink:to="cphi_ConvertibleNoteConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestAccruesOnNoteDescription" xlink:href="cphi-20221231.xsd#cphi_InterestAccruesOnNoteDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InterestAccruesOnNoteDescription_lbl" xml:lang="en-US">Interest accrues on note, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestAccruesOnNoteDescription" xlink:to="cphi_InterestAccruesOnNoteDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RedeemOfOutstandingNote" xlink:href="cphi-20221231.xsd#cphi_RedeemOfOutstandingNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_RedeemOfOutstandingNote_lbl" xml:lang="en-US">Redeem of outstanding note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedeemOfOutstandingNote" xlink:to="cphi_RedeemOfOutstandingNote_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice" xlink:href="cphi-20221231.xsd#cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice_lbl" xml:lang="en-US">Percentage of common stock price on weighted average price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice" xlink:to="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_NoteRedeemableIntoShares" xlink:href="cphi-20221231.xsd#cphi_NoteRedeemableIntoShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_NoteRedeemableIntoShares_lbl" xml:lang="en-US">Note redeemable into shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NoteRedeemableIntoShares" xlink:to="cphi_NoteRedeemableIntoShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAveragePrice" xlink:href="cphi-20221231.xsd#cphi_WeightedAveragePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_WeightedAveragePrice_lbl" xml:lang="en-US">Weighted average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragePrice" xlink:to="cphi_WeightedAveragePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Total interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Common stock issued to investor (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Weighted average price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CommonStockIssuedToInvestor" xlink:href="cphi-20221231.xsd#cphi_CommonStockIssuedToInvestor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CommonStockIssuedToInvestor_lbl" xml:lang="en-US">Common stock issued to investor (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockIssuedToInvestor" xlink:to="cphi_CommonStockIssuedToInvestor_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CommonStockIssuedToInvestor1" xlink:href="cphi-20221231.xsd#cphi_CommonStockIssuedToInvestor1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CommonStockIssuedToInvestor1_lbl" xml:lang="en-US">Common stock issued to investor (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockIssuedToInvestor1" xlink:to="cphi_CommonStockIssuedToInvestor1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CashFlowForOperatingLease" xlink:href="cphi-20221231.xsd#cphi_CashFlowForOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CashFlowForOperatingLease_lbl" xml:lang="en-US">Cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CashFlowForOperatingLease" xlink:to="cphi_CashFlowForOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OperatingLeaseRightsOfUseAssets" xlink:href="cphi-20221231.xsd#cphi_OperatingLeaseRightsOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_OperatingLeaseRightsOfUseAssets_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OperatingLeaseRightsOfUseAssets" xlink:to="cphi_OperatingLeaseRightsOfUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAveragesRemainingLeaseTerm" xlink:href="cphi-20221231.xsd#cphi_WeightedAveragesRemainingLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_WeightedAveragesRemainingLeaseTerm_lbl" xml:lang="en-US">Weighted average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragesRemainingLeaseTerm" xlink:to="cphi_WeightedAveragesRemainingLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAverageDiscountRate" xlink:href="cphi-20221231.xsd#cphi_WeightedAverageDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_WeightedAverageDiscountRate_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAverageDiscountRate" xlink:to="cphi_WeightedAverageDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Enterprise income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards for PRC tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_NetOperatingLossCarryForwardsExpirationDescription" xlink:href="cphi-20221231.xsd#cphi_NetOperatingLossCarryForwardsExpirationDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_NetOperatingLossCarryForwardsExpirationDescription_lbl" xml:lang="en-US">Net operating loss expiration, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NetOperatingLossCarryForwardsExpirationDescription" xlink:to="cphi_NetOperatingLossCarryForwardsExpirationDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">U.S. federal corporate income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ValuationAllowanceForDeferredTaxAssets" xlink:href="cphi-20221231.xsd#cphi_ValuationAllowanceForDeferredTaxAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ValuationAllowanceForDeferredTaxAssets_lbl" xml:lang="en-US">Valuation allowance for deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ValuationAllowanceForDeferredTaxAssets" xlink:to="cphi_ValuationAllowanceForDeferredTaxAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AftertaxNetIncomePercentage" xlink:href="cphi-20221231.xsd#cphi_AftertaxNetIncomePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AftertaxNetIncomePercentage_lbl" xml:lang="en-US">After tax income, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AftertaxNetIncomePercentage" xlink:to="cphi_AftertaxNetIncomePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ReserveAccountBalancesPercentage" xlink:href="cphi-20221231.xsd#cphi_ReserveAccountBalancesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ReserveAccountBalancesPercentage_lbl" xml:lang="en-US">Reserve account balances, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ReserveAccountBalancesPercentage" xlink:to="cphi_ReserveAccountBalancesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_lbl" xml:lang="en-US">General and statutory capital reserves amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock and stock option granted and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_TotalOptionOutstanding" xlink:href="cphi-20221231.xsd#cphi_TotalOptionOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_TotalOptionOutstanding_lbl" xml:lang="en-US">Total option outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TotalOptionOutstanding" xlink:to="cphi_TotalOptionOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AdditionalSharesAvailableForIssuance" xlink:href="cphi-20221231.xsd#cphi_AdditionalSharesAvailableForIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AdditionalSharesAvailableForIssuance_lbl" xml:lang="en-US">Additional shares available for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdditionalSharesAvailableForIssuance" xlink:to="cphi_AdditionalSharesAvailableForIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CommonStockPursuant" xlink:href="cphi-20221231.xsd#cphi_CommonStockPursuant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CommonStockPursuant_lbl" xml:lang="en-US">Common stock pursuant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockPursuant" xlink:to="cphi_CommonStockPursuant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xml:lang="en-US">Compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ClosingMarketPrice" xlink:href="cphi-20221231.xsd#cphi_ClosingMarketPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ClosingMarketPrice_lbl" xml:lang="en-US">Closing market price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ClosingMarketPrice" xlink:to="cphi_ClosingMarketPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital_lbl" xml:lang="en-US">Additional shares of common stock (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="us-gaap_CommonStocksIncludingAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PurchaseofCommonStockShares" xlink:href="cphi-20221231.xsd#cphi_PurchaseofCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_PurchaseofCommonStockShares_lbl" xml:lang="en-US">Purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PurchaseofCommonStockShares" xlink:to="cphi_PurchaseofCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_FairValueOfOptionsGranted" xlink:href="cphi-20221231.xsd#cphi_FairValueOfOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_FairValueOfOptionsGranted_lbl" xml:lang="en-US">Fair value of options granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_FairValueOfOptionsGranted" xlink:to="cphi_FairValueOfOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnpaidCashCompensation" xlink:href="cphi-20221231.xsd#cphi_UnpaidCashCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnpaidCashCompensation_lbl" xml:lang="en-US">Total unpaid cash compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnpaidCashCompensation" xlink:to="cphi_UnpaidCashCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US">Fair value of options granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_MarketPricePerShare" xlink:href="cphi-20221231.xsd#cphi_MarketPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_MarketPricePerShare_lbl" xml:lang="en-US">Market price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MarketPricePerShare" xlink:to="cphi_MarketPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ExpectedLifes" xlink:href="cphi-20221231.xsd#cphi_ExpectedLifes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ExpectedLifes_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ExpectedLifes" xlink:to="cphi_ExpectedLifes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Unpaid compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskPercentage" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ConcentrationRiskPercentage_lbl" xml:lang="en-US">Concentrations risk, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationRiskPercentage" xlink:to="cphi_ConcentrationRiskPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_NumberOfCustomers" xlink:href="cphi-20221231.xsd#cphi_NumberOfCustomers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_NumberOfCustomers_lbl" xml:lang="en-US">Number of customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfCustomers" xlink:to="cphi_NumberOfCustomers_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_NumberOfSuppliers" xlink:href="cphi-20221231.xsd#cphi_NumberOfSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_NumberOfSuppliers_lbl" xml:lang="en-US">Number of suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfSuppliers" xlink:to="cphi_NumberOfSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InvestorRedemption" xlink:href="cphi-20221231.xsd#cphi_InvestorRedemption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InvestorRedemption_lbl" xml:lang="en-US">Investor redemption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InvestorRedemption" xlink:to="cphi_InvestorRedemption_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAveragePrices" xlink:href="cphi-20221231.xsd#cphi_WeightedAveragePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_WeightedAveragePrices_lbl" xml:lang="en-US">Weighted average price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragePrices" xlink:to="cphi_WeightedAveragePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CommonStockInvestor" xlink:href="cphi-20221231.xsd#cphi_CommonStockInvestor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CommonStockInvestor_lbl" xml:lang="en-US">Common stock investor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockInvestor" xlink:to="cphi_CommonStockInvestor_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_OrganizationAndNatureOfOperationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Organization and Nature of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:to="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_LiquidityAndGoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl" xml:lang="en-US">Advances to Suppliers and Advances from Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAH97Uj3CrYpCI3iMnN+zBsiA7R8Hc0PMjB8aYKuSvZFd8JBtZoOjmWf0KXzrZWbYK6sWg9BSB1dSM2htVGPahyLguSlQDTSZpy8M79KgRfS+D+TLoM1dD0QJL0/qByYobg=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestRateRiskPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_InterestRateRiskPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InterestRateRiskPolicyTextBlock_lbl" xml:lang="en-US">Interest Rate Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRateRiskPolicyTextBlock" xlink:to="cphi_InterestRateRiskPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OnnyInvestmentLimitedMember" xlink:href="cphi-20221231.xsd#cphi_OnnyInvestmentLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_OnnyInvestmentLimitedMember_lbl" xml:lang="en-US">Onny Investment Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OnnyInvestmentLimitedMember" xlink:to="cphi_OnnyInvestmentLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:href="cphi-20221231.xsd#cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember_lbl" xml:lang="en-US">Hainan Helpson Medical &amp; Biotechnology Co., Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:to="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ManagementMember_lbl" xml:lang="en-US">Management [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_BankOfChinaMember" xlink:href="cphi-20221231.xsd#cphi_BankOfChinaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_BankOfChinaMember_lbl" xml:lang="en-US">Bank of China [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankOfChinaMember" xlink:to="cphi_BankOfChinaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_BankOfCommunicationsMember" xlink:href="cphi-20221231.xsd#cphi_BankOfCommunicationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_BankOfCommunicationsMember_lbl" xml:lang="en-US">Bank of Communications [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankOfCommunicationsMember" xlink:to="cphi_BankOfCommunicationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ChinaCITICBankMember" xlink:href="cphi-20221231.xsd#cphi_ChinaCITICBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ChinaCITICBankMember_lbl" xml:lang="en-US">China CITIC Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChinaCITICBankMember" xlink:to="cphi_ChinaCITICBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember" xlink:href="cphi-20221231.xsd#cphi_HaikouHaiHongXinMicrofinanceCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember_lbl" xml:lang="en-US">Haikou HaiHongXin microfinance Co., Ltd., [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember" xlink:to="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_TwoThousandTenIncentivePlanMember" xlink:href="cphi-20221231.xsd#cphi_TwoThousandTenIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_TwoThousandTenIncentivePlanMember_lbl" xml:lang="en-US">2010 Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenIncentivePlanMember" xlink:to="cphi_TwoThousandTenIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_TwoThousandTenLongTermIncentivePlanMember" xlink:href="cphi-20221231.xsd#cphi_TwoThousandTenLongTermIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_TwoThousandTenLongTermIncentivePlanMember_lbl" xml:lang="en-US">2010 Long-Term Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenLongTermIncentivePlanMember" xlink:to="cphi_TwoThousandTenLongTermIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ChairpersonMember" xlink:href="cphi-20221231.xsd#cphi_ChairpersonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ChairpersonMember_lbl" xml:lang="en-US">Chairperson [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChairpersonMember" xlink:to="cphi_ChairpersonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue, Net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerOneMember" xlink:href="cphi-20221231.xsd#cphi_CustomerOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerOneMember" xlink:to="cphi_CustomerOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RawMaterialPurchasesMember" xlink:href="cphi-20221231.xsd#cphi_RawMaterialPurchasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_RawMaterialPurchasesMember_lbl" xml:lang="en-US">Raw Material Purchases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RawMaterialPurchasesMember" xlink:to="cphi_RawMaterialPurchasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersOneMember" xlink:href="cphi-20221231.xsd#cphi_SuppliersOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_SuppliersOneMember_lbl" xml:lang="en-US">Suppliers One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersOneMember" xlink:to="cphi_SuppliersOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersTwoMember" xlink:href="cphi-20221231.xsd#cphi_SuppliersTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_SuppliersTwoMember_lbl" xml:lang="en-US">Suppliers Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersTwoMember" xlink:to="cphi_SuppliersTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SalesRevenuesNetOneMember" xlink:href="cphi-20221231.xsd#cphi_SalesRevenuesNetOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_SalesRevenuesNetOneMember_lbl" xml:lang="en-US">Revenue One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenuesNetOneMember" xlink:to="cphi_SalesRevenuesNetOneMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_SalesRevenuesNetOneMember_lbl0" xml:lang="en-US">Sales Revenues Net One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenuesNetOneMember" xlink:to="cphi_SalesRevenuesNetOneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_SalesRevenuesNetTwoMember" xlink:href="cphi-20221231.xsd#cphi_SalesRevenuesNetTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_SalesRevenuesNetTwoMember_lbl" xml:lang="en-US">Revenue Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenuesNetTwoMember" xlink:to="cphi_SalesRevenuesNetTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SalesRevenuesNetThreeMember" xlink:href="cphi-20221231.xsd#cphi_SalesRevenuesNetThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_SalesRevenuesNetThreeMember_lbl" xml:lang="en-US">Revenue Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenuesNetThreeMember" xlink:to="cphi_SalesRevenuesNetThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerTwoMember" xlink:href="cphi-20221231.xsd#cphi_CustomerTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CustomerTwoMember_lbl" xml:lang="en-US">Customer Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerTwoMember" xlink:to="cphi_CustomerTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerThreeMember" xlink:href="cphi-20221231.xsd#cphi_CustomerThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CustomerThreeMember_lbl" xml:lang="en-US">Customer Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerThreeMember" xlink:to="cphi_CustomerThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersThreeMember" xlink:href="cphi-20221231.xsd#cphi_SuppliersThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_SuppliersThreeMember_lbl" xml:lang="en-US">Suppliers Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersThreeMember" xlink:to="cphi_SuppliersThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTable" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTable_lbl" xml:lang="en-US">Lines of Credit and Construction Loan Facility [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityTable" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityLineItems" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityLineItems_lbl" xml:lang="en-US">Lines of Credit and Construction Loan Facility [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityLineItems" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesTable" xlink:href="cphi-20221231.xsd#cphi_LeasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LeasesTable_lbl" xml:lang="en-US">Leases [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesTable" xlink:to="cphi_LeasesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LeasesLineItems_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesLineItems" xlink:to="cphi_LeasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTablesTable" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTablesTable_lbl" xml:lang="en-US">Lines of Credit and Construction Loan Facility (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityTablesTable" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems_lbl" xml:lang="en-US">Lines of Credit and Construction Loan Facility [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesTablesTable" xlink:href="cphi-20221231.xsd#cphi_LeasesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LeasesTablesTable_lbl" xml:lang="en-US">Leases (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesTablesTable" xlink:to="cphi_LeasesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesTablesLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_LeasesTablesLineItems_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesTablesLineItems" xlink:to="cphi_LeasesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" xlink:href="cphi-20221231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable_lbl" xml:lang="en-US">Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" xlink:to="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems" xlink:href="cphi-20221231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems" xlink:to="cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of operating lease liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable" xlink:to="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems_lbl" xml:lang="en-US">Schedule of Operating Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:to="cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" xlink:href="cphi-20221231.xsd#cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" xlink:to="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" xlink:href="cphi-20221231.xsd#cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" xlink:to="cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OrganizationandSignificantAccountingPoliciesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_OrganizationandSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OrganizationandSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Organization and Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsTable" xlink:to="cphi_OrganizationandSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Organization and Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RelatedPartyTransactionsDetailsTable" xlink:href="cphi-20221231.xsd#cphi_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RelatedPartyTransactionsDetailsTable" xlink:to="cphi_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="cphi_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable_lbl" xml:lang="en-US">Lines of Credit and Construction Loan Facility (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems_lbl" xml:lang="en-US">Lines of Credit and Construction Loan Facility (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesDetailsTable" xlink:to="cphi_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LeasesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases (Textual)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesDetailsLineItems" xlink:to="cphi_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_IncomeTaxesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IncomeTaxesDetailsTable" xlink:to="cphi_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_IncomeTaxesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IncomeTaxesDetailsLineItems" xlink:to="cphi_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_StockholdersEquityDetailsTable" xlink:href="cphi-20221231.xsd#cphi_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_StockholdersEquityDetailsTable" xlink:to="cphi_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_StockholdersEquityDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_StockholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_StockholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Stockholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_StockholdersEquityDetailsLineItems" xlink:to="cphi_StockholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskType_Domain" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskType_Domain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConcentrationRiskType_Domain_lbl" xml:lang="en-US">ConcentrationRiskType_ [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationRiskType_Domain" xlink:to="cphi_ConcentrationRiskType_Domain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ConcentrationRiskByBenchmarksDomain" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskByBenchmarksDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConcentrationRiskByBenchmarksDomain_lbl" xml:lang="en-US">ConcentrationRiskByBenchmarks [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationRiskByBenchmarksDomain" xlink:to="cphi_ConcentrationRiskByBenchmarksDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RisksUncertaintiesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_RisksUncertaintiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RisksUncertaintiesDetailsTable_lbl" xml:lang="en-US">Risks &amp; Uncertainties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="cphi_RisksUncertaintiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RisksUncertaintiesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_RisksUncertaintiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RisksUncertaintiesDetailsLineItems_lbl" xml:lang="en-US">Risks &amp; Uncertainties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RisksUncertaintiesDetailsLineItems" xlink:to="cphi_RisksUncertaintiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SubsequentEventsDetailsTable" xlink:href="cphi-20221231.xsd#cphi_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SubsequentEventsDetailsTable" xlink:to="cphi_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SubsequentEventsDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SubsequentEventsDetailsLineItems" xlink:to="cphi_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl0" xml:lang="en-US">Accounts receivable collected with banker&apos;s acceptances.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AccumulatedDeficit_lbl0" xml:lang="en-US">Amount of accumulated deficit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccumulatedDeficit" xlink:to="cphi_AccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdditionalSharesAvailableForIssuance_lbl0" xml:lang="en-US">Number of additional shares available for issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdditionalSharesAvailableForIssuance" xlink:to="cphi_AdditionalSharesAvailableForIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdvancesToSuppliers_lbl0" xml:lang="en-US">Advances to suppliers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliers" xlink:to="cphi_AdvancesToSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for advances to suppliers and advances from customers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AftertaxNetIncomePercentage_lbl0" xml:lang="en-US">After tax net income percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AftertaxNetIncomePercentage" xlink:to="cphi_AftertaxNetIncomePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_BankersAcceptances_lbl0" xml:lang="en-US">A banker&apos;s acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptances" xlink:to="cphi_BankersAcceptances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CashFlowForOperatingLease_lbl0" xml:lang="en-US">Cash flow for operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CashFlowForOperatingLease" xlink:to="cphi_CashFlowForOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ClosingMarketPrice_lbl0" xml:lang="en-US">The shares of closing market price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ClosingMarketPrice" xlink:to="cphi_ClosingMarketPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CommonStockInvestor_lbl0" xml:lang="en-US">The shares of common stock investor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockInvestor" xlink:to="cphi_CommonStockInvestor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CommonStockIssuedToInvestor_lbl0" xml:lang="en-US">Common stock issued to investor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockIssuedToInvestor" xlink:to="cphi_CommonStockIssuedToInvestor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CommonStockIssuedToInvestor1_lbl0" xml:lang="en-US">Common stock issued to investor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockIssuedToInvestor1" xlink:to="cphi_CommonStockIssuedToInvestor1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CommonStockPursuant_lbl0" xml:lang="en-US">The shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockPursuant" xlink:to="cphi_CommonStockPursuant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CompensationConverted_lbl0" xml:lang="en-US">Compensation Converted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CompensationConverted" xlink:to="cphi_CompensationConverted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ConcentrationRiskPercentage_lbl0" xml:lang="en-US">For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the &quot;benchmark&quot; (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationRiskPercentage" xlink:to="cphi_ConcentrationRiskPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ConversionOfOfficerWagesToCommonStock_lbl0" xml:lang="en-US">Conversion of officer wages to common stock&#xd;
..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConversionOfOfficerWagesToCommonStock" xlink:to="cphi_ConversionOfOfficerWagesToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ConvertibleNote_lbl0" xml:lang="en-US">The shares of convertible note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConvertibleNote" xlink:to="cphi_ConvertibleNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ConvertibleNoteConversionPrice_lbl0" xml:lang="en-US">Convertible note conversion price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConvertibleNoteConversionPrice" xlink:to="cphi_ConvertibleNoteConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_FairValueOfOptionsGranted_lbl0" xml:lang="en-US">The fair value of options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_FairValueOfOptionsGranted" xlink:to="cphi_FairValueOfOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_IntangibleAssetsUsefulLifeDescription_lbl0" xml:lang="en-US">Description of intangible assets useful life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsUsefulLifeDescription" xlink:to="cphi_IntangibleAssetsUsefulLifeDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_InterestAccruesOnNoteDescription_lbl0" xml:lang="en-US">Description of interest accrues on Note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestAccruesOnNoteDescription" xlink:to="cphi_InterestAccruesOnNoteDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_InterestRateRiskPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for interest rate risk.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRateRiskPolicyTextBlock" xlink:to="cphi_InterestRateRiskPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl0" xml:lang="en-US">The amount of inventory purchased with banker&amp;amp;#8217;s acceptances.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_InvestorRedemption_lbl0" xml:lang="en-US">The amount of investor redemption.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InvestorRedemption" xlink:to="cphi_InvestorRedemption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LessOperatingLeaseLiabilitiesCurrentPortion_lbl0" xml:lang="en-US">Less: Operating lease liabilities, current portion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LessOperatingLeaseLiabilitiesCurrentPortion" xlink:to="cphi_LessOperatingLeaseLiabilitiesCurrentPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Liquidity and Going Concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LoanAgreementToBorrowCash_lbl0" xml:lang="en-US">loan agreement to borrow cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAgreementToBorrowCash" xlink:to="cphi_LoanAgreementToBorrowCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_MarketPricePerShare_lbl0" xml:lang="en-US">Market price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MarketPricePerShare" xlink:to="cphi_MarketPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_MotorVehicleGross_lbl0" xml:lang="en-US">Amount before moto vehicle of tangible personal property used to produce goods and services, including, but is not limited to, tools, motor equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MotorVehicleGross" xlink:to="cphi_MotorVehicleGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_NetOperatingLossCarryForwardsExpirationDescription_lbl0" xml:lang="en-US">Net operating loss carry forward expiration date description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NetOperatingLossCarryForwardsExpirationDescription" xlink:to="cphi_NetOperatingLossCarryForwardsExpirationDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_NoteRedeemableIntoShares_lbl0" xml:lang="en-US">Number of shares redeemable by Notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NoteRedeemableIntoShares" xlink:to="cphi_NoteRedeemableIntoShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_NumberOfCustomers_lbl0" xml:lang="en-US">Number of customers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfCustomers" xlink:to="cphi_NumberOfCustomers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_NumberOfSuppliers_lbl0" xml:lang="en-US">Number of suppliers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfSuppliers" xlink:to="cphi_NumberOfSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_OfficeEquipmentGross_lbl0" xml:lang="en-US">Amount before office equipment of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OfficeEquipmentGross" xlink:to="cphi_OfficeEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl0" xml:lang="en-US">Present value of lessee&apos;s discounted obligation for lease payments from operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:to="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_OperatingLeaseRightsOfUseAssets_lbl0" xml:lang="en-US">Operating lease right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OperatingLeaseRightsOfUseAssets" xlink:to="cphi_OperatingLeaseRightsOfUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for organization and nature of operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:to="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_OriginalIssueDiscount_lbl0" xml:lang="en-US">Amount of  original issue discount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OriginalIssueDiscount" xlink:to="cphi_OriginalIssueDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Other receivables, less allowance for doubtful accounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:to="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice_lbl0" xml:lang="en-US">Percentage of common stock price on weighted average price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice" xlink:to="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_PurchaseOfCommonStockShares_lbl0" xml:lang="en-US">Purchase of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PurchaseOfCommonStockShares" xlink:to="cphi_PurchaseOfCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_PurchaseofCommonStockShares_lbl0" xml:lang="en-US">Purchase of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PurchaseofCommonStockShares" xlink:to="cphi_PurchaseofCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RedeemOfOutstandingNote_lbl0" xml:lang="en-US">Amount of redeem of outstanding note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedeemOfOutstandingNote" xlink:to="cphi_RedeemOfOutstandingNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_TotalOptionOutstanding_lbl0" xml:lang="en-US">Total option outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TotalOptionOutstanding" xlink:to="cphi_TotalOptionOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" xlink:to="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_UnpaidCashCompensation_lbl0" xml:lang="en-US">Amount of unpaid cash compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnpaidCashCompensation" xlink:to="cphi_UnpaidCashCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock_lbl0" xml:lang="en-US">Useful live of Assets table text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:to="cphi_UsefulLiveOfAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ValuationAllowanceForDeferredTaxAssets_lbl0" xml:lang="en-US">Valuation allowance for deferred tax assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ValuationAllowanceForDeferredTaxAssets" xlink:to="cphi_ValuationAllowanceForDeferredTaxAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_WeightedAverageDiscountRate_lbl0" xml:lang="en-US">Weighted average discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAverageDiscountRate" xlink:to="cphi_WeightedAverageDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_WeightedAveragePrice_lbl0" xml:lang="en-US">The weighted average price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragePrice" xlink:to="cphi_WeightedAveragePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_WeightedAveragePrices_lbl0" xml:lang="en-US">The percentage of weighted average price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragePrices" xlink:to="cphi_WeightedAveragePrices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_WeightedAveragesRemainingLeaseTerm_lbl0" xml:lang="en-US">Weighted average remaining lease term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragesRemainingLeaseTerm" xlink:to="cphi_WeightedAveragesRemainingLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CustomerOneMember_lbl0" xml:lang="en-US">Customer one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerOneMember" xlink:to="cphi_CustomerOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CustomerTwoMember_lbl0" xml:lang="en-US">Customer two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerTwoMember" xlink:to="cphi_CustomerTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_PermitOfLandUseMember_lbl0" xml:lang="en-US">Permit of land use.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PermitOfLandUseMember" xlink:to="cphi_PermitOfLandUseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RawMaterialPurchasesMember_lbl0" xml:lang="en-US">Raw material purchases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RawMaterialPurchasesMember" xlink:to="cphi_RawMaterialPurchasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_TwoThousandTenIncentivePlanMember_lbl0" xml:lang="en-US">Two thousand ten incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenIncentivePlanMember" xlink:to="cphi_TwoThousandTenIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl1" xml:lang="en-US">Other Receivables Less Allowance For Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:to="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerOneMember_lbl1" xml:lang="en-US">Customer One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerOneMember" xlink:to="cphi_CustomerOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity And Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OnnyInvestmentLimitedMember_lbl0" xml:lang="en-US">Onny Investment Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OnnyInvestmentLimitedMember" xlink:to="cphi_OnnyInvestmentLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TwoThousandTenLongTermIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand Ten Long Term Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenLongTermIncentivePlanMember" xlink:to="cphi_TwoThousandTenLongTermIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OperatingLeaseRightsOfUseAssets_lbl1" xml:lang="en-US">Operating Lease Rights Of Use Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OperatingLeaseRightsOfUseAssets" xlink:to="cphi_OperatingLeaseRightsOfUseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OriginalIssueDiscount_lbl1" xml:lang="en-US">Original Issue Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OriginalIssueDiscount" xlink:to="cphi_OriginalIssueDiscount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl0" xml:lang="en-US">Notes Payable, Related Parties, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_NumberOfSuppliers_lbl1" xml:lang="en-US">Number Of Suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfSuppliers" xlink:to="cphi_NumberOfSuppliers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl0" xml:lang="en-US">Machinery and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedParties_lbl0" xml:lang="en-US">Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CommonStockIssuedToInvestor1_lbl1" xml:lang="en-US">Common Stock Issued To Investor1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockIssuedToInvestor1" xlink:to="cphi_CommonStockIssuedToInvestor1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ManagementMember_lbl0" xml:lang="en-US">Management [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl0" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForMortgageDeposits_lbl0" xml:lang="en-US">Payments for Mortgage Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMortgageDeposits" xlink:to="us-gaap_PaymentsForMortgageDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl0" xml:lang="en-US">Stock or Unit Option Plan Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_MarketPricePerShare_lbl1" xml:lang="en-US">Market Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MarketPricePerShare" xlink:to="cphi_MarketPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AftertaxNetIncomePercentage_lbl1" xml:lang="en-US">Aftertax Net Income Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AftertaxNetIncomePercentage" xlink:to="cphi_AftertaxNetIncomePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl1" xml:lang="en-US">Inventory Purchased With Bankers Acceptance Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember_lbl0" xml:lang="en-US">Haikou Hai Hong Xin Microfinance Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember" xlink:to="cphi_HaikouHaiHongXinMicrofinanceCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SuppliersTwoMember_lbl0" xml:lang="en-US">Suppliers Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersTwoMember" xlink:to="cphi_SuppliersTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankersAcceptances_lbl1" xml:lang="en-US">Bankers Acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptances" xlink:to="cphi_BankersAcceptances_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PurchaseOfCommonStockShares_lbl1" xml:lang="en-US">Purchase Of Common Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PurchaseOfCommonStockShares" xlink:to="cphi_PurchaseOfCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl0" xml:lang="en-US">Debt, Weighted Average Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital_lbl0" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="us-gaap_CommonStocksIncludingAdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl0" xml:lang="en-US">Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract10" xlink:to="cphi_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract11" xlink:to="cphi_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract12" xlink:to="cphi_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_lbl1" xml:lang="en-US">Organization And Nature Of Operations Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:to="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl0" xml:lang="en-US">Interest Expense, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract2" xlink:to="cphi_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConcentrationRiskByBenchmarksAxis_lbl0" xml:lang="en-US">Concentration Risk By Benchmarks Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationRiskByBenchmarksAxis" xlink:to="cphi_ConcentrationRiskByBenchmarksAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract1" xlink:to="cphi_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract4" xlink:to="cphi_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract3" xlink:to="cphi_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConvertibleNote_lbl1" xml:lang="en-US">Convertible Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConvertibleNote" xlink:to="cphi_ConvertibleNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract0" xlink:to="cphi_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract9" xlink:to="cphi_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalRequiredForCapitalAdequacy_lbl0" xml:lang="en-US">Banking Regulation, Total Risk-Based Capital, Capital Adequacy, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalRequiredForCapitalAdequacy" xlink:to="us-gaap_CapitalRequiredForCapitalAdequacy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract6" xlink:to="cphi_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract5" xlink:to="cphi_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract8" xlink:to="cphi_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract7" xlink:to="cphi_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAndLandImprovements_lbl0" xml:lang="en-US">Land and Land Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndLandImprovements" xlink:to="us-gaap_LandAndLandImprovements_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract_lbl" xml:lang="en-US">Schedule Of Temporary Differences To Deferred Income Tax Assets And Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CompensationConverted_lbl1" xml:lang="en-US">Compensation Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CompensationConverted" xlink:to="cphi_CompensationConverted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0" xml:lang="en-US">Short-Term Bank Loans and Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RawMaterialPurchasesMember_lbl1" xml:lang="en-US">Raw Material Purchases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RawMaterialPurchasesMember" xlink:to="cphi_RawMaterialPurchasesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_DeferredIncomeTaxLiabilityAbstract_lbl0" xml:lang="en-US">Deferred Income Tax Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:to="cphi_DeferredIncomeTaxLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl0" xml:lang="en-US">Deferred Tax Assets, Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LoanAgreementToBorrowCash_lbl1" xml:lang="en-US">Loan Agreement To Borrow Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAgreementToBorrowCash" xlink:to="cphi_LoanAgreementToBorrowCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PurchaseofCommonStockShares_lbl1" xml:lang="en-US">Purchaseof Common Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PurchaseofCommonStockShares" xlink:to="cphi_PurchaseofCommonStockShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Operating Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract" xlink:to="cphi_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl0" xml:lang="en-US">Line of Credit, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl1" xml:lang="en-US">Advances To Suppliers And Advances From Customers Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvanceToSupplies_lbl0" xml:lang="en-US">Advance To Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvanceToSupplies" xlink:to="cphi_AdvanceToSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConvertibleNoteConversionPrice_lbl1" xml:lang="en-US">Convertible Note Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConvertibleNoteConversionPrice" xlink:to="cphi_ConvertibleNoteConversionPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CommonStockInvestor_lbl1" xml:lang="en-US">Common Stock Investor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockInvestor" xlink:to="cphi_CommonStockInvestor_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl0" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Financing Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_WeightedAveragePrice_lbl1" xml:lang="en-US">Weighted Average Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragePrice" xlink:to="cphi_WeightedAveragePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ReserveAccountBalancesPercentage_lbl0" xml:lang="en-US">Reserve Account Balances Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ReserveAccountBalancesPercentage" xlink:to="cphi_ReserveAccountBalancesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomersLiabilityForAcceptancesNet_lbl0" xml:lang="en-US">Customer&apos;s Liability for Acceptances, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomersLiabilityForAcceptancesNet" xlink:to="us-gaap_CustomersLiabilityForAcceptancesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember_lbl0" xml:lang="en-US">Hainan Helpson Medical Biotechnology Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:to="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_lbl0" xml:lang="en-US">Receivable with Imputed Interest, Net Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl0" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SuppliersOneMember_lbl0" xml:lang="en-US">Suppliers One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersOneMember" xlink:to="cphi_SuppliersOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract_lbl" xml:lang="en-US">Schedule Of Assets And Liabilities Recorded At Fair Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" xlink:to="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts_lbl1" xml:lang="en-US">Trade Accounts Receivable Less Allowance For Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" xlink:to="cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RedeemOfOutstandingNote_lbl1" xml:lang="en-US">Redeem Of Outstanding Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedeemOfOutstandingNote" xlink:to="cphi_RedeemOfOutstandingNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ChinaCITICBankMember_lbl0" xml:lang="en-US">China CITICBank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChinaCITICBankMember" xlink:to="cphi_ChinaCITICBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_WeightedAverageDiscountRate_lbl1" xml:lang="en-US">Weighted Average Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAverageDiscountRate" xlink:to="cphi_WeightedAverageDiscountRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ChairpersonMember_lbl0" xml:lang="en-US">Chairperson Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChairpersonMember" xlink:to="cphi_ChairpersonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfPrincipalPaymentsAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfPrincipalPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfPrincipalPaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Principal Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfPrincipalPaymentsAbstract" xlink:to="cphi_ScheduleOfPrincipalPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CommonStockPursuant_lbl1" xml:lang="en-US">Common Stock Pursuant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockPursuant" xlink:to="cphi_CommonStockPursuant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnusedLinesOfCreditMember_lbl0" xml:lang="en-US">Unused lines of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusedLinesOfCreditMember" xlink:to="us-gaap_UnusedLinesOfCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Lives Of The Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" xlink:to="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_WeightedAveragesRemainingLeaseTerm_lbl1" xml:lang="en-US">Weighted Averages Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragesRemainingLeaseTerm" xlink:to="cphi_WeightedAveragesRemainingLeaseTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AccumulatedDeficit_lbl1" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccumulatedDeficit" xlink:to="cphi_AccumulatedDeficit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_FairValueOfOptionsGranted_lbl1" xml:lang="en-US">Fair Value Of Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_FairValueOfOptionsGranted" xlink:to="cphi_FairValueOfOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsStock_lbl0" xml:lang="en-US">Dividends, Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsStock" xlink:to="us-gaap_DividendsStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InterestRateRiskPolicyTextBlock_lbl1" xml:lang="en-US">Interest Rate Risk Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRateRiskPolicyTextBlock" xlink:to="cphi_InterestRateRiskPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankOfCommunicationsMember_lbl0" xml:lang="en-US">Bank Of Communications Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankOfCommunicationsMember" xlink:to="cphi_BankOfCommunicationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnpaidCashCompensation_lbl1" xml:lang="en-US">Unpaid Cash Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnpaidCashCompensation" xlink:to="cphi_UnpaidCashCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl0" xml:lang="en-US">Notes Payable, Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl0" xml:lang="en-US">Interest and Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CashFlowForOperatingLease_lbl1" xml:lang="en-US">Cash Flow For Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CashFlowForOperatingLease" xlink:to="cphi_CashFlowForOperatingLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_NetOperatingLossCarryForwardsExpirationDescription_lbl1" xml:lang="en-US">Net Operating Loss Carry Forwards Expiration Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NetOperatingLossCarryForwardsExpirationDescription" xlink:to="cphi_NetOperatingLossCarryForwardsExpirationDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TradeAccountsReceivableLessAllowance_lbl0" xml:lang="en-US">Trade Accounts Receivable Less Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TradeAccountsReceivableLessAllowance" xlink:to="cphi_TradeAccountsReceivableLessAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_MotorVehicleGross_lbl1" xml:lang="en-US">Motor Vehicle Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MotorVehicleGross" xlink:to="cphi_MotorVehicleGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice_lbl1" xml:lang="en-US">Percentage Of Common Stock Price On Weighted Average Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice" xlink:to="cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerTwoMember_lbl1" xml:lang="en-US">Customer Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerTwoMember" xlink:to="cphi_CustomerTwoMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConcentrationRiskPercentage_lbl1" xml:lang="en-US">Concentration Risk Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationRiskPercentage" xlink:to="cphi_ConcentrationRiskPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SalesRevenuesNetTwoMember_lbl0" xml:lang="en-US">Sales Revenues Net Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenuesNetTwoMember" xlink:to="cphi_SalesRevenuesNetTwoMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SalesRevenuesNetThreeMember_lbl0" xml:lang="en-US">Sales Revenues Net Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenuesNetThreeMember" xlink:to="cphi_SalesRevenuesNetThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConstructionLoansPayable_lbl0" xml:lang="en-US">Repayments of Construction Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConstructionLoansPayable" xlink:to="us-gaap_RepaymentsOfConstructionLoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConversionOfOfficerWagesToCommonStock_lbl1" xml:lang="en-US">Conversion Of Officer Wages To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConversionOfOfficerWagesToCommonStock" xlink:to="cphi_ConversionOfOfficerWagesToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SuppliersThreeMember_lbl0" xml:lang="en-US">Suppliers Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersThreeMember" xlink:to="cphi_SuppliersThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_MotorVehicleMember_lbl0" xml:lang="en-US">Motor Vehicle Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MotorVehicleMember" xlink:to="cphi_MotorVehicleMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvancesToSuppliers_lbl1" xml:lang="en-US">Advances To Suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliers" xlink:to="cphi_AdvancesToSuppliers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdditionalSharesAvailableForIssuance_lbl1" xml:lang="en-US">Additional Shares Available For Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdditionalSharesAvailableForIssuance" xlink:to="cphi_AdditionalSharesAvailableForIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IntangibleAssetsUsefulLifeDescription_lbl1" xml:lang="en-US">Intangible Assets Useful Life Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsUsefulLifeDescription" xlink:to="cphi_IntangibleAssetsUsefulLifeDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl0" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_DeferredIncomeTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Income Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="cphi_DeferredIncomeTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermConstructionLoanCurrent_lbl0" xml:lang="en-US">Long-Term Construction Loan, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermConstructionLoanCurrent" xlink:to="us-gaap_LongTermConstructionLoanCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ExpectedLifes_lbl0" xml:lang="en-US">Expected Lifes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ExpectedLifes" xlink:to="cphi_ExpectedLifes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionLoan_lbl0" xml:lang="en-US">Construction Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionLoan" xlink:to="us-gaap_ConstructionLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InterestAmount_lbl0" xml:lang="en-US">Interest Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestAmount" xlink:to="cphi_InterestAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl0" xml:lang="en-US">Other Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Other Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl0" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerThreeMember_lbl0" xml:lang="en-US">Customer Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerThreeMember" xlink:to="cphi_CustomerThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InterestAccruesOnNoteDescription_lbl1" xml:lang="en-US">Interest Accrues On Note Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestAccruesOnNoteDescription" xlink:to="cphi_InterestAccruesOnNoteDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl1" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OfficeEquipmentGross_lbl1" xml:lang="en-US">Office Equipment Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OfficeEquipmentGross" xlink:to="cphi_OfficeEquipmentGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl0" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Other, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ClosingMarketPrice_lbl1" xml:lang="en-US">Closing Market Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ClosingMarketPrice" xlink:to="cphi_ClosingMarketPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ValuationAllowanceForDeferredTaxAssets_lbl1" xml:lang="en-US">Valuation Allowance For Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ValuationAllowanceForDeferredTaxAssets" xlink:to="cphi_ValuationAllowanceForDeferredTaxAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock_lbl1" xml:lang="en-US">Useful Live Of Assets Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:to="cphi_UsefulLiveOfAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TwoThousandTenIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand Ten Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenIncentivePlanMember" xlink:to="cphi_TwoThousandTenIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems_lbl0" xml:lang="en-US">Linesof Creditand Construction Loan Facility Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems" xlink:to="cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InterestRate_lbl0" xml:lang="en-US">Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRate" xlink:to="cphi_InterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingsAndImprovementsGross_lbl0" xml:lang="en-US">Buildings and Improvements, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingsAndImprovementsGross" xlink:to="us-gaap_BuildingsAndImprovementsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TotalOptionOutstanding_lbl1" xml:lang="en-US">Total Option Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TotalOptionOutstanding" xlink:to="cphi_TotalOptionOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl1" xml:lang="en-US">Operating Lease Liabilities Net Of Current Portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:to="cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PermitOfLandUseMember_lbl1" xml:lang="en-US">Permit Of Land Use Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PermitOfLandUseMember" xlink:to="cphi_PermitOfLandUseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_lbl0" xml:lang="en-US">Statutory Accounting Practices, Statutory Net Income Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankOfChinaMember_lbl0" xml:lang="en-US">Bank Of China Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankOfChinaMember" xlink:to="cphi_BankOfChinaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CommonStockIssuedToInvestor_lbl1" xml:lang="en-US">Common Stock Issued To Investor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CommonStockIssuedToInvestor" xlink:to="cphi_CommonStockIssuedToInvestor_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl1" xml:lang="en-US">Accounts Receivable Collected With Bankers Acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl0" xml:lang="en-US">Long-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LeasesTablesLineItems_lbl0" xml:lang="en-US">Leases Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesTablesLineItems" xlink:to="cphi_LeasesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl0" xml:lang="en-US">Selling Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_NoteRedeemableIntoShares_lbl1" xml:lang="en-US">Note Redeemable Into Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NoteRedeemableIntoShares" xlink:to="cphi_NoteRedeemableIntoShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_WeightedAveragePrices_lbl1" xml:lang="en-US">Weighted Average Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragePrices" xlink:to="cphi_WeightedAveragePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConcentrationRiskTypeAxis_lbl0" xml:lang="en-US">Concentration Risk Type Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationRiskTypeAxis" xlink:to="cphi_ConcentrationRiskTypeAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InvestorRedemption_lbl1" xml:lang="en-US">Investor Redemption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InvestorRedemption" xlink:to="cphi_InvestorRedemption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_NumberOfCustomers_lbl1" xml:lang="en-US">Number Of Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfCustomers" xlink:to="cphi_NumberOfCustomers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SalesRevenuesNetOneMember_lbl1" xml:lang="en-US">Sales Revenues Net One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenuesNetOneMember" xlink:to="cphi_SalesRevenuesNetOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementAndServiceFeesRate_lbl0" xml:lang="en-US">ManagementAndServiceFeesRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementAndServiceFeesRate" xlink:to="us-gaap_ManagementAndServiceFeesRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent_lbl0" xml:lang="en-US">Due to Other Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LessOperatingLeaseLiabilitiesCurrentPortion_lbl1" xml:lang="en-US">Less Operating Lease Liabilities Current Portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LessOperatingLeaseLiabilitiesCurrentPortion" xlink:to="cphi_LessOperatingLeaseLiabilitiesCurrentPortion_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>cphi-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 20:27:51 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedBalanceSheet" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedIncomeStatement" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ShareholdersEquityType2or3" roleURI="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConsolidatedCashFlow" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_OrganizationandSignificantAccountingPolicies" roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_Inventory" roleURI="http://www.chinapharmaholdings.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_PropertyPlantandEquipment" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IntangibleAssets" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_OtherPayables" roleURI="http://www.chinapharmaholdings.com/role/OtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_RelatedPartyTransactions" roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LinesofCreditandConstructionLoanFacility" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConvertibleNotePayable" roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_Leases" roleURI="http://www.chinapharmaholdings.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IncomeTaxes" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_FairValueMeasurements" roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_StockholdersEquity" roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_RisksUncertainties" roleURI="http://www.chinapharmaholdings.com/role/RisksUncertainties"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_SubsequentEvents" roleURI="http://www.chinapharmaholdings.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_AccountingPoliciesByPolicy" roleURI="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_InventoryTables" roleURI="http://www.chinapharmaholdings.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_PropertyPlantandEquipmentTables" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IntangibleAssetsTables" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_OtherPayablesTables" roleURI="http://www.chinapharmaholdings.com/role/OtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LinesofCreditandConstructionLoanFacilityTables" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LeasesTables" roleURI="http://www.chinapharmaholdings.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IncomeTaxesTables" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_FairValueMeasurementsTables" roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofinventoryTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofestimatedusefullivesoftheassetsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofintangibleassetsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofaggregateannualamortizationexpenseTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofotherpayablesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofprincipalpaymentsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofoperatingleaseliabilitiesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ScheduleofassetsandliabilitiesrecordedatfairvalueTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_OrganizationandSignificantAccountingPoliciesDetails" roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_PropertyPlantandEquipmentDetails" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IntangibleAssetsDetails" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_RelatedPartyTransactionsDetails" roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LinesofCreditandConstructionLoanFacilityDetails" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_ConvertibleNotePayableDetails" roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_LeasesDetails" roleURI="http://www.chinapharmaholdings.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_IncomeTaxesDetails" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_StockholdersEquityDetails" roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_RisksUncertaintiesDetails" roleURI="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#cphi_r_SubsequentEventsDetails" roleURI="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BankersAcceptances" xlink:href="cphi-20221231.xsd#cphi_BankersAcceptances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="BankersAcceptances" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20221231.xsd#cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="TradeAccountsReceivableLessAllowanceForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceToSupplies" xlink:href="cphi-20221231.xsd#cphi_AdvanceToSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="AdvanceToSupplies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_InventoryNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermConstructionLoanCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermConstructionLoanCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermConstructionLoanCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="TradeAccountsReceivableLessAllowance" xlink:href="cphi-20221231.xsd#cphi_TradeAccountsReceivableLessAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="TradeAccountsReceivableLessAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20221231.xsd#cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="OtherReceivablesLessAllowanceForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliers" xlink:href="cphi-20221231.xsd#cphi_AdvancesToSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="AdvancesToSuppliers" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConstructionLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConstructionLoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConstructionLoansPayable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableCollectedWithBankersAcceptances" xlink:href="cphi-20221231.xsd#cphi_AccountsReceivableCollectedWithBankersAcceptances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="AccountsReceivableCollectedWithBankersAcceptances" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoryPurchasedWithBankersAcceptanceNote" xlink:href="cphi-20221231.xsd#cphi_InventoryPurchasedWithBankersAcceptanceNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="InventoryPurchasedWithBankersAcceptanceNote" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfOfficerWagesToCommonStock" xlink:href="cphi-20221231.xsd#cphi_ConversionOfOfficerWagesToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConversionOfOfficerWagesToCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OtherPayables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LinesofCreditandConstructionLoanFacilityTable" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityTable"/>
    <loc xlink:type="locator" xlink:label="LinesofCreditandConstructionLoanFacilityLineItems" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="LinesofCreditandConstructionLoanFacilityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityTable" xlink:to="LinesofCreditandConstructionLoanFacilityLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityLineItems" xlink:to="us-gaap_LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesTable" xlink:href="cphi-20221231.xsd#cphi_LeasesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="LeasesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesTable" xlink:to="LeasesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RisksUncertainties">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_OrganizationAndNatureOfOperationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationAndNatureOfOperationsPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndGoingConcernPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_LiquidityAndGoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityAndGoingConcernPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateRiskPolicyTextBlock" xlink:href="cphi-20221231.xsd#cphi_InterestRateRiskPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="InterestRateRiskPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UsefulLiveOfAssetsTableTextBlock" xlink:href="cphi-20221231.xsd#cphi_UsefulLiveOfAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="UsefulLiveOfAssetsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OtherPayablesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LinesofCreditandConstructionLoanFacilityTablesTable" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityTablesTable"/>
    <loc xlink:type="locator" xlink:label="LinesofCreditandConstructionLoanFacilityTablesLineItems" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="LinesofCreditandConstructionLoanFacilityTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityTablesTable" xlink:to="LinesofCreditandConstructionLoanFacilityTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityTablesLineItems" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesTablesTable" xlink:href="cphi-20221231.xsd#cphi_LeasesTablesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesTablesLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="LeasesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesTablesTable" xlink:to="LeasesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesTablesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndLandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LandAndLandImprovements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_BuildingsAndImprovementsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_MachineryAndEquipmentGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MotorVehicleGross" xlink:href="cphi-20221231.xsd#cphi_MotorVehicleGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="MotorVehicleGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeEquipmentGross" xlink:href="cphi-20221231.xsd#cphi_OfficeEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="OfficeEquipmentGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OfficeEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" xlink:href="cphi-20221231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems" xlink:href="cphi-20221231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" xlink:to="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PermitOfLandUseMember" xlink:href="cphi-20221231.xsd#cphi_PermitOfLandUseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="PermitOfLandUseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MotorVehicleMember" xlink:href="cphi-20221231.xsd#cphi_MotorVehicleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MotorVehicleMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable" xlink:to="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherPayablesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherPayablesAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAH97Uj3CrYpCI3iMnN+zBsiA7R8Hc0PMjB8aYKuSvZFd8JBtZoOjmWf0KXzrZWbYK6sWg9BSB1dSM2htVGPahyLguSlQDTSZpy8M79KgRfS+LzpFCTXULDVnEwWOed3I10=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherPayablesAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherPayablesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrincipalPaymentsAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfPrincipalPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnusedLinesOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusedLinesOfCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_UnusedLinesOfCreditMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofoperatingleaseliabilitiesTable" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="LeasesDetailsScheduleofoperatingleaseliabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofoperatingleaseliabilitiesTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofoperatingleaseliabilitiesTable" xlink:to="LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LessOperatingLeaseLiabilitiesCurrentPortion" xlink:href="cphi-20221231.xsd#cphi_LessOperatingLeaseLiabilitiesCurrentPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:to="LessOperatingLeaseLiabilitiesCurrentPortion" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:href="cphi-20221231.xsd#cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems" xlink:to="OperatingLeaseLiabilitiesNetOfCurrentPortion" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredIncomeTaxAssetsAbstract" xlink:href="cphi-20221231.xsd#cphi_DeferredIncomeTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="DeferredIncomeTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredIncomeTaxLiabilityAbstract" xlink:href="cphi-20221231.xsd#cphi_DeferredIncomeTaxLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="DeferredIncomeTaxLiabilityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxLiabilityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" xlink:href="cphi-20221231.xsd#cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" xlink:href="cphi-20221231.xsd#cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" xlink:href="cphi-20221231.xsd#cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" xlink:to="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable" xlink:to="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomersLiabilityForAcceptancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomersLiabilityForAcceptancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" xlink:to="us-gaap_CustomersLiabilityForAcceptancesNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandSignificantAccountingPoliciesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_OrganizationandSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationandSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ManagementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OnnyInvestmentLimitedMember" xlink:href="cphi-20221231.xsd#cphi_OnnyInvestmentLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="OnnyInvestmentLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:href="cphi-20221231.xsd#cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="HainanHelpsonMedicalBiotechnologyCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsTable" xlink:to="OrganizationandSignificantAccountingPoliciesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDeficit" xlink:href="cphi-20221231.xsd#cphi_AccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="AccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalRequiredForCapitalAdequacy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalRequiredForCapitalAdequacy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CapitalRequiredForCapitalAdequacy" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfCommonStockShares" xlink:href="cphi-20221231.xsd#cphi_PurchaseOfCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="PurchaseOfCommonStockShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsUsefulLifeDescription" xlink:href="cphi-20221231.xsd#cphi_IntangibleAssetsUsefulLifeDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsUsefulLifeDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_DividendsStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementAndServiceFeesRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd#us-gaap_ManagementAndServiceFeesRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ManagementAndServiceFeesRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="cphi-20221231.xsd#cphi_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ManagementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_InterestExpenseRelatedParty" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAgreementToBorrowCash" xlink:href="cphi-20221231.xsd#cphi_LoanAgreementToBorrowCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="LoanAgreementToBorrowCash" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_OtherNotesPayable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_NotesPayable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationConverted" xlink:href="cphi-20221231.xsd#cphi_CompensationConverted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="CompensationConverted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="LinesofCreditandConstructionLoanFacilityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BankOfChinaMember" xlink:href="cphi-20221231.xsd#cphi_BankOfChinaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BankOfChinaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BankOfCommunicationsMember" xlink:href="cphi-20221231.xsd#cphi_BankOfCommunicationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BankOfCommunicationsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChinaCITICBankMember" xlink:href="cphi-20221231.xsd#cphi_ChinaCITICBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChinaCITICBankMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HaikouHaiHongXinMicrofinanceCoLtdMember" xlink:href="cphi-20221231.xsd#cphi_HaikouHaiHongXinMicrofinanceCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="HaikouHaiHongXinMicrofinanceCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsTable" xlink:to="LinesofCreditandConstructionLoanFacilityDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionLoan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_ConstructionLoan" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForMortgageDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForMortgageDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_PaymentsForMortgageDeposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_InterestExpenseOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate" xlink:href="cphi-20221231.xsd#cphi_InterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="InterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestAmount" xlink:href="cphi-20221231.xsd#cphi_InterestAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="InterestAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LinesofCreditandConstructionLoanFacilityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ConvertibleNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalIssueDiscount" xlink:href="cphi-20221231.xsd#cphi_OriginalIssueDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="OriginalIssueDiscount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNote" xlink:href="cphi-20221231.xsd#cphi_ConvertibleNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ConvertibleNote" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNoteConversionPrice" xlink:href="cphi-20221231.xsd#cphi_ConvertibleNoteConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ConvertibleNoteConversionPrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestAccruesOnNoteDescription" xlink:href="cphi-20221231.xsd#cphi_InterestAccruesOnNoteDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="InterestAccruesOnNoteDescription" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedeemOfOutstandingNote" xlink:href="cphi-20221231.xsd#cphi_RedeemOfOutstandingNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="RedeemOfOutstandingNote" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonStockPriceOnWeightedAveragePrice" xlink:href="cphi-20221231.xsd#cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="PercentageOfCommonStockPriceOnWeightedAveragePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoteRedeemableIntoShares" xlink:href="cphi-20221231.xsd#cphi_NoteRedeemableIntoShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NoteRedeemableIntoShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAveragePrice" xlink:href="cphi-20221231.xsd#cphi_WeightedAveragePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="WeightedAveragePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestAndDebtExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_SharesIssued" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtWeightedAverageInterestRate" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedToInvestor" xlink:href="cphi-20221231.xsd#cphi_CommonStockIssuedToInvestor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="CommonStockIssuedToInvestor" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedToInvestor1" xlink:href="cphi-20221231.xsd#cphi_CommonStockIssuedToInvestor1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="CommonStockIssuedToInvestor1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowForOperatingLease" xlink:href="cphi-20221231.xsd#cphi_CashFlowForOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="CashFlowForOperatingLease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseRightsOfUseAssets" xlink:href="cphi-20221231.xsd#cphi_OperatingLeaseRightsOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="OperatingLeaseRightsOfUseAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAveragesRemainingLeaseTerm" xlink:href="cphi-20221231.xsd#cphi_WeightedAveragesRemainingLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="WeightedAveragesRemainingLeaseTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRate" xlink:href="cphi-20221231.xsd#cphi_WeightedAverageDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="WeightedAverageDiscountRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOperatingLossCarryForwardsExpirationDescription" xlink:href="cphi-20221231.xsd#cphi_NetOperatingLossCarryForwardsExpirationDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="NetOperatingLossCarryForwardsExpirationDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationAllowanceForDeferredTaxAssets" xlink:href="cphi-20221231.xsd#cphi_ValuationAllowanceForDeferredTaxAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="ValuationAllowanceForDeferredTaxAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="cphi-20221231.xsd#cphi_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_StockholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTenLongTermIncentivePlanMember" xlink:href="cphi-20221231.xsd#cphi_TwoThousandTenLongTermIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="TwoThousandTenLongTermIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChairpersonMember" xlink:href="cphi-20221231.xsd#cphi_ChairpersonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ChairpersonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTenIncentivePlanMember" xlink:href="cphi-20221231.xsd#cphi_TwoThousandTenIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTenIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="StockholdersEquityDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AftertaxNetIncomePercentage" xlink:href="cphi-20221231.xsd#cphi_AftertaxNetIncomePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="AftertaxNetIncomePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveAccountBalancesPercentage" xlink:href="cphi-20221231.xsd#cphi_ReserveAccountBalancesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ReserveAccountBalancesPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalOptionOutstanding" xlink:href="cphi-20221231.xsd#cphi_TotalOptionOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="TotalOptionOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalSharesAvailableForIssuance" xlink:href="cphi-20221231.xsd#cphi_AdditionalSharesAvailableForIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="AdditionalSharesAvailableForIssuance" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockPursuant" xlink:href="cphi-20221231.xsd#cphi_CommonStockPursuant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CommonStockPursuant" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClosingMarketPrice" xlink:href="cphi-20221231.xsd#cphi_ClosingMarketPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ClosingMarketPrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseofCommonStockShares" xlink:href="cphi-20221231.xsd#cphi_PurchaseofCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="PurchaseofCommonStockShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfOptionsGranted" xlink:href="cphi-20221231.xsd#cphi_FairValueOfOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="FairValueOfOptionsGranted" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidCashCompensation" xlink:href="cphi-20221231.xsd#cphi_UnpaidCashCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="UnpaidCashCompensation" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketPricePerShare" xlink:href="cphi-20221231.xsd#cphi_MarketPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="MarketPricePerShare" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedLifes" xlink:href="cphi-20221231.xsd#cphi_ExpectedLifes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ExpectedLifes" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RisksUncertaintiesDetailsTable" xlink:href="cphi-20221231.xsd#cphi_RisksUncertaintiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RisksUncertaintiesDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_RisksUncertaintiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="RisksUncertaintiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskTypeAxis" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="ConcentrationRiskTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskType_Domain" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskType_Domain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeAxis" xlink:to="ConcentrationRiskType_Domain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SuppliersOneMember" xlink:href="cphi-20221231.xsd#cphi_SuppliersOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SuppliersOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SuppliersTwoMember" xlink:href="cphi-20221231.xsd#cphi_SuppliersTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SuppliersTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SuppliersThreeMember" xlink:href="cphi-20221231.xsd#cphi_SuppliersThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SuppliersThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskByBenchmarksAxis" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskByBenchmarksAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="ConcentrationRiskByBenchmarksAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskByBenchmarksDomain" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskByBenchmarksDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarksAxis" xlink:to="ConcentrationRiskByBenchmarksDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarksAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarksAxis" xlink:to="us-gaap_AccountsReceivableMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RawMaterialPurchasesMember" xlink:href="cphi-20221231.xsd#cphi_RawMaterialPurchasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarksAxis" xlink:to="RawMaterialPurchasesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesRevenuesNetOneMember" xlink:href="cphi-20221231.xsd#cphi_SalesRevenuesNetOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarksAxis" xlink:to="SalesRevenuesNetOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesRevenuesNetTwoMember" xlink:href="cphi-20221231.xsd#cphi_SalesRevenuesNetTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarksAxis" xlink:to="SalesRevenuesNetTwoMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesRevenuesNetThreeMember" xlink:href="cphi-20221231.xsd#cphi_SalesRevenuesNetThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarksAxis" xlink:to="SalesRevenuesNetThreeMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember_1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_AccountsReceivableMember_1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerOneMember" xlink:href="cphi-20221231.xsd#cphi_CustomerOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerTwoMember" xlink:href="cphi-20221231.xsd#cphi_CustomerTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerThreeMember" xlink:href="cphi-20221231.xsd#cphi_CustomerThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="RisksUncertaintiesDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskPercentage" xlink:href="cphi-20221231.xsd#cphi_ConcentrationRiskPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsLineItems" xlink:to="ConcentrationRiskPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfCustomers" xlink:href="cphi-20221231.xsd#cphi_NumberOfCustomers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsLineItems" xlink:to="NumberOfCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSuppliers" xlink:href="cphi-20221231.xsd#cphi_NumberOfSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsLineItems" xlink:to="NumberOfSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="cphi-20221231.xsd#cphi_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="cphi-20221231.xsd#cphi_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InvestorRedemption" xlink:href="cphi-20221231.xsd#cphi_InvestorRedemption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="InvestorRedemption" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAveragePrices" xlink:href="cphi-20221231.xsd#cphi_WeightedAveragePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="WeightedAveragePrices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockInvestor" xlink:href="cphi-20221231.xsd#cphi_CommonStockInvestor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="CommonStockInvestor" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="cphi-20221231.xsd#cphi_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533182191168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">China Pharma Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPHI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,458,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,601,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001106644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">73-1564807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Second Floor, No. 17, Jinpan Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Haikou<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hainan Province<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">570216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">898-6681-1730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">B F Borgers CPA PC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Lakewood,
Colorado<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">5041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533175864320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,029,971<span></span>
</td>
<td class="nump">$ 4,859,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_BankersAcceptances', window );">Banker&#8217;s acceptances</a></td>
<td class="nump">13,784<span></span>
</td>
<td class="nump">91,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts', window );">Trade accounts receivable, less allowance for doubtful accounts of $16,739,527 and $18,312,707, respectively</a></td>
<td class="nump">421,531<span></span>
</td>
<td class="nump">714,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables, less allowance for doubtful accounts of $27,149 and $32,210, respectively</a></td>
<td class="nump">29,139<span></span>
</td>
<td class="nump">29,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AdvanceToSupplies', window );">Advances to suppliers</a></td>
<td class="nump">444,637<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,947,787<span></span>
</td>
<td class="nump">3,339,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">77,697<span></span>
</td>
<td class="nump">58,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">5,964,546<span></span>
</td>
<td class="nump">9,093,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">9,973,065<span></span>
</td>
<td class="nump">13,280,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">39,046<span></span>
</td>
<td class="nump">127,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,807,486<span></span>
</td>
<td class="nump">147,841<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">17,784,143<span></span>
</td>
<td class="nump">22,649,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">667,082<span></span>
</td>
<td class="nump">926,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">404,807<span></span>
</td>
<td class="nump">298,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="nump">2,390,063<span></span>
</td>
<td class="nump">1,884,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Advances from customers</a></td>
<td class="nump">520,295<span></span>
</td>
<td class="nump">210,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Borrowings from related parties</a></td>
<td class="nump">2,475,840<span></span>
</td>
<td class="nump">2,779,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">40,445<span></span>
</td>
<td class="nump">85,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Current portion of lines of credit</a></td>
<td class="nump">2,440,915<span></span>
</td>
<td class="nump">4,328,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermConstructionLoanCurrent', window );">Convertible, redeemable note payable, net of issue discount</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">12,739,447<span></span>
</td>
<td class="nump">10,513,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible, redeemable note payable, net of issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">754,698<span></span>
</td>
<td class="nump">824,407<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">13,494,145<span></span>
</td>
<td class="nump">16,631,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 500,000,000 shares authorized; 7,490,896 shares and 4,733,956 shares issued and outstanding, respectively</a></td>
<td class="nump">74,909<span></span>
</td>
<td class="nump">47,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">28,853,520<span></span>
</td>
<td class="nump">25,645,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(36,211,496)<span></span>
</td>
<td class="num">(32,238,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">11,573,065<span></span>
</td>
<td class="nump">12,563,829<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">4,289,998<span></span>
</td>
<td class="nump">6,017,881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 17,784,143<span></span>
</td>
<td class="nump">$ 22,649,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvanceToSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvanceToSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_BankersAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A banker's acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_BankersAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade accounts receivable, less allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermConstructionLoanCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermConstructionLoanCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533175952960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_TradeAccountsReceivableLessAllowance', window );">Trade accounts receivable, less allowance for doubtful accounts (in Dollars)</a></td>
<td class="nump">$ 16,739,527<span></span>
</td>
<td class="nump">$ 18,312,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts', window );">Other receivables, less allowance for doubtful accounts (in Dollars)</a></td>
<td class="nump">$ 27,149<span></span>
</td>
<td class="nump">$ 32,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,490,896<span></span>
</td>
<td class="nump">4,733,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,490,896<span></span>
</td>
<td class="nump">4,733,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other receivables, less allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_TradeAccountsReceivableLessAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_TradeAccountsReceivableLessAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533175836496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 8,104,092<span></span>
</td>
<td class="nump">$ 9,641,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">8,598,008<span></span>
</td>
<td class="nump">9,292,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross (loss) profit</a></td>
<td class="num">(493,916)<span></span>
</td>
<td class="nump">349,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">1,069,785<span></span>
</td>
<td class="nump">1,495,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,893,269<span></span>
</td>
<td class="nump">1,651,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">185,858<span></span>
</td>
<td class="nump">318,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt benefit</a></td>
<td class="num">(93,851)<span></span>
</td>
<td class="num">(255,215)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,055,061<span></span>
</td>
<td class="nump">3,209,780<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,548,977)<span></span>
</td>
<td class="num">(2,860,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">10,755<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(434,619)<span></span>
</td>
<td class="num">(542,001)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Net other expense</a></td>
<td class="num">(423,864)<span></span>
</td>
<td class="num">(538,966)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(3,972,841)<span></span>
</td>
<td class="num">(3,399,476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,972,841)<span></span>
</td>
<td class="num">(3,399,476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income (loss) - foreign currency translation adjustment</a></td>
<td class="num">(990,764)<span></span>
</td>
<td class="nump">218,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (4,963,605)<span></span>
</td>
<td class="num">$ (3,181,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding (in Shares)</a></td>
<td class="nump">5,256,855<span></span>
</td>
<td class="nump">4,612,926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533183291632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533182214816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Deficit</div></th>
<th class="th"><div>Accumulated Other	Comprehensive Income</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 45,580<span></span>
</td>
<td class="nump">$ 24,452,684<span></span>
</td>
<td class="num">$ (28,839,179)<span></span>
</td>
<td class="nump">$ 12,345,446<span></span>
</td>
<td class="nump">$ 8,004,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">4,557,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock in lieu of compensation</a></td>
<td class="nump">$ 1,760<span></span>
</td>
<td class="nump">1,177,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in lieu of compensation (in Shares)</a></td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,399,476)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,399,476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">218,383<span></span>
</td>
<td class="nump">218,383<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 47,340<span></span>
</td>
<td class="nump">25,645,367<span></span>
</td>
<td class="num">(32,238,655)<span></span>
</td>
<td class="nump">12,563,829<span></span>
</td>
<td class="nump">6,017,881<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">4,733,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for intangible assets</a></td>
<td class="nump">$ 15,522<span></span>
</td>
<td class="nump">1,691,930<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,707,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for intangible assets (in Shares)</a></td>
<td class="nump">1,552,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">41,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock for services (in Shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of note payable to common stock</a></td>
<td class="nump">$ 11,747<span></span>
</td>
<td class="nump">1,438,253<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of note payable to common stock (in Shares)</a></td>
<td class="nump">1,174,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">36,270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,972,841)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,972,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(990,764)<span></span>
</td>
<td class="num">(990,764)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 74,909<span></span>
</td>
<td class="nump">$ 28,853,520<span></span>
</td>
<td class="num">$ (36,211,496)<span></span>
</td>
<td class="nump">$ 11,573,065<span></span>
</td>
<td class="nump">$ 4,289,998<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">7,490,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533174483744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,972,841)<span></span>
</td>
<td class="num">$ (3,399,476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,700,533<span></span>
</td>
<td class="nump">3,087,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt benefit</a></td>
<td class="num">(93,851)<span></span>
</td>
<td class="num">(255,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock and stock option compensation</a></td>
<td class="nump">78,270<span></span>
</td>
<td class="nump">15,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Original issue discount accretion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade accounts and other receivables</a></td>
<td class="num">(170,194)<span></span>
</td>
<td class="num">(545,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AdvancesToSuppliers', window );">Advances to suppliers</a></td>
<td class="num">(459,959)<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">689,104<span></span>
</td>
<td class="nump">1,011,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="num">(187,734)<span></span>
</td>
<td class="num">(332,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other payables and accrued expenses</a></td>
<td class="nump">692,190<span></span>
</td>
<td class="nump">415,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Advances from customers</a></td>
<td class="nump">339,659<span></span>
</td>
<td class="num">(520,414)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(24,722)<span></span>
</td>
<td class="nump">21,505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(409,545)<span></span>
</td>
<td class="num">(249,838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(401,964)<span></span>
</td>
<td class="num">(438,055)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(401,964)<span></span>
</td>
<td class="num">(438,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConstructionLoansPayable', window );">Payments of construction term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,325,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Payments of line of credit</a></td>
<td class="num">(2,140,921)<span></span>
</td>
<td class="num">(2,526,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">564,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Borrowings and interest from related party</a></td>
<td class="nump">28,962<span></span>
</td>
<td class="nump">1,183,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments to related party</a></td>
<td class="num">(223,013)<span></span>
</td>
<td class="num">(562,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from convertible redeemable debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,828,564<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash (Used In) Provided By Financing Activities</a></td>
<td class="num">(1,770,007)<span></span>
</td>
<td class="nump">4,597,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of Exchange Rate Changes on Cash</a></td>
<td class="num">(247,572)<span></span>
</td>
<td class="num">(8,439)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(2,829,088)<span></span>
</td>
<td class="nump">3,901,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">4,859,059<span></span>
</td>
<td class="nump">957,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Period</a></td>
<td class="nump">2,029,971<span></span>
</td>
<td class="nump">4,859,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">141,797<span></span>
</td>
<td class="nump">218,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AccountsReceivableCollectedWithBankersAcceptances', window );">Accounts receivable collected with banker&#8217;s acceptances</a></td>
<td class="nump">503,383<span></span>
</td>
<td class="nump">601,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InventoryPurchasedWithBankersAcceptanceNote', window );">Inventory purchased with banker&#8217;s acceptances</a></td>
<td class="nump">575,713<span></span>
</td>
<td class="nump">565,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">168,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConversionOfOfficerWagesToCommonStock', window );">Common stock issued for intangible assets</a></td>
<td class="nump">1,707,452<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,179,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AccountsReceivableCollectedWithBankersAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable collected with banker's acceptances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AccountsReceivableCollectedWithBankersAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConversionOfOfficerWagesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of officer wages to common stock

..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConversionOfOfficerWagesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InventoryPurchasedWithBankersAcceptanceNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory purchased with banker&amp;amp;#8217;s acceptances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InventoryPurchasedWithBankersAcceptanceNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConstructionLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from repayment of borrowings to finance the cost of construction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConstructionLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533183998640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Nature of Operations &#8211;&#160;</i></b>China Pharma Holdings, Inc., a Nevada corporation (the &#8220;Company&#8221;), owns 100%
of Onny Investment Limited (&#8220;Onny&#8221;), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;
Biotechnology Co., Ltd (&#8220;Helpson&#8221;), a company organized under the laws of the People&#8217;s Republic of China (the &#8220;PRC&#8221;).
China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Onny
acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#8217;s three former
shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate
of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license
evidencing its Wholly Foreign Owned Enterprise (&#8220;WFOE&#8221;) status on June 21, 2005.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helpson
is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety
of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the
PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables,
liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription
basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the
&#8220;NMPA&#8221;, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had cash and cash equivalents of $2.0 million and an accumulated deficit of $36.2 million. The Company&#8217;s
Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,121,273 as of December 31, 2022
to provide working capital and enable the Company to make the required payments related to its former construction loan facility. The
Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production
of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt
about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate
the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, management plans to enhance
the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring
strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#8217;s existing
fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Accounting Standards Codification (ASC) 205-40, <i>Disclosure of Uncertainties about an Entity&#8217;s Ability
to Continue as a Going Concern</i> management must evaluate whether there are conditions or events, considered in the aggregate, that
raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial
statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s
plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this
methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s
ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company&#8217;s
current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is
not probable of being effectively implemented as none of the plans are entirely within the Company&#8217;s control. Accordingly, substantial
doubt is deemed to exist about the Company&#8217;s ability to continue as a going concern within one year after the date these financial
statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might
result from the outcome of the uncertainties described above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split </i></b>&#8211; Effective March 6, 2023, the Company implemented a 1-for -10 reverse stock split as more fully discussed
in Note 14. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consolidation
and Basis of Presentation&#160;</i></b>&#8211; The accompanying condensed consolidated financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and are expressed in United States
dollars. The accompanying condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned
subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helpson&#8217;s
functional currency is the Chinese Renminbi. Helpson&#8217;s revenue and expenses are translated into United States dollars at the average
exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains
or losses from translating Helpson&#8217;s financial statements are included in accumulated other comprehensive income, which is a component
of stockholders&#8217; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency
of the entity that is party to the transaction are included in the results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
Estimates&#160;</i>-&#160;</b>The methodology used to prepare the Company&#8217;s financial statements is in conformity with U.S. GAAP,
which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting periods. &#160;Significant estimates made by management include, but are not limited to, the allowance
for doubtful accounts, deferred tax asset valuation allowance, valuation of stock-based compensation, the useful life of property and
equipment, valuation of intangible assets and the assumptions used to calculate derivative liabilities. Therefore, actual results could
differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents&#160;</i></b>&#8211; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits,
money market accounts, and short-term banker&#8217;s acceptances notes purchased with maturities of three months or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trade
Accounts Receivable and Allowance for Doubtful Accounts &#8211;&#160;</i></b>Trade accounts receivables are carried at the original invoiced
amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain
individual customer accounts and an estimation of the overall economic conditions affecting the Company&#8217;s customer base. The Company
reviews a customer&#8217;s credit history before extending credit to the customer. If the financial condition of its customers were to
deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision
is made against accounts receivable to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense
totaled $93,851 and $255,215 for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period
the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against
the allowance for the years ended December 31, 2022 and 2021, respectively. Customer balances outstanding for more than one year are
allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advances
to Suppliers and Advances from Customers</i></b>&#160;&#8211; Common practice in the PRC is to make advances to suppliers for materials
and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials
are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company
reviews a supplier&#8217;s credit history and background information before advancing a payment. If the financial condition of its suppliers
were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad
debt expense in the period they are considered unlikely to be collected.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventory&#160;&#8211;
</i></b>Inventory consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable
value. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials,
direct labor and an allocated portion of the Company&#8217;s production overhead. The Company writes down excess and obsolete inventory
to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in
process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of
business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written
down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost. Provisions for inventory
write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories are carried at this lower
cost basis until sold or scrapped.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b><i>Leases
</i></b></span><b><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211; </span></i></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>At
lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including
any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease
payments using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. The Company&#8217;s
incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal
to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset
based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the
lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#8220;Short-Term Leases&#8221;).
For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed
balance sheet. </span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">After
lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease
payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease
liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference
between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized
on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation
of Long-Lived Assets</i></b>&#160;&#8211; The carrying values of long-lived assets are reviewed for impairment annually or whenever events
or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects
the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset.
If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying
value over the projected discounted cash flows estimated to be generated by the asset. If there is uncertainty both in timing and amount,
the Company will use the projected discounted cash flows to be generated by the asset. For the years ended December 31, 2022 and 2021,
the Company evaluated its long-lived assets and determined that no impairment adjustments were necessary.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
Plant and Equipment</i></b>&#160;&#8211; Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses
as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during
the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other
depreciation was included in cost of revenue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b>&#160;&#8211; Revenue is recognized when a customer obtains control of promised goods or services and is recognized
in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition,
the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with
customers. The Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide
no significant distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in
exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of
the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they
are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration;
(iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies
each performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606
at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which
of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated
to the respective performance obligation when (or as) the performance obligation is satisfied. The Company&#8217;s contracts are fixed
price and reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company&#8217;s
performance obligations are transferred to customers at a point in time, typically upon buyer&#8217;s designated carrier or the buyer
picks up the goods at the Company&#8217;s warehouse.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts
with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The
Company has received advance deposits for orders less than one year. These advances total $520,295 and $210,028 and are recorded as a
liability on the accompanying balance sheet as &#8220;Advances from customers&#8221; as of December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of Revenues</i></b>&#160;&#8211; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated
with the manufacture and delivery of products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b>&#160;&#8211; Research and development expenditures are recorded as expenses in the period in which they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit
Risk</i></b>&#160;&#8211; The carrying amount of accounts receivable included in the balance sheet represents the Company&#8217;s exposure
to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company
performs ongoing credit evaluations of each customer&#8217;s financial condition. The Company maintains allowances for doubtful accounts
and such allowances in aggregate have not exceeded management&#8217;s estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been
secured due to the state policy of protecting depositors&#8217; interests. The PRC promulgated a Bankruptcy Law in August 2006, effective
June&#160;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts
in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any
bank where the Company has accounts declare bankruptcy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b>&#160;&#8211; The Company is exposed to the risk arising from changing interest rates, which may affect the ability
of repayment of existing debts and viability of securing future debt instruments within the PRC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basic
and Diluted Loss per Common Share&#160;</i>-&#160;</b>Basic loss per common share is computed by dividing net loss by the weighted-average
number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive
common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company has potentially dilutive common shares related to the option to purchase 96,500 shares of common stock
and the 126,667 shares issuable upon conversion of the Convertible Note Payable&#160; are excluded from the computation of diluted net
loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13,<i>Financial
Instruments &#8211; Credit Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments
within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial
instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting
model for purchased financial assets with credit deterioration since their origination.&#160;The pronouncement will be effective for
public business entities that are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including
interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning
after&#160;December 15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will
have a material impact on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, <i>&#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;. </i>The
amendment simplifies the accounting for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification
(&#8220;ASC&#8221;) 740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application,
among other things. The guidance was implemented January 1, 2021 and there was no impact on the condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020, the Financial Accounting Standards Board issued ASU 2020-06,&#160;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and
Contracts in an Entity&#8217;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics
of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#8217;s
accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#8217;s own equity
such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require
liability treatment. The pronouncement will be effective for public business entities that are SEC smaller reporting company filers in
fiscal years beginning after&#160;December 15, 2023, including interim periods within those fiscal years. Early application of the guidance
will be permitted for all entities for fiscal years beginning after&#160;December 15, 2020, including interim periods within those fiscal
years. The Company adopted the standard during fiscal 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated
through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be
adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533184253200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; INVENTORY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Raw materials</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,839,641</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,131,584</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Work in process</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">557,146</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">622,380</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">551,000</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">585,722</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; padding-left: 12px"><span style="font-size: 10pt">Total Inventory</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,947,787</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">3,339,686</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179525104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; PROPERTY, PLANT AND EQUIPMENT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Permit of land use</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">404,427</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">441,783</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Building</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">9,391,433</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">10,258,885</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Plant, machinery and equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">27,780,585</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">30,122,235</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Motor vehicle</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">438,138</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">337,375</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">308,847</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">278,892</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-left: 12px"><span style="font-size: 10pt">Total</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">38,323,430</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">41,439,170</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(28,350,365</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(28,158,611</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Property, plant and equipment,
    net</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">9,973,065</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,280,559</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is computed on a straight-line basis over the estimated useful lives of the assets as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: justify"><span style="font-size: 10pt"><b>Asset</b></span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 10pt"><b>Life - years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Permit of land use</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">40 - 70</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Building</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">20 - 49</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Plant, machinery and equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5 - 10</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Motor vehicle</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5 - 10</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Office equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3-5</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of
revenue. Depreciation expense was $2,663,975 and $3,049,706 for the years ended December 31, 2022 and 2021, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179458064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 - INTANGIBLE ASSETS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets represent the cost of medical formulas approved for production by the NMPA. The Company did not obtain NMPA production approval
for any new medical formulas during the years ended December 31, 2022 and 2021 and no costs were reclassified from advances to intangible
assets during the years ended December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved
medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which
range from ten to thirteen years.&#160;&#160;It is at least reasonably possible that a change in the estimated useful lives of the medical
formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas.
Amortization expense relating to intangible assets was $36,558 and $38,114 for the years ended December 31, 2022 and 2021, respectively
which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of
their amortization period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 28, 2022, the Company entered into a Technology Transfer Contract (the &#8220;Agreement&#8221;) with Chengdu Bonier Medical
Technology Development Co., Ltd (&#8220;Bonier&#8221;). Bonier owns the know-how of a technical invention and creation of an ophthalmic
oxygen enriched atomization therapeutic instrument, which has obtained a utility model patent (the &#8220;Utility Model Patent&#8221;)
and applied for an invention patent (the &#8220;Invention Patent&#8221;) at the same time. Pursuant to the Agreement, Bonier will transfer
the ownership of the Utility Model Patent of the technical invention and the Invention Patent application right of the invention to Helpson.
Bonier or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product
research and development, writing of registration materials, registration application and other technical services, with a term of ten
years. Effective November 28, 2022 the Company issued 1,552,229 share of its common stock valued at $1,707,452 based on the closing market
price of its common stock of $1.10 per share at that date. The Company recorded the amount as Intangible assets on the accompanying balance
sheet at December 31, 2022. The value of the intangible asset will be amortized over its remaining useful life of approximately 9.7 years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will pay a service fee of 15% of the net profit of the corresponding product sales revenue, which will be paid in cash annually
after it launches to the market, contingent on the successful authorization of the above mentioned Invention Patent.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present
and also at the date of each financial statement. The Company&#8217;s evaluation is based on an estimated undiscounted net cash flow
model, which considers currently available market data for the related drug and the Company&#8217;s estimated market share. If the carrying
value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying
value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment
loss was recognized during the years ended December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consisted solely of NMPA approved medical formulas as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Gross carrying amount</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">6,554,628</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">5,294,892</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Accumulated amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(4,747,142</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(5,147,051</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Net carrying amount</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">1,807,486</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">147,841</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"><span style="font-size: 10pt">Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="font-size: 10pt">2023</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">211,939</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2024</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">211,939</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2025</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">206,055</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2026</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">176,632</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2027</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">176,632</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">824,289</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">1,807,486</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179467024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">OTHER PAYABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; OTHER PAYABLES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
payables consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Compensation payable to officer</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">951,506</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">715,506</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Compensation and interest to related parties</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">372,578</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">327,033</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Business taxes and other</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,065,979</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">841,622</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 12px"><span style="font-size: 10pt">Total
    Other Payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">2,390,063</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,884,161</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179618144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; RELATED PARTY TRANSACTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
member of the Company&#8217;s board of directors (&#8220;Board&#8221;) had previously advanced to the Company an aggregate amount of
$1,354,567 as of December 31, 2022 and December 31, 2021 which is recorded as &#8220;Other Payables &#8211; Related Parties&#8221; on
the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.&#160;&#160;Total interest
expense years ended December 31, 2022 and 2021 was $13,546 and $13,546, respectively. Compensation and interest payable to the board
member is included in Other payables in the accompanying condensed consolidated balance sheet totaling $372,578 and $327,033 as of December
31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received advances totaling $0 and $1,183,414 and repaid $223,013 and $562,659 of the advances during the years ended December
31, 2022 and 2021, respectively from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed
were $1,121,273 and $1,425,123 and are recorded as Other payables &#8211; related parties on the accompanying condensed consolidated
balance sheets as of December 31, 2022 and 2021, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange
for cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears
interest at a rate of 4.35% and is payable within one year of the loan agreement. The due date of the loan agreement has been extended
annually on identical terms, and is now due July 9, 2023. Total interest expense related to the loan for the years ended December 31,
2022 and 2021 was $28,962 and $30,194, respectively. Compensation payable to the Chairperson, Chief Executive Officer and Interim Chief
Financial Officer is included in Other payables in the accompanying condensed consolidated balance sheet totaling $951,506 and $715,506
as of December 31, 2022 and 2021, respectively. As discussed more fully in Note 12, on September 9, 2021 an aggregate of $1,179,200 of
compensation was converted into a total of 176,000 shares of common stock at the market price of $6.70 per share from the Company&#8217;s
<span>2010 Long-Term Incentive Plan, as amended. </span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179531264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Construction Loan Facility<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LinesofCreditandConstructionLoanFacilityLineItems', window );"><strong>Lines of Credit and Construction Loan Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lines
of Credit</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately
$1.4 million), of which RMB 5,000,000 (approximately $0.7 million) was advanced in April 2020, and RMB 3,000,000 (approximately $0.4
million) was advanced in July 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two
years from the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral
in certain land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the
Company&#8217;s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest expense under
this facility for the years ended December 31, 2022 and 2021 was $12,063 and $44,629, respectively. The Company repaid the remaining
RMB 5,900,000 and RMB 1,600,000 (approximately $0.85 and $0.23 million, respectively) during the year ended December 31, 2022 and 2021,
respectively as per the repayment schedule in full satisfaction of the line of credit.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2020 the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately
$1.2 million), all of which has been advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one
year on the anniversary date of the line of credit. In addition, the Company&#8217;s Chief Executive Officer and Chair of the Board personally
guaranteed the new line of credit and pledged personal assets as collateral for the loan. On June 21, 2021 the Company paid the balance
in full. On June 25, 2021 the Company entered into a new loan bearing an interest rate of 4.17%. <span>The
Company paid all principal and interest on June 21, 2022 and on June 22, 2022 entered into a new loan for the same principal amount bearing
interest at&#160;4.17% and due December 21, 2022. On December 21, 2022 the Company repaid the loan in full and entered into a new line
of credit for an aggregate amount of RMB 7,300,000 (approximately $1.0 million) with interest payable monthly at a rate of 3.9%. The
line of credit is payable in one year. The Company received an advance on the line of credit in the amount of RMB 3,800,000 (approximately
$0.56 million) on December 30, 2022. The Company has RMB 3,500,000 (approximately $0.44 million) remaining to borrow on this line of
credit. </span>In addition, the Company&#8217;s Chief Executive Officer and Chair of the Board personally guaranteed the new line of
credit and pledged personal assets as collateral for the loan. Total interest expense under this facility for the years ended December
31, 2022 and 2021 was $53,283 and $54,294, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained
an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020
under this line. The loan bears interest at the rate of 4.50% per annum. In September, 2021 the Company repaid the line of credit in
full. Also in September, 2021 the Company entered into a new line a credit in the amount of RMB 3,200,000 (approximately $0.8 million)
on the same terms. The line of credit was due on September 2, 2022. <span>The line of credit was paid
in full on September 6, 2022.&#160;On September 9, 2022, the Company received a new line of credit in the same amount. The loan bears
interest at a rate of&#160;4.5% and is due on September 7, 2023.</span> In addition, the Company&#8217;s Chief Executive Officer and
Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest
expense under this facility for the years ended December 31, 2021 and 2020 was $21,528 and $22,258, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 12, 2021, the Company obtained a short-term loan of RMB 3 million (approximately US$460,000) from Haikou HaiHongXin microfinance
Co., Ltd., with a monthly interest rate of 1.5%. The company paid off the loan in September 2021. Total interest paid on this loan was
$0 and $16,051 for the years ended December 31, 2022 and 2021, respectively. This loan was guaranteed by Haikou Financing Guarantee Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 18, 2021 the Company obtained a line of credit for RMB 10,000,000 (approximately $1.54 million) with Bank of China. The loan
bears interest at the rate of 3.85% per annum. <span>The line of credit was paid in full on the due date
of September 18, 2022. On September 30, 2022 the Company received a new line of credit in the same amount. The loan bears interest at
the rate of 3.45% and is due September 28, 2023. </span>The loan is collateralized by the Company&#8217;s new production facility and
the included production line equipment and machinery. In addition, the Company&#8217;s Chief Executive Officer and Chair of the Board
personally guaranteed the new line of credit. Total interest paid on this loan was $54,923 and $15,582 for the years ended December 31,
2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
payments required for the remaining terms of the lines of credit as of December 31, 2022 are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Lines
    of Credit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">2023</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">2,440,915</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,440,915</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company obtained a construction loan facility from Bank of China, dated June 21, 2013, in the aggregate amount of RMB 80,000,000 (approximately
$13 million). The loan facility was for an eight-year term, which commenced on July 11, 2013, the initial draw-down date.&#160;The proceeds
of the loan were used for and are collateralized by the construction of the Company&#8217;s new production facility and the included
production line equipment and machinery.&#160;&#160;The interest rate was 5.39% during the year ended December 31, 2021. During the year
ended December 31, 2021, the Company repaid all the remaining principal payments due under the loan in the amount of $2,325,039 (RMB
15,000,000).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Lines of Credit</i></b> &#8211; Based on the borrowing rates currently available to the Company for bank loans with similar
terms and maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2022 and December 31, 2021
approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LinesofCreditandConstructionLoanFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LinesofCreditandConstructionLoanFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179392800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTE PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; CONVERTIBLE NOTE PAYABLE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2021, the Company entered into a Securities Purchase
Agreement (the &#8220;Agreement&#8221;) pursuant to which the Company issued an unsecured convertible promissory note (the &#8220;Note&#8221;)
to an institutional accredited investor Streeterville Capital, LLC (the &#8220;Investor&#8221;). The Note matures fifteen months after
the purchase price of the Note is delivered from the Investor to the Company (the &#8220;Purchase Price Date&#8221;). The Note was due
on February 17, 2023. The parties are in negotiation in extending the Note. No event of default has occurred as of the date herein. The
Note has the original principal amount of $5,250,000 and Investor gave consideration of $5,000,000, reflecting original issue discount
of $250,000. The transaction contemplated under the Agreement was closed on November 19, 2021 and the Company anticipates using the proceeds
for general working capital purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Note was convertible into 350,000 shares of the Company&#8217;s common stock at a price of $15.00 per share through April 19, 2022. Thereafter,
the Note is convertible into 175,000 shares at a price of $30.00 per share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined
in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event
of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration
by 15% or 5%, depending on the nature of the Event of Default.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Agreement and the Note, the Company must obtain Investor&#8217;s consent for certain fundamental transactions such
as consolidation, merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change
of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor&#8217;s prior written consent
will be deemed an Event of Default.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
may redeem all or any part the outstanding balance of the Note, subject to $500,000 per calendar month, at any time after one hundred
twenty-one (121) days from the Purchase Price Date upon three trading days&#8217; notice, in cash or converting into shares of the Company&#8217;s
common stock, at a price equal to 85% multiplied by the lowest daily volume weighted average price during the ten trading days immediately
preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note
provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding
balance of the Note with the Investor&#8217;s consent. At inception, the Note was redeemable into 881,143 shares based on the lowest
volume weighted average price of $5.95817 on the inception date of November 19, 2021. As of December 31, 2022, the Note was convertible
into 3,836,070 shares of common stock based on 85% of the lowest volume weighted average price of $0.9910 on that date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
original issue discount of $250,000 was fully earned at the inception of the Note, and accordingly was recognized as interest expense
in the accompanying statement of operations for the year ended December 31, 2021. Total interest expense for the years ended December
31, 2022 and 2021 was $250,314 and $279,979, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2022 the Investor delivered its notice of redemption for $100,000 of the Note at the lowest volume weighted average price of
$3.113 during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total
of 32,123 shares of common stock to the Investor on March 23, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
March 30, 2022 the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the price of $3.129,
which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;63,918 shares of common stock to the Investor on March 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
June 9, 2022 the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the price of $1.98,
which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;101,010 shares of common stock to the Investor on June 13, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
August 3, 2022&#160;the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the conversion
price of $1.755, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;113,960 shares of common stock to the Investor
on August 4, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
October 17, 2022&#160;the Investor delivered its notice of redemption for $100,000&#160;of the Note and related interest at the
conversion price of $1.12, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days
immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of&#160;89,286 shares of common
stock to the Investor on October 18, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
December 1, 2022&#160;the Investor delivered its notice of redemption for $100,000&#160;of the Note and related interest at the conversion
price of $0.829, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;120,627 shares of common stock to the Investor
on December 2, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
December 5, 2022&#160;the Investor delivered its notice of redemption for $310,000&#160;of the Note and related interest at the conversion
price of $0.829, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;373,945 shares of common stock to the Investor
on December 6, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
December 13, 2022&#160;the Investor delivered its notice of redemption for $90,000&#160;of the Note and related interest at the conversion
price of $0.91, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;98,901&#160;shares of common stock to the Investor
on December 14, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
December 14, 2022&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion
price of $0.829, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;180,905 shares of common stock to the Investor
on December 15, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179472512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LeasesLineItems', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 - LEASES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain
payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right to use assets
when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions
or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing
the Company&#8217;s incremental borrowing rate at the initial measurement date. For the years ended December 31, 2022 and 2021, operating
lease cost was $78,092 and $92,085, respectively and cash paid for amounts included in the measurement of lease liabilities for operating
cash flows from operating leases was $82,015 and $98,845, respectively. As of December 31, 2022 and 2021, the Company reported operating
lease right of use assets of $39,046 and $127,958, respectively and operating use liabilities of $40,445 and $85,282, respectively. As
of December 31, 2022, its operating leases had a weighted average remaining lease term of 0.50 years and a weighted average discount
rate of 4.75%.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum
lease payments for the Company&#8217;s operating lease liabilities were as follows for the twelve month periods ended December 31:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">2023</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">41,007</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-size: 10pt">Total undiscounted cash flows</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">41,007</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Less: Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(562</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">40,445</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Less: Operating lease liabilities, current portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(40,445</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Operating lease liabilities, net of current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leases with terms less than one year for certain provincial sales offices that are not material.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533178125296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 - INCOME TAXES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary
differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities
is recognized in income in the period that includes the enactment date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the &#8220;more-likely-than-not&#8221;
threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included
as a component of other expenses. Through December 31, 2022, the Company has not identified any uncertain tax positions that it has taken.
U.S. income tax returns for the years ended December 31, 2019 through December 31, 2022 and the Chinese income tax return for the year
ended December 31, 2022 are open for possible examination.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no provision for income taxes for the years ended December 31, 2022 and 2021, respectively due to continued net losses of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Years
    Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">(Benefit) tax at statutory rate of 25%</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(973,717</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(849,869</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Prior year refund received</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Other, primarily the difference in U.S. tax rates</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">8,416</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">8,440</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Change in valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">965,301</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">841,429</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Income tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
temporary differences which give rise to the deferred income tax assets and liability are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Deferred income tax assets:</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Allowance for doubtful trade receivables</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,184,882</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,578,177</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Allowance for doubtful other receivables</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6,787</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">8,052</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Inventory obsolescence reserve</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34,921</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">137,549</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Stock compensation</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,201</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,201</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Expenses not deductible in current year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,087,328</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,187,760</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Advances for intangible assets impairment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">9,782,172</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">10,685,714</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Lease liability, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">349</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">376</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">PRC net operating loss carry forward</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">5,036,114</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">5,779,437</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">U.S. net operating loss carry forward</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,849,800</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,602,243</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Total deferred income tax assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">21,985,554</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">23,982,509</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(21,985,554</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(23,982,509</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 12px"><span style="font-size: 10pt">Net deferred income tax asset</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Deferred income tax liability:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Intangible assets</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">754,698</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">824,407</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had net operating loss carryforwards for PRC tax purposes of approximately $20.1 million which are
available to offset any future taxable income through 2026. Approximately $6.0 million of these carryforwards expired in December 2022.
The Company also has net operating losses for United States federal income tax purposes of approximately $8.7 million of which $5.1 million
is available to offset future taxable income, if any, through 2039, and $3.7 million are available for carryforward indefinitely subject
to a limitation of 80% of taxable income for each tax year.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221;), was signed into law on
December&#160;22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the
statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December&#160;31, 2017; limiting and/or
eliminating many business deductions; migrating the U.S. to a territorial tax system with a&#160;one-time&#160;transition tax on a mandatory
deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally
eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized.&#160;&#160;The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&#160;&#160;Management
considers projected future taxable income and tax planning strategies in making this assessment.&#160;&#160;Based upon an assessment
of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets
are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets
as of December 31, 2022 and 2021.&#160;&#160;Therefore, the Company provided for a valuation allowance against its deferred tax assets
of $21,985,554 and $23,982,509 as of December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education
surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179537120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; FAIR VALUE MEASUREMENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows:
Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities; Level 2 &#8211; Observable inputs other than Level
1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can
be corroborated by observable market data; and Level 3 &#8211; Unobservable inputs supported by little or no market activity for financial
instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments
for which the determination of fair value requires significant management judgment or estimation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses fair value to measure the value of the banker&#8217;s acceptance notes it holds as of December 31, 2022 and 2021.&#160;The
banker&#8217;s acceptance notes are recorded at cost which approximates fair value.&#160;The Company held the following assets and liabilities
recorded at fair value:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair Value Measurements at</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Reporting
    Date Using</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,
    <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Banker&#8217;s acceptance notes</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">13,784</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">13,784</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,784</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,784</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair Value Measurements at</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Reporting
    Date Using</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,<br/>
    2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Banker&#8217;s acceptance notes</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">91,362</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">91,362</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">91,362</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">91,362</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533180270816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 - STOCKHOLDERS&#8217; EQUITY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue 500,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001
par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or
limitations as determined solely by the Company&#8217;s Board.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to relevant PRC laws, companies registered in the PRC, including the Company&#8217;s PRC subsidiary, Helpson, are required to allocate
at least 10% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus
reserve accounts until the reserve account balances reach 50% of the company&#8217;s registered capital prior to their remittance of
funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the
parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is
$8,145,000 at December 31, 2022 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2010
Incentive Plan</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 12, 2010, the Company&#8217;s Board adopted the Company&#8217;s
2010 Incentive Plan (the &#8220;Plan&#8221;), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board
of Directors approved the First Amendment to the 2010 Incentive Plan (the &#8220;Amendment&#8221;), pursuant to which the term of the
2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October
25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase
the number of shares of the Common Stock, that are reserved thereunder by 500,000 shares from 400,000 shares to 900,000 shares. On October
27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated 2010 Long Term Incentive
Plan to increase the number of shares of common stock that are reserved thereunder by an additional 500,000 shares from 900,000 to 1,400,000.
The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its
employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries.
The Plan currently allows for equity awards of up to 1,400,000 shares of common stock. Through December 31, 2022, there were 490,000 shares
of stock and stock options granted under the Plan.&#160; A total of 66,500 options were outstanding as of December 31, 2022 under the
Plan. As such, there are 910,000 additional shares available for issuance under the Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022 the Company issued 30,000 shares of common stock pursuant to a contract with a consultant to the Company for services.
The Company recorded compensation expense totaling $42,000 based on the closing market price of its common stock of $1.40 per share on
the issuance date. The contract also calls for the issuance of up to 90,000 additional shares of common stock contingent upon the achievement
of certain milestones as described in the contract. At December 31, 2022 these milestones had not been met.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2022 the Company issued an option to purchase <span>60,000 shares of common stock at an exercise
price at $5.60 per share, under the Plan to the same consultant in the preceding paragraph. The Option vests immediately and expires
on October 3, 2027. </span>The fair value of the options granted of $36,270 was calculated using the Black-Scholes option valuation model
using the closing market price of $1.50 per share, volatility of 115.5%, risk free interest rate of 3.84% and an expected life of 2.5
years. The value was charged to general and administrative expenses on the accompanying Statement of Operations for the year ended December
31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 9, 2021 the Company issued an aggregate of 176,000 fully vested shares of common stock at the price of $6.70 per share, representing
the closing market price on that date to its Chairperson, Chief Executive Officer and Interim Chief Financial Officer under the Plan,
as amended, to partially offset certain unpaid cash compensation totaling $1,179,200.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on September 9, 2021 the Company issued an option to purchase <span>6,500 shares of common stock at an
exercise price at $14.70 per share, under the Plan. The Option vests immediately and expires on September 9, 2024. </span>The fair value
of the options granted of $15,243 was calculated using the Black-Scholes option valuation model using the closing market price of $6.70
per share, volatility of 118.4%, risk free interest rate of 0.75% and an expected life of 1.5 years. The value was charged to general
and administrative expenses on the accompanying Statement of Operations for the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 23, 2020 the Board approved the issuance of 200,000 shares of common stock from the Company&#8217;s 2010 Long-Term Incentive
Plan, as amended for the partial conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and
Interim Chief Financial Officer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179563648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks &amp; Uncertainties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">RISKS &amp; UNCERTAINTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; RISKS &amp; UNCERTAINTIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current
vulnerability due to certain concentrations</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, no customer accounted for more than 10% of sales and three customers accounted for 52.9%, 11.4% and
10.4% of accounts receivable. Two suppliers accounted for 21.7% and 11.1% of raw material purchases, and three different products accounted
for 29.2%, 27.3% and 12.5% of revenue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, no customer accounted for more than 10% of sales and three customers accounted for 52.1%, 11.2% and
10.2% of accounts receivable. Three suppliers accounted for 24.8%, 12.7% and 11.8% of raw material purchases, and three different products
accounted for 20.7%, 17.7% and 13.5% of revenue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Operations</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
from the New Coronavirus Global Pandemic (&#8220;COVID-19&#8221;)&#160;</b>- Although the outbreak of COVID-19 since the first quarter
2020 has been under control, and China has returned to normal production and social life in an orderly manner, China is still encountering
frequent resurgences in many of the major cities. For now, these resurgences have not caused material impact to our daily operations.
However, we cannot guarantee subsequent resurgence will not have any material effect on the operation of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Economic
environment -&#160;</b>Substantially all of the Company&#8217;s operations are conducted in the PRC, and therefore the Company is subject
to special considerations and significant risks not typically associated with companies operating in the United States of America. These
risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The
Company&#8217;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by
changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance
abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely
affect the Company&#8217;s operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all of the Company&#8217;s revenue is denominated in the PRC&#8217;s currency of Renminbi (RMB), which must be converted into
other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies
abroad require approval of the PRC government.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179517744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b>NOTE
14 &#8211; SUBSEQUENT EVENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
January 5, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion
price of $0.763, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;196,592 shares of common stock to the Investor
on January 6, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
January 18, 2023&#160;the Investor delivered its notice of redemption for $250,000&#160;of the Note and related interest at the conversion
price of $0.763, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;327,654 shares of common stock to the Investor
on January 19, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
March 2, 2023&#160;the Investor delivered its notice of redemption for $250,000&#160;of the Note and related interest at the conversion
price of $0.575, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;434,783 shares of common stock to the Investor
on March 9, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Effective
March 6, 2023 the Company implemented a 1-for-10 reverse split of its common stock. The reverse stock split was approved by the Company&#8217;s
Board of Directors through unanimous written consent and the Company&#8217;s stockholders at its Annual Meeting for the fiscal year ended
on December 31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of the
Company&#8217;s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock.
No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split
were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder&#8217;s
percentage interest in the Company&#8217;s outstanding common stock, except for adjustments that may result from the treatment of fractional
shares. All share and per share amounts have been retroactively restated for the years ended December 31, 2022 and 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533182111008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OrganizationAndNatureOfOperationsPolicyTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Nature of Operations &#8211;&#160;</i></b>China Pharma Holdings, Inc., a Nevada corporation (the &#8220;Company&#8221;), owns 100%
of Onny Investment Limited (&#8220;Onny&#8221;), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;
Biotechnology Co., Ltd (&#8220;Helpson&#8221;), a company organized under the laws of the People&#8217;s Republic of China (the &#8220;PRC&#8221;).
China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Onny
acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#8217;s three former
shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate
of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license
evidencing its Wholly Foreign Owned Enterprise (&#8220;WFOE&#8221;) status on June 21, 2005.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helpson
is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety
of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the
PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables,
liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription
basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the
&#8220;NMPA&#8221;, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had cash and cash equivalents of $2.0 million and an accumulated deficit of $36.2 million. The Company&#8217;s
Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,121,273 as of December 31, 2022
to provide working capital and enable the Company to make the required payments related to its former construction loan facility. The
Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production
of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt
about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate
the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, management plans to enhance
the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring
strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#8217;s existing
fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Accounting Standards Codification (ASC) 205-40, <i>Disclosure of Uncertainties about an Entity&#8217;s Ability
to Continue as a Going Concern</i> management must evaluate whether there are conditions or events, considered in the aggregate, that
raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial
statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s
plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this
methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s
ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company&#8217;s
current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is
not probable of being effectively implemented as none of the plans are entirely within the Company&#8217;s control. Accordingly, substantial
doubt is deemed to exist about the Company&#8217;s ability to continue as a going concern within one year after the date these financial
statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might
result from the outcome of the uncertainties described above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split </i></b>&#8211; Effective March 6, 2023, the Company implemented a 1-for -10 reverse stock split as more fully discussed
in Note 14. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consolidation
and Basis of Presentation&#160;</i></b>&#8211; The accompanying condensed consolidated financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and are expressed in United States
dollars. The accompanying condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned
subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helpson&#8217;s
functional currency is the Chinese Renminbi. Helpson&#8217;s revenue and expenses are translated into United States dollars at the average
exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains
or losses from translating Helpson&#8217;s financial statements are included in accumulated other comprehensive income, which is a component
of stockholders&#8217; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency
of the entity that is party to the transaction are included in the results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
Estimates&#160;</i>-&#160;</b>The methodology used to prepare the Company&#8217;s financial statements is in conformity with U.S. GAAP,
which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting periods. &#160;Significant estimates made by management include, but are not limited to, the allowance
for doubtful accounts, deferred tax asset valuation allowance, valuation of stock-based compensation, the useful life of property and
equipment, valuation of intangible assets and the assumptions used to calculate derivative liabilities. Therefore, actual results could
differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents&#160;</i></b>&#8211; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits,
money market accounts, and short-term banker&#8217;s acceptances notes purchased with maturities of three months or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trade
Accounts Receivable and Allowance for Doubtful Accounts &#8211;&#160;</i></b>Trade accounts receivables are carried at the original invoiced
amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain
individual customer accounts and an estimation of the overall economic conditions affecting the Company&#8217;s customer base. The Company
reviews a customer&#8217;s credit history before extending credit to the customer. If the financial condition of its customers were to
deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision
is made against accounts receivable to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense
totaled $93,851 and $255,215 for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period
the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against
the allowance for the years ended December 31, 2022 and 2021, respectively. Customer balances outstanding for more than one year are
allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock', window );">Advances to Suppliers and Advances from Customers</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advances
to Suppliers and Advances from Customers</i></b>&#160;&#8211; Common practice in the PRC is to make advances to suppliers for materials
and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials
are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company
reviews a supplier&#8217;s credit history and background information before advancing a payment. If the financial condition of its suppliers
were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad
debt expense in the period they are considered unlikely to be collected.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventory&#160;&#8211;
</i></b>Inventory consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable
value. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials,
direct labor and an allocated portion of the Company&#8217;s production overhead. The Company writes down excess and obsolete inventory
to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in
process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of
business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written
down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost. Provisions for inventory
write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories are carried at this lower
cost basis until sold or scrapped.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b><i>Leases
</i></b></span><b><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211; </span></i></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>At
lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including
any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease
payments using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. The Company&#8217;s
incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal
to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset
based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the
lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#8220;Short-Term Leases&#8221;).
For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed
balance sheet. </span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">After
lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease
payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease
liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference
between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized
on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation
of Long-Lived Assets</i></b>&#160;&#8211; The carrying values of long-lived assets are reviewed for impairment annually or whenever events
or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects
the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset.
If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying
value over the projected discounted cash flows estimated to be generated by the asset. If there is uncertainty both in timing and amount,
the Company will use the projected discounted cash flows to be generated by the asset. For the years ended December 31, 2022 and 2021,
the Company evaluated its long-lived assets and determined that no impairment adjustments were necessary.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
Plant and Equipment</i></b>&#160;&#8211; Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses
as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during
the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other
depreciation was included in cost of revenue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b>&#160;&#8211; Revenue is recognized when a customer obtains control of promised goods or services and is recognized
in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition,
the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with
customers. The Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide
no significant distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in
exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of
the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they
are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration;
(iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies
each performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606
at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which
of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated
to the respective performance obligation when (or as) the performance obligation is satisfied. The Company&#8217;s contracts are fixed
price and reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company&#8217;s
performance obligations are transferred to customers at a point in time, typically upon buyer&#8217;s designated carrier or the buyer
picks up the goods at the Company&#8217;s warehouse.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts
with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The
Company has received advance deposits for orders less than one year. These advances total $520,295 and $210,028 and are recorded as a
liability on the accompanying balance sheet as &#8220;Advances from customers&#8221; as of December 31, 2022 and 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of Revenues</i></b>&#160;&#8211; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated
with the manufacture and delivery of products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b>&#160;&#8211; Research and development expenditures are recorded as expenses in the period in which they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit
Risk</i></b>&#160;&#8211; The carrying amount of accounts receivable included in the balance sheet represents the Company&#8217;s exposure
to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company
performs ongoing credit evaluations of each customer&#8217;s financial condition. The Company maintains allowances for doubtful accounts
and such allowances in aggregate have not exceeded management&#8217;s estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been
secured due to the state policy of protecting depositors&#8217; interests. The PRC promulgated a Bankruptcy Law in August 2006, effective
June&#160;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts
in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any
bank where the Company has accounts declare bankruptcy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InterestRateRiskPolicyTextBlock', window );">Interest Rate Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b>&#160;&#8211; The Company is exposed to the risk arising from changing interest rates, which may affect the ability
of repayment of existing debts and viability of securing future debt instruments within the PRC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basic
and Diluted Loss per Common Share&#160;</i>-&#160;</b>Basic loss per common share is computed by dividing net loss by the weighted-average
number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive
common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company has potentially dilutive common shares related to the option to purchase 96,500 shares of common stock
and the 126,667 shares issuable upon conversion of the Convertible Note Payable&#160; are excluded from the computation of diluted net
loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13,<i>Financial
Instruments &#8211; Credit Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments
within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial
instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting
model for purchased financial assets with credit deterioration since their origination.&#160;The pronouncement will be effective for
public business entities that are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including
interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning
after&#160;December 15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will
have a material impact on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, <i>&#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;. </i>The
amendment simplifies the accounting for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification
(&#8220;ASC&#8221;) 740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application,
among other things. The guidance was implemented January 1, 2021 and there was no impact on the condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020, the Financial Accounting Standards Board issued ASU 2020-06,&#160;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and
Contracts in an Entity&#8217;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics
of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#8217;s
accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#8217;s own equity
such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require
liability treatment. The pronouncement will be effective for public business entities that are SEC smaller reporting company filers in
fiscal years beginning after&#160;December 15, 2023, including interim periods within those fiscal years. Early application of the guidance
will be permitted for all entities for fiscal years beginning after&#160;December 15, 2020, including interim periods within those fiscal
years. The Company adopted the standard during fiscal 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated
through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be
adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advances to suppliers and advances from customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InterestRateRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest rate risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InterestRateRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OrganizationAndNatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for organization and nature of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OrganizationAndNatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179430880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Raw materials</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,839,641</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,131,584</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Work in process</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">557,146</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">622,380</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">551,000</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">585,722</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; padding-left: 12px"><span style="font-size: 10pt">Total Inventory</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,947,787</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">3,339,686</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179533856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Permit of land use</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">404,427</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">441,783</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Building</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">9,391,433</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">10,258,885</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Plant, machinery and equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">27,780,585</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">30,122,235</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Motor vehicle</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">438,138</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">337,375</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">308,847</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">278,892</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-left: 12px"><span style="font-size: 10pt">Total</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">38,323,430</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">41,439,170</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(28,350,365</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(28,158,611</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Property, plant and equipment,
    net</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">9,973,065</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,280,559</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_UsefulLiveOfAssetsTableTextBlock', window );">Schedule of estimated useful lives of the assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: justify"><span style="font-size: 10pt"><b>Asset</b></span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 10pt"><b>Life - years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Permit of land use</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">40 - 70</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Building</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">20 - 49</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Plant, machinery and equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5 - 10</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Motor vehicle</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5 - 10</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Office equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3-5</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_UsefulLiveOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful live of Assets table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_UsefulLiveOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179639456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Gross carrying amount</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">6,554,628</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">5,294,892</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Accumulated amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(4,747,142</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(5,147,051</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Net carrying amount</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">1,807,486</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">147,841</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of aggregate annual amortization expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"><span style="font-size: 10pt">Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="font-size: 10pt">2023</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">211,939</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2024</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">211,939</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2025</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">206,055</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2026</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">176,632</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2027</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">176,632</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">824,289</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">1,807,486</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179430880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other payables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Compensation payable to officer</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">951,506</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">715,506</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Compensation and interest to related parties</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">372,578</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">327,033</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Business taxes and other</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,065,979</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">841,622</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 12px"><span style="font-size: 10pt">Total
    Other Payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">2,390,063</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,884,161</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533180270816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Construction Loan Facility (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems', window );"><strong>Lines of Credit and Construction Loan Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of principal payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Lines
    of Credit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">2023</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">2,440,915</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,440,915</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179498144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LeasesTablesLineItems', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">2023</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">41,007</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-size: 10pt">Total undiscounted cash flows</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">41,007</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Less: Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(562</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">40,445</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Less: Operating lease liabilities, current portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(40,445</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Operating lease liabilities, net of current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LeasesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LeasesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533178876432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Years
    Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">(Benefit) tax at statutory rate of 25%</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(973,717</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(849,869</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Prior year refund received</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Other, primarily the difference in U.S. tax rates</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">8,416</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">8,440</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Change in valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">965,301</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">841,429</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Income tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of temporary differences to deferred income tax assets and liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Deferred income tax assets:</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Allowance for doubtful trade receivables</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,184,882</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,578,177</span></td><td style="width: 1%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Allowance for doubtful other receivables</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6,787</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">8,052</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Inventory obsolescence reserve</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34,921</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">137,549</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Stock compensation</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,201</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,201</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Expenses not deductible in current year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,087,328</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,187,760</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Advances for intangible assets impairment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">9,782,172</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">10,685,714</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Lease liability, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">349</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">376</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">PRC net operating loss carry forward</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">5,036,114</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">5,779,437</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">U.S. net operating loss carry forward</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,849,800</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,602,243</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Total deferred income tax assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">21,985,554</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">23,982,509</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(21,985,554</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(23,982,509</span></td><td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 12px"><span style="font-size: 10pt">Net deferred income tax asset</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 10pt">Deferred income tax liability:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-size: 10pt">Intangible assets</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">754,698</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">824,407</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533182155248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities recorded at fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair Value Measurements at</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Reporting
    Date Using</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,
    <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Banker&#8217;s acceptance notes</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">13,784</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">13,784</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,784</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,784</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair Value Measurements at</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Reporting
    Date Using</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,<br/>
    2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Banker&#8217;s acceptance notes</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">91,362</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">91,362</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">91,362</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">91,362</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: justify"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-size: 10pt">-</span></td><td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533178733792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 25, 2005</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Organization and Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">36,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Bad debt expense</a></td>
<td class="nump">93,851<span></span>
</td>
<td class="nump">$ 255,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Uncollectible trade accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Advances from customers</a></td>
<td class="nump">$ 520,295<span></span>
</td>
<td class="nump">$ 210,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PurchaseOfCommonStockShares', window );">Purchase of common stock (in Shares)</a></td>
<td class="nump">96,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Shares issuable upon conversion of the convertible note payable (in Shares)</a></td>
<td class="nump">126,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cphi_OnnyInvestmentLimitedMember', window );">Onny Investment Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Organization and Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember', window );">Hainan Helpson Medical &amp; Biotechnology Co., Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Organization and Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Organization and Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalRequiredForCapitalAdequacy', window );">Working capital</a></td>
<td class="nump">$ 1,121,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PurchaseOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PurchaseOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalRequiredForCapitalAdequacy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum total risk-based capital required for capital adequacy as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958570-112826<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalRequiredForCapitalAdequacy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cphi_OnnyInvestmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cphi_OnnyInvestmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533182129120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Schedule of inventory - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfInventoryAbstract', window );"><strong>Schedule of Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,839,641<span></span>
</td>
<td class="nump">$ 2,131,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">557,146<span></span>
</td>
<td class="nump">622,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">551,000<span></span>
</td>
<td class="nump">585,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory</a></td>
<td class="nump">$ 2,947,787<span></span>
</td>
<td class="nump">$ 3,339,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533178516736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expanse</a></td>
<td class="nump">$ 2,663,975<span></span>
</td>
<td class="nump">$ 3,049,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533175247168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - Schedule of property, plant and equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandAndLandImprovements', window );">Permit of land use</a></td>
<td class="nump">$ 404,427<span></span>
</td>
<td class="nump">$ 441,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building</a></td>
<td class="nump">9,391,433<span></span>
</td>
<td class="nump">10,258,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Plant, machinery and equipment</a></td>
<td class="nump">27,780,585<span></span>
</td>
<td class="nump">30,122,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_MotorVehicleGross', window );">Motor vehicle</a></td>
<td class="nump">438,138<span></span>
</td>
<td class="nump">337,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OfficeEquipmentGross', window );">Office equipment</a></td>
<td class="nump">308,847<span></span>
</td>
<td class="nump">278,892<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">38,323,430<span></span>
</td>
<td class="nump">41,439,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(28,350,365)<span></span>
</td>
<td class="num">(28,158,611)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 9,973,065<span></span>
</td>
<td class="nump">$ 13,280,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_MotorVehicleGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before moto vehicle of tangible personal property used to produce goods and services, including, but is not limited to, tools, motor equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_MotorVehicleGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OfficeEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before office equipment of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OfficeEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandAndLandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandAndLandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533182243600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_PermitOfLandUseMember', window );">Permit of land use [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_PermitOfLandUseMember', window );">Permit of land use [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">70 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">49 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Plant, machinery and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Plant, machinery and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_MotorVehicleMember', window );">Motor vehicle [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_MotorVehicleMember', window );">Motor vehicle [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_PermitOfLandUseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_PermitOfLandUseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_MotorVehicleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_MotorVehicleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533178796432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IntangibleAssetsUsefulLifeDescription', window );">Intangible assets useful life, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Approved
medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which
range from ten to thirteen years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense relating to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,558<span></span>
</td>
<td class="nump">$ 38,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued (in Shares)</a></td>
<td class="nump">1,552,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Common stock value</a></td>
<td class="nump">$ 1,707,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Closing price of common stock (in Dollars per share)</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap-sup_ManagementAndServiceFeesRate', window );">Service fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IntangibleAssetsUsefulLifeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IntangibleAssetsUsefulLifeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap-sup_ManagementAndServiceFeesRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap-sup_ManagementAndServiceFeesRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap-sup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533175971232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of intangible assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfIntangibleAssetsAbstract', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 6,554,628<span></span>
</td>
<td class="nump">$ 5,294,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(4,747,142)<span></span>
</td>
<td class="num">(5,147,051)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">$ 1,807,486<span></span>
</td>
<td class="nump">$ 147,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533178111952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of aggregate annual amortization expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract', window );"><strong>Schedule of Aggregate Annual Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 211,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">211,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">206,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">176,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">176,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">824,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Total</a></td>
<td class="nump">$ 1,807,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533175861776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Payables (Details) - Schedule of other payables - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfOtherPayablesAbstract', window );"><strong>Schedule of Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Compensation payable to officer</a></td>
<td class="nump">$ 951,506<span></span>
</td>
<td class="nump">$ 715,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Compensation and interest to related parties</a></td>
<td class="nump">372,578<span></span>
</td>
<td class="nump">327,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Business taxes and other</a></td>
<td class="nump">1,065,979<span></span>
</td>
<td class="nump">841,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total Other Payables</a></td>
<td class="nump">$ 2,390,063<span></span>
</td>
<td class="nump">$ 1,884,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533174783440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 09, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 21, 2022</div></th>
<th class="th"><div>Jun. 22, 2022</div></th>
<th class="th"><div>Sep. 18, 2021</div></th>
<th class="th"><div>Jun. 25, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th">
<div>Jul. 08, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 08, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesClassifiedCurrent', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,354,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,546<span></span>
</td>
<td class="nump">$ 13,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent', window );">Other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,578<span></span>
</td>
<td class="nump">327,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Borrowings from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,121,273<span></span>
</td>
<td class="nump">1,425,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">951,506<span></span>
</td>
<td class="nump">715,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Aggregate Note payable</a></td>
<td class="nump">$ 1,179,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_CompensationConverted', window );">Compensation converted</a></td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Received advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Repaid advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Received advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Repaid advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,962<span></span>
</td>
<td class="nump">$ 30,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LoanAgreementToBorrowCash', window );">Loan agreement to borrow cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (738,379)<span></span>
</td>
<td class="nump">&#165; 4,770,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_CompensationConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation Converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_CompensationConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LoanAgreementToBorrowCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>loan agreement to borrow cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LoanAgreementToBorrowCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred and payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOtherRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromOtherRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533171702288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Construction Loan Facility (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 28, 2023</div></th>
<th class="th"><div>Sep. 07, 2023</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 21, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 21, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>Jun. 22, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 18, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 12, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 12, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>Jun. 25, 2021</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 21, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 21, 2013 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems', window );"><strong>Lines of Credit and Construction Loan Facility (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionLoan', window );">Line of credit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
<td class="nump">&#165; 3,800,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">&#165; 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">&#165; 3,200,000<span></span>
</td>
<td class="nump">$ 1,540,000<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="nump">&#165; 80,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForMortgageDeposits', window );">Advance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">&#165; 2,343,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,283<span></span>
</td>
<td class="nump">$ 21,528<span></span>
</td>
<td class="nump">$ 22,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">5.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InterestAmount', window );">Interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,325,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems', window );"><strong>Lines of Credit and Construction Loan Facility (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cphi_HaikouHaiHongXinMicrofinanceCoLtdMember', window );">Haikou HaiHongXin microfinance Co., Ltd., [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems', window );"><strong>Lines of Credit and Construction Loan Facility (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460,000<span></span>
</td>
<td class="nump">&#165; 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfChinaMember', window );">Bank of China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems', window );"><strong>Lines of Credit and Construction Loan Facility (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionLoan', window );">Line of credit amount</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForMortgageDeposits', window );">Advance amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">&#165; 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,063<span></span>
</td>
<td class="nump">44,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Repaid remaining amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InterestAmount', window );">Interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,923<span></span>
</td>
<td class="nump">15,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfCommunicationsMember', window );">Bank of Communications [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems', window );"><strong>Lines of Credit and Construction Loan Facility (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionLoan', window );">Line of credit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">&#165; 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_ChinaCITICBankMember', window );">China CITIC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems', window );"><strong>Lines of Credit and Construction Loan Facility (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionLoan', window );">Line of credit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForMortgageDeposits', window );">Advance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">&#165; 856,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForMortgageDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>outflow associated with an amount paid in advance to show an intention to complete a mortgage financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForMortgageDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cphi_HaikouHaiHongXinMicrofinanceCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cphi_HaikouHaiHongXinMicrofinanceCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfCommunicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfCommunicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_ChinaCITICBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_ChinaCITICBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533179637984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lines of Credit and Construction Loan Facility (Details) - Schedule of principal payments - Lines of Credit [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2,440,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 2,440,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_UnusedLinesOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_UnusedLinesOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533175695968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note Payable (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 14, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 13, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 05, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 17, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 03, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 09, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 19, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 21, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 15, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 18, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 13, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 23, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Notes matures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Original principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Investor consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OriginalIssueDiscount', window );">Original issue discount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Note converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Converted common stock price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConvertibleNote', window );">Convertible note (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConvertibleNoteConversionPrice', window );">Convertible note conversion price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InterestAccruesOnNoteDescription', window );">Interest accrues on note, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest
accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined
in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event
of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration
by 15% or 5%, depending on the nature of the Event of Default.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RedeemOfOutstandingNote', window );">Redeem of outstanding note | $</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice', window );">Percentage of common stock price on weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_NoteRedeemableIntoShares', window );">Note redeemable into shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,836,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.829<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 0.829<span></span>
</td>
<td class="nump">$ 0.829<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.755<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.129<span></span>
</td>
<td class="nump">$ 3.113<span></span>
</td>
<td class="nump">$ 5.95817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_WeightedAveragePrice', window );">Weighted average price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Total interest expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,314<span></span>
</td>
<td class="nump">$ 279,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common stock issued to investor (in Shares) | shares</a></td>
<td class="nump">98,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,905<span></span>
</td>
<td class="nump">373,945<span></span>
</td>
<td class="nump">120,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,960<span></span>
</td>
<td class="nump">101,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average price percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_CommonStockIssuedToInvestor', window );">Common stock issued to investor (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_CommonStockIssuedToInvestor1', window );">Common stock issued to investor (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_CommonStockIssuedToInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued to investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_CommonStockIssuedToInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_CommonStockIssuedToInvestor1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued to investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_CommonStockIssuedToInvestor1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConvertibleNoteConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible note conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConvertibleNoteConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InterestAccruesOnNoteDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of interest accrues on Note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InterestAccruesOnNoteDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_NoteRedeemableIntoShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares redeemable by Notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_NoteRedeemableIntoShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OriginalIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of  original issue discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OriginalIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock price on weighted average price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RedeemOfOutstandingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of redeem of outstanding note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RedeemOfOutstandingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_WeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_WeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533182220160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LeasesDetailsLineItems', window );"><strong>Leases (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 78,092<span></span>
</td>
<td class="nump">$ 92,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_CashFlowForOperatingLease', window );">Cash flows from operating leases</a></td>
<td class="nump">82,015<span></span>
</td>
<td class="nump">98,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OperatingLeaseRightsOfUseAssets', window );">Operating lease right of use assets</a></td>
<td class="nump">39,046<span></span>
</td>
<td class="nump">127,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating leases liabilities</a></td>
<td class="nump">$ 40,445<span></span>
</td>
<td class="nump">$ 85,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_WeightedAveragesRemainingLeaseTerm', window );">Weighted average remaining lease term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_WeightedAverageDiscountRate', window );">Weighted average discount rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_CashFlowForOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash flow for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_CashFlowForOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OperatingLeaseRightsOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OperatingLeaseRightsOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_WeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_WeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_WeightedAveragesRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_WeightedAveragesRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533180649232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of operating lease liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems', window );"><strong>Schedule of Operating Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">$ 41,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total undiscounted cash flows</a></td>
<td class="nump">41,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestNetAmount', window );">Less: Imputed interest</a></td>
<td class="num">(562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Total</a></td>
<td class="nump">40,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LessOperatingLeaseLiabilitiesCurrentPortion', window );">Less: Operating lease liabilities, current portion</a></td>
<td class="num">(40,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LessOperatingLeaseLiabilitiesCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Less: Operating lease liabilities, current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LessOperatingLeaseLiabilitiesCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The receivable or note face amount less the unamortized discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533174988784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Enterprise income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards for PRC tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_NetOperatingLossCarryForwardsExpirationDescription', window );">Net operating loss expiration, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Approximately $6.0 million of these carryforwards expired in December 2022.
The Company also has net operating losses for United States federal income tax purposes of approximately $8.7 million of which $5.1 million
is available to offset future taxable income, if any, through 2039, and $3.7 million are available for carryforward indefinitely subject
to a limitation of 80% of taxable income for each tax year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ValuationAllowanceForDeferredTaxAssets', window );">Valuation allowance for deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,985,554<span></span>
</td>
<td class="nump">$ 23,982,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">U.S. federal corporate income tax rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">U.S. federal corporate income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_NetOperatingLossCarryForwardsExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carry forward expiration date description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_NetOperatingLossCarryForwardsExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ValuationAllowanceForDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ValuationAllowanceForDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533176025488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract', window );"><strong>Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">(Benefit) tax at statutory rate of 25%</a></td>
<td class="num">$ (973,717)<span></span>
</td>
<td class="num">$ (849,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year refund received</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Other, primarily the difference in U.S. tax rates</a></td>
<td class="nump">8,416<span></span>
</td>
<td class="nump">8,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">965,301<span></span>
</td>
<td class="nump">841,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533175756352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes (Parentheticals)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract', window );"><strong>Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">(Benefit) tax at statutory rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533178418336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of temporary differences to deferred income tax assets and liability - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_DeferredIncomeTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful trade receivables</a></td>
<td class="nump">$ 4,184,882<span></span>
</td>
<td class="nump">$ 4,578,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses', window );">Allowance for doubtful other receivables</a></td>
<td class="nump">6,787<span></span>
</td>
<td class="nump">8,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory obsolescence reserve</a></td>
<td class="nump">34,921<span></span>
</td>
<td class="nump">137,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">3,201<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Expenses not deductible in current year</a></td>
<td class="nump">1,087,328<span></span>
</td>
<td class="nump">1,187,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Advances for intangible assets impairment</a></td>
<td class="nump">9,782,172<span></span>
</td>
<td class="nump">10,685,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Lease liability, net</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">PRC net operating loss carry forward</a></td>
<td class="nump">5,036,114<span></span>
</td>
<td class="nump">5,779,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">U.S. net operating loss carry forward</a></td>
<td class="nump">1,849,800<span></span>
</td>
<td class="nump">1,602,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">21,985,554<span></span>
</td>
<td class="nump">23,982,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21,985,554)<span></span>
</td>
<td class="num">(23,982,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_DeferredIncomeTaxLiabilityAbstract', window );"><strong>Deferred income tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 754,698<span></span>
</td>
<td class="nump">$ 824,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_DeferredIncomeTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_DeferredIncomeTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_DeferredIncomeTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_DeferredIncomeTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533182123696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomersLiabilityForAcceptancesNet', window );">Banker&#8217;s acceptance notes</a></td>
<td class="nump">$ 13,784<span></span>
</td>
<td class="nump">$ 91,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">13,784<span></span>
</td>
<td class="nump">91,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomersLiabilityForAcceptancesNet', window );">Banker&#8217;s acceptance notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomersLiabilityForAcceptancesNet', window );">Banker&#8217;s acceptance notes</a></td>
<td class="nump">13,784<span></span>
</td>
<td class="nump">91,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">13,784<span></span>
</td>
<td class="nump">91,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomersLiabilityForAcceptancesNet', window );">Banker&#8217;s acceptance notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomersLiabilityForAcceptancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all customer's outstanding debt to the institution that resulted from short-term negotiable time drafts drawn on and accepted by an institution (also known as banker's acceptance transactions), net of allowance for uncollectible customer's liability for acceptances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomersLiabilityForAcceptancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533173562736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2022</div></th>
<th class="th"><div>Oct. 03, 2022</div></th>
<th class="th"><div>Sep. 09, 2021</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 27, 2022</div></th>
<th class="th"><div>Dec. 15, 2022</div></th>
<th class="th"><div>Dec. 14, 2022</div></th>
<th class="th"><div>Dec. 06, 2022</div></th>
<th class="th"><div>Dec. 02, 2022</div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
<th class="th"><div>Jun. 13, 2022</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Dec. 27, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AftertaxNetIncomePercentage', window );">After tax income, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ReserveAccountBalancesPercentage', window );">Reserve account balances, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount', window );">General and statutory capital reserves amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,145,000<span></span>
</td>
<td class="nump">$ 8,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_TotalOptionOutstanding', window );">Total option outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AdditionalSharesAvailableForIssuance', window );">Additional shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_CommonStockPursuant', window );">Common stock pursuant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ClosingMarketPrice', window );">Closing market price (in Dollars per share)</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Additional shares of common stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PurchaseofCommonStockShares', window );">Purchase of common stock</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_FairValueOfOptionsGranted', window );">Fair value of options granted (in Dollars)</a></td>
<td class="nump">$ 36,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">115.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,905<span></span>
</td>
<td class="nump">98,901<span></span>
</td>
<td class="nump">373,945<span></span>
</td>
<td class="nump">120,627<span></span>
</td>
<td class="nump">113,960<span></span>
</td>
<td class="nump">101,010<span></span>
</td>
<td class="nump">32,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Fair value of options granted (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_MarketPricePerShare', window );">Market price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ExpectedLifes', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_UnpaidCashCompensation', window );">Total unpaid cash compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,179,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember', window );">2010 Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock and stock option granted and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cphi_ChairpersonMember', window );">Chairperson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Unpaid compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 864,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cphi_TwoThousandTenLongTermIncentivePlanMember', window );">2010 Long-Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdditionalSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares available for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdditionalSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AftertaxNetIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After tax net income percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AftertaxNetIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ClosingMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of closing market price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ClosingMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_CommonStockPursuant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_CommonStockPursuant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ExpectedLifes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ExpectedLifes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_FairValueOfOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_FairValueOfOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_MarketPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_MarketPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PurchaseofCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PurchaseofCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ReserveAccountBalancesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ReserveAccountBalancesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_TotalOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total option outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_TotalOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_UnpaidCashCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unpaid cash compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_UnpaidCashCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net income for the period determined using accounting principles prescribed or permitted by insurance regulators.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cphi_ChairpersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cphi_ChairpersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cphi_TwoThousandTenLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cphi_TwoThousandTenLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533171457216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks &amp; Uncertainties (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_NumberOfCustomers', window );">Number of customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">52.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=cphi_RawMaterialPurchasesMember', window );">Raw Material Purchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_NumberOfSuppliers', window );">Number of suppliers</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=cphi_SalesRevenuesNetOneMember', window );">Revenue One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">29.20%<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=cphi_SalesRevenuesNetTwoMember', window );">Revenue Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">27.30%<span></span>
</td>
<td class="nump">17.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskByBenchmarksAxis=cphi_SalesRevenuesNetThreeMember', window );">Revenue Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersOneMember', window );">Suppliers One [Member] | Raw Material Purchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">24.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersTwoMember', window );">Suppliers Two [Member] | Raw Material Purchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">21.70%<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersTwoMember', window );">Suppliers Two [Member] | Revenue One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersThreeMember', window );">Suppliers Three [Member] | Raw Material Purchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskTypeAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConcentrationRiskPercentage', window );">Concentrations risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConcentrationRiskPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConcentrationRiskPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_NumberOfSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_NumberOfSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RisksUncertaintiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RisksUncertaintiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConcentrationRiskByBenchmarksAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConcentrationRiskByBenchmarksAxis=cphi_RawMaterialPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConcentrationRiskByBenchmarksAxis=cphi_RawMaterialPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConcentrationRiskByBenchmarksAxis=cphi_SalesRevenuesNetOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConcentrationRiskByBenchmarksAxis=cphi_SalesRevenuesNetOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConcentrationRiskByBenchmarksAxis=cphi_SalesRevenuesNetTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConcentrationRiskByBenchmarksAxis=cphi_SalesRevenuesNetTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConcentrationRiskByBenchmarksAxis=cphi_SalesRevenuesNetThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConcentrationRiskByBenchmarksAxis=cphi_SalesRevenuesNetThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConcentrationRiskTypeAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConcentrationRiskTypeAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140533175960736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
<th class="th"><div>Jan. 18, 2023</div></th>
<th class="th"><div>Jan. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InvestorRedemption', window );">Investor redemption</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 0.575<span></span>
</td>
<td class="nump">$ 0.763<span></span>
</td>
<td class="nump">$ 0.763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_WeightedAveragePrices', window );">Weighted average price percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_CommonStockInvestor', window );">Common stock investor</a></td>
<td class="nump">434,783<span></span>
</td>
<td class="nump">327,654<span></span>
</td>
<td class="nump">196,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_CommonStockInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of common stock investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_CommonStockInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InvestorRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investor redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InvestorRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_WeightedAveragePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of weighted average price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_WeightedAveragePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>f10k2022_chinapharma_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cphi="http://www.chinapharmaholdings.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:us-gaap-sup="http://fasb.org/us-gaap-sup/2022q3"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cphi-20221231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cphi:OnnyInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2005-05-25</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:PermitOfLandUseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:PermitOfLandUseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:MotorVehicleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:MotorVehicleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-11-28</startDate>
            <endDate>2022-11-28</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-11-28</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-08</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-09-09</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2021-09-09</startDate>
            <endDate>2021-09-09</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-09</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-25</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-15</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-06-25</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-06-22</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-21</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2020-10-15</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-15</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cphi:HaikouHaiHongXinMicrofinanceCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-12</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-09-18</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-28</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2013-06-21</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:UnusedLinesOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-17</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-21</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-06-09</startDate>
            <endDate>2022-06-09</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-06-09</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-06-13</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-08-04</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-10-18</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-02</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-12-05</startDate>
            <endDate>2022-12-05</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-05</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-13</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-14</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-15</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-12-27</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-27</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-27</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-27</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-27</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-27</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cphi:TwoThousandTenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-10-04</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-10-04</startDate>
            <endDate>2022-10-04</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-09</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-09</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-09</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cphi:TwoThousandTenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cphi:ConcentrationRiskByBenchmarksAxis">cphi:SalesRevenuesNetThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-05</startDate>
            <endDate>2023-01-05</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-05</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-18</startDate>
            <endDate>2023-01-18</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-18</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-34471</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">China Pharma Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">73-1564807</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">Second Floor, No. 17, Jinpan Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Haikou</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">Hainan Province</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0">CN</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c0">570216</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">86</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">898-6681-1730</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">CPHI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" unitRef="usd">10601665</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">8458094</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="c0">B F Borgers CPA PC</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0">Lakewood, Colorado</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c0">5041</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">2029971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" unitRef="usd">4859059</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cphi:BankersAcceptances contextRef="c3" decimals="0" unitRef="usd">13784</cphi:BankersAcceptances>
    <cphi:BankersAcceptances contextRef="c4" decimals="0" unitRef="usd">91362</cphi:BankersAcceptances>
    <cphi:TradeAccountsReceivableLessAllowance contextRef="c3" decimals="0" unitRef="usd">16739527</cphi:TradeAccountsReceivableLessAllowance>
    <cphi:TradeAccountsReceivableLessAllowance contextRef="c4" decimals="0" unitRef="usd">18312707</cphi:TradeAccountsReceivableLessAllowance>
    <cphi:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts contextRef="c3" decimals="0" unitRef="usd">421531</cphi:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts>
    <cphi:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts contextRef="c4" decimals="0" unitRef="usd">714475</cphi:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts>
    <cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts contextRef="c3" decimals="0" unitRef="usd">27149</cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts>
    <cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts contextRef="c4" decimals="0" unitRef="usd">32210</cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c3" decimals="0" unitRef="usd">29139</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c4" decimals="0" unitRef="usd">29564</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <cphi:AdvanceToSupplies contextRef="c3" decimals="0" unitRef="usd">444637</cphi:AdvanceToSupplies>
    <cphi:AdvanceToSupplies contextRef="c4" decimals="0" unitRef="usd">471</cphi:AdvanceToSupplies>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">2947787</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="0" unitRef="usd">3339686</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" unitRef="usd">77697</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="0" unitRef="usd">58792</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">5964546</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" unitRef="usd">9093409</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">9973065</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" unitRef="usd">13280559</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" unitRef="usd">39046</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" unitRef="usd">127958</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" unitRef="usd">1807486</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="0" unitRef="usd">147841</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">17784143</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" unitRef="usd">22649767</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="0" unitRef="usd">667082</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c4" decimals="0" unitRef="usd">926749</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">404807</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">298452</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="0" unitRef="usd">2390063</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="0" unitRef="usd">1884161</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">520295</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c4" decimals="0" unitRef="usd">210028</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">2475840</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">2779690</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">40445</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="0" unitRef="usd">85282</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c3" decimals="0" unitRef="usd">2440915</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c4" decimals="0" unitRef="usd">4328936</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LongTermConstructionLoanCurrent contextRef="c3" decimals="0" unitRef="usd">3800000</us-gaap:LongTermConstructionLoanCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">12739447</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">10513298</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c4" decimals="0" unitRef="usd">5250000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="0" unitRef="usd">44181</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c3" decimals="0" unitRef="usd">754698</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c4" decimals="0" unitRef="usd">824407</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c3" decimals="0" unitRef="usd">13494145</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" unitRef="usd">16631886</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">7490896</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">7490896</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c4" decimals="0" unitRef="shares">4733956</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c4" decimals="0" unitRef="shares">4733956</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">74909</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" unitRef="usd">47340</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">28853520</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="0" unitRef="usd">25645367</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-36211496</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" unitRef="usd">-32238655</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" unitRef="usd">11573065</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="0" unitRef="usd">12563829</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">4289998</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">6017881</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">17784143</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" unitRef="usd">22649767</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">8104092</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">9641925</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" unitRef="usd">8598008</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c5" decimals="0" unitRef="usd">9292655</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" unitRef="usd">-493916</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" unitRef="usd">349270</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="c0" decimals="0" unitRef="usd">1069785</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c5" decimals="0" unitRef="usd">1495007</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">1893269</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">1651024</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">185858</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">318964</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" unitRef="usd">-93851</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c5" decimals="0" unitRef="usd">-255215</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">3055061</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" unitRef="usd">3209780</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-3548977</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-2860510</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="0" unitRef="usd">10755</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c5" decimals="0" unitRef="usd">3035</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" unitRef="usd">434619</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c5" decimals="0" unitRef="usd">542001</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" unitRef="usd">-423864</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="0" unitRef="usd">-538966</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-3972841</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">-3399476</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-3972841</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-3399476</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" unitRef="usd">-990764</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c5" decimals="0" unitRef="usd">218383</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" unitRef="usd">-4963605</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c5" decimals="0" unitRef="usd">-3181093</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">5256855</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">4612926</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="0" unitRef="shares">4557956</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" unitRef="usd">45580</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">24452684</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" unitRef="usd">-28839179</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" unitRef="usd">12345446</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" unitRef="usd">8004531</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c11" decimals="0" unitRef="usd">15243</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">15243</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c12" decimals="0" unitRef="shares">176000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c12" decimals="0" unitRef="usd">1760</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c11" decimals="0" unitRef="usd">1177440</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c5" decimals="0" unitRef="usd">1179200</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ProfitLoss contextRef="c13" decimals="0" unitRef="usd">-3399476</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">-3399476</us-gaap:ProfitLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c14" decimals="0" unitRef="usd">218383</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c5" decimals="0" unitRef="usd">218383</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding contextRef="c15" decimals="0" unitRef="shares">4733956</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" unitRef="usd">47340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" unitRef="usd">25645367</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">-32238655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" unitRef="usd">12563829</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">6017881</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c19" decimals="0" unitRef="shares">1552229</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c19" decimals="0" unitRef="usd">15522</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c20" decimals="0" unitRef="usd">1691930</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c0" decimals="0" unitRef="usd">1707452</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20" decimals="0" unitRef="usd">36270</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">36270</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c19" decimals="0" unitRef="shares">30000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c19" decimals="0" unitRef="usd">300</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c20" decimals="0" unitRef="usd">41700</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="0" unitRef="usd">42000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c19" decimals="0" unitRef="shares">1174711</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c19" decimals="0" unitRef="usd">11747</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c20" decimals="0" unitRef="usd">1438253</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c0" decimals="0" unitRef="usd">1450000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ProfitLoss contextRef="c21" decimals="0" unitRef="usd">-3972841</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">-3972841</us-gaap:ProfitLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c22" decimals="0" unitRef="usd">-990764</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c0" decimals="0" unitRef="usd">-990764</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding contextRef="c23" decimals="0" unitRef="shares">7490896</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="0" unitRef="usd">74909</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="0" unitRef="usd">28853520</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="0" unitRef="usd">-36211496</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" unitRef="usd">11573065</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">4289998</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-3972841</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-3399476</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" unitRef="usd">2700533</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="0" unitRef="usd">3087820</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" unitRef="usd">-93851</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c5" decimals="0" unitRef="usd">-255215</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:StockOptionPlanExpense contextRef="c0" decimals="0" unitRef="usd">78270</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="c5" decimals="0" unitRef="usd">15243</us-gaap:StockOptionPlanExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c5" decimals="0" unitRef="usd">-250000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c0" decimals="0" unitRef="usd">170194</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c5" decimals="0" unitRef="usd">545534</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <cphi:AdvancesToSuppliers contextRef="c0" decimals="0" unitRef="usd">459959</cphi:AdvancesToSuppliers>
    <cphi:AdvancesToSuppliers contextRef="c5" decimals="0" unitRef="usd">-1798</cphi:AdvancesToSuppliers>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" unitRef="usd">-689104</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c5" decimals="0" unitRef="usd">-1011905</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="0" unitRef="usd">-187734</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c5" decimals="0" unitRef="usd">-332779</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">692190</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c5" decimals="0" unitRef="usd">415309</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c0" decimals="0" unitRef="usd">339659</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c5" decimals="0" unitRef="usd">-520414</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="0" unitRef="usd">24722</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c5" decimals="0" unitRef="usd">-21505</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-409545</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" unitRef="usd">-249838</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">401964</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="0" unitRef="usd">438055</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-401964</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" unitRef="usd">-438055</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConstructionLoansPayable contextRef="c5" decimals="0" unitRef="usd">2325039</us-gaap:RepaymentsOfConstructionLoansPayable>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c0" decimals="0" unitRef="usd">-2140921</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c5" decimals="0" unitRef="usd">-2526542</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c0" decimals="0" unitRef="usd">564965</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c0" decimals="0" unitRef="usd">28962</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c5" decimals="0" unitRef="usd">1183414</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c0" decimals="0" unitRef="usd">223013</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c5" decimals="0" unitRef="usd">562659</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c5" decimals="0" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="c5" decimals="0" unitRef="usd">3828564</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">-1770007</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" unitRef="usd">4597738</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c0" decimals="0" unitRef="usd">-247572</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c5" decimals="0" unitRef="usd">-8439</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">-2829088</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="0" unitRef="usd">3901406</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">4859059</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c10" decimals="0" unitRef="usd">957653</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">2029971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">4859059</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" unitRef="usd">141797</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="0" unitRef="usd">218232</us-gaap:InterestPaidNet>
    <cphi:AccountsReceivableCollectedWithBankersAcceptances contextRef="c0" decimals="0" unitRef="usd">503383</cphi:AccountsReceivableCollectedWithBankersAcceptances>
    <cphi:AccountsReceivableCollectedWithBankersAcceptances contextRef="c5" decimals="0" unitRef="usd">601021</cphi:AccountsReceivableCollectedWithBankersAcceptances>
    <cphi:InventoryPurchasedWithBankersAcceptanceNote contextRef="c0" decimals="0" unitRef="usd">575713</cphi:InventoryPurchasedWithBankersAcceptanceNote>
    <cphi:InventoryPurchasedWithBankersAcceptanceNote contextRef="c5" decimals="0" unitRef="usd">565079</cphi:InventoryPurchasedWithBankersAcceptanceNote>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c5" decimals="0" unitRef="usd">168606</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cphi:ConversionOfOfficerWagesToCommonStock contextRef="c0" decimals="0" unitRef="usd">1707452</cphi:ConversionOfOfficerWagesToCommonStock>
    <us-gaap:StockIssued1 contextRef="c5" decimals="0" unitRef="usd">1179200</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Organization
and Nature of Operations &#x2013;&#160;&lt;/i&gt;&lt;/b&gt;China Pharma Holdings, Inc., a Nevada corporation (the &#x201c;Company&#x201d;), owns 100%
of Onny Investment Limited (&#x201c;Onny&#x201d;), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp;
Biotechnology Co., Ltd (&#x201c;Helpson&#x201d;), a company organized under the laws of the People&#x2019;s Republic of China (the &#x201c;PRC&#x201d;).
China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Onny
acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#x2019;s three former
shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate
of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license
evidencing its Wholly Foreign Owned Enterprise (&#x201c;WFOE&#x201d;) status on June 21, 2005.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Helpson
is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety
of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the
PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables,
liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription
basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the
&#x201c;NMPA&#x201d;, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company had cash and cash equivalents of $2.0 million and an accumulated deficit of $36.2 million. The Company&#x2019;s
Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,121,273 as of December 31, 2022
to provide working capital and enable the Company to make the required payments related to its former construction loan facility. The
Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production
of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt
about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate
the conditions that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern, management plans to enhance
the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring
strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#x2019;s existing
fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the requirements of Accounting Standards Codification (ASC) 205-40, &lt;i&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability
to Continue as a Going Concern&lt;/i&gt; management must evaluate whether there are conditions or events, considered in the aggregate, that
raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial
statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s
plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this
methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s
ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company&#x2019;s
current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is
not probable of being effectively implemented as none of the plans are entirely within the Company&#x2019;s control. Accordingly, substantial
doubt is deemed to exist about the Company&#x2019;s ability to continue as a going concern within one year after the date these financial
statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might
result from the outcome of the uncertainties described above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split &lt;/i&gt;&lt;/b&gt;&#x2013; Effective March 6, 2023, the Company implemented a 1-for -10 reverse stock split as more fully discussed
in Note 14. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Consolidation
and Basis of Presentation&#160;&lt;/i&gt;&lt;/b&gt;&#x2013; The accompanying condensed consolidated financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and are expressed in United States
dollars. The accompanying condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned
subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Helpson&#x2019;s
functional currency is the Chinese Renminbi. Helpson&#x2019;s revenue and expenses are translated into United States dollars at the average
exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains
or losses from translating Helpson&#x2019;s financial statements are included in accumulated other comprehensive income, which is a component
of stockholders&#x2019; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency
of the entity that is party to the transaction are included in the results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounting
Estimates&#160;&lt;/i&gt;-&#160;&lt;/b&gt;The methodology used to prepare the Company&#x2019;s financial statements is in conformity with U.S. GAAP,
which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting periods. &#160;Significant estimates made by management include, but are not limited to, the allowance
for doubtful accounts, deferred tax asset valuation allowance, valuation of stock-based compensation, the useful life of property and
equipment, valuation of intangible assets and the assumptions used to calculate derivative liabilities. Therefore, actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&#160;&lt;/i&gt;&lt;/b&gt;&#x2013; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits,
money market accounts, and short-term banker&#x2019;s acceptances notes purchased with maturities of three months or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Trade
Accounts Receivable and Allowance for Doubtful Accounts &#x2013;&#160;&lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced
amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain
individual customer accounts and an estimation of the overall economic conditions affecting the Company&#x2019;s customer base. The Company
reviews a customer&#x2019;s credit history before extending credit to the customer. If the financial condition of its customers were to
deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision
is made against accounts receivable to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense
totaled $93,851 and $255,215 for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period
the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against
the allowance for the years ended December 31, 2022 and 2021, respectively. Customer balances outstanding for more than one year are
allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Advances
to Suppliers and Advances from Customers&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Common practice in the PRC is to make advances to suppliers for materials
and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials
are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company
reviews a supplier&#x2019;s credit history and background information before advancing a payment. If the financial condition of its suppliers
were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad
debt expense in the period they are considered unlikely to be collected.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inventory&#160;&#x2013;
&lt;/i&gt;&lt;/b&gt;Inventory consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable
value. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials,
direct labor and an allocated portion of the Company&#x2019;s production overhead. The Company writes down excess and obsolete inventory
to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in
process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of
business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written
down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost. Provisions for inventory
write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories are carried at this lower
cost basis until sold or scrapped.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;&lt;b&gt;&lt;i&gt;Leases
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;i&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013; &lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;At
lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including
any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease
payments using an incremental borrowing rate as the Company&#x2019;s leases do not provide an implicit interest rate. The Company&#x2019;s
incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal
to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset
based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the
lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#x201c;Short-Term Leases&#x201d;).
For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed
balance sheet. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;After
lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease
payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease
liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference
between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized
on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Valuation
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; The carrying values of long-lived assets are reviewed for impairment annually or whenever events
or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects
the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset.
If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying
value over the projected discounted cash flows estimated to be generated by the asset. If there is uncertainty both in timing and amount,
the Company will use the projected discounted cash flows to be generated by the asset. For the years ended December 31, 2022 and 2021,
the Company evaluated its long-lived assets and determined that no impairment adjustments were necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property,
Plant and Equipment&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses
as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during
the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other
depreciation was included in cost of revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Revenue is recognized when a customer obtains control of promised goods or services and is recognized
in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition,
the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with
customers. The Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide
no significant distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in
exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of
the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they
are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration;
(iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies
each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606
at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which
of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated
to the respective performance obligation when (or as) the performance obligation is satisfied. The Company&#x2019;s contracts are fixed
price and reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company&#x2019;s
performance obligations are transferred to customers at a point in time, typically upon buyer&#x2019;s designated carrier or the buyer
picks up the goods at the Company&#x2019;s warehouse.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts
with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The
Company has received advance deposits for orders less than one year. These advances total $520,295 and $210,028 and are recorded as a
liability on the accompanying balance sheet as &#x201c;Advances from customers&#x201d; as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cost
of Revenues&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated
with the manufacture and delivery of products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Credit
Risk&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; The carrying amount of accounts receivable included in the balance sheet represents the Company&#x2019;s exposure
to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company
performs ongoing credit evaluations of each customer&#x2019;s financial condition. The Company maintains allowances for doubtful accounts
and such allowances in aggregate have not exceeded management&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been
secured due to the state policy of protecting depositors&#x2019; interests. The PRC promulgated a Bankruptcy Law in August 2006, effective
June&#160;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts
in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any
bank where the Company has accounts declare bankruptcy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Interest
Rate Risk&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; The Company is exposed to the risk arising from changing interest rates, which may affect the ability
of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basic
and Diluted Loss per Common Share&#160;&lt;/i&gt;-&#160;&lt;/b&gt;Basic loss per common share is computed by dividing net loss by the weighted-average
number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive
common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company has potentially dilutive common shares related to the option to purchase 96,500 shares of common stock
and the 126,667 shares issuable upon conversion of the Convertible Note Payable&#160; are excluded from the computation of diluted net
loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13,&lt;i&gt;Financial
Instruments &#x2013; Credit Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments
within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial
instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting
model for purchased financial assets with credit deterioration since their origination.&#160;The pronouncement will be effective for
public business entities that are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including
interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning
after&#160;December 15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will
have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, the FASB issued ASU 2019-12, &lt;i&gt;&#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#x201d;. &lt;/i&gt;The
amendment simplifies the accounting for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification
(&#x201c;ASC&#x201d;) 740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application,
among other things. The guidance was implemented January 1, 2021 and there was no impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2020, the Financial Accounting Standards Board issued ASU 2020-06,&#160;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and
Contracts in an Entity&#x2019;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics
of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#x2019;s
accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#x2019;s own equity
such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require
liability treatment. The pronouncement will be effective for public business entities that are SEC smaller reporting company filers in
fiscal years beginning after&#160;December 15, 2023, including interim periods within those fiscal years. Early application of the guidance
will be permitted for all entities for fiscal years beginning after&#160;December 15, 2020, including interim periods within those fiscal
years. The Company adopted the standard during fiscal 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated
through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be
adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <cphi:OrganizationAndNatureOfOperationsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Organization
and Nature of Operations &#x2013;&#160;&lt;/i&gt;&lt;/b&gt;China Pharma Holdings, Inc., a Nevada corporation (the &#x201c;Company&#x201d;), owns 100%
of Onny Investment Limited (&#x201c;Onny&#x201d;), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp;
Biotechnology Co., Ltd (&#x201c;Helpson&#x201d;), a company organized under the laws of the People&#x2019;s Republic of China (the &#x201c;PRC&#x201d;).
China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Onny
acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#x2019;s three former
shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate
of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license
evidencing its Wholly Foreign Owned Enterprise (&#x201c;WFOE&#x201d;) status on June 21, 2005.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Helpson
is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety
of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the
PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables,
liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription
basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the
&#x201c;NMPA&#x201d;, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</cphi:OrganizationAndNatureOfOperationsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c27" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c28" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c29" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <cphi:LiquidityAndGoingConcernPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company had cash and cash equivalents of $2.0 million and an accumulated deficit of $36.2 million. The Company&#x2019;s
Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,121,273 as of December 31, 2022
to provide working capital and enable the Company to make the required payments related to its former construction loan facility. The
Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production
of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt
about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate
the conditions that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern, management plans to enhance
the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring
strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#x2019;s existing
fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the requirements of Accounting Standards Codification (ASC) 205-40, &lt;i&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability
to Continue as a Going Concern&lt;/i&gt; management must evaluate whether there are conditions or events, considered in the aggregate, that
raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial
statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s
plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this
methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s
ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company&#x2019;s
current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is
not probable of being effectively implemented as none of the plans are entirely within the Company&#x2019;s control. Accordingly, substantial
doubt is deemed to exist about the Company&#x2019;s ability to continue as a going concern within one year after the date these financial
statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might
result from the outcome of the uncertainties described above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</cphi:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-5" unitRef="usd">2000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <cphi:AccumulatedDeficit contextRef="c3" decimals="-5" unitRef="usd">36200000</cphi:AccumulatedDeficit>
    <us-gaap:CapitalRequiredForCapitalAdequacy contextRef="c30" decimals="0" unitRef="usd">1121273</us-gaap:CapitalRequiredForCapitalAdequacy>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split &lt;/i&gt;&lt;/b&gt;&#x2013; Effective March 6, 2023, the Company implemented a 1-for -10 reverse stock split as more fully discussed
in Note 14. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Consolidation
and Basis of Presentation&#160;&lt;/i&gt;&lt;/b&gt;&#x2013; The accompanying condensed consolidated financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and are expressed in United States
dollars. The accompanying condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned
subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Helpson&#x2019;s
functional currency is the Chinese Renminbi. Helpson&#x2019;s revenue and expenses are translated into United States dollars at the average
exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains
or losses from translating Helpson&#x2019;s financial statements are included in accumulated other comprehensive income, which is a component
of stockholders&#x2019; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency
of the entity that is party to the transaction are included in the results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounting
Estimates&#160;&lt;/i&gt;-&#160;&lt;/b&gt;The methodology used to prepare the Company&#x2019;s financial statements is in conformity with U.S. GAAP,
which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting periods. &#160;Significant estimates made by management include, but are not limited to, the allowance
for doubtful accounts, deferred tax asset valuation allowance, valuation of stock-based compensation, the useful life of property and
equipment, valuation of intangible assets and the assumptions used to calculate derivative liabilities. Therefore, actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&#160;&lt;/i&gt;&lt;/b&gt;&#x2013; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits,
money market accounts, and short-term banker&#x2019;s acceptances notes purchased with maturities of three months or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Trade
Accounts Receivable and Allowance for Doubtful Accounts &#x2013;&#160;&lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced
amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain
individual customer accounts and an estimation of the overall economic conditions affecting the Company&#x2019;s customer base. The Company
reviews a customer&#x2019;s credit history before extending credit to the customer. If the financial condition of its customers were to
deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision
is made against accounts receivable to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense
totaled $93,851 and $255,215 for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period
the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against
the allowance for the years ended December 31, 2022 and 2021, respectively. Customer balances outstanding for more than one year are
allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InterestExpenseDebt contextRef="c0" decimals="0" unitRef="usd">93851</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c5" decimals="0" unitRef="usd">255215</us-gaap:InterestExpenseDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="0" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <cphi:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Advances
to Suppliers and Advances from Customers&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Common practice in the PRC is to make advances to suppliers for materials
and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials
are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company
reviews a supplier&#x2019;s credit history and background information before advancing a payment. If the financial condition of its suppliers
were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad
debt expense in the period they are considered unlikely to be collected.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</cphi:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inventory&#160;&#x2013;
&lt;/i&gt;&lt;/b&gt;Inventory consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable
value. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials,
direct labor and an allocated portion of the Company&#x2019;s production overhead. The Company writes down excess and obsolete inventory
to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in
process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of
business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written
down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost. Provisions for inventory
write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories are carried at this lower
cost basis until sold or scrapped.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;&lt;b&gt;&lt;i&gt;Leases
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;i&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013; &lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;At
lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including
any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease
payments using an incremental borrowing rate as the Company&#x2019;s leases do not provide an implicit interest rate. The Company&#x2019;s
incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal
to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset
based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the
lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#x201c;Short-Term Leases&#x201d;).
For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed
balance sheet. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;After
lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease
payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease
liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference
between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized
on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Valuation
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; The carrying values of long-lived assets are reviewed for impairment annually or whenever events
or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects
the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset.
If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying
value over the projected discounted cash flows estimated to be generated by the asset. If there is uncertainty both in timing and amount,
the Company will use the projected discounted cash flows to be generated by the asset. For the years ended December 31, 2022 and 2021,
the Company evaluated its long-lived assets and determined that no impairment adjustments were necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property,
Plant and Equipment&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses
as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during
the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other
depreciation was included in cost of revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Revenue is recognized when a customer obtains control of promised goods or services and is recognized
in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition,
the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with
customers. The Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide
no significant distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in
exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of
the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they
are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration;
(iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies
each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606
at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which
of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated
to the respective performance obligation when (or as) the performance obligation is satisfied. The Company&#x2019;s contracts are fixed
price and reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company&#x2019;s
performance obligations are transferred to customers at a point in time, typically upon buyer&#x2019;s designated carrier or the buyer
picks up the goods at the Company&#x2019;s warehouse.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts
with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The
Company has received advance deposits for orders less than one year. These advances total $520,295 and $210,028 and are recorded as a
liability on the accompanying balance sheet as &#x201c;Advances from customers&#x201d; as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">520295</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c4" decimals="0" unitRef="usd">210028</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cost
of Revenues&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated
with the manufacture and delivery of products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Credit
Risk&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; The carrying amount of accounts receivable included in the balance sheet represents the Company&#x2019;s exposure
to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company
performs ongoing credit evaluations of each customer&#x2019;s financial condition. The Company maintains allowances for doubtful accounts
and such allowances in aggregate have not exceeded management&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been
secured due to the state policy of protecting depositors&#x2019; interests. The PRC promulgated a Bankruptcy Law in August 2006, effective
June&#160;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts
in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any
bank where the Company has accounts declare bankruptcy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <cphi:InterestRateRiskPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Interest
Rate Risk&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; The Company is exposed to the risk arising from changing interest rates, which may affect the ability
of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</cphi:InterestRateRiskPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basic
and Diluted Loss per Common Share&#160;&lt;/i&gt;-&#160;&lt;/b&gt;Basic loss per common share is computed by dividing net loss by the weighted-average
number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive
common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company has potentially dilutive common shares related to the option to purchase 96,500 shares of common stock
and the 126,667 shares issuable upon conversion of the Convertible Note Payable&#160; are excluded from the computation of diluted net
loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <cphi:PurchaseOfCommonStockShares contextRef="c3" decimals="0" unitRef="shares">96500</cphi:PurchaseOfCommonStockShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="c0" decimals="0" unitRef="shares">126667</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13,&lt;i&gt;Financial
Instruments &#x2013; Credit Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments
within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial
instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting
model for purchased financial assets with credit deterioration since their origination.&#160;The pronouncement will be effective for
public business entities that are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including
interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning
after&#160;December 15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will
have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, the FASB issued ASU 2019-12, &lt;i&gt;&#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#x201d;. &lt;/i&gt;The
amendment simplifies the accounting for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification
(&#x201c;ASC&#x201d;) 740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application,
among other things. The guidance was implemented January 1, 2021 and there was no impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2020, the Financial Accounting Standards Board issued ASU 2020-06,&#160;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and
Contracts in an Entity&#x2019;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics
of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#x2019;s
accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#x2019;s own equity
such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require
liability treatment. The pronouncement will be effective for public business entities that are SEC smaller reporting company filers in
fiscal years beginning after&#160;December 15, 2023, including interim periods within those fiscal years. Early application of the guidance
will be permitted for all entities for fiscal years beginning after&#160;December 15, 2020, including interim periods within those fiscal
years. The Company adopted the standard during fiscal 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated
through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be
adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2013; INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,839,641&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,131,584&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;557,146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;622,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;551,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;585,722&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; padding-left: 12px"&gt;&lt;span style="font-size: 10pt"&gt;Total Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,947,787&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,339,686&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,839,641&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,131,584&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;557,146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;622,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;551,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;585,722&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; padding-left: 12px"&gt;&lt;span style="font-size: 10pt"&gt;Total Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,947,787&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,339,686&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="0" unitRef="usd">1839641</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c4" decimals="0" unitRef="usd">2131584</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c3" decimals="0" unitRef="usd">557146</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c4" decimals="0" unitRef="usd">622380</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" unitRef="usd">551000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c4" decimals="0" unitRef="usd">585722</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">2947787</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="0" unitRef="usd">3339686</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; PROPERTY, PLANT AND EQUIPMENT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Permit of land use&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;404,427&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;441,783&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,391,433&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,258,885&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Plant, machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;27,780,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,122,235&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;438,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;337,375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;308,847&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;278,892&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-left: 12px"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;38,323,430&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;41,439,170&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(28,350,365&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(28,158,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Property, plant and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,973,065&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,280,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is computed on a straight-line basis over the estimated useful lives of the assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Asset&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Life - years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Permit of land use&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;40 - 70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;20 - 49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Plant, machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 - 10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 - 10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3-5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of
revenue. Depreciation expense was $2,663,975 and $3,049,706 for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Permit of land use&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;404,427&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;441,783&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,391,433&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,258,885&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Plant, machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;27,780,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,122,235&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;438,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;337,375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;308,847&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;278,892&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-left: 12px"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;38,323,430&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;41,439,170&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(28,350,365&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(28,158,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Property, plant and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,973,065&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,280,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:LandAndLandImprovements contextRef="c3" decimals="0" unitRef="usd">404427</us-gaap:LandAndLandImprovements>
    <us-gaap:LandAndLandImprovements contextRef="c4" decimals="0" unitRef="usd">441783</us-gaap:LandAndLandImprovements>
    <us-gaap:BuildingsAndImprovementsGross contextRef="c3" decimals="0" unitRef="usd">9391433</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross contextRef="c4" decimals="0" unitRef="usd">10258885</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">27780585</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="c4" decimals="0" unitRef="usd">30122235</us-gaap:MachineryAndEquipmentGross>
    <cphi:MotorVehicleGross contextRef="c3" decimals="0" unitRef="usd">438138</cphi:MotorVehicleGross>
    <cphi:MotorVehicleGross contextRef="c4" decimals="0" unitRef="usd">337375</cphi:MotorVehicleGross>
    <cphi:OfficeEquipmentGross contextRef="c3" decimals="0" unitRef="usd">308847</cphi:OfficeEquipmentGross>
    <cphi:OfficeEquipmentGross contextRef="c4" decimals="0" unitRef="usd">278892</cphi:OfficeEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">38323430</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="0" unitRef="usd">41439170</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">28350365</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="0" unitRef="usd">28158611</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c3" decimals="0" unitRef="usd">9973065</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c4" decimals="0" unitRef="usd">13280559</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <cphi:UsefulLiveOfAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Asset&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Life - years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Permit of land use&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;40 - 70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;20 - 49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Plant, machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 - 10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 - 10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3-5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</cphi:UsefulLiveOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c31">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c32">P70Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c33">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c34">P49Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c35">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c36">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c37">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c38">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c39">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c40">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">2663975</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" unitRef="usd">3049706</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 - INTANGIBLE ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets represent the cost of medical formulas approved for production by the NMPA. The Company did not obtain NMPA production approval
for any new medical formulas during the years ended December 31, 2022 and 2021 and no costs were reclassified from advances to intangible
assets during the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Approved
medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which
range from ten to thirteen years.&#160;&#160;It is at least reasonably possible that a change in the estimated useful lives of the medical
formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas.
Amortization expense relating to intangible assets was $36,558 and $38,114 for the years ended December 31, 2022 and 2021, respectively
which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of
their amortization period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 28, 2022, the Company entered into a Technology Transfer Contract (the &#x201c;Agreement&#x201d;) with Chengdu Bonier Medical
Technology Development Co., Ltd (&#x201c;Bonier&#x201d;). Bonier owns the know-how of a technical invention and creation of an ophthalmic
oxygen enriched atomization therapeutic instrument, which has obtained a utility model patent (the &#x201c;Utility Model Patent&#x201d;)
and applied for an invention patent (the &#x201c;Invention Patent&#x201d;) at the same time. Pursuant to the Agreement, Bonier will transfer
the ownership of the Utility Model Patent of the technical invention and the Invention Patent application right of the invention to Helpson.
Bonier or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product
research and development, writing of registration materials, registration application and other technical services, with a term of ten
years. Effective November 28, 2022 the Company issued 1,552,229 share of its common stock valued at $1,707,452 based on the closing market
price of its common stock of $1.10 per share at that date. The Company recorded the amount as Intangible assets on the accompanying balance
sheet at December 31, 2022. The value of the intangible asset will be amortized over its remaining useful life of approximately 9.7 years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will pay a service fee of 15% of the net profit of the corresponding product sales revenue, which will be paid in cash annually
after it launches to the market, contingent on the successful authorization of the above mentioned Invention Patent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present
and also at the date of each financial statement. The Company&#x2019;s evaluation is based on an estimated undiscounted net cash flow
model, which considers currently available market data for the related drug and the Company&#x2019;s estimated market share. If the carrying
value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying
value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment
loss was recognized during the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consisted solely of NMPA approved medical formulas as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6,554,628&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,294,892&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(4,747,142&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(5,147,051&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,807,486&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;147,841&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;211,939&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;211,939&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;206,055&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;176,632&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;176,632&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;824,289&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,807,486&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <cphi:IntangibleAssetsUsefulLifeDescription contextRef="c0">Approved
medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which
range from ten to thirteen years.</cphi:IntangibleAssetsUsefulLifeDescription>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">36558</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" unitRef="usd">38114</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="c41" decimals="0" unitRef="shares">1552229</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DividendsStock contextRef="c41" decimals="0" unitRef="usd">1707452</us-gaap:DividendsStock>
    <us-gaap:SaleOfStockPricePerShare contextRef="c42" decimals="2" unitRef="usdPershares">1.1</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c0">P9Y8M12D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap-sup:ManagementAndServiceFeesRate contextRef="c0" decimals="2" unitRef="pure">0.15</us-gaap-sup:ManagementAndServiceFeesRate>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6,554,628&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,294,892&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(4,747,142&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(5,147,051&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,807,486&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;147,841&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" unitRef="usd">6554628</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c4" decimals="0" unitRef="usd">5294892</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" unitRef="usd">4747142</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c4" decimals="0" unitRef="usd">5147051</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" unitRef="usd">1807486</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="0" unitRef="usd">147841</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;211,939&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;211,939&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;206,055&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;176,632&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;176,632&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;824,289&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,807,486&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c3" decimals="0" unitRef="usd">211939</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c3" decimals="0" unitRef="usd">211939</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c3" decimals="0" unitRef="usd">206055</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c3" decimals="0" unitRef="usd">176632</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c3" decimals="0" unitRef="usd">176632</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c3" decimals="0" unitRef="usd">824289</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c0" decimals="0" unitRef="usd">1807486</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; OTHER PAYABLES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
payables consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Compensation payable to officer&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;951,506&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;715,506&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Compensation and interest to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;372,578&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;327,033&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Business taxes and other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,065,979&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;841,622&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 12px"&gt;&lt;span style="font-size: 10pt"&gt;Total
    Other Payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,390,063&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,884,161&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Compensation payable to officer&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;951,506&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;715,506&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Compensation and interest to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;372,578&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;327,033&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Business taxes and other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,065,979&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;841,622&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 12px"&gt;&lt;span style="font-size: 10pt"&gt;Total
    Other Payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,390,063&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,884,161&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="c3" decimals="0" unitRef="usd">951506</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="c4" decimals="0" unitRef="usd">715506</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="c3" decimals="0" unitRef="usd">372578</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="c4" decimals="0" unitRef="usd">327033</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">1065979</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">841622</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilities contextRef="c3" decimals="0" unitRef="usd">2390063</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="c4" decimals="0" unitRef="usd">1884161</us-gaap:OtherLiabilities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2013; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
member of the Company&#x2019;s board of directors (&#x201c;Board&#x201d;) had previously advanced to the Company an aggregate amount of
$1,354,567 as of December 31, 2022 and December 31, 2021 which is recorded as &#x201c;Other Payables &#x2013; Related Parties&#x201d; on
the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.&#160;&#160;Total interest
expense years ended December 31, 2022 and 2021 was $13,546 and $13,546, respectively. Compensation and interest payable to the board
member is included in Other payables in the accompanying condensed consolidated balance sheet totaling $372,578 and $327,033 as of December
31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company received advances totaling $0 and $1,183,414 and repaid $223,013 and $562,659 of the advances during the years ended December
31, 2022 and 2021, respectively from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed
were $1,121,273 and $1,425,123 and are recorded as Other payables &#x2013; related parties on the accompanying condensed consolidated
balance sheets as of December 31, 2022 and 2021, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange
for cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears
interest at a rate of 4.35% and is payable within one year of the loan agreement. The due date of the loan agreement has been extended
annually on identical terms, and is now due July 9, 2023. Total interest expense related to the loan for the years ended December 31,
2022 and 2021 was $28,962 and $30,194, respectively. Compensation payable to the Chairperson, Chief Executive Officer and Interim Chief
Financial Officer is included in Other payables in the accompanying condensed consolidated balance sheet totaling $951,506 and $715,506
as of December 31, 2022 and 2021, respectively. As discussed more fully in Note 12, on September 9, 2021 an aggregate of $1,179,200 of
compensation was converted into a total of 176,000 shares of common stock at the market price of $6.70 per share from the Company&#x2019;s
&lt;span&gt;2010 Long-Term Incentive Plan, as amended. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="c3" decimals="0" unitRef="usd">1354567</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c3" decimals="3" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseRelatedParty contextRef="c0" decimals="0" unitRef="usd">13546</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty contextRef="c5" decimals="0" unitRef="usd">13546</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">372578</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="c4" decimals="0" unitRef="usd">327033</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c43" decimals="0" unitRef="usd">0</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c44" decimals="0" unitRef="usd">1183414</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="c43" decimals="0" unitRef="usd">223013</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="c44" decimals="0" unitRef="usd">562659</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedParties contextRef="c3" decimals="0" unitRef="usd">1121273</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties contextRef="c4" decimals="0" unitRef="usd">1425123</us-gaap:DueFromRelatedParties>
    <cphi:LoanAgreementToBorrowCash contextRef="c45" decimals="0" unitRef="cny">4770000</cphi:LoanAgreementToBorrowCash>
    <cphi:LoanAgreementToBorrowCash contextRef="c45" decimals="0" unitRef="usd">-738379</cphi:LoanAgreementToBorrowCash>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c45" decimals="4" unitRef="pure">0.0435</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseRelatedParty contextRef="c46" decimals="0" unitRef="usd">28962</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty contextRef="c47" decimals="0" unitRef="usd">30194</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:OtherNotesPayable contextRef="c3" decimals="0" unitRef="usd">951506</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable contextRef="c4" decimals="0" unitRef="usd">715506</us-gaap:OtherNotesPayable>
    <us-gaap:NotesPayable contextRef="c48" decimals="0" unitRef="usd">1179200</us-gaap:NotesPayable>
    <cphi:CompensationConverted contextRef="c49" decimals="0" unitRef="usd">176000</cphi:CompensationConverted>
    <us-gaap:SharePrice contextRef="c50" decimals="2" unitRef="usdPershares">6.7</us-gaap:SharePrice>
    <us-gaap:LongTermDebtTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Lines
of Credit&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately
$1.4 million), of which RMB 5,000,000 (approximately $0.7 million) was advanced in April 2020, and RMB 3,000,000 (approximately $0.4
million) was advanced in July 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two
years from the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral
in certain land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the
Company&#x2019;s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest expense under
this facility for the years ended December 31, 2022 and 2021 was $12,063 and $44,629, respectively. The Company repaid the remaining
RMB 5,900,000 and RMB 1,600,000 (approximately $0.85 and $0.23 million, respectively) during the year ended December 31, 2022 and 2021,
respectively as per the repayment schedule in full satisfaction of the line of credit.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2020 the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately
$1.2 million), all of which has been advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one
year on the anniversary date of the line of credit. In addition, the Company&#x2019;s Chief Executive Officer and Chair of the Board personally
guaranteed the new line of credit and pledged personal assets as collateral for the loan. On June 21, 2021 the Company paid the balance
in full. On June 25, 2021 the Company entered into a new loan bearing an interest rate of 4.17%. &lt;span&gt;The
Company paid all principal and interest on June 21, 2022 and on June 22, 2022 entered into a new loan for the same principal amount bearing
interest at&#160;4.17% and due December 21, 2022. On December 21, 2022 the Company repaid the loan in full and entered into a new line
of credit for an aggregate amount of RMB 7,300,000 (approximately $1.0 million) with interest payable monthly at a rate of 3.9%. The
line of credit is payable in one year. The Company received an advance on the line of credit in the amount of RMB 3,800,000 (approximately
$0.56 million) on December 30, 2022. The Company has RMB 3,500,000 (approximately $0.44 million) remaining to borrow on this line of
credit. &lt;/span&gt;In addition, the Company&#x2019;s Chief Executive Officer and Chair of the Board personally guaranteed the new line of
credit and pledged personal assets as collateral for the loan. Total interest expense under this facility for the years ended December
31, 2022 and 2021 was $53,283 and $54,294, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained
an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020
under this line. The loan bears interest at the rate of 4.50% per annum. In September, 2021 the Company repaid the line of credit in
full. Also in September, 2021 the Company entered into a new line a credit in the amount of RMB 3,200,000 (approximately $0.8 million)
on the same terms. The line of credit was due on September 2, 2022. &lt;span&gt;The line of credit was paid
in full on September 6, 2022.&#160;On September 9, 2022, the Company received a new line of credit in the same amount. The loan bears
interest at a rate of&#160;4.5% and is due on September 7, 2023.&lt;/span&gt; In addition, the Company&#x2019;s Chief Executive Officer and
Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest
expense under this facility for the years ended December 31, 2021 and 2020 was $21,528 and $22,258, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 12, 2021, the Company obtained a short-term loan of RMB 3 million (approximately US$460,000) from Haikou HaiHongXin microfinance
Co., Ltd., with a monthly interest rate of 1.5%. The company paid off the loan in September 2021. Total interest paid on this loan was
$0 and $16,051 for the years ended December 31, 2022 and 2021, respectively. This loan was guaranteed by Haikou Financing Guarantee Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 18, 2021 the Company obtained a line of credit for RMB 10,000,000 (approximately $1.54 million) with Bank of China. The loan
bears interest at the rate of 3.85% per annum. &lt;span&gt;The line of credit was paid in full on the due date
of September 18, 2022. On September 30, 2022 the Company received a new line of credit in the same amount. The loan bears interest at
the rate of 3.45% and is due September 28, 2023. &lt;/span&gt;The loan is collateralized by the Company&#x2019;s new production facility and
the included production line equipment and machinery. In addition, the Company&#x2019;s Chief Executive Officer and Chair of the Board
personally guaranteed the new line of credit. Total interest paid on this loan was $54,923 and $15,582 for the years ended December 31,
2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principal
payments required for the remaining terms of the lines of credit as of December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Lines
    of Credit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,440,915&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,440,915&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company obtained a construction loan facility from Bank of China, dated June 21, 2013, in the aggregate amount of RMB 80,000,000 (approximately
$13 million). The loan facility was for an eight-year term, which commenced on July 11, 2013, the initial draw-down date.&#160;The proceeds
of the loan were used for and are collateralized by the construction of the Company&#x2019;s new production facility and the included
production line equipment and machinery.&#160;&#160;The interest rate was 5.39% during the year ended December 31, 2021. During the year
ended December 31, 2021, the Company repaid all the remaining principal payments due under the loan in the amount of $2,325,039 (RMB
15,000,000).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value of Lines of Credit&lt;/i&gt;&lt;/b&gt; &#x2013; Based on the borrowing rates currently available to the Company for bank loans with similar
terms and maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2022 and December 31, 2021
approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ConstructionLoan contextRef="c51" decimals="0" unitRef="cny">10000000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c51" decimals="-5" unitRef="usd">1400000</us-gaap:ConstructionLoan>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c52" decimals="0" unitRef="cny">5000000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c52" decimals="-5" unitRef="usd">700000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c53" decimals="0" unitRef="cny">3000000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c53" decimals="-5" unitRef="usd">400000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c54" decimals="4" unitRef="pure">0.0425</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseOther contextRef="c55" decimals="0" unitRef="usd">12063</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c56" decimals="0" unitRef="usd">44629</us-gaap:InterestExpenseOther>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c57" decimals="0" unitRef="cny">5900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c58" decimals="0" unitRef="cny">1600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c57" decimals="-4" unitRef="usd">850000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c58" decimals="-4" unitRef="usd">230000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ConstructionLoan contextRef="c59" decimals="0" unitRef="cny">8500000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c59" decimals="-5" unitRef="usd">1200000</us-gaap:ConstructionLoan>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c60" decimals="4" unitRef="pure">0.0405</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c61" decimals="4" unitRef="pure">0.0417</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c62" decimals="4" unitRef="pure">0.0417</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConstructionLoan contextRef="c63" decimals="0" unitRef="cny">7300000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c63" decimals="-5" unitRef="usd">1000000</us-gaap:ConstructionLoan>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c63" decimals="3" unitRef="pure">0.039</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConstructionLoan contextRef="c64" decimals="0" unitRef="cny">3800000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c64" decimals="-4" unitRef="usd">560000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c65" decimals="0" unitRef="cny">3500000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c3" decimals="-4" unitRef="usd">440000</us-gaap:ConstructionLoan>
    <us-gaap:InterestExpenseOther contextRef="c0" decimals="0" unitRef="usd">53283</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c66" decimals="0" unitRef="usd">54294</us-gaap:InterestExpenseOther>
    <us-gaap:ConstructionLoan contextRef="c67" decimals="0" unitRef="cny">3200000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c68" decimals="-5" unitRef="usd">500000</us-gaap:ConstructionLoan>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c69" decimals="0" unitRef="cny">2343340</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c69" decimals="-5" unitRef="usd">300000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c70" decimals="0" unitRef="cny">856660</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c70" decimals="-5" unitRef="usd">100000</us-gaap:PaymentsForMortgageDeposits>
    <cphi:InterestRate contextRef="c3" decimals="4" unitRef="pure">0.045</cphi:InterestRate>
    <us-gaap:ConstructionLoan contextRef="c71" decimals="0" unitRef="cny">3200000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c71" decimals="-5" unitRef="usd">800000</us-gaap:ConstructionLoan>
    <cphi:InterestRate contextRef="c72" decimals="3" unitRef="pure">0.045</cphi:InterestRate>
    <us-gaap:InterestExpenseOther contextRef="c5" decimals="0" unitRef="usd">21528</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c73" decimals="0" unitRef="usd">22258</us-gaap:InterestExpenseOther>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c74" decimals="-6" unitRef="cny">3000000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c74" decimals="0" unitRef="usd">460000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <cphi:InterestRate contextRef="c74" decimals="3" unitRef="pure">0.015</cphi:InterestRate>
    <cphi:InterestAmount contextRef="c3" decimals="0" unitRef="usd">0</cphi:InterestAmount>
    <cphi:InterestAmount contextRef="c4" decimals="0" unitRef="usd">16051</cphi:InterestAmount>
    <us-gaap:ConstructionLoan contextRef="c75" decimals="0" unitRef="cny">10000000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c75" decimals="-4" unitRef="usd">1540000</us-gaap:ConstructionLoan>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c75" decimals="4" unitRef="pure">0.0385</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c76" decimals="4" unitRef="pure">0.0345</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <cphi:InterestAmount contextRef="c57" decimals="0" unitRef="usd">54923</cphi:InterestAmount>
    <cphi:InterestAmount contextRef="c58" decimals="0" unitRef="usd">15582</cphi:InterestAmount>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Lines
    of Credit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,440,915&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,440,915&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c78" decimals="0" unitRef="usd">2440915</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt contextRef="c78" decimals="0" unitRef="usd">2440915</us-gaap:LongTermDebt>
    <us-gaap:ConstructionLoan contextRef="c77" decimals="0" unitRef="cny">80000000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="c77" decimals="-6" unitRef="usd">13000000</us-gaap:ConstructionLoan>
    <cphi:InterestRate contextRef="c4" decimals="4" unitRef="pure">0.0539</cphi:InterestRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c4" decimals="0" unitRef="usd">2325039</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c4" decimals="0" unitRef="cny">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; CONVERTIBLE NOTE PAYABLE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On November 17, 2021, the Company entered into a Securities Purchase
Agreement (the &#x201c;Agreement&#x201d;) pursuant to which the Company issued an unsecured convertible promissory note (the &#x201c;Note&#x201d;)
to an institutional accredited investor Streeterville Capital, LLC (the &#x201c;Investor&#x201d;). The Note matures fifteen months after
the purchase price of the Note is delivered from the Investor to the Company (the &#x201c;Purchase Price Date&#x201d;). The Note was due
on February 17, 2023. The parties are in negotiation in extending the Note. No event of default has occurred as of the date herein. The
Note has the original principal amount of $5,250,000 and Investor gave consideration of $5,000,000, reflecting original issue discount
of $250,000. The transaction contemplated under the Agreement was closed on November 19, 2021 and the Company anticipates using the proceeds
for general working capital purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Note was convertible into 350,000 shares of the Company&#x2019;s common stock at a price of $15.00 per share through April 19, 2022. Thereafter,
the Note is convertible into 175,000 shares at a price of $30.00 per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined
in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event
of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration
by 15% or 5%, depending on the nature of the Event of Default.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the terms of the Agreement and the Note, the Company must obtain Investor&#x2019;s consent for certain fundamental transactions such
as consolidation, merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change
of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor&#x2019;s prior written consent
will be deemed an Event of Default.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investor
may redeem all or any part the outstanding balance of the Note, subject to $500,000 per calendar month, at any time after one hundred
twenty-one (121) days from the Purchase Price Date upon three trading days&#x2019; notice, in cash or converting into shares of the Company&#x2019;s
common stock, at a price equal to 85% multiplied by the lowest daily volume weighted average price during the ten trading days immediately
preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note
provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding
balance of the Note with the Investor&#x2019;s consent. At inception, the Note was redeemable into 881,143 shares based on the lowest
volume weighted average price of $5.95817 on the inception date of November 19, 2021. As of December 31, 2022, the Note was convertible
into 3,836,070 shares of common stock based on 85% of the lowest volume weighted average price of $0.9910 on that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
original issue discount of $250,000 was fully earned at the inception of the Note, and accordingly was recognized as interest expense
in the accompanying statement of operations for the year ended December 31, 2021. Total interest expense for the years ended December
31, 2022 and 2021 was $250,314 and $279,979, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 21, 2022 the Investor delivered its notice of redemption for $100,000 of the Note at the lowest volume weighted average price of
$3.113 during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total
of 32,123 shares of common stock to the Investor on March 23, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
March 30, 2022 the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the price of $3.129,
which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;63,918 shares of common stock to the Investor on March 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
June 9, 2022 the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the price of $1.98,
which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;101,010 shares of common stock to the Investor on June 13, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
August 3, 2022&#160;the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the conversion
price of $1.755, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;113,960 shares of common stock to the Investor
on August 4, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
October 17, 2022&#160;the Investor delivered its notice of redemption for $100,000&#160;of the Note and related interest at the
conversion price of $1.12, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days
immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of&#160;89,286 shares of common
stock to the Investor on October 18, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
December 1, 2022&#160;the Investor delivered its notice of redemption for $100,000&#160;of the Note and related interest at the conversion
price of $0.829, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;120,627 shares of common stock to the Investor
on December 2, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
December 5, 2022&#160;the Investor delivered its notice of redemption for $310,000&#160;of the Note and related interest at the conversion
price of $0.829, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;373,945 shares of common stock to the Investor
on December 6, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
December 13, 2022&#160;the Investor delivered its notice of redemption for $90,000&#160;of the Note and related interest at the conversion
price of $0.91, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;98,901&#160;shares of common stock to the Investor
on December 14, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
December 14, 2022&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion
price of $0.829, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;180,905 shares of common stock to the Investor
on December 15, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentTerm contextRef="c79">P15M</us-gaap:DebtInstrumentTerm>
    <us-gaap:ConvertibleNotesPayable contextRef="c80" decimals="0" unitRef="usd">5250000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c79" decimals="0" unitRef="usd">5000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <cphi:OriginalIssueDiscount contextRef="c79" decimals="0" unitRef="usd">250000</cphi:OriginalIssueDiscount>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="c81" decimals="0" unitRef="pure">350000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c82" decimals="2" unitRef="usdPershares">15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <cphi:ConvertibleNote contextRef="c0" decimals="0" unitRef="shares">175000</cphi:ConvertibleNote>
    <cphi:ConvertibleNoteConversionPrice contextRef="c0" decimals="2" unitRef="usdPershares">30</cphi:ConvertibleNoteConversionPrice>
    <cphi:InterestAccruesOnNoteDescription contextRef="c0">Interest
accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined
in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event
of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration
by 15% or 5%, depending on the nature of the Event of Default.&#160;</cphi:InterestAccruesOnNoteDescription>
    <cphi:RedeemOfOutstandingNote contextRef="c0" decimals="0" unitRef="usd">500000</cphi:RedeemOfOutstandingNote>
    <cphi:PercentageOfCommonStockPriceOnWeightedAveragePrice contextRef="c0" decimals="2" unitRef="pure">0.85</cphi:PercentageOfCommonStockPriceOnWeightedAveragePrice>
    <cphi:NoteRedeemableIntoShares contextRef="c83" decimals="0" unitRef="shares">881143</cphi:NoteRedeemableIntoShares>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c83" decimals="5" unitRef="usdPershares">5.95817</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cphi:NoteRedeemableIntoShares contextRef="c0" decimals="0" unitRef="shares">3836070</cphi:NoteRedeemableIntoShares>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="0" unitRef="usdPershares">85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cphi:WeightedAveragePrice contextRef="c0" decimals="4" unitRef="usdPershares">0.991</cphi:WeightedAveragePrice>
    <cphi:OriginalIssueDiscount contextRef="c5" decimals="0" unitRef="usd">250000</cphi:OriginalIssueDiscount>
    <us-gaap:InterestAndDebtExpense contextRef="c0" decimals="0" unitRef="usd">250314</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c5" decimals="0" unitRef="usd">279979</us-gaap:InterestAndDebtExpense>
    <cphi:RedeemOfOutstandingNote contextRef="c84" decimals="0" unitRef="usd">100000</cphi:RedeemOfOutstandingNote>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c84" decimals="3" unitRef="usdPershares">3.113</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharesIssued contextRef="c85" decimals="0" unitRef="shares">32123</us-gaap:SharesIssued>
    <cphi:RedeemOfOutstandingNote contextRef="c86" decimals="0" unitRef="usd">200000</cphi:RedeemOfOutstandingNote>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c86" decimals="3" unitRef="usdPershares">3.129</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c87" decimals="2" unitRef="pure">0.85</us-gaap:DebtWeightedAverageInterestRate>
    <cphi:CommonStockIssuedToInvestor contextRef="c88" decimals="0" unitRef="shares">63918</cphi:CommonStockIssuedToInvestor>
    <cphi:RedeemOfOutstandingNote contextRef="c89" decimals="0" unitRef="usd">200000</cphi:RedeemOfOutstandingNote>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c89" decimals="2" unitRef="usdPershares">1.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c90" decimals="2" unitRef="pure">0.85</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:SharesIssued contextRef="c91" decimals="0" unitRef="shares">101010</us-gaap:SharesIssued>
    <cphi:RedeemOfOutstandingNote contextRef="c92" decimals="0" unitRef="usd">200000</cphi:RedeemOfOutstandingNote>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c92" decimals="3" unitRef="usdPershares">1.755</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c93" decimals="2" unitRef="pure">0.85</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:SharesIssued contextRef="c94" decimals="0" unitRef="shares">113960</us-gaap:SharesIssued>
    <cphi:RedeemOfOutstandingNote contextRef="c95" decimals="0" unitRef="usd">100000</cphi:RedeemOfOutstandingNote>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c95" decimals="2" unitRef="usdPershares">1.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c96" decimals="2" unitRef="pure">0.85</us-gaap:DebtWeightedAverageInterestRate>
    <cphi:CommonStockIssuedToInvestor1 contextRef="c97" decimals="0" unitRef="shares">89286</cphi:CommonStockIssuedToInvestor1>
    <cphi:RedeemOfOutstandingNote contextRef="c98" decimals="0" unitRef="usd">100000</cphi:RedeemOfOutstandingNote>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c98" decimals="3" unitRef="usdPershares">0.829</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c99" decimals="2" unitRef="pure">0.85</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:SharesIssued contextRef="c100" decimals="0" unitRef="shares">120627</us-gaap:SharesIssued>
    <cphi:RedeemOfOutstandingNote contextRef="c101" decimals="0" unitRef="usd">310000</cphi:RedeemOfOutstandingNote>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c101" decimals="3" unitRef="usdPershares">0.829</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c102" decimals="2" unitRef="pure">0.85</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:SharesIssued contextRef="c103" decimals="0" unitRef="shares">373945</us-gaap:SharesIssued>
    <cphi:RedeemOfOutstandingNote contextRef="c104" decimals="0" unitRef="usd">90000</cphi:RedeemOfOutstandingNote>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c104" decimals="2" unitRef="usdPershares">0.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c105" decimals="2" unitRef="pure">0.85</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:SharesIssued contextRef="c106" decimals="0" unitRef="shares">98901</us-gaap:SharesIssued>
    <cphi:RedeemOfOutstandingNote contextRef="c107" decimals="0" unitRef="usd">150000</cphi:RedeemOfOutstandingNote>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c107" decimals="3" unitRef="usdPershares">0.829</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c106" decimals="2" unitRef="pure">0.85</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:SharesIssued contextRef="c108" decimals="0" unitRef="shares">180905</us-gaap:SharesIssued>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 - LEASES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain
payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right to use assets
when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions
or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing
the Company&#x2019;s incremental borrowing rate at the initial measurement date. For the years ended December 31, 2022 and 2021, operating
lease cost was $78,092 and $92,085, respectively and cash paid for amounts included in the measurement of lease liabilities for operating
cash flows from operating leases was $82,015 and $98,845, respectively. As of December 31, 2022 and 2021, the Company reported operating
lease right of use assets of $39,046 and $127,958, respectively and operating use liabilities of $40,445 and $85,282, respectively. As
of December 31, 2022, its operating leases had a weighted average remaining lease term of 0.50 years and a weighted average discount
rate of 4.75%.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Minimum
lease payments for the Company&#x2019;s operating lease liabilities were as follows for the twelve month periods ended December 31:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;41,007&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Total undiscounted cash flows&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;41,007&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(562&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40,445&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(40,445&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Operating lease liabilities, net of current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-41; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has leases with terms less than one year for certain provincial sales offices that are not material.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="0" unitRef="usd">78092</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="0" unitRef="usd">92085</us-gaap:OperatingLeaseCost>
    <cphi:CashFlowForOperatingLease contextRef="c0" decimals="0" unitRef="usd">82015</cphi:CashFlowForOperatingLease>
    <cphi:CashFlowForOperatingLease contextRef="c5" decimals="0" unitRef="usd">98845</cphi:CashFlowForOperatingLease>
    <cphi:OperatingLeaseRightsOfUseAssets contextRef="c3" decimals="0" unitRef="usd">39046</cphi:OperatingLeaseRightsOfUseAssets>
    <cphi:OperatingLeaseRightsOfUseAssets contextRef="c4" decimals="0" unitRef="usd">127958</cphi:OperatingLeaseRightsOfUseAssets>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" unitRef="usd">40445</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="0" unitRef="usd">85282</us-gaap:OperatingLeaseLiability>
    <cphi:WeightedAveragesRemainingLeaseTerm contextRef="c0">P0Y6M</cphi:WeightedAveragesRemainingLeaseTerm>
    <cphi:WeightedAverageDiscountRate contextRef="c0" decimals="4" unitRef="pure">0.0475</cphi:WeightedAverageDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;41,007&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Total undiscounted cash flows&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;41,007&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(562&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40,445&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(40,445&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Operating lease liabilities, net of current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-41; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="0" unitRef="usd">41007</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c3" decimals="0" unitRef="usd">41007</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:ReceivableWithImputedInterestNetAmount contextRef="c3" decimals="0" unitRef="usd">562</us-gaap:ReceivableWithImputedInterestNetAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="0" unitRef="usd">40445</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <cphi:LessOperatingLeaseLiabilitiesCurrentPortion contextRef="c0" decimals="0" unitRef="usd">40445</cphi:LessOperatingLeaseLiabilitiesCurrentPortion>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 - INCOME TAXES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary
differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities
is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities
are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the &#x201c;more-likely-than-not&#x201d;
threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included
as a component of other expenses. Through December 31, 2022, the Company has not identified any uncertain tax positions that it has taken.
U.S. income tax returns for the years ended December 31, 2019 through December 31, 2022 and the Chinese income tax return for the year
ended December 31, 2022 are open for possible examination.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
was no provision for income taxes for the years ended December 31, 2022 and 2021, respectively due to continued net losses of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Years
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(Benefit) tax at statutory rate of 25%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(973,717&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(849,869&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Prior year refund received&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-42; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-43; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Other, primarily the difference in U.S. tax rates&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,416&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,440&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;965,301&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;841,429&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-44; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-45; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
temporary differences which give rise to the deferred income tax assets and liability are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Allowance for doubtful trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,184,882&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,578,177&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Allowance for doubtful other receivables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6,787&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,052&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inventory obsolescence reserve&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34,921&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;137,549&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,201&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,201&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Expenses not deductible in current year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,087,328&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,187,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Advances for intangible assets impairment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,782,172&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,685,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Lease liability, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;349&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;376&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;PRC net operating loss carry forward&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,036,114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,779,437&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;U.S. net operating loss carry forward&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,849,800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,602,243&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,985,554&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;23,982,509&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21,985,554&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(23,982,509&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 12px"&gt;&lt;span style="font-size: 10pt"&gt;Net deferred income tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-46; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-47; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Deferred income tax liability:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;754,698&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;824,407&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company had net operating loss carryforwards for PRC tax purposes of approximately $20.1 million which are
available to offset any future taxable income through 2026. Approximately $6.0 million of these carryforwards expired in December 2022.
The Company also has net operating losses for United States federal income tax purposes of approximately $8.7 million of which $5.1 million
is available to offset future taxable income, if any, through 2039, and $3.7 million are available for carryforward indefinitely subject
to a limitation of 80% of taxable income for each tax year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.
federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the &#x201c;U.S. Tax Reform&#x201d;), was signed into law on
December&#160;22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the
statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December&#160;31, 2017; limiting and/or
eliminating many business deductions; migrating the U.S. to a territorial tax system with a&#160;one-time&#160;transition tax on a mandatory
deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally
eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized.&#160;&#160;The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&#160;&#160;Management
considers projected future taxable income and tax planning strategies in making this assessment.&#160;&#160;Based upon an assessment
of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets
are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets
as of December 31, 2022 and 2021.&#160;&#160;Therefore, the Company provided for a valuation allowance against its deferred tax assets
of $21,985,554 and $23,982,509 as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education
surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Years
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(Benefit) tax at statutory rate of 25%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(973,717&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(849,869&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Prior year refund received&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-42; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-43; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Other, primarily the difference in U.S. tax rates&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,416&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,440&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;965,301&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;841,429&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-44; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-45; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="2" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="0" unitRef="usd">-973717</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="0" unitRef="usd">-849869</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c0" decimals="0" unitRef="usd">8416</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c5" decimals="0" unitRef="usd">8440</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" unitRef="usd">965301</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" unitRef="usd">841429</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Allowance for doubtful trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,184,882&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,578,177&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Allowance for doubtful other receivables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6,787&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,052&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inventory obsolescence reserve&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34,921&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;137,549&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,201&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,201&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Expenses not deductible in current year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,087,328&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,187,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Advances for intangible assets impairment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,782,172&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,685,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Lease liability, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;349&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;376&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;PRC net operating loss carry forward&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,036,114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,779,437&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;U.S. net operating loss carry forward&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,849,800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,602,243&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,985,554&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;23,982,509&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21,985,554&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(23,982,509&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 12px"&gt;&lt;span style="font-size: 10pt"&gt;Net deferred income tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-46; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-47; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Deferred income tax liability:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;754,698&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;824,407&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c3" decimals="0" unitRef="usd">4184882</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c4" decimals="0" unitRef="usd">4578177</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="c3" decimals="0" unitRef="usd">6787</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="c4" decimals="0" unitRef="usd">8052</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c3" decimals="0" unitRef="usd">34921</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c4" decimals="0" unitRef="usd">137549</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c3" decimals="0" unitRef="usd">3201</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c4" decimals="0" unitRef="usd">3201</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c3" decimals="0" unitRef="usd">1087328</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c4" decimals="0" unitRef="usd">1187760</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="c3" decimals="0" unitRef="usd">9782172</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="c4" decimals="0" unitRef="usd">10685714</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="0" unitRef="usd">349</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="0" unitRef="usd">376</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c3" decimals="0" unitRef="usd">5036114</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c4" decimals="0" unitRef="usd">5779437</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="0" unitRef="usd">1849800</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c4" decimals="0" unitRef="usd">1602243</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" unitRef="usd">21985554</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="0" unitRef="usd">23982509</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" unitRef="usd">21985554</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" unitRef="usd">23982509</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c3" decimals="0" unitRef="usd">754698</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c4" decimals="0" unitRef="usd">824407</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-5" unitRef="usd">20100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <cphi:NetOperatingLossCarryForwardsExpirationDescription contextRef="c0">Approximately $6.0 million of these carryforwards expired in December 2022.
The Company also has net operating losses for United States federal income tax purposes of approximately $8.7 million of which $5.1 million
is available to offset future taxable income, if any, through 2039, and $3.7 million are available for carryforward indefinitely subject
to a limitation of 80% of taxable income for each tax year.</cphi:NetOperatingLossCarryForwardsExpirationDescription>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c109" decimals="2" unitRef="pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c110" decimals="2" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <cphi:ValuationAllowanceForDeferredTaxAssets contextRef="c3" decimals="0" unitRef="usd">21985554</cphi:ValuationAllowanceForDeferredTaxAssets>
    <cphi:ValuationAllowanceForDeferredTaxAssets contextRef="c4" decimals="0" unitRef="usd">23982509</cphi:ValuationAllowanceForDeferredTaxAssets>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2013; FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows:
Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities; Level 2 &#x2013; Observable inputs other than Level
1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can
be corroborated by observable market data; and Level 3 &#x2013; Unobservable inputs supported by little or no market activity for financial
instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments
for which the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses fair value to measure the value of the banker&#x2019;s acceptance notes it holds as of December 31, 2022 and 2021.&#160;The
banker&#x2019;s acceptance notes are recorded at cost which approximates fair value.&#160;The Company held the following assets and liabilities
recorded at fair value:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Reporting
    Date Using&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,
    &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Banker&#x2019;s acceptance notes&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,784&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-48; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,784&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-49; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,784&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,784&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Reporting
    Date Using&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;br/&gt;
    2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Banker&#x2019;s acceptance notes&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;91,362&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;91,362&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;91,362&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-54; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;91,362&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-55; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Reporting
    Date Using&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,
    &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Banker&#x2019;s acceptance notes&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,784&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-48; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,784&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-49; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,784&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,784&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Reporting
    Date Using&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;br/&gt;
    2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Banker&#x2019;s acceptance notes&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;91,362&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;91,362&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;91,362&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-54; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;91,362&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-55; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="c3" decimals="0" unitRef="usd">13784</us-gaap:CustomersLiabilityForAcceptancesNet>
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="c112" decimals="0" unitRef="usd">13784</us-gaap:CustomersLiabilityForAcceptancesNet>
    <us-gaap:FairValueNetAssetLiability contextRef="c3" decimals="0" unitRef="usd">13784</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c112" decimals="0" unitRef="usd">13784</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="c4" decimals="0" unitRef="usd">91362</us-gaap:CustomersLiabilityForAcceptancesNet>
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="c115" decimals="0" unitRef="usd">91362</us-gaap:CustomersLiabilityForAcceptancesNet>
    <us-gaap:FairValueNetAssetLiability contextRef="c4" decimals="0" unitRef="usd">91362</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c115" decimals="0" unitRef="usd">91362</us-gaap:FairValueNetAssetLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 - STOCKHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue 500,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001
par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or
limitations as determined solely by the Company&#x2019;s Board.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According
to relevant PRC laws, companies registered in the PRC, including the Company&#x2019;s PRC subsidiary, Helpson, are required to allocate
at least 10% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus
reserve accounts until the reserve account balances reach 50% of the company&#x2019;s registered capital prior to their remittance of
funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the
parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is
$8,145,000 at December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2010
Incentive Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 12, 2010, the Company&#x2019;s Board adopted the Company&#x2019;s
2010 Incentive Plan (the &#x201c;Plan&#x201d;), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board
of Directors approved the First Amendment to the 2010 Incentive Plan (the &#x201c;Amendment&#x201d;), pursuant to which the term of the
2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October
25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase
the number of shares of the Common Stock, that are reserved thereunder by 500,000 shares from 400,000 shares to 900,000 shares. On October
27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated 2010 Long Term Incentive
Plan to increase the number of shares of common stock that are reserved thereunder by an additional 500,000 shares from 900,000 to 1,400,000.
The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its
employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries.
The Plan currently allows for equity awards of up to 1,400,000 shares of common stock. Through December 31, 2022, there were 490,000 shares
of stock and stock options granted under the Plan.&#160; A total of 66,500 options were outstanding as of December 31, 2022 under the
Plan. As such, there are 910,000 additional shares available for issuance under the Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2022 the Company issued 30,000 shares of common stock pursuant to a contract with a consultant to the Company for services.
The Company recorded compensation expense totaling $42,000 based on the closing market price of its common stock of $1.40 per share on
the issuance date. The contract also calls for the issuance of up to 90,000 additional shares of common stock contingent upon the achievement
of certain milestones as described in the contract. At December 31, 2022 these milestones had not been met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 4, 2022 the Company issued an option to purchase &lt;span&gt;60,000 shares of common stock at an exercise
price at $5.60 per share, under the Plan to the same consultant in the preceding paragraph. The Option vests immediately and expires
on October 3, 2027. &lt;/span&gt;The fair value of the options granted of $36,270 was calculated using the Black-Scholes option valuation model
using the closing market price of $1.50 per share, volatility of 115.5%, risk free interest rate of 3.84% and an expected life of 2.5
years. The value was charged to general and administrative expenses on the accompanying Statement of Operations for the year ended December
31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 9, 2021 the Company issued an aggregate of 176,000 fully vested shares of common stock at the price of $6.70 per share, representing
the closing market price on that date to its Chairperson, Chief Executive Officer and Interim Chief Financial Officer under the Plan,
as amended, to partially offset certain unpaid cash compensation totaling $1,179,200.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also
on September 9, 2021 the Company issued an option to purchase &lt;span&gt;6,500 shares of common stock at an
exercise price at $14.70 per share, under the Plan. The Option vests immediately and expires on September 9, 2024. &lt;/span&gt;The fair value
of the options granted of $15,243 was calculated using the Black-Scholes option valuation model using the closing market price of $6.70
per share, volatility of 118.4%, risk free interest rate of 0.75% and an expected life of 1.5 years. The value was charged to general
and administrative expenses on the accompanying Statement of Operations for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 23, 2020 the Board approved the issuance of 200,000 shares of common stock from the Company&#x2019;s 2010 Long-Term Incentive
Plan, as amended for the partial conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and
Interim Chief Financial Officer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <cphi:AftertaxNetIncomePercentage contextRef="c0" decimals="2" unitRef="pure">0.10</cphi:AftertaxNetIncomePercentage>
    <cphi:ReserveAccountBalancesPercentage contextRef="c0" decimals="2" unitRef="pure">0.50</cphi:ReserveAccountBalancesPercentage>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount contextRef="c0" decimals="0" unitRef="usd">8145000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount contextRef="c5" decimals="0" unitRef="usd">8145000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c117" decimals="0" unitRef="shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c118" decimals="0" unitRef="shares">400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c119" decimals="0" unitRef="shares">900000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c120" decimals="0" unitRef="shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c121" decimals="0" unitRef="shares">900000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c122" decimals="0" unitRef="shares">1400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c123" decimals="0" unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c123" decimals="0" unitRef="shares">490000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <cphi:TotalOptionOutstanding contextRef="c0" decimals="0" unitRef="shares">66500</cphi:TotalOptionOutstanding>
    <cphi:AdditionalSharesAvailableForIssuance contextRef="c3" decimals="0" unitRef="shares">910000</cphi:AdditionalSharesAvailableForIssuance>
    <cphi:CommonStockPursuant contextRef="c124" decimals="0" unitRef="shares">30000</cphi:CommonStockPursuant>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="c124" decimals="0" unitRef="usd">42000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <cphi:ClosingMarketPrice contextRef="c124" decimals="2" unitRef="usdPershares">1.4</cphi:ClosingMarketPrice>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital contextRef="c125" decimals="0" unitRef="usd">90000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <cphi:PurchaseofCommonStockShares contextRef="c126" decimals="0" unitRef="shares">60000</cphi:PurchaseofCommonStockShares>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c127" decimals="2" unitRef="usdPershares">5.6</us-gaap:StockOptionExercisePriceIncrease>
    <cphi:FairValueOfOptionsGranted contextRef="c127" decimals="0" unitRef="usd">36270</cphi:FairValueOfOptionsGranted>
    <cphi:ClosingMarketPrice contextRef="c127" decimals="2" unitRef="usdPershares">1.5</cphi:ClosingMarketPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c127" decimals="3" unitRef="pure">1.155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c127" decimals="4" unitRef="pure">0.0384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c127">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharesIssued contextRef="c128" decimals="0" unitRef="shares">176000</us-gaap:SharesIssued>
    <us-gaap:SharePrice contextRef="c128" decimals="2" unitRef="usdPershares">6.7</us-gaap:SharePrice>
    <cphi:UnpaidCashCompensation contextRef="c129" decimals="0" unitRef="usd">1179200</cphi:UnpaidCashCompensation>
    <cphi:PurchaseofCommonStockShares contextRef="c48" decimals="0" unitRef="shares">6500</cphi:PurchaseofCommonStockShares>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c130" decimals="2" unitRef="usdPershares">14.7</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c130" decimals="0" unitRef="usd">15243</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <cphi:MarketPricePerShare contextRef="c130" decimals="2" unitRef="usdPershares">6.7</cphi:MarketPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c130" decimals="3" unitRef="pure">1.184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c130" decimals="4" unitRef="pure">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <cphi:ExpectedLifes contextRef="c130">P1Y6M</cphi:ExpectedLifes>
    <us-gaap:SharesIssued contextRef="c131" decimals="0" unitRef="shares">200000</us-gaap:SharesIssued>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c132" decimals="0" unitRef="usd">864480</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &#x2013; RISKS &amp;amp; UNCERTAINTIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Current
vulnerability due to certain concentrations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2022, no customer accounted for more than 10% of sales and three customers accounted for 52.9%, 11.4% and
10.4% of accounts receivable. Two suppliers accounted for 21.7% and 11.1% of raw material purchases, and three different products accounted
for 29.2%, 27.3% and 12.5% of revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2021, no customer accounted for more than 10% of sales and three customers accounted for 52.1%, 11.2% and
10.2% of accounts receivable. Three suppliers accounted for 24.8%, 12.7% and 11.8% of raw material purchases, and three different products
accounted for 20.7%, 17.7% and 13.5% of revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nature
of Operations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Impact
from the New Coronavirus Global Pandemic (&#x201c;COVID-19&#x201d;)&#160;&lt;/b&gt;- Although the outbreak of COVID-19 since the first quarter
2020 has been under control, and China has returned to normal production and social life in an orderly manner, China is still encountering
frequent resurgences in many of the major cities. For now, these resurgences have not caused material impact to our daily operations.
However, we cannot guarantee subsequent resurgence will not have any material effect on the operation of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Economic
environment -&#160;&lt;/b&gt;Substantially all of the Company&#x2019;s operations are conducted in the PRC, and therefore the Company is subject
to special considerations and significant risks not typically associated with companies operating in the United States of America. These
risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The
Company&#x2019;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by
changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance
abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely
affect the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, all of the Company&#x2019;s revenue is denominated in the PRC&#x2019;s currency of Renminbi (RMB), which must be converted into
other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies
abroad require approval of the PRC government.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <cphi:ConcentrationRiskPercentage contextRef="c133" decimals="2" unitRef="pure">0.10</cphi:ConcentrationRiskPercentage>
    <cphi:NumberOfCustomers contextRef="c134" decimals="0" unitRef="pure">3</cphi:NumberOfCustomers>
    <cphi:ConcentrationRiskPercentage contextRef="c135" decimals="3" unitRef="pure">0.529</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c134" decimals="3" unitRef="pure">0.114</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c136" decimals="3" unitRef="pure">0.104</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c137" decimals="2" unitRef="pure">0.02</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c138" decimals="3" unitRef="pure">0.217</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c139" decimals="3" unitRef="pure">0.111</cphi:ConcentrationRiskPercentage>
    <cphi:NumberOfSuppliers contextRef="c140" decimals="0" unitRef="pure">3</cphi:NumberOfSuppliers>
    <cphi:ConcentrationRiskPercentage contextRef="c141" decimals="3" unitRef="pure">0.292</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c142" decimals="3" unitRef="pure">0.273</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c143" decimals="3" unitRef="pure">0.125</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c144" decimals="2" unitRef="pure">0.10</cphi:ConcentrationRiskPercentage>
    <cphi:NumberOfCustomers contextRef="c144" decimals="0" unitRef="pure">3</cphi:NumberOfCustomers>
    <cphi:ConcentrationRiskPercentage contextRef="c145" decimals="3" unitRef="pure">0.521</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c146" decimals="3" unitRef="pure">0.112</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c147" decimals="3" unitRef="pure">0.102</cphi:ConcentrationRiskPercentage>
    <cphi:NumberOfSuppliers contextRef="c148" decimals="0" unitRef="pure">3</cphi:NumberOfSuppliers>
    <cphi:ConcentrationRiskPercentage contextRef="c149" decimals="3" unitRef="pure">0.248</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c150" decimals="3" unitRef="pure">0.127</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c151" decimals="3" unitRef="pure">0.118</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c152" decimals="3" unitRef="pure">0.207</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c153" decimals="3" unitRef="pure">0.177</cphi:ConcentrationRiskPercentage>
    <cphi:ConcentrationRiskPercentage contextRef="c154" decimals="3" unitRef="pure">0.135</cphi:ConcentrationRiskPercentage>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;&lt;b&gt;NOTE
14 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
January 5, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion
price of $0.763, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;196,592 shares of common stock to the Investor
on January 6, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
January 18, 2023&#160;the Investor delivered its notice of redemption for $250,000&#160;of the Note and related interest at the conversion
price of $0.763, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;327,654 shares of common stock to the Investor
on January 19, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;On
March 2, 2023&#160;the Investor delivered its notice of redemption for $250,000&#160;of the Note and related interest at the conversion
price of $0.575, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding
the applicable redemption conversion. Accordingly, the Company issued a total of&#160;434,783 shares of common stock to the Investor
on March 9, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;Effective
March 6, 2023 the Company implemented a 1-for-10 reverse split of its common stock. The reverse stock split was approved by the Company&#x2019;s
Board of Directors through unanimous written consent and the Company&#x2019;s stockholders at its Annual Meeting for the fiscal year ended
on December 31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of the
Company&#x2019;s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock.
No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split
were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder&#x2019;s
percentage interest in the Company&#x2019;s outstanding common stock, except for adjustments that may result from the treatment of fractional
shares. All share and per share amounts have been retroactively restated for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <cphi:InvestorRedemption contextRef="c155" decimals="0" unitRef="usd">150000</cphi:InvestorRedemption>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c156" decimals="3" unitRef="usdPershares">0.763</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <cphi:WeightedAveragePrices contextRef="c155" decimals="2" unitRef="pure">0.85</cphi:WeightedAveragePrices>
    <cphi:CommonStockInvestor contextRef="c155" decimals="0" unitRef="shares">196592</cphi:CommonStockInvestor>
    <cphi:InvestorRedemption contextRef="c157" decimals="0" unitRef="usd">250000</cphi:InvestorRedemption>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c158" decimals="3" unitRef="usdPershares">0.763</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <cphi:WeightedAveragePrices contextRef="c157" decimals="2" unitRef="pure">0.85</cphi:WeightedAveragePrices>
    <cphi:CommonStockInvestor contextRef="c157" decimals="0" unitRef="shares">327654</cphi:CommonStockInvestor>
    <cphi:InvestorRedemption contextRef="c159" decimals="0" unitRef="usd">250000</cphi:InvestorRedemption>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c160" decimals="3" unitRef="usdPershares">0.575</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <cphi:WeightedAveragePrices contextRef="c159" decimals="2" unitRef="pure">0.85</cphi:WeightedAveragePrices>
    <cphi:CommonStockInvestor contextRef="c159" decimals="0" unitRef="shares">434783</cphi:CommonStockInvestor>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-10"
      unitRef="usdPershares">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">-0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss
      contextRef="c12"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c11"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c14"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c12"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c11"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c13"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c21"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c22"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c19"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c21"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c22"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c21"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c22"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c21"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c22"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c19"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c20"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c22"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c19"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c20"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c21"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="c0"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="c0"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="c0"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c5"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <cphi:ConversionOfOfficerWagesToCommonStock
      contextRef="c5"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="c0"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <cphi:OperatingLeaseLiabilitiesNetOfCurrentPortion
      contextRef="c3"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="c0"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="c5"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CustomersLiabilityForAcceptancesNet
      contextRef="c111"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CustomersLiabilityForAcceptancesNet
      contextRef="c113"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c111"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c113"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CustomersLiabilityForAcceptancesNet
      contextRef="c114"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CustomersLiabilityForAcceptancesNet
      contextRef="c116"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c114"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c116"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001106644</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MNI2)=I7V8.UT)(,@T:]-J$CK3 [(>LH<4*.^^*$$J-7[ZU(K RR\OP7;]0/
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M9+IY R9*3U$MM!,XMO&D,0VB< C<#L24)$$XUM-Q+[;8JV_S&\#-=5$_0)L
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M!O#_6@A]O#$OZ,Y$%W\#4$L#!!0    ( -J&?E8B=1$)?P(  .<%   8
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MSU2H5WZ4&,A5(VU;5+VUGU83WZ2O[%.:8NW0>:9I1^ MTRM.W2-P2904PT4
MNATK[<&JVG?F0EGJ<[\M:1*C=@[T?ZF4W1[<!?ULS_X"4$L#!!0    ( -J&
M?E:*KL7=!P8  $HD   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULK5K?
MD]HV$'[N?^$AG4PR4X(E6_Z1W#&3@#W-0]N;7-,^ZXSN<&-;Q!)WN?^^DG$
M2T+@1"^ S>ZGU7Y::7?MJR?:?F%K0KCWK:X:=CU9<[YY.YNQ8DUJS-[0#6G$
M/_>TK3$7E^W#C&U:@E>=4EW-H.]'LQJ7S61^U=V[:>=7=,NKLB$WK<>V=8W;
MYP^DHD_7$S#Y?N-3^;#F\L9L?K7!#^26\,^;FU9<S?8HJ[(F#2MIX[7D_GKR
M'KS-8:?02?Q3DB=V]-N34[FC](N\^+BZGOC2(E*1@DL(++X>R8)4E402=GSM
M02?[,:7B\>_OZ'DW>3&9.\S(@E;_EBN^OIXD$V]%[O&VXI_HT^^DGQ"2> 6M
M6/?I/>UD(S%BL66<UKVRN*[+9O>-O_6..%( P0D%V"M 10'&)Q2"7B%01SBE
M$/8*H:(0I"<44*^ +IU#U"M$G>]WSNH\O<0<SZ]:^N2U4EJ@R1\=79VV<'#9
MR)5URUOQ;RGT^'Q!&T:K<H4Y67FW7'R)9<.91^_%%2V^K&FU(BU[^2*!('[G
M95^W)7_VIM[GVZ7WZM?75S,NC)!0LZ(?\,-N0'ARP+H6*ZH#-V@O[-KO5ZM2
MKDA<>3>X7$W+QEO@3<EQ9<!:VK$^$2XB3TQ[2>[+HN0&A.R,-46QK;=5Y[N_
M^)JTOXC9B0!?R\A[)-['IJ U,>#F=MR_J3:AF>!U3R[<DPL[G/ $S@=<X:8@
M'N9BCL4;+P"_>="'OHFU'5+4(<GMZ'$>(I0(T<=C=G0I&(8(1DDX%%SJ@E.8
M)$$*XG0HF>F2  8A"L-H*)CK@HGOAR@ >[F!DX*]DX*+G/1*K*7;-6X)>WV1
MPW:H:.BP.$6*V0OKZ/+@>,LVN"#7$[%P&&D?R63^\@6(_'>F%>T2+',)ECL"
M&U 8[BD,K11VFXE'-]U9)4).'+L,RPL3;U:HD;->A-HB  B&@1(,+H?,7(+E
MY^P?T('V=" K'1\9VW8A)0Z18K?=LXXA$6%52;;]?2M+2-\5XDC=C9!N/8CC
M,%3DEE9SQ_K?)5ANG$$JTD(S ]&>@<@I \>;GXF-2#=3L.&K?%B-&KO5N03+
M7(+ECL &S,9[9F,KLW^*8J.BC'FBJ/!$RN$]$]R:*+/"F(WT3#N<(YQEK"VA
M:1"D:1@KYV7F:,#\@@$'#"1[!A(K Z*@$>6*.&>V;4N:XMGC+6Y8M8LCO/I/
MY.PRA39Q8@4>P8DCG*4CG"S17 U!$B3*,9B?%1OPD>[Y2'\DR04F E(]R8T#
M];A8I+J=*!*)9A0KYXHN. T@#)(((651ZY) 8 8)5++A7!>,?! GR8DD%_B'
M.L__V337Z+(>%@U]%NAYKGW\L;N_4[3,*5KN"FW(Y%'%#G[L<)='0MEPW#R4
M=Y4(",8(9T9.@9Y=(02ARBC05VV4@C10\RN[P2,V$E= N<GTV(]%J7HBC@XE
M-;#7U..\?RZQZ@=#*A/JOK"P6S4ZNERB94[1<E=H0WX/W0!@;P=8^97#E04Q
M!U6@!56@9<C T#40"U,+J!^HILT!Y0@H-QD._5-U"CA4[L!>NE_D[K-1I)>Q
MPO6Z\UV6SDNG:)E3M-P5VI#40_T/[ V !6T>22L?/G2-Y(9RXFWP,Y;[(J<#
MGHUT&HI_$(>Q2J>A> Y%2H74]HO=VC'1Y @H-YJ._-/Q="C\@;WR'^'ZLU%E
MJ/HE#0"H1#BM^YVB94[1<E=H0W(/M3^P%_^C^IQVK!'5)M KZ2""L79F.1HO
M<P64GS5\2,.A 0#L'8"+>S!VG#$4N*KX@5Z#3X,TADFH!'7F:LC\DB&'1!PJ
M?V O_7^B%6-''D.-(Z"E*Z ,&-H2:>K'D?*,+K] </C8\=!L@)<U&Y0& S0^
M>/2UTSX.4U\M@ QB,$E0@*"Z$1DDIR+N 0A3M==H$ 4 Q8$?*0V<W" 9PB1-
MT^2$KP[E/+27\Q<T9LQ^TTM<Z;=$G>3"/O[8X]DI6N84+7>%MF-R=O16A7S+
MY@_</I0BK:K(O8#WW\3"]>WNQ97=!:>;[D6+.\HYK;N?:X)7I)4"XO][*K*Q
M_D*^N[%_?6C^/U!+ P04    " #:AGY6KAU2(!T(  #Z(P  &    'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;+5:77/;MA+]*QSU3J>=B2,"X*=K:\9VG&D>
MVGCLIO<9(B&+$Y)@04BV^^OO I0)B01A*Z.;AUB4%LNSP&+/69 73UQ\;]>,
M2>^Y*NOV<K:6LCF?S]MLS2K:?N0-J^&7%1<5E7 I'N=M(QC-]:"JG&/?C^85
M+>K9XD)_=R<6%WPCRZ)F=\)K-U5%Q<LU*_G3Y0S-7K^X+Q[74GTQ7UPT])$]
M,/FMN1-P->^]Y$7%ZK;@M2?8ZG)VA<YO JP&:(N_"_;4[GWV5"A+SK^KBR_Y
MY<Q7B%C),JE<4/BS93>L+)4GP/'/SNFLOZ<:N/_YU?MG'3P$LZ0MN^'E?XM<
MKB]GR<S+V8IN2GG/GWYGNX!"Y2_C9:O_]YXZVYC,O&S32E[M!@."JJB[O_1Y
M-Q%[ U T,0#O!N#A@&!B -D-(#K0#ID.ZQ.5='$A^),GE#5X4Q_TW.C1$$U1
MJV5\D )^+6"<7-SPNN5ED5/)<N]!PA]8(]EZ?.7=T';M?89U;KTS[]O#)^^7
M__QZ,9=P4S5TGNUN<-W= $_< &'O#U[+=>O=UCG+#QW, 6T/&;]"OL9.CY]8
M]M$CZ(.'?8PM@&[>/QPYX)!^!HGV1Z9FT$S32O#*^]HP0651/WI7*D4+6;#V
MW#9OG=O [E9MW_.VH1F[G,'^;)G8LMGBYY]0Y/]FB_E$S@YF(.AG('!Y7_P)
MU:;D;6L+LAL9Z9&JI&P79R2-<1+ U&_W [ 9DC0-XJ@W/  7]N!")[A/#"+.
M"MH5C3KW:,6%+/[57]@0=^["/2 X]OV0D '@L1WQDSC!OAUOU..-G'BO:0YE
M:"F]):O9JI VB-'HUF<I2<+AE%K,<!AB%-H1QCW"V(GP0?+LNY[*5G_BC9[;
MC%? +>WDO,8C-#!9L3_ /+9"(0Z('7'2(TZ<B+^*XK&H:>D5;;MA7EZT&=_4
M$C@D$VP*K].E?4=YMIV9C/,I].&?/:2T#REU5YTUK1]9ZQ60U&W+H&*K!2D+
MNBS*Z9*3GK+DG,C90?C(-[SE.]?T+T%SIE90K607/9=K)D!;9*S8TF7)K 5I
MY_9@5Z#81VDPR$2;81B$(0GL*X?V*!<YH5_E6UIGL'B2@WQJFK)@PHX5C2$$
M89J&Z1#KV!#%:3(!%!N@V GT2[T%,<#%BQ4<'MTS2E+DC^9Q;(=\A%)_H@PA
M0[S(R6K#%&CHBUIU*U9B6?0DCLD(K,60$!S'Z018PY'(39)?=7+N,';YJLK/
M!F07>U:%<R)=@_$LIQAF;PA\;!>@D/A3N U](C=_]LFJQ4VG2*?2U4*))(W&
MV3JV.PNQ'Z"IG66X$[G)\TZPAA9OS*B-%H-82<E#E&,[H,[)K#7LB=STJ=22
MUHS?6EA[J-\VP6@%/N;&L\!/H28-D5L,<9 F9*H@&!Y%R5%:5Q6(]CU:%_T
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M\?H#/TY?/57@O&Y\*X?95.30LI!8KS =JU2:J)MBA:R01>XS<X\,4M&&1@B
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M%HG:CIA:ATKYL4$DK?1J#EYDQ]3*T$Y"6;W70=H7@8B;+)X5T<&,<2_W)A\
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M?4\MT3B=V%O:0ES&W55IPZFNI>*TWE5T6 C7XQ.\1;,SKA5%9KQ=2669:N>
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MTB:8]:40>AO8 OU3F_X%4$L#!!0    ( -J&?E;O?\5)_@,  ) (   9
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M%T21,]\H3()21+,7=#$4PI8[]()^[(T&(S+LA5Z?4N=1:%8Y__P,YX1ZT2A
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M-<50>I+4UECN.3CG.2_W*@AV)S\Z0[PLZX)BK!2AEH%],M\,V6]5:\H3M+$
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M\E[J@OLZ)*F9S\E0.GI>HVBIITU?6_^@ZJ@K+O=/&'5[FP,"82.&]G4%A>B
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MEA;@_=P8W][0 9O_H[CX/U!+ P04    " #:AGY6J"/LBA$%   M#   &0
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M<"X:Y<_-\A-V\;QCO-PH%_["LK6=;L>0-\Z;JCM,#"JIVZ>XZ_(P.+ [>>9
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MUM4 TAT!I#PWNE[EKVOV.(22K>G?_*2OA2I;@VB9#<$/ 1ET?#(:;1'F4->
MZ.'A&$SH)/P&Z*)^'*"Y@'LS7S>13F74J+1^3&L-)1J>Q,'.'ND:Q_DCE\KW
M38*+AKXFW$,S;\JH+>G[O?3<S+-^6-Q_"]-!3>84:W\D"',E[\6^+5*M<C\
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M"B1:LNLGD=9^#KI98LS&+H3!9U0L(XMFS4=9@KT2)&W7#,,PCF@8"LW5'T\
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M/^BS/<:$THZ-LE3756M25F_Q(G9>.\0$)5+X%9!BK@W507.]5\2)(*O5ZN#
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M:/P&6J^T=D?#'S ^Q,N_ %!+ P04    " #:AGY6HM:;?]("  "3!@  &0
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MF05-3] 60.=KI7#OV OZ>9S^ 5!+ P04    " #:AGY6*TG[8T("   D!0
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MY1ZP_4LIS?.-FZ YH)I]!U!+ P04    " #:AGY6<O?QRO(#  !R#@  &0
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M3P!I 69_+81^G-BVT_UELK]02P,$%     @ VH9^5@ "4]JY @  >P<  !D
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MSD": )Q?":&/'5,QVP<R_0=02P,$%     @ VH9^5F0*D?"G!P  \E$  !D
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MP,-Q1UC0;0)0S8!J)E2SH)H-U1RHYD(U#ZKY**T;N';[ =7_@2,LZ!X%J&9
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MS6C!0CI>S!W;36CI[29>;VBWF,V^SR>/P>8>):O4.]NEBX6+.[0!!:K54,U
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M\J^=?AX"HR\'N'RDQX.=$<4T'N'RHUNQ>VUX@VH*5.M M2Y4ZT&U/E13H=H
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M'W-YX0&F N3[C%*Q':@/M%>H^#=02P,$%     @ VH9^5BD/@DR[ @  AP<
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M:W-H965T<R]S:&5E=#0V+GAM;+686V_;-A3'W_,I""T;6B"S;KYFMH'$[K
M31$D3?=0[(&6CBVNDJB15&Q_^QU2CB*YBA9C:AYBD3KGQW/^XGVZY>*;C  4
MV25Q*F=6I%1V:=LRB""ALL<S2/'-FHN$*BR*C2TS 30T3DEL>XXSM!/*4FL^
M-75W8C[EN8I9"G>"R#Q)J-A?0\RW,\NUGBONV292NL*>3S.Z@0=0C]F=P))=
M4D*60"H93XF ]<RZ<B^7KJ\=C,47!EM9>28ZE17GWW3A)IQ9CHX(8@B41E#\
M>8(%Q+$F81S_'*!6V:9VK#X_TW\WR6,R*RIAP>,_6:BBF36V2 AKFL?JGF__
M@$-" \T+>"S-?[(M;/L#BP2Y5#PY.&,$"4N+7[H["%%Q</NO.'@'!^_(8>R\
MXN ?'/RWMM _./2-,D4J1H<E570^%7Q+A+9&FGXP8AIO3)^E^KL_*(%O&?JI
M^4T:\ 3(9[H#2=XM05$6R_?D5_+XL"3OSM]/;86M:%L[.! 7!=%[A>AZY):G
M*I+D0QI"6 ?8&%X9H_<<X[772EQ"T".^>T$\QQTU!?1F=\]K<%^^W=UMR<8O
M%?<-SS]-\:\?T8[<*$CD7PU!7A?0?C-4SPZ7,J,!S"P<_A+$$UCS7WYRA\YO
M38)U"5MV!*N)V2_%[+?1YQ]2!2(33 )AA:Z*[HB@"IHT;&6=JF$!FQB8GEV?
MYD[/&TSMIZHV';58TV90:C-HU>83KAJX/J 8+-V0F$M) BK$'A>++16A)/A
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M!6D,\/U""/UZ8PXYW:%V^A]02P,$%     @ VH9^5IU!.2%) P  K!$  !D
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MVW6I?$J6R7HNBM<"3*H.#3 2TTG,(#%SUA-@5P<!1@YHDYA#8BZ)>23FDUA
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MU\YMF-Q\U^-9=-H#JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL64UDW
M=MK#1/Y\AR%W_)53@^,.G>. :D:C[5\KTGJN.IKHJ!:JV:CFH)J+:AZJ^:@6
MH%J(:A&JQ93V%&27Q:,0I9Z4R=WM2N0/XH-8+HLJHK;KBJ^[Z%[>57)Q7P6=
M^O:]=G%Y]+ZIOK74^OW+EKF[W20/(DCRAW1=*$MQ7Y&C-]?5QSU/'QY?OBBS
MS;L+]4+YE)5EMMJ]?!1)M:]8+U!]_S[+RN<OZ@&^9OGGW6K?_1=02P,$%
M  @ VH9^5K% ?*?6!0  KS   !D   !X;"]W;W)K<VAE971S+W-H965T-3(N
M>&ULM9M=;]LV%(;_"J$!Q08$L4C*7ZEM('$VK$#3!<FZ712[4&PF%J(/CZ+M
M#MB/'R7+HJE))Y%P=--8,OF2Y_ E]9AB9X=$OJ8;(13Y'H5Q.G<V2FVO!H-T
MM1&1GUXF6Q'K;YX3&?E*7\J70;J5PE_GE:)PP%QW-(C\('86L_S>O5S,DIT*
M@UC<2Y+NHLB7_]R(,#G,'>J<;CP$+QN5W1@L9EO_13P*]75[+_75H%19!Y&(
MTR")B13/<^>:7BV]:58A+_%'( [IV6>2A?*4)*_9Q:?UW'&S'HE0K%0FX>L_
M>[$489@IZ7[\78@Z99M9Q?//)_5?\N!U,$]^*I9)^&>P5INY,W'(6CS[NU ]
M)(=?11'0,--;)6&:_TL.Q[+#J4-6NU0E45%9]R *XN-?_WN1B+,*=-10@145
M6+6"UU"!%Q5X'NBQ9WE8M[[R%S.9'(C,2FNU[$.>F[RVCB:(LV%\5%)_&^AZ
M:O$0I*\I^>!'VX_D:[P24NFA5X%(R8^W0G\.TY]F Z4;RHH/5H7HS5&4-8A2
M1NZ26&U2\G.\%FM;8*![6':3G;IYPT#%6[&Z))Q>$.8R5M.AY?NK4Z [O,P:
MS_6\!KU'/]09>A![$>_$!?FBI]NW.Q$]"?E77;9 L6RB7J5;?R7FCIZ)J9![
MX2P^_$!'[L>Z2)'$K+B],FXO5^?=W4*^?=:5R"<EHK0V&1YF,I#$K&0,RV0,
M01,L$YV!6$D_6X]2(G5N+LA6R.RF7@'K8C\*3G/!;('=+]Q+[<?]>4AP&:NG
MH[*G(["G7W:9-4GR7*PH0J9UO0-%VH[,46QX%@:O#V)<!C'N.N?(O^1ZM4IV
ML<H*K$2P]Y]" 4Y)L*VVL2*)66F9E&F9]#XE)YC)0!*SDC$MDS'%GI)'04JM
M^39DT\JL!-OM&!5US4/:!>-JZVY8KNV(8JG9P9\1"NW=X4436 E!4K,3PDQ"
M&+;+"\6*S2GU*C:'6^X:F<$J"G/5.Q]4A4K]PZ4(I ],HH:3*$@>X(353ZME
M$1WY+7YC(J/2$I::G13#2W38_T0&F:QU0I#4[(08+*,PEW69R*/:B>S^;R(C
MP9P=F6$U"L/:>_W_^R&!_8_*:5AJ=E(,J='^48VBLAJ6FIT00VL4'==@Q=;Q
MU](?I:S^IPHSP,:Z YOE_XT4\!, ;JAMP%AJ=EH,RK'^48ZAHAR6FIT0@W(,
M'>5@Q=;QUX.AVS0##,HQ&.4>_ .Y\Y60@1^2^YU<;?Q4CS-H==1],BPU.WY#
M@*S_K3*&2G]8:G9"#/TQ>+O,L'VZVV[#H('M"Q6([<$B=N\,BC$8Q8I]I3>!
M')9I/21]4!HSE,;&_7L4E="PU.R$&$)C(/!T6HXG=0LHF[*J:>O+N>,&YQJ(
M8C!$G9S[%DK#,JT'JH\-,6[XBKN].Y>CDA66FIT00U8<!)4NSBT4JXX<5Y?;
M^G)TW.!<;N"'P_!3.O=-"(:%6@]5'YM<_.S=(>_?N[BO%/M )6Y0B<.;95V\
MZ]5ZD@VKWJTOQX<-WC4TPV&:>3PQC$4,^J==!^Z%FVH]F'WL:7$#4GS4O[M1
M(0M+S4Z(@2P.;X5U<?>XYAVP6R6*HE1U_?8F#=XV%,1A"C+>/F>*CMY&W:_"
M4K,38U"+3_OW-BJ&8:G9IT$,AGGP-E<';Q>*5=?2<<7=]>4H:Z .SY"2!Y-2
ML[O?^1,0UF]]@J6/#2C/,)C'^C_1@TIG6&IV0@R=>?"^51=+\_I=Y.K)'KCE
MKI&=G=V",>O,^!9P=UO8X<9:#WH?>U.>H3FO_S>3'BK%8:G9"3$4YZ&_F805
M6\=?_YZ3-L"-9W#,PWDS^>93 '7?"TO-3HHA/J__-Y,>*NEAJ=D),:3GH;^9
MA!5;Q]]P+JUZ$G1P=O1;V_8E/Q&?DMSCQ^/5Y=WRU/UU?M:\<O^&7BV/9^>-
MS/$H_YTO7P*=A% \:TGW<JR7)GD\'7^\4,DV/V#^E"@]=_*/&^&OA<P*Z.^?
MDT2=+K(&RO^CL/@/4$L#!!0    ( -J&?E8F8>B<O (  & (   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;*U66V_:,!C]*U8V3:VTD9 ;M(-(*]DT
MIE6JBKH^5'TPR0=$C>/4-M#]^WUVTBC0E**I/ 1?SCGV.7;LC+9</,@5@")/
M+"_DV%HI59[;MDQ6P*CL\1(*[%EPP:C"JEC:LA1 4T-BN>TZ3F@SFA56-#)M
M5R(:\;7*LP*N!)%KQJCX>P$YWXZMOO7<<)TM5THWV-&HI$N8@;HIKP36[$8E
MS1@4,N,%$; 86]_ZYW&H\0;P)X.M;)6)=C+G_$%7ING8<O2$((=$:06*?QN8
M0)YK(9S&8ZUI-4-J8KO\K/[#>$<O<RIAPO/;+%6KL36T2 H+NL[5-=_^A-I/
MH/42GDOS)-L*&X862=92<5:3<08L*ZI_^E3GT"+T_5<(;DUPCR5X-<$[EN#7
M!-\D4UDQ.<14T6@D^)8(C48U73!A&C;:SPJ][#,EL#=#GHIFZ[F$QS44BGS?
MX%.2DQ@4S7)Y2KZ0_5YR=PEL#N(>^VYF,3GY>#JR%4Y#B]E)/>1%-:3[RI"7
M5/2(XWXFKN-Z'?3)8?HO6O1(?_@J/3Z"[@1==!NS:P)TFP!=H^?]1X!WOQ%,
MI@J8O._*J5+VNY7U"W\N2YK V,(W6H+8@!5]^M /G:]=J;VG6/Q.8CN)>DVB
MWB'U:%IL />]P%,E!5;JXZ$KO$HD-"+Z<-M$;N#@;V1OVK$<!XM?POJ[L!TK
M?F/%/VAEPM&+,$=D*;($NGQ4"H/6R$XO& 1[-KI0@]#;<_$6:L=$T)@(#IJX
M-6<GI(2B%[P**BND!)'@?L>&+E>5Y-G.3(;[IHX!Q6^ =BR%C:7PC75A#-<$
M=UGR0+)ZOW79J&2"UN"^YP^&>[E/7L(\=Q &_IZ5E[#^61B<N7MF[-9QKN]>
M/#"762%)#@LDXHJB@JCNLZJB>&E.^#E7>%^8X@H_ 4!H /8O.%?/%7UI-!\5
MT3]02P,$%     @ VH9^5K^<7/); P  2A4   T   !X;"]S='EL97,N>&UL
MW5CM3MLP%'V5*(P)I(DT#:3-:"MME9 F;1,2_-@_Y#9.:\EQ,L=E+>_#B^S)
MYFNGZ0>^7>''H$M58M_C>^ZQ[W5BVJO4@M.;*:7*F^=<5'U_JE3Y,0BJ\93F
MI#HK2BHTDA4R)TIWY22H2DE)6H%3SH-VJQ4'.6'"'_3$++_*5>6-BYE0?;_;
MF#Q[^Y+V_3 ^]SU+-RQ2VO?O3M[_G!7J\IUG[T<?CHY:=Z>7V_83 YSZ@9/T
M8@_2LU8+)P80(X_W(]_%C5%W-JG-\&--9!V/,;?N7HIV",*($X<>+7\E"3J(
M<Z?E5O7[$4EM ^S,;2?<,[=_R6Z=A*"NTD$O*\2J6"/?&K0"DE/OGO"^/R2<
MC20#KXSDC"^LN0V&<<$+Z2F]2[2D$"S5@X5#VX,-5//D3!32Q+81[-]1/7P+
M6/9 (..\$=CVK6'0*XE25(HKW3&#C?$)Y-7MVT6I%4XD683M"W_E8&XZR*B0
M*95-F-!?F@8]3C.0(]ED"G=5E & 2A6Y;J2,3 I!C(:E1]W0M&/*^0T\77YD
M&]SS;"VWIF!$T]2"ZJ:EL1W@7V>SW.NTYR_B]4IV7ZC/,ST=8?I0+_1:THS-
M37^>-0(P]A!G)V7)%Y\XFXB<VLGO'7#0(TL_;UI(]J"C0:F,M8%*W[NG4K'Q
MNN67).4MG:ME.<TS7'/[ #7_VW6>4$$EX>NB=>V_Y55^L>*H\UJ2S5-E6[!3
M8WUD>.LB+PY!9'P((@^B)KN'(#(Y )&=5WMJ/D=D^"9%!O51:.V\M7'::JP>
MG&K[_G<X1_-54&\T8UPQ4?>F+$VI>'+HTO2*C/0_BAO\>GQ*,S+CZK8!^_ZJ
M_8VF;)8GS:AK6(AZU*K]%:87QLV16L=B(J5SF@[KKIR,3-/3#1VUOL!A&[DR
MEQO!?"SF1@##XF *,!_KA<7YG^;31>=C,4Q;UXET49\NZF.]7,C0?+ X;I]$
M7^Z9)DD4Q3&VHL.A4\$06[<XAJ^;#=,&'E@<B/2\M<:SC5?([CK <KJK0K"9
MXI6(S11?:T#<ZP8>2>+.-A8'/+ L8+4#\=UQH*;</E$$6<6T83L81Y($0Z 6
MW34:Q\CJQ/!QYP?;)5&4)&X$,+>"*,(0V(TX@BD #1@21>8]N/4^"I;OJ6#U
MZ^G@#U!+ P04    " #:AGY6EXJ[',     3 @  "P   %]R96QS+RYR96QS
MG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2
MW!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N
M&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HC
ME5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,E
MC'%BM/XU@LD/['X 4$L#!!0    ( -J&?E:TRX L7@0  "TC   /    >&PO
M=V]R:V)O;VLN>&ULQ9K?<YLX$(#_%0T/=^E,KS8_G+:YNC.Y)&T]DVL\<2ZO
M'1ED6Q.07$DX<?[ZKJ!NA4-V[F7C)QL!XF.!_5:"#_?:W,VUOF,/5:GL.%HY
MMSX9#&R^$A6W;_1:*%BST*;B#A;-<F#71O#"KH1P53E(AL/C0<6EBCY^V/4U
M-8-P03N1.ZD5-/J&6RGN[>_U?I%MI)5S64JW'4?-_U)$K))*5O)1%.-H&#&[
MTO=?M)&/6CE>SG*CRW(<Q>V*6V&<S)\TSSSD#9_;IL7Q^34'D'%T/(0.%])8
MUVS1],^!<2-@XW:I=OJ3+)TPY]R)ST;7:ZF6OALXBT%P&DT<=K]M$$_,_PFC
M7BQD+LYU7E="N3:.1I0>4-F57-N(*5Z)<;3;A)VJ@ETH!T%B$]5V!=OZ,X5#
M3XKVK!W@!C$T)Q)6F$G1@--!GL&R+F4!1R_8/[SD*A>L":X- !,$,#D8(#N:
M\@ R12#3%X2<>0B_@V5ZP:[6P@20&0*9'1#R6Q) CA#(T<$@9T[G >0Q GE\
M,,@S;E<!Y%L$\BTMY)59<B4?FQ6,0PJ:R:62L#/W*2F,Y#L$\ATMY$1M8 -M
MM@'.>P3G/2T.. \>5[=]S::E#Y,/V\7W6J[]?F'"'F(9>T@=,\?5TA^4G5K;
M3=0QJA)BEURYE3!LRK<<CMNAPOP1$PODVC?"<SKE<&'9C>'*\J:LZ1!B\HB)
M[7$IE6B3AQ&%;.\ZGV*<J3UHB(GI(Z;WQ\:7:_[&^PJUX>Y*AWR8.6)B=5P*
M;KNW'::(F-@1$Y7K2K ;_M!EPHP0$ROA$Y>&W?*R%NQ?"%9M6F^%>)@+8F(9
M>,'?K719"&/_;/*N"[T08V*(B<UP+>V=97_P:OTW^P]*4.-@Z.1DY]HFF!42
M8BO,ZKD5WVL_WKC8[%W5!+-"0FR%TSS7-81*+=D4BJ8<8O::S;?MPI:%F.@P
M@U@3ORH1=G33^.M52(;I(2'6 UJ4L*,0$]-#0JR')V5);R Q023$@NC6)[UX
MF#$28F.@94!G?)9@$DF()=)JMC=ZF#P2\I'$;]_VPF'V2(CM\8QX=YSA) ;F
MD)38(>B0L7,'IIA14F*C!*GZ7("'2_N*_<5FT'-10_8),3&CI,1&0?-V-YKH
MU-4A]?(M#3$QO:3$>L$QLQ 3<TQ*[)@>"^[NT1 1\TQ*/C)Y%M$_1B$FYIF4
MV#,H9O?QP;R3$GMGOZC8RT@A)F:@E'K\\NPL2(,<SE!C!LJ(#8370&$RRC #
M9<0&PC'#9)1A!LKHWYWTSMC\O$M#3,Q &?7\U\^*LB=19NC[$F+E['.%109<
M^Q 34TY&KIRP\NT+(F:;[ 7GP7I"&6)BMLG(;8-@=FR38;;)7G24LX_9R8^8
M;;)#C7=:XO!5(V:;$?6<6<^$8^\3-,)D,R*6S;-3C_VHF'!&Q,)Y,@G9CXC)
M9M3(9K#[/*,0"W!M\16ZM]">\S*?&N9_VA=+V<A/"R_JLCR#MBMUJ7FQ^]IC
M]Z7*QQ]02P,$%     @ VH9^5GQ^Z1O4 0  QA\  !H   !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<\W9.T[#0!2%X:U$7@"3^YCP4$)%0XO8@!4F#Y'$
MEF<0R>Z)0A&.14&#YE36V/+U7UB?K/'\)>W:LNT.>;/M\^2XWQWRHMF4TC^$
MD)>;M&_S3=>GP_G*JAOV;3DOAW7HV^5[NTY!I]-9&'[.:![G/V=.7D]]^LO$
M;K7:+M-3M_S8IT/Y97#X[(;WO$FI-)/7=EBGLFC"<7<]G</E(#?GR<WD^6W1
M#,]OTH3:00I!6C_((,CJ!SD$>?V@"$&Q?M ,@F;U@VXAZ+9^T!T$W=4/NH>@
M^_I!,D49IP1)(ZP)M!;D6@B\%@1;",06)%L(S!9$6PC4%F1;"-P6A%L(Y!:D
M6PCL%L1;"/16U%L)]%;46PGTUM''-H'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*
M>BN!WHIZ*X'>BGHK@=Z&>AN!WH9Z&X'>AGH;@=XVVBPAT-M0;R/0VU!O(]#;
M4&\CT-M0;R/0VU!O(]#;4&\CT-M1;R?0VU%O)]#;46\GT-M1;R?0VT>;W01Z
M.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>D?4.Q+H'5'O2*!W1+TC@=X1]8[_
MJ7<NIUW*UY[O-3[_/ZDNYWO3]?&7Y??)T:MRP3G ;_O'+U!+ P04    " #:
MAGY6*F32ILH!  ";'P  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4
M!=!?0=E6Q'@('01LVFY;%OT!-WE 1!);MJ'P]W7"(+6BJ(A*O9M$B>UW7VSI
M;#)ZVUKRO4U=-7Z<+$*P#XSY?$&U]JFQU,21F7&U#O'1S9G5^5+/B8G!8,AR
MTP1J0C^T-9+)Z(EF>E6%WO,FOO:E:<:)H\HGO<?=Q#9KG&AKJS+7(8ZS=5-\
M2^GO$]*XLIOC%Z7U-W%"PDXFM",_!^S7O:[)N;*@WE2[\*+K.(MM*N;#MB*?
MGB]QHD<SFY4Y%29?U7%)ZJTC7?@%4:BK=%?TYGQRB#M,NRN_.K\K<RXPSIPZ
M8WT\,4>7QQV.I%W=M[$0N5">_\1C8BQ]]?=1>]H%%;_,CMO[8=RR.P_/NMOU
M>_SUC(_U+^Q#@/0A0?I0('UD('T,0?JX!>GC#J2/>Y ^^ "E$111.0JI',54
MCH(J1U&5H[#*45SE*+!R%%D%BJP"15:!(JM D56@R"I09!4HL@H4606*K )%
M5HDBJT215:+(*E%DE2BR2A19)8JL$D56B2*K1)%5H<BJ4&15*+(J%%D5BJP*
M15:%(JM"D56AR*I09,U09,U09,U09,W^4]9W8Y9__;NXO:>U+IM#/NO^R4\^
M 5!+ 0(4 Q0    ( -J&?E8'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ VH9^5@ZGGP#N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ VH9^5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #:AGY6['I2#(L'  #S,0  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ VH9^5M_6,0.\!P  ."   !@              ("!S@\  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( -J&?E8IV/\$9@,  %D,   8
M              " @< 7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " #:AGY6ABH@TEP%   ?%0  &               @(%<&P  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ VH9^5B)U$0E_ @
MYP4  !@              ("![B   'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( -J&?E:*KL7=!P8  $HD   8              " @:,C
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #:AGY6KAU2
M(!T(  #Z(P  &               @('@*0  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ VH9^5F,EA;1:%   PS0  !@
M ("!,S(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -J&
M?E8N5FE_D (  '8%   8              " @<-&  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " #:AGY6[W_%2?X#  "0"   &0
M        @(&)20  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( -J&?E:\^>.): @  "<4   9              " @;Y-  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ VH9^5H#9@U*T @  SP4
M !D              ("!758  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " #:AGY6=!YY>&X%  ">#0  &0              @(%(60
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -J&?E8I?@B&
M?@@  .X8   9              " @>U>  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ VH9^5F)IQ_M-"0  ;R   !D
M ("!HF<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #:
MAGY63BM"^<P$   E"P  &0              @($F<0  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -J&?E:BH#"0+PH  *\8   9
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M970R,2YX;6Q02P$"% ,4    " #:AGY6J3X<WJ 5   00   &0
M    @($.F   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M -J&?E:<SG_R=0(  $P%   9              " @>6M  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ VH9^5K^,A#Y( P  E <  !D
M             ("!D;   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " #:AGY6HM:;?]("  "3!@  &0              @($0M   >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -J&?E;JHJQFD (
M )L%   9              " @1FW  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ VH9^5BM)^V-" @  ) 4  !D              ("!
MX+D  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #:AGY6
MAV_*V&L"  !X!0  &0              @(%9O   >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( -J&?E8 O:*V2P0  +()   9
M      " @?N^  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ VH9^5NZ@!\B< @  5 8  !D              ("!?<,  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #:AGY6*U]@-ML$   V&0
M&0              @(%0Q@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( -J&?E8I'D[2B@(  . &   9              " @6++  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ VH9^5K<<'_U6
M @  KP4  !D              ("!(\X  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " #:AGY6S_FYW3\#  #5"0  &0
M@(&PT   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -J&
M?E9$^$3;Z0,  *P:   9              " @2;4  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ VH9^5G+W\<KR P  <@X  !D
M         ("!1M@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " #:AGY6"I-6_WP"  !Q!@  &0              @(%OW   >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -J&?E8  E/:N0(  'L'
M   9              " @2+?  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ VH9^5N5$G :F @  + <  !D              ("!$N(
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #:AGY69 J1
M\*<'  #R40  &0              @('OY   >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( -J&?E9HG6P+>Q(  (I. 0 9
M  " @<WL  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
MVH9^5C_!M*HR @  Q 0  !D              ("!?_\  'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " #:AGY6&=0C(QP,  !HE@  &0
M            @('H 0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( -J&?E:ZXA4;^0(  $X)   9              " @3L. 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ VH9^5BD/@DR[ @
MAP<  !D              ("!:Q$! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " #:AGY6"P->/&@$   Z$P  &0              @(%=
M% $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -J&?E:"
M.XEZ.@,  + )   9              " @?P8 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ VH9^5A^Q<42# @  ; 8  !D
M     ("!;1P! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -J&?E8F8>B<O (  & (   9              "
M@4<\ 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ VH9^
M5K^<7/); P  2A4   T              ( !.C\! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #:AGY6EXJ[',     3 @  "P              @ ' 0@$
M7W)E;',O+G)E;'-02P$"% ,4    " #:AGY6M,N +%X$   M(P  #P
M        @ &I0P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ VH9^5GQ^
MZ1O4 0  QA\  !H              ( !-$@! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ VH9^5BIDTJ;* 0  FQ\  !,
M     ( !0$H! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #T /0"B$
&.TP!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>161</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/OtherPayables</Role>
      <ShortName>Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Lines of Credit and Construction Loan Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility</Role>
      <ShortName>Lines of Credit and Construction Loan Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Convertible Note Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConvertibleNotePayable</Role>
      <ShortName>Convertible Note Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Risks &amp; Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/RisksUncertainties</Role>
      <ShortName>Risks &amp; Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/OtherPayablesTables</Role>
      <ShortName>Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/OtherPayables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Lines of Credit and Construction Loan Facility (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables</Role>
      <ShortName>Lines of Credit and Construction Loan Facility (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Organization and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Inventory (Details) - Schedule of inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable</Role>
      <ShortName>Inventory (Details) - Schedule of inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/InventoryTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Property, Plant and Equipment (Details) - Schedule of property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable</Role>
      <ShortName>Property, Plant and Equipment (Details) - Schedule of property, plant and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable</Role>
      <ShortName>Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Intangible Assets (Details) - Schedule of aggregate annual amortization expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of aggregate annual amortization expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IntangibleAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Other Payables (Details) - Schedule of other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable</Role>
      <ShortName>Other Payables (Details) - Schedule of other payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/OtherPayablesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/RelatedPartyTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Lines of Credit and Construction Loan Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails</Role>
      <ShortName>Lines of Credit and Construction Loan Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Lines of Credit and Construction Loan Facility (Details) - Schedule of principal payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable</Role>
      <ShortName>Lines of Credit and Construction Loan Facility (Details) - Schedule of principal payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Convertible Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails</Role>
      <ShortName>Convertible Note Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/ConvertibleNotePayable</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LeasesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Leases (Details) - Schedule of operating lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of operating lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LeasesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals</Role>
      <ShortName>Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Income Taxes (Details) - Schedule of temporary differences to deferred income tax assets and liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of temporary differences to deferred income tax assets and liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/StockholdersEquity</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Risks &amp; Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails</Role>
      <ShortName>Risks &amp; Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/RisksUncertainties</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f10k2022_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/SubsequentEvents</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesClassifiedCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_chinapharma.htm 8474, 8475</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_chinapharma.htm 8478, 8479</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToOtherRelatedPartiesClassifiedCurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_chinapharma.htm 8501</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept InterestExpenseRelatedParty in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_chinapharma.htm 8503, 8517</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromOtherRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_chinapharma.htm 8510</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_chinapharma.htm 8510</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_chinapharma.htm 8512</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted -  f10k2022_chinapharma.htm 9464, 9465</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="f10k2022_chinapharma.htm">f10k2022_chinapharma.htm</File>
    <File>cphi-20221231.xsd</File>
    <File>cphi-20221231_cal.xml</File>
    <File>cphi-20221231_def.xml</File>
    <File>cphi-20221231_lab.xml</File>
    <File>cphi-20221231_pre.xml</File>
    <File>f10k2022ex10-11_china.htm</File>
    <File>f10k2022ex23-1_china.htm</File>
    <File>f10k2022ex3-1_china.htm</File>
    <File>f10k2022ex31-1_china.htm</File>
    <File>f10k2022ex31-2_china.htm</File>
    <File>f10k2022ex32-1_china.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/us-gaap-sup/2022q3</BaseTaxonomy>
    <BaseTaxonomy items="546">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10k2022_chinapharma.htm": {
   "axisCustom": 2,
   "axisStandard": 16,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap-sup/2022q3": 1,
    "http://fasb.org/us-gaap/2022": 546,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 161,
   "dts": {
    "calculationLink": {
     "local": [
      "cphi-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cphi-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10k2022_chinapharma.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cphi-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cphi-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cphi-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 493,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 54,
    "http://www.chinapharmaholdings.com/20221231": 2,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 59
   },
   "keyCustom": 58,
   "keyStandard": 279,
   "memberCustom": 21,
   "memberStandard": 20,
   "nsprefix": "cphi",
   "nsuri": "http://www.chinapharmaholdings.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Property, Plant and Equipment",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.chinapharmaholdings.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Other Payables",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.chinapharmaholdings.com/role/OtherPayables",
     "shortName": "Other Payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.chinapharmaholdings.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Lines of Credit and Construction Loan Facility",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility",
     "shortName": "Lines of Credit and Construction Loan Facility",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Convertible Note Payable",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.chinapharmaholdings.com/role/ConvertibleNotePayable",
     "shortName": "Convertible Note Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.chinapharmaholdings.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.chinapharmaholdings.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.chinapharmaholdings.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.chinapharmaholdings.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Risks & Uncertainties",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.chinapharmaholdings.com/role/RisksUncertainties",
     "shortName": "Risks & Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.chinapharmaholdings.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cphi:OrganizationAndNatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cphi:OrganizationAndNatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Inventory (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.chinapharmaholdings.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Property, Plant and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.chinapharmaholdings.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Other Payables (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.chinapharmaholdings.com/role/OtherPayablesTables",
     "shortName": "Other Payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Lines of Credit and Construction Loan Facility (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables",
     "shortName": "Lines of Credit and Construction Loan Facility (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.chinapharmaholdings.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.chinapharmaholdings.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cphi:TradeAccountsReceivableLessAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cphi:TradeAccountsReceivableLessAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Organization and Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Inventory (Details) - Schedule of inventory",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable",
     "shortName": "Inventory (Details) - Schedule of inventory",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LandAndLandImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Property, Plant and Equipment (Details) - Schedule of property, plant and equipment",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable",
     "shortName": "Property, Plant and Equipment (Details) - Schedule of property, plant and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LandAndLandImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cphi:UsefulLiveOfAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable",
     "shortName": "Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cphi:UsefulLiveOfAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cphi:IntangibleAssetsUsefulLifeDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails",
     "shortName": "Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cphi:IntangibleAssetsUsefulLifeDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable",
     "shortName": "Intangible Assets (Details) - Schedule of intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Intangible Assets (Details) - Schedule of aggregate annual amortization expense",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable",
     "shortName": "Intangible Assets (Details) - Schedule of aggregate annual amortization expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableRelatedPartiesClassifiedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Other Payables (Details) - Schedule of other payables",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable",
     "shortName": "Other Payables (Details) - Schedule of other payables",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableRelatedPartiesClassifiedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToOtherRelatedPartiesClassifiedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToOtherRelatedPartiesClassifiedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConstructionLoan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Lines of Credit and Construction Loan Facility (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
     "shortName": "Lines of Credit and Construction Loan Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConstructionLoan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c78",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Lines of Credit and Construction Loan Facility (Details) - Schedule of principal payments",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable",
     "shortName": "Lines of Credit and Construction Loan Facility (Details) - Schedule of principal payments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c78",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c79",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Convertible Note Payable (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
     "shortName": "Convertible Note Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c79",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.chinapharmaholdings.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Leases (Details) - Schedule of operating lease liabilities",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of operating lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable",
     "shortName": "Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes (Parentheticals)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals",
     "shortName": "Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Income Taxes (Details) - Schedule of temporary differences to deferred income tax assets and liability",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable",
     "shortName": "Income Taxes (Details) - Schedule of temporary differences to deferred income tax assets and liability",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CustomersLiabilityForAcceptancesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable",
     "shortName": "Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CustomersLiabilityForAcceptancesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "2",
      "lang": null,
      "name": "cphi:AftertaxNetIncomePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c133",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "cphi:ConcentrationRiskPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Risks & Uncertainties (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails",
     "shortName": "Risks & Uncertainties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c133",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "cphi:ConcentrationRiskPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c159",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cphi:InvestorRedemption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c159",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cphi:InvestorRedemption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Organization and Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.chinapharmaholdings.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_chinapharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "cphi_AccountsReceivableCollectedWithBankersAcceptances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable collected with banker's acceptances.",
        "label": "Accounts Receivable Collected With Bankers Acceptances",
        "terseLabel": "Accounts receivable collected with banker\u2019s acceptances"
       }
      }
     },
     "localname": "AccountsReceivableCollectedWithBankersAcceptances",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_AccumulatedDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated deficit.",
        "label": "Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "AccumulatedDeficit",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_AdditionalSharesAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares available for issuance.",
        "label": "Additional Shares Available For Issuance",
        "terseLabel": "Additional shares available for issuance"
       }
      }
     },
     "localname": "AdditionalSharesAvailableForIssuance",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_AdvanceToSupplies": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance To Supplies",
        "terseLabel": "Advances to suppliers"
       }
      }
     },
     "localname": "AdvanceToSupplies",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_AdvancesToSuppliers": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances to suppliers.",
        "label": "Advances To Suppliers",
        "negatedLabel": "Advances to suppliers"
       }
      }
     },
     "localname": "AdvancesToSuppliers",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advances to suppliers and advances from customers.",
        "label": "Advances To Suppliers And Advances From Customers Policy Text Block",
        "terseLabel": "Advances to Suppliers and Advances from Customers"
       }
      }
     },
     "localname": "AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cphi_AftertaxNetIncomePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After tax net income percentage.",
        "label": "Aftertax Net Income Percentage",
        "terseLabel": "After tax income, percentage"
       }
      }
     },
     "localname": "AftertaxNetIncomePercentage",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cphi_BankOfChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Of China Member",
        "terseLabel": "Bank of China [Member]"
       }
      }
     },
     "localname": "BankOfChinaMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_BankOfCommunicationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Of Communications Member",
        "terseLabel": "Bank of Communications [Member]"
       }
      }
     },
     "localname": "BankOfCommunicationsMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_BankersAcceptances": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A banker's acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank.",
        "label": "Bankers Acceptances",
        "terseLabel": "Banker\u2019s acceptances"
       }
      }
     },
     "localname": "BankersAcceptances",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_CashFlowForOperatingLease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flow for operating lease.",
        "label": "Cash Flow For Operating Lease",
        "terseLabel": "Cash flows from operating leases"
       }
      }
     },
     "localname": "CashFlowForOperatingLease",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_ChairpersonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairperson Member",
        "terseLabel": "Chairperson [Member]"
       }
      }
     },
     "localname": "ChairpersonMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_ChinaCITICBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "China CITICBank Member",
        "terseLabel": "China CITIC Bank [Member]"
       }
      }
     },
     "localname": "ChinaCITICBankMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_ClosingMarketPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares of closing market price.",
        "label": "Closing Market Price",
        "terseLabel": "Closing market price (in Dollars per share)"
       }
      }
     },
     "localname": "ClosingMarketPrice",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cphi_CommonStockInvestor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares of common stock investor.",
        "label": "Common Stock Investor",
        "terseLabel": "Common stock investor"
       }
      }
     },
     "localname": "CommonStockInvestor",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_CommonStockIssuedToInvestor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued to investor.",
        "label": "Common Stock Issued To Investor",
        "terseLabel": "Common stock issued to investor (in Shares)"
       }
      }
     },
     "localname": "CommonStockIssuedToInvestor",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_CommonStockIssuedToInvestor1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued to investor.",
        "label": "Common Stock Issued To Investor1",
        "terseLabel": "Common stock issued to investor (in Shares)"
       }
      }
     },
     "localname": "CommonStockIssuedToInvestor1",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_CommonStockPursuant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares of common stock.",
        "label": "Common Stock Pursuant",
        "terseLabel": "Common stock pursuant"
       }
      }
     },
     "localname": "CommonStockPursuant",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_CompensationConverted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation Converted.",
        "label": "Compensation Converted",
        "terseLabel": "Compensation converted"
       }
      }
     },
     "localname": "CompensationConverted",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_ConcentrationRiskByBenchmarksAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk By Benchmarks Axis",
        "terseLabel": "Concentration Risk By Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarksAxis",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_ConcentrationRiskByBenchmarksDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConcentrationRiskByBenchmarks [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarksDomain",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_ConcentrationRiskPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage",
        "terseLabel": "Concentrations risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cphi_ConcentrationRiskTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type Axis",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeAxis",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_ConcentrationRiskType_Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConcentrationRiskType_ [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskType_Domain",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_ConversionOfOfficerWagesToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of officer wages to common stock\r   \n.",
        "label": "Conversion Of Officer Wages To Common Stock",
        "terseLabel": "Common stock issued for intangible assets"
       }
      }
     },
     "localname": "ConversionOfOfficerWagesToCommonStock",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_ConvertibleNote": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares of convertible note.",
        "label": "Convertible Note",
        "terseLabel": "Convertible note (in Shares)"
       }
      }
     },
     "localname": "ConvertibleNote",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_ConvertibleNoteConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible note conversion price.",
        "label": "Convertible Note Conversion Price",
        "terseLabel": "Convertible note conversion price (in Dollars per share)"
       }
      }
     },
     "localname": "ConvertibleNoteConversionPrice",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cphi_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer one.",
        "label": "Customer One Member",
        "terseLabel": "Customer One [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Three Member",
        "terseLabel": "Customer Three [Member]"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer two.",
        "label": "Customer Two Member",
        "terseLabel": "Customer Two [Member]"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_DeferredIncomeTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets Abstract",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_DeferredIncomeTaxLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Liability Abstract",
        "terseLabel": "Deferred income tax liability:"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilityAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ExpectedLifes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Lifes",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "ExpectedLifes",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleofassetsandliabilitiesrecordedatfairvalueTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_FairValueOfOptionsGranted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of options granted.",
        "label": "Fair Value Of Options Granted",
        "terseLabel": "Fair value of options granted (in Dollars)"
       }
      }
     },
     "localname": "FairValueOfOptionsGranted",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_HaikouHaiHongXinMicrofinanceCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Haikou Hai Hong Xin Microfinance Co Ltd Member",
        "terseLabel": "Haikou HaiHongXin microfinance Co., Ltd., [Member]"
       }
      }
     },
     "localname": "HaikouHaiHongXinMicrofinanceCoLtdMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hainan Helpson Medical Biotechnology Co Ltd Member",
        "terseLabel": "Hainan Helpson Medical &amp; Biotechnology Co., Ltd [Member]"
       }
      }
     },
     "localname": "HainanHelpsonMedicalBiotechnologyCoLtdMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_IncomeTaxesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_IncomeTaxesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_IntangibleAssetsUsefulLifeDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of intangible assets useful life.",
        "label": "Intangible Assets Useful Life Description",
        "terseLabel": "Intangible assets useful life, description"
       }
      }
     },
     "localname": "IntangibleAssetsUsefulLifeDescription",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_InterestAccruesOnNoteDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of interest accrues on Note.",
        "label": "Interest Accrues On Note Description",
        "terseLabel": "Interest accrues on note, description"
       }
      }
     },
     "localname": "InterestAccruesOnNoteDescription",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_InterestAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Amount",
        "terseLabel": "Interest amount"
       }
      }
     },
     "localname": "InterestAmount",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_InterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "InterestRate",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cphi_InterestRateRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for interest rate risk.",
        "label": "Interest Rate Risk Policy Text Block",
        "terseLabel": "Interest Rate Risk"
       }
      }
     },
     "localname": "InterestRateRiskPolicyTextBlock",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cphi_InventoryPurchasedWithBankersAcceptanceNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory purchased with banker&amp;amp;#8217;s acceptances.",
        "label": "Inventory Purchased With Bankers Acceptance Note",
        "terseLabel": "Inventory purchased with banker\u2019s acceptances"
       }
      }
     },
     "localname": "InventoryPurchasedWithBankersAcceptanceNote",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_InvestorRedemption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of investor redemption.",
        "label": "Investor Redemption",
        "terseLabel": "Investor redemption"
       }
      }
     },
     "localname": "InvestorRedemption",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_LeasesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Textual)"
       }
      }
     },
     "localname": "LeasesDetailsLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofoperatingleaseliabilitiesLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LeasesDetailsScheduleofoperatingleaseliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of operating lease liabilities [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofoperatingleaseliabilitiesTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LeasesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "localname": "LeasesDetailsTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/Leases"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Table]"
       }
      }
     },
     "localname": "LeasesTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/Leases"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LeasesTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Tables Line Items",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesTablesLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LeasesTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Tables) [Table]"
       }
      }
     },
     "localname": "LeasesTablesTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LessOperatingLeaseLiabilitiesCurrentPortion": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Less: Operating lease liabilities, current portion.",
        "label": "Less Operating Lease Liabilities Current Portion",
        "negatedLabel": "Less: Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "LessOperatingLeaseLiabilitiesCurrentPortion",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_LinesofCreditandConstructionLoanFacilityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lines of Credit and Construction Loan Facility (Details) [Line Items]"
       }
      }
     },
     "localname": "LinesofCreditandConstructionLoanFacilityDetailsLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LinesofCreditandConstructionLoanFacilityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lines of Credit and Construction Loan Facility (Details) [Table]"
       }
      }
     },
     "localname": "LinesofCreditandConstructionLoanFacilityDetailsTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LinesofCreditandConstructionLoanFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lines of Credit and Construction Loan Facility [Abstract]"
       }
      }
     },
     "localname": "LinesofCreditandConstructionLoanFacilityLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LinesofCreditandConstructionLoanFacilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lines of Credit and Construction Loan Facility [Table]"
       }
      }
     },
     "localname": "LinesofCreditandConstructionLoanFacilityTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LinesofCreditandConstructionLoanFacilityTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Linesof Creditand Construction Loan Facility Tables Line Items",
        "terseLabel": "Lines of Credit and Construction Loan Facility [Abstract]"
       }
      }
     },
     "localname": "LinesofCreditandConstructionLoanFacilityTablesLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LinesofCreditandConstructionLoanFacilityTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lines of Credit and Construction Loan Facility (Tables) [Table]"
       }
      }
     },
     "localname": "LinesofCreditandConstructionLoanFacilityTablesTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_LiquidityAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Going Concern.",
        "label": "Liquidity And Going Concern Policy Text Block",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cphi_LoanAgreementToBorrowCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "loan agreement to borrow cash.",
        "label": "Loan Agreement To Borrow Cash",
        "terseLabel": "Loan agreement to borrow cash"
       }
      }
     },
     "localname": "LoanAgreementToBorrowCash",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_MarketPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market price per share.",
        "label": "Market Price Per Share",
        "terseLabel": "Market price per share (in Dollars per share)"
       }
      }
     },
     "localname": "MarketPricePerShare",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cphi_MotorVehicleGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before moto vehicle of tangible personal property used to produce goods and services, including, but is not limited to, tools, motor equipment.",
        "label": "Motor Vehicle Gross",
        "terseLabel": "Motor vehicle"
       }
      }
     },
     "localname": "MotorVehicleGross",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_MotorVehicleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Motor Vehicle Member",
        "terseLabel": "Motor vehicle [Member]"
       }
      }
     },
     "localname": "MotorVehicleMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_NetOperatingLossCarryForwardsExpirationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carry forward expiration date description.",
        "label": "Net Operating Loss Carry Forwards Expiration Description",
        "terseLabel": "Net operating loss expiration, description"
       }
      }
     },
     "localname": "NetOperatingLossCarryForwardsExpirationDescription",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_NoteRedeemableIntoShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares redeemable by Notes.",
        "label": "Note Redeemable Into Shares",
        "terseLabel": "Note redeemable into shares (in Shares)"
       }
      }
     },
     "localname": "NoteRedeemableIntoShares",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number Of Customers",
        "terseLabel": "Number of customers"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cphi_NumberOfSuppliers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of suppliers.",
        "label": "Number Of Suppliers",
        "terseLabel": "Number of suppliers"
       }
      }
     },
     "localname": "NumberOfSuppliers",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cphi_OfficeEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before office equipment of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Office Equipment Gross",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentGross",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_OnnyInvestmentLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Onny Investment Limited Member",
        "terseLabel": "Onny Investment Limited [Member]"
       }
      }
     },
     "localname": "OnnyInvestmentLimitedMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_OperatingLeaseLiabilitiesNetOfCurrentPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liabilities Net Of Current Portion",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesNetOfCurrentPortion",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_OperatingLeaseRightsOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use assets.",
        "label": "Operating Lease Rights Of Use Assets",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightsOfUseAssets",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_OrganizationAndNatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for organization and nature of operations.",
        "label": "Organization And Nature Of Operations Policy Text Block",
        "terseLabel": "Organization and Nature of Operations"
       }
      }
     },
     "localname": "OrganizationAndNatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cphi_OrganizationandSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "OrganizationandSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_OrganizationandSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "OrganizationandSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_OriginalIssueDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of  original issue discount.",
        "label": "Original Issue Discount",
        "terseLabel": "Original issue discount"
       }
      }
     },
     "localname": "OriginalIssueDiscount",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other receivables, less allowance for doubtful accounts.",
        "label": "Other Receivables Less Allowance For Doubtful Accounts",
        "terseLabel": "Other receivables, less allowance for doubtful accounts (in Dollars)"
       }
      }
     },
     "localname": "OtherReceivablesLessAllowanceForDoubtfulAccounts",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_PercentageOfCommonStockPriceOnWeightedAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock price on weighted average price.",
        "label": "Percentage Of Common Stock Price On Weighted Average Price",
        "terseLabel": "Percentage of common stock price on weighted average price"
       }
      }
     },
     "localname": "PercentageOfCommonStockPriceOnWeightedAveragePrice",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cphi_PermitOfLandUseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Permit of land use.",
        "label": "Permit Of Land Use Member",
        "terseLabel": "Permit of land use [Member]"
       }
      }
     },
     "localname": "PermitOfLandUseMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Table]"
       }
      }
     },
     "localname": "PropertyPlantandEquipmentDetailsScheduleofestimatedusefullivesoftheassetsTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_PurchaseOfCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of common stock.",
        "label": "Purchase Of Common Stock Shares",
        "terseLabel": "Purchase of common stock (in Shares)"
       }
      }
     },
     "localname": "PurchaseOfCommonStockShares",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_PurchaseofCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of common stock.",
        "label": "Purchaseof Common Stock Shares",
        "terseLabel": "Purchase of common stock"
       }
      }
     },
     "localname": "PurchaseofCommonStockShares",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_RawMaterialPurchasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Raw material purchases.",
        "label": "Raw Material Purchases Member",
        "terseLabel": "Raw Material Purchases [Member]"
       }
      }
     },
     "localname": "RawMaterialPurchasesMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_RedeemOfOutstandingNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of redeem of outstanding note.",
        "label": "Redeem Of Outstanding Note",
        "terseLabel": "Redeem of outstanding note"
       }
      }
     },
     "localname": "RedeemOfOutstandingNote",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_ReserveAccountBalancesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve Account Balances Percentage",
        "terseLabel": "Reserve account balances, percentage"
       }
      }
     },
     "localname": "ReserveAccountBalancesPercentage",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cphi_RisksUncertaintiesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks &amp; Uncertainties (Details) [Line Items]"
       }
      }
     },
     "localname": "RisksUncertaintiesDetailsLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_RisksUncertaintiesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks &amp; Uncertainties (Details) [Table]"
       }
      }
     },
     "localname": "RisksUncertaintiesDetailsTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_SalesRevenuesNetOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Revenues Net One Member",
        "terseLabel": "Revenue One [Member]",
        "verboseLabel": "Sales Revenues Net One [Member]"
       }
      }
     },
     "localname": "SalesRevenuesNetOneMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_SalesRevenuesNetThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Revenues Net Three Member",
        "terseLabel": "Revenue Three [Member]"
       }
      }
     },
     "localname": "SalesRevenuesNetThreeMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_SalesRevenuesNetTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Revenues Net Two Member",
        "terseLabel": "Revenue Two [Member]"
       }
      }
     },
     "localname": "SalesRevenuesNetTwoMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Aggregate Annual Amortization Expense [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAggregateAnnualAmortizationExpenseAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assets And Liabilities Recorded At Fair Value Abstract"
       }
      }
     },
     "localname": "ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives Of The Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfInventoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInventoryAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Lease Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfOtherPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Payables [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOtherPayablesAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfPrincipalPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Principal Payments Abstract"
       }
      }
     },
     "localname": "ScheduleOfPrincipalPaymentsAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfIncomeTaxesCalculatedAtFederalStatutoryRatesToProvisionForIncomeTaxesAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Temporary Differences To Deferred Income Tax Assets And Liability Abstract"
       }
      }
     },
     "localname": "ScheduleOfTemporaryDifferencesToDeferredIncomeTaxAssetsAndLiabilityAbstract",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cphi_StockholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_StockholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cphi_SuppliersOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suppliers One Member",
        "terseLabel": "Suppliers One [Member]"
       }
      }
     },
     "localname": "SuppliersOneMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_SuppliersThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suppliers Three Member",
        "terseLabel": "Suppliers Three [Member]"
       }
      }
     },
     "localname": "SuppliersThreeMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_SuppliersTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suppliers Two Member",
        "terseLabel": "Suppliers Two [Member]"
       }
      }
     },
     "localname": "SuppliersTwoMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_TotalOptionOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total option outstanding.",
        "label": "Total Option Outstanding",
        "terseLabel": "Total option outstanding"
       }
      }
     },
     "localname": "TotalOptionOutstanding",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cphi_TradeAccountsReceivableLessAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable Less Allowance",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts (in Dollars)"
       }
      }
     },
     "localname": "TradeAccountsReceivableLessAllowance",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade accounts receivable, less allowance for doubtful accounts.",
        "label": "Trade Accounts Receivable Less Allowance For Doubtful Accounts",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts of $16,739,527 and $18,312,707, respectively"
       }
      }
     },
     "localname": "TradeAccountsReceivableLessAllowanceForDoubtfulAccounts",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_TwoThousandTenIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand ten incentive plan.",
        "label": "Two Thousand Ten Incentive Plan Member",
        "terseLabel": "2010 Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTenIncentivePlanMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_TwoThousandTenLongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Ten Long Term Incentive Plan Member",
        "terseLabel": "2010 Long-Term Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTenLongTermIncentivePlanMember",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cphi_UnpaidCashCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unpaid cash compensation.",
        "label": "Unpaid Cash Compensation",
        "terseLabel": "Total unpaid cash compensation (in Dollars)"
       }
      }
     },
     "localname": "UnpaidCashCompensation",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_UsefulLiveOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful live of Assets table text block.",
        "label": "Useful Live Of Assets Table Text Block",
        "terseLabel": "Schedule of estimated useful lives of the assets"
       }
      }
     },
     "localname": "UsefulLiveOfAssetsTableTextBlock",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cphi_ValuationAllowanceForDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance for deferred tax assets.",
        "label": "Valuation Allowance For Deferred Tax Assets",
        "terseLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceForDeferredTaxAssets",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cphi_WeightedAverageDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate.",
        "label": "Weighted Average Discount Rate",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRate",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cphi_WeightedAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price per share.",
        "label": "Weighted Average Price",
        "terseLabel": "Weighted average price (in Dollars per share)"
       }
      }
     },
     "localname": "WeightedAveragePrice",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cphi_WeightedAveragePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of weighted average price.",
        "label": "Weighted Average Prices",
        "terseLabel": "Weighted average price percentage"
       }
      }
     },
     "localname": "WeightedAveragePrices",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cphi_WeightedAveragesRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term.",
        "label": "Weighted Averages Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "WeightedAveragesRemainingLeaseTerm",
     "nsuri": "http://www.chinapharmaholdings.com/20221231",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Chief Financial Officer [Member]"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r237",
      "r480",
      "r526",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r520",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management [Member]"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r321",
      "r421",
      "r450",
      "r461",
      "r462",
      "r479",
      "r484",
      "r489",
      "r525",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r321",
      "r421",
      "r450",
      "r461",
      "r462",
      "r479",
      "r484",
      "r489",
      "r525",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r237",
      "r480",
      "r526",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r313",
      "r321",
      "r345",
      "r346",
      "r347",
      "r420",
      "r421",
      "r450",
      "r461",
      "r462",
      "r479",
      "r484",
      "r489",
      "r522",
      "r525",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r313",
      "r321",
      "r345",
      "r346",
      "r347",
      "r420",
      "r421",
      "r450",
      "r461",
      "r462",
      "r479",
      "r484",
      "r489",
      "r522",
      "r525",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r322",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r205",
      "r322",
      "r499",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r205",
      "r322",
      "r499",
      "r500",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r520",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Other receivables, less allowance for doubtful accounts of $27,149 and $32,210, respectively"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "OTHER PAYABLES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Business taxes and other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": {
     "auth_ref": [
      "r128",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred and payable classified as other.",
        "label": "Accounts Payable, Other",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r1",
      "r17"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Original issue discount accretion"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r85",
      "r160"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r164",
      "r446",
      "r455",
      "r456"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r32",
      "r35",
      "r108",
      "r407",
      "r451",
      "r452",
      "r506",
      "r507",
      "r508",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other\tComprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r488"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r515",
      "r516",
      "r517",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "terseLabel": "Unpaid compensation (in Dollars)"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r53",
      "r76",
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense relating to intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r123",
      "r137",
      "r162",
      "r188",
      "r226",
      "r229",
      "r233",
      "r239",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r373",
      "r377",
      "r385",
      "r488",
      "r523",
      "r524",
      "r564"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r155",
      "r168",
      "r188",
      "r239",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r373",
      "r377",
      "r385",
      "r488",
      "r523",
      "r524",
      "r564"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalRequiredForCapitalAdequacy": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum total risk-based capital required for capital adequacy as defined by regulatory framework.",
        "label": "Banking Regulation, Total Risk-Based Capital, Capital Adequacy, Minimum",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "CapitalRequiredForCapitalAdequacy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r55",
      "r158",
      "r463"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r49",
      "r55",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period",
        "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r49",
      "r114"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Increase in Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r27",
      "r130",
      "r144"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved shares"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r515",
      "r516",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in Dollars per share)",
        "verboseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r488"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 500,000,000 shares authorized; 7,490,896 shares and 4,733,956 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r7",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.",
        "label": "Common Stocks, Including Additional Paid in Capital",
        "terseLabel": "Additional shares of common stock (in Dollars)"
       }
      }
     },
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r36",
      "r170",
      "r172",
      "r178",
      "r440",
      "r447"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r65",
      "r66",
      "r111",
      "r112",
      "r237",
      "r457",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r136",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "RISKS &amp; UNCERTAINTIES"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r65",
      "r66",
      "r111",
      "r112",
      "r237",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation and Basis of Presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionLoan": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans.",
        "label": "Construction Loan",
        "terseLabel": "Line of credit amount"
       }
      }
     },
     "localname": "ConstructionLoan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r309",
      "r310",
      "r312"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Advances from customers"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Stock issued (in Shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible, redeemable note payable, net of issue discount"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r4",
      "r125",
      "r138",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Original principal amount"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r40",
      "r188",
      "r239",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r385",
      "r523"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenues"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomersLiabilityForAcceptancesNet": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate of all customer's outstanding debt to the institution that resulted from short-term negotiable time drafts drawn on and accepted by an institution (also known as banker's acceptance transactions), net of allowance for uncollectible customer's liability for acceptances.",
        "label": "Customer's Liability for Acceptances, Net",
        "terseLabel": "Banker\u2019s acceptance notes"
       }
      }
     },
     "localname": "CustomersLiabilityForAcceptancesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Payable [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r186",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r280",
      "r287",
      "r288",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "CONVERTIBLE NOTE PAYABLE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r90",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Converted common stock price per share (in Dollars per share)",
        "verboseLabel": "Conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r24",
      "r93",
      "r94",
      "r96",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Note converted into common stock"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r117",
      "r119",
      "r264",
      "r398",
      "r475",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal Payments"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r23",
      "r117",
      "r292",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r25",
      "r93",
      "r95",
      "r96",
      "r97",
      "r116",
      "r117",
      "r119",
      "r135",
      "r191",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r398",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Notes matures"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average price percentage"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r106",
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory obsolescence reserve"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Net deferred income tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r106",
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards for PRC tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r106",
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Lease liability, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r105",
      "r106",
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "PRC net operating loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r106",
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r106",
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Expenses not deductible in current year"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r106",
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful trade receivables"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": {
     "auth_ref": [
      "r106",
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses",
        "terseLabel": "Advances for intangible assets impairment"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses": {
     "auth_ref": [
      "r106",
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on financing receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Financing Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful other receivables"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r106",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r53",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expanse"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r53",
      "r224"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsStock": {
     "auth_ref": [
      "r98",
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Stock",
        "terseLabel": "Common stock value"
       }
      }
     },
     "localname": "DividendsStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromOtherRelatedPartiesCurrent": {
     "auth_ref": [
      "r120",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Due from Other Related Parties, Current",
        "terseLabel": "Received advance"
       }
      }
     },
     "localname": "DueFromOtherRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r127",
      "r147",
      "r163",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r263",
      "r411",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Borrowings from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r163",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r263",
      "r411",
      "r465",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Repaid advance"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToOtherRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r17",
      "r120",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Due to Other Related Parties, Current",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "DueToOtherRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r179",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r381",
      "r382",
      "r441",
      "r448",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r179",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r381",
      "r382",
      "r441",
      "r448",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r560"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of Exchange Rate Changes on Cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Enterprise income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r189",
      "r356",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "(Benefit) tax at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable_Parentheticals"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r554",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "U.S. federal corporate income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of plan compensation cost recognized during the period.",
        "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense",
        "terseLabel": "Compensation expense (in Dollars)"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r92",
      "r153",
      "r173",
      "r174",
      "r175",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r204",
      "r214",
      "r240",
      "r308",
      "r349",
      "r350",
      "r351",
      "r362",
      "r363",
      "r380",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r407",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r278",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r384",
      "r417",
      "r418",
      "r419",
      "r475",
      "r476",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r278",
      "r314",
      "r319",
      "r384",
      "r417",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r278",
      "r314",
      "r319",
      "r384",
      "r418",
      "r475",
      "r476",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r278",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r384",
      "r419",
      "r475",
      "r476",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r278",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r417",
      "r418",
      "r419",
      "r475",
      "r476",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofassetsandliabilitiesrecordedatfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "terseLabel": "Fair value of options granted (in Dollars)"
       }
      }
     },
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of aggregate annual amortization expense"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r161",
      "r247"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r78",
      "r426"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r78",
      "r425"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r39",
      "r188",
      "r226",
      "r228",
      "r232",
      "r234",
      "r239",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r385",
      "r473",
      "r523"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross (loss) profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r53",
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofaggregateannualamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r37",
      "r122",
      "r131",
      "r149",
      "r226",
      "r228",
      "r232",
      "r234",
      "r442",
      "r473"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r357",
      "r358",
      "r361",
      "r364",
      "r367",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r190",
      "r203",
      "r204",
      "r225",
      "r355",
      "r365",
      "r368",
      "r449"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement",
      "http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r352",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Other, primarily the difference in U.S. tax rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "(Benefit) tax at statutory rate of 25%"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "terseLabel": "Prior year refund received"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofreconciliationofincometaxescalculatedatfederalstatutoryratestoprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r50",
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Trade accounts and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "terseLabel": "Uncollectible trade accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Other payables and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r422",
      "r510"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Advances from customers"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "terseLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r118",
      "r133",
      "r176",
      "r223",
      "r397"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r44",
      "r284",
      "r293",
      "r477",
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Bad debt expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense classified as other.",
        "label": "Interest Expense, Other",
        "terseLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r181",
      "r184",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r166",
      "r464",
      "r488"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r165",
      "r213",
      "r242",
      "r243",
      "r244",
      "r423",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r505"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r42",
      "r222"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndLandImprovements": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.",
        "label": "Land and Land Improvements",
        "terseLabel": "Permit of land use"
       }
      }
     },
     "localname": "LandAndLandImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Total undiscounted cash flows"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r188",
      "r239",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r374",
      "r377",
      "r378",
      "r385",
      "r472",
      "r523",
      "r564",
      "r565"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r126",
      "r142",
      "r488",
      "r512",
      "r521",
      "r559"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r156",
      "r188",
      "r239",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r374",
      "r377",
      "r378",
      "r385",
      "r488",
      "r523",
      "r564",
      "r565"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r3",
      "r124"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "terseLabel": "Current portion of lines of credit"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermConstructionLoanCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.",
        "label": "Long-Term Construction Loan, Current",
        "terseLabel": "Convertible, redeemable note payable, net of issue discount"
       }
      }
     },
     "localname": "LongTermConstructionLoanCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r125",
      "r139",
      "r277",
      "r291",
      "r475",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r89",
      "r191",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Plant, machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementAndServiceFeesRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ManagementAndServiceFeesRate",
        "terseLabel": "Service fee percentage"
       }
      }
     },
     "localname": "ManagementAndServiceFeesRate",
     "nsuri": "http://fasb.org/us-gaap-sup/2022q3",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash (Used In) Provided By Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used in Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49",
      "r51",
      "r54"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r38",
      "r54",
      "r132",
      "r148",
      "r154",
      "r169",
      "r171",
      "r175",
      "r188",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r208",
      "r226",
      "r228",
      "r232",
      "r234",
      "r239",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r382",
      "r385",
      "r473",
      "r523"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow",
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Net other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r4",
      "r125",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Aggregate Note payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r16",
      "r121",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes Payable, Related Parties, Current",
        "terseLabel": "Compensation payable to officer"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r26",
      "r120",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).",
        "label": "Notes Payable, Related Parties, Noncurrent",
        "terseLabel": "Compensation and interest to related parties"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r226",
      "r228",
      "r232",
      "r234",
      "r473"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r402",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating leases liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "U.S. net operating loss carry forward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleoftemporarydifferencestodeferredincometaxassetsandliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r62",
      "r70",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) - foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Total Other Payables"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofotherpayablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r488"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Borrowings from related parties"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNotesPayable": {
     "auth_ref": [
      "r4",
      "r125",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes payable classified as other.",
        "label": "Other Notes Payable",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Payables [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForMortgageDeposits": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "outflow associated with an amount paid in advance to show an intention to complete a mortgage financing.",
        "label": "Payments for Mortgage Deposits",
        "terseLabel": "Advance amount"
       }
      }
     },
     "localname": "PaymentsForMortgageDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)",
        "verboseLabel": "Preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r488"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r167",
      "r245",
      "r246",
      "r466"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from convertible redeemable debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r47",
      "r511"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Payments of line of credit"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Borrowings and interest from related party"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r154",
      "r169",
      "r171",
      "r182",
      "r188",
      "r195",
      "r203",
      "r204",
      "r226",
      "r228",
      "r232",
      "r234",
      "r239",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r372",
      "r375",
      "r376",
      "r382",
      "r385",
      "r442",
      "r473",
      "r485",
      "r486",
      "r508",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss for the year"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r84",
      "r159"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Property Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Plant, machinery and equipment [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r86",
      "r143",
      "r443",
      "r488"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofestimatedusefullivesoftheassetsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r180",
      "r241"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Bad debt benefit"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow",
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableWithImputedInterestNetAmount": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The receivable or note face amount less the unamortized discount or premium.",
        "label": "Receivable with Imputed Interest, Net Amount",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestNetAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Trade Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r320",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r152",
      "r410",
      "r411",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r320",
      "r410",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r408",
      "r409",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConstructionLoansPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from repayment of borrowings to finance the cost of construction.",
        "label": "Repayments of Construction Loans Payable",
        "negatedLabel": "Payments of construction term loan"
       }
      }
     },
     "localname": "RepaymentsOfConstructionLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedLabel": "Repayments to related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r102",
      "r151",
      "r572"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r55",
      "r61",
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r98",
      "r140",
      "r454",
      "r456",
      "r488"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r153",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r204",
      "r240",
      "r349",
      "r350",
      "r351",
      "r362",
      "r363",
      "r380",
      "r451",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Repaid remaining amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r177",
      "r188",
      "r220",
      "r221",
      "r227",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r239",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r385",
      "r442",
      "r523"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r403",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Investor consideration"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Closing price of common stock (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r237",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of other payables"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r25",
      "r93",
      "r95",
      "r96",
      "r97",
      "r116",
      "r117",
      "r119",
      "r135",
      "r475",
      "r477",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of principal payments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of temporary differences to deferred income tax assets and liability"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r2",
      "r12",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services.",
        "label": "Selling Expense",
        "terseLabel": "Selling expenses"
       }
      }
     },
     "localname": "SellingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Market price per share (in Dollars per share)",
        "verboseLabel": "Price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Common stock issued to investor (in Shares)",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r15",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short-Term Bank Loans and Notes Payable",
        "terseLabel": "Short-term loan"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r30",
      "r92",
      "r153",
      "r173",
      "r174",
      "r175",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r204",
      "r214",
      "r240",
      "r308",
      "r349",
      "r350",
      "r351",
      "r362",
      "r363",
      "r380",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r407",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r214",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net income for the period determined using accounting principles prescribed or permitted by insurance regulators.",
        "label": "Statutory Accounting Practices, Statutory Net Income Amount",
        "terseLabel": "General and statutory capital reserves amount (in Dollars)"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesStatutoryNetIncomeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock issued for compensation"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r5",
      "r6",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock for intangible assets (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r29",
      "r92",
      "r93",
      "r98",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversions of note payable to common stock (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r5",
      "r6",
      "r92",
      "r93",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Shares issuable upon conversion of the convertible note payable (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "terseLabel": "Common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock in lieu of compensation (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of common stock for services (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r92",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Stock and stock option granted and outstanding"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r30",
      "r92",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock for intangible assets"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r30",
      "r92",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversions of note payable to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock in lieu of compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r5",
      "r6",
      "r98",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock option compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Increase",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "StockOptionExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock or Unit Option Plan Expense",
        "terseLabel": "Stock and stock option compensation"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r72",
      "r488",
      "r512",
      "r521",
      "r559"
     ],
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r187",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r396",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r396",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusedLinesOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unused portion of a line of credit that is available to the borrower to withdrawn upon.",
        "label": "Unused lines of Credit [Member]",
        "terseLabel": "Lines of Credit [Member]"
       }
      }
     },
     "localname": "UnusedLinesOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofprincipalpaymentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r215",
      "r216",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Accounting Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r206",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958570-112826",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r491": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r492": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r493": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r494": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r495": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r496": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r497": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r498": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001213900-23-024710-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-024710-xbrl.zip
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M05A;K4=X+_,XGZ@C8 YAES7@?#" JO3;W[=K?-Y)<SY<+>W:2ERXBKGY[Q>
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M('K@A08Z>IL71C7PE0>D:/9N%/3F JP^P"O+BCJ\\MCCXJ>\V&W9M\[(KQA
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MSE/>?S.BEQ%-ELZ2G)!-%,,7>^OC9.VI'E)EO5!B)2I\C6G?JX[-8MS%(=,
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MIWE>PF:2)JN(^G^"%_7IXV0M^EDO/$8)-)1[O6II0X?.:&8]>SR\C/=7RX3
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M&_5D(->GGE]2_3P/OT(%,'3T@DI ;&6=CZX*]$!"5WG\TM156 +^ R_BT0G
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MMVQNU<0I[K?=88.JB?.P_^^3R-U!(@0<Q01:E&#WZ_OH\1LR)5,@\I=*;SJ
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MD3'?\&@8PL._A-G<BHZC1M+V7_JKT*IHP>FQDSS0DC8/>T<O[Q-X!;&L\U]
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M:#Z:,3X1')TOI]"(N9=/0D11/)P?#)N%HG:R?:?2N6:B\"0\UTY+U\'FNK@
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MIDM(ZH#7P'>;K+O4"=Z2,U96@DK^'N \_7&Q@29VO^?]!.#J,WVY)EQ-R>_
MAFXWD[QI. Y:XQV7WV8J&>)[P$JDE&,ASTVE29(?X/10+(*\VBJ6#\1CZU/K
MR<3Q^*IY##[S0S_%%] PI!UAK:%71V/LDXHZ B/:9?F/0!U/7EIC3=&=VG"K
M)QYM+6B<A/18I&OJ;\K:JX]^^G"^V>Y2NC!][!<.8U,T7)9<=,QF0O(Z*H><
MT SGD\I'DZWZ$VH2;C[S*,T)O3;*P"UNQUR-+LHJ\,PJERIZ0O42ME.>31]E
M#>&6-_>JG!HM-WORYCZ2W7O,FSW]'CT?!)UYYI!>)-=V1Z6OCK*AN\;QQD^7
MZPLG]-XG^!)O[MHE !R3QIYIM',($P5>WC4="Q=V 5S5[8AU^C6;\"^K_4*$
M BC-#I]2[=X@1SL_\(@18XE\L#%I 3>>H]]<GW?!E0_J*H(%X\ 61]T.,&@:
MD$'//6Y.H@]]JYD.]/;@P[,A,'H/;1SWP0]Q_$(O_7$QU;H]411M7;=D^*&9
MQGH9D5]\P ^^&ZAL+XQI)ENX<G#@* 8=B!ZSD0P],+VI\'E>[B@<VG3]U>5Z
M[;MX6B/"7L-X&0X+"UYS5#I69")LU-R(1-4HM^%2JFX*DCC]]Z4?^IO=1EXW
MR*2:7I!_53K1A6?P.J>S.,\L9&.L;PQ<YH.TV<1H>!84D/,\KH@;\$R+N+XX
M3\39F'F(F,7\4L0=8@8XC^]#<G[R+H@3E"S767GG)!:?OXZ%RULN,KR0&(R$
M V<VEJDB%LQ_K^SJ6X"8YL%Y<EEV]05^Q,'!) HD6LE\:K( &VY8E0Q!!RS=
ML9DYQY<;,W6.0Z[NG28#[*$Q[3F<E?8<2FC/X8RUYU!->PZGT9[7QK3G]:RT
MY[6$]KR>L?:\5M.>U_K: QY4[14WFHIYB=.'R(.6A4D*YZ/N3S&^<C9X\>Q+
ME5/VN,*#EA]=WP*&J@W%4M#M,IN\AV H^A4&VW*CQM*$PB\?S#"]L_C*3V'-
M\]#S'WUOYP0C:2D;[@21.YX",A'@E2+ 6/#0J]%=Y3*L6T+!%$K#)U)S5[S!
M-'GGVHG3EU7LA(GCP@5C<O12_XVLCB@EW$@O;,2&J>/%RP?/AB$ZKJ-55K)M
M5$7<S+A1XH?.]IH2,&#Q;ET<.K$?C;5O,N$:M$A,!+B%I=D0FPK3*XQRZ^(2
M-JX5,F=V9F-GI U+;8Y=OTA!AA)V9:@FP3VFBN^M<I5=!VU45^HK"VZH.4ZR
MC8MHAA0:M\YM@C2EO8 ><"LR< )Q-V$;VC:8B_,2SF$,@D$, V"EIH(EC49A
M1(<JO23=3I7:T<L1#MV'C1-_2KJJP$DTZ(=B/.^@%R7>FX3U>0@FHJ,75$ZU
M:A/4)%:F*<BQ0O<B@@%](C,B6LGH)B) 1%ZKF-9F#O6M7?D)RUI;M&N<6BZ=
M_T1QV5=BI",+ ^CX]YV\XTIW<9Y>Y&/LQ^/X0JANOYE$#;@"KU[7@*YFT-_F
M*@KQ9AM$+QC?XOC1=W%2\VB/7FYWVVW@XW@"ZS(0&:,&:!BNO'-S/F0.1FD<
MS6C44@]GF:)I8^^][+U1UJ]J.=$6W:G/;\.3DP??:QJRS7$J^B=RE'BK&#YY
M<=#@FI]B-*+#F?IBOV.#R#<2$:Q=8Y*_K>F']]=1X+L^YCQ3/$8#!MY"(^<'
M"X_K7"SXQ>+Y!%3,(%J3S[&J.?V2:[4Z$!&NWR6&?2>Z? J)P7_PM]<X!COG
MW(]=#"F_KNGT<VG,>"^-T?EH0P$@OW:W'A4PT+8$8M614A9^7275^*2OH3<$
M<NR[*?:.G>2!N&;P!RS^Z 30]V:1/7Q"/@V:CC+Z/8;:ZN;SCA0QY+ED9!*M
MMG+A+[B:;OE*54OVS?L/=?;H^/*-9C1K8J+E'@]@3#,>#>WB(-%ZQ<M&6@I*
M]+"\]-,YI&F',YVMGSK!#7P?,?;.HCC_R<(C/W+<L=N0]J]G4EFDL>*HS\<H
M_@2>F)N-MGMU)BW*1GQ3BG)M;[YHL)(_3WB"[\9VXUDK&*\=9R#![9 ,AN8N
M13@;:OOF32"@NIKP"!P0#3T/W1B:H9S@[,_S,#\2)%6KGM%U16))T]ZY#%*\
MU]I"-PH"G#_\2PY/'H:N>70R=)//9]O7,7E)-Y5.DC.:9>;71)8/!.YR?1QM
M-E%(6^?2P*E<N%(TWYS7W(<*+^TCGP&YK"Z=@Q+Z7/J7?HBRF5_9[7+2+YVJ
MUTD/^4,N;0#4>9+LB+^U@U<'R#'0C[P,^'%$CHEQXD?A<OT^]$=_ TEQ<2O=
MMZ71XP5"Z6CD$S#P0:/=EJBB6TX&_4P?</Z3S-+!8P)HZ[S0\2Q]M=6T6UE/
M.IV[U;@YY+6OJKWHR$K; &WCJ<IJ>>ZK<-40<,2<AB-FI<U75QK-?EXMFG3.
M\^T.G.\3O-X%%_Z:;+")&_M;Z=:$<I ,;X%22,D^KP;-OLAL%)#I>\1A+P%8
M>S)027KEQBC/E %;9+U_*U283/HL8,]B%HK\Q1CQ D^U2<59D+CL0=8*,XV@
MW2KOQ3\[7KR<E!M7//V,&9"%5VZ'-6<OVST/QHY9B1>S\4*3$".>HT7=>Y^.
MX7GY=A+R)$39RLGKHUZ[ARH4Q^'02RC<L1VC)G#C4:KF^MQ,EMI9L/4 G0W/
MB"F0AF_4I6K(<<^!*DD*ZCKV74Q\<*I=8Q_L>,L85PH>)CSU"*($=J@MC&7&
M#DZB('#B!&Z$40*0[![+>N39.(")6#% I_A=\"MW;&3]DEK2^+MO$DA).NAU
M_]SR_J4B7;FW$5K<T#_D7SJA<T_++1>AER=]GF&<W#BILL+]]KK4MF27:=QO
MKQLZ)US-?!Q A [/0\I&H37&S(06.PHF(\6Z8O42KGV;=[+#JVB9/N"X5H,)
M3>P#\E'Z:Q][>3O[L1TGZ75-FS1IS'C'P/O[F+:SAX=?=J'=QS64Q=MPPY0X
M,21P>9>>ATD:[[*WMK-[2=#MT_4:KL(>\60I?FIK6S@7*B'(WVKI+!23:78S
M&K1DW8R;JO)#]^#8NB"OUZA/F_#06,G\+BO ID^_NAD0]O,?6'(3Y$%TR-6M
M1L_OM:^S.RUJ1G-SF57NN)/LJ]++VHBJ2N+&:Z,-XXL[PL3R$4%5O(P\>3D^
M:(>]=OB,8,S:OJ=RZ'K6LY$%V(L5M[T*9*/ XWW>8^/!($N[IJPP6^Z;!.U#
M3@X WJ!NS4ZMU#1JZ_@,?;*G3:J*9$J'3"B/C5-E%PM>0FD4Q]&3']XG" 27
MW2$26[3-9LU/=Z259DAJWT7DA MRM*9AD%64,0GJ)*3R&_BS3=<A<S'A-> E
MXY%33(![Y#LZA1;!6,M=Z)5&]5:BD%Y-[YIN:E=1B@LG:F2CT85O_AS6P4'-
M+[9@'+A2:;PGPR1+4P\F5 '+TI<0?!5IO*IE3UIV5?O$/U3R>6>##1S6:1I*
MECI ]ABI?8 ]T^A[E4P4^%?WY=@B7Q9[5I.XA;RO]9[@$:GM+-*+6WJ+._;-
M?0780E2D6IW[N%#\":?Y]7QY!=]W,6_I\^\*J=/"IJ)U[,P(HF5WD0JW]QGL
MOE;C\\QYO*__O9'/%L+LM)<0.'$C?W4=\*:/9&T$! \XT:R8[/VF&5SJ\033
M2JCK$J=_14<V;'#?D[,HOHSB]-ZYQR=X&R7CU\>(5C+OA0FPX3EE68"GK2<V
M^N[VRZS1AK>'5$T/O76]0KW_::_/LB4L[.0L/'AO3D2I$T!"..?>S/ZU64-0
M@ONRBDK=FXH;_(C#';[!&\</LQJI=11OX"M:W@7^_10%37)KVNB3(H&7.,(<
M%W,[6Y4=CU!)O,VF*+*\T"R=*C,'I$Z.C0GF"Z'*M=5R/"S4-'786B]=:I(Q
MJ/,JV:16.-X<.>$G\'"RAIB3A8/ZU[-Q$=6+%;="E\Q[1<!O4$!FV4W8D!9E
M\Y@C0[E>2_E"3Q?4@"I9AWR*L9Q_QN)]!L*>9RI@;L=&U&@9*[/PS'$Q2Z0C
M)Q'6EC%?#\3!A-<Q(O9#U]\25[3P_BW73(O%Q<\#;%$Z8%]IP@4#,ZFRT 6L
MI#!TT.#H"+6I:..DN]CN[1)?,GR]*.D:$@4KFE1,Z%WP5K'2.8V-"^_V,?;O
M_9!8D&UI2SKG#FLEJ%RQ=6M/V?3J7U94A6<0BO,]G+?ASA/+R&&FUJI];%]5
M;7'C/6:4T!.^!QO%<"M6@;#LR&H)G5.O*,L:S72:XKNE)=8G?N)*N[KLF4:O
M4)DH]!DH6B:/O'RT-?]7R/C2#>93J)]LU]@9ZU9O!P]B%T\/5T-&S\131\!Z
MP8T,E@+'J;JSAV!OU"BMGI&KK:(,?&=+FE?:.>V\Y:KV$?3B<^QN(?+K&D\K
ME<6,_\A)KIZ-HG_57(,Y*3!/%Z3TELFV\8V01**"$HJL/(9J7"9.V_< Y@2V
MKW/^+U[,J1\%I-RA]AP+[QK5UQ=_Z%6OQ;GT!.6PO/Z(48<\S6>LZG!:>J,C
MZ38(RX)OH2.K!V[+3/3GE5G6$([D> K#8LN0^\*%Z\8[G"Q# *[195$,Q-*]
M(@^?WJN$;!XBR@/*-)NVBE*2ZEXYB+B@NZ7<8 _CS7*]W*5)ZH2>']Y+;RV\
MN<8?W^ @PDU$@-&0,Q=5XZF"6-.)'BF4JB B5/74DK6Q+GL1-!I94UNT##]B
M__Z!>-\+8J+($/FM2 .LZ>U)'47>)54)J-.<+&]9%J*G'!QR,GAV7=Z!DJ]Z
MH.NQ4&=[ RW/E!]BW\0B1@I=\[F3S5Z#\] 0Q6?B<GP6H$FRUN5S\8[[Q%*J
MBI!V_0OTZLW9>D''(HX)(VE!7W+T4HW)+Y$73T[L+>G6F9P^$QWV$YR<AUGO
M\Y;6%K^?K*[#'/*V:D>,4<A[,8EI>^=<GV)<H=G/.!N3F9;GHNV;S,+[4/ O
M-/77]%8@Y3&,Y1.TD[T7H0<AN#SG>V0[S5G$7N>K)B*:*?Q6D_C9\F*E\3-H
MU7T9O-:R>XJ=O !M7B_JR\OTV,X;LM.6_WF6P@P<2I&<.AM4G=J1+[5DJS1K
M*+#N-^"WM-*J=2BT_ 6J<G=_T&UHR][SBQI&N0,5K6;CYE. C]I>S^X,;.F2
M3$*F[:NQ/D9HY@C58@Z9PJZB(NU*\L*$/]]PI%N RI@6W4(SACX)U5LR"%F@
M?VG*A7LP5$T.S,>Z1=B,NOG/2%<.5)1EV',LRRU-:0SO+^#]S^,H&;L8@[&
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M;E3OLA"<E/GASS:=8<G%A*,H,!X]P@3:UC2;4H8?>7N9:7/4*YW2&(GI'](
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M[^NP26N;N?!_V_F>G[Z09=Y%Y!A*SQIQJ*-^LK#,6B5)K#B:5LZF:D;GHQR
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MTI B38"ZEK/V9;[45^@5JF^MY8(H6Q'1)>$W9%&4K=KU](R?)Z;1M_(@,H&
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MO@^3+7:)-X:]T<(>?-C&(AY<%+A7]-EXRWHB)9GV@[]L&G6[!4D6[RM[T5J
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MZ3/<%>%?L ,Y,-RP$P7VBD)#%;C,M]A# (2^H5V'O(< *")0;;H=6FQ@27<
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M7SN^)_"-RA,IC(-82-[UE7C#6S]U O_WS&>B@_:8.5=VC7B+3O9YA<$*LY?
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MI$E;7^MCQ[=7-JU%^!6G.K *>@P\'DCQ8X:5\0J#K4=$<K+*.Y,@J5(C(U1
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M#*O"-'XJJ>'NTQA(!-S<>=6-$?D=2$OPE=>@;JX._SA+&@MF]8KI-M-N1Y"
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M)I)5*;YYY:1W)$4HS[)^2&7_?*L5^E8KU+=6:+QRR>+\D=@QG_$W6RS8,1V
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MVSK.@-TF_Q-/F7=N;*WVNIL/*3@CYLO:4-8[SN&$XZE*POVO>E"5\;D.CX9
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MR!2K!M)N#)^$^1SI1(^JA"W<I^VSX 4>U=:;L+?6ZUB>%9.?<XI^3@_ P[L
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M"U)A#468 [1UI-/A$!1YKE0E!:(!R"]4'K63+/N"=<7<0J5&= ==,_XCM;T
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MOX%L\#LSLJF)B$ 5-1T!CHIQ U7M<YUD4^1(J,JG%>HAJ'$BBV?5GJ1N8'7
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M",!*U#'?DN)SA$U,//4?Y)H\PP(W""$@V*!&@FU12/.$^V;[H9K2G*;%!-V
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MU9WGNST,N'"<DQ%<WMN<<*D*1/3X:(KAS=AAF2K-WWWJG[^VQABXX$'B 0:
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M3S$FO1Q7GW(V'I^?R<O#F#G2UGI;/P5]$O,WT((*[TRT2@N707B.TJ\? 6^
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M&6OW5L#P<40:1[;A>E SB3=E85EV#_+#9\6AOZ\M1S$U2I8$1Y(;3T>AJ7I
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MQX/C82T+!;\5\&^$]\='JJU^MH3TU.)V4>PT:>Z*S'&&<I,%4$"+ HKJ$:4
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M?C7?TB)9)ZP0_ACXM!=Q:K.SP<#KJ/4%I9R+7]>&R68H4/F/]KH=!,YASOZ
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M"+V8&BG\0$CS')/FH>70,SVC'J &GJ-_VOE.A.MB+QFYEP:P-QO$PAG7WTS
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M.KA"7;.VA^M;84W_=1?+#3=9(5@*PS&[P3)QPV5B)<<FETI:)1-W2XLF_OG
MFJ'P4D^<F=M=2'_9*,K,^5G#6: >WK/@57%\@\K23\$#RCS>9T]_4D]77;\!
M0SU7!XPP',!4%<140>K#QT^+9-3>E]_W[@=RK>2@T\0A0<WECNOD#U2U,^(V
M]RGJT9/AI36"X+ID$D!IM5+I[B6<BD7LVZ<UBY@4O-2R9,*B7B F+Q@N(OV/
MU;]\NDW84DA5G+[!XA?<&TD%!HI,2O!'+YN[7C<.VSH'W(@:2FP?ZVR'=$;4
MX;3(IHJ_)548=O?B9[1U1T0.=O(P363O4K+$AR$(VU044J7V,F'I#$OQQ41R
M!QZDWE:UQU+W)UV8]9*;*SP,[=@SK@)6E"/Q+>C_ZT58W^?T!.%;^V"\JE*6
M0.BG11@N@ P<K-37%W2II351ZA?-9!SMYA8V0#[VLIWMA;Q\5%*F5&IP9#<\
MW"&RLTPZ_.Y6ZIQW'G-48?1E7\IS,2,-S)'^Y3 ;DY68/IXK? N6QANA=AN<
MDC21KI2Q#R9P7I[3EE[5,0?!$7KJ-L#*HKV>_H-G0[GI[7*Q'Y*QR!7HXL8%
MH&_2/TV:Q-'J&J(^.*&;PC)$[\35N!!/(SMY<7!GRYGNP65XRWAN7VNF97H-
MJE9QR=@<CI5ZT:]&SZYCP$?Z-H*^9MP4'3$,77Z1T?T<[@?A:2255JN3=3GW
M:^2<R[7DC"XYR3SR/L(>!64-83Z7AO,,6<UU6\J3;L9/"0>/^LF#!TC%6[K,
MM(8![U 1?38F74BT<)F[ZBN\<?BV7=>U/R_%(DU4S<D$9STO4HH0SP.&E7K'
M1:\I]Z3-20M[K<A/HGUF*<P/@Z^GKOE:=CE-V;%+?NJ>3.V-YK*<%^R\N?."
MU"THKW+@+27@/V:1?V^)^^&QQ#TH<7]W+'%_YBO@)]#)ZDY$]4I_0AS$2\=%
MT>J2N5WQM_T[H$A[TS9YPOH;?$Z\=^ND[1_;I[J<6A>819]AYE**=Y:#XV9%
M[+^8&4)[>IJ+/GR3KA'VP05[UAJW9/%V6'/3ODQ\LIU?7."1#,*>$:#1^X4L
M.I4)X1\(L[,ZL];=H7(#70[]Q3X1L7@"-B+$AC"A/C0]PX82QB&8CAK$<":X
M))FY)>%>&]8],N':*  4]3@D@;+TB55G%[\F.W&'+I"S#IKUPD8>3CJT[-C.
M%6 HQQ_G%U*E8#Y$1M38'4N;5A_DMBIAI](:?#ZCI\7C-6/C)#;6 <&7S1=C
MXJL#_,[\I"VWU9*R%Q)#VP>4,05-^+T_6+,B/:'96T#\FH+B4F>'*I;H9B,+
M,:.[-DDA]JX0GNTJN&K0? OK&4)WLJ0VC820B$<8D$RQP*6O.3)!!K)J6PTU
MV:M=<B6)'$^Z\MR'+2"$QX,]8VJOX(O2ZX27(3\\7(-R!S8 IE!FS5#=$EE$
MPEZXX-C/R9=NKX'9;9<,-A&;R^,ISD6D5UIZ&B7VFX&CW,"UIKI1BVQ<*:)Z
MNCH5N=RT.9?W(DQGV G;$#+7*R(37>!6UN^F0> YR,-ZK RN:2.ERBS*4D_M
M9A)^+[,,Z;I1K',RA9EB5E@+;0R1F )#Y:E&I"&4%6N>.,LG<@,Q1Z*;'39
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M)A;!M2EG!B68T(K'[3K(9YN3E6@6S^M*147CMZUOD$4),TD@1]R+RV99TC*
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MDTUG"+S4_GE'"V)Z]+SVU6;>AQE&7L>&')=E< 5H34DVQ7H IBZQK%!3M;L
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MXA?AO='$JE\B6W%":,.XDBA\8A;28+<7U;93<O.43)@V\0.KS+2=W^2'0#C
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M96_.&$@2H]I4:Y+#NHQ%+E9-DL9*'/&T!5,CTLP9=SME#?Q A4\HCWCZJQA
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MLQ(4RF'47-,9<;!K2$_A!E-R8Z4INT;Z9FXUY*!@C&67:E;;0UKH?W%N4^H
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MJ?(:#)]\*"<@7\T?3.P-ZB/E2B1U\?/_?O.L>+PA=?.R-BLC[Q#HB.%^W"9
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M*D@)XS[6"7=+5OS+NG@:%CU%8 );_C:#)CY^,DNU#+>[\E0"RP/E+!FKZU=
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M=MY3;@JE0EXVO%^UXG='?/GY9YX^R[^WQQYWH1WXLX#D<JCP;I2P"#EAQI-
ME0G=ON[A$!EERUS-W6NU BB YRY>RL-X62!ATT4AO:L7\9A\8ZS+*YK.%*I
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M0L&6>N DL)CE! 2K]=*X!%YDPB.@84!O?L4K$[ZF]7_G5N8EQYN/S+@X@Q-
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M)JT'B/X0N#]T^>(YHWY&= (5[!(LRQ6;-$2!MM._7.TYX *C\5)1C3L3W,B
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M4=&70O]QV#L[9;!4YNA7\4B5O"X26YB2S<'"\#AM5_UPS49!0--$U"I?^8L
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M)?6)8Q;VD!+7MQOAPYK*OBK/([@^;CV1+Y.)OO'\]?370V<[4Q62R*S:9!S
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MH.\64Z0[)?02#_OJ>&_7@5XQRN(2L:$V(:3VT'-4";M!(C06@_"]Q_95!:)
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M8)5> &8'P>/Q"/">][V3BKANXDR8T*CZSQ2SS%@T@"/#)]C":;2LC\,CS_I
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M%#M(*7X2DLU6(J+[3O?!!TVM2. _O:&!JX<\6EU;_<D1&?<,$\7(,:(.-_F
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M->69__/O[[<WY-\43',_:A,WR!9OA-(9R%;0S<UK0M[H&=R2<O^:69H8#&_
MN2%3';5$G'^L=#G +D2+!GZ'S%R6"=VR>04290P71!E)@"U?!3[QR'>2?4Q9
MV!>:DSQ01WQA:)HJNA,P'1 X'!2UNQ= G@//FI(@$YQBF;*_Y>=$"55*-)\%
M\KN^M)?["'1K^!<V]H9.Z<IQ##L.94'3[TR7R6<KL6=#"DU\Y47I"4IDG!K4
M\(]V+1V>V F%\GZ 1-B.M<DD)FVK- 2?EE(;S"=&=7(QB,(99IZGF"<>RXU
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M$U\?8>+.\!26S?)&]^[IKXNP-6X]NH>T+J,O7Y<'AYCQ)3/Y3A S?OKU)5\
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M#6DNCG7YHLR=3W&D!S@2A90X!B4\B]A-_/"!%:.,+MCOXVG'3M.=J7QW@%T
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M3GO3LL_ZIHU3+KOWG?;C[?U<L]0M,PIWV,@Q<AECMK9>ZZ!TGT\XVDO+DT2
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MR>0W[OF]2+9)3#V6"E].8\UJ7:E5$Z?EG&"P[B"!C^6&*VUCBACQ#$CT#HZ
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MV(N:EG2+,[AE'IW5NO7=XNT7)]72LP6IJ%N(@R*& _^#!D7:U@<3&R,;G!&
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M7G.X'5'QJ 85#VL5;D:F+;KM0C1O5[\)JBGV;D75\+S+.9NN0SM;2[,S6^.
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M@7&UYI0XH0?Q5O#I+9:\+UUL/L8,DYH\@0SA:F[,BL>)HH[DS32P31Y0,"K
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MDU02*.,:L<=&H%01*.,M:F-*FRMZ6]?:>2[P\E*$^(E^,'/ES4@6O6S-]QD
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M\JE1OO8-3>4F#,A7"!M2N-;!0.OG+54NB$[/C0=;V\\E6C$)NY8Z\2F,(:G
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M.T-MT,_6K-00$KPG:B,EJDB)7FDI<0;YW4)*?#4\8!^=?8N(NL"S9R$B!EO
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M_OS_[5U;<^*X$GX_OV+.O&ZQL6S D-J3JD"&228AR09R(5O[X-@"/ &;\85
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ME'.LLW0UN 2\F'/ ^7)/N%2!4LY5(/NXGCV5A<HY!RUK3RQ9].2<H\=)1)\
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M<HX# F"@.%4 SG%0 (CEF%,%X.4&>TZ%V(_8/<?_$HN> \ Y7E<<OP!8* X
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MHGG,)GF4?.;)XO>+J4U/R+6^,QR<_!]02P,$%     @ VH9^5FU3!O<" P
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MC")&VL!0B8#+*8%?2+\*G_(0^R+XE:EV7\4)D_-]78P^6T7X1'/I\X0)8#(
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M1\URG1S:K+97;9<@CX\(V[6O%;M69P>;Y#_[82T_Z"]._OD'PA]02P,$%
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M7&R(0;^^<>!@H0=(TOZ@4'?XGK4OI7YF0UILLRE;8G:P[?H"I=H4LD?4([&
MMSP#)(NN,PY@,VQM)!NO*!.3ASLECLMI9\K%@]ZSY:/5R/%NDG7<A)5_GTGN
M::KGG:9Z25-)4U%H4O-.DUK25-)4%)H:>:>I4=)4TE04FIIYIZE9TE325!2:
MM+S3I!DP"3FA0:3#R(KX>;CR#](]KS*548X?]Y+7ON11\!=02P,$%     @
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MRK%@X8"5%P 42C"92D,"F$VA#-%T0K+4J(P1;:AA"50^1!:%AP(ED%-!(AK
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M<90J?6:(S*=8\PEV^TW6?+K]"U!+ P04    " #:AGY65F+:S"\Q  !3-P
M#0   &EM86=E7S P,2YJ<&>]> 5<E%NW]X-TB4@J,912 E+2C(A#B(" =$EW
M=XX!J'0(*!+2(# T0R,M+1U#=W?'S#=Z7L\Y[WW?>[_OWN_WNP\S[(>]UE[Q
M7WNOO1:H,=0L<..)C+P,@(&! ;Q _P H!" -X.'@X.)@X^'BXN+CXQ$0D1,3
M$1(2W;I)1D).=QM$3W>;EI:!A9N5@>D>,RTMFQ#[O?N\ @("(%81"6$^<6Y^
M ;Z?0C#P\?&)"(FHB8FI^1AI&?G^VP_J&T"*AT&&<0\3@PFX1HJ!28J!:@%
M ("!C?'K ?[Q8%S#Q,+&P<7#)R!$,Y3? *YA8&)>P\+$QL;"0E/]T'0 BQ3[
M)B.O% Z9BA$NDQ,YWZNH5#SF1\6-%*K]NRS\QLZO\0DHJ:AOW;YSEY6-G4-
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M%& UA0+ZE%=DCY-F+@^1;@9:F:^E:?MKE3)R-6F4(/>=^43(M:]OPJ^R/5"
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M[UD*>YV1'7D#/LP!4FOG=KQ3VLXHE4@_H^R=2A68O;OSKLPIYWOTO1/2]J4
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M?Q5,+5R'(B09&X9$6@8IE4_\."7AX9\_W4\+9@]&9Q UG>+D_Y!H:!9:V5&
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M24/N8-3X_P%02P$"% ,4    " #:AGY6)_^L&'P4  #LYP  $0
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M+FAT;5!+ 0(4 Q0    ( -J&?E9M4P;W @,  "<,   9              "
M 6B- P!F,3!K,C R,F5X,3 M,3%?8VAI;F$N:'1M4$L! A0#%     @ VH9^
M5GRMCGE& @  80<  !@              ( !H9 # &8Q,&LR,#(R97@R,RTQ
M7V-H:6YA+FAT;5!+ 0(4 Q0    ( -J&?E;\L#LLL0$  !T4   7
M      "  1V3 P!F,3!K,C R,F5X,RTQ7V-H:6YA+FAT;5!+ 0(4 Q0    (
M -J&?E9):L/3BP<  +4J   8              "  0.5 P!F,3!K,C R,F5X
M,S$M,5]C:&EN82YH=&U02P$"% ,4    " #:AGY67LVGTI('  !8*P  &
M            @ '$G , 9C$P:S(P,C)E>#,Q+3)?8VAI;F$N:'1M4$L! A0#
M%     @ VH9^5CNW0AC"!   P14  !@              ( !C*0# &8Q,&LR
M,#(R97@S,BTQ7V-H:6YA+FAT;5!+ 0(4 Q0    ( -J&?E968MK,+S$  %,W
M   -              "  82I P!I;6%G95\P,#$N:G!G4$L%!@     -  T
*< ,  -[: P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
